{"data": [{"Element": "<div class=\"WordSection1\">\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>ANNEX I</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"TitleA\"><span lang=\"X-NONE\">SUMMARY OF PRODUCT CHARACTERISTICS</span></p>\n<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Arzerra 100\u00a0mg concentrate for\nsolution for infusion</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Arzerra 1000\u00a0mg concentrate for\nsolution for infusion</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE\n AND QUANTITATIVE COMPOSITION</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">One ml of concentrate\ncontains 20\u00a0mg of ofatumumab.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:black\">Arzerra 100\u00a0mg concentrate for solution for infusion</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each vial contains\n100\u00a0mg of ofatumumab in 5\u00a0ml.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:black\">Arzerra 1000\u00a0mg concentrate for solution for infusion</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Each vial contains 1000\u00a0mg of\nofatumumab in 50\u00a0ml.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Ofatumumab is a human monoclonal antibody\nproduced in a recombinant murine cell line (NS0).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:black\">Excipient with known effect</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">This medicinal product\ncontains 34.8\u00a0mg sodium per 300\u00a0mg dose, 116\u00a0mg sodium per\n1000\u00a0mg dose and 232\u00a0mg sodium per 2000\u00a0mg dose.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">For the full\nlist of excipients, see section\u00a06.1.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL <span style=\"text-transform:\n uppercase\">form</span></span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Concentrate for solution for infusion (sterile\nconcentrate).</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Clear</span><span lang=\"EN-GB\"> to opalescent</span><span lang=\"EN-GB\">, colourless to pale yellow\nliquid.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Clinical\nparticulars</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic indications</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Previously untreated\nchronic lymphocytic </u><u><span lang=\"EN-GB\">leukaemia</span></u><u> (CLL)</u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span style=\"color:black\">Arzerra in combination with\nchlorambucil or bendamustine is indicated for the treatment of adult patients\nwith CLL who have not received prior therapy and who are not eligible for\nfludarabine-based therapy.</span></p>\n<p class=\"MsoNormal\"><span style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\">See section\u00a05.1 for further information.</p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\navoid\"><u><span style=\"font-size:11.0pt\">Relapsed CLL</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">Arzerra is indicated in combination with fludarabine\nand cyclophosphamide for the treatment of adult patients with relapsed CLL.</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">See section\u00a05.1 for further information.</p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u>Refractory\nCLL</u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Arzerra</span>\nis indicated for the treatment of CLL in adult patients who are refractory to\nfludarabine and alemtuzumab<span lang=\"EN-GB\" style=\"color:black\">.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">See\nsection\u00a05.1 for further information.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">4.2\u00a0\u00a0\u00a0\u00a0 Posology and method of administration</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Arzerra should be administered under the\nsupervision of a physician experienced in the use of cancer therapy</span> and\nin an environment where full resuscitation facilities are immediately\navailable.</p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\navoid\"><u><span lang=\"X-NONE\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Monitoring</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Patients should be closely monitored during administration\nof ofatumumab for the onset of infusion-related reactions, including cytokine\nrelease syndrome, particularly during the first infusion.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Pre-medication</u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Patients should receive the following pre\u2011medication\nmedicinal products 30\u00a0minutes to 2\u00a0hours prior to each Arzerra\ninfusion according to the following dosing schedules:</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<h6 style=\"line-height:normal\"><u><span lang=\"EN-GB\">Premedication schedule for\nArzerra</span></u></h6>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:-1.7pt;border-collapse:collapse;border:none\" width=\"624\">\n<tr>\n<td style=\"width:113.45pt;border:solid windowtext 1.0pt;padding:\n  0in 5.4pt 0in 5.4pt\" width=\"151\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>\u00a0</span></p>\n</td>\n<td colspan=\"2\" style=\"width:113.4pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" width=\"151\">\n<p class=\"Table\" style=\"margin:0in\"><b><span style='font-size:11.0pt;\n  font-family:\"Times New Roman\",serif'>Previously untreated CLL or relapsed CLL\n  </span></b></p>\n</td>\n<td colspan=\"4\" style=\"width:241.0pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" width=\"321\">\n<p align=\"center\" class=\"Table\" style=\"margin:0in;text-align:center\"><b><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Refractory CLL</span></b></p>\n</td>\n</tr>\n<tr style=\"height:24.8pt\">\n<td style=\"width:113.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt;height:24.8pt\" width=\"151\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Infusion number</span></p>\n</td>\n<td style=\"width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:24.8pt\" width=\"76\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>1 and 2</span></p>\n</td>\n<td style=\"width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:24.8pt\" width=\"76\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>3 to n*</span></p>\n</td>\n<td style=\"width:49.65pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:24.8pt\" width=\"66\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>1 and 2</span></p>\n</td>\n<td style=\"width:63.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:24.8pt\" width=\"85\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>3 to 8</span></p>\n</td>\n<td style=\"width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:24.8pt\" width=\"76\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>9</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:24.8pt\" width=\"95\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>10 to 12</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:113.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"151\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Intravenous corticosteroid (prednisolone or\n  equivalent)</span></p>\n</td>\n<td style=\"width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" width=\"76\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>50\u00a0mg</span></p>\n</td>\n<td style=\"width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" width=\"76\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>0 to 50\u00a0mg**</span></p>\n</td>\n<td style=\"width:49.65pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"66\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>100\u00a0mg</span></p>\n</td>\n<td style=\"width:63.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"85\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>0 to 100\u00a0mg**</span></p>\n</td>\n<td style=\"width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" width=\"76\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>100\u00a0mg</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" width=\"95\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>50 to 100\u00a0mg***</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:113.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"151\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Oral paracetamol (acetaminophen)</span></p>\n</td>\n<td colspan=\"6\" style=\"width:354.4pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"473\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>1000\u00a0mg</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:113.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"151\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Oral or intravenous antihistamine</span></p>\n</td>\n<td colspan=\"6\" style=\"width:354.4pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"473\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Diphenhydramine 50\u00a0mg or cetirizine 10\u00a0mg\n  (or equivalent)</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"7\" style=\"width:467.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" width=\"624\">\n<p class=\"Legend\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>*Up to 13\u00a0infusions in previously untreated\n  CLL; up to 7\u00a0infusions in relapsed CLL</span></p>\n<p class=\"Legend\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>**Corticosteroid may be either reduced or omitted\n  for subsequent infusions at the discretion of the physician, if a severe\n  infusion-related adverse drug reaction (ADR) did not occur with the preceding\n  infusion(s).</span></p>\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>***Corticosteroid may be reduced for subsequent\n  infusions at the discretion of the physician, if a severe infusion-related\n  ADR did not occur with the preceding infusion(s).</span></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Posology</u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Previously\nuntreated CLL</span></u></i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">For\npreviously untreated CLL, the recommended dosage and schedule is:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Cycle\u00a01: 300\u00a0mg on day\u00a01 followed\n1\u00a0week later by 1000\u00a0mg on day\u00a08</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Subsequent cycles (until best response or a\nmaximum of 12\u00a0cycles): 1000\u00a0mg on day\u00a01 every 28\u00a0days</span>.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Each cycle lasts 28\u00a0days and is counted from day\u00a01\nof the cycle.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Best response is a clinical response that did not improve\nwith 3\u00a0additional cycles of treatment.</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Relapsed\nCLL</span></u></i></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\navoid\"><span style=\"font-size:11.0pt\">For relapsed CLL, the recommended dosage\nand schedule is:</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span style=\"font-size:11.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span style=\"font-size:11.0pt\">Cycle\u00a01: 300\u00a0mg on\nday\u00a01 followed 1\u00a0week later by 1000\u00a0mg on day\u00a08</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span style=\"font-size:11.0pt\">Subsequent cycles (up to a maximum\nof 6\u00a0cycles in total): 1000\u00a0mg on day\u00a01 every 28\u00a0days.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">Each cycle lasts 28\u00a0days and is counted from day\u00a01\nof the cycle.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Previously\nuntreated CLL and relapsed CLL</span></u></i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>First infusion</i></p>\n<p class=\"MsoNormal\">The initial rate of the first infusion of <span lang=\"EN-GB\">Arzerra</span><span lang=\"EN-GB\"> </span>should be 12<span lang=\"EN-GB\">\u00a0</span>ml/h. During\ninfusion, the rate should be increased every 30\u00a0minutes to a maximum of\n400<span lang=\"EN-GB\">\u00a0</span>ml/h<span style=\"color:black\"> </span>(<span style=\"color:black\">see section\u00a06.6</span>)<span style=\"color:black\">. </span><span lang=\"EN-GB\" style=\"color:black\">If an infusion\u2011related ADR is observed\nduring infusion, see below section \u201cDose modification and reinitiation of\ntherapy after infusion\u2011related ADRs\u201d.</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Subsequent infusions</i></p>\n<p class=\"MsoNormal\">If the preceding infusion(s) has (have) been completed\nwithout severe infusion related ADRs, the subsequent infusions can start at a\nrate of 25<span lang=\"EN-GB\">\u00a0</span>ml/h and should be increased every\n30\u00a0minutes up to a maximum of 400<span lang=\"EN-GB\">\u00a0</span>ml/h (<span style=\"color:black\">see section\u00a06.6</span>). <span lang=\"EN-GB\" style=\"color:black\">If an infusion\u2011related ADR is observed during\ninfusion, see below section \u201cDose modification and reinitiation of therapy\nafter infusion\u2011related ADRs\u201d.</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt;color:black\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\navoid\"><i><span style=\"font-size:11.0pt\">Dose modification and reinitiation of\ntherapy after infusion-related ADRs</span></i></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">In the event of a mild or moderate ADR, the infusion\nshould be interrupted and restarted at half of the infusion rate at the time of\ninterruption once the patient\u2019s condition is stable. If the infusion rate had\nnot been increased from the starting rate of 12\u00a0ml/hour prior to\ninterrupting due to an ADR, the infusion should be restarted at\n12\u00a0ml/hour, the standard starting infusion rate. The infusion rate can\ncontinue to be increased according to standard procedures, to physician\ndiscretion and to patient tolerance (not to exceed doubling the rate every\n30\u00a0minutes).</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">In the event of a severe ADR, the infusion should be\ninterrupted and restarted at 12\u00a0ml/hour when the patient\u2019s condition is\nstable. The infusion rate can continue to be increased according to standard\nprocedures, to physician discretion and to patient tolerance (not to exceed\nincreasing the rate every 30\u00a0minutes).</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt;layout-grid-mode:line\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt;layout-grid-mode:line\">Arzerra should be permanently\ndiscontinued in patients who develop an anaphylactic reaction to the medicinal\nproduct.</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u>Refractory CLL</u></i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The recommended dose <span lang=\"EN-GB\">and schedule </span>is <span lang=\"EN-GB\">12\u00a0doses administered as\nfollows:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><s><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span></s>300\u00a0mg on day\u00a01 followed 1\u00a0week later by</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><s><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span></s>2000\u00a0mg weekly for <span lang=\"EN-GB\">7\u00a0doses\n(infusions\u00a02 to 8)</span> followed 4\u20115\u00a0weeks later by</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><s><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span></s>2000\u00a0mg every 28\u00a0days for 4\u00a0doses <span lang=\"EN-GB\">(infusions\u00a09 to 12)</span></p>\n<p class=\"Nottoc-headings\" style=\"margin:0in;page-break-after:auto\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;font-weight:normal'>\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>First and second infusions</i></p>\n<p class=\"MsoNormal\">The initial rate of the first and second infusion of <span lang=\"EN-GB\">Arzerra</span> should be 12\u00a0ml/hour. During infusion, the rate\nshould be increased every 30\u00a0minutes to a maximum of 200<span lang=\"EN-GB\">\u00a0</span>ml/hour<span style=\"color:black\"> (see section\u00a06.6). If an infusion-related ADR is\nobserved during an infusion, see below section \u201cDose modification and\nreinitiation of therapy after infusion-related ADRs\u201d.</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Subsequent infusions</i></p>\n<p class=\"MsoNormal\">If the preceding infusion(s) has (have) been completed\nwithout severe infusion-related ADRs, the subsequent infusions can start at a\nrate of 25\u00a0ml/hour and should be increased every 30\u00a0minutes up to a\nmaximum of 400\u00a0ml/hour <span lang=\"EN-GB\">(see section\u00a06.6)</span>. If\nan infusion-related ADR is observed during an infusion, see below section \u201cDose\nmodification and reinitiation of therapy after infusion-related ADRs\u201d.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Dose modification and\nreinitiation of therapy after infusion-related ADRs</i></p>\n<p class=\"MsoNormal\">I<span style=\"color:black\">n the event of a mild or moderate\nADR, the infusion should be interrupted and restarted at half of the infusion\nrate at the time of interruption, once the patient\u2019s condition is stable. If\nthe infusion rate had not been increased from the starting rate of\n12\u00a0ml/hour prior to interrupting due to an ADR, the infusion should be\nrestarted at 12\u00a0ml/hour, the standard starting infusion rate. The infusion\nrate</span> can continue to be increased according to standard procedures, to\nphysician discretion and to patient tolerance (not to exceed doubling the rate\nevery 30\u00a0minutes).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">In the event of <span style=\"color:black\">a severe ADR, the\ninfusion should be interrupted and restarted at 12\u00a0ml/hour, once the\npatient\u2019s condition is stable. The infusion rat</span>e can continue to be\nincreased according to standard procedures, to physician discretion and to patient\ntolerance (not to exceed increasing the rate every 30\u00a0minutes).</p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt;layout-grid-mode:line\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt;layout-grid-mode:line\">Arzerra should be permanently\ndiscontinued in patients who develop an anaphylactic reaction to the medicinal\nproduct.</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u>Special populations</u></i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Paediatric</span></i><i><span style=\"layout-grid-mode:\nline\"> population</span></i></p>\n<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">The safety and efficacy\nof Arzerra in children aged below 18\u00a0years have not been established.\nArzerra is therefore not recommended for use in this patient population.</span></p>\n<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span style=\"layout-grid-mode:\nline\">Elderly</span></i></p>\n<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">No substantial\ndifferences related to age were seen in safety and efficacy (see\nsection\u00a05.1). Based on available safety and efficacy data in the elderly,\nno dose adjustment is required (see section\u00a05.2).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span style=\"layout-grid-mode:\nline\">Renal impairment</span></i></p>\n<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">No formal studies of\nArzerra in patients with renal impairment have been performed. No dose\nadjustment is recommended for mild to moderate renal impairment </span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">(creatinine</span><span style=\"layout-grid-mode:line\"> clearance &gt;30\u00a0ml/min) (see\nsection\u00a05.2).</span></p>\n<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span style=\"layout-grid-mode:\nline\">Hepatic impairment</span></i></p>\n<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">No formal studies of </span><span lang=\"EN-GB\">Arzerra</span><span style=\"layout-grid-mode:line\"> in patients with\nhepatic impairment have been performed. </span><span lang=\"EN-GB\">H</span><span lang=\"EN-GB\">owever, patients with hepatic impairment are unlikely to require\ndose modification </span><span lang=\"EN-GB\">(see section\u00a05.2)<i>.</i></span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Method of administration</u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Arzerra is for intravenous infusion and\nmust be diluted prior to administration. </span><span lang=\"EN-GB\">For\ninstructions on dilution of the medicinal product before administration, </span><span lang=\"EN-GB\" style=\"color:black\">s</span><span lang=\"EN-GB\">ee section\u00a06.6.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>4.3\u00a0\u00a0\u00a0\u00a0 Contraindications</b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hypersensitivity to ofatumumab or to any of\nthe excipients listed in section\u00a06.1.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.4\u00a0\u00a0\u00a0\u00a0 Special warnings and precautions for use</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Infusion-related\nreactions</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Intravenous ofatumumab has been associated\nwith infusion-related reactions. These reactions may result in temporary\ninterruption or withdrawal of treatment. Pre-medication attenuates\ninfusion-related reactions but these may still occur, predominantly during the\nfirst infusion. </span><span lang=\"EN-GB\">Infusion</span><span lang=\"EN-GB\">-related</span><span lang=\"EN-GB\"> reactions may include, but are not limited to, anaphylactoid\nevents, bronchospasm, cardiac events (e.g. myocardial ischaemia/infarction,\nbradycardia), chills/rigors, cough, cytokine release syndrome, diarrhoea,\ndyspnoea, fatigue, flushing, hypertension, hypotension, nausea, pain, pulmonary\noedema, pruritus, pyrexia, rash, and urticaria. In rare cases, these reactions\nmay lead to death. </span><span lang=\"EN-GB\">Even with pre-medication, severe\nreactions, including cytokine release syndrome, have been reported following use\nof ofatumumab. In the event of a severe infusion-related reaction, the infusion\nof Arzerra must be interrupted immediately and symptomatic treatment instituted\n(see section\u00a04.2).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">If an anaphylactic reaction occurs, Arzerra should be\nimmediately and permanently discontinued and appropriate medical treatment\nshould be initiated.</span></p>\n<p class=\"MsoNormal\"><span class=\"CSIchar\"><span lang=\"EN-GB\" style=\"border:none\">\u00a0</span></span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infusion</span><span lang=\"EN-GB\">-related</span><span lang=\"EN-GB\"> reactions occur predominantly during the first infusion </span><span lang=\"EN-GB\">and tend to decrease with subsequent infusions. </span><span lang=\"EN-GB\">Patients with a history of decreased pulmonary function may be at a\ngreater risk for pulmonary complications from severe reactions and should be\nmonitored closely during infusion of Arzerra.</span></p>\n<p class=\"MsoNormal\"><span class=\"CSIchar\"><span lang=\"EN-GB\" style=\"border:none\">\u00a0</span></span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Tumour\nlysis syndrome</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In patients with CLL, tumour lysis syndrome\n(TLS) may occur with use of Arzerra. Risk factors for TLS include a high tumour\nburden, high concentrations of circulating cells (\u226525,000/mm<sup>3</sup>),\nhypovolaemia, renal insufficiency, elevated pre-treatment uric acid levels and\nelevated lactate dehydrogenase levels. Management of TLS includes correction of\nelectrolyte abnormalities, monitoring of renal function, maintenance of fluid\nbalance and supportive care.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Progressive\nmultifocal leukoencephalopathy</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Cases of progressive\nmultifocal leukoencephalopathy (PML) resulting in death have been reported in CLL\npatients receiving cytotoxic pharmacotherapy, including ofatumumab. A diagnosis\nof PML should be considered in any Arzerra patient who reports the new onset of\nor changes in pre-existing neurological signs and symptoms. If a diagnosis of\nPML is suspected Arzerra should be discontinued and referral to a neurologist\nshould be considered.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Immunisations</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety of, and ability to generate a\nprimary or anamnestic response to, immunisation with live attenuated or\ninactivated vaccines during treatment with ofatumumab has not been studied. The\nresponse to vaccination could be impaired when B-cells are depleted. </span>Due\nto the risk of infection, administration of live attenuated vaccines should be\navoided during and after treatment with ofatumumab, until B-cell counts are normalised.<span lang=\"EN-GB\"> The risks and benefits of vaccinating patients during Arzerra\ntherapy should be considered.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hepatitis\nB</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hepatitis B virus (HBV) infection and\nreactivation, in some cases resulting in fulminant hepatitis, hepatic failure\nand death, has occurred in patients treated with medicinal products classified\nas CD20-directed cytolytic antibodies, including Arzerra. Cases have been\nreported in patients who are hepatitis B surface antigen (HBsAg) positive and\nalso in those who are hepatitis B core antibody (anti-HBc) positive but HBsAg\nnegative. Reactivation has also occurred in patients who appear to have\nresolved hepatitis B infection (i.e. HBsAg negative, anti-HBc positive, and\nhepatitis B surface antibody [anti-HBs] positive).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">HBV reactivation is defined as an abrupt\nincrease in HBV replication manifesting as a rapid increase in serum HBV DNA\nlevel or detection of HBsAg in a person who was previously HBsAg negative and\nanti-HBc positive. Reactivation of HBV replication is often followed by\nhepatitis, i.e. increase in transaminase levels and, in severe cases, increase\nin bilirubin levels, liver failure, and death.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">All patients should be screened for HBV\ninfection by measuring HBsAg and anti-HBc before initiation of Arzerra\ntreatment. For patients who show evidence of prior (HBsAg negative, anti-HBc\npositive) hepatitis B infection, physicians with expertise in managing\nhepatitis B should be consulted regarding monitoring and initiation of HBV\nantiviral therapy. Arzerra treatment should not be initiated in patients with\nevidence of current hepatitis B infection (HBsAg positive) until the infection\nhas been adequately treated.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients with evidence of prior HBV\ninfection should be monitored for clinical and laboratory signs of hepatitis or\nHBV reactivation during treatment with and for 6\u201112\u00a0months following\nthe last infusion of Arzerra. HBV reactivation has been reported up to\n12\u00a0months following completion of therapy. Discontinuation of HBV\nantiviral therapy should be discussed with physicians with expertise in\nmanaging hepatitis B.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In patients who develop reactivation of HBV\nwhile receiving Arzerra, Arzerra and any concomitant chemotherapy should be\ninterrupted immediately, and appropriate treatment instituted. Insufficient\ndata exist regarding the safety of resuming Arzerra in patients who develop HBV\nreactivation. Resumption of Arzerra in patients whose HBV reactivation resolves\nshould be discussed with physicians with expertise in managing hepatitis B.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Cardiovascular</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients with a history of cardiac disease\nshould be monitored closely. </span><span lang=\"EN-GB\">Arzerra should be\ndiscontinued in patients who experience serious or life-threatening cardiac\narrhythmias.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span style=\"color:black;border:none windowtext 1.0pt;\npadding:0in\">The effect of multiple doses of Arzerra on the QTc interval was\nevaluated in a pooled analysis of three open-label studies in patients with CLL\n(N=85</span><span style=\"border:none windowtext 1.0pt;padding:0in\">). </span><span style=\"border:none windowtext 1.0pt;padding:0in\">Increases above 5\u00a0msec\nwere observed in the median/mean QT/QTc intervals in the pooled analysis.<span style=\"color:red\"> </span></span><span style=\"color:black;border:none windowtext 1.0pt;\npadding:0in\">No large changes in the mean QTc interval (i.e.\n&gt;20\u00a0milliseconds) were detected. None of the patients had an increase of\nQTc to &gt;500\u00a0msec. A concentration-dependent increase in QTc was not\ndetected. It is recommended that patients have electrolytes such as potassium\nand magnesium measured prior to and during the administration of ofatumumab.\nElectrolyte abnormalities should be corrected. The effect of ofatumumab on\npatients with prolonged QT intervals (e.g. acquired or congenital) is unknown.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Bowel\nobstruction</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Bowel obstruction has been reported in\npatients receiving anti-CD20 monoclonal antibody therapy, including ofatumumab.\nPatients who present with abdominal pain, especially early in the course of\nofatumumab therapy, should be evaluated and appropriate treatment instituted.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Laboratory\nmonitoring</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cytopenias, including prolonged and\nlate-onset neutropenia, have been reported during ofatumumab therapy. Complete\nblood counts, including neutrophil and platelet counts, should be obtained at\nregular intervals during Arzerra therapy and more frequently in patients who\ndevelop cytopenias.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Sodium\ncontent</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">This medicinal product\ncontains 34.8\u00a0mg sodium per 300\u00a0mg dose, 116\u00a0mg sodium per\n1000\u00a0mg dose and 232\u00a0mg sodium per 2000\u00a0mg dose.</span><b><i><span lang=\"EN-GB\" style=\"color:navy\"> </span></i></b><span lang=\"EN-GB\" style=\"color:black\">This should be taken into consideration by patients on a\ncontrolled sodium diet.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.5\u00a0\u00a0\u00a0\u00a0 Interaction with other medicinal products\nand other forms of interaction</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Although limited formal drug-drug\ninteraction data exist for </span><span lang=\"EN-GB\">ofatumumab</span><span lang=\"EN-GB\">, there are no known clinically significant interactions with other\nmedicinal products. </span><span lang=\"EN-GB\">No clinically relevant\npharmacokinetic interactions were observed between </span><span lang=\"EN-GB\">ofatumumab</span><span lang=\"EN-GB\"> and fludarabine, cyclophosphamide,bendamustine, chlorambucil, or\nits active metabolite, phenylacetic acid mustard.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Live attenuated or inactivated vaccine\nefficacy may be impaired with ofatumumab. Therefore, the concomitant use of\nthese agents with ofatumumab should be avoided. </span><span lang=\"EN-GB\">If the\ncoadministration is judged unavoidable, the risks and benefits of vaccinating\npatients during therapy with </span><span lang=\"EN-GB\">ofatumumab </span><span lang=\"EN-GB\">should be considered (see section\u00a04.4).</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">4.6\u00a0\u00a0\u00a0\u00a0 </span></b><b><span lang=\"EN-GB\">Fertility, pregnancy and lactation</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Women of\nchild-bearing potential</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Since\nofatumumab may cause foetal B-cell depletion, effective contraception (methods\nthat result in less than 1% pregnancy rates) has to be used during Arzerra therapy\nand for 12\u00a0months after the last Arzerra dose. After this period, planning\nof a pregnancy in relation to the underlying disease, should be evaluated by\nthe treating physician.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Ofatumumab may cause foetal B-cell\ndepletion based on findings from animal studies and on its mechanism of action\n(see section\u00a05.1).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">There are no adequate and well-controlled\nstudies in pregnant women to inform a product-associated risk. No\nteratogenicity or maternal toxicity were observed in an animal reproduction\nstudy with administration of ofatumumab to pregnant monkeys (see\nsection\u00a05.3). Ofatumumab should not be administered to pregnant women\nunless the possible benefit to the mother outweighs the possible risk to the\nfoetus.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Administration of live vaccines to neonates\nand infants exposed to ofatumumab <i>in utero</i> should be avoided until\nB-cell recovery occurs (see sections\u00a04.4 and 4.5).</span></p>\n<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">\u00a0</span></p>\n<p class=\"Nottoc-headings\" style=\"margin:0in\"><u><span style='font-size:11.0pt;\nfont-family:\"Times New Roman\",serif;font-weight:normal'>Breast-feeding</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">It is unknown whether Arzerra is excreted\nin human milk, however human IgG is secreted in human milk. The safe use of\nofatumumab in humans during lactation has not been established. The excretion of\nofatumumab in milk has not been studied in animals. Published data suggest that\nneonatal and infant consumption of breast milk does not result in substantial\nabsorption of these maternal antibodies into circulation. A risk to\nnewborns/infants cannot be excluded. Breast-feeding should be discontinued\nduring treatment with Arzerra and for 12\u00a0months following treatment.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Fertility</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">There are no\ndata on the effects of ofatumumab on human fertility. </span>Effects on male\nand female fertility have not been evaluated in animal studies.</p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.7\u00a0\u00a0\u00a0\u00a0 Effects on ability to drive and use machines</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">No studies on the effects of </span><span lang=\"EN-GB\">Arzerra<span style=\"color:black\"> on the ability to drive and use machines have been\nperformed.</span></span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">No detrimental effects\non such activities are predicted from the pharmacology of ofatumumab. The\nclinical status of the patient and the ADR profile of ofatumumab should be\nborne in mind when considering the patient's ability to perform tasks that\nrequire judgement, motor or cognitive skills (see section\u00a04.8).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.8\u00a0\u00a0\u00a0\u00a0 Undesirable effects</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Summary\nof the safety profile</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The overall safety profile of </span><span lang=\"EN-GB\">ofatumumab </span><span lang=\"EN-GB\">is based on data from\n1,168\u00a0patients in clinical trials in CLL (see </span><span style=\"layout-grid-mode:line\">section\u00a05.1</span><span lang=\"EN-GB\">). This\nincludes 643\u00a0patients treated with </span><span lang=\"EN-GB\">ofatumumab </span><span lang=\"EN-GB\">as monotherapy (in </span>patients with relapsed or refractory CLL<span lang=\"EN-GB\">) and 525\u00a0patients treated with ofatumumab in combination with\nchemotherapy (</span><span lang=\"EN-GB\">chlorambucil or bendamustine or\nfludarabine and cyclophosphamide)</span><span lang=\"EN-GB\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Tabulated\nlist of adverse reactions</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Adverse reactions reported in patients\ntreated with ofatumumab as monotherapy and with ofatumumab in combination with\nchemotherapy, are listed below by MedDRA body system organ class and by\nfrequency, using the following convention: very common (\u22651/10); common\n(\u22651/100 to &lt;1/10); uncommon (\u22651/1,000 to &lt;1/100); rare\n(\u22651/10,000 to &lt;1/1,000); very rare (&lt; 1/10,000); not known (cannot\nbe estimated from available data). Within each frequency grouping, adverse\nreactions are ranked in order of decreasing seriousness.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr style=\"page-break-inside:avoid\">\n<td style=\"border:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">MedDRA\n  System Organ Class</span></u></p>\n</td>\n<td style=\"border:solid windowtext 1.0pt;border-left:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Very\n  common</span></u></p>\n</td>\n<td style=\"border:solid windowtext 1.0pt;border-left:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Common</span></u></p>\n</td>\n<td style=\"border:solid windowtext 1.0pt;border-left:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Uncommon</span></u></p>\n</td>\n<td style=\"border:solid windowtext 1.0pt;border-left:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n</td>\n</tr>\n<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infections\n  and Infestations</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lower\n  respiratory tract infection (including pneumonia), upper respiratory tract\n  infection </span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Sepsis (including neutropenic sepsis and septic shock)\n  herpes viral infection, urinary tract infection</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hepatitis\n  B infection a</span><span lang=\"EN-GB\">nd reactivation, progressive multifocal\n  leukoencephalopathy</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Blood and lymphatic system disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Neutropenia, anaemia</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Febrile neutropenia,\n  thrombocytopenia, leukopenia</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Agranulocytosis,\n  coagulopathy, red cell aplasia, lymphopenia</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Immune system disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Hypersensitivity*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Anaphylactic reactions (including\n  anaphylactic shock)*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Nervous system disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Headache*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Metabolism and nutrition disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span class=\"CSIchar\"><span lang=\"EN-GB\" style=\"border:none\">\u00a0</span></span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tumour lysis syndrome</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cardiac disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tachycardia*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Bradycardia*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span class=\"CSIchar\"><span lang=\"EN-GB\" style=\"border:none\">\u00a0</span></span></p>\n</td>\n</tr>\n<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Vascular disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hypotension*, hypertension*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Respiratory, thoracic and mediastinal\n  disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Dyspnoea*, cough*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Bronchospasm*, chest\n  discomfort*, oropharyngeal pain*, nasal congestion*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pulmonary oedema*, hypoxia*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span class=\"CSIchar\"><span lang=\"EN-GB\" style=\"border:none\">\u00a0</span></span></p>\n</td>\n</tr>\n<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Gastrointestinal disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Nausea*, diarrhoea*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Small intestinal obstruction</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Skin and subcutaneous tissue disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Rash*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Urticaria*, pruritus*, flushing*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Musculoskeletal and connective tissue\n  disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Back pain*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">General\n  disorders and administration site conditions</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Pyrexia*, fatigue*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Cytokine release syndrome*, chills (including rigors)*,\n  hyperhidrosis*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Injury,\n  poisoning and procedural complications</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infusion-related\n  reaction*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">*These\n  events are likely attributable to ofatumumab in the setting of an infusion-related\n  reaction and typically occur after the start of infusion and within\n  24\u00a0hours after the completion of the infusion (see section\u00a04.4).</span></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Description\nof selected adverse reactions</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Infusion-related\nreactions</span></u></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Of the 1,168\u00a0patients receiving\nofatumumab in clinical trials for CLL, </span>the most frequently observed ADRs\nwere infusion-related reactions which occurred in 711\u00a0patients (61%) at\nany time during treatment. The majority of infusion-related reactions were\nGrade\u00a01 or Grade\u00a02 in severity. Seven percent of patients had\n\u2265Grade\u00a03 infusion-related reactions at any time during treatment.\nTwo percent of the infusion-related reactions led to discontinuation of\ntreatment. There were no fatal infusion-related reactions<span lang=\"EN-GB\"> (see\nsection\u00a04.4).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Infections</span></u></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Of the 1,168\u00a0patients receiving\nofatumumab in clinical trials for CLL, 682\u00a0patients (58%) experienced an\ninfection. These included bacterial, viral and fungal infections. 268 (23%) of\nthe 1,168\u00a0patients experienced \u2265Grade\u00a03 infections. 65 (6%) of\nthe 1,168\u00a0patients experienced a fatal infection.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Neutropenia</span></u></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Of the 1,168\u00a0patients receiving\nofatumumab in clinical trials, 420\u00a0patients (36%) experienced an adverse\nevent associated with a decreased neutrophil count; 129 (11%) experienced a\nserious adverse event associated with a decreased neutrophil count.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the pivotal study for untreated CLL\n(OMB110911; ofatumumab plus chlorambucil 217\u00a0patients, chlorambucil alone\n227\u00a0patients), prolonged neutropenia (defined as Grade\u00a03 or 4\nneutropenia not resolved between 24 and 42\u00a0days after last dose of study treatment)\nwas reported in 41\u00a0patients (9%) (23\u00a0patients [11%] treated with </span><span lang=\"EN-GB\">ofatumumab</span><span lang=\"EN-GB\"> and </span>chlorambucil<span lang=\"EN-GB\">, 18\u00a0patients [8%] treated with </span>chlorambucil alone<span lang=\"EN-GB\">). Nine patients (4%) treated with </span><span lang=\"EN-GB\">ofatumumab</span><span lang=\"EN-GB\"> and </span>chlorambucil,<span lang=\"EN-GB\"> and three patients\ntreated with </span>chlorambucil alone<span lang=\"EN-GB\"> had late-onset\nneutropenia (defined as Grade\u00a03 or 4 neutropenia starting at least\n42\u00a0days after the last treatment). </span><span lang=\"EN-GB\">In the pivotal\nstudy (OMB110913, ofatumumab plus fludarabine and cyclophosphamide\n181\u00a0patients; fludarabine and cyclophosphamide 178\u00a0patients) in\nrelapsed CLL patients, prolonged neutropenia was reported in 38 (11%) patients\n(18\u00a0patients [10%] treated with ofatumumab in combination with fludarabine\nand cyclophosphamide compared to 20\u00a0patients [11%] in the fludarabine and\ncyclophosphamide arm). Thirteen (7%) patients treated with ofatumumab in\ncombination with fludarabine and cyclophosphamide, and 5 (3%) patients treated\nwith fludarabine and cyclophosphamide had late-onset neutropenia.</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Cardiovascular</span></u></i></p>\n<p class=\"MsoNormal\">The effect of multiple doses of Arzerra on the QTc interval\nwas evaluated in a pooled analysis of three open-label studies in patients with\nCLL (N=85). <span style=\"border:none windowtext 1.0pt;padding:0in\">Increases\nabove 5\u00a0msec were observed in the median/mean QT/QTc intervals in the\npooled analysis.<span style=\"color:black\"> </span></span>No large changes in\nthe mean QTc interval (i.e. &gt;20\u00a0milliseconds) were detected. None of\nthe patients had an increase of QTc to &gt;500\u00a0msec. A concentration\ndependent increase in QTc was not detected.</p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Reporting of suspected adverse reactions</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Reporting suspected adverse reactions after\nauthorisation of the medicinal product is important. It allows continued\nmonitoring of the benefit/risk balance of the medicinal product. Healthcare\nprofessionals are asked to report any suspected adverse reactions via <span style=\"color:black;background:#D9D9D9\">the national reporting system listed in </span></span><span lang=\"EN-GB\"><a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"background:#D9D9D9\">Appendix V</span></a></span><span lang=\"EN-GB\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">4.9\u00a0\u00a0\u00a0\u00a0 Overdose</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">No case of overdose has been reported.</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL PROPERTIES</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">5.1\u00a0\u00a0\u00a0\u00a0 Pharmacodynamic properties</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Pharmacotherapeutic\ngroup: antineoplasic agents, monoclonal antibodies, ATC code: L01XC10</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"layout-grid-mode:\nline\">Mechanism of action</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Ofatumumab is a human monoclonal antibody (IgG1) that binds\nspecifically to a distinct epitope encompassing both the small and large\nextracellular loops of the CD20 molecule</span><span lang=\"EN-GB\">. The CD20\nmolecule is a transmembrane phosphoprotein expressed on B lymphocytes from the\npre-B to mature B lymphocyte stage and on B-cell tumours. The B-cell tumours\ninclude CLL (generally associated with lower levels of CD20 expression) and\nnon-Hodgkin's lymphomas (where &gt;90% of tumours have high levels of CD20\nexpression). The CD20 molecule is not shed from the cell surface and is not\ninternalised following antibody binding.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The binding of ofatumumab to the\nmembrane-proximal epitope of the CD20 molecule induces recruitment and\nactivation of the complement pathway at the cell surface, leading to\ncomplement-dependent cytotoxicity and resultant lysis of tumour cells.\nOfatumumab has been shown to induce appreciable lysis of cells with high\nexpression levels of complement defence molecules. Ofatumumab has also been\nshown to induce cell lysis in both high and low CD20 expressing cells and in\nrituximab-resistant cells. In addition, the binding of ofatumumab allows the\nrecruitment of natural killer cells allowing the induction of cell death\nthrough antibody-dependent cell-mediated cytotoxicity.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"layout-grid-mode:\nline\">Pharmacodynamic effects</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">Peripheral B-cell counts decreased after the first\nofatumumab infusion in patients with haematological malignancies. <span lang=\"EN-GB\">In all patients with CLL, ofatumumab induces rapid and profound\nB-cell depletion, whether given as a single agent or in combination.</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">When ofatumumab was administered as single\nagent i</span>n patients with refractory CLL, the median decrease in B-cell\ncounts was 22% after the first infusion and 92% at the eighth weekly infusion. <span lang=\"EN-GB\" style=\"color:black\">Peripheral B-cell counts remained low throughout\nthe remainder of therapy in most patients</span><span lang=\"EN-GB\" style=\"color:black\"> and remained below baseline up to 15\u00a0months after the\nlast dose in patients who responded</span><span lang=\"EN-GB\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">When ofatumumab was administered in\ncombination with chlorambucil in patients with previously untreated CLL, the\nmedian decreases in B-cell counts after the first cycle and prior to the sixth\nmonthly cycle were 94% and &gt;99%. At 6\u00a0months after the last dose, the\nmedian reductions in B-cell counts were &gt;99%</span><span lang=\"EN-GB\" style=\"color:black\">.</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">When ofatumumab was administered in\ncombination with fludarabine and cyclophosphamide in patients with relapsed\nCLL, </span><span lang=\"EN-GB\">the median decreace from baseline was 60% after\nthe first infusion and complete depletion (100%) was reached after 4\u00a0cycles</span><span lang=\"EN-GB\">.</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span style=\"layout-grid-mode:\nline\">Immunogenicity</span></u></i></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">There is a potential for immunogenicity </span><span lang=\"EN-GB\">with therapeutic proteins such as ofatumumab.</span> Serum samples\nfrom more than 1,000\u00a0patients across the CLL clinical programme were\ntested for anti\u2011ofatumumab antibodies during and after treatment periods\nranging from 8\u00a0weeks to 2\u00a0years. <span lang=\"EN-GB\">Formation of anti\u2011ofatumumab\nantibodies was observed for less than 0.5% of patients with CLL after treatment\nwith </span><span lang=\"EN-GB\">ofatumumab</span><span lang=\"EN-GB\" style=\"color:black\">.</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"layout-grid-mode:\nline\">Clinical </span></u><u><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">efficacy\nand safety</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><s><span style=\"text-decoration:\n none\">\u00a0</span></s></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u>Previously untreated\nCLL</u></i></p>\n<p class=\"MsoNormal\">Study OMB110911 (randomised,<span lang=\"EN-GB\"> open\u2011label,\nparallel-arm, multicentre)</span><span lang=\"EN-GB\"> </span>evaluated the\nefficacy of <span lang=\"EN-GB\">Arzerra </span>in combination with chlorambucil\ncompared with chlorambucil alone in 447\u00a0patients with previously untreated\nCLL<span lang=\"EN-GB\"> considered inappropriate for fludarabine-based treatment </span><span lang=\"EN-GB\">(e.g. due to advanced age or presence of co-morbidities), with\nactive disease and indicated for treatment</span>. <span lang=\"EN-GB\">Patients\nreceived either Arzerra as monthly intravenous infusions (cycle\u00a01:\n300\u00a0mg on day\u00a01 and 1000\u00a0mg on day\u00a08; subsequent cycles:\n1000\u00a0mg on day\u00a01 every </span><span lang=\"EN-GB\">28\u00a0days</span><span lang=\"EN-GB\">) in combination with chlorambucil (</span><span lang=\"EN-GB\">10\u00a0mg/m<sup>2</sup></span><span lang=\"EN-GB\" style=\"font-size:8.0pt\"> </span><span lang=\"EN-GB\">orally on\ndays\u00a01\u20117 every 28\u00a0days) or chlorambucil alone (10\u00a0mg/</span><span lang=\"EN-GB\">m<sup>2</sup></span><span lang=\"EN-GB\" style=\"font-size:8.0pt\"> </span><span lang=\"EN-GB\">orally on days\u00a01\u20117 every 28\u00a0days).</span> Patients\nreceived treatment for a minimum of 3\u00a0months until best response or up to\na maximum of 12\u00a0cycles. <span lang=\"EN-GB\">The median age was 69\u00a0years\n(range: 35 to 92\u00a0years), 27% patients were \u226575\u00a0years of age,\n63% were male and 89% were white. Median Cumulative Illness Rating Score for\nGeriatrics (CIRS-G) was 9 </span>and 31% of patients had a CIRS-G &gt;10.\nMedian creatinine clearance (CrCl), assessed with the use of the Cockroft-Gault\nformula, was 70\u00a0ml/min and 48% of patients had a CrCl of\n&lt;70\u00a0ml/min. Patients with an Eastern Cooperative Oncology Group (ECOG)\nperformance status of 0 to 2 were enrolled into the study and 91% had an ECOG\nperformance status of 0 or 1.<span style=\"font-size:10.0pt\"> </span><span lang=\"EN-GB\">Approximately 60% of patients received 3\u20116\u00a0cycles of\nArzerra and 32% received 7\u201112\u00a0cycles. </span>The <span lang=\"EN-GB\" style=\"border:none windowtext 1.0pt;padding:0in\">median number of cycles\ncompleted in patients was 6 (total Arzerra dose of 6300\u00a0mg).</span></p>\n<p class=\"MsoNormal\"><a name=\"IDX\"></a><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The primary endpoint was median </span><span lang=\"EN-GB\">progression-free survival (PFS) as assessed by a blinded Independent\nReview Committee (IRC) using the International Workshop for Chronic Lymphocytic\nLeukaemia (IWCLL) updated National Cancer Institute-sponsored Working Group\n(NCI-WG) guidelines (2008).</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\"> </span><span lang=\"EN-GB\">The </span><span lang=\"EN-GB\">overall response rate (ORR) including\ncomplete response (CR) </span><span lang=\"EN-GB\">was also assessed by an </span>IRC<span lang=\"EN-GB\"> using the 2008 IWCLL guidelines.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Arzerra in combination with chlorambucil\nshowed a statistically significant (71%) improvement in median PFS compared\nwith chlorambucil alone (HR: 0.57; 95% CI: 0.45, 0.72) (see Table\u00a01 and\nFigure\u00a01). PFS benefit with the addition of Arzerra was observed in all\npatients, including those with poor-risk biological features (such as 17p or\n11q deletion, unmutated IGHV, </span><span lang=\"EN-GB\">\u03b22M\n&gt;3500\u00a0\u03bcg/l, and ZAP-70 expression)</span><span lang=\"EN-GB\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoCaption\" style=\"margin-left:56.7pt;text-indent:-56.7pt;line-height:\nnormal\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Table\u00a01\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Summary\nof PFS with Arzerra in combination with chlorambucil compared with chlorambucil\nin previously untreated CLL</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\">\n<tr style=\"page-break-inside:avoid;height:22.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:22.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span class=\"tabletextNS1\"><b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IRC-assessed\n  primary and subgroup analyses of PFS, months</span></b></span></p>\n</td>\n<td style=\"width:141.75pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:22.9pt\" valign=\"top\" width=\"189\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Chlorambucil</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">(N=226)</span></b></p>\n</td>\n<td style=\"width:113.4pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 0in 0in 0in;height:22.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Arzerra and chlorambucil</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>(N=221)</b></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Median,\n  all patients</span></p>\n</td>\n<td style=\"width:141.75pt;border:none;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt\" valign=\"top\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.1</span></p>\n</td>\n<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>22.4</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>95%\n  CI</span></p>\n</td>\n<td style=\"width:141.75pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt\" valign=\"top\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(10.6,\n  13.8)</span></p>\n</td>\n<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(19.0,\n  25.2)</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Hazard\n  ratio</span></p>\n<p class=\"tabletextNS\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>P value</span></p>\n</td>\n<td colspan=\"2\" style=\"width:255.15pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"340\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>0.57\n  (0.45, 0.72)</span></p>\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>p&lt;0.001</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Age\n  \u226575\u00a0years (n=119)</span></p>\n</td>\n<td style=\"width:141.75pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12.2</span></p>\n</td>\n<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.8</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>Co-morbidity\u00a00 or 1 (n=126)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>10.9</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.0</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>Co-morbidity\u00a02 or more\n  (n=321)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.3</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>21.9</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>ECOG\u00a00, 1 (n=411)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.3</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.0</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>ECOG\u00a02 (n=35)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>7.9</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>20.9</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>CIRS-G \u226410 (n=310)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.1</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>21.7</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>CIRS-G </span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>&gt;</span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>10 (n=137)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12.2</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.2</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>CrCl &lt;70\u00a0ml/min (n=214)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>10.9</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.1</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>CrCl \u226570\u00a0ml/min\n  (n=227)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>14.5</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>22.1</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>17p or 11q\n  deletion (n=90)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>7.9</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.6</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV mutated\n  (\u226498%) (n=177)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12.2</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>30.5</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV unmutated\n  (&gt;98%) (n=227)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.7\n  </span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>17.3</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u03b22M\n  \u22643500\u00a0\u03bcg/l (n=109)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.8</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>25.5</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u03b22M\n  &gt;3500\u00a0\u03bcg/l (n=322)</span></p>\n</td>\n<td style=\"width:141.75pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.6</span></p>\n</td>\n<td style=\"width:113.4pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 0in 0in 0in;height:13.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>19.6</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>ZAP-70 positive\n  (n=161)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>9.7</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>17.7</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>ZAP-70\n  intermediate (n=160)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.6</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>25.3</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>ZAP-70 negative\n  (n=100)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.8</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>25.6</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV mutated\n  &amp; ZAP-70 negative (n=60)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>10.5</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>NR</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV mutated\n  &amp; ZAP-70 positive (n=35)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>7.9</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>27.2</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV unmutated\n  &amp; ZAP-70 negative (n=27)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>16.7</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>16.2</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV unmutated\n  &amp; ZAP-70 positive (n=122)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.2</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>16.2</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td colspan=\"3\" style=\"width:437.75pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"584\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;background:white\"><span lang=\"EN-GB\" style=\"color:black\">Abbreviations: \u03b22M = beta-2-microglobulin,\n  CI = confidence interval; CIRS-G = Cumulative Illness Rating Scale for\n  Geriatrics, CLL = c</span><span style=\"color:black\">hronic lymphocytic leukaemia,\n  CrCl = creatinine clearance, ECOG = Eastern Cooperative Oncology Group, </span><span lang=\"EN-GB\" style=\"color:black\">IGHV = Immunoglobulin Heavy Chain Variable\n  Region, IRC = Independent Review Committee, N = number, NR = not reached, PFS\n  = progression-free survival, ZAP-70 = zeta-chain-associated protein kinase\n  70.</span></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Limited data are available in the heterogeneous non-white\npopulation and in patients with an ECOG performance status of PS\u00a0=\u00a02.</p>\n<p class=\"MsoCaption\" style=\"line-height:normal;page-break-after:auto\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;font-weight:normal'>\u00a0</span></p>\n<p class=\"MsoCaption\" style=\"line-height:normal\"><span style='font-size:11.0pt;\nfont-family:\"Times New Roman\",serif'>Figure\u00a01\u00a0\u00a0\u00a0\u00a0\u00a0 Kaplan-Meier estimates\nof IRC-assessed PFS in previously untreated CLL</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoCaption\" style=\"line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><img alt=\"PFS_IRC_4 (2)\" border=\"0\" height=\"341\" id=\"Picture 5\" src=\"Arzerra%20II-50%20&amp;%20II-51%20-%20PI%20-%20EN%20-%20clea_files/image002.png\" width=\"590\"/></span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoCaption\" style=\"margin-left:56.7pt;text-indent:-56.7pt;line-height:\nnormal\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Table\u00a02\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Summary\nof secondary outcomes of Arzerra in combination with chlorambucil compared with\nchlorambucil in previously untreated CLL</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;background:white\"><span class=\"tabletextNS1\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>\u00a0</span></span></p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\">\n<tr style=\"page-break-inside:avoid;height:22.9pt\">\n<td style=\"width:203.85pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:22.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span class=\"tabletextNS1\"><b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IRC-assessed\n  secondary outcome</span></b></span></p>\n</td>\n<td style=\"width:120.5pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:22.9pt\" valign=\"top\" width=\"161\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Chlorambucil</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>\u00a0</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">(N=226)</span></b></p>\n</td>\n<td style=\"width:113.4pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 0in 0in 0in;height:22.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Arzerra and chlorambucil</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>(N=221)</b></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:203.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>ORR (%)</span></p>\n</td>\n<td style=\"width:120.5pt;border:none;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt\" valign=\"top\" width=\"161\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>69</span></p>\n</td>\n<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>82</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:203.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"margin-left:14.2pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>95%\n  CI</span></p>\n</td>\n<td style=\"width:120.5pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt\" valign=\"top\" width=\"161\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(62.1,\n  74.6)</span></p>\n</td>\n<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(76.7,\n  87.1)</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:203.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"margin-left:14.2pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>P value</span></p>\n</td>\n<td colspan=\"2\" style=\"width:233.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"312\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>p&lt;0.001</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:203.85pt;border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt\" width=\"272\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CR (%)</span></p>\n</td>\n<td style=\"width:120.5pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"161\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1</span></p>\n</td>\n<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:203.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"margin-left:14.2pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CR\n  with MRD negativity (% of CR)</span></p>\n</td>\n<td style=\"width:120.5pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"161\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>0</span></p>\n</td>\n<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>37</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:203.85pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Median duration\n  of response</span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>,\n  all patients, months</span></p>\n</td>\n<td style=\"width:120.5pt;border:none;border-top:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"161\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.2</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>22.1</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:203.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"margin-left:14.2pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>95%\n  CI</span></p>\n</td>\n<td style=\"width:120.5pt;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"161\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(10.8,\n  16.4)</span></p>\n</td>\n<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(19.1,\n  24.6)</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:203.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"margin-left:14.2pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>P value</span></p>\n</td>\n<td colspan=\"2\" style=\"width:233.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"312\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>p&lt;0.001</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td colspan=\"3\" style=\"width:437.75pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"584\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Abbreviations:\n  CI = confidence interval, CLL = c</span><span style='font-size:11.0pt;\n  font-family:\"Times New Roman\",serif'>hronic lymphocytic leukaemia, </span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CR =\n  complete response, IRC = Independent Review Committee, MRD = minimal residue\n  disease, N = number, ORR = overall response rate</span></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">Study OMB115991 evaluated the efficacy of Arzerra in\ncombination with bendamustine <span lang=\"EN-GB\">in 44\u00a0patients </span>with\npreviously untreated CLL <span lang=\"EN-GB\">considered inappropriate for\nfludarabine-based treatment</span>. <span lang=\"EN-GB\">Patients received Arzerra\nas monthly intravenous infusions (cycle\u00a01 300\u00a0mg on day\u00a01 and\n1000\u00a0mg on day\u00a08; subsequent cycles: 1000\u00a0mg on day\u00a01 every\n28\u00a0days) in combination with intravenous bendamustine 90\u00a0mg/m</span><sup><span lang=\"EN-GB\" style=\"font-size:8.0pt\">2</span></sup><span lang=\"EN-GB\" style=\"font-size:8.0pt\"> </span><span lang=\"EN-GB\">on days\u00a01 and 2 every\n28\u00a0days. </span>Patients received treatment for a maximum of 6\u00a0cycles.\nThe <span lang=\"EN-GB\" style=\"border:none windowtext 1.0pt;padding:0in\">median\nnumber of cycles completed in patients was 6 (total Arzerra dose of\n6300\u00a0mg).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"border:none windowtext 1.0pt;\npadding:0in\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The primary endpoint was ORR assessed by\nthe investigator </span>according to the 2008 <span lang=\"EN-GB\">IWCLL </span>guidelines<span lang=\"EN-GB\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p><span style=\"font-size:11.0pt\">The results of this study demonstrated that\nArzerra in combination with bendamustine is an effective therapy providing an\nORR of 95% </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">(95% CI: 85, 99) </span><span style=\"font-size:11.0pt\">and a CR of 43%. More than half of the patients (56%) </span><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black\">with CR were MRD negative\nfollowing the completion of study treatment.</span></p>\n<p><span lang=\"EN-GB\" style=\"font-size:11.0pt\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">No data comparing Arzerra in combination\nwith bendamustine or with </span><span lang=\"EN-GB\">chlorambucil versus a</span><span lang=\"EN-GB\"> rituximab based regimen such as rituximab with chlorambucil is\navailable. Thus, the benefit of such a new combination over a rituximab based\nregimen is unknown.</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\navoid\"><u><span style=\"font-size:11.0pt\">Relapsed CLL</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Study OMB110913\n(randomised, open-label, parallel-arm, multicentre trial) evaluated the\nefficacy of ofatumumab in combination with fludarabine and cyclophosphamide\ncompared with fludarabine and cyclophosphamide in 365\u00a0patients with\nrelapsed CLL (</span>defined as a patient who has received at least one prior\nCLL therapy and previously achieved a complete or partial remission/response,\nbut after a period of six or more months demonstrated evidence of disease\nprogression)<span lang=\"EN-GB\">. Baseline disease characteristics and prognostic\nmarkers were balanced between treatment arms and representative of a relapsed\nCLL population. Patient median age was 61\u00a0years (range: 32 to\n90\u00a0years, 7% were 75\u00a0years of age or older), 60% were male and 16%,\n55% and 28% of patients were Binet stage A, B and C, respectively. The majority\nof patients (81%) received 1\u20112\u00a0prior lines of treatments (of whom\napproximately 50% received 1\u00a0prior treatment) and 21% of patients had\nreceived prior rituximab. The median CIRS score was 7 (range:\u00a04 to 17),\n36% of patients had CrCL </span><span style=\"font-family:CourierNewPSMT\">&lt;70</span>\u00a0<span style=\"font-family:CourierNewPSMT\">ml/min,</span><span lang=\"EN-GB\"> 93% of\npatients had ECOG 0 or 1. </span>Limited data are available in the\nheterogeneous non-white population and in patients with an ECOG performance\nstatus of 2.</p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Patients received ofatumumab as intravenous\ninfusions (cycle\u00a01: 300\u00a0mg on day\u00a01 and 1000\u00a0mg on\nday\u00a08;</span><span style=\"font-size:11.0pt\"> subsequent cycles:\n1000\u00a0mg on day\u00a01 every 28\u00a0days</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">). Approximately 90% of patients received 3\u20116\u00a0cycles\nof ofatumumab and 66% completed 6\u00a0cycles.</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The primary endpoint of progression-free\nsurvival (PFS), as assessed by a blinded independent review committee (IRC)\nusing the updated National Cancer Institute-sponsored Working Group (NCI-WG)\nguidelines (2008), was prolonged in the ofatumumab plus\nfludarabine-cyclophosphamide (OFA+FC) arm compared to the\nfludarabine-cyclophosphamide (FC) arm (28.9\u00a0months versus 18.8\u00a0months;\nHR: 0.67; 95% CI: 0.51\u20110.88, p=0.0032) resulting in a 10-month\nimprovement in median PFS (see Figure\u00a02). PFS based on local\n(investigator) assessment was consistent with the primary endpoint and resulted\nin a ~11-month improvement in median PFS (OFA+FC 27.2\u00a0months versus\n16.8\u00a0months for FC; HR=0.66 (95% CI: 0.51, 0.85, p=0.0009).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"left\" class=\"MsoHeading7\" style=\"text-align:left;line-height:normal\"><b><span style=\"font-style:normal\">Figure\u00a02\u00a0\u00a0\u00a0\u00a0\u00a0 Kaplan-Meier estimates of PFS in\nrelapsed CLL</span></b></p>\n<p align=\"left\" class=\"MsoHeading7\" style=\"text-align:left;line-height:normal\"><span style=\"position:absolute;z-index:-1895825920;margin-left:-20px;margin-top:16px;\nwidth:605px;height:327px\"><img height=\"327\" src=\"Arzerra%20II-50%20&amp;%20II-51%20-%20PI%20-%20EN%20-%20clea_files/image003.jpg\" width=\"605\"/></span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">The overall response rate (ORR) was also assessed by\nan IRC using the 2008 NCI-WG guidelines. The ORR was higher for OFA+FC versus\nFC (84% versus 68%, p=0.0003). Median time to next therapy was longer for the\nOFA+FC arm versus FC (48.1\u00a0months versus 40.1\u00a0months; HR: 0.73; 95%\nCI: 0.51\u20111.05). Median time to progression was longer for the OFA+FC arm\nversus FC (42.1\u00a0months versus 26.8\u00a0months; HR: 0.63; 95% CI: 0.45\u20110.87).</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">With a median\nfollow-up of approximately 34\u00a0months, 67\u00a0deaths (37%) in the OFA+FC\narm and 69\u00a0deaths (38%) in the FC arm were reported. The overall survival\nresults showed a HR=0.78 (56.4\u00a0months versus 45.8\u00a0months for the\nOFA+FC arm versus FC arm; 95% CI: 0.56\u20111.09; p=0.1410).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Refractory CLL</u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Arzerra was administered as monotherapy to\n223\u00a0patients with refractory CLL (study Hx-CD20-406). Patient median age\nwas 64\u00a0years (range: 41 to 87\u00a0years), and the majority were male\n(73%) and white (96%). Patients received a median of 5\u00a0prior therapies,\nincluding rituximab (57%). Of these 223\u00a0patients, 95\u00a0patients were\nrefractory to fludarabine and alemtuzumab therapy (defined as </span><span lang=\"EN-GB\">failure to achieve at least a partial response with fludarabine or\nalemtuzumab treatment or disease progression within 6\u00a0months of the last\ndose of fludarabine or alemtuzumab). </span>Baseline cytogenetic (FISH) data\nwere available for 209\u00a0patients. 36\u00a0patients had a normal karyotype\nand chromosomal aberrations were detected in 174\u00a0patients; there were\n47\u00a0patients with 17p deletion, 73\u00a0patients with 11q deletion,\n23\u00a0patients with trisomy 12q, and 31\u00a0patients with 13q deletion as\nthe sole aberration.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The ORR was 49% in patients refractory to\nfludarabine and alemtuzumab (see Table\u00a03 for a summary of the efficacy\ndata from the study). </span><span lang=\"EN-GB\">Patients who had prior rituximab\ntherapy, either as monotherapy or in combination with other medicinal products,\nresponded to treatment with Arzerra at a similar rate to those who had not had\nprior rituximab therapy.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table\u00a03\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Summary\nof response to Arzerra in patients with refractory CLL</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:100.0%;border-collapse:collapse;border:none\" width=\"100%\">\n<tr>\n<td style=\"width:57.06%;border:solid windowtext 1.0pt;padding:\n  0in 5.4pt 0in 5.4pt\" width=\"57%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(Primary) endpoint<sup>1</sup></span></p>\n</td>\n<td style=\"width:42.94%;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Patients refractory to fludarabine and alemtuzumab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">n=95</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Overall\n  response rate</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">Responders, n (%)</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">47 (49)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">95.3% CI (%)</span></p>\n</td>\n<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">39, 60</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Response\n  rate in patients with prior rituximab therapy</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">Responders, n (%)</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25/56 (45)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI (%)</span></p>\n</td>\n<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31, 59</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Response\n  rate in patients with chromosomal abnormality</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:7.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">17p deletion</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">Responders, n (%)</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">10/27 (37)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI (%)</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">19, 58</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:7.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">11q deletion</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">Responders, n (%)</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">15/32 (47)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI (%)</span></p>\n</td>\n<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">29, 65</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median\n  overall survival</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">Months</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">13.9</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI</span></p>\n</td>\n<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">9.9, 18.6</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Progression-free\n  survival</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">Months</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">4.6</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI</span></p>\n</td>\n<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">3.9, 6.3</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median\n  duration of response</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">Months</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5.5</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI</span></p>\n</td>\n<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">3.7, 7.2</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median\n  time to next CLL therapy</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">Months</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">8.5</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI</span></p>\n</td>\n<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">7.2, 9.9</span></p>\n</td>\n</tr>\n<tr style=\"height:13.7pt\">\n<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><sup><span lang=\"EN-GB\">1 </span></sup><span lang=\"EN-GB\">The overall response was assessed by an </span>Independent\n  Response Committee<span lang=\"EN-GB\"> using the 1996 NCI-WG guidelines for CLL.</span></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Improvements\nalso were demonstrated in components of the NCI-WG response criteria. These included\nimprovements associated with constitutional symptoms, lymphadenopathy,\norganomegaly, or cytopenias (see Table\u00a04).</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-56.7pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">Table\u00a04\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Summary of clinical improvement\nwith a minimum duration of 2\u00a0months in refractory patients with\nabnormalities at baseline</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:100.0%;border-collapse:collapse;border:none\" width=\"100%\">\n<tr>\n<td rowspan=\"2\" style=\"width:47.72%;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Efficacy\n  endpoint or haematological parameter<sup>a</sup></span></p>\n</td>\n<td style=\"width:52.28%;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Patients with benefit/patients with abnormality at\n  baseline (%)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Patients refractory to fludarabine and alemtuzumab</span></p>\n</td>\n</tr>\n<tr style=\"height:14.2pt\">\n<td style=\"width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.2pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lymphocyte\n  count</span></p>\n</td>\n<td style=\"width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.2pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:12.3pt\">\n<td style=\"width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:12.3pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u226550% decrease</span></p>\n</td>\n<td style=\"width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:12.3pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">49/71 (69)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Normalisation (\u22644x10<sup>9</sup>/l)</span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">36/71 (51)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Complete\n  resolution of constitutional symptoms<sup>b</sup></span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">21/47 (45) </span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lymphadenopathy<sup>c</sup></span></p>\n</td>\n<td style=\"width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b3</span><span lang=\"EN-GB\">50%\n  improvement</span></p>\n</td>\n<td style=\"width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">51/88 (58)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Complete resolution</span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">17/88 (19)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Splenomegaly</span></p>\n</td>\n<td style=\"width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b3</span><span lang=\"EN-GB\">50%\n  improvement</span></p>\n</td>\n<td style=\"width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">27/47 (57)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Complete resolution </span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">23/47 (49)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hepatomegaly</span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b3</span><span lang=\"EN-GB\">50%\n  improvement</span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">14/24 (58)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Complete resolution </span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">11/24 (46)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Haemoglobin\n  &lt;11\u00a0g/dl at baseline to &gt;11\u00a0g/dl post baseline</span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">12/49 (24)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Platelet\n  counts \u2264100x10</span><sup><span lang=\"EN-GB\">9</span></sup><span lang=\"EN-GB\">/l at baseline to &gt;50% increase or &gt;100x10</span><sup><span lang=\"EN-GB\">9</span></sup><span lang=\"EN-GB\">/l post baseline</span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">19/50 (38)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Neutrophils\n  &lt;1x10</span><sup><span lang=\"EN-GB\">9</span></sup><span lang=\"EN-GB\">/l at\n  baseline to &gt;1.5x10</span><sup><span lang=\"EN-GB\">9</span></sup><span lang=\"EN-GB\">/l</span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">1/17 (6)</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Excludes\n  patients\u2019 visits from date of first transfusion, treatment with\n  erythropoietin, or treatment with growth factors. For patients with missing\n  baseline data, latest screening/unscheduled data was carried forward to\n  baseline.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Complete\n  resolution of constitutional symptoms (fever, night sweats, fatigue, weight\n  loss) defined as the presence of any symptoms at baseline, followed by no\n  symptoms present.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Lymphadenopathy\n  measured by sum of the products of greatest diameters (SPD) as assessed by\n  physical examination.</span></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Arzerra was also given to a group of patients (n=112) with\nbulky lymphadenopathy (defined as at least one lymph node &gt;5\u00a0cm) who\nwere also refractory to fludarabine. The ORR in this group was 43% (95.3% CI:\n33, 53). The median progression-free survival was 5.5\u00a0months (95% CI: 4.6,\n6.4) and the median overall survival was 17.4\u00a0months (95% CI: 15.0, 24.0).\nThe response rate in patients with prior rituximab therapy was 38% (95% CI: 23,\n61). These patients also experienced comparable clinical improvement, in terms\nof the efficacy endpoints and haematological parameters detailed above, to\npatients refractory to both fludarabine and alemtuzumab.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Additionally a group of patients (n=16) who were\nintolerant/ineligible for fludarabine treatment and/or intolerant to\nalemtuzumab treatment were treated with Arzerra. The overall response rate in\nthis group was 63% (95.3% CI: 35, 85).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">An open-label,\ntwo arm, randomised study (OMB114242) was conducted in patients with bulky\nfludarabine refractory CLL who had failed at least 2\u00a0prior therapies\n(n=122) comparing Arzerra monotherapy (n=79) to physicians\u2019 choice (PC) of\ntherapy (n=43). There was no statistically significant difference in the\nprimary endpoint of IRC assessed PFS (5.4 vs. 3.6\u00a0months, HR=0.79,\np=0.27). The PFS in the monotherapy Arzerra arm was comparable to the results\nseen with Arzerra monotherapy in study Hx-CD20-406.</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">A dose-ranging study (</span>Hx-CD20-402) <span lang=\"EN-GB\">was conducted in 33\u00a0patients with relapsed or refractory CLL.\nPatient median age was 61\u00a0years (range: 27 to 82\u00a0years), the majority\nwere male (58%), and all were white. </span>Treatment with Arzerra (w<span lang=\"EN-GB\">hen given as 4\u00a0once-weekly infusions)</span>, led to a 50%\nobjective response rate in the highest dose group (1st dose: 500\u00a0mg; 2nd,\n3rd and 4th dose: 2,000\u00a0mg) and included 12\u00a0partial remissions and\none nodular partial remission. For the highest dose group, the median time to\nprogression was 15.6\u00a0weeks (95% CI: 15,22.6) in the full analysis\npopulation, and 23\u00a0weeks (CI: 20,31) in responders. The duration of\nresponse was 16\u00a0weeks (CI: 13, 19) and the time to next CLL\ntherapy was 52.4\u00a0weeks (CI: 36.9 \u2013 non-estimable).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Paediatric population</u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\">The European Medicines Agency has waived the obligation to\nsubmit the results of studies with Arzerra in all subsets of the paediatric\npopulation in chronic lymphocytic leukaemia (see section\u00a04.2 for\ninformation on paediatric use).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic properties</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Overall, the pharmacokinetics of ofatumumab\nwere consistent across the indications, whether given as a single agent or in\ncombination with fludarabine and cyclophosphamide or chlorambucil. Ofatumumab\nhad non-linear pharmacokinetics related to its decreasing clearance over time.</span></p>\n<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"layout-grid-mode:\nline\">Absorption</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">Arzerra is administered by intravenous infusion; therefore,\nabsorption is not applicable.</p>\n<p class=\"MsoNormal\"><u><span style=\"layout-grid-mode:line\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"layout-grid-mode:\nline\">Distribution</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">Ofatumumab has a small volume of distribution, with mean Vss\nvalues ranging from 1.7 to 8.1\u00a0l across studies, dose levels, and infusion\nnumber.</p>\n<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"layout-grid-mode:\nline\">Biotransformation</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">Ofatumumab is a protein for which the expected metabolic\npathway is degradation to small peptides and individual amino acids by\nubiquitous proteolytic enzymes. Classical biotransformation studies have not\nbeen performed.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"layout-grid-mode:\nline\">Elimination</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">Ofatumumab is eliminated in two ways: a target-independent\nroute like other IgG molecules and a target-mediated route which is related to\nbinding to B-cells. There was a rapid and sustained depletion of CD20<sup>+</sup>\nB-cells after the first ofatumumab infusion, leaving a reduced number of CD20<sup>+</sup>\ncells available for the antibody to bind at subsequent infusions. As a result,\nofatumumab clearance values were lower and t<sub>\u00bd</sub> values were\nsignificantly larger after later infusions than after the initial infusion;\nduring repeated weekly infusions, ofatumumab AUC and C<sub>max</sub> values\nincreased more than the expected accumulation based on first infusion data.</p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">The main pharmacokinetic parameters of ofatumumab as a\nsingle agent or in combination are summarised in Table\u00a05.</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>\n<h6 style=\"line-height:normal\"><b><span lang=\"EN-GB\" style=\"font-style:normal\">Table\u00a05\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Ofatumumab\npharmacokinetic parameters (geometric mean)</span></b></h6>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:100.0%;border-collapse:collapse;border:none\" width=\"100%\">\n<thead>\n<tr>\n<td style=\"width:26.1%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"26%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Population\n   (treatment)</span></p>\n</td>\n<td style=\"width:14.94%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Dosing regimen </span></p>\n</td>\n<td style=\"width:11.8%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle<sup>(1)</sup></span></p>\n</td>\n<td style=\"width:12.06%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>C<sub>max</sub>\n   (\u00b5g/ml)</span></p>\n</td>\n<td style=\"width:14.22%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>AUC (\u00b5g.h/ml)</span></p>\n</td>\n<td style=\"width:10.58%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CL (ml/h)</span></p>\n</td>\n<td style=\"width:10.28%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>t<sub>\u00bd</sub>\n   (days)</span></p>\n</td>\n</tr>\n</thead>\n<tr>\n<td rowspan=\"2\" style=\"width:26.1%;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"26%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Refractory CLL</span></p>\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(ofatumumab)</span></p>\n</td>\n<td style=\"width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1<sup>st</sup>\n  infusion (300\u00a0mg) </span></p>\n</td>\n<td style=\"width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a01</span></p>\n</td>\n<td style=\"width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>61.4</span></p>\n</td>\n<td style=\"width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>\n<td style=\"width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>\n<td style=\"width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>2000\u00a0mg:\n  8\u00a0weekly infusions followed by 4\u00a0monthly infusions</span></p>\n</td>\n<td style=\"width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12<sup>th</sup>\n  dose</span></p>\n</td>\n<td style=\"width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>827</span></p>\n</td>\n<td style=\"width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>166000</span></p>\n</td>\n<td style=\"width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12.1</span></p>\n</td>\n<td style=\"width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.5</span></p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\" style=\"width:26.1%;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"26%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Previously\n  untreated patients</span></p>\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(ofatumumab +\n  chlorambucil)</span></p>\n</td>\n<td style=\"width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1<sup>st</sup>\n  infusion (300\u00a0mg)</span></p>\n</td>\n<td style=\"width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a01</span></p>\n</td>\n<td style=\"width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>51.8</span></p>\n</td>\n<td style=\"width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>2620</span></p>\n</td>\n<td style=\"width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>\n<td style=\"width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1000\u00a0mg\n  monthly infusions</span></p>\n</td>\n<td style=\"width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a04</span></p>\n</td>\n<td style=\"width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>285</span></p>\n</td>\n<td style=\"width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>65100</span></p>\n</td>\n<td style=\"width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>15.4 </span></p>\n</td>\n<td style=\"width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>18.5</span></p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\" style=\"width:26.1%;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"26%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Relapsed CLL</span></p>\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(ofatumumab +\n  FC)</span></p>\n</td>\n<td style=\"width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1<sup>st</sup>\n  infusion (300\u00a0mg)</span></p>\n</td>\n<td style=\"width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a01</span></p>\n</td>\n<td style=\"width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>61.4</span></p>\n</td>\n<td style=\"width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>3560</span></p>\n</td>\n<td style=\"width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>\n<td style=\"width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1000\u00a0mg on\n  the 8<sup>th</sup> day of cycle\u00a01 followed by 1000\u00a0mg monthly infusions</span></p>\n</td>\n<td style=\"width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a04</span></p>\n</td>\n<td style=\"width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>313</span></p>\n</td>\n<td style=\"width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>89100</span></p>\n</td>\n<td style=\"width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.2</span></p>\n</td>\n<td style=\"width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>19.9</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"7\" style=\"width:100.0%;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"100%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(<sup>1</sup>) Cycle\n  for which the pharmacokinetic parameters are presented in this table.</span></p>\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>C<sub>max</sub>:\n  maximum ofatumumab concentration at the end of infusion, AUC: exposure to\n  ofatumumab over a dosing period, CL: ofatumumab clearance after multiple\n  doses, T<sub>\u00bd</sub>: terminal half-life</span></p>\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Numbers rounded\n  to three significant digits</span></p>\n</td>\n</tr>\n</table>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Special populations</u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u>Elderly (\u226565\u00a0years\nof age)</u></i></p>\n<p class=\"MsoNormal\">Age was not found to be a significant factor for ofatumumab\npharmacokinetics in a cross-study population pharmacokinetic analysis of\npatients ranging in age from 21 to 87\u00a0years of age.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u>Paediatric population</u></i></p>\n<p class=\"MsoNormal\">No pharmacokinetic data are available in paediatric\npatients.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u>Gender</u></i></p>\n<p class=\"MsoNormal\">Gender had a modest effect (12%) on ofatumumab central\nvolume of distribution in a cross-study population analysis, with higher C<sub>max</sub>\nand AUC values observed in female patients (48% of the patients in this\nanalysis were male and 52% were female); these effects are not considered\nclinically relevant, and no dose adjustment is recommended.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u>Renal impairment</u></i></p>\n<p class=\"MsoNormal\">Baseline calculated creatinine clearance was not found to be\na significant factor on ofatumumab pharmacokinetics in a cross-study population\nanalysis in patients with calculated creatinine clearance values ranging from\n26 to 287\u00a0ml/min. No dose adjustment is recommended for mild to moderate\nrenal impairment (creatinine clearance &gt;30\u00a0ml/min). There are limited\npharmacokinetic data in patients with severe renal impairment (creatinine\nclearance &lt;30\u00a0ml/min).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u>Hepatic impairment</u></i></p>\n<p class=\"MsoNormal\">No formal studies were conducted to examine the effect of\nhepatic impairment. IgG1 molecules such as ofatumumab are catabolised by\nubiquitous proteolytic enzymes, which are not restricted to hepatic tissue;\ntherefore, changes in hepatic function are unlikely to have any effect on the\nelimination of ofatumumab.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">5.3\u00a0\u00a0\u00a0\u00a0 Preclinical safety data</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Preclinical data reveal no special hazards\nfor humans.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Intravenous and subcutaneous administration\nto monkeys resulted in the expected depletion of peripheral and lymphoid tissue\nB-cell counts with no associated toxicological findings. As anticipated, a\nreduction in the IgG humoral immune response to keyhole limpet h<span style=\"color:black\">a</span>emocyanin was noted, but there were no effects on\ndelayed-type hypersensitivity responses. In a few animals, increased red cell\ndestruction occurred, presumably as a result of monkey anti-drug antibodies<span style=\"color:green\"> </span><span style=\"color:black\">coating the red cells.</span>\nA corresponding increase in reticulocyte counts seen in these monkeys was\nindicative of a regenerative response in the bone marrow.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Intravenous administration of ofatumumab to\npregnant cynomolgus monkeys at 100\u00a0mg/kg once weekly from days\u00a020 to\n50 of gestation did not elicit maternal or foetal toxicity or teratogenicity.\nAt the end of organogenesis (day\u00a048 of gestation), the ofatumumab exposure\n(AUC<sub>inf</sub>) corresponded to 0.46 to 3.6\u00a0times the human exposure\nafter the eighth infusion of the maximum recommended human dose (MRHD) of 2000\u00a0mg.\nAt day\u00a0100 of gestation, depletion of B-cells relating to the\npharmacological activity of ofatumumab were observed in foetal cord blood and\nfoetal splenic tissues. Spleen weights decreased by approximately 15% in the low-dose\ngroup and by approximately 30% in the high-dose group, compared with control\nvalues.</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">Pre- and post-natal\ndevelopment studies have not been performed. Post-natal recovery has therefore\nnot been demonstrated.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">As ofatumumab is a monoclonal antibody,\ngenotoxicity and carcinogenicity studies have not been conducted with\nofatumumab.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL PARTICULARS</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.1\u00a0\u00a0\u00a0\u00a0 List of excipients</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT\" style=\"color:black\">Arginine</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT\" style=\"color:black\">Sodium acetate (E262)</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\" style=\"color:black\">Sodium chloride</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT\" style=\"color:black\">Polysorbate 80 (E433)</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT\" style=\"color:black\">Edetate disodium (E386)</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT\" style=\"color:black\">Hydrochloric acid (E507)\n(for pH-adjustment)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Water for injections</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">This medicinal product\nmust not be mixed with other medicinal products except those mentioned in\nsection\u00a06.6.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.3\u00a0\u00a0\u00a0\u00a0 Shelf life</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Vial</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">3\u00a0years.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Diluted\ninfusion solution</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Chemical and physical\nin-use stability has been demonstrated for 48\u00a0hours at ambient conditions\n(less than 25\u00b0C).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">From a microbiological point of view, the\nmedicinal product should be used immediately. If not used immediately, in-use\nstorage times and conditions prior to use are the responsibility of the user\nand would normally not be longer than 24\u00a0hours at 2-8\u00a0\u00baC, unless\nreconstitution/dilution has taken place in controlled and validated aseptic\nconditions.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.4\u00a0\u00a0\u00a0\u00a0 Special precautions for storage</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;background:white\"><span class=\"CSIchar\"><span lang=\"EN-GB\" style=\"border:none\">\u00a0</span></span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Store and transport\nrefrigerated (2</span><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b0</span><span lang=\"EN-GB\" style=\"color:black\">C \u2013 8</span><span lang=\"EN-GB\" style=\"font-family:\nSymbol;color:black\">\u00b0</span><span lang=\"EN-GB\" style=\"color:black\">C).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not freeze.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Keep the vial in the\nouter carton in order to protect from light.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">For storage conditions after dilution of\nthe medicinal product, see section\u00a06.3.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.5\u00a0\u00a0\u00a0\u00a0 Nature and contents of container</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:black\">Arzerra 100\u00a0mg concentrate for solution for infusion</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Clear Type I glass vial\nwith a bromobutyl rubber stopper and aluminium over-seal, containing 5\u00a0ml\nof concentrate for solution for infusion.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Arzerra is available in\npacks of 3\u00a0vials.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:black\">Arzerra 1000\u00a0mg concentrate for solution for infusion</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Clear Type I glass vial\nwith a bromobutyl rubber stopper and aluminium over\u2011seal, containing\n50\u00a0ml of concentrate for solution for infusion.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Arzerra is available in\npacks of 1\u00a0vial.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">6.6\u00a0\u00a0\u00a0\u00a0 </span></b><b><span lang=\"EN-GB\">Special\nprecautions for disposal and other handling</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Dilution</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Arzerra </span><span lang=\"EN-GB\">concentrate\nfor solution for infusion </span><span lang=\"EN-GB\">does not contain a\npreservative; therefore dilution should be carried out under aseptic\nconditions. The diluted solution for infusion must be used within 24\u00a0hours\nof preparation. Any unused solution remaining after this time should be\ndiscarded.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><u>Before\ndiluting Arzerra</u></i></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">Check the<i> </i><span lang=\"EN-GB\">Arzerra concentrate<i> </i>for particulate matter and discolouration\nprior to dilution. Ofatumumab should be a colourless to pale yellow solution.\nDo not use the Arzerra concentrate if there is discolouration.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Do not shake\nthe ofatumumab vial for this inspection.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><u>How\nto dilute the solution for infusion</u></i></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">The <span lang=\"EN-GB\">Arzerra</span>\nconcentrate must be diluted in <span lang=\"EN-GB\">sodium chloride 9\u00a0mg/ml\n(0.9%) solution for injection</span> prior to administration, using aseptic\ntechnique.</p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Arzerra 100\u00a0mg concentrate for solution for infusion</span></i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">300\u00a0mg dose: Use 3\u00a0vials (15\u00a0ml total, 5\u00a0ml per\nvial)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif;color:black'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Withdraw and discard 15\u00a0ml from a\n1000\u00a0ml bag of sodium chloride 9\u00a0mg/ml (0.9%) solution for injection;</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif;color:black'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Withdraw 5\u00a0ml of ofatumumab from each of 3</span><span lang=\"EN-GB\">\u00a0</span><span lang=\"EN-GB\">vials and inject into the 1000\u00a0ml\nbag;</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif;color:black'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Do not shake; mix diluted solution by gentle\ninversion.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Arzerra 1000\u00a0mg concentrate for solution for infusion</span></i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">1000\u00a0mg dose: Use 1\u00a0vial (50\u00a0ml total, 50\u00a0ml per\nvial)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif;color:black'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Withdraw and discard 50\u00a0ml from a\n1000\u00a0ml bag of sodium chloride 9\u00a0mg/ml (0.9%) solution for injection;</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif;color:black'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Withdraw 50\u00a0ml of ofatumumab from the vial\nand inject into the 1000\u00a0ml bag;</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif;color:black'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Do not shake; mix diluted solution by gentle\ninversion.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">2000\u00a0mg dose: Use 2\u00a0vials (100\u00a0ml total, 50\u00a0ml\nper vial)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif;color:black'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Withdraw and discard 100\u00a0ml from a\n1000\u00a0ml bag of sodium chloride 9\u00a0mg/ml (0.9%) solution for injection;</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif;color:black'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Withdraw 50\u00a0ml of ofatumumab from each of\n2\u00a0vials and inject into the 1000\u00a0ml bag;</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif;color:black'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Do not shake; mix diluted solution by gentle\ninversion.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><u>How\nto administer the diluted solution</u></i></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Arzerra must\nnot be administered as an intravenous push or bolus. Administer using an\nintravenous infusion pump</span><span lang=\"EN-GB\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The infusion must be completed within\n24\u00a0hours after preparation. Discard any unused solution after this time.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Arzerra must not be mixed with, or\nadministered as an infusion with other medicinal products or intravenous\nsolutions. Flush line before and after ofatumumab administration with sodium\nchloride 9\u00a0mg/ml (0.9%) solution for injection to avoid this.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Previously\nuntreated CLL and relapsed CLL</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">For the first infusion, administer over\n4.5\u00a0hours </span><span lang=\"EN-GB\">(</span><span lang=\"EN-GB\">see\nsection\u00a04.2</span><i><span lang=\"EN-GB\">)</span></i><span lang=\"EN-GB\">, </span><span lang=\"EN-GB\">through a peripheral line or indwelling catheter, according to the\nschedule below:</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">If the first infusion was completed without a severe adverse\nreaction, the remaining infusions of 1000\u00a0mg should be administered over\n4\u00a0hours (see section\u00a04.2</span><i><span lang=\"EN-GB\">)</span></i><span lang=\"EN-GB\">, through a peripheral line or indwelling catheter, </span><span lang=\"EN-GB\">according to the schedule below.</span><span lang=\"EN-GB\"> If any\ninfusion\u2011related adverse reactions are observed, infusion should be\ninterrupted and restarted when the patient\u2019s condition is stable (see </span><span lang=\"EN-GB\">section\u00a04.2 for further information).</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><u><span lang=\"EN-GB\">Infusion schedule</span></u></i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:100.0%;border-collapse:collapse;border:none\" width=\"100%\">\n<tr>\n<td rowspan=\"2\" style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Time after start of infusion (minutes)</span></p>\n</td>\n<td style=\"width:141.15pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion\u00a01</span></p>\n</td>\n<td style=\"width:146.55pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Subsequent infusions*</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:141.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0\u201130</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">12</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31\u201160</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">61\u201190</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">91\u2011120</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">121\u2011150</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">151\u2011180</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">300</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">180+</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\" style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">*If the\n  previous infusion was completed without severe infusion\u2011related ADRs.\n  If any infusion\u2011related ADRs are observed, infusion should be\n  interrupted and restarted when the patient\u2019s condition is stable (see </span><span lang=\"EN-GB\">section\u00a04.2 of the SmPC</span><span lang=\"EN-GB\">).</span></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Refractory CLL</u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">For the first and second infusion,\nadminister over 6.5\u00a0hours (see section\u00a04.2), through a peripheral\nline or indwelling catheter, according to the schedule below:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">If the second infusion was completed\nwithout a severe adverse reaction, the remaining infusions (3\u201112) should\nbe administered over 4\u00a0hours (see section\u00a04.2), through a peripheral\nline or indwelling catheter, according to the schedule below.</span><span lang=\"EN-GB\"> If any infusion\u2011related adverse reactions are observed,\ninfusion should be interrupted and restarted when the patient\u2019s condition is\nstable (see </span><span lang=\"EN-GB\">section\u00a04.2 for further information).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Infusion\nschedule</span></u></i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td rowspan=\"2\" style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Time after start of infusion (minutes)</span></p>\n</td>\n<td style=\"width:134.7pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusions\u00a01 and 2</span></p>\n</td>\n<td style=\"width:134.6pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusions\u00a03* to 12</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:134.7pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0\u201130</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">12</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31\u2011 60</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">61\u201190</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">91\u2011120</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">121+</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\" style=\"width:423.55pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"565\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">*If the\n  second infusion is completed without severe infusion\u2011related ADRs. If\n  any infusion\u2011related ADRs are observed, infusion should be interrupted\n  and restarted when the patient\u2019s condition is stable (see section\u00a04.2).</span></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">If any adverse reactions are observed,\ninfusion rates should be reduced (see section\u00a04.2).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Disposal</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Any unused medicinal product or waste\nmaterial should be disposed of in accordance with local requirements.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION HOLDER</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Novartis\nEuropharm Limited</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Frimley\nBusiness Park</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Camberley\nGU16 7SR</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">United Kingdom</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION NUMBER(S)</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:black\">Arzerra 100\u00a0mg concentrate for solution for infusion</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU/1/10/625/001</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:black\">Arzerra 1000\u00a0mg concentrate for solution for infusion</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">EU/1/10/625/003</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF FIRST AUTHORISATION/RENEWAL\nOF THE AUTHORISATION</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Date of\nfirst authorisation: </span><span lang=\"EN-GB\">19 April 2010</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Date of latest renewal: 17 February 2015</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 DATE OF REVISION OF THE TEXT</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Detailed\ninformation on this medicinal product </span><span lang=\"EN-GB\">is available on\nthe website of the European Medicines Agency (EMA) </span><span lang=\"EN-GB\"><a href=\"http://www.ema.europa.eu\"><span style=\"color:windowtext;text-decoration:\nnone\">http://www.ema.europa.eu</span></a></span><span lang=\"EN-GB\">/.</span></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">ANNEX\nII</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt\"><b><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND\nMANUFACTURERS RESPONSIBLE FOR BATCH RELEASE</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt\"><b><span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoBlockText\"><span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND\nREQUIREMENTS OF THE MARKETING AUTHORISATION</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoBlockText\"><span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS\nWITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<b><span lang=\"X-NONE\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>\n<p class=\"TitleB\"><span lang=\"X-NONE\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURERS OF THE BIOLOGICAL\nACTIVE SUBSTANCE AND MANUFACTURER</span>S<span lang=\"X-NONE\"> RESPONSIBLE FOR\nBATCH RELEASE</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:70.8pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Name and address of the manufacturers of\nthe biological active substance</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-right:70.8pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">Lonza Biologics plc</p>\n<p class=\"MsoNormal\">228 Bath Road</p>\n<p class=\"MsoNormal\">Slough, Berks SL1 4DX</p>\n<p class=\"MsoNormal\">United Kingdom</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Lonza Biologics, Inc.</p>\n<p class=\"MsoNormal\">101 International Drive</p>\n<p class=\"MsoNormal\">Portsmouth, NH 03801-2815</p>\n<p class=\"MsoNormal\">United States</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Name and address of the manufacturers\nresponsible for batch release</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">Glaxo Operations UK Ltd.</p>\n<p class=\"MsoNormal\">Harmire Road</p>\n<p class=\"MsoNormal\">Barnard Castle</p>\n<p class=\"MsoNormal\">Durham, DL12 8DT</p>\n<p class=\"MsoNormal\">United Kingdom</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Novartis Pharmaceuticals UK Limited</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Frimley Business Park</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Frimley</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Camberley, Surrey GU16 7SR</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">United Kingdom</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"Default\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Novartis Pharma GmbH</span></p>\n<p class=\"Default\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Roonstrasse 25</span></p>\n<p class=\"Default\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">90429 Nuremberg</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Germany</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">The printed package leaflet of the medicinal product must\nstate the name and address of the manufacturer responsible for the release of\nthe concerned batch.</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"TitleB\"><span lang=\"X-NONE\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING\nSUPPLY AND USE</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Medicinal product subject to restricted\nmedical prescription (see Annex I: Summary of Product Characteristics,\nsection\u00a04.2).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after:\navoid\"><span class=\"TitleBChar\"><span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND\nREQUIREMENTS OF THE MARKETING</span></span><b><span lang=\"EN-GB\"> AUTHORISATION</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Periodic Safety Update Reports</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The requirements for submission of periodic\nsafety update reports for this medicinal product are set out in the list of\nUnion reference dates (EURD list) provided for under Article 107c(7) of\nDirective 2001/83</span><span lang=\"EN-GB\">/EC</span><span lang=\"EN-GB\"> and any\nsubsequent updates published on the European medicines web-portal.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after:\navoid\"><span class=\"TitleBChar\"><span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR\nRESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Risk Management Plan (RMP)</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The MAH shall perform the required\npharmacovigilance activities and interventions detailed in the agreed RMP\npresented in Module 1.8.2 of the Marketing Authorisation and any agreed\nsubsequent updates of the RMP.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">An updated\nRMP should be submitted:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">At the request of the European Medicines Agency;</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Whenever the risk management system is modified,\nespecially as the result of new information being received that may lead to a\nsignificant change to the benefit/risk profile or as the result of an important\n(pharmacovigilance or risk minimisation) milestone being reached.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.4pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-right:28.3pt;text-align:center\"><b><span lang=\"EN-GB\">ANNEX III</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">LABELLING\n AND PACKAGE LEAFLET</span></b></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"TitleA\"><span lang=\"X-NONE\">A. LABELLING</span></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\" style=\"background:white\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">PARTICULARS\nTO APPEAR ON THE OUTER PACKAGING</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">CARTON</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Arzerra </span><span lang=\"EN-GB\" style=\"color:black\">100\u00a0mg concentrate for solution for\ninfusion</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">ofatumumab</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">One ml contains\n20\u00a0mg ofatumumab.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each vial contains\n100\u00a0mg ofatumumab in 5\u00a0ml.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST OF EXCIPIENTS</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT\" style=\"color:black\">Also contains: arginine,\nsodium acetate (E262), </span><span lang=\"EN-GB\" style=\"color:black\">sodium\nchloride</span><span lang=\"PT\" style=\"color:black\">, polysorbate 80 (E433),\nedetate disodium (E386), hydrochloric acid (E507), </span><span lang=\"EN-GB\" style=\"color:black\">water for injections. See leaflet for further information.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM\n AND CONTENTS</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">Concentrate\nfor solution for infusion.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"SV\">100\u00a0mg/5\u00a0ml</span></p>\n<p class=\"MsoNormal\"><span lang=\"SV\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"SV\">3\u00a0vials</span></p>\n<p class=\"MsoNormal\"><span lang=\"SV\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"SV\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Read the package leaflet before use.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Intravenous use</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL WARNING THAT THE MEDICINAL\nPRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep out of the sight and reach of\nchildren.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE\nCONDITIONS</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Store and\ntransport refrigerated.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Do not\nfreeze.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep the vial in the outer carton in order\nto protect from light.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS FOR DISPOSAL OF\nUNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL\nPRODUCTS, IF APPROPRIATE</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0 NAME\n AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Novartis Europharm Limited</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Frimley Business Park</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Camberley GU16 7SR</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">United Kingdom</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span></b></p>\n</div>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU/1/10/625/001</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Lot</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION\nIN BRAILLE</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black;background:#CCCCCC\">Justification\nfor not including Braille accepted</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">2D\nbarcode carrying the unique identifier included.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">PC:</span></p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">SN:</span></p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><span lang=\"EN-GB\">NN:</span></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><a name=\"_Hlk258415279\"><b><span lang=\"EN-GB\">MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE </span></b></a><b><span lang=\"EN-GB\">PAC</span></b><b><span lang=\"EN-GB\">KAGING UNITS</span></b></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">VIAL\nLABEL</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"IT\">Arzerra<i> </i></span><span lang=\"IT\" style=\"color:black\">100\u00a0mg sterile concentrate</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">ofatumumab</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">IV</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nOF ADMINISTRATION</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">Lot</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS\nBY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">100\u00a0mg/5\u00a0ml</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\" style=\"background:white\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">PARTICULARS\nTO APPEAR ON THE OUTER PACKAGING</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">CARTON</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Arzerra </span><span lang=\"EN-GB\" style=\"color:black\">1000\u00a0mg concentrate for solution for\ninfusion</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">ofatumumab</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">One ml contains\n20\u00a0mg ofatumumab.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each vial contains\n1000\u00a0mg ofatumumab in 50\u00a0ml.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST OF EXCIPIENTS</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT\" style=\"color:black\">Also contains: arginine,\nsodium acetate (E262), </span><span lang=\"EN-GB\" style=\"color:black\">sodium chloride</span><span lang=\"PT\" style=\"color:black\">, polysorbate 80 (E433), edetate disodium (E386),\nhydrochloric acid (E507), </span><span lang=\"EN-GB\" style=\"color:black\">water for\ninjections. See leaflet for further information.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM\n AND CONTENTS</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">Concentrate\nfor solution for infusion.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"SV\">1000\u00a0mg/50\u00a0ml</span></p>\n<p class=\"MsoNormal\"><span lang=\"SV\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"SV\">1\u00a0vial</span></p>\n<p class=\"MsoNormal\"><span lang=\"SV\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"SV\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Read the package leaflet before use.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Intravenous use</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL WARNING THAT THE MEDICINAL\nPRODUCT MUST BE STORED OUT OF THE <span style=\"text-transform:uppercase\">sight\nand</span> REACH OF CHILDREN</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep out of the sight and reach of\nchildren.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER SPECIAL WARNING(S), IF\nNECESSARY</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE\nCONDITIONS</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Store and\ntransport refrigerated.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Do not\nfreeze.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep the vial in the outer carton in order\nto protect from light.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS FOR DISPOSAL OF\nUNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL\nPRODUCTS, IF APPROPRIATE</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0 NAME\n AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Novartis Europharm Limited</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Frimley Business Park</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Camberley GU16 7SR</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">United Kingdom</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span></b></p>\n</div>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">EU/<span lang=\"EN-GB\">1/10/625/003</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Lot</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION\nIN BRAILLE</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black;background:#CCCCCC\">Justification\nfor not including Braille accepted</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">2D\nbarcode carrying the unique identifier included.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">PC:</span></p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">SN:</span></p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><span lang=\"EN-GB\">NN:</span></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black;background:#CCCCCC'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">MINIMUM\nPARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">VIAL\nLABEL</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"IT\">Arzerra<i> </i></span><span lang=\"IT\" style=\"color:black\">1000\u00a0mg sterile concentrate</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">ofatumumab</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">IV</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nOF ADMINISTRATION</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">Lot</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS\nBY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">1000\u00a0mg/50\u00a0ml</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<b><u><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></u></b>\n<p class=\"MsoNormal\" style=\"background:white\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"TitleA\"><span lang=\"X-NONE\">B. PACKAGE LEAFLET</span></p>\n<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><a name=\"OLE_LINK1\"><b><span lang=\"EN-GB\">Package leaflet: Information for the user</span></b></a></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><b><span lang=\"EN-GB\">Arzerra </span></b><b><span lang=\"EN-GB\" style=\"color:black\">100\u00a0mg\nconcentrate for solution for infusion</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><b><span lang=\"EN-GB\">Arzerra </span></b><b><span lang=\"EN-GB\" style=\"color:black\">1000\u00a0mg\nconcentrate for solution for infusion</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">ofatumumab</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Read all of this leaflet carefully\nbefore you are given this medicine because it contains important information\nfor you.</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Keep this leaflet. You may need to read it\nagain.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">If you have any further questions, ask your\ndoctor or nurse.</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">If you get any side effects, talk to your doctor\nor nurse. This includes any possible side effects not listed in this leaflet.\nSee section\u00a04.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"EN-GB\">What is in\nthis leaflet</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-right:-1.45pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-1.45pt\"><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Arzerra\nis and what it is used for</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-1.45pt\"><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nyou need to know before you are given Arzerra</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-1.45pt\"><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How Arzerra\nis given</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-1.45pt\"><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible\nside effects</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-1.45pt\"><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto store Arzerra</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-1.45pt\"><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span><span lang=\"EN-GB\">Contents of the pack and other</span><span lang=\"EN-GB\"> information</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Arzerra is and what it is used for</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Arzerra</span><span lang=\"EN-GB\"> contains ofatumumab</span><span lang=\"EN-GB\">, which belongs to a group of medicines called monoclonal antibodies.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Arzerra</span></b><b><span lang=\"EN-GB\">\nis used to treat chronic lymphocytic leukaemia</span></b><span lang=\"EN-GB\"> (CLL).\n CLL is a cancer of the blood which affects </span><span lang=\"EN-GB\">a type of\nwhite blood cell called lymphocytes. The lymphocytes multiply too quickly and\nlive too long, so there are too many of them circulating in your blood. The\ndisease can also affect other organs in your body. </span><span lang=\"EN-GB\">The\nantibody in Arzerra recognises a substance on the surface of lymphocytes and\ncauses the lymphocyte to die.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to know before you are given Arzerra</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">You must\nnot be given Arzerra:</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">if you are allergic (hypersensitive) to\nofatumumab or any of the other ingredients of this medicine (listed in section\u00a06).</span></p>\n<p class=\"MsoListParagraph\" style=\"margin-left:0in\"><span lang=\"EN-GB\" style=\"color:black\">Check with your doctor<b> </b></span><span lang=\"EN-GB\" style=\"color:black\">if you think this may apply to you.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Warnings\nand precautions</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Talk to your doctor or nurse before you are given Arzerra</span><span lang=\"EN-GB\" style=\"color:black\">:</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">if you have had <b>heart problems,</b></span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">if you have <b>lung disease,</b></span></p>\n<p class=\"MsoListParagraph\" style=\"margin-left:0in\"><span lang=\"EN-GB\" style=\"color:black\">Check with your doctor<b> </b>if you think any of these may\napply to you. You may need extra check-ups while you are being treated with\nArzerra.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;vertical-align:baseline\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoListParagraph\" style=\"margin-left:0in\"><span lang=\"EN-GB\">Your doctor\nmay test the amount of electrolytes, such as magnesium and potassium, in your\nblood<b><span style=\"color:#1F497D\"> </span></b>before and during your\ntreatment with Arzerra.<b> </b>Your doctor may treat you if any electrolyte\nimbalance is detected.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Vaccination\nand Arzerra</span></b></p>\n<p class=\"MsoNormal\">If you are having any vaccinations tell your doctor, or the\nperson giving you the vaccine, that you are being treated with Arzerra. <span lang=\"EN-GB\">Your response to the vaccine may be weakened</span> and you may not\nbe fully protected.</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Hepatitis\nB</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">You should be tested for hepatitis B (a\nliver disease) before starting Arzerra treatment. If you have had hepatitis B,\nArzerra could cause it to become active again. Your doctor may treat you with a\nsuitable anti-viral medicine to help prevent this.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you have or have had hepatitis B, </span><span lang=\"EN-GB\">tell your doctor before you are given Arzerra</span><span lang=\"EN-GB\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Infusion\nreactions</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Medicines of this type (monoclonal\nantibodies) can cause infusion reactions when they are injected into the body.\nYou will be given medicines such as anti-histamines, steroids or pain relievers\nto help reduce any reaction. See also section\u00a04, \u2018Possible side effects\u2019.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you think you have had such a reaction\nbefore, tell your doctor before you are given </span>Arzerra.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Progressive\nmultifocal leukoencephalopathy (PML)</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Progressive multifocal leukoencephalopathy\n(PML), a serious and life-threatening brain condition, has been reported with\nmedicines like Arzerra. </span><b><span lang=\"EN-GB\">Tell your doctor immediately</span></b><span lang=\"EN-GB\"> if you have memory loss, trouble thinking, difficulty with walking\nor loss of vision. If you had these symptoms prior to treatment with Arzerra, <b>tell\nyour doctor immediately</b> about any changes in these symptoms.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\navoid\"><b><span style=\"font-size:11.0pt\">Bowel obstruction</span></b></p>\n<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><b><span style=\"font-size:11.0pt\">Contact your doctor immediately</span></b><span style=\"font-size:11.0pt\"> if you experience constipation, a swollen abdomen or\nabdominal pain. These could be symptoms of a blockage in the bowel, especially\nduring the early stages of your treatment.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Children\nand adolescents</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">It is not known\nwhether Arzerra works in children and adolescents. Therefore Arzerra is not\nrecommended for use in children and adolescents.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Other\nmedicines and Arzerra</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Tell your doctor\nor pharmacist if you are using, have recently used or might use any other\nmedicines. This includes herbal medicines and other medicines you can obtain\nwithout a prescription.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Pregnancy,\nbreast-feeding and fertility</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Arzerra is not usually recommended for use during pregnancy.</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\" style=\"color:black\">Tell your doctor if you are\npregnant or breast-feeding, think you may be pregnant, or are planning to have\na baby. </span><span lang=\"EN-GB\">Your doctor will weigh up the benefit to you\nagainst the risk to your baby of taking Arzerra while you're pregnant.</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\" style=\"color:black\">Use a reliable method of\ncontraception </span><span lang=\"EN-GB\" style=\"color:black\">to avoid becoming<b> </b>pregnant\nwhile you are being treated with Arzerra, </span>and for 12\u00a0months after\nyour last dose of Arzerra. Ask your doctor for advice if you are planning to\nbecome pregnant after this period.</p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">If you do become pregnant during treatment with\nArzerra, tell your doctor.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">It is not known\nwhether the ingredients in Arzerra pass into human milk. Breast-feeding is not\nrecommended during treatment with Arzerra and for 12\u00a0months after the last\ndose.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Driving\nand using machines</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Arzerra is unlikely to affect your ability to drive or use\nmachines.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Arzerra\ncontains sodium</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Arzerra contains 34.8\u00a0mg sodium in\neach 300\u00a0mg dose, 116\u00a0mg sodium in each 1000\u00a0mg dose and\n232\u00a0mg sodium in each 2000\u00a0mg dose. You need to take this into\naccount if you are on a controlled sodium diet.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How Arzerra is given</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">If you have any\nquestions on the use of Arzerra, ask the doctor or nurse who is giving you the\ninfusion.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">The usual dose</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The usual dose of Arzerra for the first\ninfusion is 300\u00a0mg. This dose will be increased, usually to 1000\u00a0mg\nor 2000\u00a0mg, for the remaining infusions.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">How it is given</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Arzerra is\ngiven into a vein (intravenously) as an infusion (a drip) over several hours.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\">If you have\nnot been previously treated for CLL you will have a maximum of\n13\u00a0infusions.</span></b><span lang=\"EN-GB\"> You will be given an initial\ninfusion followed by a second infusion 7\u00a0days later. The remaining\ninfusions will then be given once a month for up to 11\u00a0months.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\">If you have\nbeen previously treated for CLL but the disease returns you will have a maximum\nof 7\u00a0infusions.</span></b><span lang=\"EN-GB\"> You will be given an initial\ninfusion followed by a second infusion 7\u00a0days later. The remaining\ninfusions will then be given once a month for up to 6\u00a0months.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\">If you have\nbeen previously treated for CLL </span></b><b><span lang=\"EN-GB\" style=\"color:black\">you will usually have a course of 12\u00a0infusions.</span></b><span lang=\"EN-GB\" style=\"color:black\"> You will be given an infusion once a week for\neight weeks. This is followed by a four- to five-week gap. The remaining\ninfusions will then be given once a month for four months.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Medicines\ngiven before each infusion</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Before each infusion of Arzerra, you will\nbe given <b>pre-medication</b> \u2011 medicines which help to reduce any\ninfusion reactions. These may include anti-histamines, steroids and pain relievers.\nYou will be checked closely and if you do have any reactions these will be\ntreated.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side effects</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Like all\nmedicines, this medicine can cause side effects, although not everybody gets\nthem.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Infusion-related\nreactions</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Medicines of this type (monoclonal\nantibodies) can cause infusion-related reactions, which are occasionally\nsevere, and can cause death. They are more likely during the first treatment.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Very\ncommon symptoms of an infusion-related reaction</span></b><span lang=\"EN-GB\">\n(may affect more than 1 in 10\u00a0people):</span></p>\n<p class=\"Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">feeling sick (nausea)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">high temperature</span></p>\n<p class=\"Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.8pt;line-height:normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">skin rash</span></p>\n<p class=\"Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.8pt;line-height:normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">breathlessness, cough</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">diarrhoea</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">lack of energy</span></p>\n<p class=\"Bullet\" style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;\nline-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"Bullet\" style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;\nline-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Common symptoms\nof an infusion-related reaction</span></b><span lang=\"EN-GB\"> (may affect up to 1\nin 10\u00a0people):</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">allergic reactions, sometimes severe where\nsymptoms include raised and itchy rash (hives), swelling of the face or the\nmouth (angioedema) causing difficulty breathing and collapse</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">difficulty in breathing, shortness of breath,\nchest tightness, cough</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">low blood pressure (can cause light-headedness\nwhen you stand up)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">flushing</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">excessive sweating</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">shaking or shivering</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">rapid heart beat</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">headache</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">back pain</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">high blood pressure</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">throat pain or irritation</span><a name=\"OLE_LINK2\"></a></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">blocked nose.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"Bullet\" style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;\nline-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Uncommon\nsymptoms of an infusion-related reaction</span></b><span lang=\"EN-GB\"> (may\naffect up to 1 in 100\u00a0people):</span></p>\n<p class=\"MsoCommentText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span style=\"font-size:11.0pt;font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"X-NONE\" style=\"font-size:11.0pt\">anaphylactic reaction\nincluding anaphylactic shock, where symptoms include breathlessness or\ndifficult</span><span style=\"font-size:11.0pt\">y</span><span lang=\"X-NONE\" style=\"font-size:11.0pt\"> breathing, wheezing or coughing, light-headedness,\ndizziness, changes in levels of consciousness, hypotension, with or without\nmild generali</span><span style=\"font-size:11.0pt\">s</span><span lang=\"X-NONE\" style=\"font-size:11.0pt\">ed itching, skin reddening, swelling</span><span style=\"font-size:11.0pt\"> of the face and/or throat</span><span lang=\"X-NONE\" style=\"font-size:11.0pt\">, blue discolouration of the lips, tongue or skin</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">fluid in the lungs (pulmonary oedema) causing\nbreathlessness</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;page-break-after:\navoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Symbol;\ncolor:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">slow heart beat</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;page-break-after:\navoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Symbol;\ncolor:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">blue discolouration of the lips and extremities\n(possible symptoms of hypoxia)</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><b><span lang=\"EN-GB\">Tell your doctor or a nurse immediately if you get\nany of these symptoms.</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Other\npossible side effects</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">Very common side effects</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">These may affect more than 1 in 10\u00a0people:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">frequent infections, fever, chills, sore throat\nor mouth ulcers due to infections</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">fever, coughing, difficulty breathing, wheezing,\npossible symptoms of </span><span lang=\"EN-GB\">infections of the lungs or airways\n(respiratory tract) including pneumonia</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">sore throat, feeling of pressure or pain in the\ncheeks and forehead</span><span lang=\"EN-GB\">, infections of the ear, nose or\nthroat.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Very common side effects that may show up in\nyour blood tests:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">low levels of white blood cells (neutropenia)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\" style=\"color:black\">low levels of red blood\ncells (anaemia).</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">Common side effects</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">These may affect up to 1 in 10\u00a0people:</span></p>\n<p class=\"Listlevel1\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span style=\"font-size:11.0pt;font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span style=\"font-size:11.0pt\">fever or, alternatively, a very\nlow body temperature, chest pain, shortness of breath or rapid breathing,\nshaking, chills, confusion, dizziness, decreased urination and rapid pulse,\n(possible symptoms of blood infection)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">difficulty and pain when passing urine,\nexaggerated sense of needing to urinate,</span><span lang=\"EN-GB\"> urinary tract\ninfections</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">shingles, cold sores </span><span lang=\"EN-GB\">(possible\nsymptoms of herpes viral infection that can potentially be severe)</span><span lang=\"EN-GB\">.</span></p>\n<p class=\"Bullet\" style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;\nline-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Common side effects that may show up in your\nblood tests:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">low levels of platelets in the blood (cells that\nhelp blood to clot).</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">Uncommon side effects</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">These may affect up to 1 in 100\u00a0people:</span></p>\n<p class=\"Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">blockage in the gut (intestine), which may feel\nlike stomach pain.</span></p>\n<p class=\"Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\nmargin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\" style=\"color:black\">If you have persistent\nstomach pain, <b>see your doctor as soon as possible.</b></span></p>\n<p class=\"Listlevel1\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span style=\"font-size:11.0pt;font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span style=\"font-size:11.0pt\">yellow skin and eyes, nausea, loss\nof appetite, dark urine (possible symptoms of an infection or reactivation of\nhepatitis B virus)</span></p>\n<p class=\"Listlevel1\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span style=\"font-size:11.0pt;font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span style=\"font-size:11.0pt\">memory loss, trouble with\nthinking, and difficulty with walking or loss of vision (possible symptoms of\nprogressive multifocal leukoencephalopathy)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Symbol;\ncolor:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\" style=\"color:black\">increase in potassium,\nphosphate and uric acid in the blood that can cause kidney problems (tumour\nlysis syndrome)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid;\ntext-autospace:none\"><span lang=\"EN-GB\">The symptoms of this condition include:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">producing less urine than normal</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">muscle spasms.</span></p>\n<p class=\"MsoListParagraph\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">If you notice these symptoms, <b>contact your doctor as\nsoon as possible</b>.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon side effects that may show up in your blood\ntests:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">problems with blood clotting</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\" style=\"color:black\">the bone marrow failing to\nproduce enough red or white blood cells</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Reporting\nof side effects</span></b></p>\n<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"X-NONE\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>If you\nget any side effects, talk to your doctor or nurse.<span style=\"color:red\"> </span>This\nincludes any possible side effects not listed in this leaflet. You can also\nreport side effects directly via <span style=\"color:black;background:#D9D9D9\">the\nnational reporting system listed in </span></span><a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span lang=\"X-NONE\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\nbackground:#D9D9D9'>Appendix V</span></a><span lang=\"X-NONE\" style='font-size:\n11.0pt;font-family:\"Times New Roman\",serif'>. By reporting side effects you can\nhelp provide more information on the safety of this medicine.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store Arzerra</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Keep this\nmedicine out of the sight and reach of children.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Do not use this\nmedicine after the expiry date shown on the carton and vial label. The expiry\ndate refers to the last day of that month.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Store and transport refrigerated (2\u00a0C\n\u2013 8</span><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b0</span><span lang=\"EN-GB\">C).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not freeze.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep the vial in the outer carton in order\nto protect from light.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Store the diluted infusion solution between\n2</span><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b0</span><span lang=\"EN-GB\">C\nand 8\u00a0C and use within 24\u00a0hours. Any unused infusion solution should\nbe discarded 24\u00a0hours after preparation.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents\nof the pack and other information</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">What\nArzerra contains</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">The active substance is ofatumumab. One ml of\nconcentrate contains 20\u00a0mg of ofatumumab.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"PT\" style=\"color:black\">-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">The other ingredients are </span><span lang=\"PT\" style=\"color:black\">arginine, sodium acetate (E262), </span><span lang=\"EN-GB\" style=\"color:black\">sodium chloride</span><span lang=\"PT\" style=\"color:black\">,\npolysorbate 80 (E433), edetate disodium (E386), hydrochloric acid (E507) (for\npH-adjustment), </span><span lang=\"EN-GB\" style=\"color:black\">water for\ninjections (see \u201cArzerra contains sodium\u201d under section\u00a02).</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">What\nArzerra looks like and contents of the pack</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Arzerra is a </span><span lang=\"EN-GB\">colourless to pale yellow concentrate for solution</span><span lang=\"EN-GB\" style=\"color:black\"> for infusion.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"EN-GB\" style=\"color:black\">Arzerra 100\u00a0mg</span></b><span lang=\"EN-GB\" style=\"color:black\"> is available in a pack containing 3\u00a0vials</span><span lang=\"EN-GB\">. Each glass vial is closed with a rubber stopper and aluminium\nover-seal</span><span lang=\"EN-GB\" style=\"color:black\">, and contains 5\u00a0ml\nof concentrate (100</span><span lang=\"EN-GB\">\u00a0</span><span lang=\"EN-GB\" style=\"color:black\">mg of ofatumumab).</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"EN-GB\" style=\"color:black\">Arzerra 1000\u00a0mg</span></b><span lang=\"EN-GB\" style=\"color:black\"> is available in a pack containing 1\u00a0vial</span><span lang=\"EN-GB\">. Each glass vial is closed with a rubber stopper and aluminium\nover-seal</span><span lang=\"EN-GB\" style=\"color:black\">, and contains 50\u00a0ml\nof concentrate (1000</span><span lang=\"EN-GB\">\u00a0</span><span lang=\"EN-GB\" style=\"color:black\">mg of ofatumumab).</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Marketing Authorisation Holder</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Novartis\nEuropharm Limited</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Frimley\nBusiness Park</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Camberley\nGU16 7SR</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">United Kingdom</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Manufacturer</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Glaxo Operations UK Limited (Trading as\nGlaxo Wellcome Operations), Harmire Road, Barnard Castle, County Durham, DL12\n8DT<span style=\"color:black\">,</span> United Kingdom</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">Novartis\nPharmaceuticals UK Limited, Frimley Business Park, Frimley, Camberley, Surrey\nGU16 7SR, United Kingdom</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">Novartis Pharma GmbH, Roonstrasse 25,\n90429 Nuremberg, Germany</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">For any\ninformation about this medicine, please contact the local representative of the\nMarketing Authorisation Holder:</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:-1.7pt;border-collapse:collapse\" width=\"624\">\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"FR-BE\">Belgi\u00eb/Belgique/Belgien</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR-BE\">Novartis Pharma N.V.</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR-BE\">T\u00e9l/Tel: +32 2 246 16 11</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:1.7pt\"><span lang=\"FR\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"LT\">Lietuva</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-right:-22.45pt\"><span lang=\"LT\">Novartis\n  Pharma Services Inc.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-22.45pt\"><span lang=\"LT\">Tel: +370 5\n  269 16 50</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"BG\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Novartis Bulgaria EOOD</span></p>\n<p class=\"MsoNormal\"><span lang=\"BG\">\u0422\u0435\u043b:</span> +359 2 489 98\n  28</p>\n<p class=\"MsoNormal\"><b><span lang=\"NO-BOK\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Novartis Pharma N.V.</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR-BE\">T\u00e9l/Tel: +32 2 246 16 11</span></p>\n<p class=\"MsoNormal\"><span lang=\"NO-BOK\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"SV\">\u010cesk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"SV\">Novartis s.r.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +420 225 775 111</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"HU\">Magyarorsz\u00e1g</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"HU\">Novartis Hung\u00e1ria Kft.</span></p>\n<p class=\"MsoNormal\"><span lang=\"HU\">Tel.: +36 1 457 65 00</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b>Danmark</b></p>\n<p class=\"MsoNormal\">Novartis Healthcare A/S</p>\n<p class=\"MsoNormal\">Tlf: +45 39 16 84 00</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"MT\">Malta</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"MT\">Novartis Pharma Services Inc.</span></p>\n<p class=\"MsoNormal\"><span lang=\"MT\">Tel: +</span>356 <span lang=\"FR-CH\">2122 2872</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Deutschland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Novartis Pharma GmbH</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tel: +49 911 273 0</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"NL\">Nederland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"NL\">Novartis Pharma B.V.</span></p>\n<p class=\"MsoNormal\"><span lang=\"NL\">Tel: +31 26 37 82 555</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"ET\">Eesti</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ET\">Novartis Pharma Services Inc.</span></p>\n<p class=\"MsoNormal\"><span lang=\"ET\">Tel: +372 </span><span lang=\"EN-GB\">66 30 810</span></p>\n<p class=\"MsoNormal\"><span lang=\"ET\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"NO-BOK\">Norge</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"NO-BOK\">Novartis Norge AS</span></p>\n<p class=\"MsoNormal\"><span lang=\"NO-BOK\">Tlf: +47 23 05 20 00</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"EL\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ET\">Novartis (Hellas) A.E.B.E.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EL\">\u03a4\u03b7\u03bb</span><span lang=\"ET\">: +30\n  210 281 17 12</span></p>\n<p class=\"MsoNormal\"><span lang=\"ET\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-AT\">\u00d6sterreich</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-AT\">Novartis Pharma GmbH</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-AT\">Tel: +43 1 86 6570</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Novartis Farmac\u00e9utica, S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Tel: +34 93 306 42 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"PL\">Polska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PL\">Novartis Poland Sp. z o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"PL\">Tel.: +48 22 375 4888</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"FR\">France</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR\">Novartis Pharma S.A.S.</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR\">T\u00e9l: +33 1 55 47 66 00</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"PL\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"PT\">Portugal</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Novartis Farma - Produtos Farmac\u00eauticos,\n  S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT\">Tel: +351 21 000 8600</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Hrvatska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Novartis Hrvatska d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel. +385 1 6274 220</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"FR\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b>Rom\u00e2nia</b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">Novartis Pharma Services <span lang=\"EN-GB\">Romania SRL</span></p>\n<p class=\"MsoNormal\">Tel: +40 21 31299 01</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Ireland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Novartis Ireland Limited</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +353 1 260 12 55</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"SL\">Slovenija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"SL\">Novartis Pharma Services Inc.</span></p>\n<p class=\"MsoNormal\"><span lang=\"SL\">Tel: +386 1 300 75 50</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"IS\">\u00cdsland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IS\">Vistor hf.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">S\u00edmi</span><span lang=\"IS\">: +354 535 7000</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"SK\">Slovensk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"SK\">Novartis Slovakia s.r.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"SK\">Tel: +421 2 5542 5439</span></p>\n<p class=\"MsoNormal\"><span lang=\"SK\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Italia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Novartis Farma S.p.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: +39 02 96 54 1</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"FI\">Suomi/Finland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FI\">Novartis Finland Oy</span></p>\n<p class=\"MsoNormal\"><span lang=\"FI\">Puh/Tel: +358 </span><span lang=\"DE-CH\">(0)10\n  6133 200</span></p>\n<p class=\"MsoNormal\"><span lang=\"SV\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"EL\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">Novartis Pharma Services Inc.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EL\">\u03a4\u03b7\u03bb: +357 22 690 690</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EL\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"SV\">Sverige</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"SV\">Novartis Sverige AB</span></p>\n<p class=\"MsoNormal\"><span lang=\"SV\">Tel: +46 8 732 32 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"FI\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"LV\">Latvija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"LV\">SIA \u201cNovartis Baltics\u201d</span></p>\n<p class=\"MsoNormal\"><span lang=\"LV\">Tel: +371 67 887 070</span></p>\n<p class=\"MsoNormal\"><span lang=\"FI\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">United Kingdom</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Novartis Pharmaceuticals UK Ltd.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 1276 698370</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">This\nleaflet was last revised in</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Detailed\ninformation on this medicine is available on the European Medicines Agency\n(EMA) web site: </span><span lang=\"EN-GB\">http://www.ema.europa.eu<span style=\"color:blue\">/.</span></span></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">The following\ninformation is intended for healthcare professionals only:</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b>1)\u00a0\u00a0\u00a0\u00a0\u00a0 Before\ndiluting Arzerra</b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">Check the<i> </i><span lang=\"EN-GB\">Arzerra concentrate<i> </i>for particulate matter and discolouration\nprior to dilution. Ofatumumab should be a colourless to pale yellow solution.\nDo not use the Arzerra concentrate if there is discolouration.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Do not shake\nthe ofatumumab vial for this inspection.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">2)\u00a0\u00a0\u00a0\u00a0\u00a0 How to dilute the solution for infusion</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">The <span lang=\"EN-GB\">Arzerra</span>\nconcentrate must be diluted in sodium chloride 9\u00a0mg/ml (0.9%) solution for\ninjection prior to administration, using aseptic technique.</p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">300\u00a0mg dose </span></b><span lang=\"EN-GB\">- Use three\n100\u00a0mg/5\u00a0ml vials (15\u00a0ml total, 5\u00a0ml per vial):</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Withdraw and discard 15\u00a0ml from a\n1000\u00a0ml bag of sodium chloride 9\u00a0mg/ml (0.9%) solution for injection;</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Withdraw 5\u00a0ml of ofatumumab from each of the\nthree 100\u00a0mg vials and inject into the 1000\u00a0ml bag;</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Do not shake; mix diluted solution by gentle\ninversion.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">1000\u00a0mg dose </span></b><span lang=\"EN-GB\">\u2013 Use one\n1000\u00a0mg/50\u00a0ml vial (50\u00a0ml total, 50\u00a0ml per vial):</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Withdraw and discard 50\u00a0ml from a 1000 ml\nbag of sodium chloride 9\u00a0mg/ml (0.9%) solution for injection;</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Withdraw 50\u00a0ml of ofatumumab from the\n1000\u00a0mg vial and inject into the 1000\u00a0ml bag</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Do not shake; mix diluted solution by gentle\ninversion.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">2000\u00a0mg dose </span></b><span lang=\"EN-GB\">\u2013 Use two\n1000\u00a0mg/50\u00a0ml vials (100\u00a0ml total, 50\u00a0ml per vial):</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Withdraw and discard 100\u00a0ml from a 1000 ml\nbag of sodium chloride 9\u00a0mg/ml (0.9%) solution for injection;</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Withdraw 50\u00a0ml of ofatumumab from each of the\ntwo 1000\u00a0mg vials and inject into the 1000\u00a0ml bag;</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Do not shake; mix diluted solution by gentle\ninversion.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">3)\u00a0\u00a0\u00a0\u00a0\u00a0 How to administer the diluted solution</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Arzerra must\nnot be administered as an intravenous push or bolus. Administer using an\nintravenous infusion pump</span><span lang=\"EN-GB\">.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">The infusion\nmust be completed within 24\u00a0hours after preparation. Discard any unused\nsolution after this time.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Arzerra must\nnot be mixed with, or administered as an infusion with other medicinal products\nor intravenous solutions. Flush line before and after ofatumumab administration\nwith sodium chloride 9\u00a0mg/ml (0.9%) solution for injection to avoid this.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Previously\nuntreated CLL and relapsed CLL:</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">For the\nfirst infusion, administer over 4.5 hours </span><span lang=\"EN-GB\">(</span><span lang=\"EN-GB\">see section\u00a04.2</span><span lang=\"EN-GB\"> of the SmPC), </span><span lang=\"EN-GB\">through a peripheral line or indwelling catheter, according to the\nschedule below:</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">If the first\ninfusion was completed without a severe adverse reaction, the remaining\ninfusions of 1000\u00a0mg should be administered over 4\u00a0hours (see\nsection\u00a04.2 of the SmPC), through a peripheral line or indwelling\ncatheter, according to the schedule below. If any infusion\u2011related\nadverse reactions are observed, infusion should be interrupted and restarted\nwhen the patient\u2019s condition is stable (see section\u00a04.2 of the SmPC).</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><u><span lang=\"EN-GB\">Infusion schedule</span></u></i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:100.0%;border-collapse:collapse;border:none\" width=\"100%\">\n<tr>\n<td rowspan=\"2\" style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Time after start of infusion (minutes)</span></p>\n</td>\n<td style=\"width:141.15pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion\u00a01</span></p>\n</td>\n<td style=\"width:146.55pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Subsequent infusions*</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:141.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0\u201130</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">12</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31\u201160</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">61\u201190</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">91\u2011120</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">121\u2011150</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">151\u2011180</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">300</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">180+</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\" style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">*If the\n  previous infusion was completed without severe infusion\u2011related ADRs.\n  If any infusion\u2011related ADRs are observed, infusion should be\n  interrupted and restarted when the patient\u2019s condition is stable (see </span><span lang=\"EN-GB\">section\u00a04.2 of the SmPC</span><span lang=\"EN-GB\">).</span></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Any unused medicinal product or waste\nmaterial should be disposed of in accordance with local requirements.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Refractory CLL:</u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">For the first and second infusion, administer over 6.5\u00a0hours\n(see section\u00a04.2 of the SmPC), through a peripheral line or indwelling\ncatheter, according to the schedule below:</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">If the second infusion was completed without a severe adverse\nreaction, the remaining infusions (3\u201112) should be administered over\n4\u00a0hours (see section 4.2 of the SmPC), through a peripheral line or\nindwelling catheter, according to the schedule below. If any infusion\u2011related\nadverse reactions are observed, infusion should be interrupted and restarted\nwhen the patient\u2019s condition is stable (see section\u00a04.2 of the SmPC).</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Infusion\nschedule</span></u></i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td rowspan=\"2\" style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Time after start of infusion (minutes)</span></p>\n</td>\n<td style=\"width:134.7pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusions\u00a01 and 2</span></p>\n</td>\n<td style=\"width:134.6pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusions\u00a03* to 12</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:134.7pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0\u201130</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">12</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31\u2011 60</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">61\u201190</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">91\u2011120</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">121+</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\" style=\"width:423.55pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"565\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">*If the\n  second infusion was completed without severe infusion\u2011related ADRs. If\n  any infusion\u2011related ADRs are observed, infusion should be interrupted\n  and restarted when the patient\u2019s condition is stable (see section\u00a04.2).</span></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Any unused medicinal product or waste\nmaterial should be disposed of in accordance with local requirements.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n</div>", "ID": "e3202efd-8c36-4acf-bb65-5c60f6c0142b", "Styles": "None", "Classes": "['WordSection1']", "Text": "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ", "ParentId": "55bf08e8-124a-4f47-830b-e311522999a0"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "bf960d8d-cde0-40b6-8044-9878eb6ef4cb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "433f6d75-e48b-4857-92af-12024e05e15b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "fc4d43e5-fbdc-4968-9ceb-8666d6223dc4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "21394061-4b72-4218-bbc5-6fbd7ec09033", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "56353d79-0310-498a-b729-257eed1824e4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "1e62b90a-e66d-4dad-9424-54cbdf7cd40a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "2b0efbe4-ea65-45d0-86c3-8ccbd706f896", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "f263ff9a-8a86-4e65-96bf-2a2ce98c0d2e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "d65a02e5-6362-497d-84c7-9f21d18cbeeb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "adf32531-bbb8-40dc-a259-8c4b67f66467", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "716a7ff7-4333-4576-9082-4f100fa842ad", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "1b4057e6-eeb6-40fe-a8bb-f84a23700e71", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "bf76f5cb-5f09-42b9-aff2-cc8b85b1e6b4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "8591ddd2-2c99-41f3-b5cb-95b833ccf8a2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "24e9763b-41a4-415c-bfc8-74e5f59ec1d8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "3f1ec786-8b8f-4633-81bc-97761898cebc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "383076ac-9a7c-4c11-b701-bbb90a16ff9c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "63baf720-2ce7-443f-bd6a-49b2c5be4216", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "409a3081-a16d-471a-8811-c73616c24297", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "63f516e0-db1c-4d60-9635-940338f0924f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "7979c5b4-5e27-41d5-be8c-ae2a356b27f6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "b87c178b-c7b4-4510-8bfb-1cea53cda75d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "3383c8fc-33f5-4963-b477-5aef1d40954b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>ANNEX I</b></p>", "ID": "9b548e7c-f305-49c3-ab1d-a894e14eefe6", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b>ANNEX I</b>", "ID": "a4999fb1-0c49-43f2-bf30-ccaf60c5bbe1", "Styles": "None", "Classes": "None", "Text": "ANNEX I", "ParentId": "9b548e7c-f305-49c3-ab1d-a894e14eefe6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "669dc2fb-78a1-43d9-899b-a191e05df5d2", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "65625d54-405c-4c58-9afd-b05b80477546", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "669dc2fb-78a1-43d9-899b-a191e05df5d2"}, {"Element": "<p class=\"TitleA\"><span lang=\"X-NONE\">SUMMARY OF PRODUCT CHARACTERISTICS</span></p>", "ID": "f26ab55f-232b-49c5-b4b7-8eefcbeaacb5", "Styles": "None", "Classes": "['TitleA']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"X-NONE\">SUMMARY OF PRODUCT CHARACTERISTICS</span>", "ID": "855db87f-7d77-4d46-bfb8-9deb1df9d82c", "Styles": "None", "Classes": "None", "Text": "SUMMARY OF PRODUCT CHARACTERISTICS", "ParentId": "f26ab55f-232b-49c5-b4b7-8eefcbeaacb5"}, {"Element": "<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>", "ID": "c3d9953f-1ced-433d-baa8-d29a6bf22123", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "2d4540d7-2eef-470e-9e8f-d81263671a07", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "c3d9953f-1ced-433d-baa8-d29a6bf22123"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "2764470a-0ee2-4032-8f64-4e531e36242b", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "2d4540d7-2eef-470e-9e8f-d81263671a07"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT</span></b></p>", "ID": "af5b1a87-4f89-4eca-ae65-e57539fa9df3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT</span></b>", "ID": "16dc5715-07a1-4d0a-865a-47de4a5cc4e9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "af5b1a87-4f89-4eca-ae65-e57539fa9df3"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT</span>", "ID": "404f6d23-92ea-4088-b83e-f5b368c08099", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT", "ParentId": "16dc5715-07a1-4d0a-865a-47de4a5cc4e9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c83396c1-03e7-4d39-8a7e-0ac76e9c85cb", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3b80d825-814f-4d4e-a409-d9083a43da49", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c83396c1-03e7-4d39-8a7e-0ac76e9c85cb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Arzerra 100\u00a0mg concentrate for\nsolution for infusion</span></p>", "ID": "f9b179ce-ffa7-4368-8ceb-1032f0a7364b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Arzerra 100\u00a0mg concentrate for\nsolution for infusion</span>", "ID": "ef9723e3-cc2d-4e8c-9847-50556bf239c8", "Styles": "None", "Classes": "None", "Text": "Arzerra 100\u00a0mg concentrate for solution for infusion", "ParentId": "f9b179ce-ffa7-4368-8ceb-1032f0a7364b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Arzerra 1000\u00a0mg concentrate for\nsolution for infusion</span></p>", "ID": "c45bc80f-280e-45b1-aa01-de7823a084f8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Arzerra 1000\u00a0mg concentrate for\nsolution for infusion</span>", "ID": "514de821-53d2-4281-bc43-b09340ba46e6", "Styles": "None", "Classes": "None", "Text": "Arzerra 1000\u00a0mg concentrate for solution for infusion", "ParentId": "c45bc80f-280e-45b1-aa01-de7823a084f8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fe4633b5-e1e9-4aac-866f-adf2d0cd9fb2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "523be984-a7f7-471d-8863-7fcfc390a8fe", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fe4633b5-e1e9-4aac-866f-adf2d0cd9fb2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4320a589-b6ec-481b-b0df-2aafce9cef7c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8140bef8-f4a0-485f-b2a5-28f26c7484b7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4320a589-b6ec-481b-b0df-2aafce9cef7c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE\n AND QUANTITATIVE COMPOSITION</span></b></p>", "ID": "e9594b9a-16a7-44d0-80f9-d0824e274d91", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE\n AND QUANTITATIVE COMPOSITION</span></b>", "ID": "3846a1da-98db-413d-8dd8-ae049683f9d6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e9594b9a-16a7-44d0-80f9-d0824e274d91"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE\n AND QUANTITATIVE COMPOSITION</span>", "ID": "87d7e84a-718f-4e5d-930a-2e72a49fdcf3", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE  AND QUANTITATIVE COMPOSITION", "ParentId": "3846a1da-98db-413d-8dd8-ae049683f9d6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "40b88362-b027-4747-8ccc-07230d2b4b24", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c08c452a-9f27-4823-a3e1-214f7f4f2aa6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "40b88362-b027-4747-8ccc-07230d2b4b24"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">One ml of concentrate\ncontains 20\u00a0mg of ofatumumab.</span></p>", "ID": "7a7a1ad4-f5b1-4125-8f61-b21b06b9516b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">One ml of concentrate\ncontains 20\u00a0mg of ofatumumab.</span>", "ID": "76ae4524-ef22-4883-ac5b-c0fe9ec0e392", "Styles": "color:black", "Classes": "None", "Text": "One ml of concentrate contains 20\u00a0mg of ofatumumab.", "ParentId": "7a7a1ad4-f5b1-4125-8f61-b21b06b9516b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "d6612bc4-a07c-43e0-9faf-de85ab7db68b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "8c30dbfc-1b05-4381-b1d5-06b979c66e08", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "d6612bc4-a07c-43e0-9faf-de85ab7db68b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:black\">Arzerra 100\u00a0mg concentrate for solution for infusion</span></u></p>", "ID": "3fa44802-1a12-40c9-9778-ed1d83149b4c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\" style=\"color:black\">Arzerra 100\u00a0mg concentrate for solution for infusion</span></u>", "ID": "8d0084d2-7270-4813-9995-936dc07cf94d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3fa44802-1a12-40c9-9778-ed1d83149b4c"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Arzerra 100\u00a0mg concentrate for solution for infusion</span>", "ID": "1dba303e-4d02-40be-a2c7-0c24b8a8de12", "Styles": "color:black", "Classes": "None", "Text": "Arzerra 100\u00a0mg concentrate for solution for infusion", "ParentId": "8d0084d2-7270-4813-9995-936dc07cf94d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a8d8fb87-d450-4cef-b16c-6a311cc571cf", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f2d2cb9b-cbda-4feb-92e1-2d5c2602f99e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a8d8fb87-d450-4cef-b16c-6a311cc571cf"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each vial contains\n100\u00a0mg of ofatumumab in 5\u00a0ml.</span></p>", "ID": "d79a9367-21ce-4ade-bb30-b9da4260ca8f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Each vial contains\n100\u00a0mg of ofatumumab in 5\u00a0ml.</span>", "ID": "31351fd1-97b5-4ce4-876e-ee60e7aca577", "Styles": "color:black", "Classes": "None", "Text": "Each vial contains 100\u00a0mg of ofatumumab in 5\u00a0ml.", "ParentId": "d79a9367-21ce-4ade-bb30-b9da4260ca8f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "37d66ad8-971b-4bcc-a280-6d978ea81a50", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d20fd328-62db-4162-920a-a98acece243a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "37d66ad8-971b-4bcc-a280-6d978ea81a50"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:black\">Arzerra 1000\u00a0mg concentrate for solution for infusion</span></u></p>", "ID": "75d86ab5-2f1f-4291-8d9a-0283de72b29e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\" style=\"color:black\">Arzerra 1000\u00a0mg concentrate for solution for infusion</span></u>", "ID": "3572106e-0c52-4bf2-baa2-afaa93b5e37a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "75d86ab5-2f1f-4291-8d9a-0283de72b29e"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Arzerra 1000\u00a0mg concentrate for solution for infusion</span>", "ID": "c4c700f6-ccba-417d-bce9-d7e4e92cc4f0", "Styles": "color:black", "Classes": "None", "Text": "Arzerra 1000\u00a0mg concentrate for solution for infusion", "ParentId": "3572106e-0c52-4bf2-baa2-afaa93b5e37a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c9424128-11ac-4f86-b4bc-f6686941f5db", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "41977eba-8178-4197-a361-c34b820e424d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c9424128-11ac-4f86-b4bc-f6686941f5db"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Each vial contains 1000\u00a0mg of\nofatumumab in 50\u00a0ml.</span></p>", "ID": "4e10aa11-eda2-47ad-a5fd-384ea4fadb13", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Each vial contains 1000\u00a0mg of\nofatumumab in 50\u00a0ml.</span>", "ID": "51595098-6dfb-40ee-8ebc-c7fcdfa2a8a3", "Styles": "None", "Classes": "None", "Text": "Each vial contains 1000\u00a0mg of ofatumumab in 50\u00a0ml.", "ParentId": "4e10aa11-eda2-47ad-a5fd-384ea4fadb13"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "efab4174-a6aa-45f3-8260-c9261f84be44", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0d014470-8f98-4f3f-b915-21e8cb8b2a8e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "efab4174-a6aa-45f3-8260-c9261f84be44"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Ofatumumab is a human monoclonal antibody\nproduced in a recombinant murine cell line (NS0).</span></p>", "ID": "3f5a1bbd-11dc-4e6e-a725-762d578c5e11", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Ofatumumab is a human monoclonal antibody\nproduced in a recombinant murine cell line (NS0).</span>", "ID": "f84f4dae-ebc9-4311-9271-a9cf2131ece7", "Styles": "None", "Classes": "None", "Text": "Ofatumumab is a human monoclonal antibody produced in a recombinant murine cell line (NS0).", "ParentId": "3f5a1bbd-11dc-4e6e-a725-762d578c5e11"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "2aab3d66-0314-45c0-b73e-4d1498ab8126", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "d71d44eb-d4d5-48df-b3c3-aa4eea6ea7e1", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "2aab3d66-0314-45c0-b73e-4d1498ab8126"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:black\">Excipient with known effect</span></u></p>", "ID": "bbf53294-bba5-430e-a8d6-a6a8a88e0188", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\" style=\"color:black\">Excipient with known effect</span></u>", "ID": "fed6297f-c76a-4e60-9e3e-9e3f970d14f7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bbf53294-bba5-430e-a8d6-a6a8a88e0188"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Excipient with known effect</span>", "ID": "1fdedc3a-be33-4a9f-9783-20432274c57e", "Styles": "color:black", "Classes": "None", "Text": "Excipient with known effect", "ParentId": "fed6297f-c76a-4e60-9e3e-9e3f970d14f7"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "990bc584-aac4-4f02-9970-caf303fb12a3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d738051a-8f02-4a59-80e1-c1ff5ade5ac6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "990bc584-aac4-4f02-9970-caf303fb12a3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">This medicinal product\ncontains 34.8\u00a0mg sodium per 300\u00a0mg dose, 116\u00a0mg sodium per\n1000\u00a0mg dose and 232\u00a0mg sodium per 2000\u00a0mg dose.</span></p>", "ID": "0e68b269-a340-4ffc-a06b-6913abfd3fef", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">This medicinal product\ncontains 34.8\u00a0mg sodium per 300\u00a0mg dose, 116\u00a0mg sodium per\n1000\u00a0mg dose and 232\u00a0mg sodium per 2000\u00a0mg dose.</span>", "ID": "d82989ec-774e-40f4-b802-434cd9f0e7fc", "Styles": "color:black", "Classes": "None", "Text": "This medicinal product contains 34.8\u00a0mg sodium per 300\u00a0mg dose, 116\u00a0mg sodium per 1000\u00a0mg dose and 232\u00a0mg sodium per 2000\u00a0mg dose.", "ParentId": "0e68b269-a340-4ffc-a06b-6913abfd3fef"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "173b1bf5-d8b9-410e-bc1c-200e8d5a1334", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "37f0e938-90b1-47df-8e59-f33715231fc8", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "173b1bf5-d8b9-410e-bc1c-200e8d5a1334"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">For the full\nlist of excipients, see section\u00a06.1.</span></p>", "ID": "1e8e6a08-027d-4ac4-a359-c69e3e8af2e8", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">For the full\nlist of excipients, see section\u00a06.1.</span>", "ID": "16019e5c-5bfd-4921-8b39-0ed99ae5d041", "Styles": "None", "Classes": "None", "Text": "For the full list of excipients, see section\u00a06.1.", "ParentId": "1e8e6a08-027d-4ac4-a359-c69e3e8af2e8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e41b637a-d294-4320-8ff5-e959e403d792", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "620a3e5e-50b5-4261-a5d7-fcbfa34a8d2d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e41b637a-d294-4320-8ff5-e959e403d792"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b5c72bfd-2663-482a-94bf-89745ddc0d69", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "760e7641-e3de-4f11-9ba6-a27024113122", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b5c72bfd-2663-482a-94bf-89745ddc0d69"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL <span style=\"text-transform:\n uppercase\">form</span></span></b></p>", "ID": "178d9c9d-00e6-42f2-8552-3c6d69e41a6e", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL <span style=\"text-transform:\n uppercase\">form</span></span></b>", "ID": "7bf4c3b2-86a2-462f-b2a5-5c6a133f9558", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "178d9c9d-00e6-42f2-8552-3c6d69e41a6e"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL <span style=\"text-transform:\n uppercase\">form</span></span>", "ID": "3705d7b4-8bc2-4d37-956a-e787d1344a34", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL ", "ParentId": "7bf4c3b2-86a2-462f-b2a5-5c6a133f9558"}, {"Element": "<span style=\"text-transform:\n uppercase\">form</span>", "ID": "842a858d-af62-4791-bf63-698ed23dfc84", "Styles": "text-transform:\n uppercase", "Classes": "None", "Text": "form", "ParentId": "3705d7b4-8bc2-4d37-956a-e787d1344a34"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "639fcf47-2f7e-4780-9b53-0e824edabb34", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "59bb3905-002f-4716-954e-d7ceeb77c0c8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "639fcf47-2f7e-4780-9b53-0e824edabb34"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Concentrate for solution for infusion (sterile\nconcentrate).</span></p>", "ID": "20364b18-40e0-4ba7-80cb-af0650fe30f0", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Concentrate for solution for infusion (sterile\nconcentrate).</span>", "ID": "0d0c9ef8-0e91-4f7c-9331-7af7433f5efb", "Styles": "color:black", "Classes": "None", "Text": "Concentrate for solution for infusion (sterile concentrate).", "ParentId": "20364b18-40e0-4ba7-80cb-af0650fe30f0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ef3f5ea3-2fdd-4613-bb78-4710a1731c4b", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3ee31f67-2440-486e-8e0c-fdad93bd6ad8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ef3f5ea3-2fdd-4613-bb78-4710a1731c4b"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Clear</span><span lang=\"EN-GB\"> to opalescent</span><span lang=\"EN-GB\">, colourless to pale yellow\nliquid.</span></p>", "ID": "dc7d3d7e-e90b-47fb-ae01-40dc7f6fdeaa", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Clear</span>", "ID": "c019682b-b18f-433e-b364-05a6953d8c3b", "Styles": "None", "Classes": "None", "Text": "Clear", "ParentId": "dc7d3d7e-e90b-47fb-ae01-40dc7f6fdeaa"}, {"Element": "<span lang=\"EN-GB\"> to opalescent</span>", "ID": "74578ec9-f98b-4e03-ba5d-152fc4e623ea", "Styles": "None", "Classes": "None", "Text": " to opalescent", "ParentId": "dc7d3d7e-e90b-47fb-ae01-40dc7f6fdeaa"}, {"Element": "<span lang=\"EN-GB\">, colourless to pale yellow\nliquid.</span>", "ID": "6c18db70-34a8-44e4-bb0c-6be901158492", "Styles": "None", "Classes": "None", "Text": ", colourless to pale yellow liquid.", "ParentId": "dc7d3d7e-e90b-47fb-ae01-40dc7f6fdeaa"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "afa4bdc0-d3ad-44cb-aa2b-c6fb9671a1b8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7b79fba8-af53-40f7-991f-f4f0561b6d6e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "afa4bdc0-d3ad-44cb-aa2b-c6fb9671a1b8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "999d7b64-6bee-451a-ac0d-22bae785a61f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ebff038c-9d29-42dc-bdb8-4842e9ac9a7c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "999d7b64-6bee-451a-ac0d-22bae785a61f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Clinical\nparticulars</span></b></p>", "ID": "0e0ec2af-1e54-463d-8574-4caccc36bf5c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Clinical\nparticulars</span></b>", "ID": "ed304786-ed8e-4f20-9690-fc26d9b84004", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0e0ec2af-1e54-463d-8574-4caccc36bf5c"}, {"Element": "<span lang=\"EN-GB\" style=\"text-transform:uppercase\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Clinical\nparticulars</span>", "ID": "6df587da-f727-4a27-b836-6d74b4093ecb", "Styles": "text-transform:uppercase", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Clinical particulars", "ParentId": "ed304786-ed8e-4f20-9690-fc26d9b84004"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d93e5b2b-9983-4b69-83c0-dd3287b6b248", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3ba4492d-0191-45e5-83b8-5d610773b805", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d93e5b2b-9983-4b69-83c0-dd3287b6b248"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic indications</span></b></p>", "ID": "1c2df84a-9425-48d8-95d0-1fbd089f9ab7", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic indications</span></b>", "ID": "224772b2-ea19-4e64-af1d-3cb1098103cb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1c2df84a-9425-48d8-95d0-1fbd089f9ab7"}, {"Element": "<span lang=\"EN-GB\">4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic indications</span>", "ID": "5d83bc73-84c2-471d-921a-2a2011a50d81", "Styles": "None", "Classes": "None", "Text": "4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic indications", "ParentId": "224772b2-ea19-4e64-af1d-3cb1098103cb"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4d0e3634-0d69-4027-8126-6bbf055b1e47", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8874e1b5-6fdc-4539-965d-aaeaaacb535c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4d0e3634-0d69-4027-8126-6bbf055b1e47"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Previously untreated\nchronic lymphocytic </u><u><span lang=\"EN-GB\">leukaemia</span></u><u> (CLL)</u></p>", "ID": "2b07becb-e25f-465f-adf1-948655541cef", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u>Previously untreated\nchronic lymphocytic </u>", "ID": "b526e9a7-8a02-43ed-af75-e6db0c38fb76", "Styles": "None", "Classes": "None", "Text": "Previously untreated chronic lymphocytic ", "ParentId": "2b07becb-e25f-465f-adf1-948655541cef"}, {"Element": "<u><span lang=\"EN-GB\">leukaemia</span></u>", "ID": "74d3bcdc-ea61-4257-a276-d0ecb0c07657", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2b07becb-e25f-465f-adf1-948655541cef"}, {"Element": "<span lang=\"EN-GB\">leukaemia</span>", "ID": "ab68eae6-f2fd-4257-8d92-4b9a56ed0147", "Styles": "None", "Classes": "None", "Text": "leukaemia", "ParentId": "74d3bcdc-ea61-4257-a276-d0ecb0c07657"}, {"Element": "<u> (CLL)</u>", "ID": "6fc1e783-7a76-45e3-9478-c0be8bf39305", "Styles": "None", "Classes": "None", "Text": " (CLL)", "ParentId": "2b07becb-e25f-465f-adf1-948655541cef"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e4e4408e-e1e6-4838-9106-09804cd1cece", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "180083e1-e33a-44b5-a30b-ae66821faec0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e4e4408e-e1e6-4838-9106-09804cd1cece"}, {"Element": "<p class=\"MsoNormal\"><span style=\"color:black\">Arzerra in combination with\nchlorambucil or bendamustine is indicated for the treatment of adult patients\nwith CLL who have not received prior therapy and who are not eligible for\nfludarabine-based therapy.</span></p>", "ID": "7f9cd38e-ace3-4d16-afae-37ba5d5a017b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"color:black\">Arzerra in combination with\nchlorambucil or bendamustine is indicated for the treatment of adult patients\nwith CLL who have not received prior therapy and who are not eligible for\nfludarabine-based therapy.</span>", "ID": "565fc13b-579c-4433-ac53-68726eb10a14", "Styles": "color:black", "Classes": "None", "Text": "Arzerra in combination with chlorambucil or bendamustine is indicated for the treatment of adult patients with CLL who have not received prior therapy and who are not eligible for fludarabine-based therapy.", "ParentId": "7f9cd38e-ace3-4d16-afae-37ba5d5a017b"}, {"Element": "<p class=\"MsoNormal\"><span style=\"color:black\">\u00a0</span></p>", "ID": "2e7c1617-98e6-4584-8aaf-4b15588d07a0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"color:black\">\u00a0</span>", "ID": "53b52395-446c-4788-9692-9656ebd44eaa", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "2e7c1617-98e6-4584-8aaf-4b15588d07a0"}, {"Element": "<p class=\"MsoNormal\">See section\u00a05.1 for further information.</p>", "ID": "7ae385ad-d0f2-4433-9414-d24276cd0a4b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "See section\u00a05.1 for further information.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b1009d92-edf5-459b-8aee-febdd93763cd", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bf4c5881-e77b-4ed5-a10c-8a979c5960e7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b1009d92-edf5-459b-8aee-febdd93763cd"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\navoid\"><u><span style=\"font-size:11.0pt\">Relapsed CLL</span></u></p>", "ID": "864525a4-0855-4083-acf0-40240969de28", "Styles": "margin-top:0in;text-align:left;page-break-after:\navoid", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span style=\"font-size:11.0pt\">Relapsed CLL</span></u>", "ID": "a72c52f8-496e-4095-8600-c2d1893845da", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "864525a4-0855-4083-acf0-40240969de28"}, {"Element": "<span style=\"font-size:11.0pt\">Relapsed CLL</span>", "ID": "89ba3d53-3787-4dbc-b45a-c3ac4d11b539", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "Relapsed CLL", "ParentId": "a72c52f8-496e-4095-8600-c2d1893845da"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b9ef6ce6-5250-48da-a709-461e0ddd0cb9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9749827d-27ca-46aa-9577-f5c1099f9208", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b9ef6ce6-5250-48da-a709-461e0ddd0cb9"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">Arzerra is indicated in combination with fludarabine\nand cyclophosphamide for the treatment of adult patients with relapsed CLL.</span></p>", "ID": "1348a74c-45d8-4051-af0a-318bb07248ee", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">Arzerra is indicated in combination with fludarabine\nand cyclophosphamide for the treatment of adult patients with relapsed CLL.</span>", "ID": "8b9141c1-7305-4e6d-9d87-6d23c43515e1", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "Arzerra is indicated in combination with fludarabine and cyclophosphamide for the treatment of adult patients with relapsed CLL.", "ParentId": "1348a74c-45d8-4051-af0a-318bb07248ee"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "1b6c750c-81b8-491f-866f-37340dc31c33", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">See section\u00a05.1 for further information.</p>", "ID": "1f1cabab-b63d-4dc1-af2f-3bca8c51da99", "Styles": "None", "Classes": "['MsoNormal']", "Text": "See section\u00a05.1 for further information.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cf9a109e-86ee-4b7d-9ae8-1e3cea3f153b", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "15184029-f6f1-488a-be3f-20e920a078b2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cf9a109e-86ee-4b7d-9ae8-1e3cea3f153b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u>Refractory\nCLL</u></p>", "ID": "4cd8adc8-d89a-4d79-83af-13a96f14840a", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u>Refractory\nCLL</u>", "ID": "f80daa1b-33b7-40e1-84f6-17b706338916", "Styles": "None", "Classes": "None", "Text": "Refractory CLL", "ParentId": "4cd8adc8-d89a-4d79-83af-13a96f14840a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "65ac7685-57f4-427f-9a9f-2c376be98334", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d84ee964-a896-4996-8e2a-998034d24379", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "65ac7685-57f4-427f-9a9f-2c376be98334"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Arzerra</span>\nis indicated for the treatment of CLL in adult patients who are refractory to\nfludarabine and alemtuzumab<span lang=\"EN-GB\" style=\"color:black\">.</span></p>", "ID": "7f33509a-73be-45f8-aeda-1fbac7dc01b5", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": " is indicated for the treatment of CLL in adult patients who are refractory to fludarabine and alemtuzumab", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Arzerra</span>", "ID": "3b3eba72-1baf-47c1-b1c7-c087887f3839", "Styles": "None", "Classes": "None", "Text": "Arzerra", "ParentId": "7f33509a-73be-45f8-aeda-1fbac7dc01b5"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">.</span>", "ID": "138d8dcf-282a-4119-bb38-ad863d788067", "Styles": "color:black", "Classes": "None", "Text": ".", "ParentId": "7f33509a-73be-45f8-aeda-1fbac7dc01b5"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "b11cad61-4bc1-4bf4-8f01-2c608d6fecf0", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "3bc2a923-1f22-4552-afa3-65f1321c3c79", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "b11cad61-4bc1-4bf4-8f01-2c608d6fecf0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">See\nsection\u00a05.1 for further information.</span></p>", "ID": "73702fa8-f361-4e2e-9d3b-c7782b9a4d5f", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">See\nsection\u00a05.1 for further information.</span>", "ID": "5b863d03-acc3-4e41-9379-932aeeaca192", "Styles": "None", "Classes": "None", "Text": "See section\u00a05.1 for further information.", "ParentId": "73702fa8-f361-4e2e-9d3b-c7782b9a4d5f"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "9ac4f059-7410-4b78-b2ee-6ed5b5b1e504", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "78b94b9e-3344-4718-9626-6976c61fc9de", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "9ac4f059-7410-4b78-b2ee-6ed5b5b1e504"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">4.2\u00a0\u00a0\u00a0\u00a0 Posology and method of administration</span></b></p>", "ID": "45c95db5-ea49-4948-9218-ed6efce1e284", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">4.2\u00a0\u00a0\u00a0\u00a0 Posology and method of administration</span></b>", "ID": "e127cec7-66b9-4332-b047-089557ff17d2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "45c95db5-ea49-4948-9218-ed6efce1e284"}, {"Element": "<span lang=\"EN-GB\">4.2\u00a0\u00a0\u00a0\u00a0 Posology and method of administration</span>", "ID": "12563bb9-1da4-494b-ba63-71c1b007ea74", "Styles": "None", "Classes": "None", "Text": "4.2\u00a0\u00a0\u00a0\u00a0 Posology and method of administration", "ParentId": "e127cec7-66b9-4332-b047-089557ff17d2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "da958df4-7a54-45be-bb60-108eec98d71e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "098fe069-219d-4fef-b50c-e6a154221a80", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "da958df4-7a54-45be-bb60-108eec98d71e"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "dd3a8fe1-84c8-43de-aac3-2b37dac7051b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "098fe069-219d-4fef-b50c-e6a154221a80"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "5a72a4b5-fdd2-4ec3-ac92-fc7bb1d27f93", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "dd3a8fe1-84c8-43de-aac3-2b37dac7051b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Arzerra should be administered under the\nsupervision of a physician experienced in the use of cancer therapy</span> and\nin an environment where full resuscitation facilities are immediately\navailable.</p>", "ID": "d403a0f1-e85c-48f9-924c-f52e9fc4c7a2", "Styles": "None", "Classes": "['MsoNormal']", "Text": " and in an environment where full resuscitation facilities are immediately available.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Arzerra should be administered under the\nsupervision of a physician experienced in the use of cancer therapy</span>", "ID": "2750904f-5133-4bb8-bf18-5e8cdd96e9fa", "Styles": "None", "Classes": "None", "Text": "Arzerra should be administered under the supervision of a physician experienced in the use of cancer therapy", "ParentId": "d403a0f1-e85c-48f9-924c-f52e9fc4c7a2"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "60a1d832-1376-4caa-be86-ce326c40a303", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "c915a93a-973a-420b-a784-9f080a650176", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "60a1d832-1376-4caa-be86-ce326c40a303"}, {"Element": "<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\navoid\"><u><span lang=\"X-NONE\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Monitoring</span></u></p>", "ID": "c66c3435-ffdd-4c4f-a1bd-790c13a0d1a1", "Styles": "margin-bottom:0in;line-height:normal;page-break-after:\navoid", "Classes": "['BodytextAgency']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"X-NONE\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Monitoring</span></u>", "ID": "fdf41a9e-7bd9-49f1-87a2-af2ae6ca6681", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c66c3435-ffdd-4c4f-a1bd-790c13a0d1a1"}, {"Element": "<span lang=\"X-NONE\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Monitoring</span>", "ID": "eff3cc63-77a5-4569-bfd8-8fd55c715a26", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Monitoring", "ParentId": "fdf41a9e-7bd9-49f1-87a2-af2ae6ca6681"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cf107b07-0b3d-4d8c-8f3c-c878dd4906e2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "64f26231-dc47-4bfe-b18b-4d75600faaa4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cf107b07-0b3d-4d8c-8f3c-c878dd4906e2"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Patients should be closely monitored during administration\nof ofatumumab for the onset of infusion-related reactions, including cytokine\nrelease syndrome, particularly during the first infusion.</span></p>", "ID": "092f3d16-d8cd-428f-b8ed-0e52c77e8943", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Patients should be closely monitored during administration\nof ofatumumab for the onset of infusion-related reactions, including cytokine\nrelease syndrome, particularly during the first infusion.</span>", "ID": "6fa790a3-b79b-4f78-bae4-a9708d018ba3", "Styles": "color:black", "Classes": "None", "Text": "Patients should be closely monitored during administration of ofatumumab for the onset of infusion-related reactions, including cytokine release syndrome, particularly during the first infusion.", "ParentId": "092f3d16-d8cd-428f-b8ed-0e52c77e8943"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "996b9ce9-ad98-4628-b3f5-aab135ccb758", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "aad186f6-dde7-4d7a-ba05-6cc2893f8e90", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "996b9ce9-ad98-4628-b3f5-aab135ccb758"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Pre-medication</u></p>", "ID": "e881dfef-f602-44f4-a2b5-39cf4b958448", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u>Pre-medication</u>", "ID": "62d0dbca-8d53-4e99-ad6f-b23c1f06b8e4", "Styles": "None", "Classes": "None", "Text": "Pre-medication", "ParentId": "e881dfef-f602-44f4-a2b5-39cf4b958448"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2919f773-fcc2-4eb2-8b96-dbeb85d1a1fa", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "516c76ac-b64a-41bb-802c-0ce26f2daee6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2919f773-fcc2-4eb2-8b96-dbeb85d1a1fa"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Patients should receive the following pre\u2011medication\nmedicinal products 30\u00a0minutes to 2\u00a0hours prior to each Arzerra\ninfusion according to the following dosing schedules:</span></p>", "ID": "016504ff-1179-408e-af93-fdaf76c1a5f5", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Patients should receive the following pre\u2011medication\nmedicinal products 30\u00a0minutes to 2\u00a0hours prior to each Arzerra\ninfusion according to the following dosing schedules:</span>", "ID": "479e91ad-fb98-441b-8760-ece68b09e01d", "Styles": "color:black", "Classes": "None", "Text": "Patients should receive the following pre\u2011medication medicinal products 30\u00a0minutes to 2\u00a0hours prior to each Arzerra infusion according to the following dosing schedules:", "ParentId": "016504ff-1179-408e-af93-fdaf76c1a5f5"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a16bf52f-4748-4a9c-938c-49dd2bd1d394", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<h6 style=\"line-height:normal\"><u><span lang=\"EN-GB\">Premedication schedule for\nArzerra</span></u></h6>", "ID": "b44ccc09-e405-43c3-9a03-6beed44a1788", "Styles": "line-height:normal", "Classes": "None", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\">Premedication schedule for\nArzerra</span></u>", "ID": "9a4f77c6-6144-4e9e-82db-dbc69e9491d3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b44ccc09-e405-43c3-9a03-6beed44a1788"}, {"Element": "<span lang=\"EN-GB\">Premedication schedule for\nArzerra</span>", "ID": "23b6a22d-c699-4e6b-a07c-66e749aa1c01", "Styles": "None", "Classes": "None", "Text": "Premedication schedule for Arzerra", "ParentId": "9a4f77c6-6144-4e9e-82db-dbc69e9491d3"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a21751bb-aea3-43b4-8fc5-dca8ce959514", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "69528f01-7dc3-417f-bb12-62fdc2e22b10", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a21751bb-aea3-43b4-8fc5-dca8ce959514"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:-1.7pt;border-collapse:collapse;border:none\" width=\"624\">\n<tr>\n<td style=\"width:113.45pt;border:solid windowtext 1.0pt;padding:\n  0in 5.4pt 0in 5.4pt\" width=\"151\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>\u00a0</span></p>\n</td>\n<td colspan=\"2\" style=\"width:113.4pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" width=\"151\">\n<p class=\"Table\" style=\"margin:0in\"><b><span style='font-size:11.0pt;\n  font-family:\"Times New Roman\",serif'>Previously untreated CLL or relapsed CLL\n  </span></b></p>\n</td>\n<td colspan=\"4\" style=\"width:241.0pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" width=\"321\">\n<p align=\"center\" class=\"Table\" style=\"margin:0in;text-align:center\"><b><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Refractory CLL</span></b></p>\n</td>\n</tr>\n<tr style=\"height:24.8pt\">\n<td style=\"width:113.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt;height:24.8pt\" width=\"151\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Infusion number</span></p>\n</td>\n<td style=\"width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:24.8pt\" width=\"76\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>1 and 2</span></p>\n</td>\n<td style=\"width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:24.8pt\" width=\"76\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>3 to n*</span></p>\n</td>\n<td style=\"width:49.65pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:24.8pt\" width=\"66\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>1 and 2</span></p>\n</td>\n<td style=\"width:63.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:24.8pt\" width=\"85\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>3 to 8</span></p>\n</td>\n<td style=\"width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:24.8pt\" width=\"76\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>9</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:24.8pt\" width=\"95\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>10 to 12</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:113.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"151\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Intravenous corticosteroid (prednisolone or\n  equivalent)</span></p>\n</td>\n<td style=\"width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" width=\"76\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>50\u00a0mg</span></p>\n</td>\n<td style=\"width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" width=\"76\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>0 to 50\u00a0mg**</span></p>\n</td>\n<td style=\"width:49.65pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"66\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>100\u00a0mg</span></p>\n</td>\n<td style=\"width:63.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"85\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>0 to 100\u00a0mg**</span></p>\n</td>\n<td style=\"width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" width=\"76\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>100\u00a0mg</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" width=\"95\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>50 to 100\u00a0mg***</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:113.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"151\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Oral paracetamol (acetaminophen)</span></p>\n</td>\n<td colspan=\"6\" style=\"width:354.4pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"473\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>1000\u00a0mg</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:113.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"151\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Oral or intravenous antihistamine</span></p>\n</td>\n<td colspan=\"6\" style=\"width:354.4pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"473\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Diphenhydramine 50\u00a0mg or cetirizine 10\u00a0mg\n  (or equivalent)</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"7\" style=\"width:467.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" width=\"624\">\n<p class=\"Legend\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>*Up to 13\u00a0infusions in previously untreated\n  CLL; up to 7\u00a0infusions in relapsed CLL</span></p>\n<p class=\"Legend\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>**Corticosteroid may be either reduced or omitted\n  for subsequent infusions at the discretion of the physician, if a severe\n  infusion-related adverse drug reaction (ADR) did not occur with the preceding\n  infusion(s).</span></p>\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>***Corticosteroid may be reduced for subsequent\n  infusions at the discretion of the physician, if a severe infusion-related\n  ADR did not occur with the preceding infusion(s).</span></p>\n</td>\n</tr>\n</table>", "ID": "d0845d98-fd75-4242-8017-b30f751c9aee", "Styles": "margin-left:-1.7pt;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "       ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<tr>\n<td style=\"width:113.45pt;border:solid windowtext 1.0pt;padding:\n  0in 5.4pt 0in 5.4pt\" width=\"151\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>\u00a0</span></p>\n</td>\n<td colspan=\"2\" style=\"width:113.4pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" width=\"151\">\n<p class=\"Table\" style=\"margin:0in\"><b><span style='font-size:11.0pt;\n  font-family:\"Times New Roman\",serif'>Previously untreated CLL or relapsed CLL\n  </span></b></p>\n</td>\n<td colspan=\"4\" style=\"width:241.0pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" width=\"321\">\n<p align=\"center\" class=\"Table\" style=\"margin:0in;text-align:center\"><b><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Refractory CLL</span></b></p>\n</td>\n</tr>", "ID": "972819ff-3f34-49d5-80ab-e353ec7a35f4", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "d0845d98-fd75-4242-8017-b30f751c9aee"}, {"Element": "<td style=\"width:113.45pt;border:solid windowtext 1.0pt;padding:\n  0in 5.4pt 0in 5.4pt\" width=\"151\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>\u00a0</span></p>\n</td>", "ID": "b1dcf104-de31-4c10-836f-0101bbe6b0be", "Styles": "width:113.45pt;border:solid windowtext 1.0pt;padding:\n  0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "972819ff-3f34-49d5-80ab-e353ec7a35f4"}, {"Element": "<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>\u00a0</span></p>", "ID": "342526db-62a8-4956-bb5e-6fad4ccc4e85", "Styles": "margin:0in", "Classes": "['Table']", "Text": "", "ParentId": "b1dcf104-de31-4c10-836f-0101bbe6b0be"}, {"Element": "<span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>\u00a0</span>", "ID": "a5643d48-5c78-499a-acfa-c7dc82109966", "Styles": "font-size:11.0pt;font-family:\n  \"Times New Roman\",serif", "Classes": "None", "Text": "\u00a0", "ParentId": "342526db-62a8-4956-bb5e-6fad4ccc4e85"}, {"Element": "<td colspan=\"2\" style=\"width:113.4pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" width=\"151\">\n<p class=\"Table\" style=\"margin:0in\"><b><span style='font-size:11.0pt;\n  font-family:\"Times New Roman\",serif'>Previously untreated CLL or relapsed CLL\n  </span></b></p>\n</td>", "ID": "35255974-05e2-4521-b7e0-67a8eff29354", "Styles": "width:113.4pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "972819ff-3f34-49d5-80ab-e353ec7a35f4"}, {"Element": "<p class=\"Table\" style=\"margin:0in\"><b><span style='font-size:11.0pt;\n  font-family:\"Times New Roman\",serif'>Previously untreated CLL or relapsed CLL\n  </span></b></p>", "ID": "7e89aa49-d281-4648-9cc5-76e54df60480", "Styles": "margin:0in", "Classes": "['Table']", "Text": "", "ParentId": "35255974-05e2-4521-b7e0-67a8eff29354"}, {"Element": "<b><span style='font-size:11.0pt;\n  font-family:\"Times New Roman\",serif'>Previously untreated CLL or relapsed CLL\n  </span></b>", "ID": "5bbdba0d-71ef-4b27-b835-c2e787923483", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7e89aa49-d281-4648-9cc5-76e54df60480"}, {"Element": "<span style='font-size:11.0pt;\n  font-family:\"Times New Roman\",serif'>Previously untreated CLL or relapsed CLL\n  </span>", "ID": "e4e59cc4-3202-49ca-baa6-40679ddf03bc", "Styles": "font-size:11.0pt;\n  font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Previously untreated CLL or relapsed CLL   ", "ParentId": "5bbdba0d-71ef-4b27-b835-c2e787923483"}, {"Element": "<td colspan=\"4\" style=\"width:241.0pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" width=\"321\">\n<p align=\"center\" class=\"Table\" style=\"margin:0in;text-align:center\"><b><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Refractory CLL</span></b></p>\n</td>", "ID": "f7b321e4-bd58-44cb-828d-5a8143433408", "Styles": "width:241.0pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "972819ff-3f34-49d5-80ab-e353ec7a35f4"}, {"Element": "<p align=\"center\" class=\"Table\" style=\"margin:0in;text-align:center\"><b><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Refractory CLL</span></b></p>", "ID": "538dbafd-7029-4dd7-869b-c5a37cfee604", "Styles": "margin:0in;text-align:center", "Classes": "['Table']", "Text": "", "ParentId": "f7b321e4-bd58-44cb-828d-5a8143433408"}, {"Element": "<b><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Refractory CLL</span></b>", "ID": "21eb7b95-fbc8-4f74-b5f4-82ce94def519", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "538dbafd-7029-4dd7-869b-c5a37cfee604"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Refractory CLL</span>", "ID": "02422a24-a69c-4573-9707-8e181cc2a998", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Refractory CLL", "ParentId": "21eb7b95-fbc8-4f74-b5f4-82ce94def519"}, {"Element": "<tr style=\"height:24.8pt\">\n<td style=\"width:113.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt;height:24.8pt\" width=\"151\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Infusion number</span></p>\n</td>\n<td style=\"width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:24.8pt\" width=\"76\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>1 and 2</span></p>\n</td>\n<td style=\"width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:24.8pt\" width=\"76\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>3 to n*</span></p>\n</td>\n<td style=\"width:49.65pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:24.8pt\" width=\"66\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>1 and 2</span></p>\n</td>\n<td style=\"width:63.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:24.8pt\" width=\"85\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>3 to 8</span></p>\n</td>\n<td style=\"width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:24.8pt\" width=\"76\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>9</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:24.8pt\" width=\"95\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>10 to 12</span></p>\n</td>\n</tr>", "ID": "4082c4f0-772b-4636-8814-1085b67b5f6b", "Styles": "height:24.8pt", "Classes": "None", "Text": "        ", "ParentId": "d0845d98-fd75-4242-8017-b30f751c9aee"}, {"Element": "<td style=\"width:113.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt;height:24.8pt\" width=\"151\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Infusion number</span></p>\n</td>", "ID": "e159ca4c-10ee-4493-94c6-6e5701bb07d9", "Styles": "width:113.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt;height:24.8pt", "Classes": "None", "Text": "  ", "ParentId": "4082c4f0-772b-4636-8814-1085b67b5f6b"}, {"Element": "<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Infusion number</span></p>", "ID": "ab06a980-31c8-477b-bf67-cc9f66232214", "Styles": "margin:0in", "Classes": "['Table']", "Text": "", "ParentId": "e159ca4c-10ee-4493-94c6-6e5701bb07d9"}, {"Element": "<span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Infusion number</span>", "ID": "c068e581-0354-4344-a670-4d7b2349472b", "Styles": "font-size:11.0pt;font-family:\n  \"Times New Roman\",serif", "Classes": "None", "Text": "Infusion number", "ParentId": "ab06a980-31c8-477b-bf67-cc9f66232214"}, {"Element": "<td style=\"width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:24.8pt\" width=\"76\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>1 and 2</span></p>\n</td>", "ID": "f6393503-721c-4999-8364-80463c2f3c3c", "Styles": "width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:24.8pt", "Classes": "None", "Text": "  ", "ParentId": "4082c4f0-772b-4636-8814-1085b67b5f6b"}, {"Element": "<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>1 and 2</span></p>", "ID": "453d5b2b-2f83-4280-a71f-e802b606322a", "Styles": "margin:0in", "Classes": "['Table']", "Text": "", "ParentId": "f6393503-721c-4999-8364-80463c2f3c3c"}, {"Element": "<span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>1 and 2</span>", "ID": "7a55bd18-0e3d-4bac-a64c-59b1cf4e1fcb", "Styles": "font-size:11.0pt;font-family:\n  \"Times New Roman\",serif", "Classes": "None", "Text": "1 and 2", "ParentId": "453d5b2b-2f83-4280-a71f-e802b606322a"}, {"Element": "<td style=\"width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:24.8pt\" width=\"76\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>3 to n*</span></p>\n</td>", "ID": "881855c7-ff9f-4874-880c-e9d940b16af7", "Styles": "width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:24.8pt", "Classes": "None", "Text": "  ", "ParentId": "4082c4f0-772b-4636-8814-1085b67b5f6b"}, {"Element": "<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>3 to n*</span></p>", "ID": "3b56b191-0007-4df9-8b5f-3cbb951f72ae", "Styles": "margin:0in", "Classes": "['Table']", "Text": "", "ParentId": "881855c7-ff9f-4874-880c-e9d940b16af7"}, {"Element": "<span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>3 to n*</span>", "ID": "ac7825e1-8173-4fbb-b2fd-7ab2b3e9a523", "Styles": "font-size:11.0pt;font-family:\n  \"Times New Roman\",serif", "Classes": "None", "Text": "3 to n*", "ParentId": "3b56b191-0007-4df9-8b5f-3cbb951f72ae"}, {"Element": "<td style=\"width:49.65pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:24.8pt\" width=\"66\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>1 and 2</span></p>\n</td>", "ID": "98f2fed8-2be0-4487-8aca-56481f1afe3e", "Styles": "width:49.65pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:24.8pt", "Classes": "None", "Text": "  ", "ParentId": "4082c4f0-772b-4636-8814-1085b67b5f6b"}, {"Element": "<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>1 and 2</span></p>", "ID": "e3397b48-25ec-4819-b8fe-ae42bd61451a", "Styles": "margin:0in", "Classes": "['Table']", "Text": "", "ParentId": "98f2fed8-2be0-4487-8aca-56481f1afe3e"}, {"Element": "<span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>1 and 2</span>", "ID": "0ffedd80-d195-4f3e-9d35-810273d9148b", "Styles": "font-size:11.0pt;font-family:\n  \"Times New Roman\",serif", "Classes": "None", "Text": "1 and 2", "ParentId": "e3397b48-25ec-4819-b8fe-ae42bd61451a"}, {"Element": "<td style=\"width:63.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:24.8pt\" width=\"85\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>3 to 8</span></p>\n</td>", "ID": "4ba379e4-0731-4d36-80ca-2d5982c4ca25", "Styles": "width:63.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:24.8pt", "Classes": "None", "Text": "  ", "ParentId": "4082c4f0-772b-4636-8814-1085b67b5f6b"}, {"Element": "<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>3 to 8</span></p>", "ID": "b8a6bdc6-7633-4fec-932c-93a154a9e58c", "Styles": "margin:0in", "Classes": "['Table']", "Text": "", "ParentId": "4ba379e4-0731-4d36-80ca-2d5982c4ca25"}, {"Element": "<span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>3 to 8</span>", "ID": "f43ff182-e0cd-4714-b5f7-029b7d4940fe", "Styles": "font-size:11.0pt;font-family:\n  \"Times New Roman\",serif", "Classes": "None", "Text": "3 to 8", "ParentId": "b8a6bdc6-7633-4fec-932c-93a154a9e58c"}, {"Element": "<td style=\"width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:24.8pt\" width=\"76\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>9</span></p>\n</td>", "ID": "5532ccc0-675a-4667-8280-5c88841a8cab", "Styles": "width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:24.8pt", "Classes": "None", "Text": "  ", "ParentId": "4082c4f0-772b-4636-8814-1085b67b5f6b"}, {"Element": "<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>9</span></p>", "ID": "a9620358-bbd0-4183-917c-585800d51baa", "Styles": "margin:0in", "Classes": "['Table']", "Text": "", "ParentId": "5532ccc0-675a-4667-8280-5c88841a8cab"}, {"Element": "<span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>9</span>", "ID": "5e5674ab-8a36-4b3e-973c-23491b366966", "Styles": "font-size:11.0pt;font-family:\n  \"Times New Roman\",serif", "Classes": "None", "Text": "9", "ParentId": "a9620358-bbd0-4183-917c-585800d51baa"}, {"Element": "<td style=\"width:70.9pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:24.8pt\" width=\"95\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>10 to 12</span></p>\n</td>", "ID": "94596e51-5f47-4722-a017-3e6ff9291c5a", "Styles": "width:70.9pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:24.8pt", "Classes": "None", "Text": "  ", "ParentId": "4082c4f0-772b-4636-8814-1085b67b5f6b"}, {"Element": "<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>10 to 12</span></p>", "ID": "c6f13d85-a0e6-4f0c-bea7-a5e105276a3a", "Styles": "margin:0in", "Classes": "['Table']", "Text": "", "ParentId": "94596e51-5f47-4722-a017-3e6ff9291c5a"}, {"Element": "<span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>10 to 12</span>", "ID": "0e884fd1-e00c-4bad-a1a8-deaced11edab", "Styles": "font-size:11.0pt;font-family:\n  \"Times New Roman\",serif", "Classes": "None", "Text": "10 to 12", "ParentId": "c6f13d85-a0e6-4f0c-bea7-a5e105276a3a"}, {"Element": "<tr>\n<td style=\"width:113.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"151\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Intravenous corticosteroid (prednisolone or\n  equivalent)</span></p>\n</td>\n<td style=\"width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" width=\"76\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>50\u00a0mg</span></p>\n</td>\n<td style=\"width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" width=\"76\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>0 to 50\u00a0mg**</span></p>\n</td>\n<td style=\"width:49.65pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"66\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>100\u00a0mg</span></p>\n</td>\n<td style=\"width:63.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"85\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>0 to 100\u00a0mg**</span></p>\n</td>\n<td style=\"width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" width=\"76\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>100\u00a0mg</span></p>\n</td>\n<td style=\"width:70.9pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" width=\"95\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>50 to 100\u00a0mg***</span></p>\n</td>\n</tr>", "ID": "5b705cca-0128-4ae5-af45-f185837c33b9", "Styles": "None", "Classes": "None", "Text": "        ", "ParentId": "d0845d98-fd75-4242-8017-b30f751c9aee"}, {"Element": "<td style=\"width:113.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"151\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Intravenous corticosteroid (prednisolone or\n  equivalent)</span></p>\n</td>", "ID": "fb6dd51d-200e-4dd7-8383-b18ed0233efb", "Styles": "width:113.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5b705cca-0128-4ae5-af45-f185837c33b9"}, {"Element": "<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Intravenous corticosteroid (prednisolone or\n  equivalent)</span></p>", "ID": "4066ef4f-0fc6-463f-9fe9-bfea41c00bc1", "Styles": "margin:0in", "Classes": "['Table']", "Text": "", "ParentId": "fb6dd51d-200e-4dd7-8383-b18ed0233efb"}, {"Element": "<span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Intravenous corticosteroid (prednisolone or\n  equivalent)</span>", "ID": "99893bb1-527a-4795-9879-5acb34934fef", "Styles": "font-size:11.0pt;font-family:\n  \"Times New Roman\",serif", "Classes": "None", "Text": "Intravenous corticosteroid (prednisolone or   equivalent)", "ParentId": "4066ef4f-0fc6-463f-9fe9-bfea41c00bc1"}, {"Element": "<td style=\"width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" width=\"76\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>50\u00a0mg</span></p>\n</td>", "ID": "e951493e-7aca-4e8f-a3eb-cd5b0e69930f", "Styles": "width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5b705cca-0128-4ae5-af45-f185837c33b9"}, {"Element": "<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>50\u00a0mg</span></p>", "ID": "0dd3cef4-2923-4f06-b4e0-279ae55aa185", "Styles": "margin:0in", "Classes": "['Table']", "Text": "", "ParentId": "e951493e-7aca-4e8f-a3eb-cd5b0e69930f"}, {"Element": "<span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>50\u00a0mg</span>", "ID": "06d46687-213e-45d0-92f2-c6eea2666808", "Styles": "font-size:11.0pt;font-family:\n  \"Times New Roman\",serif", "Classes": "None", "Text": "50\u00a0mg", "ParentId": "0dd3cef4-2923-4f06-b4e0-279ae55aa185"}, {"Element": "<td style=\"width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" width=\"76\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>0 to 50\u00a0mg**</span></p>\n</td>", "ID": "71b5c24f-00bd-48de-b63d-345a92b51382", "Styles": "width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5b705cca-0128-4ae5-af45-f185837c33b9"}, {"Element": "<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>0 to 50\u00a0mg**</span></p>", "ID": "db463e7e-f4cb-4b56-8f36-db522ddeafc3", "Styles": "margin:0in", "Classes": "['Table']", "Text": "", "ParentId": "71b5c24f-00bd-48de-b63d-345a92b51382"}, {"Element": "<span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>0 to 50\u00a0mg**</span>", "ID": "fd4ff736-120d-4a01-b5b0-9010649d6b7f", "Styles": "font-size:11.0pt;font-family:\n  \"Times New Roman\",serif", "Classes": "None", "Text": "0 to 50\u00a0mg**", "ParentId": "db463e7e-f4cb-4b56-8f36-db522ddeafc3"}, {"Element": "<td style=\"width:49.65pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"66\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>100\u00a0mg</span></p>\n</td>", "ID": "14ccccf8-5dba-4960-86eb-bc1fee1e8db6", "Styles": "width:49.65pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5b705cca-0128-4ae5-af45-f185837c33b9"}, {"Element": "<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>100\u00a0mg</span></p>", "ID": "3f09ead6-c60c-4c66-b4ce-acefc72fe663", "Styles": "margin:0in", "Classes": "['Table']", "Text": "", "ParentId": "14ccccf8-5dba-4960-86eb-bc1fee1e8db6"}, {"Element": "<span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>100\u00a0mg</span>", "ID": "a31572bf-7485-4d0c-8894-69b5f24db994", "Styles": "font-size:11.0pt;font-family:\n  \"Times New Roman\",serif", "Classes": "None", "Text": "100\u00a0mg", "ParentId": "3f09ead6-c60c-4c66-b4ce-acefc72fe663"}, {"Element": "<td style=\"width:63.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"85\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>0 to 100\u00a0mg**</span></p>\n</td>", "ID": "108e5052-d10d-40ee-a3fd-cf17e574feb3", "Styles": "width:63.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5b705cca-0128-4ae5-af45-f185837c33b9"}, {"Element": "<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>0 to 100\u00a0mg**</span></p>", "ID": "e15b2494-cfe1-4c19-ad0d-6fa4aabd7521", "Styles": "margin:0in", "Classes": "['Table']", "Text": "", "ParentId": "108e5052-d10d-40ee-a3fd-cf17e574feb3"}, {"Element": "<span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>0 to 100\u00a0mg**</span>", "ID": "d2bc84e8-1309-4356-b53c-78e437162c85", "Styles": "font-size:11.0pt;font-family:\n  \"Times New Roman\",serif", "Classes": "None", "Text": "0 to 100\u00a0mg**", "ParentId": "e15b2494-cfe1-4c19-ad0d-6fa4aabd7521"}, {"Element": "<td style=\"width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" width=\"76\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>100\u00a0mg</span></p>\n</td>", "ID": "793b6966-89e2-4f0d-86cc-0ae761de2ed8", "Styles": "width:56.7pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5b705cca-0128-4ae5-af45-f185837c33b9"}, {"Element": "<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>100\u00a0mg</span></p>", "ID": "7eaa9328-ffd4-4ca1-a414-2e9188d24c24", "Styles": "margin:0in", "Classes": "['Table']", "Text": "", "ParentId": "793b6966-89e2-4f0d-86cc-0ae761de2ed8"}, {"Element": "<span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>100\u00a0mg</span>", "ID": "b9a57188-9143-4ea1-918a-35620b580fdb", "Styles": "font-size:11.0pt;font-family:\n  \"Times New Roman\",serif", "Classes": "None", "Text": "100\u00a0mg", "ParentId": "7eaa9328-ffd4-4ca1-a414-2e9188d24c24"}, {"Element": "<td style=\"width:70.9pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" width=\"95\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>50 to 100\u00a0mg***</span></p>\n</td>", "ID": "a4518350-a8ab-428e-a88c-f13229332e83", "Styles": "width:70.9pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5b705cca-0128-4ae5-af45-f185837c33b9"}, {"Element": "<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>50 to 100\u00a0mg***</span></p>", "ID": "6bec32d9-3cdb-4ad1-91b3-f7fec2cd8797", "Styles": "margin:0in", "Classes": "['Table']", "Text": "", "ParentId": "a4518350-a8ab-428e-a88c-f13229332e83"}, {"Element": "<span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>50 to 100\u00a0mg***</span>", "ID": "2872b616-02fc-4312-99bd-670087008abe", "Styles": "font-size:11.0pt;font-family:\n  \"Times New Roman\",serif", "Classes": "None", "Text": "50 to 100\u00a0mg***", "ParentId": "6bec32d9-3cdb-4ad1-91b3-f7fec2cd8797"}, {"Element": "<tr>\n<td style=\"width:113.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"151\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Oral paracetamol (acetaminophen)</span></p>\n</td>\n<td colspan=\"6\" style=\"width:354.4pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"473\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>1000\u00a0mg</span></p>\n</td>\n</tr>", "ID": "54fc8d5a-1f2f-4478-b5c7-04f98ec0ee7a", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "d0845d98-fd75-4242-8017-b30f751c9aee"}, {"Element": "<td style=\"width:113.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"151\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Oral paracetamol (acetaminophen)</span></p>\n</td>", "ID": "1ce20cb3-f87d-4d68-af15-a8c74879ca90", "Styles": "width:113.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "54fc8d5a-1f2f-4478-b5c7-04f98ec0ee7a"}, {"Element": "<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Oral paracetamol (acetaminophen)</span></p>", "ID": "9c42bd42-e8b4-44a2-9771-b9b34200c72c", "Styles": "margin:0in", "Classes": "['Table']", "Text": "", "ParentId": "1ce20cb3-f87d-4d68-af15-a8c74879ca90"}, {"Element": "<span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Oral paracetamol (acetaminophen)</span>", "ID": "96b5d727-b2f0-47e3-a4d5-638c9c9a8e55", "Styles": "font-size:11.0pt;font-family:\n  \"Times New Roman\",serif", "Classes": "None", "Text": "Oral paracetamol (acetaminophen)", "ParentId": "9c42bd42-e8b4-44a2-9771-b9b34200c72c"}, {"Element": "<td colspan=\"6\" style=\"width:354.4pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"473\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>1000\u00a0mg</span></p>\n</td>", "ID": "1df4f3f5-9e11-4107-bb8d-f2487f5c485f", "Styles": "width:354.4pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "54fc8d5a-1f2f-4478-b5c7-04f98ec0ee7a"}, {"Element": "<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>1000\u00a0mg</span></p>", "ID": "21c86b4b-2346-4437-babd-12a32eba95e6", "Styles": "margin:0in", "Classes": "['Table']", "Text": "", "ParentId": "1df4f3f5-9e11-4107-bb8d-f2487f5c485f"}, {"Element": "<span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>1000\u00a0mg</span>", "ID": "faa93d32-6f13-406d-b386-4baf877023ff", "Styles": "font-size:11.0pt;font-family:\n  \"Times New Roman\",serif", "Classes": "None", "Text": "1000\u00a0mg", "ParentId": "21c86b4b-2346-4437-babd-12a32eba95e6"}, {"Element": "<tr>\n<td style=\"width:113.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"151\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Oral or intravenous antihistamine</span></p>\n</td>\n<td colspan=\"6\" style=\"width:354.4pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"473\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Diphenhydramine 50\u00a0mg or cetirizine 10\u00a0mg\n  (or equivalent)</span></p>\n</td>\n</tr>", "ID": "eab49f40-eb71-4da9-b182-896c027d061c", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "d0845d98-fd75-4242-8017-b30f751c9aee"}, {"Element": "<td style=\"width:113.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"151\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Oral or intravenous antihistamine</span></p>\n</td>", "ID": "1766dd89-fb41-4757-aa87-b8c2fba82670", "Styles": "width:113.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "eab49f40-eb71-4da9-b182-896c027d061c"}, {"Element": "<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Oral or intravenous antihistamine</span></p>", "ID": "1300bfed-c74a-4885-9c1a-9e7b6d67cdb3", "Styles": "margin:0in", "Classes": "['Table']", "Text": "", "ParentId": "1766dd89-fb41-4757-aa87-b8c2fba82670"}, {"Element": "<span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Oral or intravenous antihistamine</span>", "ID": "419c8492-9f26-4b94-aaf4-2c85685222c7", "Styles": "font-size:11.0pt;font-family:\n  \"Times New Roman\",serif", "Classes": "None", "Text": "Oral or intravenous antihistamine", "ParentId": "1300bfed-c74a-4885-9c1a-9e7b6d67cdb3"}, {"Element": "<td colspan=\"6\" style=\"width:354.4pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"473\">\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Diphenhydramine 50\u00a0mg or cetirizine 10\u00a0mg\n  (or equivalent)</span></p>\n</td>", "ID": "f29595b8-811b-440f-bc97-d44e182fe957", "Styles": "width:354.4pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "eab49f40-eb71-4da9-b182-896c027d061c"}, {"Element": "<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Diphenhydramine 50\u00a0mg or cetirizine 10\u00a0mg\n  (or equivalent)</span></p>", "ID": "e435a875-6fb1-4f97-a798-306d632be6f2", "Styles": "margin:0in", "Classes": "['Table']", "Text": "", "ParentId": "f29595b8-811b-440f-bc97-d44e182fe957"}, {"Element": "<span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>Diphenhydramine 50\u00a0mg or cetirizine 10\u00a0mg\n  (or equivalent)</span>", "ID": "7402e7a4-7c2b-4eb3-a7f5-0b6ee5e92614", "Styles": "font-size:11.0pt;font-family:\n  \"Times New Roman\",serif", "Classes": "None", "Text": "Diphenhydramine 50\u00a0mg or cetirizine 10\u00a0mg   (or equivalent)", "ParentId": "e435a875-6fb1-4f97-a798-306d632be6f2"}, {"Element": "<tr>\n<td colspan=\"7\" style=\"width:467.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" width=\"624\">\n<p class=\"Legend\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>*Up to 13\u00a0infusions in previously untreated\n  CLL; up to 7\u00a0infusions in relapsed CLL</span></p>\n<p class=\"Legend\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>**Corticosteroid may be either reduced or omitted\n  for subsequent infusions at the discretion of the physician, if a severe\n  infusion-related adverse drug reaction (ADR) did not occur with the preceding\n  infusion(s).</span></p>\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>***Corticosteroid may be reduced for subsequent\n  infusions at the discretion of the physician, if a severe infusion-related\n  ADR did not occur with the preceding infusion(s).</span></p>\n</td>\n</tr>", "ID": "4c19e07f-1050-4253-9414-190dd3929501", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "d0845d98-fd75-4242-8017-b30f751c9aee"}, {"Element": "<td colspan=\"7\" style=\"width:467.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" width=\"624\">\n<p class=\"Legend\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>*Up to 13\u00a0infusions in previously untreated\n  CLL; up to 7\u00a0infusions in relapsed CLL</span></p>\n<p class=\"Legend\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>**Corticosteroid may be either reduced or omitted\n  for subsequent infusions at the discretion of the physician, if a severe\n  infusion-related adverse drug reaction (ADR) did not occur with the preceding\n  infusion(s).</span></p>\n<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>***Corticosteroid may be reduced for subsequent\n  infusions at the discretion of the physician, if a severe infusion-related\n  ADR did not occur with the preceding infusion(s).</span></p>\n</td>", "ID": "f1c0514e-e6db-4d80-950e-861c472b8af5", "Styles": "width:467.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "4c19e07f-1050-4253-9414-190dd3929501"}, {"Element": "<p class=\"Legend\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>*Up to 13\u00a0infusions in previously untreated\n  CLL; up to 7\u00a0infusions in relapsed CLL</span></p>", "ID": "bf6314f0-4f69-4f53-8044-34e6f315fd40", "Styles": "margin:0in", "Classes": "['Legend']", "Text": "", "ParentId": "f1c0514e-e6db-4d80-950e-861c472b8af5"}, {"Element": "<span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>*Up to 13\u00a0infusions in previously untreated\n  CLL; up to 7\u00a0infusions in relapsed CLL</span>", "ID": "64a13101-4c9a-4f8d-9797-26dea5af43c3", "Styles": "font-size:11.0pt;font-family:\n  \"Times New Roman\",serif", "Classes": "None", "Text": "*Up to 13\u00a0infusions in previously untreated   CLL; up to 7\u00a0infusions in relapsed CLL", "ParentId": "bf6314f0-4f69-4f53-8044-34e6f315fd40"}, {"Element": "<p class=\"Legend\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>**Corticosteroid may be either reduced or omitted\n  for subsequent infusions at the discretion of the physician, if a severe\n  infusion-related adverse drug reaction (ADR) did not occur with the preceding\n  infusion(s).</span></p>", "ID": "45d0752d-b399-4d4f-95cc-7879e30283bb", "Styles": "margin:0in", "Classes": "['Legend']", "Text": "", "ParentId": "f1c0514e-e6db-4d80-950e-861c472b8af5"}, {"Element": "<span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>**Corticosteroid may be either reduced or omitted\n  for subsequent infusions at the discretion of the physician, if a severe\n  infusion-related adverse drug reaction (ADR) did not occur with the preceding\n  infusion(s).</span>", "ID": "a461e525-9401-4c9e-80c6-8cae568c906e", "Styles": "font-size:11.0pt;font-family:\n  \"Times New Roman\",serif", "Classes": "None", "Text": "**Corticosteroid may be either reduced or omitted   for subsequent infusions at the discretion of the physician, if a severe   infusion-related adverse drug reaction (ADR) did not occur with the preceding   infusion(s).", "ParentId": "45d0752d-b399-4d4f-95cc-7879e30283bb"}, {"Element": "<p class=\"Table\" style=\"margin:0in\"><span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>***Corticosteroid may be reduced for subsequent\n  infusions at the discretion of the physician, if a severe infusion-related\n  ADR did not occur with the preceding infusion(s).</span></p>", "ID": "59029da1-6d14-44fc-9734-98c40ecac9a9", "Styles": "margin:0in", "Classes": "['Table']", "Text": "", "ParentId": "f1c0514e-e6db-4d80-950e-861c472b8af5"}, {"Element": "<span style='font-size:11.0pt;font-family:\n  \"Times New Roman\",serif'>***Corticosteroid may be reduced for subsequent\n  infusions at the discretion of the physician, if a severe infusion-related\n  ADR did not occur with the preceding infusion(s).</span>", "ID": "7a4b433e-5de5-4d87-975f-c7c6c457cc25", "Styles": "font-size:11.0pt;font-family:\n  \"Times New Roman\",serif", "Classes": "None", "Text": "***Corticosteroid may be reduced for subsequent   infusions at the discretion of the physician, if a severe infusion-related   ADR did not occur with the preceding infusion(s).", "ParentId": "59029da1-6d14-44fc-9734-98c40ecac9a9"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a7a35ada-376b-43b5-bc67-80ef5be43e43", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Posology</u></p>", "ID": "1a53e98f-5432-4ef7-a8a3-5d67290d69d3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u>Posology</u>", "ID": "49e559fd-34ff-4ea5-a7b8-bce47a1837aa", "Styles": "None", "Classes": "None", "Text": "Posology", "ParentId": "1a53e98f-5432-4ef7-a8a3-5d67290d69d3"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "c81a5b03-092e-4377-8219-4c75cdd749ce", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Previously\nuntreated CLL</span></u></i></p>", "ID": "1f4ab000-36e7-4073-b59e-71b863855351", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><u><span lang=\"EN-GB\">Previously\nuntreated CLL</span></u></i>", "ID": "8cd8e299-d867-4a45-88f4-556347505a8f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1f4ab000-36e7-4073-b59e-71b863855351"}, {"Element": "<u><span lang=\"EN-GB\">Previously\nuntreated CLL</span></u>", "ID": "37734a95-2a85-44c8-a8b6-0cf1915a9742", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8cd8e299-d867-4a45-88f4-556347505a8f"}, {"Element": "<span lang=\"EN-GB\">Previously\nuntreated CLL</span>", "ID": "69a536cf-a750-4a52-a84e-afbb7a194790", "Styles": "None", "Classes": "None", "Text": "Previously untreated CLL", "ParentId": "37734a95-2a85-44c8-a8b6-0cf1915a9742"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">For\npreviously untreated CLL, the recommended dosage and schedule is:</span></p>", "ID": "e11e64c5-fa09-4ee5-8113-9cbd769f00d6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">For\npreviously untreated CLL, the recommended dosage and schedule is:</span>", "ID": "5c7572f0-92a7-42d4-b7af-ea3143bf686d", "Styles": "None", "Classes": "None", "Text": "For previously untreated CLL, the recommended dosage and schedule is:", "ParentId": "e11e64c5-fa09-4ee5-8113-9cbd769f00d6"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Cycle\u00a01: 300\u00a0mg on day\u00a01 followed\n1\u00a0week later by 1000\u00a0mg on day\u00a08</span></p>", "ID": "ee4afb2a-e5d7-49f5-bb31-230bab7898b7", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "4be881bd-438e-43c9-b82d-dece6d26d812", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "ee4afb2a-e5d7-49f5-bb31-230bab7898b7"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "f287c6f9-3480-48f2-a2cc-43ed4bdc26bf", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "4be881bd-438e-43c9-b82d-dece6d26d812"}, {"Element": "<span lang=\"EN-GB\">Cycle\u00a01: 300\u00a0mg on day\u00a01 followed\n1\u00a0week later by 1000\u00a0mg on day\u00a08</span>", "ID": "8dfe194b-592c-4c27-8d06-abd34777f11a", "Styles": "None", "Classes": "None", "Text": "Cycle\u00a01: 300\u00a0mg on day\u00a01 followed 1\u00a0week later by 1000\u00a0mg on day\u00a08", "ParentId": "ee4afb2a-e5d7-49f5-bb31-230bab7898b7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Subsequent cycles (until best response or a\nmaximum of 12\u00a0cycles): 1000\u00a0mg on day\u00a01 every 28\u00a0days</span>.</p>", "ID": "ee0d8f34-73c9-4d76-a5d4-3f3e403b1256", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": ".", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "a42282a5-7189-4b06-a1f4-e6867a592afc", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "ee0d8f34-73c9-4d76-a5d4-3f3e403b1256"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "aa969747-9779-4af4-a978-6587b9a52a18", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "a42282a5-7189-4b06-a1f4-e6867a592afc"}, {"Element": "<span lang=\"EN-GB\">Subsequent cycles (until best response or a\nmaximum of 12\u00a0cycles): 1000\u00a0mg on day\u00a01 every 28\u00a0days</span>", "ID": "94ad6acc-3baf-44cd-9f50-535dcab646f5", "Styles": "None", "Classes": "None", "Text": "Subsequent cycles (until best response or a maximum of 12\u00a0cycles): 1000\u00a0mg on day\u00a01 every 28\u00a0days", "ParentId": "ee0d8f34-73c9-4d76-a5d4-3f3e403b1256"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "5409cc93-93f2-4da4-8ebd-29a2d2a9e98c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">Each cycle lasts 28\u00a0days and is counted from day\u00a01\nof the cycle.</p>", "ID": "614dc643-8fbb-4ed3-9600-fc9e48694093", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Each cycle lasts 28\u00a0days and is counted from day\u00a01 of the cycle.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "7a7cefaf-107c-42e3-ad25-7bb508fa5b0c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">Best response is a clinical response that did not improve\nwith 3\u00a0additional cycles of treatment.</p>", "ID": "ffe69431-27a3-4e61-8dd4-e578eeb9f89d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Best response is a clinical response that did not improve with 3\u00a0additional cycles of treatment.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2851a7c4-4988-4dac-90b5-e75dbd4330e3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e95a843b-ca07-42e0-a727-8a7587180b30", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2851a7c4-4988-4dac-90b5-e75dbd4330e3"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Relapsed\nCLL</span></u></i></p>", "ID": "39903738-2ba8-4683-984b-f8ee370dce5a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><u><span lang=\"EN-GB\">Relapsed\nCLL</span></u></i>", "ID": "e262c0a7-47da-49c5-b3e6-45270cd452f6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "39903738-2ba8-4683-984b-f8ee370dce5a"}, {"Element": "<u><span lang=\"EN-GB\">Relapsed\nCLL</span></u>", "ID": "0b28318a-4b5f-41ff-b265-a59480ac8306", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e262c0a7-47da-49c5-b3e6-45270cd452f6"}, {"Element": "<span lang=\"EN-GB\">Relapsed\nCLL</span>", "ID": "00426eff-9cdd-4701-8fb2-dafcaddca86d", "Styles": "None", "Classes": "None", "Text": "Relapsed CLL", "ParentId": "0b28318a-4b5f-41ff-b265-a59480ac8306"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\navoid\"><span style=\"font-size:11.0pt\">For relapsed CLL, the recommended dosage\nand schedule is:</span></p>", "ID": "4d35157e-8c87-4671-9e1e-1793f83c91bd", "Styles": "margin-top:0in;text-align:left;page-break-after:\navoid", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">For relapsed CLL, the recommended dosage\nand schedule is:</span>", "ID": "00ea927c-2ca5-4bff-abc3-210ddb00d21b", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "For relapsed CLL, the recommended dosage and schedule is:", "ParentId": "4d35157e-8c87-4671-9e1e-1793f83c91bd"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span style=\"font-size:11.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span style=\"font-size:11.0pt\">Cycle\u00a01: 300\u00a0mg on\nday\u00a01 followed 1\u00a0week later by 1000\u00a0mg on day\u00a08</span></p>", "ID": "d80b74da-21f6-46a5-ae0b-8487a93c679a", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "eadfbcdb-a5ad-482f-bc36-6a49a4ed4292", "Styles": "font-size:11.0pt;font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d80b74da-21f6-46a5-ae0b-8487a93c679a"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "bf7fb3aa-083c-4ee8-b902-2e4e758b9cb1", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "eadfbcdb-a5ad-482f-bc36-6a49a4ed4292"}, {"Element": "<span style=\"font-size:11.0pt\">Cycle\u00a01: 300\u00a0mg on\nday\u00a01 followed 1\u00a0week later by 1000\u00a0mg on day\u00a08</span>", "ID": "410a1698-8b1e-4a72-a1bc-60b51dafbe6b", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "Cycle\u00a01: 300\u00a0mg on day\u00a01 followed 1\u00a0week later by 1000\u00a0mg on day\u00a08", "ParentId": "d80b74da-21f6-46a5-ae0b-8487a93c679a"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span style=\"font-size:11.0pt\">Subsequent cycles (up to a maximum\nof 6\u00a0cycles in total): 1000\u00a0mg on day\u00a01 every 28\u00a0days.</span></p>", "ID": "daa437fb-0958-4c4c-88fa-7e44e160c5e3", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "b9f4e273-95e5-459c-8538-be130f2631aa", "Styles": "font-size:11.0pt;font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "daa437fb-0958-4c4c-88fa-7e44e160c5e3"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "b1cdee3b-14dd-4d46-913f-8148b81f00eb", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "b9f4e273-95e5-459c-8538-be130f2631aa"}, {"Element": "<span style=\"font-size:11.0pt\">Subsequent cycles (up to a maximum\nof 6\u00a0cycles in total): 1000\u00a0mg on day\u00a01 every 28\u00a0days.</span>", "ID": "d10b2166-ad09-4c89-8bae-edbc363c0ccd", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "Subsequent cycles (up to a maximum of 6\u00a0cycles in total): 1000\u00a0mg on day\u00a01 every 28\u00a0days.", "ParentId": "daa437fb-0958-4c4c-88fa-7e44e160c5e3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e03bb73e-4c09-4e5d-9958-7c0dbb6fab0e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0c08cccf-a8d1-4884-84b5-e5fc009e83da", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e03bb73e-4c09-4e5d-9958-7c0dbb6fab0e"}, {"Element": "<p class=\"MsoNormal\">Each cycle lasts 28\u00a0days and is counted from day\u00a01\nof the cycle.</p>", "ID": "4b387e9f-fe4b-442d-bbfe-75ac6b1b2bc0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Each cycle lasts 28\u00a0days and is counted from day\u00a01 of the cycle.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a43de020-45fc-4d16-adcc-4ca86c37412b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Previously\nuntreated CLL and relapsed CLL</span></u></i></p>", "ID": "343cbdcd-374e-4d1f-b4cc-a5cd8f3fd191", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><u><span lang=\"EN-GB\">Previously\nuntreated CLL and relapsed CLL</span></u></i>", "ID": "1eb0c56b-3572-49bf-ab06-2619b7b8a361", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "343cbdcd-374e-4d1f-b4cc-a5cd8f3fd191"}, {"Element": "<u><span lang=\"EN-GB\">Previously\nuntreated CLL and relapsed CLL</span></u>", "ID": "66ed54be-6bfc-4433-bdc4-68ded6bba6e0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1eb0c56b-3572-49bf-ab06-2619b7b8a361"}, {"Element": "<span lang=\"EN-GB\">Previously\nuntreated CLL and relapsed CLL</span>", "ID": "11720bba-606a-4951-be44-859c4447a142", "Styles": "None", "Classes": "None", "Text": "Previously untreated CLL and relapsed CLL", "ParentId": "66ed54be-6bfc-4433-bdc4-68ded6bba6e0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>First infusion</i></p>", "ID": "1c798696-308d-4373-89c5-c7a216aff8cc", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i>First infusion</i>", "ID": "97dceba0-5c1d-4367-9054-37c7f91eb6ab", "Styles": "None", "Classes": "None", "Text": "First infusion", "ParentId": "1c798696-308d-4373-89c5-c7a216aff8cc"}, {"Element": "<p class=\"MsoNormal\">The initial rate of the first infusion of <span lang=\"EN-GB\">Arzerra</span><span lang=\"EN-GB\"> </span>should be 12<span lang=\"EN-GB\">\u00a0</span>ml/h. During\ninfusion, the rate should be increased every 30\u00a0minutes to a maximum of\n400<span lang=\"EN-GB\">\u00a0</span>ml/h<span style=\"color:black\"> </span>(<span style=\"color:black\">see section\u00a06.6</span>)<span style=\"color:black\">. </span><span lang=\"EN-GB\" style=\"color:black\">If an infusion\u2011related ADR is observed\nduring infusion, see below section \u201cDose modification and reinitiation of\ntherapy after infusion\u2011related ADRs\u201d.</span></p>", "ID": "da89a9d2-4d81-45b6-8a86-9afd3d8b29c1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The initial rate of the first infusion of should be 12ml/h. During infusion, the rate should be increased every 30\u00a0minutes to a maximum of 400ml/h()", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Arzerra</span>", "ID": "ae12bc43-0428-41b4-95b8-802173062d1e", "Styles": "None", "Classes": "None", "Text": "Arzerra", "ParentId": "da89a9d2-4d81-45b6-8a86-9afd3d8b29c1"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "f8416f8b-5a98-4e91-8867-487cb066b564", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "da89a9d2-4d81-45b6-8a86-9afd3d8b29c1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b3907a4a-8657-430a-b3b9-068a91129395", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "da89a9d2-4d81-45b6-8a86-9afd3d8b29c1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bdbd0a79-902b-4cd1-bd53-3e1079a8be1c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "da89a9d2-4d81-45b6-8a86-9afd3d8b29c1"}, {"Element": "<span style=\"color:black\"> </span>", "ID": "f8cdd857-d288-4a49-abda-ec5212399255", "Styles": "color:black", "Classes": "None", "Text": " ", "ParentId": "da89a9d2-4d81-45b6-8a86-9afd3d8b29c1"}, {"Element": "<span style=\"color:black\">see section\u00a06.6</span>", "ID": "d02d1332-1416-49cb-9343-024069080bb4", "Styles": "color:black", "Classes": "None", "Text": "see section\u00a06.6", "ParentId": "da89a9d2-4d81-45b6-8a86-9afd3d8b29c1"}, {"Element": "<span style=\"color:black\">. </span>", "ID": "e9e8cd9e-52b2-4f42-90cb-62e0816d50cf", "Styles": "color:black", "Classes": "None", "Text": ". ", "ParentId": "da89a9d2-4d81-45b6-8a86-9afd3d8b29c1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">If an infusion\u2011related ADR is observed\nduring infusion, see below section \u201cDose modification and reinitiation of\ntherapy after infusion\u2011related ADRs\u201d.</span>", "ID": "c1a7aec1-b10d-467d-ad36-989f8c6fc53c", "Styles": "color:black", "Classes": "None", "Text": "If an infusion\u2011related ADR is observed during infusion, see below section \u201cDose modification and reinitiation of therapy after infusion\u2011related ADRs\u201d.", "ParentId": "da89a9d2-4d81-45b6-8a86-9afd3d8b29c1"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "be7668cb-8efc-4bbe-9ccf-e6759f8ff24f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Subsequent infusions</i></p>", "ID": "3961afaa-aea1-4f87-9ded-1373921042a3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i>Subsequent infusions</i>", "ID": "4bd18455-f094-47c8-a036-9bc95bcf5dd9", "Styles": "None", "Classes": "None", "Text": "Subsequent infusions", "ParentId": "3961afaa-aea1-4f87-9ded-1373921042a3"}, {"Element": "<p class=\"MsoNormal\">If the preceding infusion(s) has (have) been completed\nwithout severe infusion related ADRs, the subsequent infusions can start at a\nrate of 25<span lang=\"EN-GB\">\u00a0</span>ml/h and should be increased every\n30\u00a0minutes up to a maximum of 400<span lang=\"EN-GB\">\u00a0</span>ml/h (<span style=\"color:black\">see section\u00a06.6</span>). <span lang=\"EN-GB\" style=\"color:black\">If an infusion\u2011related ADR is observed during\ninfusion, see below section \u201cDose modification and reinitiation of therapy\nafter infusion\u2011related ADRs\u201d.</span></p>", "ID": "35819f3a-195c-46fa-98f0-4de44ed2e1bb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "If the preceding infusion(s) has (have) been completed without severe infusion related ADRs, the subsequent infusions can start at a rate of 25ml/h and should be increased every 30\u00a0minutes up to a maximum of 400ml/h (). ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "46b61df1-9025-4f9c-bfd4-ffc8f2da6133", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "35819f3a-195c-46fa-98f0-4de44ed2e1bb"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e0927d63-de42-4c33-9d7c-f388cbd07b66", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "35819f3a-195c-46fa-98f0-4de44ed2e1bb"}, {"Element": "<span style=\"color:black\">see section\u00a06.6</span>", "ID": "08366010-f7f0-494b-a8f0-7a5e9bf7ba34", "Styles": "color:black", "Classes": "None", "Text": "see section\u00a06.6", "ParentId": "35819f3a-195c-46fa-98f0-4de44ed2e1bb"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">If an infusion\u2011related ADR is observed during\ninfusion, see below section \u201cDose modification and reinitiation of therapy\nafter infusion\u2011related ADRs\u201d.</span>", "ID": "678d8bc6-dd36-460a-8518-acafb6afed70", "Styles": "color:black", "Classes": "None", "Text": "If an infusion\u2011related ADR is observed during infusion, see below section \u201cDose modification and reinitiation of therapy after infusion\u2011related ADRs\u201d.", "ParentId": "35819f3a-195c-46fa-98f0-4de44ed2e1bb"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt;color:black\">\u00a0</span></p>", "ID": "d0f52337-f0f7-4515-b6d4-9d2ef792bf98", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt;color:black\">\u00a0</span>", "ID": "7f997f22-0236-4101-a1b0-dcd73708e752", "Styles": "font-size:11.0pt;color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "d0f52337-f0f7-4515-b6d4-9d2ef792bf98"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\navoid\"><i><span style=\"font-size:11.0pt\">Dose modification and reinitiation of\ntherapy after infusion-related ADRs</span></i></p>", "ID": "5671933b-2a72-4a84-8115-a91b50fc2183", "Styles": "margin-top:0in;text-align:left;page-break-after:\navoid", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><span style=\"font-size:11.0pt\">Dose modification and reinitiation of\ntherapy after infusion-related ADRs</span></i>", "ID": "ca9a57a6-1292-4baa-877d-e7e55cd5eb51", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5671933b-2a72-4a84-8115-a91b50fc2183"}, {"Element": "<span style=\"font-size:11.0pt\">Dose modification and reinitiation of\ntherapy after infusion-related ADRs</span>", "ID": "4ddd997d-f5d2-4324-b8bc-a8b1f5c35097", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "Dose modification and reinitiation of therapy after infusion-related ADRs", "ParentId": "ca9a57a6-1292-4baa-877d-e7e55cd5eb51"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">In the event of a mild or moderate ADR, the infusion\nshould be interrupted and restarted at half of the infusion rate at the time of\ninterruption once the patient\u2019s condition is stable. If the infusion rate had\nnot been increased from the starting rate of 12\u00a0ml/hour prior to\ninterrupting due to an ADR, the infusion should be restarted at\n12\u00a0ml/hour, the standard starting infusion rate. The infusion rate can\ncontinue to be increased according to standard procedures, to physician\ndiscretion and to patient tolerance (not to exceed doubling the rate every\n30\u00a0minutes).</span></p>", "ID": "9f821430-37b6-497a-a01a-1896bb696079", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">In the event of a mild or moderate ADR, the infusion\nshould be interrupted and restarted at half of the infusion rate at the time of\ninterruption once the patient\u2019s condition is stable. If the infusion rate had\nnot been increased from the starting rate of 12\u00a0ml/hour prior to\ninterrupting due to an ADR, the infusion should be restarted at\n12\u00a0ml/hour, the standard starting infusion rate. The infusion rate can\ncontinue to be increased according to standard procedures, to physician\ndiscretion and to patient tolerance (not to exceed doubling the rate every\n30\u00a0minutes).</span>", "ID": "ccb7fc63-f5e5-402d-8866-5a7eeaa4ebff", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "In the event of a mild or moderate ADR, the infusion should be interrupted and restarted at half of the infusion rate at the time of interruption once the patient\u2019s condition is stable. If the infusion rate had not been increased from the starting rate of 12\u00a0ml/hour prior to interrupting due to an ADR, the infusion should be restarted at 12\u00a0ml/hour, the standard starting infusion rate. The infusion rate can continue to be increased according to standard procedures, to physician discretion and to patient tolerance (not to exceed doubling the rate every 30\u00a0minutes).", "ParentId": "9f821430-37b6-497a-a01a-1896bb696079"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "477b46c1-6c04-434c-9109-c4e8beedfd09", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">\u00a0</span>", "ID": "8c8ae75d-caf2-485c-9724-75bc6cb54383", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "477b46c1-6c04-434c-9109-c4e8beedfd09"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">In the event of a severe ADR, the infusion should be\ninterrupted and restarted at 12\u00a0ml/hour when the patient\u2019s condition is\nstable. The infusion rate can continue to be increased according to standard\nprocedures, to physician discretion and to patient tolerance (not to exceed\nincreasing the rate every 30\u00a0minutes).</span></p>", "ID": "7953bc87-181d-41d3-b7de-fbd2bd4e13a2", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">In the event of a severe ADR, the infusion should be\ninterrupted and restarted at 12\u00a0ml/hour when the patient\u2019s condition is\nstable. The infusion rate can continue to be increased according to standard\nprocedures, to physician discretion and to patient tolerance (not to exceed\nincreasing the rate every 30\u00a0minutes).</span>", "ID": "ef6e1122-2d68-4d9a-8044-524956be6eaf", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "In the event of a severe ADR, the infusion should be interrupted and restarted at 12\u00a0ml/hour when the patient\u2019s condition is stable. The infusion rate can continue to be increased according to standard procedures, to physician discretion and to patient tolerance (not to exceed increasing the rate every 30\u00a0minutes).", "ParentId": "7953bc87-181d-41d3-b7de-fbd2bd4e13a2"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt;layout-grid-mode:line\">\u00a0</span></p>", "ID": "7e51ef48-ce59-417c-8201-05d70df69846", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt;layout-grid-mode:line\">\u00a0</span>", "ID": "67a918eb-4420-4178-9a54-4916c7eaea1e", "Styles": "font-size:11.0pt;layout-grid-mode:line", "Classes": "None", "Text": "\u00a0", "ParentId": "7e51ef48-ce59-417c-8201-05d70df69846"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt;layout-grid-mode:line\">Arzerra should be permanently\ndiscontinued in patients who develop an anaphylactic reaction to the medicinal\nproduct.</span></p>", "ID": "a37c4522-1b55-415f-9397-5f8995d15f31", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt;layout-grid-mode:line\">Arzerra should be permanently\ndiscontinued in patients who develop an anaphylactic reaction to the medicinal\nproduct.</span>", "ID": "64fc6bc7-679d-4569-8f9a-acb95af1077c", "Styles": "font-size:11.0pt;layout-grid-mode:line", "Classes": "None", "Text": "Arzerra should be permanently discontinued in patients who develop an anaphylactic reaction to the medicinal product.", "ParentId": "a37c4522-1b55-415f-9397-5f8995d15f31"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "74ce7a0c-952b-4035-adcc-7ce89cd2f558", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u>Refractory CLL</u></i></p>", "ID": "13ec9173-8342-4a41-bb5d-8231384e4a58", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><u>Refractory CLL</u></i>", "ID": "df09b506-bde5-46db-9b26-712842b8b160", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "13ec9173-8342-4a41-bb5d-8231384e4a58"}, {"Element": "<u>Refractory CLL</u>", "ID": "3a7a199a-409e-40ec-a9da-765bb0b4bd82", "Styles": "None", "Classes": "None", "Text": "Refractory CLL", "ParentId": "df09b506-bde5-46db-9b26-712842b8b160"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The recommended dose <span lang=\"EN-GB\">and schedule </span>is <span lang=\"EN-GB\">12\u00a0doses administered as\nfollows:</span></p>", "ID": "3eb13aef-0230-42ef-979f-3d86c9375954", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "The recommended dose is ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">and schedule </span>", "ID": "ec3c2207-25ec-4ad8-9429-8e24e9cb067f", "Styles": "None", "Classes": "None", "Text": "and schedule ", "ParentId": "3eb13aef-0230-42ef-979f-3d86c9375954"}, {"Element": "<span lang=\"EN-GB\">12\u00a0doses administered as\nfollows:</span>", "ID": "80396d86-889d-4993-ad45-33f79e3d3e5f", "Styles": "None", "Classes": "None", "Text": "12\u00a0doses administered as follows:", "ParentId": "3eb13aef-0230-42ef-979f-3d86c9375954"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><s><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span></s>300\u00a0mg on day\u00a01 followed 1\u00a0week later by</p>", "ID": "67081909-12f9-4aae-8f16-5d066d544670", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "300\u00a0mg on day\u00a01 followed 1\u00a0week later by", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<s><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span></s>", "ID": "52776e70-b87a-41c9-980c-7fcd8e7a0a41", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "67081909-12f9-4aae-8f16-5d066d544670"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "5722c902-ba6f-4882-8605-51b12a16233e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "52776e70-b87a-41c9-980c-7fcd8e7a0a41"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "81bf6fcc-e3d7-4e2b-b9d4-d89fe14e6783", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "5722c902-ba6f-4882-8605-51b12a16233e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><s><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span></s>2000\u00a0mg weekly for <span lang=\"EN-GB\">7\u00a0doses\n(infusions\u00a02 to 8)</span> followed 4\u20115\u00a0weeks later by</p>", "ID": "5989ca2b-a7ce-4549-97a7-f03f4d748928", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "2000\u00a0mg weekly for  followed 4\u20115\u00a0weeks later by", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<s><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span></s>", "ID": "48ac102d-9aab-4b95-b332-082be787126d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5989ca2b-a7ce-4549-97a7-f03f4d748928"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "44370ad9-b1c2-4018-a946-a7e396505cf4", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "48ac102d-9aab-4b95-b332-082be787126d"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "9e446338-28b0-4cb3-bcbe-98c62329db12", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "44370ad9-b1c2-4018-a946-a7e396505cf4"}, {"Element": "<span lang=\"EN-GB\">7\u00a0doses\n(infusions\u00a02 to 8)</span>", "ID": "7aa71429-ac6f-44d8-aa61-8e5ac2adcb06", "Styles": "None", "Classes": "None", "Text": "7\u00a0doses (infusions\u00a02 to 8)", "ParentId": "5989ca2b-a7ce-4549-97a7-f03f4d748928"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><s><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span></s>2000\u00a0mg every 28\u00a0days for 4\u00a0doses <span lang=\"EN-GB\">(infusions\u00a09 to 12)</span></p>", "ID": "e7d77c9d-fe53-490b-ac70-38d3313f922d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "2000\u00a0mg every 28\u00a0days for 4\u00a0doses ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<s><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span></s>", "ID": "bec894c3-03c9-4252-9aca-ad7263d0bde1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e7d77c9d-fe53-490b-ac70-38d3313f922d"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "1568fa77-083d-40ff-a655-0d0d4ab9b500", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "bec894c3-03c9-4252-9aca-ad7263d0bde1"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "1f8e443c-c092-45e6-b18f-c6280c39c2a4", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "1568fa77-083d-40ff-a655-0d0d4ab9b500"}, {"Element": "<span lang=\"EN-GB\">(infusions\u00a09 to 12)</span>", "ID": "069c609f-fe05-462d-8b25-2871ec523e04", "Styles": "None", "Classes": "None", "Text": "(infusions\u00a09 to 12)", "ParentId": "e7d77c9d-fe53-490b-ac70-38d3313f922d"}, {"Element": "<p class=\"Nottoc-headings\" style=\"margin:0in;page-break-after:auto\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;font-weight:normal'>\u00a0</span></p>", "ID": "5bedb654-4af2-426a-a559-7383fbb7395e", "Styles": "margin:0in;page-break-after:auto", "Classes": "['Nottoc-headings']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;font-weight:normal'>\u00a0</span>", "ID": "7f320b7d-df76-4f20-a442-866d956d44f8", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif;font-weight:normal", "Classes": "None", "Text": "\u00a0", "ParentId": "5bedb654-4af2-426a-a559-7383fbb7395e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>First and second infusions</i></p>", "ID": "ae4468e0-867d-431e-9758-d0b3e86e2e05", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i>First and second infusions</i>", "ID": "54d42117-e6b9-4cf0-b8a9-e52da17b7d43", "Styles": "None", "Classes": "None", "Text": "First and second infusions", "ParentId": "ae4468e0-867d-431e-9758-d0b3e86e2e05"}, {"Element": "<p class=\"MsoNormal\">The initial rate of the first and second infusion of <span lang=\"EN-GB\">Arzerra</span> should be 12\u00a0ml/hour. During infusion, the rate\nshould be increased every 30\u00a0minutes to a maximum of 200<span lang=\"EN-GB\">\u00a0</span>ml/hour<span style=\"color:black\"> (see section\u00a06.6). If an infusion-related ADR is\nobserved during an infusion, see below section \u201cDose modification and\nreinitiation of therapy after infusion-related ADRs\u201d.</span></p>", "ID": "d8cb73a0-15b0-42e1-8b9a-c51cbdde28bf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The initial rate of the first and second infusion of  should be 12\u00a0ml/hour. During infusion, the rate should be increased every 30\u00a0minutes to a maximum of 200ml/hour", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Arzerra</span>", "ID": "03a1a7ec-42c9-4162-ade4-f2b2d582d983", "Styles": "None", "Classes": "None", "Text": "Arzerra", "ParentId": "d8cb73a0-15b0-42e1-8b9a-c51cbdde28bf"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "15af148a-e7f4-4f44-b0dd-02ebdb8a6346", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d8cb73a0-15b0-42e1-8b9a-c51cbdde28bf"}, {"Element": "<span style=\"color:black\"> (see section\u00a06.6). If an infusion-related ADR is\nobserved during an infusion, see below section \u201cDose modification and\nreinitiation of therapy after infusion-related ADRs\u201d.</span>", "ID": "82873f6c-e58c-411e-9602-4bfbec35cb86", "Styles": "color:black", "Classes": "None", "Text": " (see section\u00a06.6). If an infusion-related ADR is observed during an infusion, see below section \u201cDose modification and reinitiation of therapy after infusion-related ADRs\u201d.", "ParentId": "d8cb73a0-15b0-42e1-8b9a-c51cbdde28bf"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "e2d8645b-7555-48a6-b47f-4524d53e4bba", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Subsequent infusions</i></p>", "ID": "751bf7cb-d41b-43fd-80dd-0c4b2314cf05", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i>Subsequent infusions</i>", "ID": "64f32b5d-1801-4290-b1a3-2327b6651cf2", "Styles": "None", "Classes": "None", "Text": "Subsequent infusions", "ParentId": "751bf7cb-d41b-43fd-80dd-0c4b2314cf05"}, {"Element": "<p class=\"MsoNormal\">If the preceding infusion(s) has (have) been completed\nwithout severe infusion-related ADRs, the subsequent infusions can start at a\nrate of 25\u00a0ml/hour and should be increased every 30\u00a0minutes up to a\nmaximum of 400\u00a0ml/hour <span lang=\"EN-GB\">(see section\u00a06.6)</span>. If\nan infusion-related ADR is observed during an infusion, see below section \u201cDose\nmodification and reinitiation of therapy after infusion-related ADRs\u201d.</p>", "ID": "e397e383-6f68-46f9-a9fc-a6addc7accb9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "If the preceding infusion(s) has (have) been completed without severe infusion-related ADRs, the subsequent infusions can start at a rate of 25\u00a0ml/hour and should be increased every 30\u00a0minutes up to a maximum of 400\u00a0ml/hour . If an infusion-related ADR is observed during an infusion, see below section \u201cDose modification and reinitiation of therapy after infusion-related ADRs\u201d.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">(see section\u00a06.6)</span>", "ID": "d67d7b4c-8acc-4b54-8224-baa0c73e150e", "Styles": "None", "Classes": "None", "Text": "(see section\u00a06.6)", "ParentId": "e397e383-6f68-46f9-a9fc-a6addc7accb9"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "5c3b4385-4a0e-4d42-b5f9-46a1d6f6692c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Dose modification and\nreinitiation of therapy after infusion-related ADRs</i></p>", "ID": "eacd421a-19ea-4db2-ae86-70f158f38660", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i>Dose modification and\nreinitiation of therapy after infusion-related ADRs</i>", "ID": "bd696321-f323-4ac0-8e9c-07d234751e96", "Styles": "None", "Classes": "None", "Text": "Dose modification and reinitiation of therapy after infusion-related ADRs", "ParentId": "eacd421a-19ea-4db2-ae86-70f158f38660"}, {"Element": "<p class=\"MsoNormal\">I<span style=\"color:black\">n the event of a mild or moderate\nADR, the infusion should be interrupted and restarted at half of the infusion\nrate at the time of interruption, once the patient\u2019s condition is stable. If\nthe infusion rate had not been increased from the starting rate of\n12\u00a0ml/hour prior to interrupting due to an ADR, the infusion should be\nrestarted at 12\u00a0ml/hour, the standard starting infusion rate. The infusion\nrate</span> can continue to be increased according to standard procedures, to\nphysician discretion and to patient tolerance (not to exceed doubling the rate\nevery 30\u00a0minutes).</p>", "ID": "f0045040-bfa9-41e5-86a1-f838a28f0965", "Styles": "None", "Classes": "['MsoNormal']", "Text": "I can continue to be increased according to standard procedures, to physician discretion and to patient tolerance (not to exceed doubling the rate every 30\u00a0minutes).", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"color:black\">n the event of a mild or moderate\nADR, the infusion should be interrupted and restarted at half of the infusion\nrate at the time of interruption, once the patient\u2019s condition is stable. If\nthe infusion rate had not been increased from the starting rate of\n12\u00a0ml/hour prior to interrupting due to an ADR, the infusion should be\nrestarted at 12\u00a0ml/hour, the standard starting infusion rate. The infusion\nrate</span>", "ID": "dcd32378-1a9e-4367-8d27-3867687e397c", "Styles": "color:black", "Classes": "None", "Text": "n the event of a mild or moderate ADR, the infusion should be interrupted and restarted at half of the infusion rate at the time of interruption, once the patient\u2019s condition is stable. If the infusion rate had not been increased from the starting rate of 12\u00a0ml/hour prior to interrupting due to an ADR, the infusion should be restarted at 12\u00a0ml/hour, the standard starting infusion rate. The infusion rate", "ParentId": "f0045040-bfa9-41e5-86a1-f838a28f0965"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "2b9339a3-57e2-4046-8f8d-951d19d086ee", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">In the event of <span style=\"color:black\">a severe ADR, the\ninfusion should be interrupted and restarted at 12\u00a0ml/hour, once the\npatient\u2019s condition is stable. The infusion rat</span>e can continue to be\nincreased according to standard procedures, to physician discretion and to patient\ntolerance (not to exceed increasing the rate every 30\u00a0minutes).</p>", "ID": "5c9a3cee-e2c1-4982-adee-2c11ecab059d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "In the event of e can continue to be increased according to standard procedures, to physician discretion and to patient tolerance (not to exceed increasing the rate every 30\u00a0minutes).", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"color:black\">a severe ADR, the\ninfusion should be interrupted and restarted at 12\u00a0ml/hour, once the\npatient\u2019s condition is stable. The infusion rat</span>", "ID": "1acc5989-45e9-482c-b802-5d6833b1109f", "Styles": "color:black", "Classes": "None", "Text": "a severe ADR, the infusion should be interrupted and restarted at 12\u00a0ml/hour, once the patient\u2019s condition is stable. The infusion rat", "ParentId": "5c9a3cee-e2c1-4982-adee-2c11ecab059d"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt;layout-grid-mode:line\">\u00a0</span></p>", "ID": "034b5353-dc56-4ff0-bdd6-25ee9fd1c670", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt;layout-grid-mode:line\">\u00a0</span>", "ID": "1f2253ba-75b0-4626-9e97-95c67cf9f771", "Styles": "font-size:11.0pt;layout-grid-mode:line", "Classes": "None", "Text": "\u00a0", "ParentId": "034b5353-dc56-4ff0-bdd6-25ee9fd1c670"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt;layout-grid-mode:line\">Arzerra should be permanently\ndiscontinued in patients who develop an anaphylactic reaction to the medicinal\nproduct.</span></p>", "ID": "044c1bd3-18db-4e16-b298-fc14042f781e", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt;layout-grid-mode:line\">Arzerra should be permanently\ndiscontinued in patients who develop an anaphylactic reaction to the medicinal\nproduct.</span>", "ID": "bc23263a-8bda-4b33-8776-676f30f9ac52", "Styles": "font-size:11.0pt;layout-grid-mode:line", "Classes": "None", "Text": "Arzerra should be permanently discontinued in patients who develop an anaphylactic reaction to the medicinal product.", "ParentId": "044c1bd3-18db-4e16-b298-fc14042f781e"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "6366e814-a853-475f-8bf5-6539b261813e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u>Special populations</u></i></p>", "ID": "35f7066b-ae6e-4c97-bf8e-934c45e93c7d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><u>Special populations</u></i>", "ID": "be39ff32-d677-4102-afe9-28a133da1749", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "35f7066b-ae6e-4c97-bf8e-934c45e93c7d"}, {"Element": "<u>Special populations</u>", "ID": "f36cf1f4-de0a-4d5b-8456-6c135f254c5c", "Styles": "None", "Classes": "None", "Text": "Special populations", "ParentId": "be39ff32-d677-4102-afe9-28a133da1749"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Paediatric</span></i><i><span style=\"layout-grid-mode:\nline\"> population</span></i></p>", "ID": "e79c91d6-d5ff-453d-b06c-865953bf2e1f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Paediatric</span></i>", "ID": "cf7d9682-4852-4194-87be-37f34f049270", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e79c91d6-d5ff-453d-b06c-865953bf2e1f"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Paediatric</span>", "ID": "e8e1be77-f35a-427b-b931-59966aa39596", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "Paediatric", "ParentId": "cf7d9682-4852-4194-87be-37f34f049270"}, {"Element": "<i><span style=\"layout-grid-mode:\nline\"> population</span></i>", "ID": "d92b2bd8-b601-408c-8df5-d655c4957f76", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e79c91d6-d5ff-453d-b06c-865953bf2e1f"}, {"Element": "<span style=\"layout-grid-mode:\nline\"> population</span>", "ID": "cc4f21cb-6f02-44dd-aeac-56c0d8d49c16", "Styles": "layout-grid-mode:\nline", "Classes": "None", "Text": " population", "ParentId": "d92b2bd8-b601-408c-8df5-d655c4957f76"}, {"Element": "<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">The safety and efficacy\nof Arzerra in children aged below 18\u00a0years have not been established.\nArzerra is therefore not recommended for use in this patient population.</span></p>", "ID": "d9725f5f-302e-4bbf-9999-8e65e210e3cc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"layout-grid-mode:line\">The safety and efficacy\nof Arzerra in children aged below 18\u00a0years have not been established.\nArzerra is therefore not recommended for use in this patient population.</span>", "ID": "201fbacb-2bda-4b35-9070-5d765ce94872", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "The safety and efficacy of Arzerra in children aged below 18\u00a0years have not been established. Arzerra is therefore not recommended for use in this patient population.", "ParentId": "d9725f5f-302e-4bbf-9999-8e65e210e3cc"}, {"Element": "<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">\u00a0</span></p>", "ID": "a36a784d-2de5-4342-81c4-51b6e47cd416", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"layout-grid-mode:line\">\u00a0</span>", "ID": "a2538bf1-55d9-4938-aec0-b5d3858b9294", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "\u00a0", "ParentId": "a36a784d-2de5-4342-81c4-51b6e47cd416"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span style=\"layout-grid-mode:\nline\">Elderly</span></i></p>", "ID": "de4a0368-c185-45b9-8bf4-3ab891657e30", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><span style=\"layout-grid-mode:\nline\">Elderly</span></i>", "ID": "de0d0fe9-5ac4-447a-8667-f7d10f7aeaef", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "de4a0368-c185-45b9-8bf4-3ab891657e30"}, {"Element": "<span style=\"layout-grid-mode:\nline\">Elderly</span>", "ID": "e24fc4ef-9b13-4469-b1c5-a84bb5feeb15", "Styles": "layout-grid-mode:\nline", "Classes": "None", "Text": "Elderly", "ParentId": "de0d0fe9-5ac4-447a-8667-f7d10f7aeaef"}, {"Element": "<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">No substantial\ndifferences related to age were seen in safety and efficacy (see\nsection\u00a05.1). Based on available safety and efficacy data in the elderly,\nno dose adjustment is required (see section\u00a05.2).</span></p>", "ID": "4918f869-968f-45dc-b47f-eb1b2010ffd0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"layout-grid-mode:line\">No substantial\ndifferences related to age were seen in safety and efficacy (see\nsection\u00a05.1). Based on available safety and efficacy data in the elderly,\nno dose adjustment is required (see section\u00a05.2).</span>", "ID": "3cfee184-9506-4b13-8fef-51a7af4b50dd", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "No substantial differences related to age were seen in safety and efficacy (see section\u00a05.1). Based on available safety and efficacy data in the elderly, no dose adjustment is required (see section\u00a05.2).", "ParentId": "4918f869-968f-45dc-b47f-eb1b2010ffd0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>", "ID": "a93a990b-dcd8-4688-850e-be8a94b34627", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span>", "ID": "dbc74854-d29f-45b0-8ead-0d15d885a5b3", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "\u00a0", "ParentId": "a93a990b-dcd8-4688-850e-be8a94b34627"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span style=\"layout-grid-mode:\nline\">Renal impairment</span></i></p>", "ID": "fffda80c-a75e-4656-a820-c0ca1339e24c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><span style=\"layout-grid-mode:\nline\">Renal impairment</span></i>", "ID": "974ff4c1-9011-4cbc-a305-93d6eb0c5b77", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fffda80c-a75e-4656-a820-c0ca1339e24c"}, {"Element": "<span style=\"layout-grid-mode:\nline\">Renal impairment</span>", "ID": "d2813937-f470-4349-9429-30d65ce3cddc", "Styles": "layout-grid-mode:\nline", "Classes": "None", "Text": "Renal impairment", "ParentId": "974ff4c1-9011-4cbc-a305-93d6eb0c5b77"}, {"Element": "<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">No formal studies of\nArzerra in patients with renal impairment have been performed. No dose\nadjustment is recommended for mild to moderate renal impairment </span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">(creatinine</span><span style=\"layout-grid-mode:line\"> clearance &gt;30\u00a0ml/min) (see\nsection\u00a05.2).</span></p>", "ID": "e2dcd9f7-3bfb-480d-b4e1-d5d8bb83c4f2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"layout-grid-mode:line\">No formal studies of\nArzerra in patients with renal impairment have been performed. No dose\nadjustment is recommended for mild to moderate renal impairment </span>", "ID": "0d2425b1-1180-48f5-b52b-43b28499d3da", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "No formal studies of Arzerra in patients with renal impairment have been performed. No dose adjustment is recommended for mild to moderate renal impairment ", "ParentId": "e2dcd9f7-3bfb-480d-b4e1-d5d8bb83c4f2"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">(creatinine</span>", "ID": "2cfc2517-4599-4a56-b80d-f61f35202690", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "(creatinine", "ParentId": "e2dcd9f7-3bfb-480d-b4e1-d5d8bb83c4f2"}, {"Element": "<span style=\"layout-grid-mode:line\"> clearance &gt;30\u00a0ml/min) (see\nsection\u00a05.2).</span>", "ID": "666bcff4-d9ac-41fb-8904-5225e3ccad20", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": " clearance >30\u00a0ml/min) (see section\u00a05.2).", "ParentId": "e2dcd9f7-3bfb-480d-b4e1-d5d8bb83c4f2"}, {"Element": "<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">\u00a0</span></p>", "ID": "a3a7cc0c-7a8c-4ac3-8f5f-db4588671358", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"layout-grid-mode:line\">\u00a0</span>", "ID": "208e7427-b8cc-421e-8af2-3330e304cfd1", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "\u00a0", "ParentId": "a3a7cc0c-7a8c-4ac3-8f5f-db4588671358"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span style=\"layout-grid-mode:\nline\">Hepatic impairment</span></i></p>", "ID": "d3abd05e-a515-45d6-91c6-fe54277eeaf4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><span style=\"layout-grid-mode:\nline\">Hepatic impairment</span></i>", "ID": "211dc943-71c9-4c7a-b177-9171d9b712ac", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d3abd05e-a515-45d6-91c6-fe54277eeaf4"}, {"Element": "<span style=\"layout-grid-mode:\nline\">Hepatic impairment</span>", "ID": "83f71fdf-bf0d-485f-812e-7e2ad673ea27", "Styles": "layout-grid-mode:\nline", "Classes": "None", "Text": "Hepatic impairment", "ParentId": "211dc943-71c9-4c7a-b177-9171d9b712ac"}, {"Element": "<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">No formal studies of </span><span lang=\"EN-GB\">Arzerra</span><span style=\"layout-grid-mode:line\"> in patients with\nhepatic impairment have been performed. </span><span lang=\"EN-GB\">H</span><span lang=\"EN-GB\">owever, patients with hepatic impairment are unlikely to require\ndose modification </span><span lang=\"EN-GB\">(see section\u00a05.2)<i>.</i></span></p>", "ID": "95bbda08-9993-4635-97fc-48e1740bf837", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"layout-grid-mode:line\">No formal studies of </span>", "ID": "23fec395-14af-45d0-97c9-919192d6033a", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "No formal studies of ", "ParentId": "95bbda08-9993-4635-97fc-48e1740bf837"}, {"Element": "<span lang=\"EN-GB\">Arzerra</span>", "ID": "f1892a11-9246-46a2-808f-d4ec4ef36379", "Styles": "None", "Classes": "None", "Text": "Arzerra", "ParentId": "95bbda08-9993-4635-97fc-48e1740bf837"}, {"Element": "<span style=\"layout-grid-mode:line\"> in patients with\nhepatic impairment have been performed. </span>", "ID": "f3ec33ae-5fc3-4bca-850a-bfccc4dd7bb0", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": " in patients with hepatic impairment have been performed. ", "ParentId": "95bbda08-9993-4635-97fc-48e1740bf837"}, {"Element": "<span lang=\"EN-GB\">H</span>", "ID": "6e947df5-49f8-4ffa-816b-80ec912c8b59", "Styles": "None", "Classes": "None", "Text": "H", "ParentId": "95bbda08-9993-4635-97fc-48e1740bf837"}, {"Element": "<span lang=\"EN-GB\">owever, patients with hepatic impairment are unlikely to require\ndose modification </span>", "ID": "d6bea8fc-ea19-4001-b7b1-5178da626f7b", "Styles": "None", "Classes": "None", "Text": "owever, patients with hepatic impairment are unlikely to require dose modification ", "ParentId": "95bbda08-9993-4635-97fc-48e1740bf837"}, {"Element": "<span lang=\"EN-GB\">(see section\u00a05.2)<i>.</i></span>", "ID": "5649a664-8cf1-4ba0-b32d-c35bac7c4776", "Styles": "None", "Classes": "None", "Text": "(see section\u00a05.2)", "ParentId": "95bbda08-9993-4635-97fc-48e1740bf837"}, {"Element": "<i>.</i>", "ID": "2b11845f-787e-422e-bbb2-5ecb50c285b3", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "5649a664-8cf1-4ba0-b32d-c35bac7c4776"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5add1bbf-84da-4ef6-935b-9872a0fbe625", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3b499276-319b-4ca4-9bda-a0863e1eae1e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5add1bbf-84da-4ef6-935b-9872a0fbe625"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Method of administration</u></p>", "ID": "607c467f-b5a2-4823-b6d0-6a32942ced4d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u>Method of administration</u>", "ID": "f1b6cc45-0c72-4a26-93ef-5cc45fa2bb2d", "Styles": "None", "Classes": "None", "Text": "Method of administration", "ParentId": "607c467f-b5a2-4823-b6d0-6a32942ced4d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8d85ae94-89e0-41ad-9671-e18dc8ff7895", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ff7c6270-b51d-475b-8885-c2a86a41b792", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8d85ae94-89e0-41ad-9671-e18dc8ff7895"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Arzerra is for intravenous infusion and\nmust be diluted prior to administration. </span><span lang=\"EN-GB\">For\ninstructions on dilution of the medicinal product before administration, </span><span lang=\"EN-GB\" style=\"color:black\">s</span><span lang=\"EN-GB\">ee section\u00a06.6.</span></p>", "ID": "203bff5a-9713-485a-89ad-e4f0e5da619c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Arzerra is for intravenous infusion and\nmust be diluted prior to administration. </span>", "ID": "49e6c236-cab7-406f-8af4-25d6e0e6fb4f", "Styles": "None", "Classes": "None", "Text": "Arzerra is for intravenous infusion and must be diluted prior to administration. ", "ParentId": "203bff5a-9713-485a-89ad-e4f0e5da619c"}, {"Element": "<span lang=\"EN-GB\">For\ninstructions on dilution of the medicinal product before administration, </span>", "ID": "96697c39-bf47-46b9-8162-eecfe9e5c293", "Styles": "None", "Classes": "None", "Text": "For instructions on dilution of the medicinal product before administration, ", "ParentId": "203bff5a-9713-485a-89ad-e4f0e5da619c"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">s</span>", "ID": "7b6ec679-3603-4131-90be-b115b0f79ff8", "Styles": "color:black", "Classes": "None", "Text": "s", "ParentId": "203bff5a-9713-485a-89ad-e4f0e5da619c"}, {"Element": "<span lang=\"EN-GB\">ee section\u00a06.6.</span>", "ID": "59cfabea-8629-438a-835c-54b51b13ca21", "Styles": "None", "Classes": "None", "Text": "ee section\u00a06.6.", "ParentId": "203bff5a-9713-485a-89ad-e4f0e5da619c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e5b3a8fe-66d2-43aa-af63-92561d122db6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8cc2c7f9-2648-4a61-957d-e50bdf7a10bf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e5b3a8fe-66d2-43aa-af63-92561d122db6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>4.3\u00a0\u00a0\u00a0\u00a0 Contraindications</b></p>", "ID": "08dd8fc8-a846-4ac3-8193-aba7e0c2d5dc", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b>4.3\u00a0\u00a0\u00a0\u00a0 Contraindications</b>", "ID": "588a1330-479a-473a-bb08-1f497fee2160", "Styles": "None", "Classes": "None", "Text": "4.3\u00a0\u00a0\u00a0\u00a0 Contraindications", "ParentId": "08dd8fc8-a846-4ac3-8193-aba7e0c2d5dc"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "d3d6f090-4969-4b7a-b132-3d7f11fc24c7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hypersensitivity to ofatumumab or to any of\nthe excipients listed in section\u00a06.1.</span></p>", "ID": "f7dc3b3c-7ea8-40ec-bccc-4f0344144514", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Hypersensitivity to ofatumumab or to any of\nthe excipients listed in section\u00a06.1.</span>", "ID": "2befb268-a70f-4b7f-bf05-3f2d6bd631dc", "Styles": "None", "Classes": "None", "Text": "Hypersensitivity to ofatumumab or to any of the excipients listed in section\u00a06.1.", "ParentId": "f7dc3b3c-7ea8-40ec-bccc-4f0344144514"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a39aef18-0603-4365-bba6-3ec872b8f8bf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a7150ac6-e025-4aec-81f4-982474d33840", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a39aef18-0603-4365-bba6-3ec872b8f8bf"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.4\u00a0\u00a0\u00a0\u00a0 Special warnings and precautions for use</span></b></p>", "ID": "27100ec9-08e6-4563-aeee-40816077c5e1", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">4.4\u00a0\u00a0\u00a0\u00a0 Special warnings and precautions for use</span></b>", "ID": "78d1a027-58c7-458a-be84-792285801bf0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "27100ec9-08e6-4563-aeee-40816077c5e1"}, {"Element": "<span lang=\"EN-GB\">4.4\u00a0\u00a0\u00a0\u00a0 Special warnings and precautions for use</span>", "ID": "9aaf82ff-2e4a-458d-93c2-ffafc27beebc", "Styles": "None", "Classes": "None", "Text": "4.4\u00a0\u00a0\u00a0\u00a0 Special warnings and precautions for use", "ParentId": "78d1a027-58c7-458a-be84-792285801bf0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "98770d54-17fb-45e1-94f5-f6531ae610b6", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ebf0aaad-2087-4c5f-bfb5-d65487f63abf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "98770d54-17fb-45e1-94f5-f6531ae610b6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Infusion-related\nreactions</span></u></p>", "ID": "191eb5f2-a117-4b13-9b5a-a34720479fe8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\">Infusion-related\nreactions</span></u>", "ID": "283ff743-d4f4-4a8d-9e34-5d5e0f6213a7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "191eb5f2-a117-4b13-9b5a-a34720479fe8"}, {"Element": "<span lang=\"EN-GB\">Infusion-related\nreactions</span>", "ID": "7470bdcc-3214-4596-a5cf-ac9fe63be305", "Styles": "None", "Classes": "None", "Text": "Infusion-related reactions", "ParentId": "283ff743-d4f4-4a8d-9e34-5d5e0f6213a7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d0d90e83-ee17-49bd-b8a7-c156427548dd", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "29a398fb-6c11-4494-88a4-22bc61abc69c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d0d90e83-ee17-49bd-b8a7-c156427548dd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Intravenous ofatumumab has been associated\nwith infusion-related reactions. These reactions may result in temporary\ninterruption or withdrawal of treatment. Pre-medication attenuates\ninfusion-related reactions but these may still occur, predominantly during the\nfirst infusion. </span><span lang=\"EN-GB\">Infusion</span><span lang=\"EN-GB\">-related</span><span lang=\"EN-GB\"> reactions may include, but are not limited to, anaphylactoid\nevents, bronchospasm, cardiac events (e.g. myocardial ischaemia/infarction,\nbradycardia), chills/rigors, cough, cytokine release syndrome, diarrhoea,\ndyspnoea, fatigue, flushing, hypertension, hypotension, nausea, pain, pulmonary\noedema, pruritus, pyrexia, rash, and urticaria. In rare cases, these reactions\nmay lead to death. </span><span lang=\"EN-GB\">Even with pre-medication, severe\nreactions, including cytokine release syndrome, have been reported following use\nof ofatumumab. In the event of a severe infusion-related reaction, the infusion\nof Arzerra must be interrupted immediately and symptomatic treatment instituted\n(see section\u00a04.2).</span></p>", "ID": "c9eef228-2740-4ef5-a79b-d89c58b2df58", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Intravenous ofatumumab has been associated\nwith infusion-related reactions. These reactions may result in temporary\ninterruption or withdrawal of treatment. Pre-medication attenuates\ninfusion-related reactions but these may still occur, predominantly during the\nfirst infusion. </span>", "ID": "3616c85b-f85b-40be-b87d-d65e14fee0ba", "Styles": "None", "Classes": "None", "Text": "Intravenous ofatumumab has been associated with infusion-related reactions. These reactions may result in temporary interruption or withdrawal of treatment. Pre-medication attenuates infusion-related reactions but these may still occur, predominantly during the first infusion. ", "ParentId": "c9eef228-2740-4ef5-a79b-d89c58b2df58"}, {"Element": "<span lang=\"EN-GB\">Infusion</span>", "ID": "451a0ed7-9791-4624-9c25-97eac1943bd6", "Styles": "None", "Classes": "None", "Text": "Infusion", "ParentId": "c9eef228-2740-4ef5-a79b-d89c58b2df58"}, {"Element": "<span lang=\"EN-GB\">-related</span>", "ID": "2d2b1385-33ef-483b-ae85-031f6b104535", "Styles": "None", "Classes": "None", "Text": "-related", "ParentId": "c9eef228-2740-4ef5-a79b-d89c58b2df58"}, {"Element": "<span lang=\"EN-GB\"> reactions may include, but are not limited to, anaphylactoid\nevents, bronchospasm, cardiac events (e.g. myocardial ischaemia/infarction,\nbradycardia), chills/rigors, cough, cytokine release syndrome, diarrhoea,\ndyspnoea, fatigue, flushing, hypertension, hypotension, nausea, pain, pulmonary\noedema, pruritus, pyrexia, rash, and urticaria. In rare cases, these reactions\nmay lead to death. </span>", "ID": "8d3050ef-5e7f-4440-898c-c988d1f2dc30", "Styles": "None", "Classes": "None", "Text": " reactions may include, but are not limited to, anaphylactoid events, bronchospasm, cardiac events (e.g. myocardial ischaemia/infarction, bradycardia), chills/rigors, cough, cytokine release syndrome, diarrhoea, dyspnoea, fatigue, flushing, hypertension, hypotension, nausea, pain, pulmonary oedema, pruritus, pyrexia, rash, and urticaria. In rare cases, these reactions may lead to death. ", "ParentId": "c9eef228-2740-4ef5-a79b-d89c58b2df58"}, {"Element": "<span lang=\"EN-GB\">Even with pre-medication, severe\nreactions, including cytokine release syndrome, have been reported following use\nof ofatumumab. In the event of a severe infusion-related reaction, the infusion\nof Arzerra must be interrupted immediately and symptomatic treatment instituted\n(see section\u00a04.2).</span>", "ID": "a11524ab-1149-4246-9d39-76e0fd035b4d", "Styles": "None", "Classes": "None", "Text": "Even with pre-medication, severe reactions, including cytokine release syndrome, have been reported following use of ofatumumab. In the event of a severe infusion-related reaction, the infusion of Arzerra must be interrupted immediately and symptomatic treatment instituted (see section\u00a04.2).", "ParentId": "c9eef228-2740-4ef5-a79b-d89c58b2df58"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ed04769f-d9f2-4b7a-a430-dc22481fbd41", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "aca511ef-cfdc-4f1c-a27c-2dbd912a3d1e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ed04769f-d9f2-4b7a-a430-dc22481fbd41"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">If an anaphylactic reaction occurs, Arzerra should be\nimmediately and permanently discontinued and appropriate medical treatment\nshould be initiated.</span></p>", "ID": "73661e87-0dfa-47db-bab7-398e6fb3083a", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">If an anaphylactic reaction occurs, Arzerra should be\nimmediately and permanently discontinued and appropriate medical treatment\nshould be initiated.</span>", "ID": "08cba0e5-1eaa-4977-acae-196e37a64443", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "If an anaphylactic reaction occurs, Arzerra should be immediately and permanently discontinued and appropriate medical treatment should be initiated.", "ParentId": "73661e87-0dfa-47db-bab7-398e6fb3083a"}, {"Element": "<p class=\"MsoNormal\"><span class=\"CSIchar\"><span lang=\"EN-GB\" style=\"border:none\">\u00a0</span></span></p>", "ID": "a44f00d9-4941-4261-9ebf-895839f42c4d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span class=\"CSIchar\"><span lang=\"EN-GB\" style=\"border:none\">\u00a0</span></span>", "ID": "ee558279-cb41-49bc-947c-0ad662af7e8e", "Styles": "None", "Classes": "['CSIchar']", "Text": "", "ParentId": "a44f00d9-4941-4261-9ebf-895839f42c4d"}, {"Element": "<span lang=\"EN-GB\" style=\"border:none\">\u00a0</span>", "ID": "dd9720bc-6720-41ec-ad87-16543b539d40", "Styles": "border:none", "Classes": "None", "Text": "\u00a0", "ParentId": "ee558279-cb41-49bc-947c-0ad662af7e8e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infusion</span><span lang=\"EN-GB\">-related</span><span lang=\"EN-GB\"> reactions occur predominantly during the first infusion </span><span lang=\"EN-GB\">and tend to decrease with subsequent infusions. </span><span lang=\"EN-GB\">Patients with a history of decreased pulmonary function may be at a\ngreater risk for pulmonary complications from severe reactions and should be\nmonitored closely during infusion of Arzerra.</span></p>", "ID": "e38627de-482f-4624-a5af-3176e794e953", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Infusion</span>", "ID": "63562d00-0949-4424-85db-34892e53d98c", "Styles": "None", "Classes": "None", "Text": "Infusion", "ParentId": "e38627de-482f-4624-a5af-3176e794e953"}, {"Element": "<span lang=\"EN-GB\">-related</span>", "ID": "f13f4606-d128-4e3b-b05a-f0b18865346a", "Styles": "None", "Classes": "None", "Text": "-related", "ParentId": "e38627de-482f-4624-a5af-3176e794e953"}, {"Element": "<span lang=\"EN-GB\"> reactions occur predominantly during the first infusion </span>", "ID": "d9fe900f-992f-43e7-a20d-4b0d109c7fd8", "Styles": "None", "Classes": "None", "Text": " reactions occur predominantly during the first infusion ", "ParentId": "e38627de-482f-4624-a5af-3176e794e953"}, {"Element": "<span lang=\"EN-GB\">and tend to decrease with subsequent infusions. </span>", "ID": "916acd36-f1e4-4026-a6bc-77d87c9bbdf0", "Styles": "None", "Classes": "None", "Text": "and tend to decrease with subsequent infusions. ", "ParentId": "e38627de-482f-4624-a5af-3176e794e953"}, {"Element": "<span lang=\"EN-GB\">Patients with a history of decreased pulmonary function may be at a\ngreater risk for pulmonary complications from severe reactions and should be\nmonitored closely during infusion of Arzerra.</span>", "ID": "da4a2287-2354-4077-8476-f24bac217603", "Styles": "None", "Classes": "None", "Text": "Patients with a history of decreased pulmonary function may be at a greater risk for pulmonary complications from severe reactions and should be monitored closely during infusion of Arzerra.", "ParentId": "e38627de-482f-4624-a5af-3176e794e953"}, {"Element": "<p class=\"MsoNormal\"><span class=\"CSIchar\"><span lang=\"EN-GB\" style=\"border:none\">\u00a0</span></span></p>", "ID": "b940f234-6677-4de4-be78-8c3ab8aa0069", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span class=\"CSIchar\"><span lang=\"EN-GB\" style=\"border:none\">\u00a0</span></span>", "ID": "a20eaf66-e0a4-49be-8097-64404670e0d6", "Styles": "None", "Classes": "['CSIchar']", "Text": "", "ParentId": "b940f234-6677-4de4-be78-8c3ab8aa0069"}, {"Element": "<span lang=\"EN-GB\" style=\"border:none\">\u00a0</span>", "ID": "d748b438-57a4-46f9-a663-f951a35a1a39", "Styles": "border:none", "Classes": "None", "Text": "\u00a0", "ParentId": "a20eaf66-e0a4-49be-8097-64404670e0d6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Tumour\nlysis syndrome</span></u></p>", "ID": "169ac5f7-9e24-46e5-b6ea-e0d8f3081d2e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\">Tumour\nlysis syndrome</span></u>", "ID": "871ab273-d536-4d15-a368-819dad2d222e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "169ac5f7-9e24-46e5-b6ea-e0d8f3081d2e"}, {"Element": "<span lang=\"EN-GB\">Tumour\nlysis syndrome</span>", "ID": "478c7dc2-cee6-48c7-ab41-8fa03108ae6d", "Styles": "None", "Classes": "None", "Text": "Tumour lysis syndrome", "ParentId": "871ab273-d536-4d15-a368-819dad2d222e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e5d00c2f-4dd5-4a36-996d-916d41297b9c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1b3a37e4-b0b2-4414-bfc2-3435b07c6a6f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e5d00c2f-4dd5-4a36-996d-916d41297b9c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In patients with CLL, tumour lysis syndrome\n(TLS) may occur with use of Arzerra. Risk factors for TLS include a high tumour\nburden, high concentrations of circulating cells (\u226525,000/mm<sup>3</sup>),\nhypovolaemia, renal insufficiency, elevated pre-treatment uric acid levels and\nelevated lactate dehydrogenase levels. Management of TLS includes correction of\nelectrolyte abnormalities, monitoring of renal function, maintenance of fluid\nbalance and supportive care.</span></p>", "ID": "8fb6beb7-bb78-42fc-acfd-1852a7c2ba9f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">In patients with CLL, tumour lysis syndrome\n(TLS) may occur with use of Arzerra. Risk factors for TLS include a high tumour\nburden, high concentrations of circulating cells (\u226525,000/mm<sup>3</sup>),\nhypovolaemia, renal insufficiency, elevated pre-treatment uric acid levels and\nelevated lactate dehydrogenase levels. Management of TLS includes correction of\nelectrolyte abnormalities, monitoring of renal function, maintenance of fluid\nbalance and supportive care.</span>", "ID": "c61e2198-190c-4014-8ffe-421e102957c5", "Styles": "None", "Classes": "None", "Text": "In patients with CLL, tumour lysis syndrome (TLS) may occur with use of Arzerra. Risk factors for TLS include a high tumour burden, high concentrations of circulating cells (\u226525,000/mm), hypovolaemia, renal insufficiency, elevated pre-treatment uric acid levels and elevated lactate dehydrogenase levels. Management of TLS includes correction of electrolyte abnormalities, monitoring of renal function, maintenance of fluid balance and supportive care.", "ParentId": "8fb6beb7-bb78-42fc-acfd-1852a7c2ba9f"}, {"Element": "<sup>3</sup>", "ID": "cea48ddc-5f84-4548-842c-56aed0760d21", "Styles": "None", "Classes": "None", "Text": "3", "ParentId": "c61e2198-190c-4014-8ffe-421e102957c5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2c0c388b-bec1-4c02-b352-54198ad0baa0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7f97ae66-a23c-44a7-a8b4-1c9586b05e8a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2c0c388b-bec1-4c02-b352-54198ad0baa0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Progressive\nmultifocal leukoencephalopathy</span></u></p>", "ID": "92758b7d-68e0-4dfe-9bed-3b1462618790", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\">Progressive\nmultifocal leukoencephalopathy</span></u>", "ID": "52b111ac-2fce-4e7a-8bf3-ad421c7a07df", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "92758b7d-68e0-4dfe-9bed-3b1462618790"}, {"Element": "<span lang=\"EN-GB\">Progressive\nmultifocal leukoencephalopathy</span>", "ID": "393254df-d3ea-4d9a-b778-9fc374552138", "Styles": "None", "Classes": "None", "Text": "Progressive multifocal leukoencephalopathy", "ParentId": "52b111ac-2fce-4e7a-8bf3-ad421c7a07df"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "97bf9eb9-c0c8-4afa-b6da-4738e27e6427", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2900c881-ece8-4be5-b174-88a4a3f263b0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "97bf9eb9-c0c8-4afa-b6da-4738e27e6427"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Cases of progressive\nmultifocal leukoencephalopathy (PML) resulting in death have been reported in CLL\npatients receiving cytotoxic pharmacotherapy, including ofatumumab. A diagnosis\nof PML should be considered in any Arzerra patient who reports the new onset of\nor changes in pre-existing neurological signs and symptoms. If a diagnosis of\nPML is suspected Arzerra should be discontinued and referral to a neurologist\nshould be considered.</span></p>", "ID": "1d251372-9bd8-41ec-bc28-419fb800b9f9", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Cases of progressive\nmultifocal leukoencephalopathy (PML) resulting in death have been reported in CLL\npatients receiving cytotoxic pharmacotherapy, including ofatumumab. A diagnosis\nof PML should be considered in any Arzerra patient who reports the new onset of\nor changes in pre-existing neurological signs and symptoms. If a diagnosis of\nPML is suspected Arzerra should be discontinued and referral to a neurologist\nshould be considered.</span>", "ID": "0c19c0c9-3a43-456a-8d88-51a4b0412aac", "Styles": "None", "Classes": "None", "Text": "Cases of progressive multifocal leukoencephalopathy (PML) resulting in death have been reported in CLL patients receiving cytotoxic pharmacotherapy, including ofatumumab. A diagnosis of PML should be considered in any Arzerra patient who reports the new onset of or changes in pre-existing neurological signs and symptoms. If a diagnosis of PML is suspected Arzerra should be discontinued and referral to a neurologist should be considered.", "ParentId": "1d251372-9bd8-41ec-bc28-419fb800b9f9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0498ed6a-3573-47b1-a182-bd426af4fdbc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0aeacd2b-0bd1-4477-b743-58d12d4162f2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0498ed6a-3573-47b1-a182-bd426af4fdbc"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Immunisations</span></u></p>", "ID": "69923511-24cd-44c2-9999-d28ba3222375", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\">Immunisations</span></u>", "ID": "b73065d7-c1f5-45b1-96a2-3d3a54750db1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "69923511-24cd-44c2-9999-d28ba3222375"}, {"Element": "<span lang=\"EN-GB\">Immunisations</span>", "ID": "6de6cf1d-0b7c-4263-9d28-7bd3036f2dbe", "Styles": "None", "Classes": "None", "Text": "Immunisations", "ParentId": "b73065d7-c1f5-45b1-96a2-3d3a54750db1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "832e62b8-a191-45ce-8e8e-dd75271c5049", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "af2e5ddb-98cd-4f7f-b37f-94d88766e56f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "832e62b8-a191-45ce-8e8e-dd75271c5049"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety of, and ability to generate a\nprimary or anamnestic response to, immunisation with live attenuated or\ninactivated vaccines during treatment with ofatumumab has not been studied. The\nresponse to vaccination could be impaired when B-cells are depleted. </span>Due\nto the risk of infection, administration of live attenuated vaccines should be\navoided during and after treatment with ofatumumab, until B-cell counts are normalised.<span lang=\"EN-GB\"> The risks and benefits of vaccinating patients during Arzerra\ntherapy should be considered.</span></p>", "ID": "2b8445b6-b3fd-4c57-bf3c-a5db48b4c34d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Due to the risk of infection, administration of live attenuated vaccines should be avoided during and after treatment with ofatumumab, until B-cell counts are normalised.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">The safety of, and ability to generate a\nprimary or anamnestic response to, immunisation with live attenuated or\ninactivated vaccines during treatment with ofatumumab has not been studied. The\nresponse to vaccination could be impaired when B-cells are depleted. </span>", "ID": "53e98faa-555a-4b78-b79b-ca3a57f03898", "Styles": "None", "Classes": "None", "Text": "The safety of, and ability to generate a primary or anamnestic response to, immunisation with live attenuated or inactivated vaccines during treatment with ofatumumab has not been studied. The response to vaccination could be impaired when B-cells are depleted. ", "ParentId": "2b8445b6-b3fd-4c57-bf3c-a5db48b4c34d"}, {"Element": "<span lang=\"EN-GB\"> The risks and benefits of vaccinating patients during Arzerra\ntherapy should be considered.</span>", "ID": "002a9190-7f6f-4b81-931b-951ed8ead618", "Styles": "None", "Classes": "None", "Text": " The risks and benefits of vaccinating patients during Arzerra therapy should be considered.", "ParentId": "2b8445b6-b3fd-4c57-bf3c-a5db48b4c34d"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "43f96d1e-1517-4a66-9426-1da3a3f66013", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f1ab923e-6269-44cd-a8ad-b0cb19229ee9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "43f96d1e-1517-4a66-9426-1da3a3f66013"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hepatitis\nB</span></u></p>", "ID": "f9e372bb-3b99-4411-b100-f0ad10fba5e9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\">Hepatitis\nB</span></u>", "ID": "ea8731f5-2350-426d-be61-1e8ac32fabae", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f9e372bb-3b99-4411-b100-f0ad10fba5e9"}, {"Element": "<span lang=\"EN-GB\">Hepatitis\nB</span>", "ID": "2818aa05-fad6-4a98-9f6f-00b80fdaec0c", "Styles": "None", "Classes": "None", "Text": "Hepatitis B", "ParentId": "ea8731f5-2350-426d-be61-1e8ac32fabae"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b3f5aff1-51bd-4ffb-b37c-4ea24a60c3ec", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e5ee96ea-1eb0-47f6-917c-7e87a9a3deda", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b3f5aff1-51bd-4ffb-b37c-4ea24a60c3ec"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hepatitis B virus (HBV) infection and\nreactivation, in some cases resulting in fulminant hepatitis, hepatic failure\nand death, has occurred in patients treated with medicinal products classified\nas CD20-directed cytolytic antibodies, including Arzerra. Cases have been\nreported in patients who are hepatitis B surface antigen (HBsAg) positive and\nalso in those who are hepatitis B core antibody (anti-HBc) positive but HBsAg\nnegative. Reactivation has also occurred in patients who appear to have\nresolved hepatitis B infection (i.e. HBsAg negative, anti-HBc positive, and\nhepatitis B surface antibody [anti-HBs] positive).</span></p>", "ID": "717400e7-fffd-44d8-9c82-e9d76f59039b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Hepatitis B virus (HBV) infection and\nreactivation, in some cases resulting in fulminant hepatitis, hepatic failure\nand death, has occurred in patients treated with medicinal products classified\nas CD20-directed cytolytic antibodies, including Arzerra. Cases have been\nreported in patients who are hepatitis B surface antigen (HBsAg) positive and\nalso in those who are hepatitis B core antibody (anti-HBc) positive but HBsAg\nnegative. Reactivation has also occurred in patients who appear to have\nresolved hepatitis B infection (i.e. HBsAg negative, anti-HBc positive, and\nhepatitis B surface antibody [anti-HBs] positive).</span>", "ID": "ae88f934-2988-43d2-a4c4-f63e11637ca1", "Styles": "None", "Classes": "None", "Text": "Hepatitis B virus (HBV) infection and reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death, has occurred in patients treated with medicinal products classified as CD20-directed cytolytic antibodies, including Arzerra. Cases have been reported in patients who are hepatitis B surface antigen (HBsAg) positive and also in those who are hepatitis B core antibody (anti-HBc) positive but HBsAg negative. Reactivation has also occurred in patients who appear to have resolved hepatitis B infection (i.e. HBsAg negative, anti-HBc positive, and hepatitis B surface antibody [anti-HBs] positive).", "ParentId": "717400e7-fffd-44d8-9c82-e9d76f59039b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2caa34c2-cb92-4d8a-80d7-5839ec63319b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "52dd3d77-f2e8-4c29-8602-56045af78dbf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2caa34c2-cb92-4d8a-80d7-5839ec63319b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">HBV reactivation is defined as an abrupt\nincrease in HBV replication manifesting as a rapid increase in serum HBV DNA\nlevel or detection of HBsAg in a person who was previously HBsAg negative and\nanti-HBc positive. Reactivation of HBV replication is often followed by\nhepatitis, i.e. increase in transaminase levels and, in severe cases, increase\nin bilirubin levels, liver failure, and death.</span></p>", "ID": "db3e55d0-62dd-4855-a2b6-d0e06ba0667e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">HBV reactivation is defined as an abrupt\nincrease in HBV replication manifesting as a rapid increase in serum HBV DNA\nlevel or detection of HBsAg in a person who was previously HBsAg negative and\nanti-HBc positive. Reactivation of HBV replication is often followed by\nhepatitis, i.e. increase in transaminase levels and, in severe cases, increase\nin bilirubin levels, liver failure, and death.</span>", "ID": "fe1400cf-391a-4117-bd2a-7346ac7a25ec", "Styles": "None", "Classes": "None", "Text": "HBV reactivation is defined as an abrupt increase in HBV replication manifesting as a rapid increase in serum HBV DNA level or detection of HBsAg in a person who was previously HBsAg negative and anti-HBc positive. Reactivation of HBV replication is often followed by hepatitis, i.e. increase in transaminase levels and, in severe cases, increase in bilirubin levels, liver failure, and death.", "ParentId": "db3e55d0-62dd-4855-a2b6-d0e06ba0667e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1605628e-8b40-48a7-8f32-baf1b39492fe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "09f345d7-1414-466d-9686-d3f46e9aff58", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1605628e-8b40-48a7-8f32-baf1b39492fe"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">All patients should be screened for HBV\ninfection by measuring HBsAg and anti-HBc before initiation of Arzerra\ntreatment. For patients who show evidence of prior (HBsAg negative, anti-HBc\npositive) hepatitis B infection, physicians with expertise in managing\nhepatitis B should be consulted regarding monitoring and initiation of HBV\nantiviral therapy. Arzerra treatment should not be initiated in patients with\nevidence of current hepatitis B infection (HBsAg positive) until the infection\nhas been adequately treated.</span></p>", "ID": "026b3560-49a7-4b91-b0ee-0bac7d3ea7bc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">All patients should be screened for HBV\ninfection by measuring HBsAg and anti-HBc before initiation of Arzerra\ntreatment. For patients who show evidence of prior (HBsAg negative, anti-HBc\npositive) hepatitis B infection, physicians with expertise in managing\nhepatitis B should be consulted regarding monitoring and initiation of HBV\nantiviral therapy. Arzerra treatment should not be initiated in patients with\nevidence of current hepatitis B infection (HBsAg positive) until the infection\nhas been adequately treated.</span>", "ID": "80983944-0aa2-4638-b80f-a643e57c2b04", "Styles": "None", "Classes": "None", "Text": "All patients should be screened for HBV infection by measuring HBsAg and anti-HBc before initiation of Arzerra treatment. For patients who show evidence of prior (HBsAg negative, anti-HBc positive) hepatitis B infection, physicians with expertise in managing hepatitis B should be consulted regarding monitoring and initiation of HBV antiviral therapy. Arzerra treatment should not be initiated in patients with evidence of current hepatitis B infection (HBsAg positive) until the infection has been adequately treated.", "ParentId": "026b3560-49a7-4b91-b0ee-0bac7d3ea7bc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c786b0b1-e0e6-47cc-966a-fdbff3704809", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "719a6f90-6c8a-4832-8978-253008732c20", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c786b0b1-e0e6-47cc-966a-fdbff3704809"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients with evidence of prior HBV\ninfection should be monitored for clinical and laboratory signs of hepatitis or\nHBV reactivation during treatment with and for 6\u201112\u00a0months following\nthe last infusion of Arzerra. HBV reactivation has been reported up to\n12\u00a0months following completion of therapy. Discontinuation of HBV\nantiviral therapy should be discussed with physicians with expertise in\nmanaging hepatitis B.</span></p>", "ID": "f88d2edc-e8db-4fba-93f3-12c856ab27d7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Patients with evidence of prior HBV\ninfection should be monitored for clinical and laboratory signs of hepatitis or\nHBV reactivation during treatment with and for 6\u201112\u00a0months following\nthe last infusion of Arzerra. HBV reactivation has been reported up to\n12\u00a0months following completion of therapy. Discontinuation of HBV\nantiviral therapy should be discussed with physicians with expertise in\nmanaging hepatitis B.</span>", "ID": "0c476ec4-6547-41ef-b3cc-000ec4efc46f", "Styles": "None", "Classes": "None", "Text": "Patients with evidence of prior HBV infection should be monitored for clinical and laboratory signs of hepatitis or HBV reactivation during treatment with and for 6\u201112\u00a0months following the last infusion of Arzerra. HBV reactivation has been reported up to 12\u00a0months following completion of therapy. Discontinuation of HBV antiviral therapy should be discussed with physicians with expertise in managing hepatitis B.", "ParentId": "f88d2edc-e8db-4fba-93f3-12c856ab27d7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c8479e58-0356-4eec-869d-c1e1511d8749", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "45b05e41-1aae-46bd-b535-64b40d00654d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c8479e58-0356-4eec-869d-c1e1511d8749"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In patients who develop reactivation of HBV\nwhile receiving Arzerra, Arzerra and any concomitant chemotherapy should be\ninterrupted immediately, and appropriate treatment instituted. Insufficient\ndata exist regarding the safety of resuming Arzerra in patients who develop HBV\nreactivation. Resumption of Arzerra in patients whose HBV reactivation resolves\nshould be discussed with physicians with expertise in managing hepatitis B.</span></p>", "ID": "d90544be-494a-49b6-bd57-e2519053185a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">In patients who develop reactivation of HBV\nwhile receiving Arzerra, Arzerra and any concomitant chemotherapy should be\ninterrupted immediately, and appropriate treatment instituted. Insufficient\ndata exist regarding the safety of resuming Arzerra in patients who develop HBV\nreactivation. Resumption of Arzerra in patients whose HBV reactivation resolves\nshould be discussed with physicians with expertise in managing hepatitis B.</span>", "ID": "41524177-79b7-40e7-b220-1b9775a08d6f", "Styles": "None", "Classes": "None", "Text": "In patients who develop reactivation of HBV while receiving Arzerra, Arzerra and any concomitant chemotherapy should be interrupted immediately, and appropriate treatment instituted. Insufficient data exist regarding the safety of resuming Arzerra in patients who develop HBV reactivation. Resumption of Arzerra in patients whose HBV reactivation resolves should be discussed with physicians with expertise in managing hepatitis B.", "ParentId": "d90544be-494a-49b6-bd57-e2519053185a"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4236cd38-37d1-47ad-9b65-f2943fa1d77a", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bd10acbd-0ffa-4d94-963c-dfe136800ec5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4236cd38-37d1-47ad-9b65-f2943fa1d77a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Cardiovascular</span></u></p>", "ID": "d2de3fac-d03b-43b0-b6b5-395d379805f0", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\">Cardiovascular</span></u>", "ID": "7509cf24-286c-45e4-8b61-030a0d02c38f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d2de3fac-d03b-43b0-b6b5-395d379805f0"}, {"Element": "<span lang=\"EN-GB\">Cardiovascular</span>", "ID": "0a5846a6-173e-40ea-b719-d0528afd8ccd", "Styles": "None", "Classes": "None", "Text": "Cardiovascular", "ParentId": "7509cf24-286c-45e4-8b61-030a0d02c38f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9f085432-8196-4f05-9857-e2bb6f55aad3", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fcdff47c-ea7c-4f3b-96ea-389b625e798d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9f085432-8196-4f05-9857-e2bb6f55aad3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients with a history of cardiac disease\nshould be monitored closely. </span><span lang=\"EN-GB\">Arzerra should be\ndiscontinued in patients who experience serious or life-threatening cardiac\narrhythmias.</span></p>", "ID": "18a2eea7-45a2-495c-85be-78572ff8d3e6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Patients with a history of cardiac disease\nshould be monitored closely. </span>", "ID": "7486d661-41e0-46e1-8436-1094de99c289", "Styles": "None", "Classes": "None", "Text": "Patients with a history of cardiac disease should be monitored closely. ", "ParentId": "18a2eea7-45a2-495c-85be-78572ff8d3e6"}, {"Element": "<span lang=\"EN-GB\">Arzerra should be\ndiscontinued in patients who experience serious or life-threatening cardiac\narrhythmias.</span>", "ID": "2485603c-5e5a-49ab-878f-077ebdddc049", "Styles": "None", "Classes": "None", "Text": "Arzerra should be discontinued in patients who experience serious or life-threatening cardiac arrhythmias.", "ParentId": "18a2eea7-45a2-495c-85be-78572ff8d3e6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "d053161a-65e8-4d73-918b-6489248b1e2b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "bfe63887-e9b1-47f4-b32a-d887961a360e", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "d053161a-65e8-4d73-918b-6489248b1e2b"}, {"Element": "<p class=\"MsoNormal\"><span style=\"color:black;border:none windowtext 1.0pt;\npadding:0in\">The effect of multiple doses of Arzerra on the QTc interval was\nevaluated in a pooled analysis of three open-label studies in patients with CLL\n(N=85</span><span style=\"border:none windowtext 1.0pt;padding:0in\">). </span><span style=\"border:none windowtext 1.0pt;padding:0in\">Increases above 5\u00a0msec\nwere observed in the median/mean QT/QTc intervals in the pooled analysis.<span style=\"color:red\"> </span></span><span style=\"color:black;border:none windowtext 1.0pt;\npadding:0in\">No large changes in the mean QTc interval (i.e.\n&gt;20\u00a0milliseconds) were detected. None of the patients had an increase of\nQTc to &gt;500\u00a0msec. A concentration-dependent increase in QTc was not\ndetected. It is recommended that patients have electrolytes such as potassium\nand magnesium measured prior to and during the administration of ofatumumab.\nElectrolyte abnormalities should be corrected. The effect of ofatumumab on\npatients with prolonged QT intervals (e.g. acquired or congenital) is unknown.</span></p>", "ID": "f7038931-c191-4b7e-875a-620ea16807e0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"color:black;border:none windowtext 1.0pt;\npadding:0in\">The effect of multiple doses of Arzerra on the QTc interval was\nevaluated in a pooled analysis of three open-label studies in patients with CLL\n(N=85</span>", "ID": "59ca61de-88de-4612-8481-40b8522b6d70", "Styles": "color:black;border:none windowtext 1.0pt;\npadding:0in", "Classes": "None", "Text": "The effect of multiple doses of Arzerra on the QTc interval was evaluated in a pooled analysis of three open-label studies in patients with CLL (N=85", "ParentId": "f7038931-c191-4b7e-875a-620ea16807e0"}, {"Element": "<span style=\"border:none windowtext 1.0pt;padding:0in\">). </span>", "ID": "e2ee434c-135a-4338-aaa4-549fc3ea08d7", "Styles": "border:none windowtext 1.0pt;padding:0in", "Classes": "None", "Text": "). ", "ParentId": "f7038931-c191-4b7e-875a-620ea16807e0"}, {"Element": "<span style=\"border:none windowtext 1.0pt;padding:0in\">Increases above 5\u00a0msec\nwere observed in the median/mean QT/QTc intervals in the pooled analysis.<span style=\"color:red\"> </span></span>", "ID": "fb32f852-0c86-4a4c-806d-ab6e9630ac1e", "Styles": "border:none windowtext 1.0pt;padding:0in", "Classes": "None", "Text": "Increases above 5\u00a0msec were observed in the median/mean QT/QTc intervals in the pooled analysis.", "ParentId": "f7038931-c191-4b7e-875a-620ea16807e0"}, {"Element": "<span style=\"color:red\"> </span>", "ID": "305ca4fd-9e22-4e17-b682-1dc9dc08f731", "Styles": "color:red", "Classes": "None", "Text": " ", "ParentId": "fb32f852-0c86-4a4c-806d-ab6e9630ac1e"}, {"Element": "<span style=\"color:black;border:none windowtext 1.0pt;\npadding:0in\">No large changes in the mean QTc interval (i.e.\n&gt;20\u00a0milliseconds) were detected. None of the patients had an increase of\nQTc to &gt;500\u00a0msec. A concentration-dependent increase in QTc was not\ndetected. It is recommended that patients have electrolytes such as potassium\nand magnesium measured prior to and during the administration of ofatumumab.\nElectrolyte abnormalities should be corrected. The effect of ofatumumab on\npatients with prolonged QT intervals (e.g. acquired or congenital) is unknown.</span>", "ID": "5e0cdc03-67f4-47ef-8916-65b378b88beb", "Styles": "color:black;border:none windowtext 1.0pt;\npadding:0in", "Classes": "None", "Text": "No large changes in the mean QTc interval (i.e. >20\u00a0milliseconds) were detected. None of the patients had an increase of QTc to >500\u00a0msec. A concentration-dependent increase in QTc was not detected. It is recommended that patients have electrolytes such as potassium and magnesium measured prior to and during the administration of ofatumumab. Electrolyte abnormalities should be corrected. The effect of ofatumumab on patients with prolonged QT intervals (e.g. acquired or congenital) is unknown.", "ParentId": "f7038931-c191-4b7e-875a-620ea16807e0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a1bbae14-9085-480f-8443-ecefde9ec99f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ed3f8734-fbb5-4cb7-b63b-db6de8c559f7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a1bbae14-9085-480f-8443-ecefde9ec99f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Bowel\nobstruction</span></u></p>", "ID": "946fb238-e3eb-4a02-a8e3-4a7cde5b057f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\">Bowel\nobstruction</span></u>", "ID": "3e50e6bf-3bfe-472a-a024-7660a49f7640", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "946fb238-e3eb-4a02-a8e3-4a7cde5b057f"}, {"Element": "<span lang=\"EN-GB\">Bowel\nobstruction</span>", "ID": "c4ed94c1-62fb-4068-9f40-ea5f5554f0c0", "Styles": "None", "Classes": "None", "Text": "Bowel obstruction", "ParentId": "3e50e6bf-3bfe-472a-a024-7660a49f7640"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "18342328-d4f5-4b3e-8623-c9b416ea7b9e", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "348baa7f-c8d5-4b41-882b-ffa52f562245", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "18342328-d4f5-4b3e-8623-c9b416ea7b9e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Bowel obstruction has been reported in\npatients receiving anti-CD20 monoclonal antibody therapy, including ofatumumab.\nPatients who present with abdominal pain, especially early in the course of\nofatumumab therapy, should be evaluated and appropriate treatment instituted.</span></p>", "ID": "40ddd2b1-c3c5-4944-a5a0-757a19aef1c9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Bowel obstruction has been reported in\npatients receiving anti-CD20 monoclonal antibody therapy, including ofatumumab.\nPatients who present with abdominal pain, especially early in the course of\nofatumumab therapy, should be evaluated and appropriate treatment instituted.</span>", "ID": "6a40e0fb-24ae-46ef-9a68-74d5335a5c33", "Styles": "None", "Classes": "None", "Text": "Bowel obstruction has been reported in patients receiving anti-CD20 monoclonal antibody therapy, including ofatumumab. Patients who present with abdominal pain, especially early in the course of ofatumumab therapy, should be evaluated and appropriate treatment instituted.", "ParentId": "40ddd2b1-c3c5-4944-a5a0-757a19aef1c9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a4de469d-681d-4caa-a408-3a7517a123c6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3e022c93-6dbe-4626-832b-a7280649dff9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a4de469d-681d-4caa-a408-3a7517a123c6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Laboratory\nmonitoring</span></u></p>", "ID": "75ac209f-fcf8-4241-b76a-ffa569b292dc", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\">Laboratory\nmonitoring</span></u>", "ID": "f4709557-7870-41c0-8cd6-ee4928911229", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "75ac209f-fcf8-4241-b76a-ffa569b292dc"}, {"Element": "<span lang=\"EN-GB\">Laboratory\nmonitoring</span>", "ID": "9f0ea95b-7ffe-4d6a-b0c4-02c1e80d1b35", "Styles": "None", "Classes": "None", "Text": "Laboratory monitoring", "ParentId": "f4709557-7870-41c0-8cd6-ee4928911229"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fbc69451-545c-41be-a0f9-e3d7b7cff3f5", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1222435b-f346-4456-98c8-7402ec7e3085", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fbc69451-545c-41be-a0f9-e3d7b7cff3f5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cytopenias, including prolonged and\nlate-onset neutropenia, have been reported during ofatumumab therapy. Complete\nblood counts, including neutrophil and platelet counts, should be obtained at\nregular intervals during Arzerra therapy and more frequently in patients who\ndevelop cytopenias.</span></p>", "ID": "7491014a-7085-4d7d-9679-3196a8b0a544", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Cytopenias, including prolonged and\nlate-onset neutropenia, have been reported during ofatumumab therapy. Complete\nblood counts, including neutrophil and platelet counts, should be obtained at\nregular intervals during Arzerra therapy and more frequently in patients who\ndevelop cytopenias.</span>", "ID": "b1c43dc9-aefb-4710-b074-986c409f2c5e", "Styles": "None", "Classes": "None", "Text": "Cytopenias, including prolonged and late-onset neutropenia, have been reported during ofatumumab therapy. Complete blood counts, including neutrophil and platelet counts, should be obtained at regular intervals during Arzerra therapy and more frequently in patients who develop cytopenias.", "ParentId": "7491014a-7085-4d7d-9679-3196a8b0a544"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "71e99462-e404-4dbc-a17e-9bad5603bf3e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6ecff0ed-4b53-4e48-b428-00cff024ad2c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "71e99462-e404-4dbc-a17e-9bad5603bf3e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Sodium\ncontent</span></u></p>", "ID": "e8e88cb3-9a3c-4df8-a85d-b59294a4e6ed", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\">Sodium\ncontent</span></u>", "ID": "00422422-0c48-40a6-8162-1efb70e48a0d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e8e88cb3-9a3c-4df8-a85d-b59294a4e6ed"}, {"Element": "<span lang=\"EN-GB\">Sodium\ncontent</span>", "ID": "fea70321-3e30-47a0-bbf8-35b0a5d88608", "Styles": "None", "Classes": "None", "Text": "Sodium content", "ParentId": "00422422-0c48-40a6-8162-1efb70e48a0d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6f43acec-102e-4280-8359-6c02ad3b8557", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a63be97b-5ad6-40f0-94b8-c964db1cf51c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6f43acec-102e-4280-8359-6c02ad3b8557"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">This medicinal product\ncontains 34.8\u00a0mg sodium per 300\u00a0mg dose, 116\u00a0mg sodium per\n1000\u00a0mg dose and 232\u00a0mg sodium per 2000\u00a0mg dose.</span><b><i><span lang=\"EN-GB\" style=\"color:navy\"> </span></i></b><span lang=\"EN-GB\" style=\"color:black\">This should be taken into consideration by patients on a\ncontrolled sodium diet.</span></p>", "ID": "aec6e62b-7566-4581-894b-63f5400b3220", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">This medicinal product\ncontains 34.8\u00a0mg sodium per 300\u00a0mg dose, 116\u00a0mg sodium per\n1000\u00a0mg dose and 232\u00a0mg sodium per 2000\u00a0mg dose.</span>", "ID": "9bb11fe0-7c31-43eb-91ef-813cf549e188", "Styles": "color:black", "Classes": "None", "Text": "This medicinal product contains 34.8\u00a0mg sodium per 300\u00a0mg dose, 116\u00a0mg sodium per 1000\u00a0mg dose and 232\u00a0mg sodium per 2000\u00a0mg dose.", "ParentId": "aec6e62b-7566-4581-894b-63f5400b3220"}, {"Element": "<b><i><span lang=\"EN-GB\" style=\"color:navy\"> </span></i></b>", "ID": "acf39c4e-05e0-4592-a0dd-07f0b6fac245", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "aec6e62b-7566-4581-894b-63f5400b3220"}, {"Element": "<i><span lang=\"EN-GB\" style=\"color:navy\"> </span></i>", "ID": "774eb4ce-4693-4d80-bc7a-185d27434b44", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "acf39c4e-05e0-4592-a0dd-07f0b6fac245"}, {"Element": "<span lang=\"EN-GB\" style=\"color:navy\"> </span>", "ID": "bd152ac6-1537-41cf-9e6e-8b790083a4cd", "Styles": "color:navy", "Classes": "None", "Text": " ", "ParentId": "774eb4ce-4693-4d80-bc7a-185d27434b44"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">This should be taken into consideration by patients on a\ncontrolled sodium diet.</span>", "ID": "554fd8ec-9f5d-4a21-a748-3deb3bcc86d1", "Styles": "color:black", "Classes": "None", "Text": "This should be taken into consideration by patients on a controlled sodium diet.", "ParentId": "aec6e62b-7566-4581-894b-63f5400b3220"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "25f39f8b-ee9e-4731-afda-47b2de5b6d8c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7adc7897-e478-4a5b-9f11-78ca197062d9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "25f39f8b-ee9e-4731-afda-47b2de5b6d8c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.5\u00a0\u00a0\u00a0\u00a0 Interaction with other medicinal products\nand other forms of interaction</span></b></p>", "ID": "4bff7adc-6069-4dd7-b6e6-d019d4104b38", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">4.5\u00a0\u00a0\u00a0\u00a0 Interaction with other medicinal products\nand other forms of interaction</span></b>", "ID": "054c6840-4ed2-4e73-ae32-6f928669266c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4bff7adc-6069-4dd7-b6e6-d019d4104b38"}, {"Element": "<span lang=\"EN-GB\">4.5\u00a0\u00a0\u00a0\u00a0 Interaction with other medicinal products\nand other forms of interaction</span>", "ID": "1e311605-0135-4f42-b42e-24e297e583a9", "Styles": "None", "Classes": "None", "Text": "4.5\u00a0\u00a0\u00a0\u00a0 Interaction with other medicinal products and other forms of interaction", "ParentId": "054c6840-4ed2-4e73-ae32-6f928669266c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "183e5082-f3a4-4e1e-991a-558a59ab9ed7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "83a5fd75-df8c-4a2f-a4f5-3d06e9263fff", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "183e5082-f3a4-4e1e-991a-558a59ab9ed7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Although limited formal drug-drug\ninteraction data exist for </span><span lang=\"EN-GB\">ofatumumab</span><span lang=\"EN-GB\">, there are no known clinically significant interactions with other\nmedicinal products. </span><span lang=\"EN-GB\">No clinically relevant\npharmacokinetic interactions were observed between </span><span lang=\"EN-GB\">ofatumumab</span><span lang=\"EN-GB\"> and fludarabine, cyclophosphamide,bendamustine, chlorambucil, or\nits active metabolite, phenylacetic acid mustard.</span></p>", "ID": "f0b0506c-ad38-4aca-8c35-c223ee5d3b21", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Although limited formal drug-drug\ninteraction data exist for </span>", "ID": "8a7eef5b-3eb3-4de6-a3d7-ecb349a8b5a4", "Styles": "None", "Classes": "None", "Text": "Although limited formal drug-drug interaction data exist for ", "ParentId": "f0b0506c-ad38-4aca-8c35-c223ee5d3b21"}, {"Element": "<span lang=\"EN-GB\">ofatumumab</span>", "ID": "44a0cae7-a60a-4ab7-8de4-06324ae7bb63", "Styles": "None", "Classes": "None", "Text": "ofatumumab", "ParentId": "f0b0506c-ad38-4aca-8c35-c223ee5d3b21"}, {"Element": "<span lang=\"EN-GB\">, there are no known clinically significant interactions with other\nmedicinal products. </span>", "ID": "61febf04-c121-4af0-ad7f-ffd365d34bc4", "Styles": "None", "Classes": "None", "Text": ", there are no known clinically significant interactions with other medicinal products. ", "ParentId": "f0b0506c-ad38-4aca-8c35-c223ee5d3b21"}, {"Element": "<span lang=\"EN-GB\">No clinically relevant\npharmacokinetic interactions were observed between </span>", "ID": "0d0883bf-9d9d-4337-83bb-53303f0c08be", "Styles": "None", "Classes": "None", "Text": "No clinically relevant pharmacokinetic interactions were observed between ", "ParentId": "f0b0506c-ad38-4aca-8c35-c223ee5d3b21"}, {"Element": "<span lang=\"EN-GB\">ofatumumab</span>", "ID": "66a173f1-a5db-43fd-a92e-a5788c6e6bff", "Styles": "None", "Classes": "None", "Text": "ofatumumab", "ParentId": "f0b0506c-ad38-4aca-8c35-c223ee5d3b21"}, {"Element": "<span lang=\"EN-GB\"> and fludarabine, cyclophosphamide,bendamustine, chlorambucil, or\nits active metabolite, phenylacetic acid mustard.</span>", "ID": "1501a619-9b57-41ed-ba75-213be10f681a", "Styles": "None", "Classes": "None", "Text": " and fludarabine, cyclophosphamide,bendamustine, chlorambucil, or its active metabolite, phenylacetic acid mustard.", "ParentId": "f0b0506c-ad38-4aca-8c35-c223ee5d3b21"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2fe86e27-349c-4dbb-bc61-b369278548f0", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "29258324-3f8c-42da-aa5f-b3b061f577d3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2fe86e27-349c-4dbb-bc61-b369278548f0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Live attenuated or inactivated vaccine\nefficacy may be impaired with ofatumumab. Therefore, the concomitant use of\nthese agents with ofatumumab should be avoided. </span><span lang=\"EN-GB\">If the\ncoadministration is judged unavoidable, the risks and benefits of vaccinating\npatients during therapy with </span><span lang=\"EN-GB\">ofatumumab </span><span lang=\"EN-GB\">should be considered (see section\u00a04.4).</span></p>", "ID": "f81940d4-e272-459e-970b-e4aa97d0766e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Live attenuated or inactivated vaccine\nefficacy may be impaired with ofatumumab. Therefore, the concomitant use of\nthese agents with ofatumumab should be avoided. </span>", "ID": "6adf3057-21e5-48bc-9496-283ca731b7c3", "Styles": "None", "Classes": "None", "Text": "Live attenuated or inactivated vaccine efficacy may be impaired with ofatumumab. Therefore, the concomitant use of these agents with ofatumumab should be avoided. ", "ParentId": "f81940d4-e272-459e-970b-e4aa97d0766e"}, {"Element": "<span lang=\"EN-GB\">If the\ncoadministration is judged unavoidable, the risks and benefits of vaccinating\npatients during therapy with </span>", "ID": "3eba4795-e406-42d2-8904-b25bec7a4209", "Styles": "None", "Classes": "None", "Text": "If the coadministration is judged unavoidable, the risks and benefits of vaccinating patients during therapy with ", "ParentId": "f81940d4-e272-459e-970b-e4aa97d0766e"}, {"Element": "<span lang=\"EN-GB\">ofatumumab </span>", "ID": "be8c6842-6a44-45f7-87bd-b3f88548daf5", "Styles": "None", "Classes": "None", "Text": "ofatumumab ", "ParentId": "f81940d4-e272-459e-970b-e4aa97d0766e"}, {"Element": "<span lang=\"EN-GB\">should be considered (see section\u00a04.4).</span>", "ID": "725a8604-0044-4491-a47a-aa36ff8ad2b9", "Styles": "None", "Classes": "None", "Text": "should be considered (see section\u00a04.4).", "ParentId": "f81940d4-e272-459e-970b-e4aa97d0766e"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "83c7233a-e57c-4610-b495-535cdcf28cee", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5fd18ab9-6085-4e4d-864d-1bd6c8cd1a87", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "83c7233a-e57c-4610-b495-535cdcf28cee"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">4.6\u00a0\u00a0\u00a0\u00a0 </span></b><b><span lang=\"EN-GB\">Fertility, pregnancy and lactation</span></b></p>", "ID": "59772f53-6441-49dc-9977-981b451f723f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">4.6\u00a0\u00a0\u00a0\u00a0 </span></b>", "ID": "23fda6e1-e07b-491d-9b61-079004c4417e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "59772f53-6441-49dc-9977-981b451f723f"}, {"Element": "<span lang=\"EN-GB\">4.6\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "01b2a9ea-8cbc-461f-a526-00af4641485e", "Styles": "None", "Classes": "None", "Text": "4.6\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "23fda6e1-e07b-491d-9b61-079004c4417e"}, {"Element": "<b><span lang=\"EN-GB\">Fertility, pregnancy and lactation</span></b>", "ID": "7f625931-d3ef-43e7-9b78-8baeafbd9da6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "59772f53-6441-49dc-9977-981b451f723f"}, {"Element": "<span lang=\"EN-GB\">Fertility, pregnancy and lactation</span>", "ID": "b36f4d5b-26bf-4fee-be37-33d3ae3ed7de", "Styles": "None", "Classes": "None", "Text": "Fertility, pregnancy and lactation", "ParentId": "7f625931-d3ef-43e7-9b78-8baeafbd9da6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "077c2d52-b232-42b6-98fd-900933f5e988", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Women of\nchild-bearing potential</span></u></p>", "ID": "1c42e053-5459-4fc9-b7e8-f944900c1a90", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\">Women of\nchild-bearing potential</span></u>", "ID": "09a844f3-7917-4459-a1d1-5f72a5412c0a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1c42e053-5459-4fc9-b7e8-f944900c1a90"}, {"Element": "<span lang=\"EN-GB\">Women of\nchild-bearing potential</span>", "ID": "1625bdf5-3475-4dff-a17e-c75edbb5cbb8", "Styles": "None", "Classes": "None", "Text": "Women of child-bearing potential", "ParentId": "09a844f3-7917-4459-a1d1-5f72a5412c0a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "ea4ea470-15a4-4f09-bc04-6628b03ac5c5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Since\nofatumumab may cause foetal B-cell depletion, effective contraception (methods\nthat result in less than 1% pregnancy rates) has to be used during Arzerra therapy\nand for 12\u00a0months after the last Arzerra dose. After this period, planning\nof a pregnancy in relation to the underlying disease, should be evaluated by\nthe treating physician.</span></p>", "ID": "03a1e2a7-fd6d-49f8-b929-5333bbb94cd2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Since\nofatumumab may cause foetal B-cell depletion, effective contraception (methods\nthat result in less than 1% pregnancy rates) has to be used during Arzerra therapy\nand for 12\u00a0months after the last Arzerra dose. After this period, planning\nof a pregnancy in relation to the underlying disease, should be evaluated by\nthe treating physician.</span>", "ID": "590b7a9e-2681-45ed-8d43-f6f9e59c5e71", "Styles": "None", "Classes": "None", "Text": "Since ofatumumab may cause foetal B-cell depletion, effective contraception (methods that result in less than 1% pregnancy rates) has to be used during Arzerra therapy and for 12\u00a0months after the last Arzerra dose. After this period, planning of a pregnancy in relation to the underlying disease, should be evaluated by the treating physician.", "ParentId": "03a1e2a7-fd6d-49f8-b929-5333bbb94cd2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4e982627-a446-4ef1-b452-d5df2f60633a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "650f2966-cb57-4a89-a04a-025f7b98a42d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4e982627-a446-4ef1-b452-d5df2f60633a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy</span></u></p>", "ID": "cfd1efce-9d0f-41b5-b4bc-412718a137c2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\">Pregnancy</span></u>", "ID": "aafdfa8b-c531-4342-a5f5-6d72bfb5229a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cfd1efce-9d0f-41b5-b4bc-412718a137c2"}, {"Element": "<span lang=\"EN-GB\">Pregnancy</span>", "ID": "f7c1f5ac-931e-4a8d-949d-eabdd4f700e7", "Styles": "None", "Classes": "None", "Text": "Pregnancy", "ParentId": "aafdfa8b-c531-4342-a5f5-6d72bfb5229a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "9cba7a7d-e8a1-4753-bce7-2bc4463e639a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Ofatumumab may cause foetal B-cell\ndepletion based on findings from animal studies and on its mechanism of action\n(see section\u00a05.1).</span></p>", "ID": "4404b80f-68a0-4154-b1ce-c50af03f0b3c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Ofatumumab may cause foetal B-cell\ndepletion based on findings from animal studies and on its mechanism of action\n(see section\u00a05.1).</span>", "ID": "a8712eee-6e3b-462b-9dfd-effdeb7bc643", "Styles": "None", "Classes": "None", "Text": "Ofatumumab may cause foetal B-cell depletion based on findings from animal studies and on its mechanism of action (see section\u00a05.1).", "ParentId": "4404b80f-68a0-4154-b1ce-c50af03f0b3c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "551038cc-e8be-4cee-a83a-ed547a012082", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "be7acbe7-582b-4a84-b0a0-d5f58ca0e7b4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "551038cc-e8be-4cee-a83a-ed547a012082"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">There are no adequate and well-controlled\nstudies in pregnant women to inform a product-associated risk. No\nteratogenicity or maternal toxicity were observed in an animal reproduction\nstudy with administration of ofatumumab to pregnant monkeys (see\nsection\u00a05.3). Ofatumumab should not be administered to pregnant women\nunless the possible benefit to the mother outweighs the possible risk to the\nfoetus.</span></p>", "ID": "9ba5527e-71a9-4d6d-917a-7d0d17c60098", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">There are no adequate and well-controlled\nstudies in pregnant women to inform a product-associated risk. No\nteratogenicity or maternal toxicity were observed in an animal reproduction\nstudy with administration of ofatumumab to pregnant monkeys (see\nsection\u00a05.3). Ofatumumab should not be administered to pregnant women\nunless the possible benefit to the mother outweighs the possible risk to the\nfoetus.</span>", "ID": "bcca0606-74b8-445f-93e2-a7272ffa94b1", "Styles": "None", "Classes": "None", "Text": "There are no adequate and well-controlled studies in pregnant women to inform a product-associated risk. No teratogenicity or maternal toxicity were observed in an animal reproduction study with administration of ofatumumab to pregnant monkeys (see section\u00a05.3). Ofatumumab should not be administered to pregnant women unless the possible benefit to the mother outweighs the possible risk to the foetus.", "ParentId": "9ba5527e-71a9-4d6d-917a-7d0d17c60098"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e2631af5-7e77-447c-a26d-18f394e58bef", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "eac18154-3879-4c8c-9db8-ad41d0601b3d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e2631af5-7e77-447c-a26d-18f394e58bef"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Administration of live vaccines to neonates\nand infants exposed to ofatumumab <i>in utero</i> should be avoided until\nB-cell recovery occurs (see sections\u00a04.4 and 4.5).</span></p>", "ID": "d72d72e0-0b67-4a0a-aa2b-5ddf13da93cb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Administration of live vaccines to neonates\nand infants exposed to ofatumumab <i>in utero</i> should be avoided until\nB-cell recovery occurs (see sections\u00a04.4 and 4.5).</span>", "ID": "94637514-c39c-4f2a-9648-f94fd571dd55", "Styles": "None", "Classes": "None", "Text": "Administration of live vaccines to neonates and infants exposed to ofatumumab  should be avoided until B-cell recovery occurs (see sections\u00a04.4 and 4.5).", "ParentId": "d72d72e0-0b67-4a0a-aa2b-5ddf13da93cb"}, {"Element": "<i>in utero</i>", "ID": "28241e81-9d87-4df6-9fe5-dca68d0ec481", "Styles": "None", "Classes": "None", "Text": "in utero", "ParentId": "94637514-c39c-4f2a-9648-f94fd571dd55"}, {"Element": "<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">\u00a0</span></p>", "ID": "4c964291-8e42-4b1b-9a9c-53d3f9163293", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"layout-grid-mode:line\">\u00a0</span>", "ID": "a575fc31-9cf1-4291-9917-3eba5419fe0a", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "\u00a0", "ParentId": "4c964291-8e42-4b1b-9a9c-53d3f9163293"}, {"Element": "<p class=\"Nottoc-headings\" style=\"margin:0in\"><u><span style='font-size:11.0pt;\nfont-family:\"Times New Roman\",serif;font-weight:normal'>Breast-feeding</span></u></p>", "ID": "66d5808c-2c1f-41d5-8395-537d561e3bf6", "Styles": "margin:0in", "Classes": "['Nottoc-headings']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span style='font-size:11.0pt;\nfont-family:\"Times New Roman\",serif;font-weight:normal'>Breast-feeding</span></u>", "ID": "6fe31b1a-2efa-4444-a43d-547cb2bc63ab", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "66d5808c-2c1f-41d5-8395-537d561e3bf6"}, {"Element": "<span style='font-size:11.0pt;\nfont-family:\"Times New Roman\",serif;font-weight:normal'>Breast-feeding</span>", "ID": "b1de0a62-6f7c-4582-affc-4869676fbf9a", "Styles": "font-size:11.0pt;\nfont-family:\"Times New Roman\",serif;font-weight:normal", "Classes": "None", "Text": "Breast-feeding", "ParentId": "6fe31b1a-2efa-4444-a43d-547cb2bc63ab"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "0d3058f4-e801-4268-a9f1-c0969e0553d4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">It is unknown whether Arzerra is excreted\nin human milk, however human IgG is secreted in human milk. The safe use of\nofatumumab in humans during lactation has not been established. The excretion of\nofatumumab in milk has not been studied in animals. Published data suggest that\nneonatal and infant consumption of breast milk does not result in substantial\nabsorption of these maternal antibodies into circulation. A risk to\nnewborns/infants cannot be excluded. Breast-feeding should be discontinued\nduring treatment with Arzerra and for 12\u00a0months following treatment.</span></p>", "ID": "22501709-7de5-4dc6-a2f1-a728d0994961", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">It is unknown whether Arzerra is excreted\nin human milk, however human IgG is secreted in human milk. The safe use of\nofatumumab in humans during lactation has not been established. The excretion of\nofatumumab in milk has not been studied in animals. Published data suggest that\nneonatal and infant consumption of breast milk does not result in substantial\nabsorption of these maternal antibodies into circulation. A risk to\nnewborns/infants cannot be excluded. Breast-feeding should be discontinued\nduring treatment with Arzerra and for 12\u00a0months following treatment.</span>", "ID": "08488459-20b2-4b8c-8670-da6efd1d32e5", "Styles": "None", "Classes": "None", "Text": "It is unknown whether Arzerra is excreted in human milk, however human IgG is secreted in human milk. The safe use of ofatumumab in humans during lactation has not been established. The excretion of ofatumumab in milk has not been studied in animals. Published data suggest that neonatal and infant consumption of breast milk does not result in substantial absorption of these maternal antibodies into circulation. A risk to newborns/infants cannot be excluded. Breast-feeding should be discontinued during treatment with Arzerra and for 12\u00a0months following treatment.", "ParentId": "22501709-7de5-4dc6-a2f1-a728d0994961"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f6d8de82-22a0-453b-a8dd-25ed27625e99", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "27d18733-5fc9-48ba-aded-afe15ce946b1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f6d8de82-22a0-453b-a8dd-25ed27625e99"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Fertility</span></u></p>", "ID": "35bd4e6e-9e18-4ea8-9e16-c96dda0003c3", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\">Fertility</span></u>", "ID": "382f99ea-fc33-4b94-9832-052c97bec189", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "35bd4e6e-9e18-4ea8-9e16-c96dda0003c3"}, {"Element": "<span lang=\"EN-GB\">Fertility</span>", "ID": "ad0d3ddf-ba0c-4377-a397-84fbe60d75fa", "Styles": "None", "Classes": "None", "Text": "Fertility", "ParentId": "382f99ea-fc33-4b94-9832-052c97bec189"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "74d62813-8806-4add-9f31-86ed1b3b5d16", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">There are no\ndata on the effects of ofatumumab on human fertility. </span>Effects on male\nand female fertility have not been evaluated in animal studies.</p>", "ID": "aaf2c8b1-df30-45c0-a1b5-da898eb57202", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "Effects on male and female fertility have not been evaluated in animal studies.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">There are no\ndata on the effects of ofatumumab on human fertility. </span>", "ID": "58512d75-72d0-4c1e-85ff-621a99c6f023", "Styles": "None", "Classes": "None", "Text": "There are no data on the effects of ofatumumab on human fertility. ", "ParentId": "aaf2c8b1-df30-45c0-a1b5-da898eb57202"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5f256dd4-b4fe-4b5d-9993-ad97fdbf064c", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6b92f00b-0116-4f52-a0d7-ec4f0f61d621", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5f256dd4-b4fe-4b5d-9993-ad97fdbf064c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.7\u00a0\u00a0\u00a0\u00a0 Effects on ability to drive and use machines</span></b></p>", "ID": "847d3863-f3e8-4aa8-ab79-b886ae4a45f5", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">4.7\u00a0\u00a0\u00a0\u00a0 Effects on ability to drive and use machines</span></b>", "ID": "c8116997-8bd4-4a4f-aa00-3fb3e7d3c578", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "847d3863-f3e8-4aa8-ab79-b886ae4a45f5"}, {"Element": "<span lang=\"EN-GB\">4.7\u00a0\u00a0\u00a0\u00a0 Effects on ability to drive and use machines</span>", "ID": "84b053ec-297d-4271-88a1-4fe75ee3b3b9", "Styles": "None", "Classes": "None", "Text": "4.7\u00a0\u00a0\u00a0\u00a0 Effects on ability to drive and use machines", "ParentId": "c8116997-8bd4-4a4f-aa00-3fb3e7d3c578"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "193e4123-5645-48af-b5cf-79501f781a14", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2a2265ef-12a1-4a7a-a2ea-a0b1269edae8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "193e4123-5645-48af-b5cf-79501f781a14"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">No studies on the effects of </span><span lang=\"EN-GB\">Arzerra<span style=\"color:black\"> on the ability to drive and use machines have been\nperformed.</span></span></p>", "ID": "885cc644-eac6-44bf-9b5e-3d63ad08194f", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">No studies on the effects of </span>", "ID": "2063b15f-c086-485b-b50a-74449ab341e7", "Styles": "color:black", "Classes": "None", "Text": "No studies on the effects of ", "ParentId": "885cc644-eac6-44bf-9b5e-3d63ad08194f"}, {"Element": "<span lang=\"EN-GB\">Arzerra<span style=\"color:black\"> on the ability to drive and use machines have been\nperformed.</span></span>", "ID": "94f037e3-0c2e-499c-92ed-1515738f3bb2", "Styles": "None", "Classes": "None", "Text": "Arzerra", "ParentId": "885cc644-eac6-44bf-9b5e-3d63ad08194f"}, {"Element": "<span style=\"color:black\"> on the ability to drive and use machines have been\nperformed.</span>", "ID": "af5eecf1-caba-4e99-b850-99a5a908f594", "Styles": "color:black", "Classes": "None", "Text": " on the ability to drive and use machines have been performed.", "ParentId": "94f037e3-0c2e-499c-92ed-1515738f3bb2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "398fb47b-341c-4477-b3ba-a5671edcdfa9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "a8dcdff1-89d7-4efa-838f-bca0ce519f19", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "398fb47b-341c-4477-b3ba-a5671edcdfa9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">No detrimental effects\non such activities are predicted from the pharmacology of ofatumumab. The\nclinical status of the patient and the ADR profile of ofatumumab should be\nborne in mind when considering the patient's ability to perform tasks that\nrequire judgement, motor or cognitive skills (see section\u00a04.8).</span></p>", "ID": "a5620070-cebe-4410-96f3-5ebedb855946", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">No detrimental effects\non such activities are predicted from the pharmacology of ofatumumab. The\nclinical status of the patient and the ADR profile of ofatumumab should be\nborne in mind when considering the patient's ability to perform tasks that\nrequire judgement, motor or cognitive skills (see section\u00a04.8).</span>", "ID": "ef5bddc2-fa8b-4202-8428-43cab84e7183", "Styles": "color:black", "Classes": "None", "Text": "No detrimental effects on such activities are predicted from the pharmacology of ofatumumab. The clinical status of the patient and the ADR profile of ofatumumab should be borne in mind when considering the patient's ability to perform tasks that require judgement, motor or cognitive skills (see section\u00a04.8).", "ParentId": "a5620070-cebe-4410-96f3-5ebedb855946"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8ccc1115-0666-4fd5-88e5-199f32734507", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "20fe40cd-834e-496b-9640-2e3529770114", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8ccc1115-0666-4fd5-88e5-199f32734507"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.8\u00a0\u00a0\u00a0\u00a0 Undesirable effects</span></b></p>", "ID": "a130d918-2532-49c3-9f19-8d66dfbd30b6", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">4.8\u00a0\u00a0\u00a0\u00a0 Undesirable effects</span></b>", "ID": "7e2a68ba-da79-4428-8495-f2ba3aaea958", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a130d918-2532-49c3-9f19-8d66dfbd30b6"}, {"Element": "<span lang=\"EN-GB\">4.8\u00a0\u00a0\u00a0\u00a0 Undesirable effects</span>", "ID": "f7b0fe2e-07fc-4dc9-9b66-af73c7c48f93", "Styles": "None", "Classes": "None", "Text": "4.8\u00a0\u00a0\u00a0\u00a0 Undesirable effects", "ParentId": "7e2a68ba-da79-4428-8495-f2ba3aaea958"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "93970768-6142-4ca0-be86-5e4b0235d1f0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "18af9242-ff96-43ce-8efa-d6ebe81b6f2f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "93970768-6142-4ca0-be86-5e4b0235d1f0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Summary\nof the safety profile</span></u></p>", "ID": "e702f2a1-d553-4ab1-8ae7-0f621b78001f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\">Summary\nof the safety profile</span></u>", "ID": "47b18112-0dcc-4bcb-99dc-8ad35a5307d2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e702f2a1-d553-4ab1-8ae7-0f621b78001f"}, {"Element": "<span lang=\"EN-GB\">Summary\nof the safety profile</span>", "ID": "6360eec2-8cc1-40e7-abfd-f2fb900650fb", "Styles": "None", "Classes": "None", "Text": "Summary of the safety profile", "ParentId": "47b18112-0dcc-4bcb-99dc-8ad35a5307d2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "c98cdeee-4153-4ba8-84b2-99c40d214d86", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The overall safety profile of </span><span lang=\"EN-GB\">ofatumumab </span><span lang=\"EN-GB\">is based on data from\n1,168\u00a0patients in clinical trials in CLL (see </span><span style=\"layout-grid-mode:line\">section\u00a05.1</span><span lang=\"EN-GB\">). This\nincludes 643\u00a0patients treated with </span><span lang=\"EN-GB\">ofatumumab </span><span lang=\"EN-GB\">as monotherapy (in </span>patients with relapsed or refractory CLL<span lang=\"EN-GB\">) and 525\u00a0patients treated with ofatumumab in combination with\nchemotherapy (</span><span lang=\"EN-GB\">chlorambucil or bendamustine or\nfludarabine and cyclophosphamide)</span><span lang=\"EN-GB\">.</span></p>", "ID": "4d2b84df-7993-4a87-9fb3-7d76188b76ba", "Styles": "None", "Classes": "['MsoNormal']", "Text": "patients with relapsed or refractory CLL", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">The overall safety profile of </span>", "ID": "62c58fcb-0ae3-4e36-ba39-c87a4838aa4a", "Styles": "None", "Classes": "None", "Text": "The overall safety profile of ", "ParentId": "4d2b84df-7993-4a87-9fb3-7d76188b76ba"}, {"Element": "<span lang=\"EN-GB\">ofatumumab </span>", "ID": "ea683d41-170b-449b-89ad-bcd0b41c0e4b", "Styles": "None", "Classes": "None", "Text": "ofatumumab ", "ParentId": "4d2b84df-7993-4a87-9fb3-7d76188b76ba"}, {"Element": "<span lang=\"EN-GB\">is based on data from\n1,168\u00a0patients in clinical trials in CLL (see </span>", "ID": "0586b045-ee56-47f0-ac4e-1bfff85b26a1", "Styles": "None", "Classes": "None", "Text": "is based on data from 1,168\u00a0patients in clinical trials in CLL (see ", "ParentId": "4d2b84df-7993-4a87-9fb3-7d76188b76ba"}, {"Element": "<span style=\"layout-grid-mode:line\">section\u00a05.1</span>", "ID": "2f345cee-65ff-429e-a6d0-daad4efacc1b", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "section\u00a05.1", "ParentId": "4d2b84df-7993-4a87-9fb3-7d76188b76ba"}, {"Element": "<span lang=\"EN-GB\">). This\nincludes 643\u00a0patients treated with </span>", "ID": "dc4df1bb-e382-44e8-a02f-36ccf4f5a400", "Styles": "None", "Classes": "None", "Text": "). This includes 643\u00a0patients treated with ", "ParentId": "4d2b84df-7993-4a87-9fb3-7d76188b76ba"}, {"Element": "<span lang=\"EN-GB\">ofatumumab </span>", "ID": "7d7c3270-7fa4-4fee-b702-d0885d0a7f76", "Styles": "None", "Classes": "None", "Text": "ofatumumab ", "ParentId": "4d2b84df-7993-4a87-9fb3-7d76188b76ba"}, {"Element": "<span lang=\"EN-GB\">as monotherapy (in </span>", "ID": "61bcd756-f10c-4dbb-b76c-e9885e70b22e", "Styles": "None", "Classes": "None", "Text": "as monotherapy (in ", "ParentId": "4d2b84df-7993-4a87-9fb3-7d76188b76ba"}, {"Element": "<span lang=\"EN-GB\">) and 525\u00a0patients treated with ofatumumab in combination with\nchemotherapy (</span>", "ID": "4d73e0fa-9dc9-4a7f-9a70-befa1df62981", "Styles": "None", "Classes": "None", "Text": ") and 525\u00a0patients treated with ofatumumab in combination with chemotherapy (", "ParentId": "4d2b84df-7993-4a87-9fb3-7d76188b76ba"}, {"Element": "<span lang=\"EN-GB\">chlorambucil or bendamustine or\nfludarabine and cyclophosphamide)</span>", "ID": "0f19b5de-eb8b-4a40-bbe6-c1c4d04b2490", "Styles": "None", "Classes": "None", "Text": "chlorambucil or bendamustine or fludarabine and cyclophosphamide)", "ParentId": "4d2b84df-7993-4a87-9fb3-7d76188b76ba"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "0f023e27-60cd-4951-be43-59ed900957dd", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "4d2b84df-7993-4a87-9fb3-7d76188b76ba"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5eb49108-e81c-4858-8961-69ebc39b0f81", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bcfb665f-4c64-4372-8400-c24c13d9ba34", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5eb49108-e81c-4858-8961-69ebc39b0f81"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Tabulated\nlist of adverse reactions</span></u></p>", "ID": "4a95573c-10c3-432d-8fd1-4a2accd51e70", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\">Tabulated\nlist of adverse reactions</span></u>", "ID": "8d21dda2-8511-495f-8188-eac55a218338", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4a95573c-10c3-432d-8fd1-4a2accd51e70"}, {"Element": "<span lang=\"EN-GB\">Tabulated\nlist of adverse reactions</span>", "ID": "a9f6829e-b33b-4de1-a7a0-b38a79a3eb43", "Styles": "None", "Classes": "None", "Text": "Tabulated list of adverse reactions", "ParentId": "8d21dda2-8511-495f-8188-eac55a218338"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "3451c093-526d-4712-8634-4f7b214acdef", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Adverse reactions reported in patients\ntreated with ofatumumab as monotherapy and with ofatumumab in combination with\nchemotherapy, are listed below by MedDRA body system organ class and by\nfrequency, using the following convention: very common (\u22651/10); common\n(\u22651/100 to &lt;1/10); uncommon (\u22651/1,000 to &lt;1/100); rare\n(\u22651/10,000 to &lt;1/1,000); very rare (&lt; 1/10,000); not known (cannot\nbe estimated from available data). Within each frequency grouping, adverse\nreactions are ranked in order of decreasing seriousness.</span></p>", "ID": "7494a007-e818-4506-bba7-ac974b53f579", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Adverse reactions reported in patients\ntreated with ofatumumab as monotherapy and with ofatumumab in combination with\nchemotherapy, are listed below by MedDRA body system organ class and by\nfrequency, using the following convention: very common (\u22651/10); common\n(\u22651/100 to &lt;1/10); uncommon (\u22651/1,000 to &lt;1/100); rare\n(\u22651/10,000 to &lt;1/1,000); very rare (&lt; 1/10,000); not known (cannot\nbe estimated from available data). Within each frequency grouping, adverse\nreactions are ranked in order of decreasing seriousness.</span>", "ID": "3f21b095-d401-4cd4-b8fb-ffc0b0a7dafd", "Styles": "None", "Classes": "None", "Text": "Adverse reactions reported in patients treated with ofatumumab as monotherapy and with ofatumumab in combination with chemotherapy, are listed below by MedDRA body system organ class and by frequency, using the following convention: very common (\u22651/10); common (\u22651/100 to <1/10); uncommon (\u22651/1,000 to <1/100); rare (\u22651/10,000 to <1/1,000); very rare (< 1/10,000); not known (cannot be estimated from available data). Within each frequency grouping, adverse reactions are ranked in order of decreasing seriousness.", "ParentId": "7494a007-e818-4506-bba7-ac974b53f579"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "18634a17-3e66-4f8e-b2f9-5a0890f573ed", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7e3aebe2-bb51-46de-b072-4774408c118b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "18634a17-3e66-4f8e-b2f9-5a0890f573ed"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr style=\"page-break-inside:avoid\">\n<td style=\"border:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">MedDRA\n  System Organ Class</span></u></p>\n</td>\n<td style=\"border:solid windowtext 1.0pt;border-left:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Very\n  common</span></u></p>\n</td>\n<td style=\"border:solid windowtext 1.0pt;border-left:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Common</span></u></p>\n</td>\n<td style=\"border:solid windowtext 1.0pt;border-left:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Uncommon</span></u></p>\n</td>\n<td style=\"border:solid windowtext 1.0pt;border-left:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n</td>\n</tr>\n<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infections\n  and Infestations</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lower\n  respiratory tract infection (including pneumonia), upper respiratory tract\n  infection </span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Sepsis (including neutropenic sepsis and septic shock)\n  herpes viral infection, urinary tract infection</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hepatitis\n  B infection a</span><span lang=\"EN-GB\">nd reactivation, progressive multifocal\n  leukoencephalopathy</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Blood and lymphatic system disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Neutropenia, anaemia</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Febrile neutropenia,\n  thrombocytopenia, leukopenia</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Agranulocytosis,\n  coagulopathy, red cell aplasia, lymphopenia</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Immune system disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Hypersensitivity*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Anaphylactic reactions (including\n  anaphylactic shock)*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Nervous system disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Headache*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Metabolism and nutrition disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span class=\"CSIchar\"><span lang=\"EN-GB\" style=\"border:none\">\u00a0</span></span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tumour lysis syndrome</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cardiac disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tachycardia*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Bradycardia*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span class=\"CSIchar\"><span lang=\"EN-GB\" style=\"border:none\">\u00a0</span></span></p>\n</td>\n</tr>\n<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Vascular disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hypotension*, hypertension*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Respiratory, thoracic and mediastinal\n  disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Dyspnoea*, cough*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Bronchospasm*, chest\n  discomfort*, oropharyngeal pain*, nasal congestion*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pulmonary oedema*, hypoxia*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span class=\"CSIchar\"><span lang=\"EN-GB\" style=\"border:none\">\u00a0</span></span></p>\n</td>\n</tr>\n<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Gastrointestinal disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Nausea*, diarrhoea*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Small intestinal obstruction</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Skin and subcutaneous tissue disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Rash*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Urticaria*, pruritus*, flushing*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Musculoskeletal and connective tissue\n  disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Back pain*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">General\n  disorders and administration site conditions</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Pyrexia*, fatigue*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Cytokine release syndrome*, chills (including rigors)*,\n  hyperhidrosis*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Injury,\n  poisoning and procedural complications</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infusion-related\n  reaction*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">*These\n  events are likely attributable to ofatumumab in the setting of an infusion-related\n  reaction and typically occur after the start of infusion and within\n  24\u00a0hours after the completion of the infusion (see section\u00a04.4).</span></p>\n</td>\n</tr>\n</table>", "ID": "dd2e9821-18bd-45b1-be5b-80b9466797cc", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "                ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"border:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">MedDRA\n  System Organ Class</span></u></p>\n</td>\n<td style=\"border:solid windowtext 1.0pt;border-left:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Very\n  common</span></u></p>\n</td>\n<td style=\"border:solid windowtext 1.0pt;border-left:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Common</span></u></p>\n</td>\n<td style=\"border:solid windowtext 1.0pt;border-left:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Uncommon</span></u></p>\n</td>\n<td style=\"border:solid windowtext 1.0pt;border-left:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n</td>\n</tr>", "ID": "20450023-7306-4d70-9ef4-0470c572c4ec", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "      ", "ParentId": "dd2e9821-18bd-45b1-be5b-80b9466797cc"}, {"Element": "<td style=\"border:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">MedDRA\n  System Organ Class</span></u></p>\n</td>", "ID": "d1b02161-c37b-4736-9981-dfb368d9e267", "Styles": "border:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "20450023-7306-4d70-9ef4-0470c572c4ec"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">MedDRA\n  System Organ Class</span></u></p>", "ID": "8702c5bf-1d2f-4ece-a703-c3bbe53dd975", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d1b02161-c37b-4736-9981-dfb368d9e267"}, {"Element": "<u><span lang=\"EN-GB\">MedDRA\n  System Organ Class</span></u>", "ID": "5380bde0-9327-4f4f-9da6-fc17885aa071", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8702c5bf-1d2f-4ece-a703-c3bbe53dd975"}, {"Element": "<span lang=\"EN-GB\">MedDRA\n  System Organ Class</span>", "ID": "5d68a503-cf8f-42d0-acfb-2166f14a2f67", "Styles": "None", "Classes": "None", "Text": "MedDRA   System Organ Class", "ParentId": "5380bde0-9327-4f4f-9da6-fc17885aa071"}, {"Element": "<td style=\"border:solid windowtext 1.0pt;border-left:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Very\n  common</span></u></p>\n</td>", "ID": "7be05a8c-2a05-48a2-b92e-c063232ee9ef", "Styles": "border:solid windowtext 1.0pt;border-left:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "20450023-7306-4d70-9ef4-0470c572c4ec"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Very\n  common</span></u></p>", "ID": "656d8ad8-782e-4ab9-bd72-35a08a216749", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7be05a8c-2a05-48a2-b92e-c063232ee9ef"}, {"Element": "<u><span lang=\"EN-GB\">Very\n  common</span></u>", "ID": "538fe3fc-ddec-4e83-bdf4-595d19c39723", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "656d8ad8-782e-4ab9-bd72-35a08a216749"}, {"Element": "<span lang=\"EN-GB\">Very\n  common</span>", "ID": "a7b95ce2-d073-4595-b687-709d98dfaf67", "Styles": "None", "Classes": "None", "Text": "Very   common", "ParentId": "538fe3fc-ddec-4e83-bdf4-595d19c39723"}, {"Element": "<td style=\"border:solid windowtext 1.0pt;border-left:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Common</span></u></p>\n</td>", "ID": "c9bfb0e8-459a-491a-9d90-50af98e62d2b", "Styles": "border:solid windowtext 1.0pt;border-left:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "20450023-7306-4d70-9ef4-0470c572c4ec"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Common</span></u></p>", "ID": "1d51f6bb-b246-4b9b-a961-20534af989d3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c9bfb0e8-459a-491a-9d90-50af98e62d2b"}, {"Element": "<u><span lang=\"EN-GB\">Common</span></u>", "ID": "a6d61ccf-685c-44b6-ad1b-1bc4e3865eef", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1d51f6bb-b246-4b9b-a961-20534af989d3"}, {"Element": "<span lang=\"EN-GB\">Common</span>", "ID": "e44837c6-ae50-41f6-af5f-d565c040c691", "Styles": "None", "Classes": "None", "Text": "Common", "ParentId": "a6d61ccf-685c-44b6-ad1b-1bc4e3865eef"}, {"Element": "<td style=\"border:solid windowtext 1.0pt;border-left:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Uncommon</span></u></p>\n</td>", "ID": "bf14ed87-b591-46cb-9fe6-2c1d3aac2cf9", "Styles": "border:solid windowtext 1.0pt;border-left:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "20450023-7306-4d70-9ef4-0470c572c4ec"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Uncommon</span></u></p>", "ID": "e8cfcc07-638d-46a0-adb6-5086f7469c38", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bf14ed87-b591-46cb-9fe6-2c1d3aac2cf9"}, {"Element": "<u><span lang=\"EN-GB\">Uncommon</span></u>", "ID": "23ec8e5d-771e-4b91-8ca7-1f5a8ecd2838", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e8cfcc07-638d-46a0-adb6-5086f7469c38"}, {"Element": "<span lang=\"EN-GB\">Uncommon</span>", "ID": "917dbfa9-5cdc-4304-90cc-27a644077deb", "Styles": "None", "Classes": "None", "Text": "Uncommon", "ParentId": "23ec8e5d-771e-4b91-8ca7-1f5a8ecd2838"}, {"Element": "<td style=\"border:solid windowtext 1.0pt;border-left:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n</td>", "ID": "9f19dc46-3dbd-4cc7-982a-41b8460117a1", "Styles": "border:solid windowtext 1.0pt;border-left:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "20450023-7306-4d70-9ef4-0470c572c4ec"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "d7e91452-9015-42ec-be36-01d9b57c5098", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9f19dc46-3dbd-4cc7-982a-41b8460117a1"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "2ed99f13-01a1-4895-a358-a86c7f09b8cb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d7e91452-9015-42ec-be36-01d9b57c5098"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "8906a223-defa-42cb-9229-f3dda43a4a0f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2ed99f13-01a1-4895-a358-a86c7f09b8cb"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "8a3f6ae7-3803-4e67-8582-0fd1c45d62fd", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "8906a223-defa-42cb-9229-f3dda43a4a0f"}, {"Element": "<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infections\n  and Infestations</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lower\n  respiratory tract infection (including pneumonia), upper respiratory tract\n  infection </span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Sepsis (including neutropenic sepsis and septic shock)\n  herpes viral infection, urinary tract infection</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hepatitis\n  B infection a</span><span lang=\"EN-GB\">nd reactivation, progressive multifocal\n  leukoencephalopathy</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "541ba952-f1ac-442a-9d8e-568797a2e28d", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "dd2e9821-18bd-45b1-be5b-80b9466797cc"}, {"Element": "<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infections\n  and Infestations</span></p>\n</td>", "ID": "f02a198b-3ddf-4b15-bd40-5f919617ef63", "Styles": "border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "541ba952-f1ac-442a-9d8e-568797a2e28d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infections\n  and Infestations</span></p>", "ID": "7ac8b657-4e28-4c57-9748-1a022f0409d8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f02a198b-3ddf-4b15-bd40-5f919617ef63"}, {"Element": "<span lang=\"EN-GB\">Infections\n  and Infestations</span>", "ID": "8ccef753-8d5d-4287-a41a-aa8e332201b6", "Styles": "None", "Classes": "None", "Text": "Infections   and Infestations", "ParentId": "7ac8b657-4e28-4c57-9748-1a022f0409d8"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lower\n  respiratory tract infection (including pneumonia), upper respiratory tract\n  infection </span></p>\n</td>", "ID": "2bb0cff9-03aa-43ae-977c-9988c101f627", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "541ba952-f1ac-442a-9d8e-568797a2e28d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lower\n  respiratory tract infection (including pneumonia), upper respiratory tract\n  infection </span></p>", "ID": "35b863c3-a520-48ab-8fa7-64e989b4f8f4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2bb0cff9-03aa-43ae-977c-9988c101f627"}, {"Element": "<span lang=\"EN-GB\">Lower\n  respiratory tract infection (including pneumonia), upper respiratory tract\n  infection </span>", "ID": "049ff66c-566e-45c0-a9c2-d9d9198cb9f1", "Styles": "None", "Classes": "None", "Text": "Lower   respiratory tract infection (including pneumonia), upper respiratory tract   infection ", "ParentId": "35b863c3-a520-48ab-8fa7-64e989b4f8f4"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Sepsis (including neutropenic sepsis and septic shock)\n  herpes viral infection, urinary tract infection</span></p>\n</td>", "ID": "7fe678c1-61e4-43a8-9604-bd01c38b42d2", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "541ba952-f1ac-442a-9d8e-568797a2e28d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Sepsis (including neutropenic sepsis and septic shock)\n  herpes viral infection, urinary tract infection</span></p>", "ID": "388d7900-5afd-4a2b-ad2b-e499ed42d96f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7fe678c1-61e4-43a8-9604-bd01c38b42d2"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Sepsis (including neutropenic sepsis and septic shock)\n  herpes viral infection, urinary tract infection</span>", "ID": "99f383e9-7d2e-48de-9376-ca560da022c4", "Styles": "color:black", "Classes": "None", "Text": "Sepsis (including neutropenic sepsis and septic shock)   herpes viral infection, urinary tract infection", "ParentId": "388d7900-5afd-4a2b-ad2b-e499ed42d96f"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hepatitis\n  B infection a</span><span lang=\"EN-GB\">nd reactivation, progressive multifocal\n  leukoencephalopathy</span></p>\n</td>", "ID": "1c11e995-239e-4222-a78e-2c671d912b25", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "541ba952-f1ac-442a-9d8e-568797a2e28d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hepatitis\n  B infection a</span><span lang=\"EN-GB\">nd reactivation, progressive multifocal\n  leukoencephalopathy</span></p>", "ID": "e9f2b994-3b34-470b-b184-e11d7165b7c7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1c11e995-239e-4222-a78e-2c671d912b25"}, {"Element": "<span lang=\"EN-GB\">Hepatitis\n  B infection a</span>", "ID": "d3b843ab-2657-4c27-aeff-be671375fa4c", "Styles": "None", "Classes": "None", "Text": "Hepatitis   B infection a", "ParentId": "e9f2b994-3b34-470b-b184-e11d7165b7c7"}, {"Element": "<span lang=\"EN-GB\">nd reactivation, progressive multifocal\n  leukoencephalopathy</span>", "ID": "856e5041-ec87-43e2-af01-20a2c89bca11", "Styles": "None", "Classes": "None", "Text": "nd reactivation, progressive multifocal   leukoencephalopathy", "ParentId": "e9f2b994-3b34-470b-b184-e11d7165b7c7"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "76004851-6fcc-42e9-8250-3483bed5f2d3", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "541ba952-f1ac-442a-9d8e-568797a2e28d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "44deb739-5d01-425b-a96d-617c8395fea1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "76004851-6fcc-42e9-8250-3483bed5f2d3"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b43abc6c-6d25-4000-abbd-a19cb0f0c730", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "44deb739-5d01-425b-a96d-617c8395fea1"}, {"Element": "<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Blood and lymphatic system disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Neutropenia, anaemia</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Febrile neutropenia,\n  thrombocytopenia, leukopenia</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Agranulocytosis,\n  coagulopathy, red cell aplasia, lymphopenia</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n</td>\n</tr>", "ID": "11ecd8f5-6da8-4666-b823-9d01a884c773", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "dd2e9821-18bd-45b1-be5b-80b9466797cc"}, {"Element": "<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Blood and lymphatic system disorders</span></p>\n</td>", "ID": "e9e00d9d-f9a8-4f44-bbfa-44ffcbbfac4b", "Styles": "border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "11ecd8f5-6da8-4666-b823-9d01a884c773"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Blood and lymphatic system disorders</span></p>", "ID": "4a35d046-a7cd-41b6-b458-5676eef6f609", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e9e00d9d-f9a8-4f44-bbfa-44ffcbbfac4b"}, {"Element": "<span lang=\"EN-GB\">Blood and lymphatic system disorders</span>", "ID": "48015e57-c06c-48a8-b32c-30c8ad9129f1", "Styles": "None", "Classes": "None", "Text": "Blood and lymphatic system disorders", "ParentId": "4a35d046-a7cd-41b6-b458-5676eef6f609"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Neutropenia, anaemia</span></p>\n</td>", "ID": "e99e9201-0228-48b9-915b-37230c385029", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "11ecd8f5-6da8-4666-b823-9d01a884c773"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Neutropenia, anaemia</span></p>", "ID": "4ea451b0-540f-420e-b67c-f6eef884a9db", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e99e9201-0228-48b9-915b-37230c385029"}, {"Element": "<span lang=\"EN-GB\">Neutropenia, anaemia</span>", "ID": "65759dd5-dc3e-4d5d-a04f-15e17cc985d8", "Styles": "None", "Classes": "None", "Text": "Neutropenia, anaemia", "ParentId": "4ea451b0-540f-420e-b67c-f6eef884a9db"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Febrile neutropenia,\n  thrombocytopenia, leukopenia</span></p>\n</td>", "ID": "9cc7e938-af44-4fad-9bde-52bc0009e905", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "11ecd8f5-6da8-4666-b823-9d01a884c773"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Febrile neutropenia,\n  thrombocytopenia, leukopenia</span></p>", "ID": "77085340-38ce-428e-b7f2-9ab8c99ee17f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9cc7e938-af44-4fad-9bde-52bc0009e905"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Febrile neutropenia,\n  thrombocytopenia, leukopenia</span>", "ID": "65949b47-e8f0-4776-8456-78152ca2ce65", "Styles": "color:black", "Classes": "None", "Text": "Febrile neutropenia,   thrombocytopenia, leukopenia", "ParentId": "77085340-38ce-428e-b7f2-9ab8c99ee17f"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Agranulocytosis,\n  coagulopathy, red cell aplasia, lymphopenia</span></p>\n</td>", "ID": "5417a784-fa84-4d15-b326-b53f7eb662ae", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "11ecd8f5-6da8-4666-b823-9d01a884c773"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Agranulocytosis,\n  coagulopathy, red cell aplasia, lymphopenia</span></p>", "ID": "6a1cc3c0-5c11-4434-b926-d11f9d2c16bf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5417a784-fa84-4d15-b326-b53f7eb662ae"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Agranulocytosis,\n  coagulopathy, red cell aplasia, lymphopenia</span>", "ID": "529f2e82-f97a-4772-bb1e-b3e00c5436b8", "Styles": "color:black", "Classes": "None", "Text": "Agranulocytosis,   coagulopathy, red cell aplasia, lymphopenia", "ParentId": "6a1cc3c0-5c11-4434-b926-d11f9d2c16bf"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n</td>", "ID": "5fe3a276-7445-4ce8-ba0a-5cc4e5185e37", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "11ecd8f5-6da8-4666-b823-9d01a884c773"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "0f389ebc-ddbd-4d4c-9d59-781ddb1419f0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5fe3a276-7445-4ce8-ba0a-5cc4e5185e37"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "29524dd9-1a81-4f81-8253-a5477b5d76b0", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "0f389ebc-ddbd-4d4c-9d59-781ddb1419f0"}, {"Element": "<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Immune system disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Hypersensitivity*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Anaphylactic reactions (including\n  anaphylactic shock)*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "bf6b0e2c-93e9-41d8-bf98-15b8980a045a", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "dd2e9821-18bd-45b1-be5b-80b9466797cc"}, {"Element": "<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Immune system disorders</span></p>\n</td>", "ID": "59b35706-9407-47ea-9357-2bb8c4875b79", "Styles": "border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "bf6b0e2c-93e9-41d8-bf98-15b8980a045a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Immune system disorders</span></p>", "ID": "b0fac63a-c352-492a-bc64-69f6ac4e453b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "59b35706-9407-47ea-9357-2bb8c4875b79"}, {"Element": "<span lang=\"EN-GB\">Immune system disorders</span>", "ID": "d82b15d0-0ad6-45ef-92b3-c788a0baa246", "Styles": "None", "Classes": "None", "Text": "Immune system disorders", "ParentId": "b0fac63a-c352-492a-bc64-69f6ac4e453b"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "4470e2d8-ed12-40c3-a477-682aba3bf611", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "bf6b0e2c-93e9-41d8-bf98-15b8980a045a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f4239f22-87a5-45f6-855f-e9b153ce44cd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4470e2d8-ed12-40c3-a477-682aba3bf611"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "38bed86a-6c82-4784-ab00-73d0baa4cfa3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f4239f22-87a5-45f6-855f-e9b153ce44cd"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Hypersensitivity*</span></p>\n</td>", "ID": "4f0f83c1-c79a-4bdc-8879-c0ddd58cc869", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "bf6b0e2c-93e9-41d8-bf98-15b8980a045a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Hypersensitivity*</span></p>", "ID": "7fd6559e-3842-4b8c-8afa-6c1fd17d9c7f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4f0f83c1-c79a-4bdc-8879-c0ddd58cc869"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Hypersensitivity*</span>", "ID": "9a15fa3d-1716-4fae-834e-e60e62e86413", "Styles": "color:black", "Classes": "None", "Text": "Hypersensitivity*", "ParentId": "7fd6559e-3842-4b8c-8afa-6c1fd17d9c7f"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Anaphylactic reactions (including\n  anaphylactic shock)*</span></p>\n</td>", "ID": "ad4d60d8-0189-4b88-bd86-075d4a52c58d", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "bf6b0e2c-93e9-41d8-bf98-15b8980a045a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Anaphylactic reactions (including\n  anaphylactic shock)*</span></p>", "ID": "f9e968aa-3665-4e28-b0f6-4a81bd79075a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ad4d60d8-0189-4b88-bd86-075d4a52c58d"}, {"Element": "<span lang=\"EN-GB\">Anaphylactic reactions (including\n  anaphylactic shock)*</span>", "ID": "7106561e-1880-4a93-be08-fa9eb67644c6", "Styles": "None", "Classes": "None", "Text": "Anaphylactic reactions (including   anaphylactic shock)*", "ParentId": "f9e968aa-3665-4e28-b0f6-4a81bd79075a"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "d95bfb70-3a80-4af3-a39f-bea82eb75fc9", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "bf6b0e2c-93e9-41d8-bf98-15b8980a045a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4a7b64b5-fb81-45e0-be5f-d83b3a41c48f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d95bfb70-3a80-4af3-a39f-bea82eb75fc9"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "95a37c28-6510-454e-9c0b-d31c34fd6c16", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4a7b64b5-fb81-45e0-be5f-d83b3a41c48f"}, {"Element": "<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Nervous system disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Headache*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "11b326b7-ab24-41b3-b208-c305fcd4b447", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "dd2e9821-18bd-45b1-be5b-80b9466797cc"}, {"Element": "<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Nervous system disorders</span></p>\n</td>", "ID": "beabebd3-64bd-4aa6-9a4a-4d552ba4f1cc", "Styles": "border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "11b326b7-ab24-41b3-b208-c305fcd4b447"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Nervous system disorders</span></p>", "ID": "b33adac8-bd9a-429a-8aad-20b2811d0cb0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "beabebd3-64bd-4aa6-9a4a-4d552ba4f1cc"}, {"Element": "<span lang=\"EN-GB\">Nervous system disorders</span>", "ID": "30c7eb75-3bdf-41f3-93b1-fe9d607ad15e", "Styles": "None", "Classes": "None", "Text": "Nervous system disorders", "ParentId": "b33adac8-bd9a-429a-8aad-20b2811d0cb0"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "9e590bc4-e408-4a68-80a2-8a038d7c04cb", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "11b326b7-ab24-41b3-b208-c305fcd4b447"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a2b94384-ea00-4151-aff4-3498d6f64c24", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9e590bc4-e408-4a68-80a2-8a038d7c04cb"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "52666460-2080-4911-a83c-744fab7d264d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a2b94384-ea00-4151-aff4-3498d6f64c24"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Headache*</span></p>\n</td>", "ID": "189bc329-482c-46cb-8641-c0c12e17a63f", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "11b326b7-ab24-41b3-b208-c305fcd4b447"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Headache*</span></p>", "ID": "ab78e9dd-dc45-4b5d-9b78-97f0fddf6b3b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "189bc329-482c-46cb-8641-c0c12e17a63f"}, {"Element": "<span lang=\"EN-GB\">Headache*</span>", "ID": "c4b795ea-5d04-49a5-aa6c-4db7cee455bb", "Styles": "None", "Classes": "None", "Text": "Headache*", "ParentId": "ab78e9dd-dc45-4b5d-9b78-97f0fddf6b3b"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "ed7e93ef-2817-4385-93e0-7688b98b9ab1", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "11b326b7-ab24-41b3-b208-c305fcd4b447"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2362acac-d3dd-4d54-81d8-d9ba55987a45", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ed7e93ef-2817-4385-93e0-7688b98b9ab1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e312fa42-e523-47c9-9187-c4389dc66185", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2362acac-d3dd-4d54-81d8-d9ba55987a45"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "22b76319-d911-47b0-9874-0bffc27033b2", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "11b326b7-ab24-41b3-b208-c305fcd4b447"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a2423bd4-f59e-45f1-9775-ae1be3df309a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "22b76319-d911-47b0-9874-0bffc27033b2"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bff6b6f3-3588-4cd6-8e26-d13954eb5d26", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a2423bd4-f59e-45f1-9775-ae1be3df309a"}, {"Element": "<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Metabolism and nutrition disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span class=\"CSIchar\"><span lang=\"EN-GB\" style=\"border:none\">\u00a0</span></span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tumour lysis syndrome</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "f04e7eb3-7d36-4a70-b2ba-329f8af45a9e", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "dd2e9821-18bd-45b1-be5b-80b9466797cc"}, {"Element": "<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Metabolism and nutrition disorders</span></p>\n</td>", "ID": "34a99a28-292f-4dd0-8568-c1b99e9db45a", "Styles": "border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f04e7eb3-7d36-4a70-b2ba-329f8af45a9e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Metabolism and nutrition disorders</span></p>", "ID": "54d7ad59-48b7-49dd-b529-f9a5c0b7937a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "34a99a28-292f-4dd0-8568-c1b99e9db45a"}, {"Element": "<span lang=\"EN-GB\">Metabolism and nutrition disorders</span>", "ID": "765e124b-5482-4404-a813-9f6b1b707b48", "Styles": "None", "Classes": "None", "Text": "Metabolism and nutrition disorders", "ParentId": "54d7ad59-48b7-49dd-b529-f9a5c0b7937a"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "df7e2d9f-4303-481a-8fc6-4633a6d7e4a1", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f04e7eb3-7d36-4a70-b2ba-329f8af45a9e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "443adf4d-1272-40bb-acca-16512a0cb84a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "df7e2d9f-4303-481a-8fc6-4633a6d7e4a1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8a2fa9f9-0b5a-43c3-bcfa-bb481b128092", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "443adf4d-1272-40bb-acca-16512a0cb84a"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span class=\"CSIchar\"><span lang=\"EN-GB\" style=\"border:none\">\u00a0</span></span></p>\n</td>", "ID": "c711718a-58c7-4cfe-94cb-68d017ebac33", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f04e7eb3-7d36-4a70-b2ba-329f8af45a9e"}, {"Element": "<p class=\"MsoNormal\"><span class=\"CSIchar\"><span lang=\"EN-GB\" style=\"border:none\">\u00a0</span></span></p>", "ID": "604890a0-5eb4-45c1-b88b-3ca675eaaac4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c711718a-58c7-4cfe-94cb-68d017ebac33"}, {"Element": "<span class=\"CSIchar\"><span lang=\"EN-GB\" style=\"border:none\">\u00a0</span></span>", "ID": "f4c0a685-1cb6-4b77-b1c8-b8866c683f59", "Styles": "None", "Classes": "['CSIchar']", "Text": "", "ParentId": "604890a0-5eb4-45c1-b88b-3ca675eaaac4"}, {"Element": "<span lang=\"EN-GB\" style=\"border:none\">\u00a0</span>", "ID": "99a101b6-3d99-4f9f-b8b1-b065d3239e2d", "Styles": "border:none", "Classes": "None", "Text": "\u00a0", "ParentId": "f4c0a685-1cb6-4b77-b1c8-b8866c683f59"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tumour lysis syndrome</span></p>\n</td>", "ID": "22d1c1e7-c012-4000-abc7-8bf174c68873", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f04e7eb3-7d36-4a70-b2ba-329f8af45a9e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tumour lysis syndrome</span></p>", "ID": "2fbc7b83-9152-447b-b217-3fea51988279", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "22d1c1e7-c012-4000-abc7-8bf174c68873"}, {"Element": "<span lang=\"EN-GB\">Tumour lysis syndrome</span>", "ID": "a5a6764c-d029-4261-b0bd-4c93b8a3b65e", "Styles": "None", "Classes": "None", "Text": "Tumour lysis syndrome", "ParentId": "2fbc7b83-9152-447b-b217-3fea51988279"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "c8a8f161-3adc-43dc-b395-955e23593b89", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f04e7eb3-7d36-4a70-b2ba-329f8af45a9e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "074b7059-2ad2-442c-ba5f-99277ae98019", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c8a8f161-3adc-43dc-b395-955e23593b89"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fa31e7d3-d92d-4fed-a4a0-aa18b26547fa", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "074b7059-2ad2-442c-ba5f-99277ae98019"}, {"Element": "<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cardiac disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tachycardia*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Bradycardia*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span class=\"CSIchar\"><span lang=\"EN-GB\" style=\"border:none\">\u00a0</span></span></p>\n</td>\n</tr>", "ID": "33f2070a-8099-40ba-b8eb-668acb37ba8a", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "dd2e9821-18bd-45b1-be5b-80b9466797cc"}, {"Element": "<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cardiac disorders</span></p>\n</td>", "ID": "cf588c6c-f16a-4cfe-a4a5-9c9f82949e72", "Styles": "border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "33f2070a-8099-40ba-b8eb-668acb37ba8a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cardiac disorders</span></p>", "ID": "093b6111-35aa-4768-91c0-3b943a63aa0d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cf588c6c-f16a-4cfe-a4a5-9c9f82949e72"}, {"Element": "<span lang=\"EN-GB\">Cardiac disorders</span>", "ID": "b544ad72-8fc8-4cb6-adc2-32ac0f3d1947", "Styles": "None", "Classes": "None", "Text": "Cardiac disorders", "ParentId": "093b6111-35aa-4768-91c0-3b943a63aa0d"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "12c63bd5-b1fe-4e9c-a0e4-fb27b8dd0b2d", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "33f2070a-8099-40ba-b8eb-668acb37ba8a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "73f83334-3877-4f79-925d-9956d1519aab", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "12c63bd5-b1fe-4e9c-a0e4-fb27b8dd0b2d"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "99541f3f-e3d1-41b2-84c7-78edb7acd35e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "73f83334-3877-4f79-925d-9956d1519aab"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tachycardia*</span></p>\n</td>", "ID": "ebe7067a-37af-4445-b62b-a401340be760", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "33f2070a-8099-40ba-b8eb-668acb37ba8a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tachycardia*</span></p>", "ID": "fcd96629-8bb3-4926-8551-28fe6cc26b71", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ebe7067a-37af-4445-b62b-a401340be760"}, {"Element": "<span lang=\"EN-GB\">Tachycardia*</span>", "ID": "acc0c3b4-6548-4e84-8cfa-a7f488646936", "Styles": "None", "Classes": "None", "Text": "Tachycardia*", "ParentId": "fcd96629-8bb3-4926-8551-28fe6cc26b71"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Bradycardia*</span></p>\n</td>", "ID": "6a061a79-0470-49a9-a0df-3067194de302", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "33f2070a-8099-40ba-b8eb-668acb37ba8a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Bradycardia*</span></p>", "ID": "d8904aaf-7ff1-4a1f-9152-1da2adc11bff", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6a061a79-0470-49a9-a0df-3067194de302"}, {"Element": "<span lang=\"EN-GB\">Bradycardia*</span>", "ID": "d05be5a4-1b2a-40e5-a019-94b8c306039c", "Styles": "None", "Classes": "None", "Text": "Bradycardia*", "ParentId": "d8904aaf-7ff1-4a1f-9152-1da2adc11bff"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span class=\"CSIchar\"><span lang=\"EN-GB\" style=\"border:none\">\u00a0</span></span></p>\n</td>", "ID": "44c65b4a-613a-4560-834c-67353be81bda", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "33f2070a-8099-40ba-b8eb-668acb37ba8a"}, {"Element": "<p class=\"MsoNormal\"><span class=\"CSIchar\"><span lang=\"EN-GB\" style=\"border:none\">\u00a0</span></span></p>", "ID": "1607fe91-f6fc-43d1-b19d-b536594c5915", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "44c65b4a-613a-4560-834c-67353be81bda"}, {"Element": "<span class=\"CSIchar\"><span lang=\"EN-GB\" style=\"border:none\">\u00a0</span></span>", "ID": "54d7298d-b8b2-44af-a1d7-2627823c761c", "Styles": "None", "Classes": "['CSIchar']", "Text": "", "ParentId": "1607fe91-f6fc-43d1-b19d-b536594c5915"}, {"Element": "<span lang=\"EN-GB\" style=\"border:none\">\u00a0</span>", "ID": "503ebbfc-494f-4b47-9b62-e1fcf6ee97c4", "Styles": "border:none", "Classes": "None", "Text": "\u00a0", "ParentId": "54d7298d-b8b2-44af-a1d7-2627823c761c"}, {"Element": "<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Vascular disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hypotension*, hypertension*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "5b19f4ea-eb02-48b3-bc9c-b2cd9b90282c", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "dd2e9821-18bd-45b1-be5b-80b9466797cc"}, {"Element": "<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Vascular disorders</span></p>\n</td>", "ID": "3433cb83-eb8e-44b5-97c1-64e608d0d327", "Styles": "border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5b19f4ea-eb02-48b3-bc9c-b2cd9b90282c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Vascular disorders</span></p>", "ID": "ceb779e7-1b27-4c27-8eb3-d96eb4f79088", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3433cb83-eb8e-44b5-97c1-64e608d0d327"}, {"Element": "<span lang=\"EN-GB\">Vascular disorders</span>", "ID": "9c56df95-8a96-484e-87a2-27972633407e", "Styles": "None", "Classes": "None", "Text": "Vascular disorders", "ParentId": "ceb779e7-1b27-4c27-8eb3-d96eb4f79088"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "9bd31dd8-c2d2-4e8e-b4f5-5c2fd6012330", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5b19f4ea-eb02-48b3-bc9c-b2cd9b90282c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "18f950ec-c7bf-4a00-b033-e954568b540b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9bd31dd8-c2d2-4e8e-b4f5-5c2fd6012330"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a3f2bc3a-ce98-4c6d-9b3a-df85d9d08c4f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "18f950ec-c7bf-4a00-b033-e954568b540b"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hypotension*, hypertension*</span></p>\n</td>", "ID": "6d6e1335-2a87-46b9-9ad6-81c975a41cd7", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5b19f4ea-eb02-48b3-bc9c-b2cd9b90282c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hypotension*, hypertension*</span></p>", "ID": "d4bcceed-4485-4032-9c24-921b6351f2bb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6d6e1335-2a87-46b9-9ad6-81c975a41cd7"}, {"Element": "<span lang=\"EN-GB\">Hypotension*, hypertension*</span>", "ID": "ee64d6e6-3b3a-4a42-91d4-3bbce2dca254", "Styles": "None", "Classes": "None", "Text": "Hypotension*, hypertension*", "ParentId": "d4bcceed-4485-4032-9c24-921b6351f2bb"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "d54d174c-155d-46a7-b467-a0972a3bce3f", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5b19f4ea-eb02-48b3-bc9c-b2cd9b90282c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "51d01f84-2891-44f6-98d2-b7a1e4ed9fc6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d54d174c-155d-46a7-b467-a0972a3bce3f"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a29b9d8d-7c93-469c-b584-2eddda4a5968", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "51d01f84-2891-44f6-98d2-b7a1e4ed9fc6"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "d744b02a-865b-4ee1-858c-b30b72ba7451", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5b19f4ea-eb02-48b3-bc9c-b2cd9b90282c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "143775ef-10a2-4eb0-8c71-ae9924c77cb1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d744b02a-865b-4ee1-858c-b30b72ba7451"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "24210eae-c5b3-416a-9d5e-f4d325d2b155", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "143775ef-10a2-4eb0-8c71-ae9924c77cb1"}, {"Element": "<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Respiratory, thoracic and mediastinal\n  disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Dyspnoea*, cough*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Bronchospasm*, chest\n  discomfort*, oropharyngeal pain*, nasal congestion*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pulmonary oedema*, hypoxia*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span class=\"CSIchar\"><span lang=\"EN-GB\" style=\"border:none\">\u00a0</span></span></p>\n</td>\n</tr>", "ID": "c2839761-7738-4c93-979e-4bd23e54e4db", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "dd2e9821-18bd-45b1-be5b-80b9466797cc"}, {"Element": "<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Respiratory, thoracic and mediastinal\n  disorders</span></p>\n</td>", "ID": "01445a58-ba60-4999-8547-865a61f44027", "Styles": "border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c2839761-7738-4c93-979e-4bd23e54e4db"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Respiratory, thoracic and mediastinal\n  disorders</span></p>", "ID": "ed0645ca-0ba5-4f91-9d45-68e3f7dda2ec", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "01445a58-ba60-4999-8547-865a61f44027"}, {"Element": "<span lang=\"EN-GB\">Respiratory, thoracic and mediastinal\n  disorders</span>", "ID": "37e256f3-edfa-41f8-b3ba-792be02e2c50", "Styles": "None", "Classes": "None", "Text": "Respiratory, thoracic and mediastinal   disorders", "ParentId": "ed0645ca-0ba5-4f91-9d45-68e3f7dda2ec"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Dyspnoea*, cough*</span></p>\n</td>", "ID": "f9a1774e-b9bd-490f-8145-c0f0f6186c7b", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c2839761-7738-4c93-979e-4bd23e54e4db"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Dyspnoea*, cough*</span></p>", "ID": "6be30c46-55b3-4f8f-9a2f-afdb430a516f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f9a1774e-b9bd-490f-8145-c0f0f6186c7b"}, {"Element": "<span lang=\"EN-GB\">Dyspnoea*, cough*</span>", "ID": "5004dcef-2fec-49c7-add7-8231b5b12306", "Styles": "None", "Classes": "None", "Text": "Dyspnoea*, cough*", "ParentId": "6be30c46-55b3-4f8f-9a2f-afdb430a516f"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Bronchospasm*, chest\n  discomfort*, oropharyngeal pain*, nasal congestion*</span></p>\n</td>", "ID": "09357d45-0423-4749-8644-2db8f6f2a903", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c2839761-7738-4c93-979e-4bd23e54e4db"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Bronchospasm*, chest\n  discomfort*, oropharyngeal pain*, nasal congestion*</span></p>", "ID": "00d2be81-2589-447d-a0f4-d0f7bad2d986", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "09357d45-0423-4749-8644-2db8f6f2a903"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Bronchospasm*, chest\n  discomfort*, oropharyngeal pain*, nasal congestion*</span>", "ID": "2cf6acaf-e73f-4282-9052-7bd46a4f1a0d", "Styles": "color:black", "Classes": "None", "Text": "Bronchospasm*, chest   discomfort*, oropharyngeal pain*, nasal congestion*", "ParentId": "00d2be81-2589-447d-a0f4-d0f7bad2d986"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pulmonary oedema*, hypoxia*</span></p>\n</td>", "ID": "06f07299-0928-4161-8823-1ceec3b23c69", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c2839761-7738-4c93-979e-4bd23e54e4db"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pulmonary oedema*, hypoxia*</span></p>", "ID": "726db352-34cf-44a8-bab8-898ea370be4c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "06f07299-0928-4161-8823-1ceec3b23c69"}, {"Element": "<span lang=\"EN-GB\">Pulmonary oedema*, hypoxia*</span>", "ID": "42206ef4-9fd5-4af6-87ee-eae26dbc63fc", "Styles": "None", "Classes": "None", "Text": "Pulmonary oedema*, hypoxia*", "ParentId": "726db352-34cf-44a8-bab8-898ea370be4c"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span class=\"CSIchar\"><span lang=\"EN-GB\" style=\"border:none\">\u00a0</span></span></p>\n</td>", "ID": "32080e7e-5c02-46d8-b2eb-43940bc16978", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c2839761-7738-4c93-979e-4bd23e54e4db"}, {"Element": "<p class=\"MsoNormal\"><span class=\"CSIchar\"><span lang=\"EN-GB\" style=\"border:none\">\u00a0</span></span></p>", "ID": "69e4c481-cd02-4d0b-b9fa-0126bb1d739d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "32080e7e-5c02-46d8-b2eb-43940bc16978"}, {"Element": "<span class=\"CSIchar\"><span lang=\"EN-GB\" style=\"border:none\">\u00a0</span></span>", "ID": "abfa4348-7165-491e-b36b-ad448992bd29", "Styles": "None", "Classes": "['CSIchar']", "Text": "", "ParentId": "69e4c481-cd02-4d0b-b9fa-0126bb1d739d"}, {"Element": "<span lang=\"EN-GB\" style=\"border:none\">\u00a0</span>", "ID": "17cc10d1-b261-43e7-a2f7-f27a84493eec", "Styles": "border:none", "Classes": "None", "Text": "\u00a0", "ParentId": "abfa4348-7165-491e-b36b-ad448992bd29"}, {"Element": "<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Gastrointestinal disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Nausea*, diarrhoea*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Small intestinal obstruction</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "879211f2-9362-4794-a90d-36791bc67592", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "dd2e9821-18bd-45b1-be5b-80b9466797cc"}, {"Element": "<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Gastrointestinal disorders</span></p>\n</td>", "ID": "fcc35483-9062-48fd-bb9a-ebb38e5efd95", "Styles": "border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "879211f2-9362-4794-a90d-36791bc67592"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Gastrointestinal disorders</span></p>", "ID": "bd4162c7-0932-4ff5-961e-01913ab826a9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fcc35483-9062-48fd-bb9a-ebb38e5efd95"}, {"Element": "<span lang=\"EN-GB\">Gastrointestinal disorders</span>", "ID": "e5598e22-0e5c-4e73-b657-f03858a61288", "Styles": "None", "Classes": "None", "Text": "Gastrointestinal disorders", "ParentId": "bd4162c7-0932-4ff5-961e-01913ab826a9"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Nausea*, diarrhoea*</span></p>\n</td>", "ID": "9a588eb7-f708-4f29-a513-d481c49c91e6", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "879211f2-9362-4794-a90d-36791bc67592"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Nausea*, diarrhoea*</span></p>", "ID": "fb8f57d1-0399-444e-97f8-3a252ed95696", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9a588eb7-f708-4f29-a513-d481c49c91e6"}, {"Element": "<span lang=\"EN-GB\">Nausea*, diarrhoea*</span>", "ID": "2247b401-644e-45b1-9bad-b31cf034e8a4", "Styles": "None", "Classes": "None", "Text": "Nausea*, diarrhoea*", "ParentId": "fb8f57d1-0399-444e-97f8-3a252ed95696"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "c6f9502b-3c77-4386-9e2e-8d0d360d0c6d", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "879211f2-9362-4794-a90d-36791bc67592"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "82233370-abdb-4040-8845-a83e244ffc0c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c6f9502b-3c77-4386-9e2e-8d0d360d0c6d"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d7032bb7-8993-4d05-b89b-e47733f0d76d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "82233370-abdb-4040-8845-a83e244ffc0c"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Small intestinal obstruction</span></p>\n</td>", "ID": "77fb3bb4-45e5-435e-9f7a-67f401808b87", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "879211f2-9362-4794-a90d-36791bc67592"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Small intestinal obstruction</span></p>", "ID": "fe237a82-85d2-42b6-96b0-6faa45f89f0a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "77fb3bb4-45e5-435e-9f7a-67f401808b87"}, {"Element": "<span lang=\"EN-GB\">Small intestinal obstruction</span>", "ID": "04adc914-bc19-49b5-b149-2605487ce44c", "Styles": "None", "Classes": "None", "Text": "Small intestinal obstruction", "ParentId": "fe237a82-85d2-42b6-96b0-6faa45f89f0a"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "cdea67be-7d0a-44ea-88f2-4bf7c2cfbcc6", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "879211f2-9362-4794-a90d-36791bc67592"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "093085ab-7a40-44b5-bd4c-5547c7fb9fd8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cdea67be-7d0a-44ea-88f2-4bf7c2cfbcc6"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f1ce3f99-934f-4f90-be95-a19eb5d9ee88", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "093085ab-7a40-44b5-bd4c-5547c7fb9fd8"}, {"Element": "<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Skin and subcutaneous tissue disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Rash*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Urticaria*, pruritus*, flushing*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "ccd55f95-129f-4d5b-85fd-1fe50c454f3b", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "dd2e9821-18bd-45b1-be5b-80b9466797cc"}, {"Element": "<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Skin and subcutaneous tissue disorders</span></p>\n</td>", "ID": "5c70d57e-a318-4429-8eca-4c31550bfa29", "Styles": "border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ccd55f95-129f-4d5b-85fd-1fe50c454f3b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Skin and subcutaneous tissue disorders</span></p>", "ID": "7867ca17-ef68-49b6-969a-6a08cf518d15", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5c70d57e-a318-4429-8eca-4c31550bfa29"}, {"Element": "<span lang=\"EN-GB\">Skin and subcutaneous tissue disorders</span>", "ID": "29d46e18-2119-4356-b001-84ee945aba4c", "Styles": "None", "Classes": "None", "Text": "Skin and subcutaneous tissue disorders", "ParentId": "7867ca17-ef68-49b6-969a-6a08cf518d15"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Rash*</span></p>\n</td>", "ID": "76b17f7a-67b8-4423-8ac9-88f1d28620d0", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ccd55f95-129f-4d5b-85fd-1fe50c454f3b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Rash*</span></p>", "ID": "4b332045-bee4-4cd4-852c-14700a75c99b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "76b17f7a-67b8-4423-8ac9-88f1d28620d0"}, {"Element": "<span lang=\"EN-GB\">Rash*</span>", "ID": "29daa1ba-358e-4014-aded-2abed53f1c30", "Styles": "None", "Classes": "None", "Text": "Rash*", "ParentId": "4b332045-bee4-4cd4-852c-14700a75c99b"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Urticaria*, pruritus*, flushing*</span></p>\n</td>", "ID": "8794ce92-9349-496c-8940-faf0bf6b1471", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ccd55f95-129f-4d5b-85fd-1fe50c454f3b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Urticaria*, pruritus*, flushing*</span></p>", "ID": "bf74cdc7-301a-465e-b4e9-76ccd064d9c9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8794ce92-9349-496c-8940-faf0bf6b1471"}, {"Element": "<span lang=\"EN-GB\">Urticaria*, pruritus*, flushing*</span>", "ID": "db4faf8f-ef3c-45ae-b5f4-6e48c6ba51d2", "Styles": "None", "Classes": "None", "Text": "Urticaria*, pruritus*, flushing*", "ParentId": "bf74cdc7-301a-465e-b4e9-76ccd064d9c9"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "0770fa70-3e5b-4024-ab9e-3f3b66a214ab", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ccd55f95-129f-4d5b-85fd-1fe50c454f3b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7dcf41ac-21e3-4b78-8aa4-c226e62c8254", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0770fa70-3e5b-4024-ab9e-3f3b66a214ab"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "20de827e-e32f-4446-9e62-0166438799bf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7dcf41ac-21e3-4b78-8aa4-c226e62c8254"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "c57a2762-d5df-4873-b47f-5b3d90622c14", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ccd55f95-129f-4d5b-85fd-1fe50c454f3b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4c1dc073-57d5-45f0-a179-b811896a9fed", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c57a2762-d5df-4873-b47f-5b3d90622c14"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d8c64ce7-24ba-4ee8-b2ed-2921174eeb5e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4c1dc073-57d5-45f0-a179-b811896a9fed"}, {"Element": "<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Musculoskeletal and connective tissue\n  disorders</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Back pain*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "efeb0ff9-5d88-4504-b2c2-2c63cfcc2232", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "dd2e9821-18bd-45b1-be5b-80b9466797cc"}, {"Element": "<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Musculoskeletal and connective tissue\n  disorders</span></p>\n</td>", "ID": "bb41d25b-e402-44eb-b95b-176015703df2", "Styles": "border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "efeb0ff9-5d88-4504-b2c2-2c63cfcc2232"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Musculoskeletal and connective tissue\n  disorders</span></p>", "ID": "6881aaaf-bcf9-46f8-9805-d432e18503ff", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bb41d25b-e402-44eb-b95b-176015703df2"}, {"Element": "<span lang=\"EN-GB\">Musculoskeletal and connective tissue\n  disorders</span>", "ID": "45b6840b-98a0-4a77-b29c-2085c2947cb0", "Styles": "None", "Classes": "None", "Text": "Musculoskeletal and connective tissue   disorders", "ParentId": "6881aaaf-bcf9-46f8-9805-d432e18503ff"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "6e811831-9a2e-4d9b-93fb-720cd1983956", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "efeb0ff9-5d88-4504-b2c2-2c63cfcc2232"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0bed3d33-ce54-4194-a998-3ec3a2be868e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6e811831-9a2e-4d9b-93fb-720cd1983956"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b5380796-783d-4394-b995-c2ac8635ec67", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0bed3d33-ce54-4194-a998-3ec3a2be868e"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Back pain*</span></p>\n</td>", "ID": "e8dbdd0c-0e5e-4676-9ec9-a87188be2a04", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "efeb0ff9-5d88-4504-b2c2-2c63cfcc2232"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Back pain*</span></p>", "ID": "94123354-cf60-4a9f-877d-723ffc8f3389", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e8dbdd0c-0e5e-4676-9ec9-a87188be2a04"}, {"Element": "<span lang=\"EN-GB\">Back pain*</span>", "ID": "6c2340ed-8324-48fc-8094-9f1f3d17ecc2", "Styles": "None", "Classes": "None", "Text": "Back pain*", "ParentId": "94123354-cf60-4a9f-877d-723ffc8f3389"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "5ef0ea10-5bfa-435d-8fef-50d2f4a8eead", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "efeb0ff9-5d88-4504-b2c2-2c63cfcc2232"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "38e194f5-ee90-479f-a1e5-5a58a9c000a5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5ef0ea10-5bfa-435d-8fef-50d2f4a8eead"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d931e190-1a48-47b6-9e46-61740496db96", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "38e194f5-ee90-479f-a1e5-5a58a9c000a5"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "47b3452d-78b8-4e6b-90b4-eeb38524e17e", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "efeb0ff9-5d88-4504-b2c2-2c63cfcc2232"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1430fe03-afec-4382-a3a4-0968c1fcc22d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "47b3452d-78b8-4e6b-90b4-eeb38524e17e"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a2511e99-bef9-44b5-a4f9-a0e37440fcb1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1430fe03-afec-4382-a3a4-0968c1fcc22d"}, {"Element": "<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">General\n  disorders and administration site conditions</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Pyrexia*, fatigue*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Cytokine release syndrome*, chills (including rigors)*,\n  hyperhidrosis*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "0d65f034-d39e-441f-8507-3a8262fe3bc4", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "dd2e9821-18bd-45b1-be5b-80b9466797cc"}, {"Element": "<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">General\n  disorders and administration site conditions</span></p>\n</td>", "ID": "5ccbfeef-8818-4caf-a76e-af7585dce752", "Styles": "border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "0d65f034-d39e-441f-8507-3a8262fe3bc4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">General\n  disorders and administration site conditions</span></p>", "ID": "b6108449-7ff3-41a9-99b7-b304ba633b9e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5ccbfeef-8818-4caf-a76e-af7585dce752"}, {"Element": "<span lang=\"EN-GB\">General\n  disorders and administration site conditions</span>", "ID": "7c46598a-840b-4c5b-b26f-d204d84087ba", "Styles": "None", "Classes": "None", "Text": "General   disorders and administration site conditions", "ParentId": "b6108449-7ff3-41a9-99b7-b304ba633b9e"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Pyrexia*, fatigue*</span></p>\n</td>", "ID": "d7da94d7-2554-4f4b-b2f7-65dfecedc5a7", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "0d65f034-d39e-441f-8507-3a8262fe3bc4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Pyrexia*, fatigue*</span></p>", "ID": "78bc2134-65de-4ebc-be10-b799ce40d1d4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7da94d7-2554-4f4b-b2f7-65dfecedc5a7"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Pyrexia*, fatigue*</span>", "ID": "545979aa-af2a-46b3-8f79-3f2fdb5b13b0", "Styles": "color:black", "Classes": "None", "Text": "Pyrexia*, fatigue*", "ParentId": "78bc2134-65de-4ebc-be10-b799ce40d1d4"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Cytokine release syndrome*, chills (including rigors)*,\n  hyperhidrosis*</span></p>\n</td>", "ID": "492422fb-d11c-49d1-b8d0-2def655631b1", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "0d65f034-d39e-441f-8507-3a8262fe3bc4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Cytokine release syndrome*, chills (including rigors)*,\n  hyperhidrosis*</span></p>", "ID": "e45c54eb-8f0c-4d28-a862-0e4708c71d0a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "492422fb-d11c-49d1-b8d0-2def655631b1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Cytokine release syndrome*, chills (including rigors)*,\n  hyperhidrosis*</span>", "ID": "05f732b9-fb8b-4c17-bc41-66f206cc5833", "Styles": "color:black", "Classes": "None", "Text": "Cytokine release syndrome*, chills (including rigors)*,   hyperhidrosis*", "ParentId": "e45c54eb-8f0c-4d28-a862-0e4708c71d0a"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "960a2dbd-5c25-4bdc-86d8-92e388c4ee30", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "0d65f034-d39e-441f-8507-3a8262fe3bc4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "db7536a4-08cc-482b-86c2-c83b5c7bfb02", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "960a2dbd-5c25-4bdc-86d8-92e388c4ee30"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c0137a3a-9b9f-4ff3-9e9a-8833f74b6dbe", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "db7536a4-08cc-482b-86c2-c83b5c7bfb02"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "055d4be0-eae8-456f-a6ca-973829e379b5", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "0d65f034-d39e-441f-8507-3a8262fe3bc4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "704e2fea-1c42-4f0b-ab4f-bf9c13fea5c7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "055d4be0-eae8-456f-a6ca-973829e379b5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4c2d516b-ffc5-498a-a4f0-687b0dba433b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "704e2fea-1c42-4f0b-ab4f-bf9c13fea5c7"}, {"Element": "<tr>\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Injury,\n  poisoning and procedural complications</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infusion-related\n  reaction*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "4042c5c8-35dd-49c4-8d9c-face60f3eeec", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "dd2e9821-18bd-45b1-be5b-80b9466797cc"}, {"Element": "<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Injury,\n  poisoning and procedural complications</span></p>\n</td>", "ID": "548fd8f8-215a-4139-8084-8894a765c232", "Styles": "border:solid windowtext 1.0pt;border-top:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4042c5c8-35dd-49c4-8d9c-face60f3eeec"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Injury,\n  poisoning and procedural complications</span></p>", "ID": "d7ef79ae-51ed-4ae1-b4b6-4b9cef8507d8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "548fd8f8-215a-4139-8084-8894a765c232"}, {"Element": "<span lang=\"EN-GB\">Injury,\n  poisoning and procedural complications</span>", "ID": "cb3ce3e3-c5a0-4ec4-8b8d-63e8d01cb044", "Styles": "None", "Classes": "None", "Text": "Injury,   poisoning and procedural complications", "ParentId": "d7ef79ae-51ed-4ae1-b4b6-4b9cef8507d8"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n</td>", "ID": "428bccea-142a-424f-bb0c-6bddcc2aca26", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4042c5c8-35dd-49c4-8d9c-face60f3eeec"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "98b77add-8b13-4dfe-9133-79cf1d59954b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "428bccea-142a-424f-bb0c-6bddcc2aca26"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "81124408-6193-4f59-bdea-754b08ac7b25", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "98b77add-8b13-4dfe-9133-79cf1d59954b"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infusion-related\n  reaction*</span></p>\n</td>", "ID": "ba877618-3ee1-47c9-b1dd-e0524400791f", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4042c5c8-35dd-49c4-8d9c-face60f3eeec"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infusion-related\n  reaction*</span></p>", "ID": "8adf9d58-6a26-45bc-8e88-008a2c02356d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ba877618-3ee1-47c9-b1dd-e0524400791f"}, {"Element": "<span lang=\"EN-GB\">Infusion-related\n  reaction*</span>", "ID": "e5a3b9ab-ff6e-45a2-85c8-dfe9bb6dc280", "Styles": "None", "Classes": "None", "Text": "Infusion-related   reaction*", "ParentId": "8adf9d58-6a26-45bc-8e88-008a2c02356d"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "29f34421-c7dc-4589-957d-7901e4a6c62a", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4042c5c8-35dd-49c4-8d9c-face60f3eeec"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "634d3f27-dde8-4a1e-846a-21855bb1d4ef", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "29f34421-c7dc-4589-957d-7901e4a6c62a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "084f7520-9bb9-47d1-a9ea-c49f6f162943", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "634d3f27-dde8-4a1e-846a-21855bb1d4ef"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "26db659b-d06c-43bb-9379-b03275fa890c", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4042c5c8-35dd-49c4-8d9c-face60f3eeec"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "934bdd72-1e5f-4358-8b83-d4d8fbbf6335", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "26db659b-d06c-43bb-9379-b03275fa890c"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3d327520-70c2-419f-8582-50594a4e21ef", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "934bdd72-1e5f-4358-8b83-d4d8fbbf6335"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">*These\n  events are likely attributable to ofatumumab in the setting of an infusion-related\n  reaction and typically occur after the start of infusion and within\n  24\u00a0hours after the completion of the infusion (see section\u00a04.4).</span></p>\n</td>\n</tr>", "ID": "611085bc-fd86-4300-9c19-0b9306cda436", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "dd2e9821-18bd-45b1-be5b-80b9466797cc"}, {"Element": "<td colspan=\"5\" style=\"border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">*These\n  events are likely attributable to ofatumumab in the setting of an infusion-related\n  reaction and typically occur after the start of infusion and within\n  24\u00a0hours after the completion of the infusion (see section\u00a04.4).</span></p>\n</td>", "ID": "830a417f-9b84-4a89-afb1-a0bfd0c1ce59", "Styles": "border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "611085bc-fd86-4300-9c19-0b9306cda436"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">*These\n  events are likely attributable to ofatumumab in the setting of an infusion-related\n  reaction and typically occur after the start of infusion and within\n  24\u00a0hours after the completion of the infusion (see section\u00a04.4).</span></p>", "ID": "026d6109-63b5-403b-8ece-5355c7f06c2c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "830a417f-9b84-4a89-afb1-a0bfd0c1ce59"}, {"Element": "<span lang=\"EN-GB\">*These\n  events are likely attributable to ofatumumab in the setting of an infusion-related\n  reaction and typically occur after the start of infusion and within\n  24\u00a0hours after the completion of the infusion (see section\u00a04.4).</span>", "ID": "734f98b3-a1cc-4620-87f1-6b041fcdf8df", "Styles": "None", "Classes": "None", "Text": "*These   events are likely attributable to ofatumumab in the setting of an infusion-related   reaction and typically occur after the start of infusion and within   24\u00a0hours after the completion of the infusion (see section\u00a04.4).", "ParentId": "026d6109-63b5-403b-8ece-5355c7f06c2c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e004964b-d55c-4b86-9ece-e4bc3e7a8e37", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0c285a91-9e7a-4e19-81b6-8b8b42b6ede8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e004964b-d55c-4b86-9ece-e4bc3e7a8e37"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Description\nof selected adverse reactions</span></u></p>", "ID": "92ec85ce-5fbf-4ee8-9149-d3623beeb0fe", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\">Description\nof selected adverse reactions</span></u>", "ID": "358a65d9-05f6-4e16-ac9b-e5f37e579139", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "92ec85ce-5fbf-4ee8-9149-d3623beeb0fe"}, {"Element": "<span lang=\"EN-GB\">Description\nof selected adverse reactions</span>", "ID": "d95b4f65-8b6e-4acd-ac92-49605720a820", "Styles": "None", "Classes": "None", "Text": "Description of selected adverse reactions", "ParentId": "358a65d9-05f6-4e16-ac9b-e5f37e579139"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8aff4eb5-6126-455a-88ea-26be97ae35ca", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6b8b7ca6-8f62-4687-a838-cafc7af321ea", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8aff4eb5-6126-455a-88ea-26be97ae35ca"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Infusion-related\nreactions</span></u></i></p>", "ID": "5cdc1727-9e0d-418d-998c-fbaf2d001942", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><u><span lang=\"EN-GB\">Infusion-related\nreactions</span></u></i>", "ID": "8ce3d4d7-8880-417e-b140-edb6b49aa346", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5cdc1727-9e0d-418d-998c-fbaf2d001942"}, {"Element": "<u><span lang=\"EN-GB\">Infusion-related\nreactions</span></u>", "ID": "727c52b5-721b-4cf7-8857-11c588f3e097", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8ce3d4d7-8880-417e-b140-edb6b49aa346"}, {"Element": "<span lang=\"EN-GB\">Infusion-related\nreactions</span>", "ID": "5868ec19-c0c9-477b-8a73-9057324a9438", "Styles": "None", "Classes": "None", "Text": "Infusion-related reactions", "ParentId": "727c52b5-721b-4cf7-8857-11c588f3e097"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Of the 1,168\u00a0patients receiving\nofatumumab in clinical trials for CLL, </span>the most frequently observed ADRs\nwere infusion-related reactions which occurred in 711\u00a0patients (61%) at\nany time during treatment. The majority of infusion-related reactions were\nGrade\u00a01 or Grade\u00a02 in severity. Seven percent of patients had\n\u2265Grade\u00a03 infusion-related reactions at any time during treatment.\nTwo percent of the infusion-related reactions led to discontinuation of\ntreatment. There were no fatal infusion-related reactions<span lang=\"EN-GB\"> (see\nsection\u00a04.4).</span></p>", "ID": "97545b14-d8c1-4218-814f-81fe72499a99", "Styles": "None", "Classes": "['MsoNormal']", "Text": "the most frequently observed ADRs were infusion-related reactions which occurred in 711\u00a0patients (61%) at any time during treatment. The majority of infusion-related reactions were Grade\u00a01 or Grade\u00a02 in severity. Seven percent of patients had \u2265Grade\u00a03 infusion-related reactions at any time during treatment. Two percent of the infusion-related reactions led to discontinuation of treatment. There were no fatal infusion-related reactions", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Of the 1,168\u00a0patients receiving\nofatumumab in clinical trials for CLL, </span>", "ID": "49e1f391-c434-483a-88c2-5308ed28211c", "Styles": "None", "Classes": "None", "Text": "Of the 1,168\u00a0patients receiving ofatumumab in clinical trials for CLL, ", "ParentId": "97545b14-d8c1-4218-814f-81fe72499a99"}, {"Element": "<span lang=\"EN-GB\"> (see\nsection\u00a04.4).</span>", "ID": "16deed14-b4b8-4058-b31a-a46d5fdb1301", "Styles": "None", "Classes": "None", "Text": " (see section\u00a04.4).", "ParentId": "97545b14-d8c1-4218-814f-81fe72499a99"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "409d4102-a00f-40a0-b723-1cbc4f166bf6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b188d0ea-2bb8-4843-8a79-f3db76d98720", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "409d4102-a00f-40a0-b723-1cbc4f166bf6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Infections</span></u></i></p>", "ID": "b894687c-ece1-4229-9aed-c9d87ed929e5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><u><span lang=\"EN-GB\">Infections</span></u></i>", "ID": "c15dc0a2-745c-4d12-8de3-06ff253f8f28", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b894687c-ece1-4229-9aed-c9d87ed929e5"}, {"Element": "<u><span lang=\"EN-GB\">Infections</span></u>", "ID": "33dbf4ab-05eb-4433-9eeb-377e07059588", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c15dc0a2-745c-4d12-8de3-06ff253f8f28"}, {"Element": "<span lang=\"EN-GB\">Infections</span>", "ID": "6737c70e-9b8c-44dc-b4e2-5177a98bb924", "Styles": "None", "Classes": "None", "Text": "Infections", "ParentId": "33dbf4ab-05eb-4433-9eeb-377e07059588"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Of the 1,168\u00a0patients receiving\nofatumumab in clinical trials for CLL, 682\u00a0patients (58%) experienced an\ninfection. These included bacterial, viral and fungal infections. 268 (23%) of\nthe 1,168\u00a0patients experienced \u2265Grade\u00a03 infections. 65 (6%) of\nthe 1,168\u00a0patients experienced a fatal infection.</span></p>", "ID": "28e57192-47d2-4d0b-a54b-c353910699e0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Of the 1,168\u00a0patients receiving\nofatumumab in clinical trials for CLL, 682\u00a0patients (58%) experienced an\ninfection. These included bacterial, viral and fungal infections. 268 (23%) of\nthe 1,168\u00a0patients experienced \u2265Grade\u00a03 infections. 65 (6%) of\nthe 1,168\u00a0patients experienced a fatal infection.</span>", "ID": "2b9b73ae-bc1e-4fd6-99a4-b990673c4703", "Styles": "None", "Classes": "None", "Text": "Of the 1,168\u00a0patients receiving ofatumumab in clinical trials for CLL, 682\u00a0patients (58%) experienced an infection. These included bacterial, viral and fungal infections. 268 (23%) of the 1,168\u00a0patients experienced \u2265Grade\u00a03 infections. 65 (6%) of the 1,168\u00a0patients experienced a fatal infection.", "ParentId": "28e57192-47d2-4d0b-a54b-c353910699e0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "471c87f6-081c-4f06-9684-134a475c97d4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0b263b06-1d85-4e10-b9b9-6f56f685dc07", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "471c87f6-081c-4f06-9684-134a475c97d4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Neutropenia</span></u></i></p>", "ID": "ee1e81ba-fbde-4b6b-bf34-f5245f8a5709", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><u><span lang=\"EN-GB\">Neutropenia</span></u></i>", "ID": "e3568068-f862-49f4-b553-2fe5a0a8e1e9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ee1e81ba-fbde-4b6b-bf34-f5245f8a5709"}, {"Element": "<u><span lang=\"EN-GB\">Neutropenia</span></u>", "ID": "f6565ccb-1f80-4b72-be8a-fd6e32b124e0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e3568068-f862-49f4-b553-2fe5a0a8e1e9"}, {"Element": "<span lang=\"EN-GB\">Neutropenia</span>", "ID": "ee6f8ca7-3739-48d2-9cf5-f4aa89252a58", "Styles": "None", "Classes": "None", "Text": "Neutropenia", "ParentId": "f6565ccb-1f80-4b72-be8a-fd6e32b124e0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Of the 1,168\u00a0patients receiving\nofatumumab in clinical trials, 420\u00a0patients (36%) experienced an adverse\nevent associated with a decreased neutrophil count; 129 (11%) experienced a\nserious adverse event associated with a decreased neutrophil count.</span></p>", "ID": "929369a4-fe5d-4ee4-a82f-04ac958d3d83", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Of the 1,168\u00a0patients receiving\nofatumumab in clinical trials, 420\u00a0patients (36%) experienced an adverse\nevent associated with a decreased neutrophil count; 129 (11%) experienced a\nserious adverse event associated with a decreased neutrophil count.</span>", "ID": "569014ea-aea4-43fd-827e-aa92bdf3c340", "Styles": "None", "Classes": "None", "Text": "Of the 1,168\u00a0patients receiving ofatumumab in clinical trials, 420\u00a0patients (36%) experienced an adverse event associated with a decreased neutrophil count; 129 (11%) experienced a serious adverse event associated with a decreased neutrophil count.", "ParentId": "929369a4-fe5d-4ee4-a82f-04ac958d3d83"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7711105a-888d-4045-b8df-bc8632591b79", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "455dc8d2-a6c8-4245-a701-781f8faa2f38", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7711105a-888d-4045-b8df-bc8632591b79"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the pivotal study for untreated CLL\n(OMB110911; ofatumumab plus chlorambucil 217\u00a0patients, chlorambucil alone\n227\u00a0patients), prolonged neutropenia (defined as Grade\u00a03 or 4\nneutropenia not resolved between 24 and 42\u00a0days after last dose of study treatment)\nwas reported in 41\u00a0patients (9%) (23\u00a0patients [11%] treated with </span><span lang=\"EN-GB\">ofatumumab</span><span lang=\"EN-GB\"> and </span>chlorambucil<span lang=\"EN-GB\">, 18\u00a0patients [8%] treated with </span>chlorambucil alone<span lang=\"EN-GB\">). Nine patients (4%) treated with </span><span lang=\"EN-GB\">ofatumumab</span><span lang=\"EN-GB\"> and </span>chlorambucil,<span lang=\"EN-GB\"> and three patients\ntreated with </span>chlorambucil alone<span lang=\"EN-GB\"> had late-onset\nneutropenia (defined as Grade\u00a03 or 4 neutropenia starting at least\n42\u00a0days after the last treatment). </span><span lang=\"EN-GB\">In the pivotal\nstudy (OMB110913, ofatumumab plus fludarabine and cyclophosphamide\n181\u00a0patients; fludarabine and cyclophosphamide 178\u00a0patients) in\nrelapsed CLL patients, prolonged neutropenia was reported in 38 (11%) patients\n(18\u00a0patients [10%] treated with ofatumumab in combination with fludarabine\nand cyclophosphamide compared to 20\u00a0patients [11%] in the fludarabine and\ncyclophosphamide arm). Thirteen (7%) patients treated with ofatumumab in\ncombination with fludarabine and cyclophosphamide, and 5 (3%) patients treated\nwith fludarabine and cyclophosphamide had late-onset neutropenia.</span></p>", "ID": "241af191-07f4-44b6-bbd0-f8b8daff8e23", "Styles": "None", "Classes": "['MsoNormal']", "Text": "chlorambucilchlorambucil alonechlorambucil,chlorambucil alone", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">In the pivotal study for untreated CLL\n(OMB110911; ofatumumab plus chlorambucil 217\u00a0patients, chlorambucil alone\n227\u00a0patients), prolonged neutropenia (defined as Grade\u00a03 or 4\nneutropenia not resolved between 24 and 42\u00a0days after last dose of study treatment)\nwas reported in 41\u00a0patients (9%) (23\u00a0patients [11%] treated with </span>", "ID": "43248695-af64-4398-8188-62c60d3ed93d", "Styles": "None", "Classes": "None", "Text": "In the pivotal study for untreated CLL (OMB110911; ofatumumab plus chlorambucil 217\u00a0patients, chlorambucil alone 227\u00a0patients), prolonged neutropenia (defined as Grade\u00a03 or 4 neutropenia not resolved between 24 and 42\u00a0days after last dose of study treatment) was reported in 41\u00a0patients (9%) (23\u00a0patients [11%] treated with ", "ParentId": "241af191-07f4-44b6-bbd0-f8b8daff8e23"}, {"Element": "<span lang=\"EN-GB\">ofatumumab</span>", "ID": "3b8e1f54-ab72-440e-aa0a-87f01d097769", "Styles": "None", "Classes": "None", "Text": "ofatumumab", "ParentId": "241af191-07f4-44b6-bbd0-f8b8daff8e23"}, {"Element": "<span lang=\"EN-GB\"> and </span>", "ID": "3857f8a9-60f0-463a-b2ff-d45844d4f6bb", "Styles": "None", "Classes": "None", "Text": " and ", "ParentId": "241af191-07f4-44b6-bbd0-f8b8daff8e23"}, {"Element": "<span lang=\"EN-GB\">, 18\u00a0patients [8%] treated with </span>", "ID": "89a271f8-2c12-46da-a5db-6887c39b61e3", "Styles": "None", "Classes": "None", "Text": ", 18\u00a0patients [8%] treated with ", "ParentId": "241af191-07f4-44b6-bbd0-f8b8daff8e23"}, {"Element": "<span lang=\"EN-GB\">). Nine patients (4%) treated with </span>", "ID": "0e468080-7c10-4bd1-b943-2774e3350367", "Styles": "None", "Classes": "None", "Text": "). Nine patients (4%) treated with ", "ParentId": "241af191-07f4-44b6-bbd0-f8b8daff8e23"}, {"Element": "<span lang=\"EN-GB\">ofatumumab</span>", "ID": "6da87ad7-1229-4c71-841d-8ba0dc2deb85", "Styles": "None", "Classes": "None", "Text": "ofatumumab", "ParentId": "241af191-07f4-44b6-bbd0-f8b8daff8e23"}, {"Element": "<span lang=\"EN-GB\"> and </span>", "ID": "5798672b-3e77-4f1a-81b5-cb0f09e88e32", "Styles": "None", "Classes": "None", "Text": " and ", "ParentId": "241af191-07f4-44b6-bbd0-f8b8daff8e23"}, {"Element": "<span lang=\"EN-GB\"> and three patients\ntreated with </span>", "ID": "c18cc6b1-6b08-46cc-8fc3-47d7a79b005e", "Styles": "None", "Classes": "None", "Text": " and three patients treated with ", "ParentId": "241af191-07f4-44b6-bbd0-f8b8daff8e23"}, {"Element": "<span lang=\"EN-GB\"> had late-onset\nneutropenia (defined as Grade\u00a03 or 4 neutropenia starting at least\n42\u00a0days after the last treatment). </span>", "ID": "cf4d4863-5bd1-4ccb-82a3-9a9ac0a440b9", "Styles": "None", "Classes": "None", "Text": " had late-onset neutropenia (defined as Grade\u00a03 or 4 neutropenia starting at least 42\u00a0days after the last treatment). ", "ParentId": "241af191-07f4-44b6-bbd0-f8b8daff8e23"}, {"Element": "<span lang=\"EN-GB\">In the pivotal\nstudy (OMB110913, ofatumumab plus fludarabine and cyclophosphamide\n181\u00a0patients; fludarabine and cyclophosphamide 178\u00a0patients) in\nrelapsed CLL patients, prolonged neutropenia was reported in 38 (11%) patients\n(18\u00a0patients [10%] treated with ofatumumab in combination with fludarabine\nand cyclophosphamide compared to 20\u00a0patients [11%] in the fludarabine and\ncyclophosphamide arm). Thirteen (7%) patients treated with ofatumumab in\ncombination with fludarabine and cyclophosphamide, and 5 (3%) patients treated\nwith fludarabine and cyclophosphamide had late-onset neutropenia.</span>", "ID": "7268514d-d875-4c95-80b2-25f3828f08cf", "Styles": "None", "Classes": "None", "Text": "In the pivotal study (OMB110913, ofatumumab plus fludarabine and cyclophosphamide 181\u00a0patients; fludarabine and cyclophosphamide 178\u00a0patients) in relapsed CLL patients, prolonged neutropenia was reported in 38 (11%) patients (18\u00a0patients [10%] treated with ofatumumab in combination with fludarabine and cyclophosphamide compared to 20\u00a0patients [11%] in the fludarabine and cyclophosphamide arm). Thirteen (7%) patients treated with ofatumumab in combination with fludarabine and cyclophosphamide, and 5 (3%) patients treated with fludarabine and cyclophosphamide had late-onset neutropenia.", "ParentId": "241af191-07f4-44b6-bbd0-f8b8daff8e23"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "13bb1e3a-ea7a-44fe-8016-fcd14f54984c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Cardiovascular</span></u></i></p>", "ID": "452a4b09-a2ac-4c2e-b70d-2d4c50bd66f0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><u><span lang=\"EN-GB\">Cardiovascular</span></u></i>", "ID": "ea7d3c7b-59d0-4910-b825-2499ed31929b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "452a4b09-a2ac-4c2e-b70d-2d4c50bd66f0"}, {"Element": "<u><span lang=\"EN-GB\">Cardiovascular</span></u>", "ID": "eb872e58-fb22-43da-a161-91f20cc41682", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ea7d3c7b-59d0-4910-b825-2499ed31929b"}, {"Element": "<span lang=\"EN-GB\">Cardiovascular</span>", "ID": "2e29a378-0454-439e-84b9-e1ccf505d753", "Styles": "None", "Classes": "None", "Text": "Cardiovascular", "ParentId": "eb872e58-fb22-43da-a161-91f20cc41682"}, {"Element": "<p class=\"MsoNormal\">The effect of multiple doses of Arzerra on the QTc interval\nwas evaluated in a pooled analysis of three open-label studies in patients with\nCLL (N=85). <span style=\"border:none windowtext 1.0pt;padding:0in\">Increases\nabove 5\u00a0msec were observed in the median/mean QT/QTc intervals in the\npooled analysis.<span style=\"color:black\"> </span></span>No large changes in\nthe mean QTc interval (i.e. &gt;20\u00a0milliseconds) were detected. None of\nthe patients had an increase of QTc to &gt;500\u00a0msec. A concentration\ndependent increase in QTc was not detected.</p>", "ID": "20e82edc-854a-49b7-a6a1-eaa7f3b283e9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The effect of multiple doses of Arzerra on the QTc interval was evaluated in a pooled analysis of three open-label studies in patients with CLL (N=85). No large changes in the mean QTc interval (i.e. >20\u00a0milliseconds) were detected. None of the patients had an increase of QTc to >500\u00a0msec. A concentration dependent increase in QTc was not detected.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"border:none windowtext 1.0pt;padding:0in\">Increases\nabove 5\u00a0msec were observed in the median/mean QT/QTc intervals in the\npooled analysis.<span style=\"color:black\"> </span></span>", "ID": "886e6546-31d5-4d56-9873-542e55459382", "Styles": "border:none windowtext 1.0pt;padding:0in", "Classes": "None", "Text": "Increases above 5\u00a0msec were observed in the median/mean QT/QTc intervals in the pooled analysis.", "ParentId": "20e82edc-854a-49b7-a6a1-eaa7f3b283e9"}, {"Element": "<span style=\"color:black\"> </span>", "ID": "ed68c87b-403d-469a-9ab8-0af646b21464", "Styles": "color:black", "Classes": "None", "Text": " ", "ParentId": "886e6546-31d5-4d56-9873-542e55459382"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5c4865ee-3cca-471f-ba9d-5d82d2a9881f", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1ecf0f12-0bd1-4ccd-b110-88b6174f1bc9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5c4865ee-3cca-471f-ba9d-5d82d2a9881f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Reporting of suspected adverse reactions</span></u></p>", "ID": "a45d398e-3df1-463d-bac3-7d8e1749de9b", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\">Reporting of suspected adverse reactions</span></u>", "ID": "98aa6887-dd93-4094-a518-c49b875e77a9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a45d398e-3df1-463d-bac3-7d8e1749de9b"}, {"Element": "<span lang=\"EN-GB\">Reporting of suspected adverse reactions</span>", "ID": "b4e95a56-8e80-47e8-a3a4-2406a7f731e2", "Styles": "None", "Classes": "None", "Text": "Reporting of suspected adverse reactions", "ParentId": "98aa6887-dd93-4094-a518-c49b875e77a9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3cf8dc40-542a-46e3-80ce-dbdebb491416", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6fd8a8ed-0fd1-4cc1-9fe6-c77594eb5ea5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3cf8dc40-542a-46e3-80ce-dbdebb491416"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Reporting suspected adverse reactions after\nauthorisation of the medicinal product is important. It allows continued\nmonitoring of the benefit/risk balance of the medicinal product. Healthcare\nprofessionals are asked to report any suspected adverse reactions via <span style=\"color:black;background:#D9D9D9\">the national reporting system listed in </span></span><span lang=\"EN-GB\"><a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"background:#D9D9D9\">Appendix V</span></a></span><span lang=\"EN-GB\">.</span></p>", "ID": "457ad5fc-1363-4317-a41c-0156832bc5f6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Reporting suspected adverse reactions after\nauthorisation of the medicinal product is important. It allows continued\nmonitoring of the benefit/risk balance of the medicinal product. Healthcare\nprofessionals are asked to report any suspected adverse reactions via <span style=\"color:black;background:#D9D9D9\">the national reporting system listed in </span></span>", "ID": "bf61b579-18b6-41a1-9843-32ae4e4143b0", "Styles": "None", "Classes": "None", "Text": "Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via ", "ParentId": "457ad5fc-1363-4317-a41c-0156832bc5f6"}, {"Element": "<span style=\"color:black;background:#D9D9D9\">the national reporting system listed in </span>", "ID": "f2d0099a-a6d1-4c81-bad2-e267b0606377", "Styles": "color:black;background:#D9D9D9", "Classes": "None", "Text": "the national reporting system listed in ", "ParentId": "bf61b579-18b6-41a1-9843-32ae4e4143b0"}, {"Element": "<span lang=\"EN-GB\"><a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"background:#D9D9D9\">Appendix V</span></a></span>", "ID": "0f7c5080-3e75-471d-b8a9-7eb2160682fd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "457ad5fc-1363-4317-a41c-0156832bc5f6"}, {"Element": "<a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"background:#D9D9D9\">Appendix V</span></a>", "ID": "441af627-7266-45af-a36c-56ce25da078e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0f7c5080-3e75-471d-b8a9-7eb2160682fd"}, {"Element": "<span style=\"background:#D9D9D9\">Appendix V</span>", "ID": "39ce5b8b-1535-4f34-bfb4-5771c3007ef6", "Styles": "background:#D9D9D9", "Classes": "None", "Text": "Appendix V", "ParentId": "441af627-7266-45af-a36c-56ce25da078e"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "9c979830-98cb-4723-b0b4-62652843e82e", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "457ad5fc-1363-4317-a41c-0156832bc5f6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "01799ded-acfd-479f-a98f-9c8ea88ab103", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "61d9c2b7-279f-4f11-b6c0-fd889ce07bbe", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "01799ded-acfd-479f-a98f-9c8ea88ab103"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">4.9\u00a0\u00a0\u00a0\u00a0 Overdose</span></b></p>", "ID": "bb3d01cd-3229-40a2-a1b9-dd99a27a268d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">4.9\u00a0\u00a0\u00a0\u00a0 Overdose</span></b>", "ID": "149f456d-2321-4308-9e87-fd9c5b5e2de2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bb3d01cd-3229-40a2-a1b9-dd99a27a268d"}, {"Element": "<span lang=\"EN-GB\">4.9\u00a0\u00a0\u00a0\u00a0 Overdose</span>", "ID": "3b58735e-9c55-4adb-9fbf-3939bbc5aa5f", "Styles": "None", "Classes": "None", "Text": "4.9\u00a0\u00a0\u00a0\u00a0 Overdose", "ParentId": "149f456d-2321-4308-9e87-fd9c5b5e2de2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "008c56b0-ef77-4a66-91eb-cf81fc2ad98c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "709fb4bd-5ff7-441a-8ec4-b54f9c7aaabf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "008c56b0-ef77-4a66-91eb-cf81fc2ad98c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">No case of overdose has been reported.</span></p>", "ID": "8c5b7055-7598-4117-8793-1df74645cd20", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">No case of overdose has been reported.</span>", "ID": "3051977e-f022-40a8-9078-e0c548f141c4", "Styles": "None", "Classes": "None", "Text": "No case of overdose has been reported.", "ParentId": "8c5b7055-7598-4117-8793-1df74645cd20"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "5b87c14f-f820-4951-844c-ce92cff69a49", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "93e13b60-d14e-46b2-8036-2a042208f826", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL PROPERTIES</span></b></p>", "ID": "e212e9c4-ae14-4760-9fd1-260f6ec1a225", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL PROPERTIES</span></b>", "ID": "2d04e139-1aeb-4efb-8758-febd644f7a70", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e212e9c4-ae14-4760-9fd1-260f6ec1a225"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL PROPERTIES</span>", "ID": "d6fb01e8-acfd-4b88-8206-e255ba6a1e99", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL PROPERTIES", "ParentId": "2d04e139-1aeb-4efb-8758-febd644f7a70"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "70ce104b-d146-4bcd-a96b-bb6734b58b11", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "14111c8d-b7b3-4901-9ddd-5e7150c42622", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "70ce104b-d146-4bcd-a96b-bb6734b58b11"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">5.1\u00a0\u00a0\u00a0\u00a0 Pharmacodynamic properties</span></b></p>", "ID": "c8f4c098-1862-47f1-a9a3-d90fac80a825", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">5.1\u00a0\u00a0\u00a0\u00a0 Pharmacodynamic properties</span></b>", "ID": "6552dd38-c038-4363-ac80-e5e983b57a6b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c8f4c098-1862-47f1-a9a3-d90fac80a825"}, {"Element": "<span lang=\"EN-GB\">5.1\u00a0\u00a0\u00a0\u00a0 Pharmacodynamic properties</span>", "ID": "5540ddd5-c929-49ab-b4b3-3a5cee045bb3", "Styles": "None", "Classes": "None", "Text": "5.1\u00a0\u00a0\u00a0\u00a0 Pharmacodynamic properties", "ParentId": "6552dd38-c038-4363-ac80-e5e983b57a6b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b8c2ff8a-3911-47df-b0da-8b4b2f7ba8ad", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "473d19fc-364b-4fb3-9e0f-59e0f795c8e0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b8c2ff8a-3911-47df-b0da-8b4b2f7ba8ad"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Pharmacotherapeutic\ngroup: antineoplasic agents, monoclonal antibodies, ATC code: L01XC10</span></p>", "ID": "fe4a2eea-6ec8-46f3-9f9a-895ad87134f2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Pharmacotherapeutic\ngroup: antineoplasic agents, monoclonal antibodies, ATC code: L01XC10</span>", "ID": "cdea8c75-3ff5-4485-8660-bbeb9dda74fa", "Styles": "None", "Classes": "None", "Text": "Pharmacotherapeutic group: antineoplasic agents, monoclonal antibodies, ATC code: L01XC10", "ParentId": "fe4a2eea-6ec8-46f3-9f9a-895ad87134f2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "70b27537-aed2-48e4-b88d-c53ae34090e9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f34117fc-c016-4396-add8-bba0f9ee8f2a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "70b27537-aed2-48e4-b88d-c53ae34090e9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"layout-grid-mode:\nline\">Mechanism of action</span></u></p>", "ID": "83736109-d39e-44fa-9689-3181941e6b6d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span style=\"layout-grid-mode:\nline\">Mechanism of action</span></u>", "ID": "9c08a750-138a-4e49-a509-1b1151b43847", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "83736109-d39e-44fa-9689-3181941e6b6d"}, {"Element": "<span style=\"layout-grid-mode:\nline\">Mechanism of action</span>", "ID": "3b851d6a-f9c3-4d1a-b20a-0416ed061db1", "Styles": "layout-grid-mode:\nline", "Classes": "None", "Text": "Mechanism of action", "ParentId": "9c08a750-138a-4e49-a509-1b1151b43847"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5313a256-1245-4a46-ba0b-5c46b5e226cb", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dcabf205-c7b2-44df-9416-2706c85ccec4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5313a256-1245-4a46-ba0b-5c46b5e226cb"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Ofatumumab is a human monoclonal antibody (IgG1) that binds\nspecifically to a distinct epitope encompassing both the small and large\nextracellular loops of the CD20 molecule</span><span lang=\"EN-GB\">. The CD20\nmolecule is a transmembrane phosphoprotein expressed on B lymphocytes from the\npre-B to mature B lymphocyte stage and on B-cell tumours. The B-cell tumours\ninclude CLL (generally associated with lower levels of CD20 expression) and\nnon-Hodgkin's lymphomas (where &gt;90% of tumours have high levels of CD20\nexpression). The CD20 molecule is not shed from the cell surface and is not\ninternalised following antibody binding.</span></p>", "ID": "c1bb2028-911a-40a5-921c-22a34311f49a", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Ofatumumab is a human monoclonal antibody (IgG1) that binds\nspecifically to a distinct epitope encompassing both the small and large\nextracellular loops of the CD20 molecule</span>", "ID": "25dc6954-648e-4d84-affe-ddf03977d6dd", "Styles": "color:black", "Classes": "None", "Text": "Ofatumumab is a human monoclonal antibody (IgG1) that binds specifically to a distinct epitope encompassing both the small and large extracellular loops of the CD20 molecule", "ParentId": "c1bb2028-911a-40a5-921c-22a34311f49a"}, {"Element": "<span lang=\"EN-GB\">. The CD20\nmolecule is a transmembrane phosphoprotein expressed on B lymphocytes from the\npre-B to mature B lymphocyte stage and on B-cell tumours. The B-cell tumours\ninclude CLL (generally associated with lower levels of CD20 expression) and\nnon-Hodgkin's lymphomas (where &gt;90% of tumours have high levels of CD20\nexpression). The CD20 molecule is not shed from the cell surface and is not\ninternalised following antibody binding.</span>", "ID": "82147e4b-c2e5-477d-8f74-17286c8ef65f", "Styles": "None", "Classes": "None", "Text": ". The CD20 molecule is a transmembrane phosphoprotein expressed on B lymphocytes from the pre-B to mature B lymphocyte stage and on B-cell tumours. The B-cell tumours include CLL (generally associated with lower levels of CD20 expression) and non-Hodgkin's lymphomas (where >90% of tumours have high levels of CD20 expression). The CD20 molecule is not shed from the cell surface and is not internalised following antibody binding.", "ParentId": "c1bb2028-911a-40a5-921c-22a34311f49a"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "68e073cd-ef5c-45a4-a2c5-bdee62c5c5d3", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d72a45d5-0db1-440b-9eb0-9ce65c1b7a5a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "68e073cd-ef5c-45a4-a2c5-bdee62c5c5d3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The binding of ofatumumab to the\nmembrane-proximal epitope of the CD20 molecule induces recruitment and\nactivation of the complement pathway at the cell surface, leading to\ncomplement-dependent cytotoxicity and resultant lysis of tumour cells.\nOfatumumab has been shown to induce appreciable lysis of cells with high\nexpression levels of complement defence molecules. Ofatumumab has also been\nshown to induce cell lysis in both high and low CD20 expressing cells and in\nrituximab-resistant cells. In addition, the binding of ofatumumab allows the\nrecruitment of natural killer cells allowing the induction of cell death\nthrough antibody-dependent cell-mediated cytotoxicity.</span></p>", "ID": "939bc6b2-af13-4ef0-b418-5877b8874f8a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">The binding of ofatumumab to the\nmembrane-proximal epitope of the CD20 molecule induces recruitment and\nactivation of the complement pathway at the cell surface, leading to\ncomplement-dependent cytotoxicity and resultant lysis of tumour cells.\nOfatumumab has been shown to induce appreciable lysis of cells with high\nexpression levels of complement defence molecules. Ofatumumab has also been\nshown to induce cell lysis in both high and low CD20 expressing cells and in\nrituximab-resistant cells. In addition, the binding of ofatumumab allows the\nrecruitment of natural killer cells allowing the induction of cell death\nthrough antibody-dependent cell-mediated cytotoxicity.</span>", "ID": "2895d1c6-527e-4e65-8d0a-d1b5572d3028", "Styles": "None", "Classes": "None", "Text": "The binding of ofatumumab to the membrane-proximal epitope of the CD20 molecule induces recruitment and activation of the complement pathway at the cell surface, leading to complement-dependent cytotoxicity and resultant lysis of tumour cells. Ofatumumab has been shown to induce appreciable lysis of cells with high expression levels of complement defence molecules. Ofatumumab has also been shown to induce cell lysis in both high and low CD20 expressing cells and in rituximab-resistant cells. In addition, the binding of ofatumumab allows the recruitment of natural killer cells allowing the induction of cell death through antibody-dependent cell-mediated cytotoxicity.", "ParentId": "939bc6b2-af13-4ef0-b418-5877b8874f8a"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b61f1610-ec62-4bfe-9549-543725d04032", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4ec34763-e8b5-4012-9ce4-b6af65d954be", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b61f1610-ec62-4bfe-9549-543725d04032"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"layout-grid-mode:\nline\">Pharmacodynamic effects</span></u></p>", "ID": "a62b0ebb-b6ea-4a4a-b3cd-e0e94d1a0985", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span style=\"layout-grid-mode:\nline\">Pharmacodynamic effects</span></u>", "ID": "7d614d70-0688-4be6-951f-8ff80eb83089", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a62b0ebb-b6ea-4a4a-b3cd-e0e94d1a0985"}, {"Element": "<span style=\"layout-grid-mode:\nline\">Pharmacodynamic effects</span>", "ID": "f3106896-e46c-4f61-b6d9-4ee7e3da6278", "Styles": "layout-grid-mode:\nline", "Classes": "None", "Text": "Pharmacodynamic effects", "ParentId": "7d614d70-0688-4be6-951f-8ff80eb83089"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "aca2df88-b095-4cbe-8bd5-1364934dd635", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "da232b80-6c86-43e4-bc77-ed923aeec73a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "aca2df88-b095-4cbe-8bd5-1364934dd635"}, {"Element": "<p class=\"MsoNormal\">Peripheral B-cell counts decreased after the first\nofatumumab infusion in patients with haematological malignancies. <span lang=\"EN-GB\">In all patients with CLL, ofatumumab induces rapid and profound\nB-cell depletion, whether given as a single agent or in combination.</span></p>", "ID": "2c9c8d27-757a-41dd-95f4-839bc644a445", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Peripheral B-cell counts decreased after the first ofatumumab infusion in patients with haematological malignancies. ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">In all patients with CLL, ofatumumab induces rapid and profound\nB-cell depletion, whether given as a single agent or in combination.</span>", "ID": "7729b3b2-72b8-43be-82ea-8ad5ab4cd4a6", "Styles": "None", "Classes": "None", "Text": "In all patients with CLL, ofatumumab induces rapid and profound B-cell depletion, whether given as a single agent or in combination.", "ParentId": "2c9c8d27-757a-41dd-95f4-839bc644a445"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "d2e73388-28b9-4e6c-9ffc-c788dcdc6665", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">When ofatumumab was administered as single\nagent i</span>n patients with refractory CLL, the median decrease in B-cell\ncounts was 22% after the first infusion and 92% at the eighth weekly infusion. <span lang=\"EN-GB\" style=\"color:black\">Peripheral B-cell counts remained low throughout\nthe remainder of therapy in most patients</span><span lang=\"EN-GB\" style=\"color:black\"> and remained below baseline up to 15\u00a0months after the\nlast dose in patients who responded</span><span lang=\"EN-GB\">.</span></p>", "ID": "018e3073-0cd2-432f-bb29-6d6782cf9769", "Styles": "None", "Classes": "['MsoNormal']", "Text": "n patients with refractory CLL, the median decrease in B-cell counts was 22% after the first infusion and 92% at the eighth weekly infusion. ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">When ofatumumab was administered as single\nagent i</span>", "ID": "aabcd217-f763-426c-9dc1-cf45683ee7e4", "Styles": "None", "Classes": "None", "Text": "When ofatumumab was administered as single agent i", "ParentId": "018e3073-0cd2-432f-bb29-6d6782cf9769"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Peripheral B-cell counts remained low throughout\nthe remainder of therapy in most patients</span>", "ID": "c3273975-8ceb-49c8-9ee5-cd1840cdf7d5", "Styles": "color:black", "Classes": "None", "Text": "Peripheral B-cell counts remained low throughout the remainder of therapy in most patients", "ParentId": "018e3073-0cd2-432f-bb29-6d6782cf9769"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\"> and remained below baseline up to 15\u00a0months after the\nlast dose in patients who responded</span>", "ID": "c92ea836-f092-4da6-9a77-2752491e918c", "Styles": "color:black", "Classes": "None", "Text": " and remained below baseline up to 15\u00a0months after the last dose in patients who responded", "ParentId": "018e3073-0cd2-432f-bb29-6d6782cf9769"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "750bbe51-614c-4165-9bd2-906e28383d21", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "018e3073-0cd2-432f-bb29-6d6782cf9769"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "746bb229-8cbc-42e5-b0ae-665003e70557", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3a1d709b-8ed4-4e5e-862e-0a3ee167542a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "746bb229-8cbc-42e5-b0ae-665003e70557"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">When ofatumumab was administered in\ncombination with chlorambucil in patients with previously untreated CLL, the\nmedian decreases in B-cell counts after the first cycle and prior to the sixth\nmonthly cycle were 94% and &gt;99%. At 6\u00a0months after the last dose, the\nmedian reductions in B-cell counts were &gt;99%</span><span lang=\"EN-GB\" style=\"color:black\">.</span></p>", "ID": "d2b6ee7d-5a79-4093-a421-b93e033b7e2b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">When ofatumumab was administered in\ncombination with chlorambucil in patients with previously untreated CLL, the\nmedian decreases in B-cell counts after the first cycle and prior to the sixth\nmonthly cycle were 94% and &gt;99%. At 6\u00a0months after the last dose, the\nmedian reductions in B-cell counts were &gt;99%</span>", "ID": "afffa29c-09a1-40d8-9210-0ab74b9e8955", "Styles": "None", "Classes": "None", "Text": "When ofatumumab was administered in combination with chlorambucil in patients with previously untreated CLL, the median decreases in B-cell counts after the first cycle and prior to the sixth monthly cycle were 94% and >99%. At 6\u00a0months after the last dose, the median reductions in B-cell counts were >99%", "ParentId": "d2b6ee7d-5a79-4093-a421-b93e033b7e2b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">.</span>", "ID": "f042a101-a537-479a-a9bb-f3f27dddd239", "Styles": "color:black", "Classes": "None", "Text": ".", "ParentId": "d2b6ee7d-5a79-4093-a421-b93e033b7e2b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "e9102a6c-a7ea-47bb-8c33-95e254cdc2c3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">When ofatumumab was administered in\ncombination with fludarabine and cyclophosphamide in patients with relapsed\nCLL, </span><span lang=\"EN-GB\">the median decreace from baseline was 60% after\nthe first infusion and complete depletion (100%) was reached after 4\u00a0cycles</span><span lang=\"EN-GB\">.</span></p>", "ID": "2dae264c-7824-4eb6-9a8c-26ed74fc4230", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">When ofatumumab was administered in\ncombination with fludarabine and cyclophosphamide in patients with relapsed\nCLL, </span>", "ID": "d542f7c5-050a-4680-94d3-a40fc47b9662", "Styles": "None", "Classes": "None", "Text": "When ofatumumab was administered in combination with fludarabine and cyclophosphamide in patients with relapsed CLL, ", "ParentId": "2dae264c-7824-4eb6-9a8c-26ed74fc4230"}, {"Element": "<span lang=\"EN-GB\">the median decreace from baseline was 60% after\nthe first infusion and complete depletion (100%) was reached after 4\u00a0cycles</span>", "ID": "7d6d5b5a-a3e8-4512-84a9-a3bfb6fd1161", "Styles": "None", "Classes": "None", "Text": "the median decreace from baseline was 60% after the first infusion and complete depletion (100%) was reached after 4\u00a0cycles", "ParentId": "2dae264c-7824-4eb6-9a8c-26ed74fc4230"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "53697e63-3c11-4630-b6b8-80f93fd9991f", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "2dae264c-7824-4eb6-9a8c-26ed74fc4230"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "2e61a8d5-0cc8-4ece-bf6a-8e7d60f8d342", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span style=\"layout-grid-mode:\nline\">Immunogenicity</span></u></i></p>", "ID": "4b8599fd-8f10-4d02-aea0-9fbe5d4631f3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><u><span style=\"layout-grid-mode:\nline\">Immunogenicity</span></u></i>", "ID": "413a55d3-2804-4799-af37-10b94dacb6d3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4b8599fd-8f10-4d02-aea0-9fbe5d4631f3"}, {"Element": "<u><span style=\"layout-grid-mode:\nline\">Immunogenicity</span></u>", "ID": "690889e6-107a-4d84-b029-5445e0d93256", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "413a55d3-2804-4799-af37-10b94dacb6d3"}, {"Element": "<span style=\"layout-grid-mode:\nline\">Immunogenicity</span>", "ID": "1b8ed07e-9626-4901-b7f6-40b2398f7c83", "Styles": "layout-grid-mode:\nline", "Classes": "None", "Text": "Immunogenicity", "ParentId": "690889e6-107a-4d84-b029-5445e0d93256"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">There is a potential for immunogenicity </span><span lang=\"EN-GB\">with therapeutic proteins such as ofatumumab.</span> Serum samples\nfrom more than 1,000\u00a0patients across the CLL clinical programme were\ntested for anti\u2011ofatumumab antibodies during and after treatment periods\nranging from 8\u00a0weeks to 2\u00a0years. <span lang=\"EN-GB\">Formation of anti\u2011ofatumumab\nantibodies was observed for less than 0.5% of patients with CLL after treatment\nwith </span><span lang=\"EN-GB\">ofatumumab</span><span lang=\"EN-GB\" style=\"color:black\">.</span></p>", "ID": "b156124d-dc59-496d-92e4-2f6fe7f2c811", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": " Serum samples from more than 1,000\u00a0patients across the CLL clinical programme were tested for anti\u2011ofatumumab antibodies during and after treatment periods ranging from 8\u00a0weeks to 2\u00a0years. ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">There is a potential for immunogenicity </span>", "ID": "816f6e4f-aafa-4302-84c0-42e3fe76fae8", "Styles": "color:black", "Classes": "None", "Text": "There is a potential for immunogenicity ", "ParentId": "b156124d-dc59-496d-92e4-2f6fe7f2c811"}, {"Element": "<span lang=\"EN-GB\">with therapeutic proteins such as ofatumumab.</span>", "ID": "4aa38a86-a1f1-48b5-9677-6553bf6fecc5", "Styles": "None", "Classes": "None", "Text": "with therapeutic proteins such as ofatumumab.", "ParentId": "b156124d-dc59-496d-92e4-2f6fe7f2c811"}, {"Element": "<span lang=\"EN-GB\">Formation of anti\u2011ofatumumab\nantibodies was observed for less than 0.5% of patients with CLL after treatment\nwith </span>", "ID": "414ee484-b31e-4f75-9a12-954f3507616d", "Styles": "None", "Classes": "None", "Text": "Formation of anti\u2011ofatumumab antibodies was observed for less than 0.5% of patients with CLL after treatment with ", "ParentId": "b156124d-dc59-496d-92e4-2f6fe7f2c811"}, {"Element": "<span lang=\"EN-GB\">ofatumumab</span>", "ID": "3c868d85-c692-4fc6-8980-044abfa85a6c", "Styles": "None", "Classes": "None", "Text": "ofatumumab", "ParentId": "b156124d-dc59-496d-92e4-2f6fe7f2c811"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">.</span>", "ID": "c3c29204-5aac-43c9-9599-341db04b8fee", "Styles": "color:black", "Classes": "None", "Text": ".", "ParentId": "b156124d-dc59-496d-92e4-2f6fe7f2c811"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "9f5bc3b8-a540-420e-acc4-55d6febe24f9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"layout-grid-mode:\nline\">Clinical </span></u><u><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">efficacy\nand safety</span></u></p>", "ID": "0a3710bf-9852-4491-ba86-781fe9fdd5a6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span style=\"layout-grid-mode:\nline\">Clinical </span></u>", "ID": "e0f8d6d0-9a9b-4f26-91d5-6ef244d2329b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0a3710bf-9852-4491-ba86-781fe9fdd5a6"}, {"Element": "<span style=\"layout-grid-mode:\nline\">Clinical </span>", "ID": "8f5d4c99-be49-4f9e-a6e4-0850ed6b9d72", "Styles": "layout-grid-mode:\nline", "Classes": "None", "Text": "Clinical ", "ParentId": "e0f8d6d0-9a9b-4f26-91d5-6ef244d2329b"}, {"Element": "<u><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">efficacy\nand safety</span></u>", "ID": "821d2bf5-fa01-4417-888c-e59dd50ae21e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0a3710bf-9852-4491-ba86-781fe9fdd5a6"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">efficacy\nand safety</span>", "ID": "4e98f021-c328-4742-b4ac-4786e3cb8ab4", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "efficacy and safety", "ParentId": "821d2bf5-fa01-4417-888c-e59dd50ae21e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><s><span style=\"text-decoration:\n none\">\u00a0</span></s></p>", "ID": "b16455ef-17b5-4609-9914-b2a0670b755e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<s><span style=\"text-decoration:\n none\">\u00a0</span></s>", "ID": "d1b6f9a3-1246-4e96-be70-409c6149f9c4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b16455ef-17b5-4609-9914-b2a0670b755e"}, {"Element": "<span style=\"text-decoration:\n none\">\u00a0</span>", "ID": "8d0a9335-d22a-4ed0-8322-6524a301a91e", "Styles": "text-decoration:\n none", "Classes": "None", "Text": "\u00a0", "ParentId": "d1b6f9a3-1246-4e96-be70-409c6149f9c4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u>Previously untreated\nCLL</u></i></p>", "ID": "662c35c5-437f-4853-a74a-21dd26dc2f83", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><u>Previously untreated\nCLL</u></i>", "ID": "3443b1a0-0130-4d07-af44-fd5542bd363b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "662c35c5-437f-4853-a74a-21dd26dc2f83"}, {"Element": "<u>Previously untreated\nCLL</u>", "ID": "86c75b6f-5847-41d2-882c-ffe210724195", "Styles": "None", "Classes": "None", "Text": "Previously untreated CLL", "ParentId": "3443b1a0-0130-4d07-af44-fd5542bd363b"}, {"Element": "<p class=\"MsoNormal\">Study OMB110911 (randomised,<span lang=\"EN-GB\"> open\u2011label,\nparallel-arm, multicentre)</span><span lang=\"EN-GB\"> </span>evaluated the\nefficacy of <span lang=\"EN-GB\">Arzerra </span>in combination with chlorambucil\ncompared with chlorambucil alone in 447\u00a0patients with previously untreated\nCLL<span lang=\"EN-GB\"> considered inappropriate for fludarabine-based treatment </span><span lang=\"EN-GB\">(e.g. due to advanced age or presence of co-morbidities), with\nactive disease and indicated for treatment</span>. <span lang=\"EN-GB\">Patients\nreceived either Arzerra as monthly intravenous infusions (cycle\u00a01:\n300\u00a0mg on day\u00a01 and 1000\u00a0mg on day\u00a08; subsequent cycles:\n1000\u00a0mg on day\u00a01 every </span><span lang=\"EN-GB\">28\u00a0days</span><span lang=\"EN-GB\">) in combination with chlorambucil (</span><span lang=\"EN-GB\">10\u00a0mg/m<sup>2</sup></span><span lang=\"EN-GB\" style=\"font-size:8.0pt\"> </span><span lang=\"EN-GB\">orally on\ndays\u00a01\u20117 every 28\u00a0days) or chlorambucil alone (10\u00a0mg/</span><span lang=\"EN-GB\">m<sup>2</sup></span><span lang=\"EN-GB\" style=\"font-size:8.0pt\"> </span><span lang=\"EN-GB\">orally on days\u00a01\u20117 every 28\u00a0days).</span> Patients\nreceived treatment for a minimum of 3\u00a0months until best response or up to\na maximum of 12\u00a0cycles. <span lang=\"EN-GB\">The median age was 69\u00a0years\n(range: 35 to 92\u00a0years), 27% patients were \u226575\u00a0years of age,\n63% were male and 89% were white. Median Cumulative Illness Rating Score for\nGeriatrics (CIRS-G) was 9 </span>and 31% of patients had a CIRS-G &gt;10.\nMedian creatinine clearance (CrCl), assessed with the use of the Cockroft-Gault\nformula, was 70\u00a0ml/min and 48% of patients had a CrCl of\n&lt;70\u00a0ml/min. Patients with an Eastern Cooperative Oncology Group (ECOG)\nperformance status of 0 to 2 were enrolled into the study and 91% had an ECOG\nperformance status of 0 or 1.<span style=\"font-size:10.0pt\"> </span><span lang=\"EN-GB\">Approximately 60% of patients received 3\u20116\u00a0cycles of\nArzerra and 32% received 7\u201112\u00a0cycles. </span>The <span lang=\"EN-GB\" style=\"border:none windowtext 1.0pt;padding:0in\">median number of cycles\ncompleted in patients was 6 (total Arzerra dose of 6300\u00a0mg).</span></p>", "ID": "5b066d08-d531-4c2c-b5ad-d0869f729d08", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Study OMB110911 (randomised,evaluated the efficacy of in combination with chlorambucil compared with chlorambucil alone in 447\u00a0patients with previously untreated CLL.  Patients received treatment for a minimum of 3\u00a0months until best response or up to a maximum of 12\u00a0cycles. and 31% of patients had a CIRS-G >10. Median creatinine clearance (CrCl), assessed with the use of the Cockroft-Gault formula, was 70\u00a0ml/min and 48% of patients had a CrCl of <70\u00a0ml/min. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 were enrolled into the study and 91% had an ECOG performance status of 0 or 1.The ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\"> open\u2011label,\nparallel-arm, multicentre)</span>", "ID": "16b8289a-392b-4dcd-96ec-d5a57df13301", "Styles": "None", "Classes": "None", "Text": " open\u2011label, parallel-arm, multicentre)", "ParentId": "5b066d08-d531-4c2c-b5ad-d0869f729d08"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "f786f093-1d3c-4a67-aa0b-1994afed4e0b", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "5b066d08-d531-4c2c-b5ad-d0869f729d08"}, {"Element": "<span lang=\"EN-GB\">Arzerra </span>", "ID": "23d1c42a-c709-4c00-8c8a-72ff7870e92e", "Styles": "None", "Classes": "None", "Text": "Arzerra ", "ParentId": "5b066d08-d531-4c2c-b5ad-d0869f729d08"}, {"Element": "<span lang=\"EN-GB\"> considered inappropriate for fludarabine-based treatment </span>", "ID": "44432a9b-4b20-41aa-9cb9-4723c95eee2f", "Styles": "None", "Classes": "None", "Text": " considered inappropriate for fludarabine-based treatment ", "ParentId": "5b066d08-d531-4c2c-b5ad-d0869f729d08"}, {"Element": "<span lang=\"EN-GB\">(e.g. due to advanced age or presence of co-morbidities), with\nactive disease and indicated for treatment</span>", "ID": "d5faca10-4063-4e82-8be6-b27ee4a793ca", "Styles": "None", "Classes": "None", "Text": "(e.g. due to advanced age or presence of co-morbidities), with active disease and indicated for treatment", "ParentId": "5b066d08-d531-4c2c-b5ad-d0869f729d08"}, {"Element": "<span lang=\"EN-GB\">Patients\nreceived either Arzerra as monthly intravenous infusions (cycle\u00a01:\n300\u00a0mg on day\u00a01 and 1000\u00a0mg on day\u00a08; subsequent cycles:\n1000\u00a0mg on day\u00a01 every </span>", "ID": "325e63ad-2a1d-4078-a922-0424dcdecd42", "Styles": "None", "Classes": "None", "Text": "Patients received either Arzerra as monthly intravenous infusions (cycle\u00a01: 300\u00a0mg on day\u00a01 and 1000\u00a0mg on day\u00a08; subsequent cycles: 1000\u00a0mg on day\u00a01 every ", "ParentId": "5b066d08-d531-4c2c-b5ad-d0869f729d08"}, {"Element": "<span lang=\"EN-GB\">28\u00a0days</span>", "ID": "88b48bbe-bdea-4c22-b60c-8b9a735bd8f7", "Styles": "None", "Classes": "None", "Text": "28\u00a0days", "ParentId": "5b066d08-d531-4c2c-b5ad-d0869f729d08"}, {"Element": "<span lang=\"EN-GB\">) in combination with chlorambucil (</span>", "ID": "383602df-b3e2-4a57-a760-a24d29c5d47e", "Styles": "None", "Classes": "None", "Text": ") in combination with chlorambucil (", "ParentId": "5b066d08-d531-4c2c-b5ad-d0869f729d08"}, {"Element": "<span lang=\"EN-GB\">10\u00a0mg/m<sup>2</sup></span>", "ID": "61773172-90ff-4d53-838a-a392e6fb523c", "Styles": "None", "Classes": "None", "Text": "10\u00a0mg/m", "ParentId": "5b066d08-d531-4c2c-b5ad-d0869f729d08"}, {"Element": "<sup>2</sup>", "ID": "333f5dda-eba2-44da-a65a-41089f1087e0", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "61773172-90ff-4d53-838a-a392e6fb523c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:8.0pt\"> </span>", "ID": "cabd4493-25dc-4e6d-8538-4e9a539bd3ff", "Styles": "font-size:8.0pt", "Classes": "None", "Text": " ", "ParentId": "5b066d08-d531-4c2c-b5ad-d0869f729d08"}, {"Element": "<span lang=\"EN-GB\">orally on\ndays\u00a01\u20117 every 28\u00a0days) or chlorambucil alone (10\u00a0mg/</span>", "ID": "8cc1dc2f-22e2-4f3a-b0b4-34979907a727", "Styles": "None", "Classes": "None", "Text": "orally on days\u00a01\u20117 every 28\u00a0days) or chlorambucil alone (10\u00a0mg/", "ParentId": "5b066d08-d531-4c2c-b5ad-d0869f729d08"}, {"Element": "<span lang=\"EN-GB\">m<sup>2</sup></span>", "ID": "4e5e9086-2322-407e-8e6b-9adb73a44afd", "Styles": "None", "Classes": "None", "Text": "m", "ParentId": "5b066d08-d531-4c2c-b5ad-d0869f729d08"}, {"Element": "<sup>2</sup>", "ID": "ae87efd8-5961-4792-a218-d8faa7e939eb", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "4e5e9086-2322-407e-8e6b-9adb73a44afd"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:8.0pt\"> </span>", "ID": "16558471-5de8-4e85-87bb-52b14e7612d3", "Styles": "font-size:8.0pt", "Classes": "None", "Text": " ", "ParentId": "5b066d08-d531-4c2c-b5ad-d0869f729d08"}, {"Element": "<span lang=\"EN-GB\">orally on days\u00a01\u20117 every 28\u00a0days).</span>", "ID": "0bc11563-7868-4184-8db7-46e72af8240a", "Styles": "None", "Classes": "None", "Text": "orally on days\u00a01\u20117 every 28\u00a0days).", "ParentId": "5b066d08-d531-4c2c-b5ad-d0869f729d08"}, {"Element": "<span lang=\"EN-GB\">The median age was 69\u00a0years\n(range: 35 to 92\u00a0years), 27% patients were \u226575\u00a0years of age,\n63% were male and 89% were white. Median Cumulative Illness Rating Score for\nGeriatrics (CIRS-G) was 9 </span>", "ID": "7605e35e-f98c-4bdf-aa71-cbbbf70e5d25", "Styles": "None", "Classes": "None", "Text": "The median age was 69\u00a0years (range: 35 to 92\u00a0years), 27% patients were \u226575\u00a0years of age, 63% were male and 89% were white. Median Cumulative Illness Rating Score for Geriatrics (CIRS-G) was 9 ", "ParentId": "5b066d08-d531-4c2c-b5ad-d0869f729d08"}, {"Element": "<span style=\"font-size:10.0pt\"> </span>", "ID": "354ff30e-c0cc-4fdb-a779-b8bd87fa9213", "Styles": "font-size:10.0pt", "Classes": "None", "Text": " ", "ParentId": "5b066d08-d531-4c2c-b5ad-d0869f729d08"}, {"Element": "<span lang=\"EN-GB\">Approximately 60% of patients received 3\u20116\u00a0cycles of\nArzerra and 32% received 7\u201112\u00a0cycles. </span>", "ID": "54f3043f-5297-4e12-bae7-4bde410df74b", "Styles": "None", "Classes": "None", "Text": "Approximately 60% of patients received 3\u20116\u00a0cycles of Arzerra and 32% received 7\u201112\u00a0cycles. ", "ParentId": "5b066d08-d531-4c2c-b5ad-d0869f729d08"}, {"Element": "<span lang=\"EN-GB\" style=\"border:none windowtext 1.0pt;padding:0in\">median number of cycles\ncompleted in patients was 6 (total Arzerra dose of 6300\u00a0mg).</span>", "ID": "55664e02-f2cb-4420-9cff-9a5d1022fbb4", "Styles": "border:none windowtext 1.0pt;padding:0in", "Classes": "None", "Text": "median number of cycles completed in patients was 6 (total Arzerra dose of 6300\u00a0mg).", "ParentId": "5b066d08-d531-4c2c-b5ad-d0869f729d08"}, {"Element": "<p class=\"MsoNormal\"><a name=\"IDX\"></a><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bcc11352-3910-4d97-9c57-44ac26dbdf76", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<a name=\"IDX\"></a>", "ID": "55cfcded-a88f-449e-805b-f78f0367e1f1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bcc11352-3910-4d97-9c57-44ac26dbdf76"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4a18e31a-388c-402b-8fe3-364bce838066", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bcc11352-3910-4d97-9c57-44ac26dbdf76"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The primary endpoint was median </span><span lang=\"EN-GB\">progression-free survival (PFS) as assessed by a blinded Independent\nReview Committee (IRC) using the International Workshop for Chronic Lymphocytic\nLeukaemia (IWCLL) updated National Cancer Institute-sponsored Working Group\n(NCI-WG) guidelines (2008).</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\"> </span><span lang=\"EN-GB\">The </span><span lang=\"EN-GB\">overall response rate (ORR) including\ncomplete response (CR) </span><span lang=\"EN-GB\">was also assessed by an </span>IRC<span lang=\"EN-GB\"> using the 2008 IWCLL guidelines.</span></p>", "ID": "7cd07bd8-b2bd-40a8-ae7d-d6357e1c4742", "Styles": "None", "Classes": "['MsoNormal']", "Text": "IRC", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">The primary endpoint was median </span>", "ID": "56b9a49f-4ec4-4a94-9069-6cb797cc57fb", "Styles": "None", "Classes": "None", "Text": "The primary endpoint was median ", "ParentId": "7cd07bd8-b2bd-40a8-ae7d-d6357e1c4742"}, {"Element": "<span lang=\"EN-GB\">progression-free survival (PFS) as assessed by a blinded Independent\nReview Committee (IRC) using the International Workshop for Chronic Lymphocytic\nLeukaemia (IWCLL) updated National Cancer Institute-sponsored Working Group\n(NCI-WG) guidelines (2008).</span>", "ID": "ff211c6b-b3c0-491e-bdc9-e41c66a1df7c", "Styles": "None", "Classes": "None", "Text": "progression-free survival (PFS) as assessed by a blinded Independent Review Committee (IRC) using the International Workshop for Chronic Lymphocytic Leukaemia (IWCLL) updated National Cancer Institute-sponsored Working Group (NCI-WG) guidelines (2008).", "ParentId": "7cd07bd8-b2bd-40a8-ae7d-d6357e1c4742"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt\"> </span>", "ID": "120a6e9e-d878-401c-b965-d86348474bec", "Styles": "font-size:9.0pt", "Classes": "None", "Text": " ", "ParentId": "7cd07bd8-b2bd-40a8-ae7d-d6357e1c4742"}, {"Element": "<span lang=\"EN-GB\">The </span>", "ID": "19e78187-b960-405d-96d7-b5d74d0f0479", "Styles": "None", "Classes": "None", "Text": "The ", "ParentId": "7cd07bd8-b2bd-40a8-ae7d-d6357e1c4742"}, {"Element": "<span lang=\"EN-GB\">overall response rate (ORR) including\ncomplete response (CR) </span>", "ID": "fc5bf779-3cf9-4c0c-8d31-6a63baa7ba4d", "Styles": "None", "Classes": "None", "Text": "overall response rate (ORR) including complete response (CR) ", "ParentId": "7cd07bd8-b2bd-40a8-ae7d-d6357e1c4742"}, {"Element": "<span lang=\"EN-GB\">was also assessed by an </span>", "ID": "1293dbbc-eb94-4054-b608-0b974930f5ac", "Styles": "None", "Classes": "None", "Text": "was also assessed by an ", "ParentId": "7cd07bd8-b2bd-40a8-ae7d-d6357e1c4742"}, {"Element": "<span lang=\"EN-GB\"> using the 2008 IWCLL guidelines.</span>", "ID": "b9a696d5-4b5e-431b-b8d5-bc0a77b342cc", "Styles": "None", "Classes": "None", "Text": " using the 2008 IWCLL guidelines.", "ParentId": "7cd07bd8-b2bd-40a8-ae7d-d6357e1c4742"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d9278134-8a34-4419-a5fe-52f2b7e3a8de", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "87852c76-05ef-4f81-9566-77ccca645d08", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d9278134-8a34-4419-a5fe-52f2b7e3a8de"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Arzerra in combination with chlorambucil\nshowed a statistically significant (71%) improvement in median PFS compared\nwith chlorambucil alone (HR: 0.57; 95% CI: 0.45, 0.72) (see Table\u00a01 and\nFigure\u00a01). PFS benefit with the addition of Arzerra was observed in all\npatients, including those with poor-risk biological features (such as 17p or\n11q deletion, unmutated IGHV, </span><span lang=\"EN-GB\">\u03b22M\n&gt;3500\u00a0\u03bcg/l, and ZAP-70 expression)</span><span lang=\"EN-GB\">.</span></p>", "ID": "1490411d-3ba1-45b6-8d32-0e5f04821fa1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Arzerra in combination with chlorambucil\nshowed a statistically significant (71%) improvement in median PFS compared\nwith chlorambucil alone (HR: 0.57; 95% CI: 0.45, 0.72) (see Table\u00a01 and\nFigure\u00a01). PFS benefit with the addition of Arzerra was observed in all\npatients, including those with poor-risk biological features (such as 17p or\n11q deletion, unmutated IGHV, </span>", "ID": "a5b44baf-7098-4456-8404-887cb1498ae4", "Styles": "None", "Classes": "None", "Text": "Arzerra in combination with chlorambucil showed a statistically significant (71%) improvement in median PFS compared with chlorambucil alone (HR: 0.57; 95% CI: 0.45, 0.72) (see Table\u00a01 and Figure\u00a01). PFS benefit with the addition of Arzerra was observed in all patients, including those with poor-risk biological features (such as 17p or 11q deletion, unmutated IGHV, ", "ParentId": "1490411d-3ba1-45b6-8d32-0e5f04821fa1"}, {"Element": "<span lang=\"EN-GB\">\u03b22M\n&gt;3500\u00a0\u03bcg/l, and ZAP-70 expression)</span>", "ID": "8692254e-4f06-40b5-9e10-5d66b1c75528", "Styles": "None", "Classes": "None", "Text": "\u03b22M >3500\u00a0\u03bcg/l, and ZAP-70 expression)", "ParentId": "1490411d-3ba1-45b6-8d32-0e5f04821fa1"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "7733e7c7-d76e-4580-91e7-628b01ad847c", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "1490411d-3ba1-45b6-8d32-0e5f04821fa1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bdc5c927-62ce-4be0-bba5-ab92bd117069", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b7f2372c-ba87-4e35-b7c3-d8be8170f2ae", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bdc5c927-62ce-4be0-bba5-ab92bd117069"}, {"Element": "<p class=\"MsoCaption\" style=\"margin-left:56.7pt;text-indent:-56.7pt;line-height:\nnormal\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Table\u00a01\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Summary\nof PFS with Arzerra in combination with chlorambucil compared with chlorambucil\nin previously untreated CLL</span></p>", "ID": "d26edd0c-c5ac-4e69-aa48-68b105bb1273", "Styles": "margin-left:56.7pt;text-indent:-56.7pt;line-height:\nnormal", "Classes": "['MsoCaption']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Table\u00a01\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Summary\nof PFS with Arzerra in combination with chlorambucil compared with chlorambucil\nin previously untreated CLL</span>", "ID": "df07437e-504c-41a7-8dcb-95854ed8e55f", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Table\u00a01\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Summary of PFS with Arzerra in combination with chlorambucil compared with chlorambucil in previously untreated CLL", "ParentId": "d26edd0c-c5ac-4e69-aa48-68b105bb1273"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "1b03f267-f243-4e9e-8b3a-d51394ac39c6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\">\n<tr style=\"page-break-inside:avoid;height:22.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:22.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span class=\"tabletextNS1\"><b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IRC-assessed\n  primary and subgroup analyses of PFS, months</span></b></span></p>\n</td>\n<td style=\"width:141.75pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:22.9pt\" valign=\"top\" width=\"189\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Chlorambucil</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">(N=226)</span></b></p>\n</td>\n<td style=\"width:113.4pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 0in 0in 0in;height:22.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Arzerra and chlorambucil</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>(N=221)</b></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Median,\n  all patients</span></p>\n</td>\n<td style=\"width:141.75pt;border:none;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt\" valign=\"top\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.1</span></p>\n</td>\n<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>22.4</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>95%\n  CI</span></p>\n</td>\n<td style=\"width:141.75pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt\" valign=\"top\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(10.6,\n  13.8)</span></p>\n</td>\n<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(19.0,\n  25.2)</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Hazard\n  ratio</span></p>\n<p class=\"tabletextNS\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>P value</span></p>\n</td>\n<td colspan=\"2\" style=\"width:255.15pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"340\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>0.57\n  (0.45, 0.72)</span></p>\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>p&lt;0.001</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Age\n  \u226575\u00a0years (n=119)</span></p>\n</td>\n<td style=\"width:141.75pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12.2</span></p>\n</td>\n<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.8</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>Co-morbidity\u00a00 or 1 (n=126)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>10.9</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.0</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>Co-morbidity\u00a02 or more\n  (n=321)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.3</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>21.9</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>ECOG\u00a00, 1 (n=411)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.3</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.0</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>ECOG\u00a02 (n=35)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>7.9</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>20.9</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>CIRS-G \u226410 (n=310)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.1</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>21.7</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>CIRS-G </span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>&gt;</span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>10 (n=137)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12.2</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.2</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>CrCl &lt;70\u00a0ml/min (n=214)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>10.9</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.1</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>CrCl \u226570\u00a0ml/min\n  (n=227)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>14.5</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>22.1</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>17p or 11q\n  deletion (n=90)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>7.9</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.6</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV mutated\n  (\u226498%) (n=177)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12.2</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>30.5</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV unmutated\n  (&gt;98%) (n=227)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.7\n  </span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>17.3</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u03b22M\n  \u22643500\u00a0\u03bcg/l (n=109)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.8</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>25.5</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u03b22M\n  &gt;3500\u00a0\u03bcg/l (n=322)</span></p>\n</td>\n<td style=\"width:141.75pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.6</span></p>\n</td>\n<td style=\"width:113.4pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 0in 0in 0in;height:13.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>19.6</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>ZAP-70 positive\n  (n=161)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>9.7</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>17.7</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>ZAP-70\n  intermediate (n=160)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.6</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>25.3</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>ZAP-70 negative\n  (n=100)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.8</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>25.6</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV mutated\n  &amp; ZAP-70 negative (n=60)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>10.5</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>NR</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV mutated\n  &amp; ZAP-70 positive (n=35)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>7.9</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>27.2</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV unmutated\n  &amp; ZAP-70 negative (n=27)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>16.7</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>16.2</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV unmutated\n  &amp; ZAP-70 positive (n=122)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.2</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>16.2</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td colspan=\"3\" style=\"width:437.75pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"584\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;background:white\"><span lang=\"EN-GB\" style=\"color:black\">Abbreviations: \u03b22M = beta-2-microglobulin,\n  CI = confidence interval; CIRS-G = Cumulative Illness Rating Scale for\n  Geriatrics, CLL = c</span><span style=\"color:black\">hronic lymphocytic leukaemia,\n  CrCl = creatinine clearance, ECOG = Eastern Cooperative Oncology Group, </span><span lang=\"EN-GB\" style=\"color:black\">IGHV = Immunoglobulin Heavy Chain Variable\n  Region, IRC = Independent Review Committee, N = number, NR = not reached, PFS\n  = progression-free survival, ZAP-70 = zeta-chain-associated protein kinase\n  70.</span></p>\n</td>\n</tr>\n</table>", "ID": "2aa72055-d462-4e48-baa5-2f186e01aa28", "Styles": "border-collapse:collapse", "Classes": "['MsoNormalTable']", "Text": "                           ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<tr style=\"page-break-inside:avoid;height:22.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:22.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span class=\"tabletextNS1\"><b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IRC-assessed\n  primary and subgroup analyses of PFS, months</span></b></span></p>\n</td>\n<td style=\"width:141.75pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:22.9pt\" valign=\"top\" width=\"189\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Chlorambucil</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">(N=226)</span></b></p>\n</td>\n<td style=\"width:113.4pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 0in 0in 0in;height:22.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Arzerra and chlorambucil</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>(N=221)</b></p>\n</td>\n</tr>", "ID": "b77ef93f-432e-4710-b5ce-abc7fbe6fcb9", "Styles": "page-break-inside:avoid;height:22.9pt", "Classes": "None", "Text": "    ", "ParentId": "2aa72055-d462-4e48-baa5-2f186e01aa28"}, {"Element": "<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:22.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span class=\"tabletextNS1\"><b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IRC-assessed\n  primary and subgroup analyses of PFS, months</span></b></span></p>\n</td>", "ID": "0b71c4d1-35f3-469a-946b-b053e5249846", "Styles": "width:182.6pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:22.9pt", "Classes": "None", "Text": "  ", "ParentId": "b77ef93f-432e-4710-b5ce-abc7fbe6fcb9"}, {"Element": "<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span class=\"tabletextNS1\"><b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IRC-assessed\n  primary and subgroup analyses of PFS, months</span></b></span></p>", "ID": "01c2accc-d9ad-4cc2-834f-7c612905a2c4", "Styles": "page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "0b71c4d1-35f3-469a-946b-b053e5249846"}, {"Element": "<span class=\"tabletextNS1\"><b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IRC-assessed\n  primary and subgroup analyses of PFS, months</span></b></span>", "ID": "62c6f175-b589-46cc-b9ae-a7c9c05921c6", "Styles": "None", "Classes": "['tabletextNS1']", "Text": "", "ParentId": "01c2accc-d9ad-4cc2-834f-7c612905a2c4"}, {"Element": "<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IRC-assessed\n  primary and subgroup analyses of PFS, months</span></b>", "ID": "0f83b654-df88-4a9f-8b8d-44cb4e06a931", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "62c6f175-b589-46cc-b9ae-a7c9c05921c6"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IRC-assessed\n  primary and subgroup analyses of PFS, months</span>", "ID": "07c087ed-d7de-400f-b3c2-0ca202a88850", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "IRC-assessed   primary and subgroup analyses of PFS, months", "ParentId": "0f83b654-df88-4a9f-8b8d-44cb4e06a931"}, {"Element": "<td style=\"width:141.75pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:22.9pt\" valign=\"top\" width=\"189\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Chlorambucil</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">(N=226)</span></b></p>\n</td>", "ID": "eaf11eb1-ce9b-4147-8739-030396c40f34", "Styles": "width:141.75pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:22.9pt", "Classes": "None", "Text": "    ", "ParentId": "b77ef93f-432e-4710-b5ce-abc7fbe6fcb9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Chlorambucil</b></p>", "ID": "e05388f0-98fa-420a-a197-00e87829dc17", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "eaf11eb1-ce9b-4147-8739-030396c40f34"}, {"Element": "<b>Chlorambucil</b>", "ID": "14c09865-1a16-47f8-a145-700505ebe08e", "Styles": "None", "Classes": "None", "Text": "Chlorambucil", "ParentId": "e05388f0-98fa-420a-a197-00e87829dc17"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "89e257ce-3c32-43a0-aa35-1ae37847785f", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "eaf11eb1-ce9b-4147-8739-030396c40f34"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "e34658e4-9533-4f8d-8aae-bc8100f4e9c2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "89e257ce-3c32-43a0-aa35-1ae37847785f"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f4d0ddf6-e282-4eb4-aa66-2c8759c8123b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e34658e4-9533-4f8d-8aae-bc8100f4e9c2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">(N=226)</span></b></p>", "ID": "e61ba2cd-3152-408b-bff1-4658780dc9ff", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "eaf11eb1-ce9b-4147-8739-030396c40f34"}, {"Element": "<b><span lang=\"EN-GB\">(N=226)</span></b>", "ID": "5b46baa5-f8f1-4bb1-925f-4c31d3b94ecd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e61ba2cd-3152-408b-bff1-4658780dc9ff"}, {"Element": "<span lang=\"EN-GB\">(N=226)</span>", "ID": "06659433-9df8-4b4c-881b-082efbb9265b", "Styles": "None", "Classes": "None", "Text": "(N=226)", "ParentId": "5b46baa5-f8f1-4bb1-925f-4c31d3b94ecd"}, {"Element": "<td style=\"width:113.4pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 0in 0in 0in;height:22.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Arzerra and chlorambucil</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>(N=221)</b></p>\n</td>", "ID": "fb9979c0-a4f7-4bf5-8e27-9756a87d97e5", "Styles": "width:113.4pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 0in 0in 0in;height:22.9pt", "Classes": "None", "Text": "   ", "ParentId": "b77ef93f-432e-4710-b5ce-abc7fbe6fcb9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Arzerra and chlorambucil</b></p>", "ID": "7d1f2c9d-b5be-4fb4-9889-f90b21ed2418", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fb9979c0-a4f7-4bf5-8e27-9756a87d97e5"}, {"Element": "<b>Arzerra and chlorambucil</b>", "ID": "6a93d3e7-1078-48bc-bd69-1e1e8931ecee", "Styles": "None", "Classes": "None", "Text": "Arzerra and chlorambucil", "ParentId": "7d1f2c9d-b5be-4fb4-9889-f90b21ed2418"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>(N=221)</b></p>", "ID": "79482987-a663-4902-b2e4-a33675167aae", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fb9979c0-a4f7-4bf5-8e27-9756a87d97e5"}, {"Element": "<b>(N=221)</b>", "ID": "1e2fdecd-d157-4ecc-8bfb-aae3fbc4344d", "Styles": "None", "Classes": "None", "Text": "(N=221)", "ParentId": "79482987-a663-4902-b2e4-a33675167aae"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Median,\n  all patients</span></p>\n</td>\n<td style=\"width:141.75pt;border:none;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt\" valign=\"top\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.1</span></p>\n</td>\n<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>22.4</span></p>\n</td>\n</tr>", "ID": "07eb8557-d725-4e29-8a80-5235a34bf911", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "2aa72055-d462-4e48-baa5-2f186e01aa28"}, {"Element": "<td style=\"width:182.6pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Median,\n  all patients</span></p>\n</td>", "ID": "aea9e3ca-7984-426f-bee2-cf2b4389937f", "Styles": "width:182.6pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "07eb8557-d725-4e29-8a80-5235a34bf911"}, {"Element": "<p class=\"tabletextNS\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Median,\n  all patients</span></p>", "ID": "e35deb45-3b5e-4b48-9d3b-34581eb7ef0e", "Styles": "margin-left:9.0pt;page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "aea9e3ca-7984-426f-bee2-cf2b4389937f"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Median,\n  all patients</span>", "ID": "8eefe8fe-e709-4aa4-81ab-12c796344670", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Median,   all patients", "ParentId": "e35deb45-3b5e-4b48-9d3b-34581eb7ef0e"}, {"Element": "<td style=\"width:141.75pt;border:none;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt\" valign=\"top\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.1</span></p>\n</td>", "ID": "e60e3799-2913-4f42-859f-f6fa22f46120", "Styles": "width:141.75pt;border:none;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "07eb8557-d725-4e29-8a80-5235a34bf911"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.1</span></p>", "ID": "f2429844-72d9-47c2-bf5d-0c2528c5db9e", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "e60e3799-2913-4f42-859f-f6fa22f46120"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.1</span>", "ID": "dc2842c9-d5a2-41a7-b41a-9abf733fde87", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "13.1", "ParentId": "f2429844-72d9-47c2-bf5d-0c2528c5db9e"}, {"Element": "<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>22.4</span></p>\n</td>", "ID": "86f0e869-8fbf-449d-b97d-87df6392b60b", "Styles": "width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "07eb8557-d725-4e29-8a80-5235a34bf911"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>22.4</span></p>", "ID": "778155b5-d46f-426e-9d21-f68ab3691583", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "86f0e869-8fbf-449d-b97d-87df6392b60b"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>22.4</span>", "ID": "b2ca0201-72b6-43fa-b25d-e167c33097f2", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "22.4", "ParentId": "778155b5-d46f-426e-9d21-f68ab3691583"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>95%\n  CI</span></p>\n</td>\n<td style=\"width:141.75pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt\" valign=\"top\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(10.6,\n  13.8)</span></p>\n</td>\n<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(19.0,\n  25.2)</span></p>\n</td>\n</tr>", "ID": "96634fcc-490d-4853-b386-98e9fc7ee27e", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "2aa72055-d462-4e48-baa5-2f186e01aa28"}, {"Element": "<td style=\"width:182.6pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>95%\n  CI</span></p>\n</td>", "ID": "7008dfb1-0c6a-418b-902a-d42bf11d4706", "Styles": "width:182.6pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "96634fcc-490d-4853-b386-98e9fc7ee27e"}, {"Element": "<p class=\"tabletextNS\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>95%\n  CI</span></p>", "ID": "5458a9f2-b931-4063-bdc4-cdaf35d9dfb6", "Styles": "margin-left:9.0pt;page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "7008dfb1-0c6a-418b-902a-d42bf11d4706"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>95%\n  CI</span>", "ID": "1ea46173-4bac-4326-8397-b544fbcec407", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "95%   CI", "ParentId": "5458a9f2-b931-4063-bdc4-cdaf35d9dfb6"}, {"Element": "<td style=\"width:141.75pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt\" valign=\"top\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(10.6,\n  13.8)</span></p>\n</td>", "ID": "8e1864dc-e4da-427f-9fda-5ddd32c05a28", "Styles": "width:141.75pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "96634fcc-490d-4853-b386-98e9fc7ee27e"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(10.6,\n  13.8)</span></p>", "ID": "78c7dcb0-93e8-4f66-b892-8f23f725c8ed", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "8e1864dc-e4da-427f-9fda-5ddd32c05a28"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(10.6,\n  13.8)</span>", "ID": "f5d04190-8b1f-4139-b6b3-bc9a43a434c0", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "(10.6,   13.8)", "ParentId": "78c7dcb0-93e8-4f66-b892-8f23f725c8ed"}, {"Element": "<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(19.0,\n  25.2)</span></p>\n</td>", "ID": "669fe63e-8824-4a5a-a494-b90a099b1cdc", "Styles": "width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "96634fcc-490d-4853-b386-98e9fc7ee27e"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(19.0,\n  25.2)</span></p>", "ID": "aec59add-cc06-456e-a150-3e9936bb0cd7", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "669fe63e-8824-4a5a-a494-b90a099b1cdc"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(19.0,\n  25.2)</span>", "ID": "07b5786d-1cf3-45ec-8001-1659527710d4", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "(19.0,   25.2)", "ParentId": "aec59add-cc06-456e-a150-3e9936bb0cd7"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Hazard\n  ratio</span></p>\n<p class=\"tabletextNS\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>P value</span></p>\n</td>\n<td colspan=\"2\" style=\"width:255.15pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"340\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>0.57\n  (0.45, 0.72)</span></p>\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>p&lt;0.001</span></p>\n</td>\n</tr>", "ID": "82d6d913-06eb-4698-8d7e-21f72abd355b", "Styles": "height:13.9pt", "Classes": "None", "Text": "   ", "ParentId": "2aa72055-d462-4e48-baa5-2f186e01aa28"}, {"Element": "<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Hazard\n  ratio</span></p>\n<p class=\"tabletextNS\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>P value</span></p>\n</td>", "ID": "8304fc7e-ca69-4b90-83f9-bd15132d78dd", "Styles": "width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "   ", "ParentId": "82d6d913-06eb-4698-8d7e-21f72abd355b"}, {"Element": "<p class=\"tabletextNS\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Hazard\n  ratio</span></p>", "ID": "343d4966-6954-4e4b-ae87-e5c512a75166", "Styles": "margin-left:9.0pt;page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "8304fc7e-ca69-4b90-83f9-bd15132d78dd"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Hazard\n  ratio</span>", "ID": "5d042452-91a1-48ae-8d37-3f809979bc92", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Hazard   ratio", "ParentId": "343d4966-6954-4e4b-ae87-e5c512a75166"}, {"Element": "<p class=\"tabletextNS\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>P value</span></p>", "ID": "db77d366-b2cc-40f8-9f68-9aeb6b61b4da", "Styles": "margin-left:9.0pt;page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "8304fc7e-ca69-4b90-83f9-bd15132d78dd"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>P value</span>", "ID": "379d6b6b-e0f3-4872-a1e4-3f3a8bef7446", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "P value", "ParentId": "db77d366-b2cc-40f8-9f68-9aeb6b61b4da"}, {"Element": "<td colspan=\"2\" style=\"width:255.15pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"340\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>0.57\n  (0.45, 0.72)</span></p>\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>p&lt;0.001</span></p>\n</td>", "ID": "063f7722-af8b-4644-b4c0-e5f6d1ef9190", "Styles": "width:255.15pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "   ", "ParentId": "82d6d913-06eb-4698-8d7e-21f72abd355b"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>0.57\n  (0.45, 0.72)</span></p>", "ID": "dfad5e9c-81ab-4588-a9b7-7ebed5e9d7c2", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "063f7722-af8b-4644-b4c0-e5f6d1ef9190"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>0.57\n  (0.45, 0.72)</span>", "ID": "4678c269-2ef7-4add-aaab-13481aacc2a2", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "0.57   (0.45, 0.72)", "ParentId": "dfad5e9c-81ab-4588-a9b7-7ebed5e9d7c2"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>p&lt;0.001</span></p>", "ID": "fd5530b6-5e1d-4467-bc97-56db368b2e2e", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "063f7722-af8b-4644-b4c0-e5f6d1ef9190"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>p&lt;0.001</span>", "ID": "b3c53b27-6a66-4ee8-90e4-e6305dd13481", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "p<0.001", "ParentId": "fd5530b6-5e1d-4467-bc97-56db368b2e2e"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Age\n  \u226575\u00a0years (n=119)</span></p>\n</td>\n<td style=\"width:141.75pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12.2</span></p>\n</td>\n<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.8</span></p>\n</td>\n</tr>", "ID": "e6677c62-6509-4aa7-991a-01e2e480829b", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "2aa72055-d462-4e48-baa5-2f186e01aa28"}, {"Element": "<td style=\"width:182.6pt;border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Age\n  \u226575\u00a0years (n=119)</span></p>\n</td>", "ID": "5f731fe9-b1b3-40ff-adc3-54bfd6f15333", "Styles": "width:182.6pt;border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "e6677c62-6509-4aa7-991a-01e2e480829b"}, {"Element": "<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Age\n  \u226575\u00a0years (n=119)</span></p>", "ID": "34159d39-8978-4ae8-87b6-7b79b911e013", "Styles": "page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "5f731fe9-b1b3-40ff-adc3-54bfd6f15333"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Age\n  \u226575\u00a0years (n=119)</span>", "ID": "1f98e504-86ca-44a8-856c-863359b8a0e8", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Age   \u226575\u00a0years (n=119)", "ParentId": "34159d39-8978-4ae8-87b6-7b79b911e013"}, {"Element": "<td style=\"width:141.75pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12.2</span></p>\n</td>", "ID": "9ce14c4c-0334-4f21-b869-a321cfc47825", "Styles": "width:141.75pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "e6677c62-6509-4aa7-991a-01e2e480829b"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12.2</span></p>", "ID": "db75a5d2-1b17-4c93-876d-175878815afe", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "9ce14c4c-0334-4f21-b869-a321cfc47825"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12.2</span>", "ID": "ec6c5dbb-9410-44cb-b743-318bc62318c4", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "12.2", "ParentId": "db75a5d2-1b17-4c93-876d-175878815afe"}, {"Element": "<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.8</span></p>\n</td>", "ID": "a14e7632-b2c7-44b9-990f-005d45cf7f17", "Styles": "width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "e6677c62-6509-4aa7-991a-01e2e480829b"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.8</span></p>", "ID": "63f5f1a3-bb92-44a7-b38b-669219277977", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "a14e7632-b2c7-44b9-990f-005d45cf7f17"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.8</span>", "ID": "fe01e1d8-ead7-41e3-83fc-f50f20aaa4ad", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "23.8", "ParentId": "63f5f1a3-bb92-44a7-b38b-669219277977"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>Co-morbidity\u00a00 or 1 (n=126)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>10.9</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.0</span></p>\n</td>\n</tr>", "ID": "6e7ce3be-4356-410d-96d5-4f9028ee4843", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "2aa72055-d462-4e48-baa5-2f186e01aa28"}, {"Element": "<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>Co-morbidity\u00a00 or 1 (n=126)</span></p>\n</td>", "ID": "a495414d-7218-4ea7-af9f-bdd7adc986ca", "Styles": "width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "6e7ce3be-4356-410d-96d5-4f9028ee4843"}, {"Element": "<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>Co-morbidity\u00a00 or 1 (n=126)</span></p>", "ID": "50e7b6e7-5180-47ed-9acd-929f6bac2fa3", "Styles": "page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "a495414d-7218-4ea7-af9f-bdd7adc986ca"}, {"Element": "<span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>Co-morbidity\u00a00 or 1 (n=126)</span>", "ID": "24f89b1a-cc20-40e5-beb6-e97b5729c627", "Styles": "font-size:\n  11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Co-morbidity\u00a00 or 1 (n=126)", "ParentId": "50e7b6e7-5180-47ed-9acd-929f6bac2fa3"}, {"Element": "<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>10.9</span></p>\n</td>", "ID": "f29f8b62-b4fe-4f03-a6be-c66d9a501857", "Styles": "width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "6e7ce3be-4356-410d-96d5-4f9028ee4843"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>10.9</span></p>", "ID": "0eda5b23-84c3-444e-a809-6bb172f91bf0", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "f29f8b62-b4fe-4f03-a6be-c66d9a501857"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>10.9</span>", "ID": "6139b023-baf8-45c4-aab7-39b0757012a8", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "10.9", "ParentId": "0eda5b23-84c3-444e-a809-6bb172f91bf0"}, {"Element": "<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.0</span></p>\n</td>", "ID": "7948b19d-3ff2-4c09-80a3-542c435bf89a", "Styles": "width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "6e7ce3be-4356-410d-96d5-4f9028ee4843"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.0</span></p>", "ID": "76f79c46-5775-445f-97c0-4c6c338eb542", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "7948b19d-3ff2-4c09-80a3-542c435bf89a"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.0</span>", "ID": "0295f4b0-dfd6-40d9-98d5-a373b570c582", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "23.0", "ParentId": "76f79c46-5775-445f-97c0-4c6c338eb542"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>Co-morbidity\u00a02 or more\n  (n=321)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.3</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>21.9</span></p>\n</td>\n</tr>", "ID": "444b91cf-126a-41b6-ad93-c77b15d0d9c6", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "2aa72055-d462-4e48-baa5-2f186e01aa28"}, {"Element": "<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>Co-morbidity\u00a02 or more\n  (n=321)</span></p>\n</td>", "ID": "c98ee869-44f3-44e0-8012-1d18747cfa67", "Styles": "width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "444b91cf-126a-41b6-ad93-c77b15d0d9c6"}, {"Element": "<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>Co-morbidity\u00a02 or more\n  (n=321)</span></p>", "ID": "6b7bc3f1-e19d-4bf5-8edd-e9312a346244", "Styles": "page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "c98ee869-44f3-44e0-8012-1d18747cfa67"}, {"Element": "<span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>Co-morbidity\u00a02 or more\n  (n=321)</span>", "ID": "2375d24a-6780-476f-9797-94a0d820ef35", "Styles": "font-size:\n  11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Co-morbidity\u00a02 or more   (n=321)", "ParentId": "6b7bc3f1-e19d-4bf5-8edd-e9312a346244"}, {"Element": "<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.3</span></p>\n</td>", "ID": "05c1b650-30fa-4534-9716-7575bf0b4dcd", "Styles": "width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "444b91cf-126a-41b6-ad93-c77b15d0d9c6"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.3</span></p>", "ID": "595a72d9-821b-4f90-b095-4d8bb21e0474", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "05c1b650-30fa-4534-9716-7575bf0b4dcd"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.3</span>", "ID": "316160c6-dedd-4d0a-bff2-c071eaeab088", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "13.3", "ParentId": "595a72d9-821b-4f90-b095-4d8bb21e0474"}, {"Element": "<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>21.9</span></p>\n</td>", "ID": "15ea8596-096d-4c2e-82e4-328a7cfaf377", "Styles": "width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "444b91cf-126a-41b6-ad93-c77b15d0d9c6"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>21.9</span></p>", "ID": "7beb3b2a-a7f2-40fb-bd39-c961f4a082b4", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "15ea8596-096d-4c2e-82e4-328a7cfaf377"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>21.9</span>", "ID": "988e506d-617d-4bda-bfbc-ed9a81d3536c", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "21.9", "ParentId": "7beb3b2a-a7f2-40fb-bd39-c961f4a082b4"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>ECOG\u00a00, 1 (n=411)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.3</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.0</span></p>\n</td>\n</tr>", "ID": "242d5455-b8c5-41fe-9ac0-30307ee8e1ad", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "2aa72055-d462-4e48-baa5-2f186e01aa28"}, {"Element": "<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>ECOG\u00a00, 1 (n=411)</span></p>\n</td>", "ID": "91f338eb-424a-4415-9723-083e241dbe29", "Styles": "width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "242d5455-b8c5-41fe-9ac0-30307ee8e1ad"}, {"Element": "<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>ECOG\u00a00, 1 (n=411)</span></p>", "ID": "68a67415-fbf3-4463-b324-2047a8861708", "Styles": "page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "91f338eb-424a-4415-9723-083e241dbe29"}, {"Element": "<span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>ECOG\u00a00, 1 (n=411)</span>", "ID": "85a7d150-48d8-4b4d-83a5-e0e08fff4da7", "Styles": "font-size:\n  11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "ECOG\u00a00, 1 (n=411)", "ParentId": "68a67415-fbf3-4463-b324-2047a8861708"}, {"Element": "<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.3</span></p>\n</td>", "ID": "230c013e-5cb4-46ab-898f-bbd1d3f530f2", "Styles": "width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "242d5455-b8c5-41fe-9ac0-30307ee8e1ad"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.3</span></p>", "ID": "902f117a-43ba-485e-8c23-984b898fa500", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "230c013e-5cb4-46ab-898f-bbd1d3f530f2"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.3</span>", "ID": "eaba9c01-7e49-4716-a0b4-494e8b2c8e64", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "13.3", "ParentId": "902f117a-43ba-485e-8c23-984b898fa500"}, {"Element": "<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.0</span></p>\n</td>", "ID": "7df32891-b240-4adb-8419-9e7ed281db95", "Styles": "width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "242d5455-b8c5-41fe-9ac0-30307ee8e1ad"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.0</span></p>", "ID": "3bae4dfc-18a1-4a8d-80a1-0a4542fa5d31", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "7df32891-b240-4adb-8419-9e7ed281db95"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.0</span>", "ID": "e9f1ee05-b7e1-40f2-8a59-da0a42f7cbd5", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "23.0", "ParentId": "3bae4dfc-18a1-4a8d-80a1-0a4542fa5d31"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>ECOG\u00a02 (n=35)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>7.9</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>20.9</span></p>\n</td>\n</tr>", "ID": "c7b2902f-3299-4903-b6fc-ed342bf5a683", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "2aa72055-d462-4e48-baa5-2f186e01aa28"}, {"Element": "<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>ECOG\u00a02 (n=35)</span></p>\n</td>", "ID": "7dd14a16-d82d-4e18-b9c9-222498dccf4f", "Styles": "width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "c7b2902f-3299-4903-b6fc-ed342bf5a683"}, {"Element": "<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>ECOG\u00a02 (n=35)</span></p>", "ID": "a5ce20f5-4b0b-4cfd-a1b2-8ad9ab459ac8", "Styles": "page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "7dd14a16-d82d-4e18-b9c9-222498dccf4f"}, {"Element": "<span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>ECOG\u00a02 (n=35)</span>", "ID": "708d58fc-2f34-4dff-9731-264976bf721e", "Styles": "font-size:\n  11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "ECOG\u00a02 (n=35)", "ParentId": "a5ce20f5-4b0b-4cfd-a1b2-8ad9ab459ac8"}, {"Element": "<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>7.9</span></p>\n</td>", "ID": "d1bdf247-ba12-46f7-92c6-bed08c66947f", "Styles": "width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "c7b2902f-3299-4903-b6fc-ed342bf5a683"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>7.9</span></p>", "ID": "439542e2-2e4e-4623-996a-574aea6dad5a", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "d1bdf247-ba12-46f7-92c6-bed08c66947f"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>7.9</span>", "ID": "79945c08-db6a-4122-a427-40a149daaa27", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "7.9", "ParentId": "439542e2-2e4e-4623-996a-574aea6dad5a"}, {"Element": "<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>20.9</span></p>\n</td>", "ID": "a00db201-556d-4791-b057-1d0d30da5873", "Styles": "width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "c7b2902f-3299-4903-b6fc-ed342bf5a683"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>20.9</span></p>", "ID": "69f86378-d481-415b-94fe-d38817d15859", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "a00db201-556d-4791-b057-1d0d30da5873"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>20.9</span>", "ID": "64f55ca6-9b70-407d-884e-bb7b206ce9d2", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "20.9", "ParentId": "69f86378-d481-415b-94fe-d38817d15859"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>CIRS-G \u226410 (n=310)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.1</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>21.7</span></p>\n</td>\n</tr>", "ID": "2701d709-5ff5-4241-a851-e74d49447d9f", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "2aa72055-d462-4e48-baa5-2f186e01aa28"}, {"Element": "<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>CIRS-G \u226410 (n=310)</span></p>\n</td>", "ID": "2d7c00bf-b61a-4181-b1de-53a7c398ab8b", "Styles": "width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "2701d709-5ff5-4241-a851-e74d49447d9f"}, {"Element": "<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>CIRS-G \u226410 (n=310)</span></p>", "ID": "c7f41175-9099-4df3-aa85-1a55a85a9067", "Styles": "page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "2d7c00bf-b61a-4181-b1de-53a7c398ab8b"}, {"Element": "<span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>CIRS-G \u226410 (n=310)</span>", "ID": "1c773372-92ef-40a4-ad64-9245d9a8a2bd", "Styles": "font-size:\n  11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "CIRS-G \u226410 (n=310)", "ParentId": "c7f41175-9099-4df3-aa85-1a55a85a9067"}, {"Element": "<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.1</span></p>\n</td>", "ID": "16cfcf58-c4d1-4608-b25b-1c4f59366146", "Styles": "width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "2701d709-5ff5-4241-a851-e74d49447d9f"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.1</span></p>", "ID": "44712412-be33-4321-ba40-e47db8e2d842", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "16cfcf58-c4d1-4608-b25b-1c4f59366146"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.1</span>", "ID": "9fc7026f-76c4-4d24-a3fb-47f704cd39a8", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "13.1", "ParentId": "44712412-be33-4321-ba40-e47db8e2d842"}, {"Element": "<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>21.7</span></p>\n</td>", "ID": "74ea76a2-3834-4a0b-a191-ff03cc8346fb", "Styles": "width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "2701d709-5ff5-4241-a851-e74d49447d9f"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>21.7</span></p>", "ID": "bda4fc69-2a41-41b8-bf9f-ff259bee01c5", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "74ea76a2-3834-4a0b-a191-ff03cc8346fb"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>21.7</span>", "ID": "87452d85-4084-430f-8b93-cb1d202c46cb", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "21.7", "ParentId": "bda4fc69-2a41-41b8-bf9f-ff259bee01c5"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>CIRS-G </span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>&gt;</span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>10 (n=137)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12.2</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.2</span></p>\n</td>\n</tr>", "ID": "2e4b0c9d-0e7f-435d-8ac6-2bdb268266cf", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "2aa72055-d462-4e48-baa5-2f186e01aa28"}, {"Element": "<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>CIRS-G </span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>&gt;</span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>10 (n=137)</span></p>\n</td>", "ID": "25946773-5785-45e3-9913-4688c5054995", "Styles": "width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "2e4b0c9d-0e7f-435d-8ac6-2bdb268266cf"}, {"Element": "<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>CIRS-G </span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>&gt;</span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>10 (n=137)</span></p>", "ID": "306dd86b-c41a-4043-9499-41535d3d728d", "Styles": "page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "25946773-5785-45e3-9913-4688c5054995"}, {"Element": "<span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>CIRS-G </span>", "ID": "d897a22a-a1f0-4841-b8f6-7266b2d32584", "Styles": "font-size:\n  11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "CIRS-G ", "ParentId": "306dd86b-c41a-4043-9499-41535d3d728d"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>&gt;</span>", "ID": "5ce8c96d-29a6-4b94-9e1b-1fa319083861", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": ">", "ParentId": "306dd86b-c41a-4043-9499-41535d3d728d"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>10 (n=137)</span>", "ID": "d21bf951-8b09-4168-a2de-296e8b81a289", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "10 (n=137)", "ParentId": "306dd86b-c41a-4043-9499-41535d3d728d"}, {"Element": "<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12.2</span></p>\n</td>", "ID": "b3e7f7ef-11f3-4740-b11a-26c012f36ab5", "Styles": "width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "2e4b0c9d-0e7f-435d-8ac6-2bdb268266cf"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12.2</span></p>", "ID": "dbb0ffdc-47cc-4aaa-a55f-a2ba916de62d", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "b3e7f7ef-11f3-4740-b11a-26c012f36ab5"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12.2</span>", "ID": "eea3cd77-a7f7-4eea-8eb3-3a928d65bea3", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "12.2", "ParentId": "dbb0ffdc-47cc-4aaa-a55f-a2ba916de62d"}, {"Element": "<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.2</span></p>\n</td>", "ID": "b893c949-a548-49f9-8bc1-77ce59488291", "Styles": "width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "2e4b0c9d-0e7f-435d-8ac6-2bdb268266cf"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.2</span></p>", "ID": "a4cc0af5-faf6-48e9-8c58-a600bbe630e0", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "b893c949-a548-49f9-8bc1-77ce59488291"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.2</span>", "ID": "9632a3b4-0ad3-44a2-b7ca-a40deaee3d2a", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "23.2", "ParentId": "a4cc0af5-faf6-48e9-8c58-a600bbe630e0"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>CrCl &lt;70\u00a0ml/min (n=214)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>10.9</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.1</span></p>\n</td>\n</tr>", "ID": "e07155ee-a9c7-41b1-93f0-00b4c4a928ca", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "2aa72055-d462-4e48-baa5-2f186e01aa28"}, {"Element": "<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>CrCl &lt;70\u00a0ml/min (n=214)</span></p>\n</td>", "ID": "1b0d2dd4-cba6-444e-88ae-2c7ddc108ac6", "Styles": "width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "e07155ee-a9c7-41b1-93f0-00b4c4a928ca"}, {"Element": "<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>CrCl &lt;70\u00a0ml/min (n=214)</span></p>", "ID": "6e5f1114-fab7-467d-8bd5-d188af52e911", "Styles": "page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "1b0d2dd4-cba6-444e-88ae-2c7ddc108ac6"}, {"Element": "<span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>CrCl &lt;70\u00a0ml/min (n=214)</span>", "ID": "0eb5fccc-47d8-4a15-b371-01053ca005d3", "Styles": "font-size:\n  11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "CrCl <70\u00a0ml/min (n=214)", "ParentId": "6e5f1114-fab7-467d-8bd5-d188af52e911"}, {"Element": "<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>10.9</span></p>\n</td>", "ID": "2d970a3a-81d8-4d31-9a31-35835db62f9a", "Styles": "width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "e07155ee-a9c7-41b1-93f0-00b4c4a928ca"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>10.9</span></p>", "ID": "8a964da1-bcdc-4ec4-8152-fac1ee8ff4ff", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "2d970a3a-81d8-4d31-9a31-35835db62f9a"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>10.9</span>", "ID": "2d8ac8ac-f9b9-4794-8be4-8b423111f6fd", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "10.9", "ParentId": "8a964da1-bcdc-4ec4-8152-fac1ee8ff4ff"}, {"Element": "<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.1</span></p>\n</td>", "ID": "2862ea43-0da8-46b8-aeb5-72fa002fbedc", "Styles": "width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "e07155ee-a9c7-41b1-93f0-00b4c4a928ca"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.1</span></p>", "ID": "7eb952ee-0314-4554-b455-fac25eeb71b7", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "2862ea43-0da8-46b8-aeb5-72fa002fbedc"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>23.1</span>", "ID": "d97da9c1-da8e-4ab4-8531-28714b4465cc", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "23.1", "ParentId": "7eb952ee-0314-4554-b455-fac25eeb71b7"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>CrCl \u226570\u00a0ml/min\n  (n=227)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>14.5</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>22.1</span></p>\n</td>\n</tr>", "ID": "9100c832-1646-45ee-97c2-28c68922eed1", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "2aa72055-d462-4e48-baa5-2f186e01aa28"}, {"Element": "<td style=\"width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>CrCl \u226570\u00a0ml/min\n  (n=227)</span></p>\n</td>", "ID": "00194ce8-742a-4469-aa9b-ca2921c14ad7", "Styles": "width:182.6pt;border:solid windowtext 1.0pt;border-bottom:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "9100c832-1646-45ee-97c2-28c68922eed1"}, {"Element": "<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>CrCl \u226570\u00a0ml/min\n  (n=227)</span></p>", "ID": "a5d4cc99-3712-418c-b634-889d501f9f28", "Styles": "page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "00194ce8-742a-4469-aa9b-ca2921c14ad7"}, {"Element": "<span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>CrCl \u226570\u00a0ml/min\n  (n=227)</span>", "ID": "2dfb9989-d667-4117-894d-d595c5a514ba", "Styles": "font-size:\n  11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "CrCl \u226570\u00a0ml/min   (n=227)", "ParentId": "a5d4cc99-3712-418c-b634-889d501f9f28"}, {"Element": "<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>14.5</span></p>\n</td>", "ID": "a9f40c16-2f49-4358-a788-845b9926c9b2", "Styles": "width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "9100c832-1646-45ee-97c2-28c68922eed1"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>14.5</span></p>", "ID": "a1556cad-2bd8-4ab4-b731-6040e3ad5590", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "a9f40c16-2f49-4358-a788-845b9926c9b2"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>14.5</span>", "ID": "f58108af-0e25-4a88-b465-7b55f5288f5e", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "14.5", "ParentId": "a1556cad-2bd8-4ab4-b731-6040e3ad5590"}, {"Element": "<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>22.1</span></p>\n</td>", "ID": "50136b8a-ca47-428c-937e-438d5b60f55e", "Styles": "width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "9100c832-1646-45ee-97c2-28c68922eed1"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>22.1</span></p>", "ID": "8f9089f4-054c-4f4c-bae9-ee3ad35649eb", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "50136b8a-ca47-428c-937e-438d5b60f55e"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>22.1</span>", "ID": "99fc3f4d-a6a5-4764-a4a7-b4161b2df46c", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "22.1", "ParentId": "8f9089f4-054c-4f4c-bae9-ee3ad35649eb"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>17p or 11q\n  deletion (n=90)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>7.9</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.6</span></p>\n</td>\n</tr>", "ID": "90cce2e3-bd27-4897-bdd1-920919abfae7", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "2aa72055-d462-4e48-baa5-2f186e01aa28"}, {"Element": "<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>17p or 11q\n  deletion (n=90)</span></p>\n</td>", "ID": "f71871b0-c9ff-4637-bf6c-3a01bbf2d306", "Styles": "width:182.6pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "90cce2e3-bd27-4897-bdd1-920919abfae7"}, {"Element": "<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>17p or 11q\n  deletion (n=90)</span></p>", "ID": "02647bd5-339f-4698-9044-d7e9bad19913", "Styles": "page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "f71871b0-c9ff-4637-bf6c-3a01bbf2d306"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>17p or 11q\n  deletion (n=90)</span>", "ID": "5c0a468e-202d-4210-bb49-408a4f2a8f08", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "17p or 11q   deletion (n=90)", "ParentId": "02647bd5-339f-4698-9044-d7e9bad19913"}, {"Element": "<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>7.9</span></p>\n</td>", "ID": "1904eacd-da32-4609-b67d-bf8b71b1b3bf", "Styles": "width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "90cce2e3-bd27-4897-bdd1-920919abfae7"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>7.9</span></p>", "ID": "a8003147-664f-4a5d-ac8a-b07225fe7d53", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "1904eacd-da32-4609-b67d-bf8b71b1b3bf"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>7.9</span>", "ID": "eca4ff31-b197-497f-b673-16d6eb1b7080", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "7.9", "ParentId": "a8003147-664f-4a5d-ac8a-b07225fe7d53"}, {"Element": "<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.6</span></p>\n</td>", "ID": "1f7d7de5-1ea8-4ba3-8356-ef4b94ee6892", "Styles": "width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "90cce2e3-bd27-4897-bdd1-920919abfae7"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.6</span></p>", "ID": "9a8fe6fb-88fb-4ca1-823e-f2121e0d6788", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "1f7d7de5-1ea8-4ba3-8356-ef4b94ee6892"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.6</span>", "ID": "92827937-dc66-48c0-b554-feaad3d61fb1", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "13.6", "ParentId": "9a8fe6fb-88fb-4ca1-823e-f2121e0d6788"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV mutated\n  (\u226498%) (n=177)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12.2</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>30.5</span></p>\n</td>\n</tr>", "ID": "c543db52-3430-463b-bffd-f791015bf39b", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "2aa72055-d462-4e48-baa5-2f186e01aa28"}, {"Element": "<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV mutated\n  (\u226498%) (n=177)</span></p>\n</td>", "ID": "dd87f1a2-b196-4445-b0ef-1aba8d8e8cf5", "Styles": "width:182.6pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "c543db52-3430-463b-bffd-f791015bf39b"}, {"Element": "<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV mutated\n  (\u226498%) (n=177)</span></p>", "ID": "81f64f80-e845-437c-a2bf-97f5d98b7bd5", "Styles": "page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "dd87f1a2-b196-4445-b0ef-1aba8d8e8cf5"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV mutated\n  (\u226498%) (n=177)</span>", "ID": "cf142342-b24b-4899-897f-0c1ceb516183", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "IGHV mutated   (\u226498%) (n=177)", "ParentId": "81f64f80-e845-437c-a2bf-97f5d98b7bd5"}, {"Element": "<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12.2</span></p>\n</td>", "ID": "569b50ab-22bc-40e5-bcf2-a29ce6aff796", "Styles": "width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "c543db52-3430-463b-bffd-f791015bf39b"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12.2</span></p>", "ID": "c40574b0-37f4-4431-9f89-f52a0b17eb72", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "569b50ab-22bc-40e5-bcf2-a29ce6aff796"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12.2</span>", "ID": "386ae27f-d3bf-4b30-b33a-e4773ebad0ee", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "12.2", "ParentId": "c40574b0-37f4-4431-9f89-f52a0b17eb72"}, {"Element": "<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>30.5</span></p>\n</td>", "ID": "c4a08865-a155-4c1a-98f2-0618a4aec432", "Styles": "width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "c543db52-3430-463b-bffd-f791015bf39b"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>30.5</span></p>", "ID": "2caeb82a-00b0-4907-ab0c-cc3bcd8bf367", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "c4a08865-a155-4c1a-98f2-0618a4aec432"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>30.5</span>", "ID": "5acfd5be-fc40-44b4-a9b0-78652368f640", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "30.5", "ParentId": "2caeb82a-00b0-4907-ab0c-cc3bcd8bf367"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV unmutated\n  (&gt;98%) (n=227)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.7\n  </span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>17.3</span></p>\n</td>\n</tr>", "ID": "23bcc210-3ac6-4648-848c-7b4ed0ad3422", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "2aa72055-d462-4e48-baa5-2f186e01aa28"}, {"Element": "<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV unmutated\n  (&gt;98%) (n=227)</span></p>\n</td>", "ID": "1edb1843-ed41-487b-877d-0750b60d5ef7", "Styles": "width:182.6pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "23bcc210-3ac6-4648-848c-7b4ed0ad3422"}, {"Element": "<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV unmutated\n  (&gt;98%) (n=227)</span></p>", "ID": "362947e0-cb0a-4f37-8955-6e248cb21e15", "Styles": "page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "1edb1843-ed41-487b-877d-0750b60d5ef7"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV unmutated\n  (&gt;98%) (n=227)</span>", "ID": "65a05e77-a32f-4de6-aacc-6962be009153", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "IGHV unmutated   (>98%) (n=227)", "ParentId": "362947e0-cb0a-4f37-8955-6e248cb21e15"}, {"Element": "<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.7\n  </span></p>\n</td>", "ID": "2591484d-03ac-4125-9982-517270eb941b", "Styles": "width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "23bcc210-3ac6-4648-848c-7b4ed0ad3422"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.7\n  </span></p>", "ID": "e1e49d75-5b10-4a9b-9010-c38e2b15ff85", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "2591484d-03ac-4125-9982-517270eb941b"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.7\n  </span>", "ID": "8d518cf9-18df-4368-8c03-52dcb7f6841b", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "11.7   ", "ParentId": "e1e49d75-5b10-4a9b-9010-c38e2b15ff85"}, {"Element": "<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>17.3</span></p>\n</td>", "ID": "9f71e89d-a464-458c-9e78-ae6931688dcc", "Styles": "width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "23bcc210-3ac6-4648-848c-7b4ed0ad3422"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>17.3</span></p>", "ID": "1dc987e7-fcdc-485b-9ddc-24a1226d01bf", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "9f71e89d-a464-458c-9e78-ae6931688dcc"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>17.3</span>", "ID": "092b0df7-6280-49e2-925e-1ae4050b2925", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "17.3", "ParentId": "1dc987e7-fcdc-485b-9ddc-24a1226d01bf"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u03b22M\n  \u22643500\u00a0\u03bcg/l (n=109)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.8</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>25.5</span></p>\n</td>\n</tr>", "ID": "83f9e28c-b20a-47a3-8535-5e85bdf9fee3", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "2aa72055-d462-4e48-baa5-2f186e01aa28"}, {"Element": "<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u03b22M\n  \u22643500\u00a0\u03bcg/l (n=109)</span></p>\n</td>", "ID": "78b28565-d9f1-4ca6-b7d8-c4c138c4e3ad", "Styles": "width:182.6pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "83f9e28c-b20a-47a3-8535-5e85bdf9fee3"}, {"Element": "<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u03b22M\n  \u22643500\u00a0\u03bcg/l (n=109)</span></p>", "ID": "f86dd30d-4ed2-435c-8000-1292a3654050", "Styles": "page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "78b28565-d9f1-4ca6-b7d8-c4c138c4e3ad"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u03b22M\n  \u22643500\u00a0\u03bcg/l (n=109)</span>", "ID": "3317062a-ca01-4140-9c45-ef60393b392a", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "\u03b22M   \u22643500\u00a0\u03bcg/l (n=109)", "ParentId": "f86dd30d-4ed2-435c-8000-1292a3654050"}, {"Element": "<td style=\"width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.8</span></p>\n</td>", "ID": "3d83c304-3163-4e55-9144-c59f5595ff8a", "Styles": "width:141.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "83f9e28c-b20a-47a3-8535-5e85bdf9fee3"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.8</span></p>", "ID": "859523af-2bdc-4679-bcc1-c1aa3b4d8e64", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "3d83c304-3163-4e55-9144-c59f5595ff8a"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.8</span>", "ID": "e5809824-6e48-44e2-a113-13d39506845e", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "13.8", "ParentId": "859523af-2bdc-4679-bcc1-c1aa3b4d8e64"}, {"Element": "<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>25.5</span></p>\n</td>", "ID": "556ceddd-22f4-458b-a9db-507c98c47a7c", "Styles": "width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "83f9e28c-b20a-47a3-8535-5e85bdf9fee3"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>25.5</span></p>", "ID": "286a1bbe-8023-46f0-94aa-d3a99fd75cf3", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "556ceddd-22f4-458b-a9db-507c98c47a7c"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>25.5</span>", "ID": "6e851c69-656d-4a6c-953b-51b59d40e8b0", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "25.5", "ParentId": "286a1bbe-8023-46f0-94aa-d3a99fd75cf3"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u03b22M\n  &gt;3500\u00a0\u03bcg/l (n=322)</span></p>\n</td>\n<td style=\"width:141.75pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.6</span></p>\n</td>\n<td style=\"width:113.4pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 0in 0in 0in;height:13.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>19.6</span></p>\n</td>\n</tr>", "ID": "237c6b7f-d317-458e-8d2f-252f99ea8491", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "2aa72055-d462-4e48-baa5-2f186e01aa28"}, {"Element": "<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u03b22M\n  &gt;3500\u00a0\u03bcg/l (n=322)</span></p>\n</td>", "ID": "9f915286-9968-4ea3-a4d1-04e0153db1a4", "Styles": "width:182.6pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "237c6b7f-d317-458e-8d2f-252f99ea8491"}, {"Element": "<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u03b22M\n  &gt;3500\u00a0\u03bcg/l (n=322)</span></p>", "ID": "5ace2ab0-44b4-46d4-b16c-6d9e07ab59a8", "Styles": "page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "9f915286-9968-4ea3-a4d1-04e0153db1a4"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u03b22M\n  &gt;3500\u00a0\u03bcg/l (n=322)</span>", "ID": "71c4c87b-3d78-4e90-a75c-ff494e95e313", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "\u03b22M   >3500\u00a0\u03bcg/l (n=322)", "ParentId": "5ace2ab0-44b4-46d4-b16c-6d9e07ab59a8"}, {"Element": "<td style=\"width:141.75pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.6</span></p>\n</td>", "ID": "8fbb5ae5-181b-4082-94d7-0c11f0caa982", "Styles": "width:141.75pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "237c6b7f-d317-458e-8d2f-252f99ea8491"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.6</span></p>", "ID": "7bd4b7d7-c876-4c41-b9a2-258310b624ef", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "8fbb5ae5-181b-4082-94d7-0c11f0caa982"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.6</span>", "ID": "f6bb28af-de3d-42d8-a7c7-da5eec841ac2", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "11.6", "ParentId": "7bd4b7d7-c876-4c41-b9a2-258310b624ef"}, {"Element": "<td style=\"width:113.4pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 0in 0in 0in;height:13.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>19.6</span></p>\n</td>", "ID": "75d3aaa8-6a4c-4157-82e4-57002333277d", "Styles": "width:113.4pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "237c6b7f-d317-458e-8d2f-252f99ea8491"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>19.6</span></p>", "ID": "aef2da8c-2508-421c-bbb6-9bea57f44a4b", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "75d3aaa8-6a4c-4157-82e4-57002333277d"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>19.6</span>", "ID": "6666d7f7-d0c0-430d-b0bb-3c2c66bc36ec", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "19.6", "ParentId": "aef2da8c-2508-421c-bbb6-9bea57f44a4b"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>ZAP-70 positive\n  (n=161)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>9.7</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>17.7</span></p>\n</td>\n</tr>", "ID": "d8cc3975-04e3-4f5e-a921-5d39587e9380", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "2aa72055-d462-4e48-baa5-2f186e01aa28"}, {"Element": "<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>ZAP-70 positive\n  (n=161)</span></p>\n</td>", "ID": "4acc08a5-7cc2-4b1c-8c9c-1e55107a61eb", "Styles": "width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "d8cc3975-04e3-4f5e-a921-5d39587e9380"}, {"Element": "<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>ZAP-70 positive\n  (n=161)</span></p>", "ID": "0f1fd2eb-2178-46ac-a44d-84afb93d7df0", "Styles": "page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "4acc08a5-7cc2-4b1c-8c9c-1e55107a61eb"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>ZAP-70 positive\n  (n=161)</span>", "ID": "3df296f7-f138-4f64-be9b-9d570ef549d8", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "ZAP-70 positive   (n=161)", "ParentId": "0f1fd2eb-2178-46ac-a44d-84afb93d7df0"}, {"Element": "<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>9.7</span></p>\n</td>", "ID": "a08991c6-58dd-418d-9f8a-fef79c86fcb7", "Styles": "width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "d8cc3975-04e3-4f5e-a921-5d39587e9380"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>9.7</span></p>", "ID": "7d2ea79d-1cba-46a1-b9bf-669ee2818479", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "a08991c6-58dd-418d-9f8a-fef79c86fcb7"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>9.7</span>", "ID": "c854afa3-7fa3-4fda-bc18-dc97e5209ffe", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "9.7", "ParentId": "7d2ea79d-1cba-46a1-b9bf-669ee2818479"}, {"Element": "<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>17.7</span></p>\n</td>", "ID": "c52a99ab-b4dd-40d6-b006-bf0c37ea9a1a", "Styles": "width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "d8cc3975-04e3-4f5e-a921-5d39587e9380"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>17.7</span></p>", "ID": "9493f372-a5cd-4bcf-b6fd-116aef8bd825", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "c52a99ab-b4dd-40d6-b006-bf0c37ea9a1a"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>17.7</span>", "ID": "a0305507-2677-4a03-b5f4-cf51e397f5d9", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "17.7", "ParentId": "9493f372-a5cd-4bcf-b6fd-116aef8bd825"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>ZAP-70\n  intermediate (n=160)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.6</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>25.3</span></p>\n</td>\n</tr>", "ID": "b74229ec-0a73-44e1-b5d8-18db51cbde48", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "2aa72055-d462-4e48-baa5-2f186e01aa28"}, {"Element": "<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>ZAP-70\n  intermediate (n=160)</span></p>\n</td>", "ID": "e2d698a8-0a4e-4d99-9d93-02b23027fc22", "Styles": "width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "b74229ec-0a73-44e1-b5d8-18db51cbde48"}, {"Element": "<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>ZAP-70\n  intermediate (n=160)</span></p>", "ID": "61854012-6097-4a60-a459-29da70b5e032", "Styles": "page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "e2d698a8-0a4e-4d99-9d93-02b23027fc22"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>ZAP-70\n  intermediate (n=160)</span>", "ID": "6021cf96-55b4-4bd6-949d-2337db095e56", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "ZAP-70   intermediate (n=160)", "ParentId": "61854012-6097-4a60-a459-29da70b5e032"}, {"Element": "<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.6</span></p>\n</td>", "ID": "f314a148-023a-42ba-9229-ed7e300883d9", "Styles": "width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "b74229ec-0a73-44e1-b5d8-18db51cbde48"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.6</span></p>", "ID": "ea20c491-9df6-4989-8db3-cb99ccea1503", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "f314a148-023a-42ba-9229-ed7e300883d9"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.6</span>", "ID": "b1d84daa-4b2d-4975-bc79-49422a24b28b", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "13.6", "ParentId": "ea20c491-9df6-4989-8db3-cb99ccea1503"}, {"Element": "<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>25.3</span></p>\n</td>", "ID": "50899ff6-9599-4eb3-aa72-ed6adcb36252", "Styles": "width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "b74229ec-0a73-44e1-b5d8-18db51cbde48"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>25.3</span></p>", "ID": "18242b28-e9ad-4a70-ad15-f088f93e2c5e", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "50899ff6-9599-4eb3-aa72-ed6adcb36252"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>25.3</span>", "ID": "4041ff8d-9339-496c-b9d3-7bfe1d552970", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "25.3", "ParentId": "18242b28-e9ad-4a70-ad15-f088f93e2c5e"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>ZAP-70 negative\n  (n=100)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.8</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>25.6</span></p>\n</td>\n</tr>", "ID": "39dfecb3-9954-417a-925f-22ed3dc4e160", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "2aa72055-d462-4e48-baa5-2f186e01aa28"}, {"Element": "<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>ZAP-70 negative\n  (n=100)</span></p>\n</td>", "ID": "c2d2ad6b-07da-48ce-8365-da4eeee9b8fc", "Styles": "width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "39dfecb3-9954-417a-925f-22ed3dc4e160"}, {"Element": "<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>ZAP-70 negative\n  (n=100)</span></p>", "ID": "c4e48d9c-360b-4ca9-9fd5-856168b6cbf0", "Styles": "page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "c2d2ad6b-07da-48ce-8365-da4eeee9b8fc"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>ZAP-70 negative\n  (n=100)</span>", "ID": "79411539-2064-4d21-942e-544bff5dae37", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "ZAP-70 negative   (n=100)", "ParentId": "c4e48d9c-360b-4ca9-9fd5-856168b6cbf0"}, {"Element": "<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.8</span></p>\n</td>", "ID": "16a57111-bdf0-41ec-b93c-9ee4288f1e23", "Styles": "width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "39dfecb3-9954-417a-925f-22ed3dc4e160"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.8</span></p>", "ID": "6fb96c8d-e361-476b-a1c3-19ba5a37093b", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "16a57111-bdf0-41ec-b93c-9ee4288f1e23"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.8</span>", "ID": "9f9c693b-b3a6-4978-83fd-2480557a5c0c", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "13.8", "ParentId": "6fb96c8d-e361-476b-a1c3-19ba5a37093b"}, {"Element": "<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>25.6</span></p>\n</td>", "ID": "5e119486-328a-41ed-a5f0-c478f27250a8", "Styles": "width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "39dfecb3-9954-417a-925f-22ed3dc4e160"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>25.6</span></p>", "ID": "90bf9c1a-230a-47b6-85b9-0d90a1de0409", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "5e119486-328a-41ed-a5f0-c478f27250a8"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>25.6</span>", "ID": "59d3029e-3456-441d-a204-883b17748f30", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "25.6", "ParentId": "90bf9c1a-230a-47b6-85b9-0d90a1de0409"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV mutated\n  &amp; ZAP-70 negative (n=60)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>10.5</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>NR</span></p>\n</td>\n</tr>", "ID": "8f064731-0e4f-44cb-864c-b2d09484bfa5", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "2aa72055-d462-4e48-baa5-2f186e01aa28"}, {"Element": "<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV mutated\n  &amp; ZAP-70 negative (n=60)</span></p>\n</td>", "ID": "c3d9a731-ec4f-4b45-b51c-5e8d3bc7d5f6", "Styles": "width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "8f064731-0e4f-44cb-864c-b2d09484bfa5"}, {"Element": "<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV mutated\n  &amp; ZAP-70 negative (n=60)</span></p>", "ID": "f8aea75f-7484-4fcb-a7a6-0ec1eb3cbbcf", "Styles": "page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "c3d9a731-ec4f-4b45-b51c-5e8d3bc7d5f6"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV mutated\n  &amp; ZAP-70 negative (n=60)</span>", "ID": "805fbce8-0ad0-42f9-adf3-3b742f66674a", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "IGHV mutated   & ZAP-70 negative (n=60)", "ParentId": "f8aea75f-7484-4fcb-a7a6-0ec1eb3cbbcf"}, {"Element": "<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>10.5</span></p>\n</td>", "ID": "2e68bdf9-420f-4a85-aa0c-08a35fee6225", "Styles": "width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "8f064731-0e4f-44cb-864c-b2d09484bfa5"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>10.5</span></p>", "ID": "e4c17ccb-c28f-4c5e-8c07-36384f04c520", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "2e68bdf9-420f-4a85-aa0c-08a35fee6225"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>10.5</span>", "ID": "e301221b-666a-4b0e-91a1-d377136deca4", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "10.5", "ParentId": "e4c17ccb-c28f-4c5e-8c07-36384f04c520"}, {"Element": "<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>NR</span></p>\n</td>", "ID": "cd841ec7-c700-4aa1-8cdd-ff0f8646e04a", "Styles": "width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "8f064731-0e4f-44cb-864c-b2d09484bfa5"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>NR</span></p>", "ID": "7dfb1b82-19d7-4bce-8518-08f04605d924", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "cd841ec7-c700-4aa1-8cdd-ff0f8646e04a"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>NR</span>", "ID": "54fff682-9c26-4f44-94c5-f5302b7c72e7", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "NR", "ParentId": "7dfb1b82-19d7-4bce-8518-08f04605d924"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV mutated\n  &amp; ZAP-70 positive (n=35)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>7.9</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>27.2</span></p>\n</td>\n</tr>", "ID": "073414ba-2344-4d1d-8d45-644c170a7495", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "2aa72055-d462-4e48-baa5-2f186e01aa28"}, {"Element": "<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV mutated\n  &amp; ZAP-70 positive (n=35)</span></p>\n</td>", "ID": "edabef36-b686-4e62-b647-f58a74df0a64", "Styles": "width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "073414ba-2344-4d1d-8d45-644c170a7495"}, {"Element": "<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV mutated\n  &amp; ZAP-70 positive (n=35)</span></p>", "ID": "967eaa14-3fcb-4c22-8aa2-0fd2ccbfda22", "Styles": "page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "edabef36-b686-4e62-b647-f58a74df0a64"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV mutated\n  &amp; ZAP-70 positive (n=35)</span>", "ID": "669adf90-8547-4fdc-9f42-8fbbc00b4887", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "IGHV mutated   & ZAP-70 positive (n=35)", "ParentId": "967eaa14-3fcb-4c22-8aa2-0fd2ccbfda22"}, {"Element": "<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>7.9</span></p>\n</td>", "ID": "d9e91247-2d85-4b82-b375-d118418a90f7", "Styles": "width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "073414ba-2344-4d1d-8d45-644c170a7495"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>7.9</span></p>", "ID": "8d310391-f6f2-4813-9f04-fa21f493edb6", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "d9e91247-2d85-4b82-b375-d118418a90f7"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>7.9</span>", "ID": "32c54b2e-5da1-4dd0-967f-f59dd56ef416", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "7.9", "ParentId": "8d310391-f6f2-4813-9f04-fa21f493edb6"}, {"Element": "<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>27.2</span></p>\n</td>", "ID": "d099c90c-7ec9-44b5-a51a-35cff1c0ad02", "Styles": "width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "073414ba-2344-4d1d-8d45-644c170a7495"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>27.2</span></p>", "ID": "9f28d5ad-4ac8-48d7-a8ec-134c530a97d3", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "d099c90c-7ec9-44b5-a51a-35cff1c0ad02"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>27.2</span>", "ID": "7b14338a-131f-4ede-aa93-bb599eed4e65", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "27.2", "ParentId": "9f28d5ad-4ac8-48d7-a8ec-134c530a97d3"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV unmutated\n  &amp; ZAP-70 negative (n=27)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>16.7</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>16.2</span></p>\n</td>\n</tr>", "ID": "82be7d60-9fe0-441e-98bb-cea3421ac5ca", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "2aa72055-d462-4e48-baa5-2f186e01aa28"}, {"Element": "<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV unmutated\n  &amp; ZAP-70 negative (n=27)</span></p>\n</td>", "ID": "d5b511a0-b305-41df-82bc-857c5b4810d6", "Styles": "width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "82be7d60-9fe0-441e-98bb-cea3421ac5ca"}, {"Element": "<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV unmutated\n  &amp; ZAP-70 negative (n=27)</span></p>", "ID": "71e8794e-a279-4e70-a55d-f9f269e67525", "Styles": "page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "d5b511a0-b305-41df-82bc-857c5b4810d6"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV unmutated\n  &amp; ZAP-70 negative (n=27)</span>", "ID": "98b20859-0980-407c-bb29-90d5625c1f7a", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "IGHV unmutated   & ZAP-70 negative (n=27)", "ParentId": "71e8794e-a279-4e70-a55d-f9f269e67525"}, {"Element": "<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>16.7</span></p>\n</td>", "ID": "0e13a054-9d1f-46ef-b218-8ab4c0ec16bd", "Styles": "width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "82be7d60-9fe0-441e-98bb-cea3421ac5ca"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>16.7</span></p>", "ID": "b3a2c065-6030-4b00-bc7c-0a8d24749f2d", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "0e13a054-9d1f-46ef-b218-8ab4c0ec16bd"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>16.7</span>", "ID": "26d94634-1e4b-4bcf-9da3-db0e122e6046", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "16.7", "ParentId": "b3a2c065-6030-4b00-bc7c-0a8d24749f2d"}, {"Element": "<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>16.2</span></p>\n</td>", "ID": "af08f793-c07d-40be-9b25-51ffbd9b4f7d", "Styles": "width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "82be7d60-9fe0-441e-98bb-cea3421ac5ca"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>16.2</span></p>", "ID": "42613212-668a-4246-ab59-1dade265e1a0", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "af08f793-c07d-40be-9b25-51ffbd9b4f7d"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>16.2</span>", "ID": "ace2533a-0502-41c9-a79e-a0bde6454fed", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "16.2", "ParentId": "42613212-668a-4246-ab59-1dade265e1a0"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV unmutated\n  &amp; ZAP-70 positive (n=122)</span></p>\n</td>\n<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.2</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>16.2</span></p>\n</td>\n</tr>", "ID": "08dbf826-c7d6-4cf3-a37d-9f6397e568b5", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "2aa72055-d462-4e48-baa5-2f186e01aa28"}, {"Element": "<td style=\"width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"243\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV unmutated\n  &amp; ZAP-70 positive (n=122)</span></p>\n</td>", "ID": "5d5c9847-7bf4-402b-848a-44f94f586608", "Styles": "width:182.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "08dbf826-c7d6-4cf3-a37d-9f6397e568b5"}, {"Element": "<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV unmutated\n  &amp; ZAP-70 positive (n=122)</span></p>", "ID": "bafb02e5-37a9-4dc5-a65e-2f96b8dc8afc", "Styles": "page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "5d5c9847-7bf4-402b-848a-44f94f586608"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IGHV unmutated\n  &amp; ZAP-70 positive (n=122)</span>", "ID": "3a3c4c5a-6d93-4e8c-873c-6353e4ab5365", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "IGHV unmutated   & ZAP-70 positive (n=122)", "ParentId": "bafb02e5-37a9-4dc5-a65e-2f96b8dc8afc"}, {"Element": "<td style=\"width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"189\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.2</span></p>\n</td>", "ID": "531eeb58-6e0d-4d60-bfd3-fc14cce60a29", "Styles": "width:141.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "08dbf826-c7d6-4cf3-a37d-9f6397e568b5"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.2</span></p>", "ID": "2e4ae9f2-4e88-42b6-8b10-b817199ce899", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "531eeb58-6e0d-4d60-bfd3-fc14cce60a29"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.2</span>", "ID": "e44ec20c-e9ef-4122-9081-033560b6e610", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "11.2", "ParentId": "2e4ae9f2-4e88-42b6-8b10-b817199ce899"}, {"Element": "<td style=\"width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>16.2</span></p>\n</td>", "ID": "0462e544-a73e-4c02-aa82-43c785c37a79", "Styles": "width:113.4pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "08dbf826-c7d6-4cf3-a37d-9f6397e568b5"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>16.2</span></p>", "ID": "51ffe595-c854-480e-ba30-6789ca2a2a68", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "0462e544-a73e-4c02-aa82-43c785c37a79"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>16.2</span>", "ID": "0b85fa18-deac-4101-bcd7-0ff0e54e4c80", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "16.2", "ParentId": "51ffe595-c854-480e-ba30-6789ca2a2a68"}, {"Element": "<tr style=\"height:13.9pt\">\n<td colspan=\"3\" style=\"width:437.75pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"584\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;background:white\"><span lang=\"EN-GB\" style=\"color:black\">Abbreviations: \u03b22M = beta-2-microglobulin,\n  CI = confidence interval; CIRS-G = Cumulative Illness Rating Scale for\n  Geriatrics, CLL = c</span><span style=\"color:black\">hronic lymphocytic leukaemia,\n  CrCl = creatinine clearance, ECOG = Eastern Cooperative Oncology Group, </span><span lang=\"EN-GB\" style=\"color:black\">IGHV = Immunoglobulin Heavy Chain Variable\n  Region, IRC = Independent Review Committee, N = number, NR = not reached, PFS\n  = progression-free survival, ZAP-70 = zeta-chain-associated protein kinase\n  70.</span></p>\n</td>\n</tr>", "ID": "986f0595-4dd2-4648-86d2-ed64e990f981", "Styles": "height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "2aa72055-d462-4e48-baa5-2f186e01aa28"}, {"Element": "<td colspan=\"3\" style=\"width:437.75pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"584\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;background:white\"><span lang=\"EN-GB\" style=\"color:black\">Abbreviations: \u03b22M = beta-2-microglobulin,\n  CI = confidence interval; CIRS-G = Cumulative Illness Rating Scale for\n  Geriatrics, CLL = c</span><span style=\"color:black\">hronic lymphocytic leukaemia,\n  CrCl = creatinine clearance, ECOG = Eastern Cooperative Oncology Group, </span><span lang=\"EN-GB\" style=\"color:black\">IGHV = Immunoglobulin Heavy Chain Variable\n  Region, IRC = Independent Review Committee, N = number, NR = not reached, PFS\n  = progression-free survival, ZAP-70 = zeta-chain-associated protein kinase\n  70.</span></p>\n</td>", "ID": "eb49c441-db1f-4ebc-ad57-6784584675e4", "Styles": "width:437.75pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "986f0595-4dd2-4648-86d2-ed64e990f981"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;background:white\"><span lang=\"EN-GB\" style=\"color:black\">Abbreviations: \u03b22M = beta-2-microglobulin,\n  CI = confidence interval; CIRS-G = Cumulative Illness Rating Scale for\n  Geriatrics, CLL = c</span><span style=\"color:black\">hronic lymphocytic leukaemia,\n  CrCl = creatinine clearance, ECOG = Eastern Cooperative Oncology Group, </span><span lang=\"EN-GB\" style=\"color:black\">IGHV = Immunoglobulin Heavy Chain Variable\n  Region, IRC = Independent Review Committee, N = number, NR = not reached, PFS\n  = progression-free survival, ZAP-70 = zeta-chain-associated protein kinase\n  70.</span></p>", "ID": "353555c7-9e05-44bb-b870-ac98d156a431", "Styles": "page-break-after:avoid;background:white", "Classes": "['MsoNormal']", "Text": "", "ParentId": "eb49c441-db1f-4ebc-ad57-6784584675e4"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Abbreviations: \u03b22M = beta-2-microglobulin,\n  CI = confidence interval; CIRS-G = Cumulative Illness Rating Scale for\n  Geriatrics, CLL = c</span>", "ID": "9c68f414-5096-4328-9bfc-e5aa5608dc10", "Styles": "color:black", "Classes": "None", "Text": "Abbreviations: \u03b22M = beta-2-microglobulin,   CI = confidence interval; CIRS-G = Cumulative Illness Rating Scale for   Geriatrics, CLL = c", "ParentId": "353555c7-9e05-44bb-b870-ac98d156a431"}, {"Element": "<span style=\"color:black\">hronic lymphocytic leukaemia,\n  CrCl = creatinine clearance, ECOG = Eastern Cooperative Oncology Group, </span>", "ID": "3cdfe500-04a7-4811-8553-ab43c9b07fa5", "Styles": "color:black", "Classes": "None", "Text": "hronic lymphocytic leukaemia,   CrCl = creatinine clearance, ECOG = Eastern Cooperative Oncology Group, ", "ParentId": "353555c7-9e05-44bb-b870-ac98d156a431"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">IGHV = Immunoglobulin Heavy Chain Variable\n  Region, IRC = Independent Review Committee, N = number, NR = not reached, PFS\n  = progression-free survival, ZAP-70 = zeta-chain-associated protein kinase\n  70.</span>", "ID": "fcaaa64f-eb80-431c-87ad-8b947c49203f", "Styles": "color:black", "Classes": "None", "Text": "IGHV = Immunoglobulin Heavy Chain Variable   Region, IRC = Independent Review Committee, N = number, NR = not reached, PFS   = progression-free survival, ZAP-70 = zeta-chain-associated protein kinase   70.", "ParentId": "353555c7-9e05-44bb-b870-ac98d156a431"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "2e38a671-0631-4bbc-ab9c-608326b9abac", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">Limited data are available in the heterogeneous non-white\npopulation and in patients with an ECOG performance status of PS\u00a0=\u00a02.</p>", "ID": "553c79d8-62d4-4fe1-9cec-803253cb5765", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Limited data are available in the heterogeneous non-white population and in patients with an ECOG performance status of PS\u00a0=\u00a02.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoCaption\" style=\"line-height:normal;page-break-after:auto\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;font-weight:normal'>\u00a0</span></p>", "ID": "1d374684-3958-48cb-bbc0-689ef63d4133", "Styles": "line-height:normal;page-break-after:auto", "Classes": "['MsoCaption']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;font-weight:normal'>\u00a0</span>", "ID": "9be9b66e-9780-42a7-b136-aa6ed40a0a6e", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif;font-weight:normal", "Classes": "None", "Text": "\u00a0", "ParentId": "1d374684-3958-48cb-bbc0-689ef63d4133"}, {"Element": "<p class=\"MsoCaption\" style=\"line-height:normal\"><span style='font-size:11.0pt;\nfont-family:\"Times New Roman\",serif'>Figure\u00a01\u00a0\u00a0\u00a0\u00a0\u00a0 Kaplan-Meier estimates\nof IRC-assessed PFS in previously untreated CLL</span></p>", "ID": "0a7090ac-1adf-4810-87a3-efdbe827c465", "Styles": "line-height:normal", "Classes": "['MsoCaption']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style='font-size:11.0pt;\nfont-family:\"Times New Roman\",serif'>Figure\u00a01\u00a0\u00a0\u00a0\u00a0\u00a0 Kaplan-Meier estimates\nof IRC-assessed PFS in previously untreated CLL</span>", "ID": "c85d8c59-fad3-440b-bf0d-c1e44ac4b36c", "Styles": "font-size:11.0pt;\nfont-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Figure\u00a01\u00a0\u00a0\u00a0\u00a0\u00a0 Kaplan-Meier estimates of IRC-assessed PFS in previously untreated CLL", "ParentId": "0a7090ac-1adf-4810-87a3-efdbe827c465"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "d4e8bdad-fde3-4439-9542-a867c5691d55", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoCaption\" style=\"line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><img alt=\"PFS_IRC_4 (2)\" border=\"0\" height=\"341\" id=\"Picture 5\" src=\"Arzerra%20II-50%20&amp;%20II-51%20-%20PI%20-%20EN%20-%20clea_files/image002.png\" width=\"590\"/></span></p>", "ID": "d374f32e-7a04-456c-bcf3-12ef0278ca18", "Styles": "line-height:normal", "Classes": "['MsoCaption']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><img alt=\"PFS_IRC_4 (2)\" border=\"0\" height=\"341\" id=\"Picture 5\" src=\"Arzerra%20II-50%20&amp;%20II-51%20-%20PI%20-%20EN%20-%20clea_files/image002.png\" width=\"590\"/></span>", "ID": "dcfec2f5-e820-40bc-9609-e05613818f84", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "", "ParentId": "d374f32e-7a04-456c-bcf3-12ef0278ca18"}, {"Element": "<img alt=\"PFS_IRC_4 (2)\" border=\"0\" height=\"341\" id=\"Picture 5\" src=\"Arzerra%20II-50%20&amp;%20II-51%20-%20PI%20-%20EN%20-%20clea_files/image002.png\" width=\"590\"/>", "ID": "93613aa0-7a57-4ae1-9745-3cbc29ec72f3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dcfec2f5-e820-40bc-9609-e05613818f84"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3efea6f5-f1dc-4113-b622-afe94a78eb5a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "07cc28f7-77b8-4cd7-8a61-8f1ae2746ac2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3efea6f5-f1dc-4113-b622-afe94a78eb5a"}, {"Element": "<p class=\"MsoCaption\" style=\"margin-left:56.7pt;text-indent:-56.7pt;line-height:\nnormal\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Table\u00a02\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Summary\nof secondary outcomes of Arzerra in combination with chlorambucil compared with\nchlorambucil in previously untreated CLL</span></p>", "ID": "7cd2d854-9fde-4710-a2e4-a3d0d188c041", "Styles": "margin-left:56.7pt;text-indent:-56.7pt;line-height:\nnormal", "Classes": "['MsoCaption']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Table\u00a02\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Summary\nof secondary outcomes of Arzerra in combination with chlorambucil compared with\nchlorambucil in previously untreated CLL</span>", "ID": "796c5ad4-5302-4111-a209-19bf9a486bd7", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Table\u00a02\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Summary of secondary outcomes of Arzerra in combination with chlorambucil compared with chlorambucil in previously untreated CLL", "ParentId": "7cd2d854-9fde-4710-a2e4-a3d0d188c041"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;background:white\"><span class=\"tabletextNS1\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>\u00a0</span></span></p>", "ID": "3e456545-56f4-4e7c-bb66-f24d8002e0e1", "Styles": "page-break-after:avoid;background:white", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span class=\"tabletextNS1\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>\u00a0</span></span>", "ID": "85dc59a8-50c0-4536-a2e3-206a7360506c", "Styles": "None", "Classes": "['tabletextNS1']", "Text": "", "ParentId": "3e456545-56f4-4e7c-bb66-f24d8002e0e1"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>\u00a0</span>", "ID": "c725cae3-8405-49ad-adfc-4e620fb825eb", "Styles": "font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "\u00a0", "ParentId": "85dc59a8-50c0-4536-a2e3-206a7360506c"}, {"Element": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\">\n<tr style=\"page-break-inside:avoid;height:22.9pt\">\n<td style=\"width:203.85pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:22.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span class=\"tabletextNS1\"><b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IRC-assessed\n  secondary outcome</span></b></span></p>\n</td>\n<td style=\"width:120.5pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:22.9pt\" valign=\"top\" width=\"161\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Chlorambucil</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>\u00a0</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">(N=226)</span></b></p>\n</td>\n<td style=\"width:113.4pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 0in 0in 0in;height:22.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Arzerra and chlorambucil</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>(N=221)</b></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:203.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>ORR (%)</span></p>\n</td>\n<td style=\"width:120.5pt;border:none;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt\" valign=\"top\" width=\"161\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>69</span></p>\n</td>\n<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>82</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:203.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"margin-left:14.2pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>95%\n  CI</span></p>\n</td>\n<td style=\"width:120.5pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt\" valign=\"top\" width=\"161\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(62.1,\n  74.6)</span></p>\n</td>\n<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(76.7,\n  87.1)</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:203.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"margin-left:14.2pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>P value</span></p>\n</td>\n<td colspan=\"2\" style=\"width:233.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"312\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>p&lt;0.001</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:203.85pt;border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt\" width=\"272\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CR (%)</span></p>\n</td>\n<td style=\"width:120.5pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"161\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1</span></p>\n</td>\n<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:203.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"margin-left:14.2pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CR\n  with MRD negativity (% of CR)</span></p>\n</td>\n<td style=\"width:120.5pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"161\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>0</span></p>\n</td>\n<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>37</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:203.85pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Median duration\n  of response</span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>,\n  all patients, months</span></p>\n</td>\n<td style=\"width:120.5pt;border:none;border-top:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"161\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.2</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>22.1</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:203.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"margin-left:14.2pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>95%\n  CI</span></p>\n</td>\n<td style=\"width:120.5pt;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"161\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(10.8,\n  16.4)</span></p>\n</td>\n<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(19.1,\n  24.6)</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td style=\"width:203.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"margin-left:14.2pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>P value</span></p>\n</td>\n<td colspan=\"2\" style=\"width:233.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"312\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>p&lt;0.001</span></p>\n</td>\n</tr>\n<tr style=\"height:13.9pt\">\n<td colspan=\"3\" style=\"width:437.75pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"584\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Abbreviations:\n  CI = confidence interval, CLL = c</span><span style='font-size:11.0pt;\n  font-family:\"Times New Roman\",serif'>hronic lymphocytic leukaemia, </span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CR =\n  complete response, IRC = Independent Review Committee, MRD = minimal residue\n  disease, N = number, ORR = overall response rate</span></p>\n</td>\n</tr>\n</table>", "ID": "cfdc1f08-d8bc-4ef4-89f4-5fd606e5b9f5", "Styles": "border-collapse:collapse", "Classes": "['MsoNormalTable']", "Text": "           ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<tr style=\"page-break-inside:avoid;height:22.9pt\">\n<td style=\"width:203.85pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:22.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span class=\"tabletextNS1\"><b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IRC-assessed\n  secondary outcome</span></b></span></p>\n</td>\n<td style=\"width:120.5pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:22.9pt\" valign=\"top\" width=\"161\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Chlorambucil</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>\u00a0</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">(N=226)</span></b></p>\n</td>\n<td style=\"width:113.4pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 0in 0in 0in;height:22.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Arzerra and chlorambucil</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>(N=221)</b></p>\n</td>\n</tr>", "ID": "d7e87596-13f4-4cd5-b942-4a8ba219dfcc", "Styles": "page-break-inside:avoid;height:22.9pt", "Classes": "None", "Text": "    ", "ParentId": "cfdc1f08-d8bc-4ef4-89f4-5fd606e5b9f5"}, {"Element": "<td style=\"width:203.85pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:22.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span class=\"tabletextNS1\"><b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IRC-assessed\n  secondary outcome</span></b></span></p>\n</td>", "ID": "d71297ad-4e41-4124-a86e-c9b0fab709b7", "Styles": "width:203.85pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:22.9pt", "Classes": "None", "Text": "  ", "ParentId": "d7e87596-13f4-4cd5-b942-4a8ba219dfcc"}, {"Element": "<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span class=\"tabletextNS1\"><b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IRC-assessed\n  secondary outcome</span></b></span></p>", "ID": "569d108c-1f41-42cb-ad96-1d8c60627194", "Styles": "page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "d71297ad-4e41-4124-a86e-c9b0fab709b7"}, {"Element": "<span class=\"tabletextNS1\"><b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IRC-assessed\n  secondary outcome</span></b></span>", "ID": "b4e7d743-21f9-42c9-b932-a856eba81955", "Styles": "None", "Classes": "['tabletextNS1']", "Text": "", "ParentId": "569d108c-1f41-42cb-ad96-1d8c60627194"}, {"Element": "<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IRC-assessed\n  secondary outcome</span></b>", "ID": "8ebe8de3-8f6f-4f31-94cc-7d90f7a62c41", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b4e7d743-21f9-42c9-b932-a856eba81955"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>IRC-assessed\n  secondary outcome</span>", "ID": "32204f96-79df-4538-9c5c-5883edae776d", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "IRC-assessed   secondary outcome", "ParentId": "8ebe8de3-8f6f-4f31-94cc-7d90f7a62c41"}, {"Element": "<td style=\"width:120.5pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:22.9pt\" valign=\"top\" width=\"161\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Chlorambucil</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>\u00a0</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">(N=226)</span></b></p>\n</td>", "ID": "e0c428f5-2674-4f2e-b276-f5d132887c13", "Styles": "width:120.5pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:22.9pt", "Classes": "None", "Text": "    ", "ParentId": "d7e87596-13f4-4cd5-b942-4a8ba219dfcc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Chlorambucil</b></p>", "ID": "92775432-b7e2-4625-89b6-6cad1f049734", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e0c428f5-2674-4f2e-b276-f5d132887c13"}, {"Element": "<b>Chlorambucil</b>", "ID": "765046dc-c0e8-45ea-808b-bb16790540f7", "Styles": "None", "Classes": "None", "Text": "Chlorambucil", "ParentId": "92775432-b7e2-4625-89b6-6cad1f049734"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>\u00a0</b></p>", "ID": "6821a80b-d098-4020-a4c4-5d814bf06d41", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e0c428f5-2674-4f2e-b276-f5d132887c13"}, {"Element": "<b>\u00a0</b>", "ID": "efc46b82-89d5-46ce-8dee-f7333ec4ae81", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6821a80b-d098-4020-a4c4-5d814bf06d41"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">(N=226)</span></b></p>", "ID": "c9b96456-f366-4a52-9c27-ba40f4a737d1", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e0c428f5-2674-4f2e-b276-f5d132887c13"}, {"Element": "<b><span lang=\"EN-GB\">(N=226)</span></b>", "ID": "d82eb1f5-a740-4848-a42b-be074c0de37f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c9b96456-f366-4a52-9c27-ba40f4a737d1"}, {"Element": "<span lang=\"EN-GB\">(N=226)</span>", "ID": "3faf494c-e758-4b86-93c3-f727ebf2ea93", "Styles": "None", "Classes": "None", "Text": "(N=226)", "ParentId": "d82eb1f5-a740-4848-a42b-be074c0de37f"}, {"Element": "<td style=\"width:113.4pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 0in 0in 0in;height:22.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Arzerra and chlorambucil</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>(N=221)</b></p>\n</td>", "ID": "aac48a55-67cd-4445-9b89-f94a19386fd1", "Styles": "width:113.4pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 0in 0in 0in;height:22.9pt", "Classes": "None", "Text": "   ", "ParentId": "d7e87596-13f4-4cd5-b942-4a8ba219dfcc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Arzerra and chlorambucil</b></p>", "ID": "d939c644-dabb-46a6-a861-ab15347c4516", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "aac48a55-67cd-4445-9b89-f94a19386fd1"}, {"Element": "<b>Arzerra and chlorambucil</b>", "ID": "4a709c8a-e634-4f38-a084-20cddfb492c5", "Styles": "None", "Classes": "None", "Text": "Arzerra and chlorambucil", "ParentId": "d939c644-dabb-46a6-a861-ab15347c4516"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>(N=221)</b></p>", "ID": "79bcc7fd-d08c-4cb8-9a92-d77dffb0f8f0", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "aac48a55-67cd-4445-9b89-f94a19386fd1"}, {"Element": "<b>(N=221)</b>", "ID": "a276d529-2f9f-4475-878d-5a6989c7ddd6", "Styles": "None", "Classes": "None", "Text": "(N=221)", "ParentId": "79bcc7fd-d08c-4cb8-9a92-d77dffb0f8f0"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:203.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>ORR (%)</span></p>\n</td>\n<td style=\"width:120.5pt;border:none;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt\" valign=\"top\" width=\"161\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>69</span></p>\n</td>\n<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>82</span></p>\n</td>\n</tr>", "ID": "e4007f72-9730-400b-b52a-6850936380e8", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "cfdc1f08-d8bc-4ef4-89f4-5fd606e5b9f5"}, {"Element": "<td style=\"width:203.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>ORR (%)</span></p>\n</td>", "ID": "c77c6c5f-c99c-4077-9769-fb3264a61fe0", "Styles": "width:203.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "e4007f72-9730-400b-b52a-6850936380e8"}, {"Element": "<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>ORR (%)</span></p>", "ID": "baf9be3e-be5a-4201-a864-60f4ee033539", "Styles": "page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "c77c6c5f-c99c-4077-9769-fb3264a61fe0"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>ORR (%)</span>", "ID": "6eb5ef1a-2a70-4837-a389-22873d28c064", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "ORR (%)", "ParentId": "baf9be3e-be5a-4201-a864-60f4ee033539"}, {"Element": "<td style=\"width:120.5pt;border:none;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt\" valign=\"top\" width=\"161\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>69</span></p>\n</td>", "ID": "aca01722-7d1b-429c-a993-5f6f1772085b", "Styles": "width:120.5pt;border:none;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "e4007f72-9730-400b-b52a-6850936380e8"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>69</span></p>", "ID": "c276cf38-939c-4e6d-8df5-b17fca8f48f0", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "aca01722-7d1b-429c-a993-5f6f1772085b"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>69</span>", "ID": "c8483d12-80b9-4788-a983-f4e31bd946f2", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "69", "ParentId": "c276cf38-939c-4e6d-8df5-b17fca8f48f0"}, {"Element": "<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>82</span></p>\n</td>", "ID": "5d4fbfc1-ce2b-418f-93ea-31c6dca2f93e", "Styles": "width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "e4007f72-9730-400b-b52a-6850936380e8"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>82</span></p>", "ID": "2e9098cc-4246-4fe0-a6f9-7e2b1b448932", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "5d4fbfc1-ce2b-418f-93ea-31c6dca2f93e"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>82</span>", "ID": "4829b10a-b8e1-452f-9519-821a132ee060", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "82", "ParentId": "2e9098cc-4246-4fe0-a6f9-7e2b1b448932"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:203.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"margin-left:14.2pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>95%\n  CI</span></p>\n</td>\n<td style=\"width:120.5pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt\" valign=\"top\" width=\"161\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(62.1,\n  74.6)</span></p>\n</td>\n<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(76.7,\n  87.1)</span></p>\n</td>\n</tr>", "ID": "07b86f2a-98db-47d3-a008-f9934b543b04", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "cfdc1f08-d8bc-4ef4-89f4-5fd606e5b9f5"}, {"Element": "<td style=\"width:203.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"margin-left:14.2pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>95%\n  CI</span></p>\n</td>", "ID": "69de9054-02cf-4be5-8322-9489bbcae2f5", "Styles": "width:203.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "07b86f2a-98db-47d3-a008-f9934b543b04"}, {"Element": "<p class=\"tabletextNS\" style=\"margin-left:14.2pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>95%\n  CI</span></p>", "ID": "4ec983d4-bab4-4886-adca-483bfecd3287", "Styles": "margin-left:14.2pt;page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "69de9054-02cf-4be5-8322-9489bbcae2f5"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>95%\n  CI</span>", "ID": "1443fa41-92ad-4acf-88a0-75f32691173b", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "95%   CI", "ParentId": "4ec983d4-bab4-4886-adca-483bfecd3287"}, {"Element": "<td style=\"width:120.5pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt\" valign=\"top\" width=\"161\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(62.1,\n  74.6)</span></p>\n</td>", "ID": "17155e0d-7428-4edc-a286-1a3d3d768f9b", "Styles": "width:120.5pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "07b86f2a-98db-47d3-a008-f9934b543b04"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(62.1,\n  74.6)</span></p>", "ID": "b09b2312-54c7-4948-ac5b-19e732337e2b", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "17155e0d-7428-4edc-a286-1a3d3d768f9b"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(62.1,\n  74.6)</span>", "ID": "ad8cd7c9-ba4b-43d5-b64f-2d479af33090", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "(62.1,   74.6)", "ParentId": "b09b2312-54c7-4948-ac5b-19e732337e2b"}, {"Element": "<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" valign=\"top\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(76.7,\n  87.1)</span></p>\n</td>", "ID": "27489c63-0749-4b0f-8eff-0f7a6624ef9f", "Styles": "width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "07b86f2a-98db-47d3-a008-f9934b543b04"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(76.7,\n  87.1)</span></p>", "ID": "4774cc9a-5289-4844-99ea-0ca60ea5b0ab", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "27489c63-0749-4b0f-8eff-0f7a6624ef9f"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(76.7,\n  87.1)</span>", "ID": "2fa99113-4c72-4a3d-b9ae-f6c38f73d1e3", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "(76.7,   87.1)", "ParentId": "4774cc9a-5289-4844-99ea-0ca60ea5b0ab"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:203.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"margin-left:14.2pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>P value</span></p>\n</td>\n<td colspan=\"2\" style=\"width:233.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"312\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>p&lt;0.001</span></p>\n</td>\n</tr>", "ID": "092d1c4c-bcff-458f-8543-6b151ebbdf22", "Styles": "height:13.9pt", "Classes": "None", "Text": "   ", "ParentId": "cfdc1f08-d8bc-4ef4-89f4-5fd606e5b9f5"}, {"Element": "<td style=\"width:203.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"margin-left:14.2pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>P value</span></p>\n</td>", "ID": "fce70a66-0e45-45a5-971d-d94083a4d0fa", "Styles": "width:203.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "092d1c4c-bcff-458f-8543-6b151ebbdf22"}, {"Element": "<p class=\"tabletextNS\" style=\"margin-left:14.2pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>P value</span></p>", "ID": "bc3a15c1-0250-43ec-a716-7cb87e20dcaf", "Styles": "margin-left:14.2pt;page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "fce70a66-0e45-45a5-971d-d94083a4d0fa"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>P value</span>", "ID": "ee80d523-2cb5-40f5-aaf1-218ac326c1fa", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "P value", "ParentId": "bc3a15c1-0250-43ec-a716-7cb87e20dcaf"}, {"Element": "<td colspan=\"2\" style=\"width:233.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"312\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>p&lt;0.001</span></p>\n</td>", "ID": "52f1c70d-63ec-4d85-9d05-67c6d8c58b42", "Styles": "width:233.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "092d1c4c-bcff-458f-8543-6b151ebbdf22"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>p&lt;0.001</span></p>", "ID": "4a674dec-686a-418c-bd6d-768b16ce891a", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "52f1c70d-63ec-4d85-9d05-67c6d8c58b42"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>p&lt;0.001</span>", "ID": "0e482671-a820-40aa-bf04-d3ff89b43edc", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "p<0.001", "ParentId": "4a674dec-686a-418c-bd6d-768b16ce891a"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:203.85pt;border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt\" width=\"272\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CR (%)</span></p>\n</td>\n<td style=\"width:120.5pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"161\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1</span></p>\n</td>\n<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12</span></p>\n</td>\n</tr>", "ID": "c0bdd0b8-4d36-473a-9a5a-0d83bd24c9ca", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "cfdc1f08-d8bc-4ef4-89f4-5fd606e5b9f5"}, {"Element": "<td style=\"width:203.85pt;border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt\" width=\"272\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CR (%)</span></p>\n</td>", "ID": "4b8f2c61-f4dc-4cfd-bdec-2ed41e7a9076", "Styles": "width:203.85pt;border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "c0bdd0b8-4d36-473a-9a5a-0d83bd24c9ca"}, {"Element": "<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CR (%)</span></p>", "ID": "ba65e2bb-4b08-4588-aa75-7af86ad0c3c4", "Styles": "page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "4b8f2c61-f4dc-4cfd-bdec-2ed41e7a9076"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CR (%)</span>", "ID": "717705a2-72cb-4fdd-8edc-37494042d350", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "CR (%)", "ParentId": "ba65e2bb-4b08-4588-aa75-7af86ad0c3c4"}, {"Element": "<td style=\"width:120.5pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"161\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1</span></p>\n</td>", "ID": "f34b25c2-2293-4b7a-ae65-bccecd04a9a1", "Styles": "width:120.5pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "c0bdd0b8-4d36-473a-9a5a-0d83bd24c9ca"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1</span></p>", "ID": "fa800ba2-ddc7-403c-8538-e156d5198aa1", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "f34b25c2-2293-4b7a-ae65-bccecd04a9a1"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1</span>", "ID": "1746567c-0881-4a8d-a4f6-39a454fa27c0", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "1", "ParentId": "fa800ba2-ddc7-403c-8538-e156d5198aa1"}, {"Element": "<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12</span></p>\n</td>", "ID": "8c083903-024b-480e-a492-db4ba07292c0", "Styles": "width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "c0bdd0b8-4d36-473a-9a5a-0d83bd24c9ca"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12</span></p>", "ID": "c097cc34-b42c-49ec-969d-9f39ee38150e", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "8c083903-024b-480e-a492-db4ba07292c0"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12</span>", "ID": "62fffde1-c86b-40d5-afd9-6181ab2c34cb", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "12", "ParentId": "c097cc34-b42c-49ec-969d-9f39ee38150e"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:203.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"margin-left:14.2pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CR\n  with MRD negativity (% of CR)</span></p>\n</td>\n<td style=\"width:120.5pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"161\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>0</span></p>\n</td>\n<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>37</span></p>\n</td>\n</tr>", "ID": "52432480-66f2-4a6b-b539-c2dc33192200", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "cfdc1f08-d8bc-4ef4-89f4-5fd606e5b9f5"}, {"Element": "<td style=\"width:203.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"margin-left:14.2pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CR\n  with MRD negativity (% of CR)</span></p>\n</td>", "ID": "7d19aae2-6a6c-4ae4-a932-25bfaa804f61", "Styles": "width:203.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "52432480-66f2-4a6b-b539-c2dc33192200"}, {"Element": "<p class=\"tabletextNS\" style=\"margin-left:14.2pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CR\n  with MRD negativity (% of CR)</span></p>", "ID": "33bf12ce-984d-4bba-8e7f-c62fe19dce1a", "Styles": "margin-left:14.2pt;page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "7d19aae2-6a6c-4ae4-a932-25bfaa804f61"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CR\n  with MRD negativity (% of CR)</span>", "ID": "387c82bc-e254-4a3c-aa64-c3eb2b441c8c", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "CR   with MRD negativity (% of CR)", "ParentId": "33bf12ce-984d-4bba-8e7f-c62fe19dce1a"}, {"Element": "<td style=\"width:120.5pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"161\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>0</span></p>\n</td>", "ID": "463f5659-01b3-462d-828c-47ae59e492f4", "Styles": "width:120.5pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "52432480-66f2-4a6b-b539-c2dc33192200"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>0</span></p>", "ID": "21fccc5f-f533-4b33-8ce8-8fed04fccab4", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "463f5659-01b3-462d-828c-47ae59e492f4"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>0</span>", "ID": "72a8686b-9dc6-4e89-8134-b3c395029037", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "0", "ParentId": "21fccc5f-f533-4b33-8ce8-8fed04fccab4"}, {"Element": "<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>37</span></p>\n</td>", "ID": "e12b5b48-50bd-4cb3-9b05-0e66d25c5516", "Styles": "width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "52432480-66f2-4a6b-b539-c2dc33192200"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>37</span></p>", "ID": "8c3e4e76-9bd8-4470-8af9-0d9eba6cffd8", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "e12b5b48-50bd-4cb3-9b05-0e66d25c5516"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>37</span>", "ID": "4300f131-b705-4de1-88a9-c5e8048049e7", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "37", "ParentId": "8c3e4e76-9bd8-4470-8af9-0d9eba6cffd8"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:203.85pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Median duration\n  of response</span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>,\n  all patients, months</span></p>\n</td>\n<td style=\"width:120.5pt;border:none;border-top:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"161\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.2</span></p>\n</td>\n<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>22.1</span></p>\n</td>\n</tr>", "ID": "854d97ee-7bcf-497f-97b2-0d71a9de4bc7", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "cfdc1f08-d8bc-4ef4-89f4-5fd606e5b9f5"}, {"Element": "<td style=\"width:203.85pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Median duration\n  of response</span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>,\n  all patients, months</span></p>\n</td>", "ID": "5c678fb6-4f98-49d1-a9a9-8b35e4151e22", "Styles": "width:203.85pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "854d97ee-7bcf-497f-97b2-0d71a9de4bc7"}, {"Element": "<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Median duration\n  of response</span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>,\n  all patients, months</span></p>", "ID": "1a5610b6-8aeb-4bf5-a6d4-2f9c7778cdb8", "Styles": "page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "5c678fb6-4f98-49d1-a9a9-8b35e4151e22"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Median duration\n  of response</span>", "ID": "e9166ea9-011d-440f-bf44-b8a5de72c5ac", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Median duration   of response", "ParentId": "1a5610b6-8aeb-4bf5-a6d4-2f9c7778cdb8"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>,\n  all patients, months</span>", "ID": "98e3cb3b-86c5-4c03-b0f3-fc043ce4cb42", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": ",   all patients, months", "ParentId": "1a5610b6-8aeb-4bf5-a6d4-2f9c7778cdb8"}, {"Element": "<td style=\"width:120.5pt;border:none;border-top:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"161\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.2</span></p>\n</td>", "ID": "744e0fa1-be62-432d-9da6-a4742922eb93", "Styles": "width:120.5pt;border:none;border-top:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "854d97ee-7bcf-497f-97b2-0d71a9de4bc7"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.2</span></p>", "ID": "2540afe6-7e15-4d23-a09a-4c186e0f9a0f", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "744e0fa1-be62-432d-9da6-a4742922eb93"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>13.2</span>", "ID": "a0decc1e-f51b-4cc3-b588-0fe0fa61d774", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "13.2", "ParentId": "2540afe6-7e15-4d23-a09a-4c186e0f9a0f"}, {"Element": "<td style=\"width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>22.1</span></p>\n</td>", "ID": "0532b564-5147-43a7-9a8c-7383ca0cc075", "Styles": "width:113.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "854d97ee-7bcf-497f-97b2-0d71a9de4bc7"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>22.1</span></p>", "ID": "8b18a90c-91a6-4f6a-9480-5a1cde00706f", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "0532b564-5147-43a7-9a8c-7383ca0cc075"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>22.1</span>", "ID": "d75d478e-8dc5-48cc-9c27-530f0f4d50fa", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "22.1", "ParentId": "8b18a90c-91a6-4f6a-9480-5a1cde00706f"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:203.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"margin-left:14.2pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>95%\n  CI</span></p>\n</td>\n<td style=\"width:120.5pt;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"161\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(10.8,\n  16.4)</span></p>\n</td>\n<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(19.1,\n  24.6)</span></p>\n</td>\n</tr>", "ID": "23232ec9-78f3-4a9d-ab99-497216e8c6c1", "Styles": "height:13.9pt", "Classes": "None", "Text": "    ", "ParentId": "cfdc1f08-d8bc-4ef4-89f4-5fd606e5b9f5"}, {"Element": "<td style=\"width:203.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"margin-left:14.2pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>95%\n  CI</span></p>\n</td>", "ID": "a4159ab7-0be5-4edf-b10a-e4e497ff0400", "Styles": "width:203.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "23232ec9-78f3-4a9d-ab99-497216e8c6c1"}, {"Element": "<p class=\"tabletextNS\" style=\"margin-left:14.2pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>95%\n  CI</span></p>", "ID": "1b454e58-39a0-4ed9-82bf-adf661cf1e21", "Styles": "margin-left:14.2pt;page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "a4159ab7-0be5-4edf-b10a-e4e497ff0400"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>95%\n  CI</span>", "ID": "b548575f-70cf-4603-94b3-28b38883955f", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "95%   CI", "ParentId": "1b454e58-39a0-4ed9-82bf-adf661cf1e21"}, {"Element": "<td style=\"width:120.5pt;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" width=\"161\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(10.8,\n  16.4)</span></p>\n</td>", "ID": "e4126020-40fb-4c88-a6d0-a0f7cb132d68", "Styles": "width:120.5pt;padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "23232ec9-78f3-4a9d-ab99-497216e8c6c1"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(10.8,\n  16.4)</span></p>", "ID": "4e6dc863-9664-4646-896a-ba83994b105e", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "e4126020-40fb-4c88-a6d0-a0f7cb132d68"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(10.8,\n  16.4)</span>", "ID": "47158144-ef5e-44d3-9849-7a63a634f07a", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "(10.8,   16.4)", "ParentId": "4e6dc863-9664-4646-896a-ba83994b105e"}, {"Element": "<td style=\"width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt\" width=\"151\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(19.1,\n  24.6)</span></p>\n</td>", "ID": "93184114-b22c-49bb-8942-0ea38f35c500", "Styles": "width:113.4pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "23232ec9-78f3-4a9d-ab99-497216e8c6c1"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(19.1,\n  24.6)</span></p>", "ID": "36f51088-af18-44ba-a8e9-7c5670824a50", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "93184114-b22c-49bb-8942-0ea38f35c500"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(19.1,\n  24.6)</span>", "ID": "401f4044-cf12-4704-95e9-3b2904c67de1", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "(19.1,   24.6)", "ParentId": "36f51088-af18-44ba-a8e9-7c5670824a50"}, {"Element": "<tr style=\"height:13.9pt\">\n<td style=\"width:203.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"margin-left:14.2pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>P value</span></p>\n</td>\n<td colspan=\"2\" style=\"width:233.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"312\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>p&lt;0.001</span></p>\n</td>\n</tr>", "ID": "a8609ab6-de06-4be4-91b4-dabab31801ee", "Styles": "height:13.9pt", "Classes": "None", "Text": "   ", "ParentId": "cfdc1f08-d8bc-4ef4-89f4-5fd606e5b9f5"}, {"Element": "<td style=\"width:203.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"272\">\n<p class=\"tabletextNS\" style=\"margin-left:14.2pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>P value</span></p>\n</td>", "ID": "c92b0ac6-29a7-48d5-a797-adc64bb39ddc", "Styles": "width:203.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "a8609ab6-de06-4be4-91b4-dabab31801ee"}, {"Element": "<p class=\"tabletextNS\" style=\"margin-left:14.2pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>P value</span></p>", "ID": "a67dcbd4-5199-4d79-bb9b-f5cb9136f6c0", "Styles": "margin-left:14.2pt;page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "c92b0ac6-29a7-48d5-a797-adc64bb39ddc"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>P value</span>", "ID": "9ae0e252-d0bf-4647-b807-61e7ab5687a4", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "P value", "ParentId": "a67dcbd4-5199-4d79-bb9b-f5cb9136f6c0"}, {"Element": "<td colspan=\"2\" style=\"width:233.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"312\">\n<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>p&lt;0.001</span></p>\n</td>", "ID": "805997c6-1d0b-4326-991c-22d828736f71", "Styles": "width:233.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "a8609ab6-de06-4be4-91b4-dabab31801ee"}, {"Element": "<p align=\"center\" class=\"tabletextNS\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>p&lt;0.001</span></p>", "ID": "1aa6ab04-3a74-43df-b4fa-250287104a53", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "805997c6-1d0b-4326-991c-22d828736f71"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>p&lt;0.001</span>", "ID": "9e37851c-20f7-4600-88a8-6bc81d3f393e", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "p<0.001", "ParentId": "1aa6ab04-3a74-43df-b4fa-250287104a53"}, {"Element": "<tr style=\"height:13.9pt\">\n<td colspan=\"3\" style=\"width:437.75pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"584\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Abbreviations:\n  CI = confidence interval, CLL = c</span><span style='font-size:11.0pt;\n  font-family:\"Times New Roman\",serif'>hronic lymphocytic leukaemia, </span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CR =\n  complete response, IRC = Independent Review Committee, MRD = minimal residue\n  disease, N = number, ORR = overall response rate</span></p>\n</td>\n</tr>", "ID": "0e74a8a2-d4b9-4195-89d9-425d95cc3bf0", "Styles": "height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "cfdc1f08-d8bc-4ef4-89f4-5fd606e5b9f5"}, {"Element": "<td colspan=\"3\" style=\"width:437.75pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt\" valign=\"top\" width=\"584\">\n<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Abbreviations:\n  CI = confidence interval, CLL = c</span><span style='font-size:11.0pt;\n  font-family:\"Times New Roman\",serif'>hronic lymphocytic leukaemia, </span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CR =\n  complete response, IRC = Independent Review Committee, MRD = minimal residue\n  disease, N = number, ORR = overall response rate</span></p>\n</td>", "ID": "d0399c71-d409-4a1f-b3c0-75667350468b", "Styles": "width:437.75pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt", "Classes": "None", "Text": "  ", "ParentId": "0e74a8a2-d4b9-4195-89d9-425d95cc3bf0"}, {"Element": "<p class=\"tabletextNS\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Abbreviations:\n  CI = confidence interval, CLL = c</span><span style='font-size:11.0pt;\n  font-family:\"Times New Roman\",serif'>hronic lymphocytic leukaemia, </span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CR =\n  complete response, IRC = Independent Review Committee, MRD = minimal residue\n  disease, N = number, ORR = overall response rate</span></p>", "ID": "ec9d64cd-8860-446f-9b50-7fb2557f9437", "Styles": "page-break-after:avoid", "Classes": "['tabletextNS']", "Text": "", "ParentId": "d0399c71-d409-4a1f-b3c0-75667350468b"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Abbreviations:\n  CI = confidence interval, CLL = c</span>", "ID": "b5fc98cc-ad6b-43f7-95bb-56e5408b2466", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Abbreviations:   CI = confidence interval, CLL = c", "ParentId": "ec9d64cd-8860-446f-9b50-7fb2557f9437"}, {"Element": "<span style='font-size:11.0pt;\n  font-family:\"Times New Roman\",serif'>hronic lymphocytic leukaemia, </span>", "ID": "117e9a69-ba50-43f4-971b-fcf036dd97aa", "Styles": "font-size:11.0pt;\n  font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "hronic lymphocytic leukaemia, ", "ParentId": "ec9d64cd-8860-446f-9b50-7fb2557f9437"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CR =\n  complete response, IRC = Independent Review Committee, MRD = minimal residue\n  disease, N = number, ORR = overall response rate</span>", "ID": "59cdedfc-65fb-42c1-b4ac-40e3bd9fc26a", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "CR =   complete response, IRC = Independent Review Committee, MRD = minimal residue   disease, N = number, ORR = overall response rate", "ParentId": "ec9d64cd-8860-446f-9b50-7fb2557f9437"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "566daf76-81c7-4ce7-a06f-846fe4dcf867", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "aa7d22b2-11a3-4cb3-8441-bd980b7b0913", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "566daf76-81c7-4ce7-a06f-846fe4dcf867"}, {"Element": "<p class=\"MsoNormal\">Study OMB115991 evaluated the efficacy of Arzerra in\ncombination with bendamustine <span lang=\"EN-GB\">in 44\u00a0patients </span>with\npreviously untreated CLL <span lang=\"EN-GB\">considered inappropriate for\nfludarabine-based treatment</span>. <span lang=\"EN-GB\">Patients received Arzerra\nas monthly intravenous infusions (cycle\u00a01 300\u00a0mg on day\u00a01 and\n1000\u00a0mg on day\u00a08; subsequent cycles: 1000\u00a0mg on day\u00a01 every\n28\u00a0days) in combination with intravenous bendamustine 90\u00a0mg/m</span><sup><span lang=\"EN-GB\" style=\"font-size:8.0pt\">2</span></sup><span lang=\"EN-GB\" style=\"font-size:8.0pt\"> </span><span lang=\"EN-GB\">on days\u00a01 and 2 every\n28\u00a0days. </span>Patients received treatment for a maximum of 6\u00a0cycles.\nThe <span lang=\"EN-GB\" style=\"border:none windowtext 1.0pt;padding:0in\">median\nnumber of cycles completed in patients was 6 (total Arzerra dose of\n6300\u00a0mg).</span></p>", "ID": "5dd2439f-1c2e-4213-88c9-ff2bc50fadbf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Study OMB115991 evaluated the efficacy of Arzerra in combination with bendamustine with previously untreated CLL . Patients received treatment for a maximum of 6\u00a0cycles. The ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">in 44\u00a0patients </span>", "ID": "a710f4e7-bab7-43ec-b843-ded7ca82aae6", "Styles": "None", "Classes": "None", "Text": "in 44\u00a0patients ", "ParentId": "5dd2439f-1c2e-4213-88c9-ff2bc50fadbf"}, {"Element": "<span lang=\"EN-GB\">considered inappropriate for\nfludarabine-based treatment</span>", "ID": "8eb6c4fe-e940-40c7-8761-ff1a8330459e", "Styles": "None", "Classes": "None", "Text": "considered inappropriate for fludarabine-based treatment", "ParentId": "5dd2439f-1c2e-4213-88c9-ff2bc50fadbf"}, {"Element": "<span lang=\"EN-GB\">Patients received Arzerra\nas monthly intravenous infusions (cycle\u00a01 300\u00a0mg on day\u00a01 and\n1000\u00a0mg on day\u00a08; subsequent cycles: 1000\u00a0mg on day\u00a01 every\n28\u00a0days) in combination with intravenous bendamustine 90\u00a0mg/m</span>", "ID": "630b8fcf-8adf-4960-8e01-edb34c1c1f85", "Styles": "None", "Classes": "None", "Text": "Patients received Arzerra as monthly intravenous infusions (cycle\u00a01 300\u00a0mg on day\u00a01 and 1000\u00a0mg on day\u00a08; subsequent cycles: 1000\u00a0mg on day\u00a01 every 28\u00a0days) in combination with intravenous bendamustine 90\u00a0mg/m", "ParentId": "5dd2439f-1c2e-4213-88c9-ff2bc50fadbf"}, {"Element": "<sup><span lang=\"EN-GB\" style=\"font-size:8.0pt\">2</span></sup>", "ID": "4d5199d4-0c2b-40c8-b9b2-98606c1c04a3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5dd2439f-1c2e-4213-88c9-ff2bc50fadbf"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:8.0pt\">2</span>", "ID": "a71f8cbe-18cc-4ad7-b939-a460f65e7031", "Styles": "font-size:8.0pt", "Classes": "None", "Text": "2", "ParentId": "4d5199d4-0c2b-40c8-b9b2-98606c1c04a3"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:8.0pt\"> </span>", "ID": "254854b6-651f-4021-a7c9-d112b4c8ba05", "Styles": "font-size:8.0pt", "Classes": "None", "Text": " ", "ParentId": "5dd2439f-1c2e-4213-88c9-ff2bc50fadbf"}, {"Element": "<span lang=\"EN-GB\">on days\u00a01 and 2 every\n28\u00a0days. </span>", "ID": "ff8c09d3-2239-4c98-8b64-0ce44957aac6", "Styles": "None", "Classes": "None", "Text": "on days\u00a01 and 2 every 28\u00a0days. ", "ParentId": "5dd2439f-1c2e-4213-88c9-ff2bc50fadbf"}, {"Element": "<span lang=\"EN-GB\" style=\"border:none windowtext 1.0pt;padding:0in\">median\nnumber of cycles completed in patients was 6 (total Arzerra dose of\n6300\u00a0mg).</span>", "ID": "a83cd8d7-6bdd-451a-a48b-8642a5e08dec", "Styles": "border:none windowtext 1.0pt;padding:0in", "Classes": "None", "Text": "median number of cycles completed in patients was 6 (total Arzerra dose of 6300\u00a0mg).", "ParentId": "5dd2439f-1c2e-4213-88c9-ff2bc50fadbf"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"border:none windowtext 1.0pt;\npadding:0in\">\u00a0</span></p>", "ID": "0bcf829b-3924-4e4e-bf8e-8c883a946f86", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"border:none windowtext 1.0pt;\npadding:0in\">\u00a0</span>", "ID": "c4f5b4b1-058b-45a0-a809-520a1a4a861b", "Styles": "border:none windowtext 1.0pt;\npadding:0in", "Classes": "None", "Text": "\u00a0", "ParentId": "0bcf829b-3924-4e4e-bf8e-8c883a946f86"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The primary endpoint was ORR assessed by\nthe investigator </span>according to the 2008 <span lang=\"EN-GB\">IWCLL </span>guidelines<span lang=\"EN-GB\">.</span></p>", "ID": "f0f543e0-7252-489b-9f3e-4dcdbcf968f6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "according to the 2008 guidelines", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">The primary endpoint was ORR assessed by\nthe investigator </span>", "ID": "9e0153eb-5e0c-44d8-892b-01b1e4df644a", "Styles": "None", "Classes": "None", "Text": "The primary endpoint was ORR assessed by the investigator ", "ParentId": "f0f543e0-7252-489b-9f3e-4dcdbcf968f6"}, {"Element": "<span lang=\"EN-GB\">IWCLL </span>", "ID": "312ed49e-6eb1-4b44-af9d-13726131f99e", "Styles": "None", "Classes": "None", "Text": "IWCLL ", "ParentId": "f0f543e0-7252-489b-9f3e-4dcdbcf968f6"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "73973d3c-1eb6-41fb-a509-49fabbbb77ad", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "f0f543e0-7252-489b-9f3e-4dcdbcf968f6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0271fc2b-9806-4a4f-b58b-8805fd97f335", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e1ee46b7-11dd-4e45-b002-e4cf72d55525", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0271fc2b-9806-4a4f-b58b-8805fd97f335"}, {"Element": "<p><span style=\"font-size:11.0pt\">The results of this study demonstrated that\nArzerra in combination with bendamustine is an effective therapy providing an\nORR of 95% </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">(95% CI: 85, 99) </span><span style=\"font-size:11.0pt\">and a CR of 43%. More than half of the patients (56%) </span><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black\">with CR were MRD negative\nfollowing the completion of study treatment.</span></p>", "ID": "3422acf4-a0ba-4913-b896-d5495c5246a3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">The results of this study demonstrated that\nArzerra in combination with bendamustine is an effective therapy providing an\nORR of 95% </span>", "ID": "bd436f7c-60dc-4c6d-9e6a-0ece167ac070", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "The results of this study demonstrated that Arzerra in combination with bendamustine is an effective therapy providing an ORR of 95% ", "ParentId": "3422acf4-a0ba-4913-b896-d5495c5246a3"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt\">(95% CI: 85, 99) </span>", "ID": "1189b49e-c8a4-4c71-9913-493b3fadf3ed", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "(95% CI: 85, 99) ", "ParentId": "3422acf4-a0ba-4913-b896-d5495c5246a3"}, {"Element": "<span style=\"font-size:11.0pt\">and a CR of 43%. More than half of the patients (56%) </span>", "ID": "e8de0ff4-0375-42d2-91b0-6231c4c3b3e8", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "and a CR of 43%. More than half of the patients (56%) ", "ParentId": "3422acf4-a0ba-4913-b896-d5495c5246a3"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black\">with CR were MRD negative\nfollowing the completion of study treatment.</span>", "ID": "2fb536e9-78e9-4d21-a23c-fce67b2bdb68", "Styles": "font-size:11.0pt;color:black", "Classes": "None", "Text": "with CR were MRD negative following the completion of study treatment.", "ParentId": "3422acf4-a0ba-4913-b896-d5495c5246a3"}, {"Element": "<p><span lang=\"EN-GB\" style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "afd50dcd-53b3-4f4e-8834-0c0b0d38181b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt\">\u00a0</span>", "ID": "ba3a5967-8c5a-4d0f-a072-7d072343be6d", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "afd50dcd-53b3-4f4e-8834-0c0b0d38181b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">No data comparing Arzerra in combination\nwith bendamustine or with </span><span lang=\"EN-GB\">chlorambucil versus a</span><span lang=\"EN-GB\"> rituximab based regimen such as rituximab with chlorambucil is\navailable. Thus, the benefit of such a new combination over a rituximab based\nregimen is unknown.</span></p>", "ID": "2840e866-97ba-4260-9f46-c75f1858eb48", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">No data comparing Arzerra in combination\nwith bendamustine or with </span>", "ID": "a004273b-ace9-47fa-bb7e-887a0f3394b0", "Styles": "None", "Classes": "None", "Text": "No data comparing Arzerra in combination with bendamustine or with ", "ParentId": "2840e866-97ba-4260-9f46-c75f1858eb48"}, {"Element": "<span lang=\"EN-GB\">chlorambucil versus a</span>", "ID": "86549395-cd09-4eba-a514-91fe666f7a20", "Styles": "None", "Classes": "None", "Text": "chlorambucil versus a", "ParentId": "2840e866-97ba-4260-9f46-c75f1858eb48"}, {"Element": "<span lang=\"EN-GB\"> rituximab based regimen such as rituximab with chlorambucil is\navailable. Thus, the benefit of such a new combination over a rituximab based\nregimen is unknown.</span>", "ID": "b0da090d-63d4-49a4-96fa-d160f825c47e", "Styles": "None", "Classes": "None", "Text": " rituximab based regimen such as rituximab with chlorambucil is available. Thus, the benefit of such a new combination over a rituximab based regimen is unknown.", "ParentId": "2840e866-97ba-4260-9f46-c75f1858eb48"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "f2c17ece-e96a-418a-9bd3-1944416d1ea1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\navoid\"><u><span style=\"font-size:11.0pt\">Relapsed CLL</span></u></p>", "ID": "dc3a6fb8-7cc1-4eda-8c6c-c4ebf4b5f7d7", "Styles": "margin-top:0in;text-align:left;page-break-after:\navoid", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span style=\"font-size:11.0pt\">Relapsed CLL</span></u>", "ID": "e4a66810-e938-48a1-a6ac-a61d790a6205", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dc3a6fb8-7cc1-4eda-8c6c-c4ebf4b5f7d7"}, {"Element": "<span style=\"font-size:11.0pt\">Relapsed CLL</span>", "ID": "258fd45a-44c6-45c9-9f7f-9199877dba0c", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "Relapsed CLL", "ParentId": "e4a66810-e938-48a1-a6ac-a61d790a6205"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "de777d63-3014-45c6-bbf8-6850a422a25e", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2c180b74-6397-47af-abb6-f3440ad10090", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "de777d63-3014-45c6-bbf8-6850a422a25e"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Study OMB110913\n(randomised, open-label, parallel-arm, multicentre trial) evaluated the\nefficacy of ofatumumab in combination with fludarabine and cyclophosphamide\ncompared with fludarabine and cyclophosphamide in 365\u00a0patients with\nrelapsed CLL (</span>defined as a patient who has received at least one prior\nCLL therapy and previously achieved a complete or partial remission/response,\nbut after a period of six or more months demonstrated evidence of disease\nprogression)<span lang=\"EN-GB\">. Baseline disease characteristics and prognostic\nmarkers were balanced between treatment arms and representative of a relapsed\nCLL population. Patient median age was 61\u00a0years (range: 32 to\n90\u00a0years, 7% were 75\u00a0years of age or older), 60% were male and 16%,\n55% and 28% of patients were Binet stage A, B and C, respectively. The majority\nof patients (81%) received 1\u20112\u00a0prior lines of treatments (of whom\napproximately 50% received 1\u00a0prior treatment) and 21% of patients had\nreceived prior rituximab. The median CIRS score was 7 (range:\u00a04 to 17),\n36% of patients had CrCL </span><span style=\"font-family:CourierNewPSMT\">&lt;70</span>\u00a0<span style=\"font-family:CourierNewPSMT\">ml/min,</span><span lang=\"EN-GB\"> 93% of\npatients had ECOG 0 or 1. </span>Limited data are available in the\nheterogeneous non-white population and in patients with an ECOG performance\nstatus of 2.</p>", "ID": "de1c1c7f-a9b0-4c2c-8880-a72d983439fe", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "defined as a patient who has received at least one prior CLL therapy and previously achieved a complete or partial remission/response, but after a period of six or more months demonstrated evidence of disease progression)\u00a0Limited data are available in the heterogeneous non-white population and in patients with an ECOG performance status of 2.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Study OMB110913\n(randomised, open-label, parallel-arm, multicentre trial) evaluated the\nefficacy of ofatumumab in combination with fludarabine and cyclophosphamide\ncompared with fludarabine and cyclophosphamide in 365\u00a0patients with\nrelapsed CLL (</span>", "ID": "ce37c962-e496-4b56-b0bd-163a4ae21099", "Styles": "None", "Classes": "None", "Text": "Study OMB110913 (randomised, open-label, parallel-arm, multicentre trial) evaluated the efficacy of ofatumumab in combination with fludarabine and cyclophosphamide compared with fludarabine and cyclophosphamide in 365\u00a0patients with relapsed CLL (", "ParentId": "de1c1c7f-a9b0-4c2c-8880-a72d983439fe"}, {"Element": "<span lang=\"EN-GB\">. Baseline disease characteristics and prognostic\nmarkers were balanced between treatment arms and representative of a relapsed\nCLL population. Patient median age was 61\u00a0years (range: 32 to\n90\u00a0years, 7% were 75\u00a0years of age or older), 60% were male and 16%,\n55% and 28% of patients were Binet stage A, B and C, respectively. The majority\nof patients (81%) received 1\u20112\u00a0prior lines of treatments (of whom\napproximately 50% received 1\u00a0prior treatment) and 21% of patients had\nreceived prior rituximab. The median CIRS score was 7 (range:\u00a04 to 17),\n36% of patients had CrCL </span>", "ID": "81270049-c6df-4427-a773-cfa9fcf3be67", "Styles": "None", "Classes": "None", "Text": ". Baseline disease characteristics and prognostic markers were balanced between treatment arms and representative of a relapsed CLL population. Patient median age was 61\u00a0years (range: 32 to 90\u00a0years, 7% were 75\u00a0years of age or older), 60% were male and 16%, 55% and 28% of patients were Binet stage A, B and C, respectively. The majority of patients (81%) received 1\u20112\u00a0prior lines of treatments (of whom approximately 50% received 1\u00a0prior treatment) and 21% of patients had received prior rituximab. The median CIRS score was 7 (range:\u00a04 to 17), 36% of patients had CrCL ", "ParentId": "de1c1c7f-a9b0-4c2c-8880-a72d983439fe"}, {"Element": "<span style=\"font-family:CourierNewPSMT\">&lt;70</span>", "ID": "32e7e196-3ef2-4f4d-8d2d-bcea1d4e4a84", "Styles": "font-family:CourierNewPSMT", "Classes": "None", "Text": "<70", "ParentId": "de1c1c7f-a9b0-4c2c-8880-a72d983439fe"}, {"Element": "<span style=\"font-family:CourierNewPSMT\">ml/min,</span>", "ID": "0bd03e3f-3666-4ad0-9dce-d46ba43da280", "Styles": "font-family:CourierNewPSMT", "Classes": "None", "Text": "ml/min,", "ParentId": "de1c1c7f-a9b0-4c2c-8880-a72d983439fe"}, {"Element": "<span lang=\"EN-GB\"> 93% of\npatients had ECOG 0 or 1. </span>", "ID": "7db68b75-9682-4fd4-8ac0-fa6c9eabe079", "Styles": "None", "Classes": "None", "Text": " 93% of patients had ECOG 0 or 1. ", "ParentId": "de1c1c7f-a9b0-4c2c-8880-a72d983439fe"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "d4515467-4397-4a0e-883b-0235d1d10d16", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">\u00a0</span>", "ID": "b3899d97-104b-49d7-ae1a-fddb1c29b02d", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "d4515467-4397-4a0e-883b-0235d1d10d16"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Patients received ofatumumab as intravenous\ninfusions (cycle\u00a01: 300\u00a0mg on day\u00a01 and 1000\u00a0mg on\nday\u00a08;</span><span style=\"font-size:11.0pt\"> subsequent cycles:\n1000\u00a0mg on day\u00a01 every 28\u00a0days</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">). Approximately 90% of patients received 3\u20116\u00a0cycles\nof ofatumumab and 66% completed 6\u00a0cycles.</span></p>", "ID": "99fedaa4-b329-4e0b-8b66-90721ffd08fb", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt\">Patients received ofatumumab as intravenous\ninfusions (cycle\u00a01: 300\u00a0mg on day\u00a01 and 1000\u00a0mg on\nday\u00a08;</span>", "ID": "684ababa-df97-4ee8-98d4-542585d4f1ef", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "Patients received ofatumumab as intravenous infusions (cycle\u00a01: 300\u00a0mg on day\u00a01 and 1000\u00a0mg on day\u00a08;", "ParentId": "99fedaa4-b329-4e0b-8b66-90721ffd08fb"}, {"Element": "<span style=\"font-size:11.0pt\"> subsequent cycles:\n1000\u00a0mg on day\u00a01 every 28\u00a0days</span>", "ID": "8c198c69-a919-4c96-9e86-b5fb6a2bf75a", "Styles": "font-size:11.0pt", "Classes": "None", "Text": " subsequent cycles: 1000\u00a0mg on day\u00a01 every 28\u00a0days", "ParentId": "99fedaa4-b329-4e0b-8b66-90721ffd08fb"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt\">). Approximately 90% of patients received 3\u20116\u00a0cycles\nof ofatumumab and 66% completed 6\u00a0cycles.</span>", "ID": "c956a161-3a07-47ea-a918-3e10b3860ebc", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "). Approximately 90% of patients received 3\u20116\u00a0cycles of ofatumumab and 66% completed 6\u00a0cycles.", "ParentId": "99fedaa4-b329-4e0b-8b66-90721ffd08fb"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "c6decfbb-a39c-4030-9635-61f7bbf1e02d", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt\">\u00a0</span>", "ID": "d7a31b05-93e3-4213-a7fc-d862b322d3f4", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "c6decfbb-a39c-4030-9635-61f7bbf1e02d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The primary endpoint of progression-free\nsurvival (PFS), as assessed by a blinded independent review committee (IRC)\nusing the updated National Cancer Institute-sponsored Working Group (NCI-WG)\nguidelines (2008), was prolonged in the ofatumumab plus\nfludarabine-cyclophosphamide (OFA+FC) arm compared to the\nfludarabine-cyclophosphamide (FC) arm (28.9\u00a0months versus 18.8\u00a0months;\nHR: 0.67; 95% CI: 0.51\u20110.88, p=0.0032) resulting in a 10-month\nimprovement in median PFS (see Figure\u00a02). PFS based on local\n(investigator) assessment was consistent with the primary endpoint and resulted\nin a ~11-month improvement in median PFS (OFA+FC 27.2\u00a0months versus\n16.8\u00a0months for FC; HR=0.66 (95% CI: 0.51, 0.85, p=0.0009).</span></p>", "ID": "4914ae10-a84f-42e5-b98a-3e507836f723", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">The primary endpoint of progression-free\nsurvival (PFS), as assessed by a blinded independent review committee (IRC)\nusing the updated National Cancer Institute-sponsored Working Group (NCI-WG)\nguidelines (2008), was prolonged in the ofatumumab plus\nfludarabine-cyclophosphamide (OFA+FC) arm compared to the\nfludarabine-cyclophosphamide (FC) arm (28.9\u00a0months versus 18.8\u00a0months;\nHR: 0.67; 95% CI: 0.51\u20110.88, p=0.0032) resulting in a 10-month\nimprovement in median PFS (see Figure\u00a02). PFS based on local\n(investigator) assessment was consistent with the primary endpoint and resulted\nin a ~11-month improvement in median PFS (OFA+FC 27.2\u00a0months versus\n16.8\u00a0months for FC; HR=0.66 (95% CI: 0.51, 0.85, p=0.0009).</span>", "ID": "fe2097b4-a3be-48a6-9e18-e7df6f61e8ab", "Styles": "None", "Classes": "None", "Text": "The primary endpoint of progression-free survival (PFS), as assessed by a blinded independent review committee (IRC) using the updated National Cancer Institute-sponsored Working Group (NCI-WG) guidelines (2008), was prolonged in the ofatumumab plus fludarabine-cyclophosphamide (OFA+FC) arm compared to the fludarabine-cyclophosphamide (FC) arm (28.9\u00a0months versus 18.8\u00a0months; HR: 0.67; 95% CI: 0.51\u20110.88, p=0.0032) resulting in a 10-month improvement in median PFS (see Figure\u00a02). PFS based on local (investigator) assessment was consistent with the primary endpoint and resulted in a ~11-month improvement in median PFS (OFA+FC 27.2\u00a0months versus 16.8\u00a0months for FC; HR=0.66 (95% CI: 0.51, 0.85, p=0.0009).", "ParentId": "4914ae10-a84f-42e5-b98a-3e507836f723"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a880a7e5-347e-4ebf-9619-f61d8a65e520", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "34d0e2f7-b759-4e47-b2b0-cba030741e4e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a880a7e5-347e-4ebf-9619-f61d8a65e520"}, {"Element": "<p align=\"left\" class=\"MsoHeading7\" style=\"text-align:left;line-height:normal\"><b><span style=\"font-style:normal\">Figure\u00a02\u00a0\u00a0\u00a0\u00a0\u00a0 Kaplan-Meier estimates of PFS in\nrelapsed CLL</span></b></p>", "ID": "63bd5a69-437b-4b61-addc-40c45a18c2bb", "Styles": "text-align:left;line-height:normal", "Classes": "['MsoHeading7']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span style=\"font-style:normal\">Figure\u00a02\u00a0\u00a0\u00a0\u00a0\u00a0 Kaplan-Meier estimates of PFS in\nrelapsed CLL</span></b>", "ID": "4630d93f-18a9-4509-b010-87f4b9512f89", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "63bd5a69-437b-4b61-addc-40c45a18c2bb"}, {"Element": "<span style=\"font-style:normal\">Figure\u00a02\u00a0\u00a0\u00a0\u00a0\u00a0 Kaplan-Meier estimates of PFS in\nrelapsed CLL</span>", "ID": "2ccda0a3-959e-4589-9256-5f236a9746d0", "Styles": "font-style:normal", "Classes": "None", "Text": "Figure\u00a02\u00a0\u00a0\u00a0\u00a0\u00a0 Kaplan-Meier estimates of PFS in relapsed CLL", "ParentId": "4630d93f-18a9-4509-b010-87f4b9512f89"}, {"Element": "<p align=\"left\" class=\"MsoHeading7\" style=\"text-align:left;line-height:normal\"><span style=\"position:absolute;z-index:-1895825920;margin-left:-20px;margin-top:16px;\nwidth:605px;height:327px\"><img height=\"327\" src=\"Arzerra%20II-50%20&amp;%20II-51%20-%20PI%20-%20EN%20-%20clea_files/image003.jpg\" width=\"605\"/></span></p>", "ID": "ecedda60-4ed9-4579-a228-64ea6d1e61b7", "Styles": "text-align:left;line-height:normal", "Classes": "['MsoHeading7']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"position:absolute;z-index:-1895825920;margin-left:-20px;margin-top:16px;\nwidth:605px;height:327px\"><img height=\"327\" src=\"Arzerra%20II-50%20&amp;%20II-51%20-%20PI%20-%20EN%20-%20clea_files/image003.jpg\" width=\"605\"/></span>", "ID": "693a28a7-20d5-4ce4-ac90-405620bd42f8", "Styles": "position:absolute;z-index:-1895825920;margin-left:-20px;margin-top:16px;\nwidth:605px;height:327px", "Classes": "None", "Text": "", "ParentId": "ecedda60-4ed9-4579-a228-64ea6d1e61b7"}, {"Element": "<img height=\"327\" src=\"Arzerra%20II-50%20&amp;%20II-51%20-%20PI%20-%20EN%20-%20clea_files/image003.jpg\" width=\"605\"/>", "ID": "2930875b-034b-4d28-88e8-b701ced562d0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "693a28a7-20d5-4ce4-ac90-405620bd42f8"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "62e9096a-2ed3-42b3-b5aa-7b1ac311bf38", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">\u00a0</span>", "ID": "41d1ade4-9c38-49a7-9d74-cdabe70ddf0e", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "62e9096a-2ed3-42b3-b5aa-7b1ac311bf38"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "d7ad1d5c-a911-4979-a316-bd8cc60915a7", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">\u00a0</span>", "ID": "7dc5a359-3cd8-4e43-a5e8-c9b38fceae5b", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "d7ad1d5c-a911-4979-a316-bd8cc60915a7"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "28bc089f-70cb-4c37-b82b-2b14d7730769", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">\u00a0</span>", "ID": "6f8e16b8-67c4-445a-9465-43cf53ad1b63", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "28bc089f-70cb-4c37-b82b-2b14d7730769"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "84f16a7c-2471-4b6d-8c53-705ec5f81891", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">\u00a0</span>", "ID": "89a9d025-2f4a-4a54-86d1-57f2ac86d33b", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "84f16a7c-2471-4b6d-8c53-705ec5f81891"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "efb60094-f5d3-4d5a-86d9-1d94879c8069", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">\u00a0</span>", "ID": "10f4eba5-9453-4922-b832-8ef7f52772e2", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "efb60094-f5d3-4d5a-86d9-1d94879c8069"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "64cba3ee-f0a6-428f-8ed5-0f30e3d27b2d", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">\u00a0</span>", "ID": "1e9f2bb5-d644-46a5-bf67-6cea9efdc886", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "64cba3ee-f0a6-428f-8ed5-0f30e3d27b2d"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "c91dba09-532d-474b-b509-534cd1832652", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">\u00a0</span>", "ID": "1ff1e176-3c29-4cf6-adc2-7169ae5d9d98", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "c91dba09-532d-474b-b509-534cd1832652"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "915e03c1-655c-4645-a2da-0e991223edb0", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">\u00a0</span>", "ID": "8572c9bb-7fc7-4032-8266-a4b57c948ee7", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "915e03c1-655c-4645-a2da-0e991223edb0"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "76dfb23f-49f0-4861-9792-f6691bbebc3b", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">\u00a0</span>", "ID": "adb94cbb-5d18-4868-a0f6-92b247cdb733", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "76dfb23f-49f0-4861-9792-f6691bbebc3b"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "f050ebb3-1838-4fba-8931-86ad3c3b35d6", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">\u00a0</span>", "ID": "d74fab6b-5c39-4e60-b38b-675b5fd22fce", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "f050ebb3-1838-4fba-8931-86ad3c3b35d6"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "804604bc-f7fa-46d3-9cd5-d9953f8ad269", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">\u00a0</span>", "ID": "7746b847-16c4-46da-85de-8830f587b62a", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "804604bc-f7fa-46d3-9cd5-d9953f8ad269"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "035bcca6-697e-4d48-aeb3-4b4571c0ffc0", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">\u00a0</span>", "ID": "1bd872a0-1b07-4b81-8ae8-5d699e430e73", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "035bcca6-697e-4d48-aeb3-4b4571c0ffc0"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "456e2da1-7f41-427d-a81b-8953750579d6", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">\u00a0</span>", "ID": "a291ec6d-5976-4484-b5db-4125318a9d36", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "456e2da1-7f41-427d-a81b-8953750579d6"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "f4f6b12f-d195-487a-8567-5e5017e5a5d2", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">\u00a0</span>", "ID": "44f6e87e-f903-47f3-a3bd-95646bc5ec82", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "f4f6b12f-d195-487a-8567-5e5017e5a5d2"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "c0ac0344-09c5-4284-a2a2-2edc42b8b85e", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">\u00a0</span>", "ID": "5bcb2e7c-ae7f-4b34-add9-56420c624b74", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "c0ac0344-09c5-4284-a2a2-2edc42b8b85e"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "26b1b7c2-824d-4ccd-8a00-95e41e54fa1b", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">\u00a0</span>", "ID": "efcc33da-4e42-4d45-a446-c148d6d4a216", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "26b1b7c2-824d-4ccd-8a00-95e41e54fa1b"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "5199b375-02fe-4afc-b9d2-100d172de57e", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">\u00a0</span>", "ID": "08a3a1a7-9cd2-47aa-860a-1cda058ae9a1", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "5199b375-02fe-4afc-b9d2-100d172de57e"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "f7d82214-c560-4086-bbfd-9149dbc67759", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">\u00a0</span>", "ID": "caef19e2-daa0-4f8a-9c57-b774fbe3572f", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "f7d82214-c560-4086-bbfd-9149dbc67759"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "ee0b2867-ab90-4f13-a731-f2fc3323dff7", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">\u00a0</span>", "ID": "c6569434-587d-424c-b4a9-670eafa53490", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "ee0b2867-ab90-4f13-a731-f2fc3323dff7"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "c38a9fcc-bdf1-48e9-9263-5dc355b36d24", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">\u00a0</span>", "ID": "5817f557-8aa9-4a28-8dcc-7b3c7e1696dc", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "c38a9fcc-bdf1-48e9-9263-5dc355b36d24"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">The overall response rate (ORR) was also assessed by\nan IRC using the 2008 NCI-WG guidelines. The ORR was higher for OFA+FC versus\nFC (84% versus 68%, p=0.0003). Median time to next therapy was longer for the\nOFA+FC arm versus FC (48.1\u00a0months versus 40.1\u00a0months; HR: 0.73; 95%\nCI: 0.51\u20111.05). Median time to progression was longer for the OFA+FC arm\nversus FC (42.1\u00a0months versus 26.8\u00a0months; HR: 0.63; 95% CI: 0.45\u20110.87).</span></p>", "ID": "f2160b44-6b0a-413c-aaf6-a722ff241526", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">The overall response rate (ORR) was also assessed by\nan IRC using the 2008 NCI-WG guidelines. The ORR was higher for OFA+FC versus\nFC (84% versus 68%, p=0.0003). Median time to next therapy was longer for the\nOFA+FC arm versus FC (48.1\u00a0months versus 40.1\u00a0months; HR: 0.73; 95%\nCI: 0.51\u20111.05). Median time to progression was longer for the OFA+FC arm\nversus FC (42.1\u00a0months versus 26.8\u00a0months; HR: 0.63; 95% CI: 0.45\u20110.87).</span>", "ID": "3348a7b9-7259-4e83-9bb5-3dfec3d48b82", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "The overall response rate (ORR) was also assessed by an IRC using the 2008 NCI-WG guidelines. The ORR was higher for OFA+FC versus FC (84% versus 68%, p=0.0003). Median time to next therapy was longer for the OFA+FC arm versus FC (48.1\u00a0months versus 40.1\u00a0months; HR: 0.73; 95% CI: 0.51\u20111.05). Median time to progression was longer for the OFA+FC arm versus FC (42.1\u00a0months versus 26.8\u00a0months; HR: 0.63; 95% CI: 0.45\u20110.87).", "ParentId": "f2160b44-6b0a-413c-aaf6-a722ff241526"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "9eef56cd-f551-4413-b910-c171d91bc62f", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">\u00a0</span>", "ID": "ef3d7725-9856-4197-8748-655c5f441844", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "9eef56cd-f551-4413-b910-c171d91bc62f"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">With a median\nfollow-up of approximately 34\u00a0months, 67\u00a0deaths (37%) in the OFA+FC\narm and 69\u00a0deaths (38%) in the FC arm were reported. The overall survival\nresults showed a HR=0.78 (56.4\u00a0months versus 45.8\u00a0months for the\nOFA+FC arm versus FC arm; 95% CI: 0.56\u20111.09; p=0.1410).</span></p>", "ID": "10fd7c81-c645-4688-930b-071ce4e2198c", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">With a median\nfollow-up of approximately 34\u00a0months, 67\u00a0deaths (37%) in the OFA+FC\narm and 69\u00a0deaths (38%) in the FC arm were reported. The overall survival\nresults showed a HR=0.78 (56.4\u00a0months versus 45.8\u00a0months for the\nOFA+FC arm versus FC arm; 95% CI: 0.56\u20111.09; p=0.1410).</span>", "ID": "f0b83b7c-63e7-4e28-8a0c-1947de6a83ea", "Styles": "None", "Classes": "None", "Text": "With a median follow-up of approximately 34\u00a0months, 67\u00a0deaths (37%) in the OFA+FC arm and 69\u00a0deaths (38%) in the FC arm were reported. The overall survival results showed a HR=0.78 (56.4\u00a0months versus 45.8\u00a0months for the OFA+FC arm versus FC arm; 95% CI: 0.56\u20111.09; p=0.1410).", "ParentId": "10fd7c81-c645-4688-930b-071ce4e2198c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "01a5db11-f333-4f12-bdad-988fb20de991", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "44638cc2-f56e-413c-b275-132c45a502bc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "01a5db11-f333-4f12-bdad-988fb20de991"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Refractory CLL</u></p>", "ID": "12307a39-aebe-4e1d-afb8-c1a89d9e1dd1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u>Refractory CLL</u>", "ID": "129ee5a0-2a91-4a88-a322-f5834021c6d6", "Styles": "None", "Classes": "None", "Text": "Refractory CLL", "ParentId": "12307a39-aebe-4e1d-afb8-c1a89d9e1dd1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "881e6232-feef-452f-8ba7-0242251bf498", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a054a417-4647-4ac9-81d5-1360aa8492b1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "881e6232-feef-452f-8ba7-0242251bf498"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Arzerra was administered as monotherapy to\n223\u00a0patients with refractory CLL (study Hx-CD20-406). Patient median age\nwas 64\u00a0years (range: 41 to 87\u00a0years), and the majority were male\n(73%) and white (96%). Patients received a median of 5\u00a0prior therapies,\nincluding rituximab (57%). Of these 223\u00a0patients, 95\u00a0patients were\nrefractory to fludarabine and alemtuzumab therapy (defined as </span><span lang=\"EN-GB\">failure to achieve at least a partial response with fludarabine or\nalemtuzumab treatment or disease progression within 6\u00a0months of the last\ndose of fludarabine or alemtuzumab). </span>Baseline cytogenetic (FISH) data\nwere available for 209\u00a0patients. 36\u00a0patients had a normal karyotype\nand chromosomal aberrations were detected in 174\u00a0patients; there were\n47\u00a0patients with 17p deletion, 73\u00a0patients with 11q deletion,\n23\u00a0patients with trisomy 12q, and 31\u00a0patients with 13q deletion as\nthe sole aberration.</p>", "ID": "6fbdd637-1c49-4be9-8984-68506bec97a7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Baseline cytogenetic (FISH) data were available for 209\u00a0patients. 36\u00a0patients had a normal karyotype and chromosomal aberrations were detected in 174\u00a0patients; there were 47\u00a0patients with 17p deletion, 73\u00a0patients with 11q deletion, 23\u00a0patients with trisomy 12q, and 31\u00a0patients with 13q deletion as the sole aberration.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Arzerra was administered as monotherapy to\n223\u00a0patients with refractory CLL (study Hx-CD20-406). Patient median age\nwas 64\u00a0years (range: 41 to 87\u00a0years), and the majority were male\n(73%) and white (96%). Patients received a median of 5\u00a0prior therapies,\nincluding rituximab (57%). Of these 223\u00a0patients, 95\u00a0patients were\nrefractory to fludarabine and alemtuzumab therapy (defined as </span>", "ID": "8efc5fb1-f34d-41b7-9e49-d7dd717b5871", "Styles": "None", "Classes": "None", "Text": "Arzerra was administered as monotherapy to 223\u00a0patients with refractory CLL (study Hx-CD20-406). Patient median age was 64\u00a0years (range: 41 to 87\u00a0years), and the majority were male (73%) and white (96%). Patients received a median of 5\u00a0prior therapies, including rituximab (57%). Of these 223\u00a0patients, 95\u00a0patients were refractory to fludarabine and alemtuzumab therapy (defined as ", "ParentId": "6fbdd637-1c49-4be9-8984-68506bec97a7"}, {"Element": "<span lang=\"EN-GB\">failure to achieve at least a partial response with fludarabine or\nalemtuzumab treatment or disease progression within 6\u00a0months of the last\ndose of fludarabine or alemtuzumab). </span>", "ID": "d5981642-70ae-4abf-89b7-c49b15b4cef4", "Styles": "None", "Classes": "None", "Text": "failure to achieve at least a partial response with fludarabine or alemtuzumab treatment or disease progression within 6\u00a0months of the last dose of fludarabine or alemtuzumab). ", "ParentId": "6fbdd637-1c49-4be9-8984-68506bec97a7"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a751d3d4-f6a6-49f6-bb35-9af4e0b66fc8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The ORR was 49% in patients refractory to\nfludarabine and alemtuzumab (see Table\u00a03 for a summary of the efficacy\ndata from the study). </span><span lang=\"EN-GB\">Patients who had prior rituximab\ntherapy, either as monotherapy or in combination with other medicinal products,\nresponded to treatment with Arzerra at a similar rate to those who had not had\nprior rituximab therapy.</span></p>", "ID": "c2a87545-fee3-4b15-8042-a27665e3435b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">The ORR was 49% in patients refractory to\nfludarabine and alemtuzumab (see Table\u00a03 for a summary of the efficacy\ndata from the study). </span>", "ID": "f073a6b0-4057-4d50-ae4a-fd0299ad1a56", "Styles": "None", "Classes": "None", "Text": "The ORR was 49% in patients refractory to fludarabine and alemtuzumab (see Table\u00a03 for a summary of the efficacy data from the study). ", "ParentId": "c2a87545-fee3-4b15-8042-a27665e3435b"}, {"Element": "<span lang=\"EN-GB\">Patients who had prior rituximab\ntherapy, either as monotherapy or in combination with other medicinal products,\nresponded to treatment with Arzerra at a similar rate to those who had not had\nprior rituximab therapy.</span>", "ID": "9fa04a99-9dfc-4747-b80e-c1e50060b3f0", "Styles": "None", "Classes": "None", "Text": "Patients who had prior rituximab therapy, either as monotherapy or in combination with other medicinal products, responded to treatment with Arzerra at a similar rate to those who had not had prior rituximab therapy.", "ParentId": "c2a87545-fee3-4b15-8042-a27665e3435b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7b87a8a5-946d-4530-a0be-67f9d4c62f60", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f04c6ef6-a5f4-4668-b9cd-44d52e5c913d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7b87a8a5-946d-4530-a0be-67f9d4c62f60"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table\u00a03\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Summary\nof response to Arzerra in patients with refractory CLL</span></b></p>", "ID": "07149b91-4f4b-488c-8db0-bd52d5a2aa0a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">Table\u00a03\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Summary\nof response to Arzerra in patients with refractory CLL</span></b>", "ID": "256ac6d0-32eb-4f8b-89a5-6e596b0065fa", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "07149b91-4f4b-488c-8db0-bd52d5a2aa0a"}, {"Element": "<span lang=\"EN-GB\">Table\u00a03\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Summary\nof response to Arzerra in patients with refractory CLL</span>", "ID": "cd75bce1-dc38-4bcd-ade0-6e1fb7b0e28a", "Styles": "None", "Classes": "None", "Text": "Table\u00a03\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Summary of response to Arzerra in patients with refractory CLL", "ParentId": "256ac6d0-32eb-4f8b-89a5-6e596b0065fa"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d8e805f4-510e-45b0-97c1-343fbf3252e2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "43fad78b-1308-49b8-a460-d1dd9824da4d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d8e805f4-510e-45b0-97c1-343fbf3252e2"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:100.0%;border-collapse:collapse;border:none\" width=\"100%\">\n<tr>\n<td style=\"width:57.06%;border:solid windowtext 1.0pt;padding:\n  0in 5.4pt 0in 5.4pt\" width=\"57%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(Primary) endpoint<sup>1</sup></span></p>\n</td>\n<td style=\"width:42.94%;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Patients refractory to fludarabine and alemtuzumab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">n=95</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Overall\n  response rate</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">Responders, n (%)</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">47 (49)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">95.3% CI (%)</span></p>\n</td>\n<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">39, 60</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Response\n  rate in patients with prior rituximab therapy</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">Responders, n (%)</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25/56 (45)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI (%)</span></p>\n</td>\n<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31, 59</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Response\n  rate in patients with chromosomal abnormality</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:7.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">17p deletion</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">Responders, n (%)</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">10/27 (37)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI (%)</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">19, 58</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:7.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">11q deletion</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">Responders, n (%)</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">15/32 (47)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI (%)</span></p>\n</td>\n<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">29, 65</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median\n  overall survival</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">Months</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">13.9</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI</span></p>\n</td>\n<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">9.9, 18.6</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Progression-free\n  survival</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">Months</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">4.6</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI</span></p>\n</td>\n<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">3.9, 6.3</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median\n  duration of response</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">Months</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5.5</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI</span></p>\n</td>\n<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">3.7, 7.2</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median\n  time to next CLL therapy</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">Months</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">8.5</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI</span></p>\n</td>\n<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">7.2, 9.9</span></p>\n</td>\n</tr>\n<tr style=\"height:13.7pt\">\n<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><sup><span lang=\"EN-GB\">1 </span></sup><span lang=\"EN-GB\">The overall response was assessed by an </span>Independent\n  Response Committee<span lang=\"EN-GB\"> using the 1996 NCI-WG guidelines for CLL.</span></p>\n</td>\n</tr>\n</table>", "ID": "ca2382de-b302-453d-8955-cb3133ecad6e", "Styles": "width:100.0%;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "                            ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<tr>\n<td style=\"width:57.06%;border:solid windowtext 1.0pt;padding:\n  0in 5.4pt 0in 5.4pt\" width=\"57%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(Primary) endpoint<sup>1</sup></span></p>\n</td>\n<td style=\"width:42.94%;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Patients refractory to fludarabine and alemtuzumab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">n=95</span></p>\n</td>\n</tr>", "ID": "3d39031e-3f69-46e6-b3ca-4de699eabd60", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "ca2382de-b302-453d-8955-cb3133ecad6e"}, {"Element": "<td style=\"width:57.06%;border:solid windowtext 1.0pt;padding:\n  0in 5.4pt 0in 5.4pt\" width=\"57%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(Primary) endpoint<sup>1</sup></span></p>\n</td>", "ID": "8b4082df-8cd8-47da-b8f7-943903101046", "Styles": "width:57.06%;border:solid windowtext 1.0pt;padding:\n  0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3d39031e-3f69-46e6-b3ca-4de699eabd60"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(Primary) endpoint<sup>1</sup></span></p>", "ID": "c28f1fdb-daef-488c-9dc4-212bddbcdd6c", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8b4082df-8cd8-47da-b8f7-943903101046"}, {"Element": "<span lang=\"EN-GB\">(Primary) endpoint<sup>1</sup></span>", "ID": "e93682a3-819b-4c54-bad7-f88ef430797d", "Styles": "None", "Classes": "None", "Text": "(Primary) endpoint", "ParentId": "c28f1fdb-daef-488c-9dc4-212bddbcdd6c"}, {"Element": "<sup>1</sup>", "ID": "33601554-c3f7-4e99-886a-adcd7f371cd9", "Styles": "None", "Classes": "None", "Text": "1", "ParentId": "e93682a3-819b-4c54-bad7-f88ef430797d"}, {"Element": "<td style=\"width:42.94%;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Patients refractory to fludarabine and alemtuzumab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">n=95</span></p>\n</td>", "ID": "29d5de56-91ce-4169-b4fd-57901ed9504f", "Styles": "width:42.94%;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "3d39031e-3f69-46e6-b3ca-4de699eabd60"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Patients refractory to fludarabine and alemtuzumab</span></p>", "ID": "3743df7c-ef0d-4741-8e88-a198e34b31d6", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "29d5de56-91ce-4169-b4fd-57901ed9504f"}, {"Element": "<span lang=\"EN-GB\">Patients refractory to fludarabine and alemtuzumab</span>", "ID": "ab548ccb-d36f-487b-9dae-eaa19810ed01", "Styles": "None", "Classes": "None", "Text": "Patients refractory to fludarabine and alemtuzumab", "ParentId": "3743df7c-ef0d-4741-8e88-a198e34b31d6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">n=95</span></p>", "ID": "36aedac0-b276-415d-8ad0-c3c089ce543a", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "29d5de56-91ce-4169-b4fd-57901ed9504f"}, {"Element": "<span lang=\"EN-GB\">n=95</span>", "ID": "31fe18a9-e570-4c2b-973b-1f612a052045", "Styles": "None", "Classes": "None", "Text": "n=95", "ParentId": "36aedac0-b276-415d-8ad0-c3c089ce543a"}, {"Element": "<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Overall\n  response rate</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>", "ID": "b445d7cf-1a5a-47da-9f0f-e02d36208a84", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "ca2382de-b302-453d-8955-cb3133ecad6e"}, {"Element": "<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Overall\n  response rate</span></p>\n</td>", "ID": "d2890836-72c9-4f7d-b802-976cb960ee0a", "Styles": "width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b445d7cf-1a5a-47da-9f0f-e02d36208a84"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Overall\n  response rate</span></p>", "ID": "e5bcb2ad-af5e-49cb-be53-59aab6b7267d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d2890836-72c9-4f7d-b802-976cb960ee0a"}, {"Element": "<span lang=\"EN-GB\">Overall\n  response rate</span>", "ID": "7d8a7a69-d7e5-4424-b721-1110c091bd70", "Styles": "None", "Classes": "None", "Text": "Overall   response rate", "ParentId": "e5bcb2ad-af5e-49cb-be53-59aab6b7267d"}, {"Element": "<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "d14bc5d1-4773-49a8-8256-cf304662ad25", "Styles": "width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b445d7cf-1a5a-47da-9f0f-e02d36208a84"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "6299dee1-f1a8-43e0-afac-c64940b07cfd", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d14bc5d1-4773-49a8-8256-cf304662ad25"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "ffb9ae6b-4dc0-41d9-b053-bab8302fcf56", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6299dee1-f1a8-43e0-afac-c64940b07cfd"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a65eb548-6a15-43cc-a57d-5bb3653af23e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ffb9ae6b-4dc0-41d9-b053-bab8302fcf56"}, {"Element": "<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">Responders, n (%)</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">47 (49)</span></p>\n</td>\n</tr>", "ID": "ffb3e6d0-187f-4ee8-82e8-5a96221ec06f", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "ca2382de-b302-453d-8955-cb3133ecad6e"}, {"Element": "<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">Responders, n (%)</span></p>\n</td>", "ID": "a8103343-502d-4762-b2b8-638f1fa3a241", "Styles": "width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ffb3e6d0-187f-4ee8-82e8-5a96221ec06f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">Responders, n (%)</span></p>", "ID": "fd573b64-36f3-42dd-bc35-cece2a3d7e5f", "Styles": "margin-left:24.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a8103343-502d-4762-b2b8-638f1fa3a241"}, {"Element": "<span lang=\"EN-GB\">Responders, n (%)</span>", "ID": "6ccd384c-4e1e-4b48-a222-3bfb1593d291", "Styles": "None", "Classes": "None", "Text": "Responders, n (%)", "ParentId": "fd573b64-36f3-42dd-bc35-cece2a3d7e5f"}, {"Element": "<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">47 (49)</span></p>\n</td>", "ID": "ba9aefcc-2060-4d92-aa6f-cdc95f41f977", "Styles": "width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ffb3e6d0-187f-4ee8-82e8-5a96221ec06f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">47 (49)</span></p>", "ID": "eac0798e-8eb0-4f5f-8d4c-34d6fa7125af", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ba9aefcc-2060-4d92-aa6f-cdc95f41f977"}, {"Element": "<span lang=\"EN-GB\">47 (49)</span>", "ID": "e6ef7a27-3cf3-465b-a011-49ac38672d02", "Styles": "None", "Classes": "None", "Text": "47 (49)", "ParentId": "eac0798e-8eb0-4f5f-8d4c-34d6fa7125af"}, {"Element": "<tr>\n<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">95.3% CI (%)</span></p>\n</td>\n<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">39, 60</span></p>\n</td>\n</tr>", "ID": "e761b46d-44d7-4208-8118-c730ee2a3119", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "ca2382de-b302-453d-8955-cb3133ecad6e"}, {"Element": "<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">95.3% CI (%)</span></p>\n</td>", "ID": "46684057-4a13-4229-b25e-86e53f6fd636", "Styles": "width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e761b46d-44d7-4208-8118-c730ee2a3119"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">95.3% CI (%)</span></p>", "ID": "6437fdf6-8879-4b6f-83fa-2d4441d0f7a1", "Styles": "margin-left:24.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "46684057-4a13-4229-b25e-86e53f6fd636"}, {"Element": "<span lang=\"EN-GB\">95.3% CI (%)</span>", "ID": "26d9f01b-7940-4fe3-9dbf-62fcac7559d9", "Styles": "None", "Classes": "None", "Text": "95.3% CI (%)", "ParentId": "6437fdf6-8879-4b6f-83fa-2d4441d0f7a1"}, {"Element": "<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">39, 60</span></p>\n</td>", "ID": "e62261b6-1e64-4fce-9974-ce84f80ed8ac", "Styles": "width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e761b46d-44d7-4208-8118-c730ee2a3119"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">39, 60</span></p>", "ID": "e1e0075c-b369-45fa-a41b-7357dd0a4baf", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e62261b6-1e64-4fce-9974-ce84f80ed8ac"}, {"Element": "<span lang=\"EN-GB\">39, 60</span>", "ID": "bfc0d4fb-9c6a-4111-97fe-c04b5da80e25", "Styles": "None", "Classes": "None", "Text": "39, 60", "ParentId": "e1e0075c-b369-45fa-a41b-7357dd0a4baf"}, {"Element": "<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Response\n  rate in patients with prior rituximab therapy</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "b26f86a9-536d-48b9-a294-146ba7a626ee", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "ca2382de-b302-453d-8955-cb3133ecad6e"}, {"Element": "<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Response\n  rate in patients with prior rituximab therapy</span></p>\n</td>", "ID": "a4a02ba5-ab09-4668-ba39-6d8768b03c35", "Styles": "width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b26f86a9-536d-48b9-a294-146ba7a626ee"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Response\n  rate in patients with prior rituximab therapy</span></p>", "ID": "e3c7c055-d858-44af-99cc-b0285f9bfbf6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a4a02ba5-ab09-4668-ba39-6d8768b03c35"}, {"Element": "<span lang=\"EN-GB\">Response\n  rate in patients with prior rituximab therapy</span>", "ID": "cd963050-a7c5-4aff-9c58-7693d48cd30e", "Styles": "None", "Classes": "None", "Text": "Response   rate in patients with prior rituximab therapy", "ParentId": "e3c7c055-d858-44af-99cc-b0285f9bfbf6"}, {"Element": "<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "4295cf4f-6ad4-44b9-87f5-d71cde140d40", "Styles": "width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b26f86a9-536d-48b9-a294-146ba7a626ee"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5b218c20-97eb-4d2b-b75b-d23806b50d5f", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4295cf4f-6ad4-44b9-87f5-d71cde140d40"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "79e187a5-18ae-4ed4-81b6-61ad43baed56", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5b218c20-97eb-4d2b-b75b-d23806b50d5f"}, {"Element": "<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">Responders, n (%)</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25/56 (45)</span></p>\n</td>\n</tr>", "ID": "c25bd52d-8bd8-42ea-82a3-b849197864a1", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "ca2382de-b302-453d-8955-cb3133ecad6e"}, {"Element": "<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">Responders, n (%)</span></p>\n</td>", "ID": "5fa5ebd6-7804-41f4-83ac-f6b41e7ccc63", "Styles": "width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c25bd52d-8bd8-42ea-82a3-b849197864a1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">Responders, n (%)</span></p>", "ID": "63a56de3-673b-474d-bdcf-563cc3a92658", "Styles": "margin-left:24.1pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5fa5ebd6-7804-41f4-83ac-f6b41e7ccc63"}, {"Element": "<span lang=\"EN-GB\">Responders, n (%)</span>", "ID": "02b24a2e-8788-4c96-905d-6892b255eb51", "Styles": "None", "Classes": "None", "Text": "Responders, n (%)", "ParentId": "63a56de3-673b-474d-bdcf-563cc3a92658"}, {"Element": "<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25/56 (45)</span></p>\n</td>", "ID": "dc5b0271-0a2b-4f3c-a9ae-ff9c032a714b", "Styles": "width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c25bd52d-8bd8-42ea-82a3-b849197864a1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25/56 (45)</span></p>", "ID": "6d5d15ab-c1c8-458c-be07-478b4ad097bd", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dc5b0271-0a2b-4f3c-a9ae-ff9c032a714b"}, {"Element": "<span lang=\"EN-GB\">25/56 (45)</span>", "ID": "f402f23b-cda6-451e-a0c1-9885c501b291", "Styles": "None", "Classes": "None", "Text": "25/56 (45)", "ParentId": "6d5d15ab-c1c8-458c-be07-478b4ad097bd"}, {"Element": "<tr>\n<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI (%)</span></p>\n</td>\n<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31, 59</span></p>\n</td>\n</tr>", "ID": "a0d3dfbf-c2db-4c26-a32b-2754e9a622be", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "ca2382de-b302-453d-8955-cb3133ecad6e"}, {"Element": "<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI (%)</span></p>\n</td>", "ID": "a23a9cf8-e847-4fa2-b792-69f23c7c9501", "Styles": "width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a0d3dfbf-c2db-4c26-a32b-2754e9a622be"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI (%)</span></p>", "ID": "fa7efb01-5cfc-4493-9dc9-c7abfaa2371d", "Styles": "margin-left:24.1pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a23a9cf8-e847-4fa2-b792-69f23c7c9501"}, {"Element": "<span lang=\"EN-GB\">95% CI (%)</span>", "ID": "c416c776-473b-445e-916d-6b58022b5843", "Styles": "None", "Classes": "None", "Text": "95% CI (%)", "ParentId": "fa7efb01-5cfc-4493-9dc9-c7abfaa2371d"}, {"Element": "<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31, 59</span></p>\n</td>", "ID": "a8c6f2a5-f50b-4538-892f-5edcd9801061", "Styles": "width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a0d3dfbf-c2db-4c26-a32b-2754e9a622be"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31, 59</span></p>", "ID": "ea7bc901-e175-4cde-a9bb-fcb186ed7af4", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a8c6f2a5-f50b-4538-892f-5edcd9801061"}, {"Element": "<span lang=\"EN-GB\">31, 59</span>", "ID": "e2b583c0-80f0-49cd-b14e-c2bcb2cc7aa1", "Styles": "None", "Classes": "None", "Text": "31, 59", "ParentId": "ea7bc901-e175-4cde-a9bb-fcb186ed7af4"}, {"Element": "<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Response\n  rate in patients with chromosomal abnormality</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "c4b38e84-555e-4fbf-8ef7-7c95912bda19", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "ca2382de-b302-453d-8955-cb3133ecad6e"}, {"Element": "<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Response\n  rate in patients with chromosomal abnormality</span></p>\n</td>", "ID": "aa1a85d1-bead-4665-9f29-3c8befeeeafc", "Styles": "width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c4b38e84-555e-4fbf-8ef7-7c95912bda19"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Response\n  rate in patients with chromosomal abnormality</span></p>", "ID": "2c3ba661-f8ec-4a2e-abd0-18d87f2a4ed9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "aa1a85d1-bead-4665-9f29-3c8befeeeafc"}, {"Element": "<span lang=\"EN-GB\">Response\n  rate in patients with chromosomal abnormality</span>", "ID": "071bc4e2-0639-4b47-afa3-dbcae0de6387", "Styles": "None", "Classes": "None", "Text": "Response   rate in patients with chromosomal abnormality", "ParentId": "2c3ba661-f8ec-4a2e-abd0-18d87f2a4ed9"}, {"Element": "<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "7d1a6a2b-7999-4e84-a926-b2314d1b9622", "Styles": "width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c4b38e84-555e-4fbf-8ef7-7c95912bda19"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d979074a-2ab5-4baa-a3c7-d052175fa778", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7d1a6a2b-7999-4e84-a926-b2314d1b9622"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5b2108fd-2a9d-406f-b6cc-23b788c89da1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d979074a-2ab5-4baa-a3c7-d052175fa778"}, {"Element": "<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:7.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">17p deletion</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "3071ea84-e050-47e7-821f-37201a75cbea", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "ca2382de-b302-453d-8955-cb3133ecad6e"}, {"Element": "<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:7.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">17p deletion</span></p>\n</td>", "ID": "741941eb-5a95-4082-a43b-457d7d4850f5", "Styles": "width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3071ea84-e050-47e7-821f-37201a75cbea"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:7.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">17p deletion</span></p>", "ID": "a2abd24f-37d6-43bd-89d9-2d947c270213", "Styles": "margin-left:7.1pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "741941eb-5a95-4082-a43b-457d7d4850f5"}, {"Element": "<span lang=\"EN-GB\">17p deletion</span>", "ID": "6fcb1110-b558-4173-b5b7-265a471efbd0", "Styles": "None", "Classes": "None", "Text": "17p deletion", "ParentId": "a2abd24f-37d6-43bd-89d9-2d947c270213"}, {"Element": "<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "8db6eab3-f25c-4fba-9e1d-161e676d6a3f", "Styles": "width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3071ea84-e050-47e7-821f-37201a75cbea"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "635addc6-e635-460e-876f-570c0722a8f4", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8db6eab3-f25c-4fba-9e1d-161e676d6a3f"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a9559754-e64b-4069-b3e1-7304bd3ee640", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "635addc6-e635-460e-876f-570c0722a8f4"}, {"Element": "<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">Responders, n (%)</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">10/27 (37)</span></p>\n</td>\n</tr>", "ID": "a3846515-2754-459b-b3c0-f09695164a36", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "ca2382de-b302-453d-8955-cb3133ecad6e"}, {"Element": "<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">Responders, n (%)</span></p>\n</td>", "ID": "f1b17912-dede-4ebe-bf33-17d2a8cb6322", "Styles": "width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a3846515-2754-459b-b3c0-f09695164a36"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">Responders, n (%)</span></p>", "ID": "c32c53d7-555a-42fa-9174-ddd633c0c802", "Styles": "margin-left:24.1pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f1b17912-dede-4ebe-bf33-17d2a8cb6322"}, {"Element": "<span lang=\"EN-GB\">Responders, n (%)</span>", "ID": "f80737ce-bb32-4540-ac8d-1576bf675fd6", "Styles": "None", "Classes": "None", "Text": "Responders, n (%)", "ParentId": "c32c53d7-555a-42fa-9174-ddd633c0c802"}, {"Element": "<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">10/27 (37)</span></p>\n</td>", "ID": "b7966596-b5a1-452b-9c37-4e0945c84ed6", "Styles": "width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a3846515-2754-459b-b3c0-f09695164a36"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">10/27 (37)</span></p>", "ID": "e18d51f6-f897-4f4f-9139-300ae069954d", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b7966596-b5a1-452b-9c37-4e0945c84ed6"}, {"Element": "<span lang=\"EN-GB\">10/27 (37)</span>", "ID": "10812fd2-75ba-464c-90ab-ec591e7928a1", "Styles": "None", "Classes": "None", "Text": "10/27 (37)", "ParentId": "e18d51f6-f897-4f4f-9139-300ae069954d"}, {"Element": "<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI (%)</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">19, 58</span></p>\n</td>\n</tr>", "ID": "6549649e-2fc4-4665-b3fe-6035dfaf9282", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "ca2382de-b302-453d-8955-cb3133ecad6e"}, {"Element": "<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI (%)</span></p>\n</td>", "ID": "090f5e1f-134b-4b52-9b6e-476203bc99f6", "Styles": "width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6549649e-2fc4-4665-b3fe-6035dfaf9282"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI (%)</span></p>", "ID": "619e4155-4acf-4ddd-a3f1-be39ab345dd5", "Styles": "margin-left:24.1pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "090f5e1f-134b-4b52-9b6e-476203bc99f6"}, {"Element": "<span lang=\"EN-GB\">95% CI (%)</span>", "ID": "46e4900c-3f2b-43ff-b80b-c82b9497dd7a", "Styles": "None", "Classes": "None", "Text": "95% CI (%)", "ParentId": "619e4155-4acf-4ddd-a3f1-be39ab345dd5"}, {"Element": "<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">19, 58</span></p>\n</td>", "ID": "d97e2e54-2249-45a6-a828-7de99d7ebf34", "Styles": "width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6549649e-2fc4-4665-b3fe-6035dfaf9282"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">19, 58</span></p>", "ID": "0f5c4b1e-90c0-42d9-bc53-16e5c77baf73", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d97e2e54-2249-45a6-a828-7de99d7ebf34"}, {"Element": "<span lang=\"EN-GB\">19, 58</span>", "ID": "781ee295-aa2d-4fc9-9006-d3a33202b602", "Styles": "None", "Classes": "None", "Text": "19, 58", "ParentId": "0f5c4b1e-90c0-42d9-bc53-16e5c77baf73"}, {"Element": "<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:7.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">11q deletion</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "5ab2fe09-5470-4426-94ea-5986f209354b", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "ca2382de-b302-453d-8955-cb3133ecad6e"}, {"Element": "<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:7.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">11q deletion</span></p>\n</td>", "ID": "985b3801-4df9-484f-a9fe-1d61b02c72ee", "Styles": "width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5ab2fe09-5470-4426-94ea-5986f209354b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:7.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">11q deletion</span></p>", "ID": "396517d3-5e29-4152-80f2-ded5d74542f5", "Styles": "margin-left:7.1pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "985b3801-4df9-484f-a9fe-1d61b02c72ee"}, {"Element": "<span lang=\"EN-GB\">11q deletion</span>", "ID": "52c66a6e-9445-42a6-a73b-e85dcd1b4631", "Styles": "None", "Classes": "None", "Text": "11q deletion", "ParentId": "396517d3-5e29-4152-80f2-ded5d74542f5"}, {"Element": "<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "1058c978-f60f-462f-8568-f4d3d4339164", "Styles": "width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5ab2fe09-5470-4426-94ea-5986f209354b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9f660c96-387a-40aa-bf10-c6197a484f09", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1058c978-f60f-462f-8568-f4d3d4339164"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d3478825-8dc3-4e93-86cf-8bc4e06421aa", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9f660c96-387a-40aa-bf10-c6197a484f09"}, {"Element": "<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">Responders, n (%)</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">15/32 (47)</span></p>\n</td>\n</tr>", "ID": "2104bbf5-cc4f-4bed-bbf2-99c4b1de23d2", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "ca2382de-b302-453d-8955-cb3133ecad6e"}, {"Element": "<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">Responders, n (%)</span></p>\n</td>", "ID": "dd5c5094-d695-4c6a-ac44-f9d6f3bcb7d0", "Styles": "width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2104bbf5-cc4f-4bed-bbf2-99c4b1de23d2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">Responders, n (%)</span></p>", "ID": "b974222f-8a20-407d-86b9-c06935c9e5d3", "Styles": "margin-left:24.1pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dd5c5094-d695-4c6a-ac44-f9d6f3bcb7d0"}, {"Element": "<span lang=\"EN-GB\">Responders, n (%)</span>", "ID": "dc67a4de-494a-4bee-a0a4-3b8e5c83c4fa", "Styles": "None", "Classes": "None", "Text": "Responders, n (%)", "ParentId": "b974222f-8a20-407d-86b9-c06935c9e5d3"}, {"Element": "<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">15/32 (47)</span></p>\n</td>", "ID": "5c53b8fc-5e39-4fef-8bb7-eda557767f63", "Styles": "width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2104bbf5-cc4f-4bed-bbf2-99c4b1de23d2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">15/32 (47)</span></p>", "ID": "1a4aec8d-e328-4b7e-9e73-7f747192129b", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5c53b8fc-5e39-4fef-8bb7-eda557767f63"}, {"Element": "<span lang=\"EN-GB\">15/32 (47)</span>", "ID": "45575862-17ee-411b-ba91-d68117758a04", "Styles": "None", "Classes": "None", "Text": "15/32 (47)", "ParentId": "1a4aec8d-e328-4b7e-9e73-7f747192129b"}, {"Element": "<tr>\n<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI (%)</span></p>\n</td>\n<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">29, 65</span></p>\n</td>\n</tr>", "ID": "625b0346-535c-45fa-9517-b238a14f503a", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "ca2382de-b302-453d-8955-cb3133ecad6e"}, {"Element": "<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI (%)</span></p>\n</td>", "ID": "4770708e-c1a4-4a6e-8954-86d06b04a0de", "Styles": "width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "625b0346-535c-45fa-9517-b238a14f503a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI (%)</span></p>", "ID": "db208cb9-5032-4b6e-bab1-7be73db0c48d", "Styles": "margin-left:24.1pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4770708e-c1a4-4a6e-8954-86d06b04a0de"}, {"Element": "<span lang=\"EN-GB\">95% CI (%)</span>", "ID": "e621d5f1-5c54-4e91-9829-2df57726bf35", "Styles": "None", "Classes": "None", "Text": "95% CI (%)", "ParentId": "db208cb9-5032-4b6e-bab1-7be73db0c48d"}, {"Element": "<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">29, 65</span></p>\n</td>", "ID": "e83155c6-d8c1-4560-b9df-4d13ff37ebdb", "Styles": "width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "625b0346-535c-45fa-9517-b238a14f503a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">29, 65</span></p>", "ID": "c9c8a627-202c-4038-b446-c487883a9bb2", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e83155c6-d8c1-4560-b9df-4d13ff37ebdb"}, {"Element": "<span lang=\"EN-GB\">29, 65</span>", "ID": "013f3c80-885e-4de3-9759-523896bc7f56", "Styles": "None", "Classes": "None", "Text": "29, 65", "ParentId": "c9c8a627-202c-4038-b446-c487883a9bb2"}, {"Element": "<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median\n  overall survival</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "b503fdcf-61b0-4896-bf9f-ed9abd49a4e9", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "ca2382de-b302-453d-8955-cb3133ecad6e"}, {"Element": "<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median\n  overall survival</span></p>\n</td>", "ID": "43f09955-691a-4d81-a535-77c662118cb5", "Styles": "width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b503fdcf-61b0-4896-bf9f-ed9abd49a4e9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median\n  overall survival</span></p>", "ID": "e8ee5f15-0302-406b-8d38-3c5d44ecd3e1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "43f09955-691a-4d81-a535-77c662118cb5"}, {"Element": "<span lang=\"EN-GB\">Median\n  overall survival</span>", "ID": "ef89257c-28bf-4a41-9258-365493fd38cb", "Styles": "None", "Classes": "None", "Text": "Median   overall survival", "ParentId": "e8ee5f15-0302-406b-8d38-3c5d44ecd3e1"}, {"Element": "<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "14f0d848-519d-4535-9810-74b6bbb02490", "Styles": "width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b503fdcf-61b0-4896-bf9f-ed9abd49a4e9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "24f86143-f3c7-4da7-b125-78367fac1166", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "14f0d848-519d-4535-9810-74b6bbb02490"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6017037d-94eb-4fca-8dfe-7c5feb951228", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "24f86143-f3c7-4da7-b125-78367fac1166"}, {"Element": "<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">Months</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">13.9</span></p>\n</td>\n</tr>", "ID": "8fd63a61-2ca3-4e34-a8df-69d619bdfb2e", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "ca2382de-b302-453d-8955-cb3133ecad6e"}, {"Element": "<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">Months</span></p>\n</td>", "ID": "c2d81803-c10a-4f99-8dfb-df1bf94c6fa2", "Styles": "width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8fd63a61-2ca3-4e34-a8df-69d619bdfb2e"}, {"Element": "<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">Months</span></p>", "ID": "f077f1b5-0542-4c7c-a714-47f974a2aff8", "Styles": "text-indent:24.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c2d81803-c10a-4f99-8dfb-df1bf94c6fa2"}, {"Element": "<span lang=\"EN-GB\">Months</span>", "ID": "f5c8d795-7ddd-49c7-9096-535967894fb8", "Styles": "None", "Classes": "None", "Text": "Months", "ParentId": "f077f1b5-0542-4c7c-a714-47f974a2aff8"}, {"Element": "<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">13.9</span></p>\n</td>", "ID": "bd7c3e7e-9b6f-40b5-b775-377854e263a4", "Styles": "width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8fd63a61-2ca3-4e34-a8df-69d619bdfb2e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">13.9</span></p>", "ID": "bd00e09b-ec80-41b1-af2c-9bc3af01cbd8", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bd7c3e7e-9b6f-40b5-b775-377854e263a4"}, {"Element": "<span lang=\"EN-GB\">13.9</span>", "ID": "497d15d7-b0a3-4852-acb7-8e7bc88d0b1c", "Styles": "None", "Classes": "None", "Text": "13.9", "ParentId": "bd00e09b-ec80-41b1-af2c-9bc3af01cbd8"}, {"Element": "<tr>\n<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI</span></p>\n</td>\n<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">9.9, 18.6</span></p>\n</td>\n</tr>", "ID": "41886701-bcec-4631-8933-6666b63ac137", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "ca2382de-b302-453d-8955-cb3133ecad6e"}, {"Element": "<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI</span></p>\n</td>", "ID": "c1f10b36-a3c1-46a0-ab07-d9602df67a36", "Styles": "width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "41886701-bcec-4631-8933-6666b63ac137"}, {"Element": "<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI</span></p>", "ID": "11bfd8d2-dc01-446f-a8b7-4a5bcffa7834", "Styles": "text-indent:24.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c1f10b36-a3c1-46a0-ab07-d9602df67a36"}, {"Element": "<span lang=\"EN-GB\">95% CI</span>", "ID": "0e8d0d88-04ed-43a6-a5e9-f910b9487fb4", "Styles": "None", "Classes": "None", "Text": "95% CI", "ParentId": "11bfd8d2-dc01-446f-a8b7-4a5bcffa7834"}, {"Element": "<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">9.9, 18.6</span></p>\n</td>", "ID": "f46d7cbd-0e3f-4630-be6d-69b7f1763137", "Styles": "width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "41886701-bcec-4631-8933-6666b63ac137"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">9.9, 18.6</span></p>", "ID": "0a971892-9936-4857-8ef0-a0376a58d725", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f46d7cbd-0e3f-4630-be6d-69b7f1763137"}, {"Element": "<span lang=\"EN-GB\">9.9, 18.6</span>", "ID": "79e05501-3ade-467d-b424-d665578fb29f", "Styles": "None", "Classes": "None", "Text": "9.9, 18.6", "ParentId": "0a971892-9936-4857-8ef0-a0376a58d725"}, {"Element": "<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Progression-free\n  survival</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "b8a239c1-7741-47b8-aff4-6a435261fa46", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "ca2382de-b302-453d-8955-cb3133ecad6e"}, {"Element": "<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Progression-free\n  survival</span></p>\n</td>", "ID": "af8c4a10-8a89-4216-ba1c-c74bb1212516", "Styles": "width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b8a239c1-7741-47b8-aff4-6a435261fa46"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Progression-free\n  survival</span></p>", "ID": "246eba09-a1d7-4a5c-80f9-b02ae4502850", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "af8c4a10-8a89-4216-ba1c-c74bb1212516"}, {"Element": "<span lang=\"EN-GB\">Progression-free\n  survival</span>", "ID": "2d4452f9-5b06-4f73-964c-94d37838d2b8", "Styles": "None", "Classes": "None", "Text": "Progression-free   survival", "ParentId": "246eba09-a1d7-4a5c-80f9-b02ae4502850"}, {"Element": "<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "344d4fca-097f-49fa-a09a-7d1eb6583d5c", "Styles": "width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b8a239c1-7741-47b8-aff4-6a435261fa46"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "32b9c712-d208-4b4a-88c3-9792088bfafa", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "344d4fca-097f-49fa-a09a-7d1eb6583d5c"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5be5aa0f-77a9-4970-ab92-82ca7e7f6ffa", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "32b9c712-d208-4b4a-88c3-9792088bfafa"}, {"Element": "<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">Months</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">4.6</span></p>\n</td>\n</tr>", "ID": "ccbf7e3c-f690-4f97-be9d-270710a992ce", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "ca2382de-b302-453d-8955-cb3133ecad6e"}, {"Element": "<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">Months</span></p>\n</td>", "ID": "8da808d2-4606-4798-85c8-f1e1471c8ef1", "Styles": "width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ccbf7e3c-f690-4f97-be9d-270710a992ce"}, {"Element": "<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">Months</span></p>", "ID": "0ef4284a-73df-4e72-9136-57f6f3275e15", "Styles": "text-indent:24.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8da808d2-4606-4798-85c8-f1e1471c8ef1"}, {"Element": "<span lang=\"EN-GB\">Months</span>", "ID": "095405b0-eeed-42c5-a5b4-d29751ecdcce", "Styles": "None", "Classes": "None", "Text": "Months", "ParentId": "0ef4284a-73df-4e72-9136-57f6f3275e15"}, {"Element": "<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">4.6</span></p>\n</td>", "ID": "793221df-7bf6-4638-9a26-e1cf11b09407", "Styles": "width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ccbf7e3c-f690-4f97-be9d-270710a992ce"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">4.6</span></p>", "ID": "94a64c74-aa67-4b19-91b5-82b59cb63475", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "793221df-7bf6-4638-9a26-e1cf11b09407"}, {"Element": "<span lang=\"EN-GB\">4.6</span>", "ID": "9e17ab9f-7388-461b-911f-fb1b65175fac", "Styles": "None", "Classes": "None", "Text": "4.6", "ParentId": "94a64c74-aa67-4b19-91b5-82b59cb63475"}, {"Element": "<tr>\n<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI</span></p>\n</td>\n<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">3.9, 6.3</span></p>\n</td>\n</tr>", "ID": "38965d55-0d4f-4011-bf90-c6cb805ff0a6", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "ca2382de-b302-453d-8955-cb3133ecad6e"}, {"Element": "<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI</span></p>\n</td>", "ID": "036537c4-e919-4e9b-b16b-c92532dfbf90", "Styles": "width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "38965d55-0d4f-4011-bf90-c6cb805ff0a6"}, {"Element": "<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI</span></p>", "ID": "b02b1227-e92d-4d09-b399-5c3536954316", "Styles": "text-indent:24.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "036537c4-e919-4e9b-b16b-c92532dfbf90"}, {"Element": "<span lang=\"EN-GB\">95% CI</span>", "ID": "34ea2360-bbcd-4be7-a105-575a8260ec87", "Styles": "None", "Classes": "None", "Text": "95% CI", "ParentId": "b02b1227-e92d-4d09-b399-5c3536954316"}, {"Element": "<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">3.9, 6.3</span></p>\n</td>", "ID": "10864dba-9ca2-449d-9aa3-df965db66eae", "Styles": "width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "38965d55-0d4f-4011-bf90-c6cb805ff0a6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">3.9, 6.3</span></p>", "ID": "d55b2e56-8a05-4794-8805-bdf50a800440", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "10864dba-9ca2-449d-9aa3-df965db66eae"}, {"Element": "<span lang=\"EN-GB\">3.9, 6.3</span>", "ID": "94a3a311-443e-4ead-9e7e-f6bf6ee4349e", "Styles": "None", "Classes": "None", "Text": "3.9, 6.3", "ParentId": "d55b2e56-8a05-4794-8805-bdf50a800440"}, {"Element": "<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median\n  duration of response</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "8b8c39ef-4b20-403b-81fd-46573928cd4c", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "ca2382de-b302-453d-8955-cb3133ecad6e"}, {"Element": "<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median\n  duration of response</span></p>\n</td>", "ID": "921a6ed1-cede-46e1-98bd-69fdb6653ab4", "Styles": "width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8b8c39ef-4b20-403b-81fd-46573928cd4c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median\n  duration of response</span></p>", "ID": "237185e2-5ce4-49fc-a67f-85cbb2877e10", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "921a6ed1-cede-46e1-98bd-69fdb6653ab4"}, {"Element": "<span lang=\"EN-GB\">Median\n  duration of response</span>", "ID": "d525d6f5-85e2-4cd0-9656-3fe411aaf120", "Styles": "None", "Classes": "None", "Text": "Median   duration of response", "ParentId": "237185e2-5ce4-49fc-a67f-85cbb2877e10"}, {"Element": "<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "68530bb6-76cb-4703-9529-bdde79517f7f", "Styles": "width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8b8c39ef-4b20-403b-81fd-46573928cd4c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "56ad040b-d6e3-4a3c-babc-65f120d1d1ab", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "68530bb6-76cb-4703-9529-bdde79517f7f"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "436c8cf2-889f-435a-a129-6e7f052197e3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "56ad040b-d6e3-4a3c-babc-65f120d1d1ab"}, {"Element": "<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">Months</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5.5</span></p>\n</td>\n</tr>", "ID": "ba097dab-e3ad-4ee3-afb5-5d5c8b086377", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "ca2382de-b302-453d-8955-cb3133ecad6e"}, {"Element": "<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">Months</span></p>\n</td>", "ID": "bfc25a8a-ea22-4436-9b2b-beb843ea77f3", "Styles": "width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ba097dab-e3ad-4ee3-afb5-5d5c8b086377"}, {"Element": "<p class=\"MsoNormal\" style=\"text-indent:24.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">Months</span></p>", "ID": "3585f200-638b-465a-8f01-b9f2a164cbc8", "Styles": "text-indent:24.1pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bfc25a8a-ea22-4436-9b2b-beb843ea77f3"}, {"Element": "<span lang=\"EN-GB\">Months</span>", "ID": "9225c006-a1ae-464a-9565-05a358522b09", "Styles": "None", "Classes": "None", "Text": "Months", "ParentId": "3585f200-638b-465a-8f01-b9f2a164cbc8"}, {"Element": "<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5.5</span></p>\n</td>", "ID": "4a38c88d-29cf-4860-9c0e-f70480596e0f", "Styles": "width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ba097dab-e3ad-4ee3-afb5-5d5c8b086377"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5.5</span></p>", "ID": "864bfe95-5aaf-4894-9766-86ca8b54df0a", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4a38c88d-29cf-4860-9c0e-f70480596e0f"}, {"Element": "<span lang=\"EN-GB\">5.5</span>", "ID": "7ed392d8-d725-43cf-bb0f-868e815d636b", "Styles": "None", "Classes": "None", "Text": "5.5", "ParentId": "864bfe95-5aaf-4894-9766-86ca8b54df0a"}, {"Element": "<tr>\n<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI</span></p>\n</td>\n<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">3.7, 7.2</span></p>\n</td>\n</tr>", "ID": "0bb87082-8418-46cf-b7d9-762a6af55c22", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "ca2382de-b302-453d-8955-cb3133ecad6e"}, {"Element": "<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI</span></p>\n</td>", "ID": "b33bba2d-1c30-46b4-9b7d-b9e07ded650c", "Styles": "width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "0bb87082-8418-46cf-b7d9-762a6af55c22"}, {"Element": "<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI</span></p>", "ID": "772cdb63-d336-486f-8e82-e54fa7f7a608", "Styles": "text-indent:24.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b33bba2d-1c30-46b4-9b7d-b9e07ded650c"}, {"Element": "<span lang=\"EN-GB\">95% CI</span>", "ID": "20ca9354-5f58-4b03-9679-fd09711745d8", "Styles": "None", "Classes": "None", "Text": "95% CI", "ParentId": "772cdb63-d336-486f-8e82-e54fa7f7a608"}, {"Element": "<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">3.7, 7.2</span></p>\n</td>", "ID": "58760f3b-ec46-4c44-b939-b90d1bd12921", "Styles": "width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "0bb87082-8418-46cf-b7d9-762a6af55c22"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">3.7, 7.2</span></p>", "ID": "20c51a34-b11f-494e-b8fe-c9e2f6b859e9", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "58760f3b-ec46-4c44-b939-b90d1bd12921"}, {"Element": "<span lang=\"EN-GB\">3.7, 7.2</span>", "ID": "976a8f1a-4537-4535-8f7c-a4a08036b5d5", "Styles": "None", "Classes": "None", "Text": "3.7, 7.2", "ParentId": "20c51a34-b11f-494e-b8fe-c9e2f6b859e9"}, {"Element": "<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median\n  time to next CLL therapy</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "c0274754-f726-478c-adc0-0ee058d7a37c", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "ca2382de-b302-453d-8955-cb3133ecad6e"}, {"Element": "<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median\n  time to next CLL therapy</span></p>\n</td>", "ID": "dfc0080e-3652-48b9-9152-b73427341c48", "Styles": "width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c0274754-f726-478c-adc0-0ee058d7a37c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median\n  time to next CLL therapy</span></p>", "ID": "689858ad-3f3b-4652-ad06-1d28e41ba000", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dfc0080e-3652-48b9-9152-b73427341c48"}, {"Element": "<span lang=\"EN-GB\">Median\n  time to next CLL therapy</span>", "ID": "d054df02-ca6b-4c51-b483-af93d436ef32", "Styles": "None", "Classes": "None", "Text": "Median   time to next CLL therapy", "ParentId": "689858ad-3f3b-4652-ad06-1d28e41ba000"}, {"Element": "<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "6714e09c-e6cf-4a61-a7a2-7448e19978fe", "Styles": "width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c0274754-f726-478c-adc0-0ee058d7a37c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d9a04a68-07c3-4eaf-ac98-12ba3b2e2b0d", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6714e09c-e6cf-4a61-a7a2-7448e19978fe"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "955d7eda-5e08-429d-b965-ff09fee4cff2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d9a04a68-07c3-4eaf-ac98-12ba3b2e2b0d"}, {"Element": "<tr>\n<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">Months</span></p>\n</td>\n<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">8.5</span></p>\n</td>\n</tr>", "ID": "203dd1de-94cd-4aac-a8e0-63bcebd5d1fd", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "ca2382de-b302-453d-8955-cb3133ecad6e"}, {"Element": "<td style=\"width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">Months</span></p>\n</td>", "ID": "12d00dbd-e65a-43e4-a18a-d3442f94dd3d", "Styles": "width:57.06%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "203dd1de-94cd-4aac-a8e0-63bcebd5d1fd"}, {"Element": "<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">Months</span></p>", "ID": "5bbcf02b-8918-431f-be3a-4794ffa0fcc8", "Styles": "text-indent:24.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "12d00dbd-e65a-43e4-a18a-d3442f94dd3d"}, {"Element": "<span lang=\"EN-GB\">Months</span>", "ID": "f99c73b3-f7c7-4bcc-8cfe-4636f7c64a30", "Styles": "None", "Classes": "None", "Text": "Months", "ParentId": "5bbcf02b-8918-431f-be3a-4794ffa0fcc8"}, {"Element": "<td style=\"width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">8.5</span></p>\n</td>", "ID": "4cd19cfa-bbf3-4c94-8d8c-44126f02e6b4", "Styles": "width:42.94%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "203dd1de-94cd-4aac-a8e0-63bcebd5d1fd"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">8.5</span></p>", "ID": "27d652d8-8ce9-4c7b-9c68-2d8975261f4f", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4cd19cfa-bbf3-4c94-8d8c-44126f02e6b4"}, {"Element": "<span lang=\"EN-GB\">8.5</span>", "ID": "977e25e9-1ba3-42b8-a9cb-1fccaacb71c7", "Styles": "None", "Classes": "None", "Text": "8.5", "ParentId": "27d652d8-8ce9-4c7b-9c68-2d8975261f4f"}, {"Element": "<tr>\n<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI</span></p>\n</td>\n<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">7.2, 9.9</span></p>\n</td>\n</tr>", "ID": "c2020cd0-4670-4153-b7b9-f95a2d965488", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "ca2382de-b302-453d-8955-cb3133ecad6e"}, {"Element": "<td style=\"width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57%\">\n<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI</span></p>\n</td>", "ID": "7957ec04-dd56-4edd-a157-b915af3cee9a", "Styles": "width:57.06%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c2020cd0-4670-4153-b7b9-f95a2d965488"}, {"Element": "<p class=\"MsoNormal\" style=\"text-indent:24.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">95% CI</span></p>", "ID": "0fdded5b-3454-47d7-b790-fbfde7b1d02c", "Styles": "text-indent:24.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7957ec04-dd56-4edd-a157-b915af3cee9a"}, {"Element": "<span lang=\"EN-GB\">95% CI</span>", "ID": "e102f797-6061-489c-b29a-b83bdc1819c0", "Styles": "None", "Classes": "None", "Text": "95% CI", "ParentId": "0fdded5b-3454-47d7-b790-fbfde7b1d02c"}, {"Element": "<td style=\"width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">7.2, 9.9</span></p>\n</td>", "ID": "b969318c-4dd7-4adc-9649-e28dbcea0cd2", "Styles": "width:42.94%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c2020cd0-4670-4153-b7b9-f95a2d965488"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">7.2, 9.9</span></p>", "ID": "6bdd5cc8-3e32-4a1f-9396-c0fba76f70f1", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b969318c-4dd7-4adc-9649-e28dbcea0cd2"}, {"Element": "<span lang=\"EN-GB\">7.2, 9.9</span>", "ID": "ff097681-4347-4c27-8093-46c49b664afe", "Styles": "None", "Classes": "None", "Text": "7.2, 9.9", "ParentId": "6bdd5cc8-3e32-4a1f-9396-c0fba76f70f1"}, {"Element": "<tr style=\"height:13.7pt\">\n<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><sup><span lang=\"EN-GB\">1 </span></sup><span lang=\"EN-GB\">The overall response was assessed by an </span>Independent\n  Response Committee<span lang=\"EN-GB\"> using the 1996 NCI-WG guidelines for CLL.</span></p>\n</td>\n</tr>", "ID": "ee56c8d0-d53a-43da-b2de-66e7f9e2d337", "Styles": "height:13.7pt", "Classes": "None", "Text": "  ", "ParentId": "ca2382de-b302-453d-8955-cb3133ecad6e"}, {"Element": "<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><sup><span lang=\"EN-GB\">1 </span></sup><span lang=\"EN-GB\">The overall response was assessed by an </span>Independent\n  Response Committee<span lang=\"EN-GB\"> using the 1996 NCI-WG guidelines for CLL.</span></p>\n</td>", "ID": "ef18e795-fb94-4a29-8756-a2f28b2dd3f4", "Styles": "width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt", "Classes": "None", "Text": "  ", "ParentId": "ee56c8d0-d53a-43da-b2de-66e7f9e2d337"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><sup><span lang=\"EN-GB\">1 </span></sup><span lang=\"EN-GB\">The overall response was assessed by an </span>Independent\n  Response Committee<span lang=\"EN-GB\"> using the 1996 NCI-WG guidelines for CLL.</span></p>", "ID": "301092f4-924c-4972-8968-9f495ae5d360", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Independent   Response Committee", "ParentId": "ef18e795-fb94-4a29-8756-a2f28b2dd3f4"}, {"Element": "<sup><span lang=\"EN-GB\">1 </span></sup>", "ID": "48fb9dfd-7bba-4ae6-84cc-85e8f2d8817b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "301092f4-924c-4972-8968-9f495ae5d360"}, {"Element": "<span lang=\"EN-GB\">1 </span>", "ID": "f7a0c76b-12cd-4c65-9058-ac670dd73fa5", "Styles": "None", "Classes": "None", "Text": "1 ", "ParentId": "48fb9dfd-7bba-4ae6-84cc-85e8f2d8817b"}, {"Element": "<span lang=\"EN-GB\">The overall response was assessed by an </span>", "ID": "eb594526-6008-4aaf-ba96-c88b208f9aad", "Styles": "None", "Classes": "None", "Text": "The overall response was assessed by an ", "ParentId": "301092f4-924c-4972-8968-9f495ae5d360"}, {"Element": "<span lang=\"EN-GB\"> using the 1996 NCI-WG guidelines for CLL.</span>", "ID": "faf8fb43-b0d9-47e8-b0f6-b28bf799854c", "Styles": "None", "Classes": "None", "Text": " using the 1996 NCI-WG guidelines for CLL.", "ParentId": "301092f4-924c-4972-8968-9f495ae5d360"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3e2fcb09-7736-445c-8431-78647b23567e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "517cb437-8776-4100-831f-138ab760b5e1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3e2fcb09-7736-445c-8431-78647b23567e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Improvements\nalso were demonstrated in components of the NCI-WG response criteria. These included\nimprovements associated with constitutional symptoms, lymphadenopathy,\norganomegaly, or cytopenias (see Table\u00a04).</span></p>", "ID": "da905023-c654-439f-8dd2-e24606fdbe20", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Improvements\nalso were demonstrated in components of the NCI-WG response criteria. These included\nimprovements associated with constitutional symptoms, lymphadenopathy,\norganomegaly, or cytopenias (see Table\u00a04).</span>", "ID": "6518e24e-dd67-4aeb-8226-e72daf1fa52a", "Styles": "None", "Classes": "None", "Text": "Improvements also were demonstrated in components of the NCI-WG response criteria. These included improvements associated with constitutional symptoms, lymphadenopathy, organomegaly, or cytopenias (see Table\u00a04).", "ParentId": "da905023-c654-439f-8dd2-e24606fdbe20"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "df3ee750-0f1a-4090-bd77-1b91e310ca9e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a8fefa78-c8a7-4887-a8b5-604973dd8b93", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "df3ee750-0f1a-4090-bd77-1b91e310ca9e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-56.7pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">Table\u00a04\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Summary of clinical improvement\nwith a minimum duration of 2\u00a0months in refractory patients with\nabnormalities at baseline</span></b></p>", "ID": "edf0cd5e-9952-4234-8e01-d5e9f8e11a8c", "Styles": "margin-left:56.7pt;text-indent:-56.7pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">Table\u00a04\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Summary of clinical improvement\nwith a minimum duration of 2\u00a0months in refractory patients with\nabnormalities at baseline</span></b>", "ID": "e15ae6be-997b-4cc7-906d-60fda7b22aaa", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "edf0cd5e-9952-4234-8e01-d5e9f8e11a8c"}, {"Element": "<span lang=\"EN-GB\">Table\u00a04\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Summary of clinical improvement\nwith a minimum duration of 2\u00a0months in refractory patients with\nabnormalities at baseline</span>", "ID": "a1137eb6-399d-435b-8e67-9a148975360d", "Styles": "None", "Classes": "None", "Text": "Table\u00a04\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Summary of clinical improvement with a minimum duration of 2\u00a0months in refractory patients with abnormalities at baseline", "ParentId": "e15ae6be-997b-4cc7-906d-60fda7b22aaa"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e175b529-6150-44ae-9a05-81a69215b3de", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "749ba5ba-eb60-4e86-bb18-0893cac7da0f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e175b529-6150-44ae-9a05-81a69215b3de"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:100.0%;border-collapse:collapse;border:none\" width=\"100%\">\n<tr>\n<td rowspan=\"2\" style=\"width:47.72%;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Efficacy\n  endpoint or haematological parameter<sup>a</sup></span></p>\n</td>\n<td style=\"width:52.28%;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Patients with benefit/patients with abnormality at\n  baseline (%)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Patients refractory to fludarabine and alemtuzumab</span></p>\n</td>\n</tr>\n<tr style=\"height:14.2pt\">\n<td style=\"width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.2pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lymphocyte\n  count</span></p>\n</td>\n<td style=\"width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.2pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:12.3pt\">\n<td style=\"width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:12.3pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u226550% decrease</span></p>\n</td>\n<td style=\"width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:12.3pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">49/71 (69)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Normalisation (\u22644x10<sup>9</sup>/l)</span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">36/71 (51)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Complete\n  resolution of constitutional symptoms<sup>b</sup></span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">21/47 (45) </span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lymphadenopathy<sup>c</sup></span></p>\n</td>\n<td style=\"width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b3</span><span lang=\"EN-GB\">50%\n  improvement</span></p>\n</td>\n<td style=\"width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">51/88 (58)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Complete resolution</span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">17/88 (19)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Splenomegaly</span></p>\n</td>\n<td style=\"width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b3</span><span lang=\"EN-GB\">50%\n  improvement</span></p>\n</td>\n<td style=\"width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">27/47 (57)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Complete resolution </span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">23/47 (49)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hepatomegaly</span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b3</span><span lang=\"EN-GB\">50%\n  improvement</span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">14/24 (58)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Complete resolution </span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">11/24 (46)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Haemoglobin\n  &lt;11\u00a0g/dl at baseline to &gt;11\u00a0g/dl post baseline</span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">12/49 (24)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Platelet\n  counts \u2264100x10</span><sup><span lang=\"EN-GB\">9</span></sup><span lang=\"EN-GB\">/l at baseline to &gt;50% increase or &gt;100x10</span><sup><span lang=\"EN-GB\">9</span></sup><span lang=\"EN-GB\">/l post baseline</span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">19/50 (38)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Neutrophils\n  &lt;1x10</span><sup><span lang=\"EN-GB\">9</span></sup><span lang=\"EN-GB\">/l at\n  baseline to &gt;1.5x10</span><sup><span lang=\"EN-GB\">9</span></sup><span lang=\"EN-GB\">/l</span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">1/17 (6)</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Excludes\n  patients\u2019 visits from date of first transfusion, treatment with\n  erythropoietin, or treatment with growth factors. For patients with missing\n  baseline data, latest screening/unscheduled data was carried forward to\n  baseline.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Complete\n  resolution of constitutional symptoms (fever, night sweats, fatigue, weight\n  loss) defined as the presence of any symptoms at baseline, followed by no\n  symptoms present.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Lymphadenopathy\n  measured by sum of the products of greatest diameters (SPD) as assessed by\n  physical examination.</span></p>\n</td>\n</tr>\n</table>", "ID": "35ab69cb-816f-49d4-9427-c5767ad71dbf", "Styles": "width:100.0%;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "                    ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<tr>\n<td rowspan=\"2\" style=\"width:47.72%;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Efficacy\n  endpoint or haematological parameter<sup>a</sup></span></p>\n</td>\n<td style=\"width:52.28%;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Patients with benefit/patients with abnormality at\n  baseline (%)</span></p>\n</td>\n</tr>", "ID": "2326d6d3-2829-4798-9a72-25752e81ba4b", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "35ab69cb-816f-49d4-9427-c5767ad71dbf"}, {"Element": "<td rowspan=\"2\" style=\"width:47.72%;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Efficacy\n  endpoint or haematological parameter<sup>a</sup></span></p>\n</td>", "ID": "c6137f68-1d32-44d8-8890-aec1cc45b786", "Styles": "width:47.72%;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2326d6d3-2829-4798-9a72-25752e81ba4b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Efficacy\n  endpoint or haematological parameter<sup>a</sup></span></p>", "ID": "e848a38e-d69b-4ab0-8a4c-e65a34d6c59a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c6137f68-1d32-44d8-8890-aec1cc45b786"}, {"Element": "<span lang=\"EN-GB\">Efficacy\n  endpoint or haematological parameter<sup>a</sup></span>", "ID": "3ab2e88b-727a-4e94-b8d6-5763d573dac3", "Styles": "None", "Classes": "None", "Text": "Efficacy   endpoint or haematological parameter", "ParentId": "e848a38e-d69b-4ab0-8a4c-e65a34d6c59a"}, {"Element": "<sup>a</sup>", "ID": "69d5c3a6-432c-4d6e-aad4-4b43d38c7178", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "3ab2e88b-727a-4e94-b8d6-5763d573dac3"}, {"Element": "<td style=\"width:52.28%;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Patients with benefit/patients with abnormality at\n  baseline (%)</span></p>\n</td>", "ID": "99a7760d-b695-4aa8-a95e-960489ac35ec", "Styles": "width:52.28%;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2326d6d3-2829-4798-9a72-25752e81ba4b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Patients with benefit/patients with abnormality at\n  baseline (%)</span></p>", "ID": "5354b733-fb41-42c2-804f-87cc814f4201", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "99a7760d-b695-4aa8-a95e-960489ac35ec"}, {"Element": "<span lang=\"EN-GB\">Patients with benefit/patients with abnormality at\n  baseline (%)</span>", "ID": "22e49a18-b71d-419b-b84a-e7e5269e0561", "Styles": "None", "Classes": "None", "Text": "Patients with benefit/patients with abnormality at   baseline (%)", "ParentId": "5354b733-fb41-42c2-804f-87cc814f4201"}, {"Element": "<tr>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Patients refractory to fludarabine and alemtuzumab</span></p>\n</td>\n</tr>", "ID": "3aa4b650-64ad-44cd-ac0c-e3bf23cd98e4", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "35ab69cb-816f-49d4-9427-c5767ad71dbf"}, {"Element": "<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Patients refractory to fludarabine and alemtuzumab</span></p>\n</td>", "ID": "928de7f2-c33d-4912-9206-27d436379748", "Styles": "width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3aa4b650-64ad-44cd-ac0c-e3bf23cd98e4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Patients refractory to fludarabine and alemtuzumab</span></p>", "ID": "242be681-577c-4cda-a281-baca38044c69", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "928de7f2-c33d-4912-9206-27d436379748"}, {"Element": "<span lang=\"EN-GB\">Patients refractory to fludarabine and alemtuzumab</span>", "ID": "94c84819-d62a-4ed8-b91b-7e493014636d", "Styles": "None", "Classes": "None", "Text": "Patients refractory to fludarabine and alemtuzumab", "ParentId": "242be681-577c-4cda-a281-baca38044c69"}, {"Element": "<tr style=\"height:14.2pt\">\n<td style=\"width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.2pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lymphocyte\n  count</span></p>\n</td>\n<td style=\"width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.2pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "c83940dd-7930-4b1b-bba9-a44c7a0f9ba0", "Styles": "height:14.2pt", "Classes": "None", "Text": "   ", "ParentId": "35ab69cb-816f-49d4-9427-c5767ad71dbf"}, {"Element": "<td style=\"width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.2pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lymphocyte\n  count</span></p>\n</td>", "ID": "595a8a57-2582-46e3-b3a0-ab1d5088dae9", "Styles": "width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.2pt", "Classes": "None", "Text": "  ", "ParentId": "c83940dd-7930-4b1b-bba9-a44c7a0f9ba0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lymphocyte\n  count</span></p>", "ID": "20d6cc98-6532-4769-aad9-c9ab492c5543", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "595a8a57-2582-46e3-b3a0-ab1d5088dae9"}, {"Element": "<span lang=\"EN-GB\">Lymphocyte\n  count</span>", "ID": "4c145d49-e146-4c0e-8525-06314795574c", "Styles": "None", "Classes": "None", "Text": "Lymphocyte   count", "ParentId": "20d6cc98-6532-4769-aad9-c9ab492c5543"}, {"Element": "<td style=\"width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.2pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "c47273f1-622a-4022-ab1b-40127df309e1", "Styles": "width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.2pt", "Classes": "None", "Text": "  ", "ParentId": "c83940dd-7930-4b1b-bba9-a44c7a0f9ba0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "80a71d20-25bb-4ffb-aba9-38ef9771e022", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c47273f1-622a-4022-ab1b-40127df309e1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9676634e-41c6-465c-845f-b7da23e16e3a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "80a71d20-25bb-4ffb-aba9-38ef9771e022"}, {"Element": "<tr style=\"height:12.3pt\">\n<td style=\"width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:12.3pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u226550% decrease</span></p>\n</td>\n<td style=\"width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:12.3pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">49/71 (69)</span></p>\n</td>\n</tr>", "ID": "3bf7fdab-534c-4b6d-81fa-54f0e16f1726", "Styles": "height:12.3pt", "Classes": "None", "Text": "   ", "ParentId": "35ab69cb-816f-49d4-9427-c5767ad71dbf"}, {"Element": "<td style=\"width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:12.3pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u226550% decrease</span></p>\n</td>", "ID": "886c8f9e-5acb-4273-a660-8cb7db42fe48", "Styles": "width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:12.3pt", "Classes": "None", "Text": "  ", "ParentId": "3bf7fdab-534c-4b6d-81fa-54f0e16f1726"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u226550% decrease</span></p>", "ID": "3987afda-60b4-41a4-91f6-90687df0b478", "Styles": "margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "886c8f9e-5acb-4273-a660-8cb7db42fe48"}, {"Element": "<span lang=\"EN-GB\">\u226550% decrease</span>", "ID": "46e92f04-e39c-47d1-8deb-7a70a806056e", "Styles": "None", "Classes": "None", "Text": "\u226550% decrease", "ParentId": "3987afda-60b4-41a4-91f6-90687df0b478"}, {"Element": "<td style=\"width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:12.3pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">49/71 (69)</span></p>\n</td>", "ID": "e71c1a05-d7ee-4590-9d08-18662d662253", "Styles": "width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:12.3pt", "Classes": "None", "Text": "  ", "ParentId": "3bf7fdab-534c-4b6d-81fa-54f0e16f1726"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">49/71 (69)</span></p>", "ID": "7396547a-79ac-4486-88bb-ed687e9af4a8", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e71c1a05-d7ee-4590-9d08-18662d662253"}, {"Element": "<span lang=\"EN-GB\">49/71 (69)</span>", "ID": "f97d2fe0-d69c-40d0-97ff-a2667ca510f5", "Styles": "None", "Classes": "None", "Text": "49/71 (69)", "ParentId": "7396547a-79ac-4486-88bb-ed687e9af4a8"}, {"Element": "<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Normalisation (\u22644x10<sup>9</sup>/l)</span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">36/71 (51)</span></p>\n</td>\n</tr>", "ID": "b4045d20-bd31-4055-928b-5522a8f33134", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "35ab69cb-816f-49d4-9427-c5767ad71dbf"}, {"Element": "<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Normalisation (\u22644x10<sup>9</sup>/l)</span></p>\n</td>", "ID": "6adcbcd9-4e82-4bfb-907e-8d256b5644ff", "Styles": "width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b4045d20-bd31-4055-928b-5522a8f33134"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Normalisation (\u22644x10<sup>9</sup>/l)</span></p>", "ID": "e74e2ac4-dc1a-491c-ae56-9880a6ff5f80", "Styles": "margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6adcbcd9-4e82-4bfb-907e-8d256b5644ff"}, {"Element": "<span lang=\"EN-GB\">Normalisation (\u22644x10<sup>9</sup>/l)</span>", "ID": "ba27ca75-20d4-4830-9fcd-85391a677b14", "Styles": "None", "Classes": "None", "Text": "Normalisation (\u22644x10/l)", "ParentId": "e74e2ac4-dc1a-491c-ae56-9880a6ff5f80"}, {"Element": "<sup>9</sup>", "ID": "6f10cf7b-8e08-41d9-856a-077fb7edc3ad", "Styles": "None", "Classes": "None", "Text": "9", "ParentId": "ba27ca75-20d4-4830-9fcd-85391a677b14"}, {"Element": "<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">36/71 (51)</span></p>\n</td>", "ID": "8e88bb73-f2c9-4d1a-b0d5-0596c10a5892", "Styles": "width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b4045d20-bd31-4055-928b-5522a8f33134"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">36/71 (51)</span></p>", "ID": "071ec135-b502-4218-8824-b57ed7f29fec", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8e88bb73-f2c9-4d1a-b0d5-0596c10a5892"}, {"Element": "<span lang=\"EN-GB\">36/71 (51)</span>", "ID": "ff9cb0ee-0ee1-4e44-ba65-135e699bc823", "Styles": "None", "Classes": "None", "Text": "36/71 (51)", "ParentId": "071ec135-b502-4218-8824-b57ed7f29fec"}, {"Element": "<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Complete\n  resolution of constitutional symptoms<sup>b</sup></span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">21/47 (45) </span></p>\n</td>\n</tr>", "ID": "7582bed0-3759-4b30-a9ad-5a7c6781b220", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "35ab69cb-816f-49d4-9427-c5767ad71dbf"}, {"Element": "<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Complete\n  resolution of constitutional symptoms<sup>b</sup></span></p>\n</td>", "ID": "2b7d903e-68af-418a-a3f4-caa082d970ca", "Styles": "width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7582bed0-3759-4b30-a9ad-5a7c6781b220"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Complete\n  resolution of constitutional symptoms<sup>b</sup></span></p>", "ID": "ec70f62b-984e-4f92-8831-f13f830db8d2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2b7d903e-68af-418a-a3f4-caa082d970ca"}, {"Element": "<span lang=\"EN-GB\">Complete\n  resolution of constitutional symptoms<sup>b</sup></span>", "ID": "8ab6a675-8d1a-42f6-b92d-686852c9819e", "Styles": "None", "Classes": "None", "Text": "Complete   resolution of constitutional symptoms", "ParentId": "ec70f62b-984e-4f92-8831-f13f830db8d2"}, {"Element": "<sup>b</sup>", "ID": "3a4a8d68-f0e8-4c26-832b-c31a66a6b74b", "Styles": "None", "Classes": "None", "Text": "b", "ParentId": "8ab6a675-8d1a-42f6-b92d-686852c9819e"}, {"Element": "<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">21/47 (45) </span></p>\n</td>", "ID": "09c345ed-ec9b-4ae7-bf74-610b1b9f606d", "Styles": "width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7582bed0-3759-4b30-a9ad-5a7c6781b220"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">21/47 (45) </span></p>", "ID": "f1e6c79f-b05c-4a86-b173-574d88f4804f", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "09c345ed-ec9b-4ae7-bf74-610b1b9f606d"}, {"Element": "<span lang=\"EN-GB\">21/47 (45) </span>", "ID": "f40d3af9-cacf-4b5e-b726-d8724b3aace8", "Styles": "None", "Classes": "None", "Text": "21/47 (45) ", "ParentId": "f1e6c79f-b05c-4a86-b173-574d88f4804f"}, {"Element": "<tr>\n<td style=\"width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lymphadenopathy<sup>c</sup></span></p>\n</td>\n<td style=\"width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "bf55ec51-5af7-4ebf-bd58-a075ac22aa6a", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "35ab69cb-816f-49d4-9427-c5767ad71dbf"}, {"Element": "<td style=\"width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lymphadenopathy<sup>c</sup></span></p>\n</td>", "ID": "e0e22594-624e-4849-9239-296a7f7c0079", "Styles": "width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "bf55ec51-5af7-4ebf-bd58-a075ac22aa6a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lymphadenopathy<sup>c</sup></span></p>", "ID": "eea15ac0-43d4-4876-b377-fcc68173afbb", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e0e22594-624e-4849-9239-296a7f7c0079"}, {"Element": "<span lang=\"EN-GB\">Lymphadenopathy<sup>c</sup></span>", "ID": "b54f7abf-2928-461a-8811-ab81d6fe4760", "Styles": "None", "Classes": "None", "Text": "Lymphadenopathy", "ParentId": "eea15ac0-43d4-4876-b377-fcc68173afbb"}, {"Element": "<sup>c</sup>", "ID": "23403ce2-4ba0-4595-b977-add28b0198b7", "Styles": "None", "Classes": "None", "Text": "c", "ParentId": "b54f7abf-2928-461a-8811-ab81d6fe4760"}, {"Element": "<td style=\"width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "ad4143ef-8552-4682-850d-60497db1a9f2", "Styles": "width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "bf55ec51-5af7-4ebf-bd58-a075ac22aa6a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "73687ca0-5384-4258-8550-117d2819e3b5", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ad4143ef-8552-4682-850d-60497db1a9f2"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e64ae850-e585-4118-a2c2-c2d021761163", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "73687ca0-5384-4258-8550-117d2819e3b5"}, {"Element": "<tr>\n<td style=\"width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b3</span><span lang=\"EN-GB\">50%\n  improvement</span></p>\n</td>\n<td style=\"width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">51/88 (58)</span></p>\n</td>\n</tr>", "ID": "e78ea627-4a2a-468b-9f84-c891310cdede", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "35ab69cb-816f-49d4-9427-c5767ad71dbf"}, {"Element": "<td style=\"width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b3</span><span lang=\"EN-GB\">50%\n  improvement</span></p>\n</td>", "ID": "a05feb8a-937d-4544-8a4b-6429380d3374", "Styles": "width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e78ea627-4a2a-468b-9f84-c891310cdede"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b3</span><span lang=\"EN-GB\">50%\n  improvement</span></p>", "ID": "128acd06-9280-42c9-8986-414c5b87872b", "Styles": "margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a05feb8a-937d-4544-8a4b-6429380d3374"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b3</span>", "ID": "ac77e374-d5b8-40b5-9372-8cc43694015c", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b3", "ParentId": "128acd06-9280-42c9-8986-414c5b87872b"}, {"Element": "<span lang=\"EN-GB\">50%\n  improvement</span>", "ID": "e6ce7016-1034-4d67-91b1-0007864e81a8", "Styles": "None", "Classes": "None", "Text": "50%   improvement", "ParentId": "128acd06-9280-42c9-8986-414c5b87872b"}, {"Element": "<td style=\"width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">51/88 (58)</span></p>\n</td>", "ID": "922be2fe-76ba-4529-a4d1-1a0a3667859b", "Styles": "width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e78ea627-4a2a-468b-9f84-c891310cdede"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">51/88 (58)</span></p>", "ID": "46ab6f95-1cc7-43c1-93e8-11facfc3f8f3", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "922be2fe-76ba-4529-a4d1-1a0a3667859b"}, {"Element": "<span lang=\"EN-GB\">51/88 (58)</span>", "ID": "d6c35bd4-5e27-4028-aa14-e1e105dbb733", "Styles": "None", "Classes": "None", "Text": "51/88 (58)", "ParentId": "46ab6f95-1cc7-43c1-93e8-11facfc3f8f3"}, {"Element": "<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Complete resolution</span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">17/88 (19)</span></p>\n</td>\n</tr>", "ID": "4a211d27-f835-40ba-b220-1423ae1059e5", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "35ab69cb-816f-49d4-9427-c5767ad71dbf"}, {"Element": "<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Complete resolution</span></p>\n</td>", "ID": "f46cf3d2-78be-4700-89ca-9b7184dba0ba", "Styles": "width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4a211d27-f835-40ba-b220-1423ae1059e5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Complete resolution</span></p>", "ID": "04bd15e8-ecd1-4f5e-9a2b-c70d8216cc86", "Styles": "margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f46cf3d2-78be-4700-89ca-9b7184dba0ba"}, {"Element": "<span lang=\"EN-GB\">Complete resolution</span>", "ID": "b9082fd2-013b-40bb-965d-fdd6286ca7de", "Styles": "None", "Classes": "None", "Text": "Complete resolution", "ParentId": "04bd15e8-ecd1-4f5e-9a2b-c70d8216cc86"}, {"Element": "<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">17/88 (19)</span></p>\n</td>", "ID": "1775b59e-69cc-4d17-ad1d-87e10aefefab", "Styles": "width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4a211d27-f835-40ba-b220-1423ae1059e5"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">17/88 (19)</span></p>", "ID": "2f124b50-7a85-4ba0-8e7d-ee47083fce0b", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1775b59e-69cc-4d17-ad1d-87e10aefefab"}, {"Element": "<span lang=\"EN-GB\">17/88 (19)</span>", "ID": "fbeb3aa5-cc0a-414f-a49b-88fe9c327399", "Styles": "None", "Classes": "None", "Text": "17/88 (19)", "ParentId": "2f124b50-7a85-4ba0-8e7d-ee47083fce0b"}, {"Element": "<tr>\n<td style=\"width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Splenomegaly</span></p>\n</td>\n<td style=\"width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "a64c7550-2b17-44b0-9d3c-7cccb728a651", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "35ab69cb-816f-49d4-9427-c5767ad71dbf"}, {"Element": "<td style=\"width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Splenomegaly</span></p>\n</td>", "ID": "53119f76-aef4-41b9-af21-cb5f9f6ce6ee", "Styles": "width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a64c7550-2b17-44b0-9d3c-7cccb728a651"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Splenomegaly</span></p>", "ID": "8d75e297-2d21-4e5d-8c11-5c598d365c53", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53119f76-aef4-41b9-af21-cb5f9f6ce6ee"}, {"Element": "<span lang=\"EN-GB\">Splenomegaly</span>", "ID": "cb6a0826-51bb-4182-b15d-9e47bf8e25d9", "Styles": "None", "Classes": "None", "Text": "Splenomegaly", "ParentId": "8d75e297-2d21-4e5d-8c11-5c598d365c53"}, {"Element": "<td style=\"width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "c56b9eb2-9d1d-4e06-adda-b4813cda94ab", "Styles": "width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a64c7550-2b17-44b0-9d3c-7cccb728a651"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "421dc5b4-e581-4d13-b4c4-a4431492848d", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c56b9eb2-9d1d-4e06-adda-b4813cda94ab"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ea2e3595-e882-4425-909e-a4b25e0a1206", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "421dc5b4-e581-4d13-b4c4-a4431492848d"}, {"Element": "<tr>\n<td style=\"width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b3</span><span lang=\"EN-GB\">50%\n  improvement</span></p>\n</td>\n<td style=\"width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">27/47 (57)</span></p>\n</td>\n</tr>", "ID": "e2a51221-5fd4-46f3-be65-ae350f2fd716", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "35ab69cb-816f-49d4-9427-c5767ad71dbf"}, {"Element": "<td style=\"width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b3</span><span lang=\"EN-GB\">50%\n  improvement</span></p>\n</td>", "ID": "d8773af2-243c-4f0c-b1f4-820b35730a7f", "Styles": "width:47.72%;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e2a51221-5fd4-46f3-be65-ae350f2fd716"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b3</span><span lang=\"EN-GB\">50%\n  improvement</span></p>", "ID": "66d69106-d7ec-4dbe-a406-2be4f72cfa2c", "Styles": "margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d8773af2-243c-4f0c-b1f4-820b35730a7f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b3</span>", "ID": "c9bed56a-dbc5-45c2-8908-e185240a0ef8", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b3", "ParentId": "66d69106-d7ec-4dbe-a406-2be4f72cfa2c"}, {"Element": "<span lang=\"EN-GB\">50%\n  improvement</span>", "ID": "4db93464-6e56-4c65-9de1-496bce25ee17", "Styles": "None", "Classes": "None", "Text": "50%   improvement", "ParentId": "66d69106-d7ec-4dbe-a406-2be4f72cfa2c"}, {"Element": "<td style=\"width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">27/47 (57)</span></p>\n</td>", "ID": "238e4e92-8731-4ea1-ae8f-7be681cc7dd7", "Styles": "width:52.28%;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e2a51221-5fd4-46f3-be65-ae350f2fd716"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">27/47 (57)</span></p>", "ID": "2176c8d1-ca84-4f4b-8afa-18eb55e453ee", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "238e4e92-8731-4ea1-ae8f-7be681cc7dd7"}, {"Element": "<span lang=\"EN-GB\">27/47 (57)</span>", "ID": "3b8ec2ef-d536-4a27-8101-67a409c42f89", "Styles": "None", "Classes": "None", "Text": "27/47 (57)", "ParentId": "2176c8d1-ca84-4f4b-8afa-18eb55e453ee"}, {"Element": "<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Complete resolution </span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">23/47 (49)</span></p>\n</td>\n</tr>", "ID": "c7c7ff1c-0842-4319-b2e9-a6d5d1307f22", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "35ab69cb-816f-49d4-9427-c5767ad71dbf"}, {"Element": "<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Complete resolution </span></p>\n</td>", "ID": "55be32a5-1ec1-408a-b0fb-5b426273350c", "Styles": "width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c7c7ff1c-0842-4319-b2e9-a6d5d1307f22"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Complete resolution </span></p>", "ID": "79172fc9-9a08-443a-a77d-9aa208f30618", "Styles": "margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "55be32a5-1ec1-408a-b0fb-5b426273350c"}, {"Element": "<span lang=\"EN-GB\">Complete resolution </span>", "ID": "aea66696-95c1-4540-ad86-b1aad6df81e7", "Styles": "None", "Classes": "None", "Text": "Complete resolution ", "ParentId": "79172fc9-9a08-443a-a77d-9aa208f30618"}, {"Element": "<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">23/47 (49)</span></p>\n</td>", "ID": "cc663a2a-676e-453e-8025-723bcb86d524", "Styles": "width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c7c7ff1c-0842-4319-b2e9-a6d5d1307f22"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">23/47 (49)</span></p>", "ID": "17ccbe8a-8344-49b3-bc03-334031186d9e", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cc663a2a-676e-453e-8025-723bcb86d524"}, {"Element": "<span lang=\"EN-GB\">23/47 (49)</span>", "ID": "0f69e431-0702-46c9-89c6-c28c3726cdb8", "Styles": "None", "Classes": "None", "Text": "23/47 (49)", "ParentId": "17ccbe8a-8344-49b3-bc03-334031186d9e"}, {"Element": "<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hepatomegaly</span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "366bf0d0-7244-45a1-8805-0cb0f45be99e", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "35ab69cb-816f-49d4-9427-c5767ad71dbf"}, {"Element": "<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hepatomegaly</span></p>\n</td>", "ID": "8e3a6855-1fb6-475a-a0cd-b19f7fa52979", "Styles": "width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "366bf0d0-7244-45a1-8805-0cb0f45be99e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hepatomegaly</span></p>", "ID": "195b5c31-6d5e-4da3-8192-574c37d869bb", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8e3a6855-1fb6-475a-a0cd-b19f7fa52979"}, {"Element": "<span lang=\"EN-GB\">Hepatomegaly</span>", "ID": "3775e4c6-72f3-4aeb-8426-926f2192c7ea", "Styles": "None", "Classes": "None", "Text": "Hepatomegaly", "ParentId": "195b5c31-6d5e-4da3-8192-574c37d869bb"}, {"Element": "<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "709cb7e3-4158-4417-81d8-d11a8ed1087e", "Styles": "width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "366bf0d0-7244-45a1-8805-0cb0f45be99e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0cb19580-55ff-4190-a914-9ef238332080", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "709cb7e3-4158-4417-81d8-d11a8ed1087e"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e3cf076d-11ce-4573-8ec1-67cd47c56a17", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0cb19580-55ff-4190-a914-9ef238332080"}, {"Element": "<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b3</span><span lang=\"EN-GB\">50%\n  improvement</span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">14/24 (58)</span></p>\n</td>\n</tr>", "ID": "89d34419-f2e1-40ae-9634-e7f43160a6e8", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "35ab69cb-816f-49d4-9427-c5767ad71dbf"}, {"Element": "<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b3</span><span lang=\"EN-GB\">50%\n  improvement</span></p>\n</td>", "ID": "6b6da5e0-3af2-4b2d-9475-d471fda8b8e0", "Styles": "width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "89d34419-f2e1-40ae-9634-e7f43160a6e8"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b3</span><span lang=\"EN-GB\">50%\n  improvement</span></p>", "ID": "a70b8d0e-53b8-4647-a376-64ac67d6f29e", "Styles": "margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6b6da5e0-3af2-4b2d-9475-d471fda8b8e0"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b3</span>", "ID": "e03b367a-4f8f-4cd2-8da5-307fe73fbe97", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b3", "ParentId": "a70b8d0e-53b8-4647-a376-64ac67d6f29e"}, {"Element": "<span lang=\"EN-GB\">50%\n  improvement</span>", "ID": "73e8e646-f365-4063-9b70-d7b199f290e2", "Styles": "None", "Classes": "None", "Text": "50%   improvement", "ParentId": "a70b8d0e-53b8-4647-a376-64ac67d6f29e"}, {"Element": "<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">14/24 (58)</span></p>\n</td>", "ID": "f5276490-c6de-4113-b3d3-1fb099ae47e7", "Styles": "width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "89d34419-f2e1-40ae-9634-e7f43160a6e8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">14/24 (58)</span></p>", "ID": "86a2630c-8d29-45a9-a6f7-ea8d0fd73c8b", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f5276490-c6de-4113-b3d3-1fb099ae47e7"}, {"Element": "<span lang=\"EN-GB\">14/24 (58)</span>", "ID": "094b839a-b455-46aa-add3-d4f473c59f2b", "Styles": "None", "Classes": "None", "Text": "14/24 (58)", "ParentId": "86a2630c-8d29-45a9-a6f7-ea8d0fd73c8b"}, {"Element": "<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Complete resolution </span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">11/24 (46)</span></p>\n</td>\n</tr>", "ID": "294f3a3a-34a7-45f3-b796-c6ec2b8a6440", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "35ab69cb-816f-49d4-9427-c5767ad71dbf"}, {"Element": "<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Complete resolution </span></p>\n</td>", "ID": "79477121-3ee6-4350-b627-7253241095a6", "Styles": "width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "294f3a3a-34a7-45f3-b796-c6ec2b8a6440"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Complete resolution </span></p>", "ID": "28f9e699-d04f-4b97-bdb1-ced160bde748", "Styles": "margin-left:27.0pt;text-indent:-3.0pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "79477121-3ee6-4350-b627-7253241095a6"}, {"Element": "<span lang=\"EN-GB\">Complete resolution </span>", "ID": "7e22950d-050c-40f3-be32-ee464716bd1f", "Styles": "None", "Classes": "None", "Text": "Complete resolution ", "ParentId": "28f9e699-d04f-4b97-bdb1-ced160bde748"}, {"Element": "<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">11/24 (46)</span></p>\n</td>", "ID": "b24d1f7c-84f1-4308-8761-8144ec208d73", "Styles": "width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "294f3a3a-34a7-45f3-b796-c6ec2b8a6440"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">11/24 (46)</span></p>", "ID": "274884bb-8ed6-48fc-9413-32f4c339f0b5", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b24d1f7c-84f1-4308-8761-8144ec208d73"}, {"Element": "<span lang=\"EN-GB\">11/24 (46)</span>", "ID": "43f85cb3-0966-452b-8c59-8a3f139c6bab", "Styles": "None", "Classes": "None", "Text": "11/24 (46)", "ParentId": "274884bb-8ed6-48fc-9413-32f4c339f0b5"}, {"Element": "<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Haemoglobin\n  &lt;11\u00a0g/dl at baseline to &gt;11\u00a0g/dl post baseline</span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">12/49 (24)</span></p>\n</td>\n</tr>", "ID": "fac2ada0-8c88-4fc3-b9df-886fafcb1540", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "35ab69cb-816f-49d4-9427-c5767ad71dbf"}, {"Element": "<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Haemoglobin\n  &lt;11\u00a0g/dl at baseline to &gt;11\u00a0g/dl post baseline</span></p>\n</td>", "ID": "a7ab7f50-9306-4531-ab59-48d5ee00eb5d", "Styles": "width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "fac2ada0-8c88-4fc3-b9df-886fafcb1540"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Haemoglobin\n  &lt;11\u00a0g/dl at baseline to &gt;11\u00a0g/dl post baseline</span></p>", "ID": "a4b4402a-5a95-4dbc-96d0-f4266c80b889", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a7ab7f50-9306-4531-ab59-48d5ee00eb5d"}, {"Element": "<span lang=\"EN-GB\">Haemoglobin\n  &lt;11\u00a0g/dl at baseline to &gt;11\u00a0g/dl post baseline</span>", "ID": "1454e900-f1b5-47dc-b54b-d8876a55f58e", "Styles": "None", "Classes": "None", "Text": "Haemoglobin   <11\u00a0g/dl at baseline to >11\u00a0g/dl post baseline", "ParentId": "a4b4402a-5a95-4dbc-96d0-f4266c80b889"}, {"Element": "<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">12/49 (24)</span></p>\n</td>", "ID": "5a176ce9-dc4b-4fb6-b109-693ffdca5a50", "Styles": "width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "fac2ada0-8c88-4fc3-b9df-886fafcb1540"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">12/49 (24)</span></p>", "ID": "36049103-8725-494a-a2b7-d8f1d9395a03", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5a176ce9-dc4b-4fb6-b109-693ffdca5a50"}, {"Element": "<span lang=\"EN-GB\">12/49 (24)</span>", "ID": "d29c6d9a-46f7-4907-b136-f3fb02ce4adf", "Styles": "None", "Classes": "None", "Text": "12/49 (24)", "ParentId": "36049103-8725-494a-a2b7-d8f1d9395a03"}, {"Element": "<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Platelet\n  counts \u2264100x10</span><sup><span lang=\"EN-GB\">9</span></sup><span lang=\"EN-GB\">/l at baseline to &gt;50% increase or &gt;100x10</span><sup><span lang=\"EN-GB\">9</span></sup><span lang=\"EN-GB\">/l post baseline</span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">19/50 (38)</span></p>\n</td>\n</tr>", "ID": "bfb35cf1-ce95-4146-af4d-4a0d5c63a5ea", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "35ab69cb-816f-49d4-9427-c5767ad71dbf"}, {"Element": "<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Platelet\n  counts \u2264100x10</span><sup><span lang=\"EN-GB\">9</span></sup><span lang=\"EN-GB\">/l at baseline to &gt;50% increase or &gt;100x10</span><sup><span lang=\"EN-GB\">9</span></sup><span lang=\"EN-GB\">/l post baseline</span></p>\n</td>", "ID": "d57e36d6-2550-45f9-93aa-7df0f912d1f8", "Styles": "width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "bfb35cf1-ce95-4146-af4d-4a0d5c63a5ea"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Platelet\n  counts \u2264100x10</span><sup><span lang=\"EN-GB\">9</span></sup><span lang=\"EN-GB\">/l at baseline to &gt;50% increase or &gt;100x10</span><sup><span lang=\"EN-GB\">9</span></sup><span lang=\"EN-GB\">/l post baseline</span></p>", "ID": "7f04f1f1-c83f-48e7-9cce-fbc0a4756ac1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d57e36d6-2550-45f9-93aa-7df0f912d1f8"}, {"Element": "<span lang=\"EN-GB\">Platelet\n  counts \u2264100x10</span>", "ID": "7f02bfa1-017e-4484-8895-134347498c3c", "Styles": "None", "Classes": "None", "Text": "Platelet   counts \u2264100x10", "ParentId": "7f04f1f1-c83f-48e7-9cce-fbc0a4756ac1"}, {"Element": "<sup><span lang=\"EN-GB\">9</span></sup>", "ID": "9f121663-3c2e-4deb-ad02-75dc02f6d130", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7f04f1f1-c83f-48e7-9cce-fbc0a4756ac1"}, {"Element": "<span lang=\"EN-GB\">9</span>", "ID": "86734b52-5d6f-4329-90f7-7d5c1ad3de82", "Styles": "None", "Classes": "None", "Text": "9", "ParentId": "9f121663-3c2e-4deb-ad02-75dc02f6d130"}, {"Element": "<span lang=\"EN-GB\">/l at baseline to &gt;50% increase or &gt;100x10</span>", "ID": "34b7209f-0cf5-49b2-be03-78ddb5fa71e2", "Styles": "None", "Classes": "None", "Text": "/l at baseline to >50% increase or >100x10", "ParentId": "7f04f1f1-c83f-48e7-9cce-fbc0a4756ac1"}, {"Element": "<sup><span lang=\"EN-GB\">9</span></sup>", "ID": "1f5f2ec3-0b21-4de9-a128-2a68882f7860", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7f04f1f1-c83f-48e7-9cce-fbc0a4756ac1"}, {"Element": "<span lang=\"EN-GB\">9</span>", "ID": "3aac0302-82eb-4db8-a4d7-0c6bfa4399bd", "Styles": "None", "Classes": "None", "Text": "9", "ParentId": "1f5f2ec3-0b21-4de9-a128-2a68882f7860"}, {"Element": "<span lang=\"EN-GB\">/l post baseline</span>", "ID": "9f7fc143-00b0-41d9-a4a1-e200f8db3252", "Styles": "None", "Classes": "None", "Text": "/l post baseline", "ParentId": "7f04f1f1-c83f-48e7-9cce-fbc0a4756ac1"}, {"Element": "<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">19/50 (38)</span></p>\n</td>", "ID": "424ecfa2-adae-40f1-a210-01cb47e4c7bc", "Styles": "width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "bfb35cf1-ce95-4146-af4d-4a0d5c63a5ea"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">19/50 (38)</span></p>", "ID": "f4219290-ed67-43f7-ac33-c3c754f66abe", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "424ecfa2-adae-40f1-a210-01cb47e4c7bc"}, {"Element": "<span lang=\"EN-GB\">19/50 (38)</span>", "ID": "a58d1d34-d821-4a50-974f-b37f1df50c21", "Styles": "None", "Classes": "None", "Text": "19/50 (38)", "ParentId": "f4219290-ed67-43f7-ac33-c3c754f66abe"}, {"Element": "<tr>\n<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Neutrophils\n  &lt;1x10</span><sup><span lang=\"EN-GB\">9</span></sup><span lang=\"EN-GB\">/l at\n  baseline to &gt;1.5x10</span><sup><span lang=\"EN-GB\">9</span></sup><span lang=\"EN-GB\">/l</span></p>\n</td>\n<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">1/17 (6)</span></p>\n</td>\n</tr>", "ID": "de0f701d-d1ae-4e2e-b968-5354f29eff71", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "35ab69cb-816f-49d4-9427-c5767ad71dbf"}, {"Element": "<td style=\"width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Neutrophils\n  &lt;1x10</span><sup><span lang=\"EN-GB\">9</span></sup><span lang=\"EN-GB\">/l at\n  baseline to &gt;1.5x10</span><sup><span lang=\"EN-GB\">9</span></sup><span lang=\"EN-GB\">/l</span></p>\n</td>", "ID": "6cc66712-d30a-4932-84c4-f05d651e6fb2", "Styles": "width:47.72%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "de0f701d-d1ae-4e2e-b968-5354f29eff71"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Neutrophils\n  &lt;1x10</span><sup><span lang=\"EN-GB\">9</span></sup><span lang=\"EN-GB\">/l at\n  baseline to &gt;1.5x10</span><sup><span lang=\"EN-GB\">9</span></sup><span lang=\"EN-GB\">/l</span></p>", "ID": "9fd11ab0-56a7-48ef-aafb-d7559887a09f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6cc66712-d30a-4932-84c4-f05d651e6fb2"}, {"Element": "<span lang=\"EN-GB\">Neutrophils\n  &lt;1x10</span>", "ID": "85006d32-6bb8-4fcf-9a94-58f44ab80488", "Styles": "None", "Classes": "None", "Text": "Neutrophils   <1x10", "ParentId": "9fd11ab0-56a7-48ef-aafb-d7559887a09f"}, {"Element": "<sup><span lang=\"EN-GB\">9</span></sup>", "ID": "41a6fc9e-a229-4af1-9e3a-4ec90016d814", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9fd11ab0-56a7-48ef-aafb-d7559887a09f"}, {"Element": "<span lang=\"EN-GB\">9</span>", "ID": "213d8b3c-d7d6-4530-b0d2-185ff9e50d1f", "Styles": "None", "Classes": "None", "Text": "9", "ParentId": "41a6fc9e-a229-4af1-9e3a-4ec90016d814"}, {"Element": "<span lang=\"EN-GB\">/l at\n  baseline to &gt;1.5x10</span>", "ID": "11da208b-6da9-462b-b90d-7f3797f754a2", "Styles": "None", "Classes": "None", "Text": "/l at   baseline to >1.5x10", "ParentId": "9fd11ab0-56a7-48ef-aafb-d7559887a09f"}, {"Element": "<sup><span lang=\"EN-GB\">9</span></sup>", "ID": "3eb1eb31-91ea-4eaa-b296-c20073c5b370", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9fd11ab0-56a7-48ef-aafb-d7559887a09f"}, {"Element": "<span lang=\"EN-GB\">9</span>", "ID": "ff9791ab-a954-499c-ae69-96be175e6f53", "Styles": "None", "Classes": "None", "Text": "9", "ParentId": "3eb1eb31-91ea-4eaa-b296-c20073c5b370"}, {"Element": "<span lang=\"EN-GB\">/l</span>", "ID": "bf5ae887-3ffd-48f5-b2ae-2ab60e674db4", "Styles": "None", "Classes": "None", "Text": "/l", "ParentId": "9fd11ab0-56a7-48ef-aafb-d7559887a09f"}, {"Element": "<td style=\"width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"52%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">1/17 (6)</span></p>\n</td>", "ID": "ffa956f0-d3c4-4fbc-af60-c5f0c6bc1f55", "Styles": "width:52.28%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "de0f701d-d1ae-4e2e-b968-5354f29eff71"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">1/17 (6)</span></p>", "ID": "3b488a8a-69cd-42ba-8b5b-e8231244c793", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ffa956f0-d3c4-4fbc-af60-c5f0c6bc1f55"}, {"Element": "<span lang=\"EN-GB\">1/17 (6)</span>", "ID": "36c1c4eb-bd91-4309-8446-44ff179dde59", "Styles": "None", "Classes": "None", "Text": "1/17 (6)", "ParentId": "3b488a8a-69cd-42ba-8b5b-e8231244c793"}, {"Element": "<tr>\n<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Excludes\n  patients\u2019 visits from date of first transfusion, treatment with\n  erythropoietin, or treatment with growth factors. For patients with missing\n  baseline data, latest screening/unscheduled data was carried forward to\n  baseline.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Complete\n  resolution of constitutional symptoms (fever, night sweats, fatigue, weight\n  loss) defined as the presence of any symptoms at baseline, followed by no\n  symptoms present.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Lymphadenopathy\n  measured by sum of the products of greatest diameters (SPD) as assessed by\n  physical examination.</span></p>\n</td>\n</tr>", "ID": "ae98a870-8714-4799-b1dc-c1c70cea17e8", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "35ab69cb-816f-49d4-9427-c5767ad71dbf"}, {"Element": "<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Excludes\n  patients\u2019 visits from date of first transfusion, treatment with\n  erythropoietin, or treatment with growth factors. For patients with missing\n  baseline data, latest screening/unscheduled data was carried forward to\n  baseline.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Complete\n  resolution of constitutional symptoms (fever, night sweats, fatigue, weight\n  loss) defined as the presence of any symptoms at baseline, followed by no\n  symptoms present.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Lymphadenopathy\n  measured by sum of the products of greatest diameters (SPD) as assessed by\n  physical examination.</span></p>\n</td>", "ID": "0092620b-31c1-4082-8278-102c02706215", "Styles": "width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "ae98a870-8714-4799-b1dc-c1c70cea17e8"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Excludes\n  patients\u2019 visits from date of first transfusion, treatment with\n  erythropoietin, or treatment with growth factors. For patients with missing\n  baseline data, latest screening/unscheduled data was carried forward to\n  baseline.</span></p>", "ID": "9fc05510-45dc-40f2-80f0-b3ffe035a7df", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0092620b-31c1-4082-8278-102c02706215"}, {"Element": "<sup><span lang=\"EN-GB\">a</span></sup>", "ID": "db84d51b-4170-4666-a370-c9be046f0106", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9fc05510-45dc-40f2-80f0-b3ffe035a7df"}, {"Element": "<span lang=\"EN-GB\">a</span>", "ID": "2d597850-0d08-4581-9a51-823c929e4796", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "db84d51b-4170-4666-a370-c9be046f0106"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Excludes\n  patients\u2019 visits from date of first transfusion, treatment with\n  erythropoietin, or treatment with growth factors. For patients with missing\n  baseline data, latest screening/unscheduled data was carried forward to\n  baseline.</span>", "ID": "34ed01bd-aebe-4cf7-981a-7705a2a0e92f", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Excludes   patients\u2019 visits from date of first transfusion, treatment with   erythropoietin, or treatment with growth factors. For patients with missing   baseline data, latest screening/unscheduled data was carried forward to   baseline.", "ParentId": "9fc05510-45dc-40f2-80f0-b3ffe035a7df"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Complete\n  resolution of constitutional symptoms (fever, night sweats, fatigue, weight\n  loss) defined as the presence of any symptoms at baseline, followed by no\n  symptoms present.</span></p>", "ID": "9df13af8-6e26-4f55-83d8-8e931cf7070d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0092620b-31c1-4082-8278-102c02706215"}, {"Element": "<sup><span lang=\"EN-GB\">b</span></sup>", "ID": "6d441b3c-3bb7-45fd-b38b-c08418f0cfd5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9df13af8-6e26-4f55-83d8-8e931cf7070d"}, {"Element": "<span lang=\"EN-GB\">b</span>", "ID": "e71234cc-7e62-402c-a044-1739163580c4", "Styles": "None", "Classes": "None", "Text": "b", "ParentId": "6d441b3c-3bb7-45fd-b38b-c08418f0cfd5"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Complete\n  resolution of constitutional symptoms (fever, night sweats, fatigue, weight\n  loss) defined as the presence of any symptoms at baseline, followed by no\n  symptoms present.</span>", "ID": "1a611081-ac0b-4cd6-92b4-7412bcbac8a7", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Complete   resolution of constitutional symptoms (fever, night sweats, fatigue, weight   loss) defined as the presence of any symptoms at baseline, followed by no   symptoms present.", "ParentId": "9df13af8-6e26-4f55-83d8-8e931cf7070d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Lymphadenopathy\n  measured by sum of the products of greatest diameters (SPD) as assessed by\n  physical examination.</span></p>", "ID": "ab3c3abc-b342-444b-9128-ce2f1b11b7ea", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0092620b-31c1-4082-8278-102c02706215"}, {"Element": "<sup><span lang=\"EN-GB\">c</span></sup>", "ID": "f0a3884e-892d-46de-ad38-701c4c145c2f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ab3c3abc-b342-444b-9128-ce2f1b11b7ea"}, {"Element": "<span lang=\"EN-GB\">c</span>", "ID": "e9d5bc55-ca54-41a8-9fcd-030e30818d86", "Styles": "None", "Classes": "None", "Text": "c", "ParentId": "f0a3884e-892d-46de-ad38-701c4c145c2f"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Lymphadenopathy\n  measured by sum of the products of greatest diameters (SPD) as assessed by\n  physical examination.</span>", "ID": "a6979cac-8b79-45b3-8942-52c0d6c7aa6a", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Lymphadenopathy   measured by sum of the products of greatest diameters (SPD) as assessed by   physical examination.", "ParentId": "ab3c3abc-b342-444b-9128-ce2f1b11b7ea"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a674ec84-b42c-46d5-a20f-70b4d1b9a1b4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">Arzerra was also given to a group of patients (n=112) with\nbulky lymphadenopathy (defined as at least one lymph node &gt;5\u00a0cm) who\nwere also refractory to fludarabine. The ORR in this group was 43% (95.3% CI:\n33, 53). The median progression-free survival was 5.5\u00a0months (95% CI: 4.6,\n6.4) and the median overall survival was 17.4\u00a0months (95% CI: 15.0, 24.0).\nThe response rate in patients with prior rituximab therapy was 38% (95% CI: 23,\n61). These patients also experienced comparable clinical improvement, in terms\nof the efficacy endpoints and haematological parameters detailed above, to\npatients refractory to both fludarabine and alemtuzumab.</p>", "ID": "c1c841f8-8fcb-4acb-83c6-8732f32bd734", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Arzerra was also given to a group of patients (n=112) with bulky lymphadenopathy (defined as at least one lymph node >5\u00a0cm) who were also refractory to fludarabine. The ORR in this group was 43% (95.3% CI: 33, 53). The median progression-free survival was 5.5\u00a0months (95% CI: 4.6, 6.4) and the median overall survival was 17.4\u00a0months (95% CI: 15.0, 24.0). The response rate in patients with prior rituximab therapy was 38% (95% CI: 23, 61). These patients also experienced comparable clinical improvement, in terms of the efficacy endpoints and haematological parameters detailed above, to patients refractory to both fludarabine and alemtuzumab.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "bc070100-c58e-4c46-848f-e568dccd2f49", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">Additionally a group of patients (n=16) who were\nintolerant/ineligible for fludarabine treatment and/or intolerant to\nalemtuzumab treatment were treated with Arzerra. The overall response rate in\nthis group was 63% (95.3% CI: 35, 85).</p>", "ID": "06bda0cb-430c-422e-95e4-11aa10423632", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Additionally a group of patients (n=16) who were intolerant/ineligible for fludarabine treatment and/or intolerant to alemtuzumab treatment were treated with Arzerra. The overall response rate in this group was 63% (95.3% CI: 35, 85).", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "ecb2b5e9-7705-4aec-ad27-393b61fffe2f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">An open-label,\ntwo arm, randomised study (OMB114242) was conducted in patients with bulky\nfludarabine refractory CLL who had failed at least 2\u00a0prior therapies\n(n=122) comparing Arzerra monotherapy (n=79) to physicians\u2019 choice (PC) of\ntherapy (n=43). There was no statistically significant difference in the\nprimary endpoint of IRC assessed PFS (5.4 vs. 3.6\u00a0months, HR=0.79,\np=0.27). The PFS in the monotherapy Arzerra arm was comparable to the results\nseen with Arzerra monotherapy in study Hx-CD20-406.</span></p>", "ID": "fbea1ca0-80d0-4029-8386-76910c8b6d63", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">An open-label,\ntwo arm, randomised study (OMB114242) was conducted in patients with bulky\nfludarabine refractory CLL who had failed at least 2\u00a0prior therapies\n(n=122) comparing Arzerra monotherapy (n=79) to physicians\u2019 choice (PC) of\ntherapy (n=43). There was no statistically significant difference in the\nprimary endpoint of IRC assessed PFS (5.4 vs. 3.6\u00a0months, HR=0.79,\np=0.27). The PFS in the monotherapy Arzerra arm was comparable to the results\nseen with Arzerra monotherapy in study Hx-CD20-406.</span>", "ID": "7e1e6f48-041e-4b34-9f5c-4ece61ed3338", "Styles": "None", "Classes": "None", "Text": "An open-label, two arm, randomised study (OMB114242) was conducted in patients with bulky fludarabine refractory CLL who had failed at least 2\u00a0prior therapies (n=122) comparing Arzerra monotherapy (n=79) to physicians\u2019 choice (PC) of therapy (n=43). There was no statistically significant difference in the primary endpoint of IRC assessed PFS (5.4 vs. 3.6\u00a0months, HR=0.79, p=0.27). The PFS in the monotherapy Arzerra arm was comparable to the results seen with Arzerra monotherapy in study Hx-CD20-406.", "ParentId": "fbea1ca0-80d0-4029-8386-76910c8b6d63"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "2f73dde3-a6cd-4cb4-921f-d35d610fb262", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">A dose-ranging study (</span>Hx-CD20-402) <span lang=\"EN-GB\">was conducted in 33\u00a0patients with relapsed or refractory CLL.\nPatient median age was 61\u00a0years (range: 27 to 82\u00a0years), the majority\nwere male (58%), and all were white. </span>Treatment with Arzerra (w<span lang=\"EN-GB\">hen given as 4\u00a0once-weekly infusions)</span>, led to a 50%\nobjective response rate in the highest dose group (1st dose: 500\u00a0mg; 2nd,\n3rd and 4th dose: 2,000\u00a0mg) and included 12\u00a0partial remissions and\none nodular partial remission. For the highest dose group, the median time to\nprogression was 15.6\u00a0weeks (95% CI: 15,22.6) in the full analysis\npopulation, and 23\u00a0weeks (CI: 20,31) in responders. The duration of\nresponse was 16\u00a0weeks (CI: 13, 19) and the time to next CLL\ntherapy was 52.4\u00a0weeks (CI: 36.9 \u2013 non-estimable).</p>", "ID": "53478166-6c0a-408b-8a33-cdda23b4b8c2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Hx-CD20-402) Treatment with Arzerra (w, led to a 50% objective response rate in the highest dose group (1st dose: 500\u00a0mg; 2nd, 3rd and 4th dose: 2,000\u00a0mg) and included 12\u00a0partial remissions and one nodular partial remission. For the highest dose group, the median time to progression was 15.6\u00a0weeks (95% CI: 15,22.6) in the full analysis population, and 23\u00a0weeks (CI: 20,31) in responders. The duration of response was 16\u00a0weeks (CI: 13, 19) and the time to next CLL therapy was 52.4\u00a0weeks (CI: 36.9 \u2013 non-estimable).", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">A dose-ranging study (</span>", "ID": "ffc788bf-9024-4e57-8530-4b65827e78a1", "Styles": "None", "Classes": "None", "Text": "A dose-ranging study (", "ParentId": "53478166-6c0a-408b-8a33-cdda23b4b8c2"}, {"Element": "<span lang=\"EN-GB\">was conducted in 33\u00a0patients with relapsed or refractory CLL.\nPatient median age was 61\u00a0years (range: 27 to 82\u00a0years), the majority\nwere male (58%), and all were white. </span>", "ID": "8201bff1-1e85-43f7-91c6-31e83c6804b9", "Styles": "None", "Classes": "None", "Text": "was conducted in 33\u00a0patients with relapsed or refractory CLL. Patient median age was 61\u00a0years (range: 27 to 82\u00a0years), the majority were male (58%), and all were white. ", "ParentId": "53478166-6c0a-408b-8a33-cdda23b4b8c2"}, {"Element": "<span lang=\"EN-GB\">hen given as 4\u00a0once-weekly infusions)</span>", "ID": "153732d7-272d-45fb-9966-9bbac6fe2762", "Styles": "None", "Classes": "None", "Text": "hen given as 4\u00a0once-weekly infusions)", "ParentId": "53478166-6c0a-408b-8a33-cdda23b4b8c2"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "80613ca9-8153-4d24-b001-0c836607264d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Paediatric population</u></p>", "ID": "321ad21d-bdf6-4512-ad6d-b97ae257a1cd", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u>Paediatric population</u>", "ID": "3662a2e4-55d1-4750-b729-7d467dd3852c", "Styles": "None", "Classes": "None", "Text": "Paediatric population", "ParentId": "321ad21d-bdf6-4512-ad6d-b97ae257a1cd"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "ab893944-96c4-43b2-b017-84f985743ef1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">The European Medicines Agency has waived the obligation to\nsubmit the results of studies with Arzerra in all subsets of the paediatric\npopulation in chronic lymphocytic leukaemia (see section\u00a04.2 for\ninformation on paediatric use).</p>", "ID": "9c13e638-50a5-4873-9145-d4df86833014", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The European Medicines Agency has waived the obligation to submit the results of studies with Arzerra in all subsets of the paediatric population in chronic lymphocytic leukaemia (see section\u00a04.2 for information on paediatric use).", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "bf771d36-76da-4bdb-9f04-002345f71930", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic properties</span></b></p>", "ID": "9d20323a-79f1-4744-a60a-28b74b053d2c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic properties</span></b>", "ID": "e8f5b153-7edc-420d-a13e-9f5bd780539f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9d20323a-79f1-4744-a60a-28b74b053d2c"}, {"Element": "<span lang=\"EN-GB\">5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic properties</span>", "ID": "fcc8c9c1-1447-45bc-89af-141ca3b4a2d6", "Styles": "None", "Classes": "None", "Text": "5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic properties", "ParentId": "e8f5b153-7edc-420d-a13e-9f5bd780539f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7bc58ac5-76ee-4acc-a4b8-cc582c2424a9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "59555e1f-4901-47d1-b3c1-c79ee1748c58", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7bc58ac5-76ee-4acc-a4b8-cc582c2424a9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Overall, the pharmacokinetics of ofatumumab\nwere consistent across the indications, whether given as a single agent or in\ncombination with fludarabine and cyclophosphamide or chlorambucil. Ofatumumab\nhad non-linear pharmacokinetics related to its decreasing clearance over time.</span></p>", "ID": "0d2ff679-e8f5-410c-8531-a5b614860de4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Overall, the pharmacokinetics of ofatumumab\nwere consistent across the indications, whether given as a single agent or in\ncombination with fludarabine and cyclophosphamide or chlorambucil. Ofatumumab\nhad non-linear pharmacokinetics related to its decreasing clearance over time.</span>", "ID": "69d9aeb8-98f8-4725-b7e5-89b24112ba85", "Styles": "None", "Classes": "None", "Text": "Overall, the pharmacokinetics of ofatumumab were consistent across the indications, whether given as a single agent or in combination with fludarabine and cyclophosphamide or chlorambucil. Ofatumumab had non-linear pharmacokinetics related to its decreasing clearance over time.", "ParentId": "0d2ff679-e8f5-410c-8531-a5b614860de4"}, {"Element": "<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">\u00a0</span></p>", "ID": "4a43660a-86aa-48c2-ade2-4cd6b3ebc3ca", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"layout-grid-mode:line\">\u00a0</span>", "ID": "52151ccf-d9bf-4cdc-b98e-cf5d2cd5d524", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "\u00a0", "ParentId": "4a43660a-86aa-48c2-ade2-4cd6b3ebc3ca"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"layout-grid-mode:\nline\">Absorption</span></u></p>", "ID": "4fd37164-16e4-4b4d-af2c-bb5f611226e4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span style=\"layout-grid-mode:\nline\">Absorption</span></u>", "ID": "67360517-0524-49de-b6c3-ea429d6574b4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4fd37164-16e4-4b4d-af2c-bb5f611226e4"}, {"Element": "<span style=\"layout-grid-mode:\nline\">Absorption</span>", "ID": "ad9eb7ca-c859-4ff7-9555-058d628acbf9", "Styles": "layout-grid-mode:\nline", "Classes": "None", "Text": "Absorption", "ParentId": "67360517-0524-49de-b6c3-ea429d6574b4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8ff4f432-fe56-4e37-ab94-5c77ce8636c3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "585741ca-17f2-4d87-9aee-4471a56c4dfc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8ff4f432-fe56-4e37-ab94-5c77ce8636c3"}, {"Element": "<p class=\"MsoNormal\">Arzerra is administered by intravenous infusion; therefore,\nabsorption is not applicable.</p>", "ID": "b117c16e-153c-431d-808a-a10a75ec7bf1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Arzerra is administered by intravenous infusion; therefore, absorption is not applicable.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\"><u><span style=\"layout-grid-mode:line\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "f4c7c23c-fdee-4ed8-ac46-34237f35a70f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span style=\"layout-grid-mode:line\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "c0f28683-006c-4e55-9dce-5901a555ef46", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f4c7c23c-fdee-4ed8-ac46-34237f35a70f"}, {"Element": "<span style=\"layout-grid-mode:line\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "a7ec3f42-1691-4fc0-aa3f-bfd2c60734f2", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "", "ParentId": "c0f28683-006c-4e55-9dce-5901a555ef46"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "b95c29fe-a436-455d-a6b6-c49e15acabcc", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "a7ec3f42-1691-4fc0-aa3f-bfd2c60734f2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"layout-grid-mode:\nline\">Distribution</span></u></p>", "ID": "fa7792ba-3e4b-4de0-aea0-8a13b3f53053", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span style=\"layout-grid-mode:\nline\">Distribution</span></u>", "ID": "dde228dd-e6d9-466d-81f8-4c0d8db7720e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fa7792ba-3e4b-4de0-aea0-8a13b3f53053"}, {"Element": "<span style=\"layout-grid-mode:\nline\">Distribution</span>", "ID": "68232c5e-a647-409b-81bf-7fde6b5dcce4", "Styles": "layout-grid-mode:\nline", "Classes": "None", "Text": "Distribution", "ParentId": "dde228dd-e6d9-466d-81f8-4c0d8db7720e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "38a2fa70-220e-413b-a064-c95415fe19b8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1c2e71b8-971f-4fb6-b99c-e7001cfeef3a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "38a2fa70-220e-413b-a064-c95415fe19b8"}, {"Element": "<p class=\"MsoNormal\">Ofatumumab has a small volume of distribution, with mean Vss\nvalues ranging from 1.7 to 8.1\u00a0l across studies, dose levels, and infusion\nnumber.</p>", "ID": "2dbb6063-ff3c-49a9-982a-6f47ec9d56b6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Ofatumumab has a small volume of distribution, with mean Vss values ranging from 1.7 to 8.1\u00a0l across studies, dose levels, and infusion number.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">\u00a0</span></p>", "ID": "a4c96e0a-37b2-44c6-99bb-5e30ece1167b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"layout-grid-mode:line\">\u00a0</span>", "ID": "000e669f-25b4-4126-bae4-7cb1e0b272ae", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "\u00a0", "ParentId": "a4c96e0a-37b2-44c6-99bb-5e30ece1167b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"layout-grid-mode:\nline\">Biotransformation</span></u></p>", "ID": "be9fa67b-c297-4a48-8c7b-5b7c967298ff", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span style=\"layout-grid-mode:\nline\">Biotransformation</span></u>", "ID": "d6ce0bc2-3623-409e-b387-97cc2214dc0f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "be9fa67b-c297-4a48-8c7b-5b7c967298ff"}, {"Element": "<span style=\"layout-grid-mode:\nline\">Biotransformation</span>", "ID": "a25eb1b3-5e11-4b7a-9711-eaf3d6dc01c8", "Styles": "layout-grid-mode:\nline", "Classes": "None", "Text": "Biotransformation", "ParentId": "d6ce0bc2-3623-409e-b387-97cc2214dc0f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "382ec785-3637-4376-beec-20bf23063cd5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d3f3743a-9bf9-4784-b71d-d1b3bba06ea1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "382ec785-3637-4376-beec-20bf23063cd5"}, {"Element": "<p class=\"MsoNormal\">Ofatumumab is a protein for which the expected metabolic\npathway is degradation to small peptides and individual amino acids by\nubiquitous proteolytic enzymes. Classical biotransformation studies have not\nbeen performed.</p>", "ID": "7b76d67d-779d-4a34-a286-dfdeab5e3475", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Ofatumumab is a protein for which the expected metabolic pathway is degradation to small peptides and individual amino acids by ubiquitous proteolytic enzymes. Classical biotransformation studies have not been performed.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "da286e23-0d12-4d66-9594-ce8885a27535", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"layout-grid-mode:\nline\">Elimination</span></u></p>", "ID": "8cd3ab83-8aac-47fd-8e0c-cb000820bc60", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span style=\"layout-grid-mode:\nline\">Elimination</span></u>", "ID": "137db594-ad2d-41d6-8153-0b8e9db2ca2e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8cd3ab83-8aac-47fd-8e0c-cb000820bc60"}, {"Element": "<span style=\"layout-grid-mode:\nline\">Elimination</span>", "ID": "ccf6c2a8-63f0-4745-8dc3-d588b6c2c75b", "Styles": "layout-grid-mode:\nline", "Classes": "None", "Text": "Elimination", "ParentId": "137db594-ad2d-41d6-8153-0b8e9db2ca2e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8f8f83a8-c970-4023-b478-5d4d6f132721", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b358f1a4-d502-47b8-9760-d072a86f8718", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8f8f83a8-c970-4023-b478-5d4d6f132721"}, {"Element": "<p class=\"MsoNormal\">Ofatumumab is eliminated in two ways: a target-independent\nroute like other IgG molecules and a target-mediated route which is related to\nbinding to B-cells. There was a rapid and sustained depletion of CD20<sup>+</sup>\nB-cells after the first ofatumumab infusion, leaving a reduced number of CD20<sup>+</sup>\ncells available for the antibody to bind at subsequent infusions. As a result,\nofatumumab clearance values were lower and t<sub>\u00bd</sub> values were\nsignificantly larger after later infusions than after the initial infusion;\nduring repeated weekly infusions, ofatumumab AUC and C<sub>max</sub> values\nincreased more than the expected accumulation based on first infusion data.</p>", "ID": "dee24871-14a3-42ce-8dea-bdd42d75eeac", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Ofatumumab is eliminated in two ways: a target-independent route like other IgG molecules and a target-mediated route which is related to binding to B-cells. There was a rapid and sustained depletion of CD20 B-cells after the first ofatumumab infusion, leaving a reduced number of CD20 cells available for the antibody to bind at subsequent infusions. As a result, ofatumumab clearance values were lower and t values were significantly larger after later infusions than after the initial infusion; during repeated weekly infusions, ofatumumab AUC and C values increased more than the expected accumulation based on first infusion data.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<sup>+</sup>", "ID": "d40baffa-6be3-4829-a457-6070eda488da", "Styles": "None", "Classes": "None", "Text": "+", "ParentId": "dee24871-14a3-42ce-8dea-bdd42d75eeac"}, {"Element": "<sup>+</sup>", "ID": "523a5d7e-2828-48ed-92e0-75b569e08914", "Styles": "None", "Classes": "None", "Text": "+", "ParentId": "dee24871-14a3-42ce-8dea-bdd42d75eeac"}, {"Element": "<sub>\u00bd</sub>", "ID": "a9dae367-3f88-4885-9215-3b5bffd6190b", "Styles": "None", "Classes": "None", "Text": "\u00bd", "ParentId": "dee24871-14a3-42ce-8dea-bdd42d75eeac"}, {"Element": "<sub>max</sub>", "ID": "9fbd3b33-b07c-43ba-8e9e-a5290dd5b3a7", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "dee24871-14a3-42ce-8dea-bdd42d75eeac"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "13938dd5-f1ab-4b74-8e81-5c33b99c82e3", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">\u00a0</span>", "ID": "ea5bdf28-dd3f-4ceb-8b21-3606e9714132", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "13938dd5-f1ab-4b74-8e81-5c33b99c82e3"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">The main pharmacokinetic parameters of ofatumumab as a\nsingle agent or in combination are summarised in Table\u00a05.</span></p>", "ID": "cbdcce74-984f-49a9-9bc6-9c12c63b9454", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">The main pharmacokinetic parameters of ofatumumab as a\nsingle agent or in combination are summarised in Table\u00a05.</span>", "ID": "479c183d-8f53-4a01-8d6c-f9a15b795008", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "The main pharmacokinetic parameters of ofatumumab as a single agent or in combination are summarised in Table\u00a05.", "ParentId": "cbdcce74-984f-49a9-9bc6-9c12c63b9454"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "23546f1b-6209-4621-9a59-e325dd759724", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">\u00a0</span>", "ID": "605d2c7f-ccba-4d29-852e-8477e7aa2319", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "23546f1b-6209-4621-9a59-e325dd759724"}, {"Element": "<h6 style=\"line-height:normal\"><b><span lang=\"EN-GB\" style=\"font-style:normal\">Table\u00a05\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Ofatumumab\npharmacokinetic parameters (geometric mean)</span></b></h6>", "ID": "dcb10b00-9ac0-4681-8d27-f73deba9921f", "Styles": "line-height:normal", "Classes": "None", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-style:normal\">Table\u00a05\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Ofatumumab\npharmacokinetic parameters (geometric mean)</span></b>", "ID": "0d83c1a6-7a1a-4321-8a96-031e85e233b2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dcb10b00-9ac0-4681-8d27-f73deba9921f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-style:normal\">Table\u00a05\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Ofatumumab\npharmacokinetic parameters (geometric mean)</span>", "ID": "38dd24bb-f0dd-46eb-bf41-1cbffd55312a", "Styles": "font-style:normal", "Classes": "None", "Text": "Table\u00a05\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Ofatumumab pharmacokinetic parameters (geometric mean)", "ParentId": "0d83c1a6-7a1a-4321-8a96-031e85e233b2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9d9ae41e-a656-4a43-a608-6911cfcb859e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "19f4c350-1303-4951-983b-5d3f65788e10", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9d9ae41e-a656-4a43-a608-6911cfcb859e"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:100.0%;border-collapse:collapse;border:none\" width=\"100%\">\n<thead>\n<tr>\n<td style=\"width:26.1%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"26%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Population\n   (treatment)</span></p>\n</td>\n<td style=\"width:14.94%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Dosing regimen </span></p>\n</td>\n<td style=\"width:11.8%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle<sup>(1)</sup></span></p>\n</td>\n<td style=\"width:12.06%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>C<sub>max</sub>\n   (\u00b5g/ml)</span></p>\n</td>\n<td style=\"width:14.22%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>AUC (\u00b5g.h/ml)</span></p>\n</td>\n<td style=\"width:10.58%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CL (ml/h)</span></p>\n</td>\n<td style=\"width:10.28%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>t<sub>\u00bd</sub>\n   (days)</span></p>\n</td>\n</tr>\n</thead>\n<tr>\n<td rowspan=\"2\" style=\"width:26.1%;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"26%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Refractory CLL</span></p>\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(ofatumumab)</span></p>\n</td>\n<td style=\"width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1<sup>st</sup>\n  infusion (300\u00a0mg) </span></p>\n</td>\n<td style=\"width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a01</span></p>\n</td>\n<td style=\"width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>61.4</span></p>\n</td>\n<td style=\"width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>\n<td style=\"width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>\n<td style=\"width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>2000\u00a0mg:\n  8\u00a0weekly infusions followed by 4\u00a0monthly infusions</span></p>\n</td>\n<td style=\"width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12<sup>th</sup>\n  dose</span></p>\n</td>\n<td style=\"width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>827</span></p>\n</td>\n<td style=\"width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>166000</span></p>\n</td>\n<td style=\"width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12.1</span></p>\n</td>\n<td style=\"width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.5</span></p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\" style=\"width:26.1%;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"26%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Previously\n  untreated patients</span></p>\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(ofatumumab +\n  chlorambucil)</span></p>\n</td>\n<td style=\"width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1<sup>st</sup>\n  infusion (300\u00a0mg)</span></p>\n</td>\n<td style=\"width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a01</span></p>\n</td>\n<td style=\"width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>51.8</span></p>\n</td>\n<td style=\"width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>2620</span></p>\n</td>\n<td style=\"width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>\n<td style=\"width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1000\u00a0mg\n  monthly infusions</span></p>\n</td>\n<td style=\"width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a04</span></p>\n</td>\n<td style=\"width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>285</span></p>\n</td>\n<td style=\"width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>65100</span></p>\n</td>\n<td style=\"width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>15.4 </span></p>\n</td>\n<td style=\"width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>18.5</span></p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\" style=\"width:26.1%;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"26%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Relapsed CLL</span></p>\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(ofatumumab +\n  FC)</span></p>\n</td>\n<td style=\"width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1<sup>st</sup>\n  infusion (300\u00a0mg)</span></p>\n</td>\n<td style=\"width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a01</span></p>\n</td>\n<td style=\"width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>61.4</span></p>\n</td>\n<td style=\"width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>3560</span></p>\n</td>\n<td style=\"width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>\n<td style=\"width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1000\u00a0mg on\n  the 8<sup>th</sup> day of cycle\u00a01 followed by 1000\u00a0mg monthly infusions</span></p>\n</td>\n<td style=\"width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a04</span></p>\n</td>\n<td style=\"width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>313</span></p>\n</td>\n<td style=\"width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>89100</span></p>\n</td>\n<td style=\"width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.2</span></p>\n</td>\n<td style=\"width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>19.9</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"7\" style=\"width:100.0%;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"100%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(<sup>1</sup>) Cycle\n  for which the pharmacokinetic parameters are presented in this table.</span></p>\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>C<sub>max</sub>:\n  maximum ofatumumab concentration at the end of infusion, AUC: exposure to\n  ofatumumab over a dosing period, CL: ofatumumab clearance after multiple\n  doses, T<sub>\u00bd</sub>: terminal half-life</span></p>\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Numbers rounded\n  to three significant digits</span></p>\n</td>\n</tr>\n</table>", "ID": "e27e1f84-ddff-4987-92cc-941235c19c26", "Styles": "width:100.0%;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "         ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<thead>\n<tr>\n<td style=\"width:26.1%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"26%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Population\n   (treatment)</span></p>\n</td>\n<td style=\"width:14.94%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Dosing regimen </span></p>\n</td>\n<td style=\"width:11.8%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle<sup>(1)</sup></span></p>\n</td>\n<td style=\"width:12.06%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>C<sub>max</sub>\n   (\u00b5g/ml)</span></p>\n</td>\n<td style=\"width:14.22%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>AUC (\u00b5g.h/ml)</span></p>\n</td>\n<td style=\"width:10.58%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CL (ml/h)</span></p>\n</td>\n<td style=\"width:10.28%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>t<sub>\u00bd</sub>\n   (days)</span></p>\n</td>\n</tr>\n</thead>", "ID": "399933f5-f8f4-48d7-811f-6fe74e08bec2", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "e27e1f84-ddff-4987-92cc-941235c19c26"}, {"Element": "<tr>\n<td style=\"width:26.1%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"26%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Population\n   (treatment)</span></p>\n</td>\n<td style=\"width:14.94%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Dosing regimen </span></p>\n</td>\n<td style=\"width:11.8%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle<sup>(1)</sup></span></p>\n</td>\n<td style=\"width:12.06%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>C<sub>max</sub>\n   (\u00b5g/ml)</span></p>\n</td>\n<td style=\"width:14.22%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>AUC (\u00b5g.h/ml)</span></p>\n</td>\n<td style=\"width:10.58%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CL (ml/h)</span></p>\n</td>\n<td style=\"width:10.28%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>t<sub>\u00bd</sub>\n   (days)</span></p>\n</td>\n</tr>", "ID": "c832b61b-1a21-49d6-8665-7dee1be6c713", "Styles": "None", "Classes": "None", "Text": "        ", "ParentId": "399933f5-f8f4-48d7-811f-6fe74e08bec2"}, {"Element": "<td style=\"width:26.1%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"26%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Population\n   (treatment)</span></p>\n</td>", "ID": "f64e720a-273e-4e79-b6e9-eb0aaebb1714", "Styles": "width:26.1%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c832b61b-1a21-49d6-8665-7dee1be6c713"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Population\n   (treatment)</span></p>", "ID": "bf14bcc5-d39b-4a0e-8bde-426d1f3292a6", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "f64e720a-273e-4e79-b6e9-eb0aaebb1714"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Population\n   (treatment)</span>", "ID": "5f3819b2-caf2-4da5-851a-9a2150d9c1b0", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Population    (treatment)", "ParentId": "bf14bcc5-d39b-4a0e-8bde-426d1f3292a6"}, {"Element": "<td style=\"width:14.94%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Dosing regimen </span></p>\n</td>", "ID": "67eda73a-6a9f-4f1d-b793-55094d9c64d4", "Styles": "width:14.94%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c832b61b-1a21-49d6-8665-7dee1be6c713"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Dosing regimen </span></p>", "ID": "ea988616-2e7f-433e-8bcc-39ab70edfaf4", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "67eda73a-6a9f-4f1d-b793-55094d9c64d4"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Dosing regimen </span>", "ID": "c88217a2-365a-4832-ab0c-50029f31b0d7", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Dosing regimen ", "ParentId": "ea988616-2e7f-433e-8bcc-39ab70edfaf4"}, {"Element": "<td style=\"width:11.8%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle<sup>(1)</sup></span></p>\n</td>", "ID": "4a61addf-791c-4ad6-b90e-6222c181d745", "Styles": "width:11.8%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c832b61b-1a21-49d6-8665-7dee1be6c713"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle<sup>(1)</sup></span></p>", "ID": "438a0567-fded-447d-93dd-378ec7afdc81", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "4a61addf-791c-4ad6-b90e-6222c181d745"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle<sup>(1)</sup></span>", "ID": "81df934d-8078-4aeb-af02-2ecebe091496", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Cycle", "ParentId": "438a0567-fded-447d-93dd-378ec7afdc81"}, {"Element": "<sup>(1)</sup>", "ID": "5ccf9aa6-a982-4e83-903e-d762aa887869", "Styles": "None", "Classes": "None", "Text": "(1)", "ParentId": "81df934d-8078-4aeb-af02-2ecebe091496"}, {"Element": "<td style=\"width:12.06%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>C<sub>max</sub>\n   (\u00b5g/ml)</span></p>\n</td>", "ID": "70a78268-5a36-42e7-a069-0b189453182b", "Styles": "width:12.06%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c832b61b-1a21-49d6-8665-7dee1be6c713"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>C<sub>max</sub>\n   (\u00b5g/ml)</span></p>", "ID": "91396d9b-229f-477b-b62c-98508509f7df", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "70a78268-5a36-42e7-a069-0b189453182b"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>C<sub>max</sub>\n   (\u00b5g/ml)</span>", "ID": "2f92a184-d1dc-4714-8433-e55523ea5682", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "C    (\u00b5g/ml)", "ParentId": "91396d9b-229f-477b-b62c-98508509f7df"}, {"Element": "<sub>max</sub>", "ID": "0de32727-959f-449b-a316-01aa5b33d7aa", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "2f92a184-d1dc-4714-8433-e55523ea5682"}, {"Element": "<td style=\"width:14.22%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>AUC (\u00b5g.h/ml)</span></p>\n</td>", "ID": "4a83b933-413f-4b60-a29d-0b6436bbd9e9", "Styles": "width:14.22%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c832b61b-1a21-49d6-8665-7dee1be6c713"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>AUC (\u00b5g.h/ml)</span></p>", "ID": "802db7da-326b-4bf1-8464-43fc33cfd5d9", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "4a83b933-413f-4b60-a29d-0b6436bbd9e9"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>AUC (\u00b5g.h/ml)</span>", "ID": "7a93fdcc-f1e9-468d-b1b8-a748a5b0c3a0", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "AUC (\u00b5g.h/ml)", "ParentId": "802db7da-326b-4bf1-8464-43fc33cfd5d9"}, {"Element": "<td style=\"width:10.58%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CL (ml/h)</span></p>\n</td>", "ID": "87ee0f64-4a78-4136-8b25-ae57242de67e", "Styles": "width:10.58%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c832b61b-1a21-49d6-8665-7dee1be6c713"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CL (ml/h)</span></p>", "ID": "59fe3818-d7b2-41e4-a193-8cff5d32dcfb", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "87ee0f64-4a78-4136-8b25-ae57242de67e"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CL (ml/h)</span>", "ID": "937a8d64-2484-4033-af6a-1c7c24e9880a", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "CL (ml/h)", "ParentId": "59fe3818-d7b2-41e4-a193-8cff5d32dcfb"}, {"Element": "<td style=\"width:10.28%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>t<sub>\u00bd</sub>\n   (days)</span></p>\n</td>", "ID": "77b7a3f7-c662-40ea-8e3f-b5e498f4b1a5", "Styles": "width:10.28%;border-top:solid windowtext 1.0pt;\n   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n   padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c832b61b-1a21-49d6-8665-7dee1be6c713"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>t<sub>\u00bd</sub>\n   (days)</span></p>", "ID": "1fd6ac8a-f008-4fa7-8e59-928217273efe", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "77b7a3f7-c662-40ea-8e3f-b5e498f4b1a5"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>t<sub>\u00bd</sub>\n   (days)</span>", "ID": "5788cace-fe5d-4f6c-9d17-1170fd178dc6", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "t    (days)", "ParentId": "1fd6ac8a-f008-4fa7-8e59-928217273efe"}, {"Element": "<sub>\u00bd</sub>", "ID": "8175cbaf-290c-422d-9df6-cd0a2a43fae0", "Styles": "None", "Classes": "None", "Text": "\u00bd", "ParentId": "5788cace-fe5d-4f6c-9d17-1170fd178dc6"}, {"Element": "<tr>\n<td rowspan=\"2\" style=\"width:26.1%;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"26%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Refractory CLL</span></p>\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(ofatumumab)</span></p>\n</td>\n<td style=\"width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1<sup>st</sup>\n  infusion (300\u00a0mg) </span></p>\n</td>\n<td style=\"width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a01</span></p>\n</td>\n<td style=\"width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>61.4</span></p>\n</td>\n<td style=\"width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>\n<td style=\"width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>\n<td style=\"width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>\n</tr>", "ID": "a7fbc763-5344-4cba-9899-266479900ed2", "Styles": "None", "Classes": "None", "Text": "        ", "ParentId": "e27e1f84-ddff-4987-92cc-941235c19c26"}, {"Element": "<td rowspan=\"2\" style=\"width:26.1%;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"26%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Refractory CLL</span></p>\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(ofatumumab)</span></p>\n</td>", "ID": "396907cc-9880-45c6-8dcb-b17360ef8acd", "Styles": "width:26.1%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "a7fbc763-5344-4cba-9899-266479900ed2"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Refractory CLL</span></p>", "ID": "4e94501e-237c-4e62-b4a1-cf4568298013", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "396907cc-9880-45c6-8dcb-b17360ef8acd"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Refractory CLL</span>", "ID": "cf6d4f97-c4c5-4838-8b16-b20cfdba6b19", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Refractory CLL", "ParentId": "4e94501e-237c-4e62-b4a1-cf4568298013"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(ofatumumab)</span></p>", "ID": "6d94ff51-f693-48d7-a65a-86a4af29a3d5", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "396907cc-9880-45c6-8dcb-b17360ef8acd"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(ofatumumab)</span>", "ID": "ae9c9a84-ead4-423a-81c4-88bd6c0a8204", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "(ofatumumab)", "ParentId": "6d94ff51-f693-48d7-a65a-86a4af29a3d5"}, {"Element": "<td style=\"width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1<sup>st</sup>\n  infusion (300\u00a0mg) </span></p>\n</td>", "ID": "c8609a24-2d8b-4333-833e-aa26fcaf76d2", "Styles": "width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a7fbc763-5344-4cba-9899-266479900ed2"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1<sup>st</sup>\n  infusion (300\u00a0mg) </span></p>", "ID": "c365774f-e607-450a-8e84-3b65667d0818", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "c8609a24-2d8b-4333-833e-aa26fcaf76d2"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1<sup>st</sup>\n  infusion (300\u00a0mg) </span>", "ID": "8c10168c-fe38-483b-ae23-1456869bbc94", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "1   infusion (300\u00a0mg) ", "ParentId": "c365774f-e607-450a-8e84-3b65667d0818"}, {"Element": "<sup>st</sup>", "ID": "9ae122b8-aea6-47d2-bd0b-2fa732227bd5", "Styles": "None", "Classes": "None", "Text": "st", "ParentId": "8c10168c-fe38-483b-ae23-1456869bbc94"}, {"Element": "<td style=\"width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a01</span></p>\n</td>", "ID": "2abf9120-80aa-4fe3-803f-3cdb771e1f7d", "Styles": "width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a7fbc763-5344-4cba-9899-266479900ed2"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a01</span></p>", "ID": "e1d89598-5196-496a-8f82-0c1f102f7b58", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "2abf9120-80aa-4fe3-803f-3cdb771e1f7d"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a01</span>", "ID": "2ab26a6e-513a-4da1-a751-933c825e156a", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Cycle\u00a01", "ParentId": "e1d89598-5196-496a-8f82-0c1f102f7b58"}, {"Element": "<td style=\"width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>61.4</span></p>\n</td>", "ID": "694868d7-8ecc-4a54-a744-d7d4149a1c1a", "Styles": "width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a7fbc763-5344-4cba-9899-266479900ed2"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>61.4</span></p>", "ID": "5ba715a9-bd00-4b60-a58a-a65505456e8d", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "694868d7-8ecc-4a54-a744-d7d4149a1c1a"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>61.4</span>", "ID": "7041dc13-e2c4-45f2-9cdf-35bec74981a9", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "61.4", "ParentId": "5ba715a9-bd00-4b60-a58a-a65505456e8d"}, {"Element": "<td style=\"width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>", "ID": "a7755774-95ca-4e6c-9860-250fa2cd5e53", "Styles": "width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a7fbc763-5344-4cba-9899-266479900ed2"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>", "ID": "be0eacc2-e0cc-4d96-ac61-c50914ba97e8", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "a7755774-95ca-4e6c-9860-250fa2cd5e53"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span>", "ID": "e5c747cb-b425-4a86-b5b4-0e4ea2ec9b97", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "\u00a0", "ParentId": "be0eacc2-e0cc-4d96-ac61-c50914ba97e8"}, {"Element": "<td style=\"width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>", "ID": "dfbb62b2-44fb-4d21-86c3-f638499e56e2", "Styles": "width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a7fbc763-5344-4cba-9899-266479900ed2"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>", "ID": "96e05abf-e47d-4b1f-b4d1-55ec3de16206", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "dfbb62b2-44fb-4d21-86c3-f638499e56e2"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span>", "ID": "7b1eda74-fe99-446d-a27e-e48df26778ab", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "\u00a0", "ParentId": "96e05abf-e47d-4b1f-b4d1-55ec3de16206"}, {"Element": "<td style=\"width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>", "ID": "ead2868b-9687-4e08-a864-5b967f9ca112", "Styles": "width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a7fbc763-5344-4cba-9899-266479900ed2"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>", "ID": "2c233d71-29a3-4f66-9254-3e458647f212", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "ead2868b-9687-4e08-a864-5b967f9ca112"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span>", "ID": "1fb88a94-3f9d-4c6c-98c9-e02c3760ce47", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "\u00a0", "ParentId": "2c233d71-29a3-4f66-9254-3e458647f212"}, {"Element": "<tr>\n<td style=\"width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>2000\u00a0mg:\n  8\u00a0weekly infusions followed by 4\u00a0monthly infusions</span></p>\n</td>\n<td style=\"width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12<sup>th</sup>\n  dose</span></p>\n</td>\n<td style=\"width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>827</span></p>\n</td>\n<td style=\"width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>166000</span></p>\n</td>\n<td style=\"width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12.1</span></p>\n</td>\n<td style=\"width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.5</span></p>\n</td>\n</tr>", "ID": "967482ed-095e-4d1f-aa49-ee75f2384e8d", "Styles": "None", "Classes": "None", "Text": "       ", "ParentId": "e27e1f84-ddff-4987-92cc-941235c19c26"}, {"Element": "<td style=\"width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>2000\u00a0mg:\n  8\u00a0weekly infusions followed by 4\u00a0monthly infusions</span></p>\n</td>", "ID": "2a6900c6-2d8a-4ff4-905b-65c0c02dddf2", "Styles": "width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "967482ed-095e-4d1f-aa49-ee75f2384e8d"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>2000\u00a0mg:\n  8\u00a0weekly infusions followed by 4\u00a0monthly infusions</span></p>", "ID": "3109c787-cd4c-4a78-b465-8154e96e1a52", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "2a6900c6-2d8a-4ff4-905b-65c0c02dddf2"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>2000\u00a0mg:\n  8\u00a0weekly infusions followed by 4\u00a0monthly infusions</span>", "ID": "c3d6b24e-91e4-45c2-8ce5-5e71cbc736e9", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "2000\u00a0mg:   8\u00a0weekly infusions followed by 4\u00a0monthly infusions", "ParentId": "3109c787-cd4c-4a78-b465-8154e96e1a52"}, {"Element": "<td style=\"width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12<sup>th</sup>\n  dose</span></p>\n</td>", "ID": "f620531f-b49e-4023-a2df-e2c92e0ea6ba", "Styles": "width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "967482ed-095e-4d1f-aa49-ee75f2384e8d"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12<sup>th</sup>\n  dose</span></p>", "ID": "bba3de5a-dfe9-49a0-ab8c-93d3c54eafca", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "f620531f-b49e-4023-a2df-e2c92e0ea6ba"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12<sup>th</sup>\n  dose</span>", "ID": "59f3773a-1681-452a-bca5-a294e25e7c6b", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "12   dose", "ParentId": "bba3de5a-dfe9-49a0-ab8c-93d3c54eafca"}, {"Element": "<sup>th</sup>", "ID": "0623c522-8cb0-4dcb-a103-2c6aa2caeacf", "Styles": "None", "Classes": "None", "Text": "th", "ParentId": "59f3773a-1681-452a-bca5-a294e25e7c6b"}, {"Element": "<td style=\"width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>827</span></p>\n</td>", "ID": "7c4f3a97-4c8a-47b3-b945-8aac2aa60b0d", "Styles": "width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "967482ed-095e-4d1f-aa49-ee75f2384e8d"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>827</span></p>", "ID": "31fb88c7-62db-4759-a325-9b00af249e60", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "7c4f3a97-4c8a-47b3-b945-8aac2aa60b0d"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>827</span>", "ID": "265e83e6-e1ec-400a-bba3-756e3631706b", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "827", "ParentId": "31fb88c7-62db-4759-a325-9b00af249e60"}, {"Element": "<td style=\"width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>166000</span></p>\n</td>", "ID": "7ea54b0c-749e-40ab-86bf-ecba6851a72f", "Styles": "width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "967482ed-095e-4d1f-aa49-ee75f2384e8d"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>166000</span></p>", "ID": "f8551456-5a7d-4f5c-9021-8202b7acd2cb", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "7ea54b0c-749e-40ab-86bf-ecba6851a72f"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>166000</span>", "ID": "8d1476fc-8148-47ab-ac15-63e79f2455ab", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "166000", "ParentId": "f8551456-5a7d-4f5c-9021-8202b7acd2cb"}, {"Element": "<td style=\"width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12.1</span></p>\n</td>", "ID": "3151b6dd-3228-4949-9478-af5d0cde5e46", "Styles": "width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "967482ed-095e-4d1f-aa49-ee75f2384e8d"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12.1</span></p>", "ID": "24e72be9-3976-474c-bde9-7f0345355ef9", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "3151b6dd-3228-4949-9478-af5d0cde5e46"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>12.1</span>", "ID": "27e15c04-a5aa-476b-8dfa-9be2f1e5bbdb", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "12.1", "ParentId": "24e72be9-3976-474c-bde9-7f0345355ef9"}, {"Element": "<td style=\"width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.5</span></p>\n</td>", "ID": "0b865b22-3d0e-4512-9af1-c6272545026e", "Styles": "width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "967482ed-095e-4d1f-aa49-ee75f2384e8d"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.5</span></p>", "ID": "29be596c-e103-4510-9a91-80ae5cf7e102", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "0b865b22-3d0e-4512-9af1-c6272545026e"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.5</span>", "ID": "dcdb75ad-a53b-4d9b-b797-f62467947117", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "11.5", "ParentId": "29be596c-e103-4510-9a91-80ae5cf7e102"}, {"Element": "<tr>\n<td rowspan=\"2\" style=\"width:26.1%;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"26%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Previously\n  untreated patients</span></p>\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(ofatumumab +\n  chlorambucil)</span></p>\n</td>\n<td style=\"width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1<sup>st</sup>\n  infusion (300\u00a0mg)</span></p>\n</td>\n<td style=\"width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a01</span></p>\n</td>\n<td style=\"width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>51.8</span></p>\n</td>\n<td style=\"width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>2620</span></p>\n</td>\n<td style=\"width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>\n<td style=\"width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>\n</tr>", "ID": "dd5dc7ca-3e2d-4e1f-a892-5cfa329d7c1f", "Styles": "None", "Classes": "None", "Text": "        ", "ParentId": "e27e1f84-ddff-4987-92cc-941235c19c26"}, {"Element": "<td rowspan=\"2\" style=\"width:26.1%;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"26%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Previously\n  untreated patients</span></p>\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(ofatumumab +\n  chlorambucil)</span></p>\n</td>", "ID": "9cdc4279-6876-4f72-ac30-0fdafa94bae5", "Styles": "width:26.1%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "dd5dc7ca-3e2d-4e1f-a892-5cfa329d7c1f"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Previously\n  untreated patients</span></p>", "ID": "0c14e189-9a07-4b72-8f77-4c91d04bd49c", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "9cdc4279-6876-4f72-ac30-0fdafa94bae5"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Previously\n  untreated patients</span>", "ID": "b75f7ce1-f8fa-4e9f-893c-c459c0137fab", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Previously   untreated patients", "ParentId": "0c14e189-9a07-4b72-8f77-4c91d04bd49c"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(ofatumumab +\n  chlorambucil)</span></p>", "ID": "63a7895b-8838-4b15-bc27-a7c1167e9ebc", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "9cdc4279-6876-4f72-ac30-0fdafa94bae5"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(ofatumumab +\n  chlorambucil)</span>", "ID": "e221097d-9977-47d9-9bba-cd8433c0dd5c", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "(ofatumumab +   chlorambucil)", "ParentId": "63a7895b-8838-4b15-bc27-a7c1167e9ebc"}, {"Element": "<td style=\"width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1<sup>st</sup>\n  infusion (300\u00a0mg)</span></p>\n</td>", "ID": "8fe45b76-712b-415d-8853-ed582c4269f6", "Styles": "width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "dd5dc7ca-3e2d-4e1f-a892-5cfa329d7c1f"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1<sup>st</sup>\n  infusion (300\u00a0mg)</span></p>", "ID": "0227073e-dc49-434f-9ece-407355d804d9", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "8fe45b76-712b-415d-8853-ed582c4269f6"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1<sup>st</sup>\n  infusion (300\u00a0mg)</span>", "ID": "4db7b036-03f7-412e-8243-7f6b7b30f067", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "1   infusion (300\u00a0mg)", "ParentId": "0227073e-dc49-434f-9ece-407355d804d9"}, {"Element": "<sup>st</sup>", "ID": "e40485bd-fcfc-429c-8ed8-184e9411878b", "Styles": "None", "Classes": "None", "Text": "st", "ParentId": "4db7b036-03f7-412e-8243-7f6b7b30f067"}, {"Element": "<td style=\"width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a01</span></p>\n</td>", "ID": "c5b26271-75f9-4943-86ea-b25c3cb8bc01", "Styles": "width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "dd5dc7ca-3e2d-4e1f-a892-5cfa329d7c1f"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a01</span></p>", "ID": "b7fb830f-a427-4dc0-8d6c-784728fab81b", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "c5b26271-75f9-4943-86ea-b25c3cb8bc01"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a01</span>", "ID": "52fb36fd-1803-42ba-b0c2-05fd3ec3bd61", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Cycle\u00a01", "ParentId": "b7fb830f-a427-4dc0-8d6c-784728fab81b"}, {"Element": "<td style=\"width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>51.8</span></p>\n</td>", "ID": "a888bd07-0297-4aeb-9407-5320cb99f8b9", "Styles": "width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "dd5dc7ca-3e2d-4e1f-a892-5cfa329d7c1f"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>51.8</span></p>", "ID": "46b46e6c-1e43-4778-8ac0-46ab4a65bef1", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "a888bd07-0297-4aeb-9407-5320cb99f8b9"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>51.8</span>", "ID": "4dc5208a-25ac-446f-aaae-88e397274746", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "51.8", "ParentId": "46b46e6c-1e43-4778-8ac0-46ab4a65bef1"}, {"Element": "<td style=\"width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>2620</span></p>\n</td>", "ID": "16b67403-6e59-430c-ab21-fdcfd2e3bfdb", "Styles": "width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "dd5dc7ca-3e2d-4e1f-a892-5cfa329d7c1f"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>2620</span></p>", "ID": "c6a2731a-a9c1-4c4b-af70-83c2947c8a4d", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "16b67403-6e59-430c-ab21-fdcfd2e3bfdb"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>2620</span>", "ID": "93eba9bc-0d22-4d5b-9d78-a4ae8430d895", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "2620", "ParentId": "c6a2731a-a9c1-4c4b-af70-83c2947c8a4d"}, {"Element": "<td style=\"width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>", "ID": "e3b48b2a-992b-4110-9127-f3cb4e9fb297", "Styles": "width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "dd5dc7ca-3e2d-4e1f-a892-5cfa329d7c1f"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>", "ID": "a95cdb47-1652-4e91-90ed-5f316ad2e72d", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "e3b48b2a-992b-4110-9127-f3cb4e9fb297"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span>", "ID": "9bcff5e4-8f20-4ce6-b0b3-53c57eab39a8", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "\u00a0", "ParentId": "a95cdb47-1652-4e91-90ed-5f316ad2e72d"}, {"Element": "<td style=\"width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>", "ID": "ac779261-afd9-4e66-9302-6fe90da01f3f", "Styles": "width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "dd5dc7ca-3e2d-4e1f-a892-5cfa329d7c1f"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>", "ID": "18c8502a-d5d1-488c-9105-d3d303ab3069", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "ac779261-afd9-4e66-9302-6fe90da01f3f"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span>", "ID": "3302cf82-c6ad-4dca-a4a3-400f4addd1e7", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "\u00a0", "ParentId": "18c8502a-d5d1-488c-9105-d3d303ab3069"}, {"Element": "<tr>\n<td style=\"width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1000\u00a0mg\n  monthly infusions</span></p>\n</td>\n<td style=\"width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a04</span></p>\n</td>\n<td style=\"width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>285</span></p>\n</td>\n<td style=\"width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>65100</span></p>\n</td>\n<td style=\"width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>15.4 </span></p>\n</td>\n<td style=\"width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>18.5</span></p>\n</td>\n</tr>", "ID": "8a03d070-b0cb-4128-92b9-7de3effbd1db", "Styles": "None", "Classes": "None", "Text": "       ", "ParentId": "e27e1f84-ddff-4987-92cc-941235c19c26"}, {"Element": "<td style=\"width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1000\u00a0mg\n  monthly infusions</span></p>\n</td>", "ID": "8ea193d5-9666-4a1d-9551-c391fb2f0e8a", "Styles": "width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8a03d070-b0cb-4128-92b9-7de3effbd1db"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1000\u00a0mg\n  monthly infusions</span></p>", "ID": "12f1de48-5e38-4001-beb2-8080227033ce", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "8ea193d5-9666-4a1d-9551-c391fb2f0e8a"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1000\u00a0mg\n  monthly infusions</span>", "ID": "7c1f06f7-fd32-4f56-80aa-79b1e01d5c3d", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "1000\u00a0mg   monthly infusions", "ParentId": "12f1de48-5e38-4001-beb2-8080227033ce"}, {"Element": "<td style=\"width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a04</span></p>\n</td>", "ID": "2b01b41d-8f19-459f-ab2c-2406a8c1f2c4", "Styles": "width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8a03d070-b0cb-4128-92b9-7de3effbd1db"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a04</span></p>", "ID": "e1e64b6d-c554-4ac9-9923-54f37f0f326f", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "2b01b41d-8f19-459f-ab2c-2406a8c1f2c4"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a04</span>", "ID": "c0fa35f5-23e3-489b-884e-8912999bb557", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Cycle\u00a04", "ParentId": "e1e64b6d-c554-4ac9-9923-54f37f0f326f"}, {"Element": "<td style=\"width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>285</span></p>\n</td>", "ID": "c12fd921-ed43-4228-976b-11e7720c38ef", "Styles": "width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8a03d070-b0cb-4128-92b9-7de3effbd1db"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>285</span></p>", "ID": "6d0f8121-4235-429c-aae5-95f26e3a1d28", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "c12fd921-ed43-4228-976b-11e7720c38ef"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>285</span>", "ID": "c6c6d712-2d23-401c-9cac-5ef286ff8ea5", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "285", "ParentId": "6d0f8121-4235-429c-aae5-95f26e3a1d28"}, {"Element": "<td style=\"width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>65100</span></p>\n</td>", "ID": "5f4ad603-0a31-4bef-8dcf-7d6938fcd03d", "Styles": "width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8a03d070-b0cb-4128-92b9-7de3effbd1db"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>65100</span></p>", "ID": "fdf3d62f-ea6e-4706-a0ca-be0a0f2ee114", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "5f4ad603-0a31-4bef-8dcf-7d6938fcd03d"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>65100</span>", "ID": "20cc05cd-d324-4536-a0a3-7b52d9d50c07", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "65100", "ParentId": "fdf3d62f-ea6e-4706-a0ca-be0a0f2ee114"}, {"Element": "<td style=\"width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>15.4 </span></p>\n</td>", "ID": "3a7405d3-4a1c-4010-9ab1-7e9677b38aab", "Styles": "width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8a03d070-b0cb-4128-92b9-7de3effbd1db"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>15.4 </span></p>", "ID": "a4e06cdc-12e1-40d4-a509-076205c2582a", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "3a7405d3-4a1c-4010-9ab1-7e9677b38aab"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>15.4 </span>", "ID": "7943fefc-fd27-444d-a06a-62c1c16916fe", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "15.4 ", "ParentId": "a4e06cdc-12e1-40d4-a509-076205c2582a"}, {"Element": "<td style=\"width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>18.5</span></p>\n</td>", "ID": "01683ed0-4039-4d50-8f80-6d41a62fd2a7", "Styles": "width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8a03d070-b0cb-4128-92b9-7de3effbd1db"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>18.5</span></p>", "ID": "040d260c-a39d-4522-95f7-7c4d3ff0ddd7", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "01683ed0-4039-4d50-8f80-6d41a62fd2a7"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>18.5</span>", "ID": "c62b2dc4-ee87-4164-989d-931a0c42d4a3", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "18.5", "ParentId": "040d260c-a39d-4522-95f7-7c4d3ff0ddd7"}, {"Element": "<tr>\n<td rowspan=\"2\" style=\"width:26.1%;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"26%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Relapsed CLL</span></p>\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(ofatumumab +\n  FC)</span></p>\n</td>\n<td style=\"width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1<sup>st</sup>\n  infusion (300\u00a0mg)</span></p>\n</td>\n<td style=\"width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a01</span></p>\n</td>\n<td style=\"width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>61.4</span></p>\n</td>\n<td style=\"width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>3560</span></p>\n</td>\n<td style=\"width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>\n<td style=\"width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>\n</tr>", "ID": "4074be85-dae5-47b0-8d2d-c037f236cf14", "Styles": "None", "Classes": "None", "Text": "        ", "ParentId": "e27e1f84-ddff-4987-92cc-941235c19c26"}, {"Element": "<td rowspan=\"2\" style=\"width:26.1%;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"26%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Relapsed CLL</span></p>\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(ofatumumab +\n  FC)</span></p>\n</td>", "ID": "32e9ed97-2468-4074-8c92-71d650672eba", "Styles": "width:26.1%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "4074be85-dae5-47b0-8d2d-c037f236cf14"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Relapsed CLL</span></p>", "ID": "e03d7ea6-b43a-40b9-8685-70fa1ce93a3e", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "32e9ed97-2468-4074-8c92-71d650672eba"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Relapsed CLL</span>", "ID": "72931f85-3c84-4206-85c3-22b4037b32e5", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Relapsed CLL", "ParentId": "e03d7ea6-b43a-40b9-8685-70fa1ce93a3e"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(ofatumumab +\n  FC)</span></p>", "ID": "74237675-b856-470d-9c3c-2cb9d4b7bac4", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "32e9ed97-2468-4074-8c92-71d650672eba"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(ofatumumab +\n  FC)</span>", "ID": "b0e4b3c9-f7e4-44c1-979f-d6997279dee5", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "(ofatumumab +   FC)", "ParentId": "74237675-b856-470d-9c3c-2cb9d4b7bac4"}, {"Element": "<td style=\"width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1<sup>st</sup>\n  infusion (300\u00a0mg)</span></p>\n</td>", "ID": "e8cc9c8d-de3f-4ac5-87e8-02ddbb9d1d65", "Styles": "width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4074be85-dae5-47b0-8d2d-c037f236cf14"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1<sup>st</sup>\n  infusion (300\u00a0mg)</span></p>", "ID": "18c65bd8-6cd4-4bb4-b1d3-8fbdbf2b5be8", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "e8cc9c8d-de3f-4ac5-87e8-02ddbb9d1d65"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1<sup>st</sup>\n  infusion (300\u00a0mg)</span>", "ID": "d656cd2e-2e32-4ec7-b5a5-b3aa5cbf6ec6", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "1   infusion (300\u00a0mg)", "ParentId": "18c65bd8-6cd4-4bb4-b1d3-8fbdbf2b5be8"}, {"Element": "<sup>st</sup>", "ID": "1ae561c2-c809-4897-9e89-f46c9d6a6aa8", "Styles": "None", "Classes": "None", "Text": "st", "ParentId": "d656cd2e-2e32-4ec7-b5a5-b3aa5cbf6ec6"}, {"Element": "<td style=\"width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a01</span></p>\n</td>", "ID": "a2f6ff28-750f-406f-b665-e58a402913d6", "Styles": "width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4074be85-dae5-47b0-8d2d-c037f236cf14"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a01</span></p>", "ID": "57621496-a956-49b0-a4cb-c4969543f2b9", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "a2f6ff28-750f-406f-b665-e58a402913d6"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a01</span>", "ID": "11a7e372-953a-4910-b17e-d3f9e6639a9b", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Cycle\u00a01", "ParentId": "57621496-a956-49b0-a4cb-c4969543f2b9"}, {"Element": "<td style=\"width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>61.4</span></p>\n</td>", "ID": "ca755566-f3cc-4172-bd53-c8dcef236b3a", "Styles": "width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4074be85-dae5-47b0-8d2d-c037f236cf14"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>61.4</span></p>", "ID": "ca8df2fe-f5fc-442a-90c5-9226599bec0a", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "ca755566-f3cc-4172-bd53-c8dcef236b3a"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>61.4</span>", "ID": "fe974bda-250a-4952-a5ee-46257f7ebcef", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "61.4", "ParentId": "ca8df2fe-f5fc-442a-90c5-9226599bec0a"}, {"Element": "<td style=\"width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>3560</span></p>\n</td>", "ID": "c90c3495-cb20-435d-b49e-5810c5923f69", "Styles": "width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4074be85-dae5-47b0-8d2d-c037f236cf14"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>3560</span></p>", "ID": "c7473a29-2707-4005-8c17-ff55267cf409", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "c90c3495-cb20-435d-b49e-5810c5923f69"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>3560</span>", "ID": "491bbe80-56aa-4943-b8a4-b774b9a6a1dc", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "3560", "ParentId": "c7473a29-2707-4005-8c17-ff55267cf409"}, {"Element": "<td style=\"width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>", "ID": "e1b80ec8-408d-4d2c-916d-915ed9c73e60", "Styles": "width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4074be85-dae5-47b0-8d2d-c037f236cf14"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>", "ID": "c716503a-d231-4606-b736-00ef2aba97ca", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "e1b80ec8-408d-4d2c-916d-915ed9c73e60"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span>", "ID": "06c4e753-f9dd-4424-8c31-4c5b3382ecdb", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "\u00a0", "ParentId": "c716503a-d231-4606-b736-00ef2aba97ca"}, {"Element": "<td style=\"width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n</td>", "ID": "476e8e4e-6c44-48e2-8047-247a96b9744c", "Styles": "width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4074be85-dae5-47b0-8d2d-c037f236cf14"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>", "ID": "e45816dc-4dfb-4428-a2b5-df83d4438512", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "476e8e4e-6c44-48e2-8047-247a96b9744c"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span>", "ID": "49eaf113-dad4-4d9b-ae06-4d09cd4c6843", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "\u00a0", "ParentId": "e45816dc-4dfb-4428-a2b5-df83d4438512"}, {"Element": "<tr>\n<td style=\"width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1000\u00a0mg on\n  the 8<sup>th</sup> day of cycle\u00a01 followed by 1000\u00a0mg monthly infusions</span></p>\n</td>\n<td style=\"width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a04</span></p>\n</td>\n<td style=\"width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>313</span></p>\n</td>\n<td style=\"width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>89100</span></p>\n</td>\n<td style=\"width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.2</span></p>\n</td>\n<td style=\"width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>19.9</span></p>\n</td>\n</tr>", "ID": "1d0a2525-f0ba-4b3c-9440-b7a5645903c8", "Styles": "None", "Classes": "None", "Text": "       ", "ParentId": "e27e1f84-ddff-4987-92cc-941235c19c26"}, {"Element": "<td style=\"width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1000\u00a0mg on\n  the 8<sup>th</sup> day of cycle\u00a01 followed by 1000\u00a0mg monthly infusions</span></p>\n</td>", "ID": "6a8b8782-0a41-4330-b178-0f8e6b28c0d2", "Styles": "width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1d0a2525-f0ba-4b3c-9440-b7a5645903c8"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1000\u00a0mg on\n  the 8<sup>th</sup> day of cycle\u00a01 followed by 1000\u00a0mg monthly infusions</span></p>", "ID": "74998e72-8d28-44e9-84eb-30fd687ebaa9", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "6a8b8782-0a41-4330-b178-0f8e6b28c0d2"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1000\u00a0mg on\n  the 8<sup>th</sup> day of cycle\u00a01 followed by 1000\u00a0mg monthly infusions</span>", "ID": "2f48b5a9-0af2-4051-bd1e-6de4cff839e0", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "1000\u00a0mg on   the 8 day of cycle\u00a01 followed by 1000\u00a0mg monthly infusions", "ParentId": "74998e72-8d28-44e9-84eb-30fd687ebaa9"}, {"Element": "<sup>th</sup>", "ID": "ebe45f29-ec21-42d7-ab8d-a5659e3cf4c3", "Styles": "None", "Classes": "None", "Text": "th", "ParentId": "2f48b5a9-0af2-4051-bd1e-6de4cff839e0"}, {"Element": "<td style=\"width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"11%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a04</span></p>\n</td>", "ID": "917f6edb-e5a6-44c5-94a2-d4302859d6ae", "Styles": "width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1d0a2525-f0ba-4b3c-9440-b7a5645903c8"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a04</span></p>", "ID": "e2b7a646-597c-4db4-9ebf-f5b2e06bf258", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "917f6edb-e5a6-44c5-94a2-d4302859d6ae"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Cycle\u00a04</span>", "ID": "aa4b7a6a-b3d5-4c4f-a498-350af8eb77b3", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Cycle\u00a04", "ParentId": "e2b7a646-597c-4db4-9ebf-f5b2e06bf258"}, {"Element": "<td style=\"width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>313</span></p>\n</td>", "ID": "90cc93e9-5a4a-437a-8a47-9f7921981649", "Styles": "width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1d0a2525-f0ba-4b3c-9440-b7a5645903c8"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>313</span></p>", "ID": "e63a8b8a-755c-40ea-a2fe-42ef955ffa1e", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "90cc93e9-5a4a-437a-8a47-9f7921981649"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>313</span>", "ID": "1fde43ce-57ca-4e5b-b408-9410b6f6e0d5", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "313", "ParentId": "e63a8b8a-755c-40ea-a2fe-42ef955ffa1e"}, {"Element": "<td style=\"width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>89100</span></p>\n</td>", "ID": "3d148d3a-0e4a-42cf-9d2e-50c7d7443d6b", "Styles": "width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1d0a2525-f0ba-4b3c-9440-b7a5645903c8"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>89100</span></p>", "ID": "1f91c748-41d0-4859-bf68-d5b98e96a246", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "3d148d3a-0e4a-42cf-9d2e-50c7d7443d6b"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>89100</span>", "ID": "c5d097d9-b8f6-4c72-b313-931f903a28f8", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "89100", "ParentId": "1f91c748-41d0-4859-bf68-d5b98e96a246"}, {"Element": "<td style=\"width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.2</span></p>\n</td>", "ID": "cb5e4bd4-5cc2-40a4-848e-540cd2cf5af1", "Styles": "width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1d0a2525-f0ba-4b3c-9440-b7a5645903c8"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.2</span></p>", "ID": "bb75395e-0561-484c-b55c-fbb8e1735bf6", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "cb5e4bd4-5cc2-40a4-848e-540cd2cf5af1"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>11.2</span>", "ID": "d635bf7b-1177-4913-8471-db5511c01c6f", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "11.2", "ParentId": "bb75395e-0561-484c-b55c-fbb8e1735bf6"}, {"Element": "<td style=\"width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"10%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>19.9</span></p>\n</td>", "ID": "9c656a9b-7005-4840-9b15-bee55c645d10", "Styles": "width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1d0a2525-f0ba-4b3c-9440-b7a5645903c8"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>19.9</span></p>", "ID": "01cbd944-31fa-4532-9213-4c0686555e42", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "9c656a9b-7005-4840-9b15-bee55c645d10"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>19.9</span>", "ID": "1cb8501d-c305-48a4-86be-6b586fd91738", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "19.9", "ParentId": "01cbd944-31fa-4532-9213-4c0686555e42"}, {"Element": "<tr>\n<td colspan=\"7\" style=\"width:100.0%;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"100%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(<sup>1</sup>) Cycle\n  for which the pharmacokinetic parameters are presented in this table.</span></p>\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>C<sub>max</sub>:\n  maximum ofatumumab concentration at the end of infusion, AUC: exposure to\n  ofatumumab over a dosing period, CL: ofatumumab clearance after multiple\n  doses, T<sub>\u00bd</sub>: terminal half-life</span></p>\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Numbers rounded\n  to three significant digits</span></p>\n</td>\n</tr>", "ID": "47b6c1de-8a58-472c-8585-79dc5dcc09cf", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "e27e1f84-ddff-4987-92cc-941235c19c26"}, {"Element": "<td colspan=\"7\" style=\"width:100.0%;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"100%\">\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(<sup>1</sup>) Cycle\n  for which the pharmacokinetic parameters are presented in this table.</span></p>\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>C<sub>max</sub>:\n  maximum ofatumumab concentration at the end of infusion, AUC: exposure to\n  ofatumumab over a dosing period, CL: ofatumumab clearance after multiple\n  doses, T<sub>\u00bd</sub>: terminal half-life</span></p>\n<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Numbers rounded\n  to three significant digits</span></p>\n</td>", "ID": "03ab710e-bcf1-497b-8dc0-c6c87d1b9ccb", "Styles": "width:100.0%;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "47b6c1de-8a58-472c-8585-79dc5dcc09cf"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(<sup>1</sup>) Cycle\n  for which the pharmacokinetic parameters are presented in this table.</span></p>", "ID": "8ae7c847-90c7-4716-9f81-02af858ae6da", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "03ab710e-bcf1-497b-8dc0-c6c87d1b9ccb"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>(<sup>1</sup>) Cycle\n  for which the pharmacokinetic parameters are presented in this table.</span>", "ID": "12824022-bba7-4edb-a62b-156cb959385a", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "() Cycle   for which the pharmacokinetic parameters are presented in this table.", "ParentId": "8ae7c847-90c7-4716-9f81-02af858ae6da"}, {"Element": "<sup>1</sup>", "ID": "b8f137cb-e72a-46a3-9147-51354d036d94", "Styles": "None", "Classes": "None", "Text": "1", "ParentId": "12824022-bba7-4edb-a62b-156cb959385a"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>C<sub>max</sub>:\n  maximum ofatumumab concentration at the end of infusion, AUC: exposure to\n  ofatumumab over a dosing period, CL: ofatumumab clearance after multiple\n  doses, T<sub>\u00bd</sub>: terminal half-life</span></p>", "ID": "be48ac58-22b6-4abd-8a70-89334cb1a9a5", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "03ab710e-bcf1-497b-8dc0-c6c87d1b9ccb"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>C<sub>max</sub>:\n  maximum ofatumumab concentration at the end of infusion, AUC: exposure to\n  ofatumumab over a dosing period, CL: ofatumumab clearance after multiple\n  doses, T<sub>\u00bd</sub>: terminal half-life</span>", "ID": "2860148d-d0f1-42af-ab2c-d57334151fa5", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "C:   maximum ofatumumab concentration at the end of infusion, AUC: exposure to   ofatumumab over a dosing period, CL: ofatumumab clearance after multiple   doses, T: terminal half-life", "ParentId": "be48ac58-22b6-4abd-8a70-89334cb1a9a5"}, {"Element": "<sub>max</sub>", "ID": "29e4064d-c1e1-4dc9-881c-ff39ddd7eb55", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "2860148d-d0f1-42af-ab2c-d57334151fa5"}, {"Element": "<sub>\u00bd</sub>", "ID": "50b1d4cc-6fbd-4b30-93e6-7ee68e4d9aca", "Styles": "None", "Classes": "None", "Text": "\u00bd", "ParentId": "2860148d-d0f1-42af-ab2c-d57334151fa5"}, {"Element": "<p class=\"Table\" style=\"margin:0in;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Numbers rounded\n  to three significant digits</span></p>", "ID": "fbf2d74a-27f2-4fe0-a976-5695837aebad", "Styles": "margin:0in;page-break-after:avoid", "Classes": "['Table']", "Text": "", "ParentId": "03ab710e-bcf1-497b-8dc0-c6c87d1b9ccb"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Numbers rounded\n  to three significant digits</span>", "ID": "f47414cf-d3f7-4b02-9816-62b4a34bd0e4", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Numbers rounded   to three significant digits", "ParentId": "fbf2d74a-27f2-4fe0-a976-5695837aebad"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">\u00a0</span></p>", "ID": "4e3155fe-f6c7-4a46-92a1-00ef743d0f36", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt\">\u00a0</span>", "ID": "6141d784-e68b-4f4b-9599-db40ecc2d40b", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "4e3155fe-f6c7-4a46-92a1-00ef743d0f36"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Special populations</u></p>", "ID": "34a2527b-c1ab-4aa9-823e-703b9058fa64", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u>Special populations</u>", "ID": "ad813218-c990-4dbc-b29f-747cbe500946", "Styles": "None", "Classes": "None", "Text": "Special populations", "ParentId": "34a2527b-c1ab-4aa9-823e-703b9058fa64"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "8d78052a-d015-48db-8277-ceae82c28407", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u>Elderly (\u226565\u00a0years\nof age)</u></i></p>", "ID": "0728c396-9ac7-4b08-a349-4bcb2c7fd9f0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><u>Elderly (\u226565\u00a0years\nof age)</u></i>", "ID": "e59fef60-0028-4929-b524-6633d8148b7d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0728c396-9ac7-4b08-a349-4bcb2c7fd9f0"}, {"Element": "<u>Elderly (\u226565\u00a0years\nof age)</u>", "ID": "f8575bdc-6446-44ba-8603-93df188740d2", "Styles": "None", "Classes": "None", "Text": "Elderly (\u226565\u00a0years of age)", "ParentId": "e59fef60-0028-4929-b524-6633d8148b7d"}, {"Element": "<p class=\"MsoNormal\">Age was not found to be a significant factor for ofatumumab\npharmacokinetics in a cross-study population pharmacokinetic analysis of\npatients ranging in age from 21 to 87\u00a0years of age.</p>", "ID": "105262f8-d6e1-4c68-8c29-9e1fb1d4bc31", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Age was not found to be a significant factor for ofatumumab pharmacokinetics in a cross-study population pharmacokinetic analysis of patients ranging in age from 21 to 87\u00a0years of age.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "80bc14d0-941a-4ea8-8268-6c9503f45215", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u>Paediatric population</u></i></p>", "ID": "17838b7b-3ca6-483c-97d6-1df0e972f198", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><u>Paediatric population</u></i>", "ID": "d1309cf5-d31a-4b61-b6cb-166848fc0df3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "17838b7b-3ca6-483c-97d6-1df0e972f198"}, {"Element": "<u>Paediatric population</u>", "ID": "2ddc4024-6005-409d-9077-af1f480814c7", "Styles": "None", "Classes": "None", "Text": "Paediatric population", "ParentId": "d1309cf5-d31a-4b61-b6cb-166848fc0df3"}, {"Element": "<p class=\"MsoNormal\">No pharmacokinetic data are available in paediatric\npatients.</p>", "ID": "61d785cb-c145-454c-b84d-85a6c3a74883", "Styles": "None", "Classes": "['MsoNormal']", "Text": "No pharmacokinetic data are available in paediatric patients.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "8f484d83-09f7-4f08-be3c-727e3ff8952a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u>Gender</u></i></p>", "ID": "146d8e29-d7b3-4248-bcc6-7fdb7e362832", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><u>Gender</u></i>", "ID": "603ddd9f-0deb-4d7d-bf59-902674755d67", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "146d8e29-d7b3-4248-bcc6-7fdb7e362832"}, {"Element": "<u>Gender</u>", "ID": "0793c021-a55a-4e7b-b568-ff87cbc63111", "Styles": "None", "Classes": "None", "Text": "Gender", "ParentId": "603ddd9f-0deb-4d7d-bf59-902674755d67"}, {"Element": "<p class=\"MsoNormal\">Gender had a modest effect (12%) on ofatumumab central\nvolume of distribution in a cross-study population analysis, with higher C<sub>max</sub>\nand AUC values observed in female patients (48% of the patients in this\nanalysis were male and 52% were female); these effects are not considered\nclinically relevant, and no dose adjustment is recommended.</p>", "ID": "70e2beef-3f48-4b9f-b26e-65d6fd159d22", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Gender had a modest effect (12%) on ofatumumab central volume of distribution in a cross-study population analysis, with higher C and AUC values observed in female patients (48% of the patients in this analysis were male and 52% were female); these effects are not considered clinically relevant, and no dose adjustment is recommended.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<sub>max</sub>", "ID": "03f77f2e-1878-4f6d-ac29-9767bbb30649", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "70e2beef-3f48-4b9f-b26e-65d6fd159d22"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "4c80baf4-d246-4a01-a2fd-61bb3a42fd74", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u>Renal impairment</u></i></p>", "ID": "16f92371-d89b-48fe-acbe-f583a6ace267", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><u>Renal impairment</u></i>", "ID": "3ec70374-ea3d-4812-bf91-39e1e4e595d3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "16f92371-d89b-48fe-acbe-f583a6ace267"}, {"Element": "<u>Renal impairment</u>", "ID": "1c350e83-5936-4412-9c83-74a8ee49038e", "Styles": "None", "Classes": "None", "Text": "Renal impairment", "ParentId": "3ec70374-ea3d-4812-bf91-39e1e4e595d3"}, {"Element": "<p class=\"MsoNormal\">Baseline calculated creatinine clearance was not found to be\na significant factor on ofatumumab pharmacokinetics in a cross-study population\nanalysis in patients with calculated creatinine clearance values ranging from\n26 to 287\u00a0ml/min. No dose adjustment is recommended for mild to moderate\nrenal impairment (creatinine clearance &gt;30\u00a0ml/min). There are limited\npharmacokinetic data in patients with severe renal impairment (creatinine\nclearance &lt;30\u00a0ml/min).</p>", "ID": "e240ad59-65da-46d3-b223-707658be4ac0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Baseline calculated creatinine clearance was not found to be a significant factor on ofatumumab pharmacokinetics in a cross-study population analysis in patients with calculated creatinine clearance values ranging from 26 to 287\u00a0ml/min. No dose adjustment is recommended for mild to moderate renal impairment (creatinine clearance >30\u00a0ml/min). There are limited pharmacokinetic data in patients with severe renal impairment (creatinine clearance <30\u00a0ml/min).", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "f1d94f75-5277-4ca9-bc86-6b4f4f7a9133", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u>Hepatic impairment</u></i></p>", "ID": "e20e0310-8e2f-4862-96d6-b01229f5a407", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><u>Hepatic impairment</u></i>", "ID": "ecbef55e-641e-4c3f-9fc9-5efcd5fa443a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e20e0310-8e2f-4862-96d6-b01229f5a407"}, {"Element": "<u>Hepatic impairment</u>", "ID": "e778c710-bdcb-4413-80dc-be1b7371925b", "Styles": "None", "Classes": "None", "Text": "Hepatic impairment", "ParentId": "ecbef55e-641e-4c3f-9fc9-5efcd5fa443a"}, {"Element": "<p class=\"MsoNormal\">No formal studies were conducted to examine the effect of\nhepatic impairment. IgG1 molecules such as ofatumumab are catabolised by\nubiquitous proteolytic enzymes, which are not restricted to hepatic tissue;\ntherefore, changes in hepatic function are unlikely to have any effect on the\nelimination of ofatumumab.</p>", "ID": "6aec0a52-cf9c-4cac-a3d1-6c5eb9b3f14b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "No formal studies were conducted to examine the effect of hepatic impairment. IgG1 molecules such as ofatumumab are catabolised by ubiquitous proteolytic enzymes, which are not restricted to hepatic tissue; therefore, changes in hepatic function are unlikely to have any effect on the elimination of ofatumumab.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "038bbc0f-46ad-4239-81e0-dc4d345d2802", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">5.3\u00a0\u00a0\u00a0\u00a0 Preclinical safety data</span></b></p>", "ID": "a24b7492-9e3d-4590-9592-3a0d83c92c59", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">5.3\u00a0\u00a0\u00a0\u00a0 Preclinical safety data</span></b>", "ID": "3d4c52ab-04f4-4e0d-b2b8-778a2f4621d7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a24b7492-9e3d-4590-9592-3a0d83c92c59"}, {"Element": "<span lang=\"EN-GB\">5.3\u00a0\u00a0\u00a0\u00a0 Preclinical safety data</span>", "ID": "b3285a02-e52e-4a24-81fb-dabdfb36e582", "Styles": "None", "Classes": "None", "Text": "5.3\u00a0\u00a0\u00a0\u00a0 Preclinical safety data", "ParentId": "3d4c52ab-04f4-4e0d-b2b8-778a2f4621d7"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "9bd1ff7b-b439-4ac1-8780-65d729957e76", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Preclinical data reveal no special hazards\nfor humans.</span></p>", "ID": "f0224c60-5608-4c35-8837-b8e7fcd04001", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Preclinical data reveal no special hazards\nfor humans.</span>", "ID": "e2f052fc-ef5a-45be-91f3-e3fdcccc15ee", "Styles": "None", "Classes": "None", "Text": "Preclinical data reveal no special hazards for humans.", "ParentId": "f0224c60-5608-4c35-8837-b8e7fcd04001"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6ac7d038-bd41-477d-86ab-c83987106ef7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9a4c345c-0ca0-4bb0-981d-42b5a832f3a8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6ac7d038-bd41-477d-86ab-c83987106ef7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Intravenous and subcutaneous administration\nto monkeys resulted in the expected depletion of peripheral and lymphoid tissue\nB-cell counts with no associated toxicological findings. As anticipated, a\nreduction in the IgG humoral immune response to keyhole limpet h<span style=\"color:black\">a</span>emocyanin was noted, but there were no effects on\ndelayed-type hypersensitivity responses. In a few animals, increased red cell\ndestruction occurred, presumably as a result of monkey anti-drug antibodies<span style=\"color:green\"> </span><span style=\"color:black\">coating the red cells.</span>\nA corresponding increase in reticulocyte counts seen in these monkeys was\nindicative of a regenerative response in the bone marrow.</span></p>", "ID": "1b148a85-86e6-4b09-b047-607e03a53552", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Intravenous and subcutaneous administration\nto monkeys resulted in the expected depletion of peripheral and lymphoid tissue\nB-cell counts with no associated toxicological findings. As anticipated, a\nreduction in the IgG humoral immune response to keyhole limpet h<span style=\"color:black\">a</span>emocyanin was noted, but there were no effects on\ndelayed-type hypersensitivity responses. In a few animals, increased red cell\ndestruction occurred, presumably as a result of monkey anti-drug antibodies<span style=\"color:green\"> </span><span style=\"color:black\">coating the red cells.</span>\nA corresponding increase in reticulocyte counts seen in these monkeys was\nindicative of a regenerative response in the bone marrow.</span>", "ID": "13ebf103-f7c8-4cfc-a235-4246ba648354", "Styles": "None", "Classes": "None", "Text": "Intravenous and subcutaneous administration to monkeys resulted in the expected depletion of peripheral and lymphoid tissue B-cell counts with no associated toxicological findings. As anticipated, a reduction in the IgG humoral immune response to keyhole limpet hemocyanin was noted, but there were no effects on delayed-type hypersensitivity responses. In a few animals, increased red cell destruction occurred, presumably as a result of monkey anti-drug antibodies A corresponding increase in reticulocyte counts seen in these monkeys was indicative of a regenerative response in the bone marrow.", "ParentId": "1b148a85-86e6-4b09-b047-607e03a53552"}, {"Element": "<span style=\"color:black\">a</span>", "ID": "95d45120-2e57-434e-bf8f-e928aea51847", "Styles": "color:black", "Classes": "None", "Text": "a", "ParentId": "13ebf103-f7c8-4cfc-a235-4246ba648354"}, {"Element": "<span style=\"color:green\"> </span>", "ID": "ecab46da-cc49-4666-a8ba-361cd3ad3680", "Styles": "color:green", "Classes": "None", "Text": " ", "ParentId": "13ebf103-f7c8-4cfc-a235-4246ba648354"}, {"Element": "<span style=\"color:black\">coating the red cells.</span>", "ID": "d6d14210-cc26-4d51-9fb7-bce23403712f", "Styles": "color:black", "Classes": "None", "Text": "coating the red cells.", "ParentId": "13ebf103-f7c8-4cfc-a235-4246ba648354"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f4c9c574-9b8e-4761-a12a-3b969730ac46", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fa9cfd86-7a30-49c6-aed3-3324b5f1fd60", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f4c9c574-9b8e-4761-a12a-3b969730ac46"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Intravenous administration of ofatumumab to\npregnant cynomolgus monkeys at 100\u00a0mg/kg once weekly from days\u00a020 to\n50 of gestation did not elicit maternal or foetal toxicity or teratogenicity.\nAt the end of organogenesis (day\u00a048 of gestation), the ofatumumab exposure\n(AUC<sub>inf</sub>) corresponded to 0.46 to 3.6\u00a0times the human exposure\nafter the eighth infusion of the maximum recommended human dose (MRHD) of 2000\u00a0mg.\nAt day\u00a0100 of gestation, depletion of B-cells relating to the\npharmacological activity of ofatumumab were observed in foetal cord blood and\nfoetal splenic tissues. Spleen weights decreased by approximately 15% in the low-dose\ngroup and by approximately 30% in the high-dose group, compared with control\nvalues.</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">Pre- and post-natal\ndevelopment studies have not been performed. Post-natal recovery has therefore\nnot been demonstrated.</span></p>", "ID": "61bceff2-89f8-4603-b781-00bffcc5236a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Intravenous administration of ofatumumab to\npregnant cynomolgus monkeys at 100\u00a0mg/kg once weekly from days\u00a020 to\n50 of gestation did not elicit maternal or foetal toxicity or teratogenicity.\nAt the end of organogenesis (day\u00a048 of gestation), the ofatumumab exposure\n(AUC<sub>inf</sub>) corresponded to 0.46 to 3.6\u00a0times the human exposure\nafter the eighth infusion of the maximum recommended human dose (MRHD) of 2000\u00a0mg.\nAt day\u00a0100 of gestation, depletion of B-cells relating to the\npharmacological activity of ofatumumab were observed in foetal cord blood and\nfoetal splenic tissues. Spleen weights decreased by approximately 15% in the low-dose\ngroup and by approximately 30% in the high-dose group, compared with control\nvalues.</span>", "ID": "5a84c46b-ffe1-492f-8448-83c06e58143f", "Styles": "None", "Classes": "None", "Text": "Intravenous administration of ofatumumab to pregnant cynomolgus monkeys at 100\u00a0mg/kg once weekly from days\u00a020 to 50 of gestation did not elicit maternal or foetal toxicity or teratogenicity. At the end of organogenesis (day\u00a048 of gestation), the ofatumumab exposure (AUC) corresponded to 0.46 to 3.6\u00a0times the human exposure after the eighth infusion of the maximum recommended human dose (MRHD) of 2000\u00a0mg. At day\u00a0100 of gestation, depletion of B-cells relating to the pharmacological activity of ofatumumab were observed in foetal cord blood and foetal splenic tissues. Spleen weights decreased by approximately 15% in the low-dose group and by approximately 30% in the high-dose group, compared with control values.", "ParentId": "61bceff2-89f8-4603-b781-00bffcc5236a"}, {"Element": "<sub>inf</sub>", "ID": "f68e826e-d118-4119-8a34-0cf5e8f0a6a1", "Styles": "None", "Classes": "None", "Text": "inf", "ParentId": "5a84c46b-ffe1-492f-8448-83c06e58143f"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "4cf16f76-16b2-49d8-b328-e3054f9a11a8", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "61bceff2-89f8-4603-b781-00bffcc5236a"}, {"Element": "<span lang=\"EN-GB\">Pre- and post-natal\ndevelopment studies have not been performed. Post-natal recovery has therefore\nnot been demonstrated.</span>", "ID": "b202ac47-2faa-4b19-ae53-c3b7089cd6ca", "Styles": "None", "Classes": "None", "Text": "Pre- and post-natal development studies have not been performed. Post-natal recovery has therefore not been demonstrated.", "ParentId": "61bceff2-89f8-4603-b781-00bffcc5236a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "289a15af-ab5e-44ac-8630-65e3c986a375", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cea94a44-7dd8-4031-a783-97811cf5d77c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "289a15af-ab5e-44ac-8630-65e3c986a375"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">As ofatumumab is a monoclonal antibody,\ngenotoxicity and carcinogenicity studies have not been conducted with\nofatumumab.</span></p>", "ID": "6031e46b-54ef-4367-ba81-14d71091fa11", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">As ofatumumab is a monoclonal antibody,\ngenotoxicity and carcinogenicity studies have not been conducted with\nofatumumab.</span>", "ID": "1c82f2d7-f621-4e9d-9e18-339dcdd143ff", "Styles": "None", "Classes": "None", "Text": "As ofatumumab is a monoclonal antibody, genotoxicity and carcinogenicity studies have not been conducted with ofatumumab.", "ParentId": "6031e46b-54ef-4367-ba81-14d71091fa11"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6e00d23b-1eed-4ae7-ab2e-4cea7222eed1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c6fc3865-9c9b-4877-a725-3705b0bbd1c1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6e00d23b-1eed-4ae7-ab2e-4cea7222eed1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "79cda62c-65bc-4f4f-959d-7ed1b5da54ff", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1fe1bd53-6d24-4cc5-96e9-f1af299da02a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "79cda62c-65bc-4f4f-959d-7ed1b5da54ff"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL PARTICULARS</span></b></p>", "ID": "475a92c4-7f85-4ca0-a5ce-e49fd2beb0f0", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL PARTICULARS</span></b>", "ID": "dba17d6d-4423-4031-87ca-47b0df50497d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "475a92c4-7f85-4ca0-a5ce-e49fd2beb0f0"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL PARTICULARS</span>", "ID": "d2005922-6065-4bb8-93a6-7453ef80e773", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL PARTICULARS", "ParentId": "dba17d6d-4423-4031-87ca-47b0df50497d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1dd02492-5160-4f58-8519-2909b03021ef", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d1f5614f-79f1-4456-a1e7-c2bd476b579b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1dd02492-5160-4f58-8519-2909b03021ef"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.1\u00a0\u00a0\u00a0\u00a0 List of excipients</span></b></p>", "ID": "20f0b155-72bd-4876-a327-a58d25adeb48", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">6.1\u00a0\u00a0\u00a0\u00a0 List of excipients</span></b>", "ID": "d89d441d-d8ee-4411-b9a7-114bad559ca6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "20f0b155-72bd-4876-a327-a58d25adeb48"}, {"Element": "<span lang=\"EN-GB\">6.1\u00a0\u00a0\u00a0\u00a0 List of excipients</span>", "ID": "0c3f7e90-ec8a-40c5-b853-8d00815caed0", "Styles": "None", "Classes": "None", "Text": "6.1\u00a0\u00a0\u00a0\u00a0 List of excipients", "ParentId": "d89d441d-d8ee-4411-b9a7-114bad559ca6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4e69f4b5-f725-4365-b868-eb4ef9795264", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0c946640-54ea-4d4c-82b6-bc9128817db4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4e69f4b5-f725-4365-b868-eb4ef9795264"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT\" style=\"color:black\">Arginine</span></p>", "ID": "8ba04dfd-fedf-4f10-afe9-06fe47d02773", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"PT\" style=\"color:black\">Arginine</span>", "ID": "17acfba8-d912-4d97-bd2a-346098eddb12", "Styles": "color:black", "Classes": "None", "Text": "Arginine", "ParentId": "8ba04dfd-fedf-4f10-afe9-06fe47d02773"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT\" style=\"color:black\">Sodium acetate (E262)</span></p>", "ID": "61f0fa9d-d679-4c71-af06-c3b732bb5332", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"PT\" style=\"color:black\">Sodium acetate (E262)</span>", "ID": "af72494a-bc25-44ba-8cd4-8a7d4916f5fb", "Styles": "color:black", "Classes": "None", "Text": "Sodium acetate (E262)", "ParentId": "61f0fa9d-d679-4c71-af06-c3b732bb5332"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\" style=\"color:black\">Sodium chloride</span></p>", "ID": "0512743b-db24-4b8f-a963-7caf82ab21cb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"IT\" style=\"color:black\">Sodium chloride</span>", "ID": "19848724-9cab-4226-868a-4cfcfaf654e3", "Styles": "color:black", "Classes": "None", "Text": "Sodium chloride", "ParentId": "0512743b-db24-4b8f-a963-7caf82ab21cb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT\" style=\"color:black\">Polysorbate 80 (E433)</span></p>", "ID": "b293a69d-60e8-44ac-b24a-8af36d188d94", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"PT\" style=\"color:black\">Polysorbate 80 (E433)</span>", "ID": "a1fe5a76-f906-4af4-9068-4d7503d693a0", "Styles": "color:black", "Classes": "None", "Text": "Polysorbate 80 (E433)", "ParentId": "b293a69d-60e8-44ac-b24a-8af36d188d94"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT\" style=\"color:black\">Edetate disodium (E386)</span></p>", "ID": "d17ccdbb-88a4-46b5-a1aa-0a44967f0eb5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"PT\" style=\"color:black\">Edetate disodium (E386)</span>", "ID": "dd02d208-fa10-4ec7-8c1c-3029a0cff7d1", "Styles": "color:black", "Classes": "None", "Text": "Edetate disodium (E386)", "ParentId": "d17ccdbb-88a4-46b5-a1aa-0a44967f0eb5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT\" style=\"color:black\">Hydrochloric acid (E507)\n(for pH-adjustment)</span></p>", "ID": "ea2c0700-063f-4cb7-bd39-77f1f0b75705", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"PT\" style=\"color:black\">Hydrochloric acid (E507)\n(for pH-adjustment)</span>", "ID": "8824b51f-446f-4797-94e9-d98ebd5879e2", "Styles": "color:black", "Classes": "None", "Text": "Hydrochloric acid (E507) (for pH-adjustment)", "ParentId": "ea2c0700-063f-4cb7-bd39-77f1f0b75705"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Water for injections</span></p>", "ID": "4ab2d85e-0981-400b-8cf6-d8ece85c4aa6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Water for injections</span>", "ID": "6f8e776d-727b-45c1-8e6f-ff54dc8b789c", "Styles": "color:black", "Classes": "None", "Text": "Water for injections", "ParentId": "4ab2d85e-0981-400b-8cf6-d8ece85c4aa6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c6e28a49-e058-4e3d-a46e-bd56b7a41ac7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "072778b1-3dc8-4ad2-852b-a51366a0310e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c6e28a49-e058-4e3d-a46e-bd56b7a41ac7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities</span></b></p>", "ID": "cab000aa-9461-49a1-a20d-86f6569f4d90", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities</span></b>", "ID": "d7c6fd76-09d1-4215-90cc-e5968f891b76", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cab000aa-9461-49a1-a20d-86f6569f4d90"}, {"Element": "<span lang=\"EN-GB\">6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities</span>", "ID": "dc886cf3-c84c-4e2f-9d2c-2a9ddb1b2f88", "Styles": "None", "Classes": "None", "Text": "6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities", "ParentId": "d7c6fd76-09d1-4215-90cc-e5968f891b76"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "64494a56-578e-4799-81c9-034c403b0132", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6091f663-754e-410f-8200-421f9e6500a3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "64494a56-578e-4799-81c9-034c403b0132"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">This medicinal product\nmust not be mixed with other medicinal products except those mentioned in\nsection\u00a06.6.</span></p>", "ID": "950cbc30-1e81-4abf-b034-baa3b50d1d6e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">This medicinal product\nmust not be mixed with other medicinal products except those mentioned in\nsection\u00a06.6.</span>", "ID": "8438d7d8-1464-47c3-b534-c52487a69fa4", "Styles": "color:black", "Classes": "None", "Text": "This medicinal product must not be mixed with other medicinal products except those mentioned in section\u00a06.6.", "ParentId": "950cbc30-1e81-4abf-b034-baa3b50d1d6e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6feed94f-42fc-4177-923c-4ef1a5ba7028", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5018ff52-e253-4274-b712-562a4808f634", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6feed94f-42fc-4177-923c-4ef1a5ba7028"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.3\u00a0\u00a0\u00a0\u00a0 Shelf life</span></b></p>", "ID": "2e0dd76c-a626-49e4-b204-56a7cd200769", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">6.3\u00a0\u00a0\u00a0\u00a0 Shelf life</span></b>", "ID": "3529590c-92cb-4456-8dd6-b96093d4b782", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2e0dd76c-a626-49e4-b204-56a7cd200769"}, {"Element": "<span lang=\"EN-GB\">6.3\u00a0\u00a0\u00a0\u00a0 Shelf life</span>", "ID": "f072e2c2-01e3-4f54-86a0-ba781c335510", "Styles": "None", "Classes": "None", "Text": "6.3\u00a0\u00a0\u00a0\u00a0 Shelf life", "ParentId": "3529590c-92cb-4456-8dd6-b96093d4b782"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7f2682aa-b157-4e9a-a24c-f0fb4d7779cb", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "85e29879-43a3-4b51-8dcb-05102b1ccbc1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7f2682aa-b157-4e9a-a24c-f0fb4d7779cb"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Vial</span></u></p>", "ID": "7e2c73af-4a0d-4958-9ed9-1a18dc3c2cc0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\">Vial</span></u>", "ID": "a0500172-fa79-4eab-b59b-3bfca26c3ef8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7e2c73af-4a0d-4958-9ed9-1a18dc3c2cc0"}, {"Element": "<span lang=\"EN-GB\">Vial</span>", "ID": "a9997cb6-55c5-4144-b16a-560d71f8aff9", "Styles": "None", "Classes": "None", "Text": "Vial", "ParentId": "a0500172-fa79-4eab-b59b-3bfca26c3ef8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">3\u00a0years.</span></p>", "ID": "a1f86437-c08d-4375-81b8-c425bf1320b8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">3\u00a0years.</span>", "ID": "eab9d2b4-f3c7-43d5-a93a-2fb749d218ef", "Styles": "None", "Classes": "None", "Text": "3\u00a0years.", "ParentId": "a1f86437-c08d-4375-81b8-c425bf1320b8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4cebf042-63b3-4de5-9dc0-6de1418fbc98", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "30e1027a-aec0-42f4-9cea-3bd5f7eafdeb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4cebf042-63b3-4de5-9dc0-6de1418fbc98"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Diluted\ninfusion solution</span></u></p>", "ID": "a3197a64-74e6-4940-9ad2-7035a08811b3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\">Diluted\ninfusion solution</span></u>", "ID": "029d5e79-ab61-4851-a408-bf7693ab2746", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a3197a64-74e6-4940-9ad2-7035a08811b3"}, {"Element": "<span lang=\"EN-GB\">Diluted\ninfusion solution</span>", "ID": "7fb2617a-7f6a-4f61-89cc-21f6e19f857a", "Styles": "None", "Classes": "None", "Text": "Diluted infusion solution", "ParentId": "029d5e79-ab61-4851-a408-bf7693ab2746"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Chemical and physical\nin-use stability has been demonstrated for 48\u00a0hours at ambient conditions\n(less than 25\u00b0C).</span></p>", "ID": "e61f7a96-86fb-4a90-883f-ab76a9ca08fd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Chemical and physical\nin-use stability has been demonstrated for 48\u00a0hours at ambient conditions\n(less than 25\u00b0C).</span>", "ID": "6e21b532-5a36-4aa6-95b5-32511122feba", "Styles": "color:black", "Classes": "None", "Text": "Chemical and physical in-use stability has been demonstrated for 48\u00a0hours at ambient conditions (less than 25\u00b0C).", "ParentId": "e61f7a96-86fb-4a90-883f-ab76a9ca08fd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "866e6f33-435e-45fb-aa98-49cd2a752456", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "31ae1f67-2061-4993-b164-6e6c40580884", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "866e6f33-435e-45fb-aa98-49cd2a752456"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">From a microbiological point of view, the\nmedicinal product should be used immediately. If not used immediately, in-use\nstorage times and conditions prior to use are the responsibility of the user\nand would normally not be longer than 24\u00a0hours at 2-8\u00a0\u00baC, unless\nreconstitution/dilution has taken place in controlled and validated aseptic\nconditions.</span></p>", "ID": "34ea3a72-05bc-4177-8efe-781131f147c0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">From a microbiological point of view, the\nmedicinal product should be used immediately. If not used immediately, in-use\nstorage times and conditions prior to use are the responsibility of the user\nand would normally not be longer than 24\u00a0hours at 2-8\u00a0\u00baC, unless\nreconstitution/dilution has taken place in controlled and validated aseptic\nconditions.</span>", "ID": "e38d8e9b-ef37-4f50-b84f-a874f4d7c33e", "Styles": "None", "Classes": "None", "Text": "From a microbiological point of view, the medicinal product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24\u00a0hours at 2-8\u00a0\u00baC, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.", "ParentId": "34ea3a72-05bc-4177-8efe-781131f147c0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c63fb398-efb0-4086-860b-5edb231bd3b4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "023c8285-88d0-427b-a0fb-70f991f83c72", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c63fb398-efb0-4086-860b-5edb231bd3b4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.4\u00a0\u00a0\u00a0\u00a0 Special precautions for storage</span></b></p>", "ID": "26bd2072-526c-4664-b134-c3d61b511b05", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">6.4\u00a0\u00a0\u00a0\u00a0 Special precautions for storage</span></b>", "ID": "3feb84ff-0d4f-4806-bb08-9b6dd2d7c9b0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "26bd2072-526c-4664-b134-c3d61b511b05"}, {"Element": "<span lang=\"EN-GB\">6.4\u00a0\u00a0\u00a0\u00a0 Special precautions for storage</span>", "ID": "1baebaac-d352-4847-b7ce-9826aad21f6e", "Styles": "None", "Classes": "None", "Text": "6.4\u00a0\u00a0\u00a0\u00a0 Special precautions for storage", "ParentId": "3feb84ff-0d4f-4806-bb08-9b6dd2d7c9b0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;background:white\"><span class=\"CSIchar\"><span lang=\"EN-GB\" style=\"border:none\">\u00a0</span></span></p>", "ID": "b5c30cf5-37f5-4b21-a335-da9a93a6a32a", "Styles": "page-break-after:avoid;background:white", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span class=\"CSIchar\"><span lang=\"EN-GB\" style=\"border:none\">\u00a0</span></span>", "ID": "ada4ad95-38e3-4d65-b293-9f9556a7070d", "Styles": "None", "Classes": "['CSIchar']", "Text": "", "ParentId": "b5c30cf5-37f5-4b21-a335-da9a93a6a32a"}, {"Element": "<span lang=\"EN-GB\" style=\"border:none\">\u00a0</span>", "ID": "47f42eea-1e4c-4dec-9c7f-40e3051e17bf", "Styles": "border:none", "Classes": "None", "Text": "\u00a0", "ParentId": "ada4ad95-38e3-4d65-b293-9f9556a7070d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Store and transport\nrefrigerated (2</span><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b0</span><span lang=\"EN-GB\" style=\"color:black\">C \u2013 8</span><span lang=\"EN-GB\" style=\"font-family:\nSymbol;color:black\">\u00b0</span><span lang=\"EN-GB\" style=\"color:black\">C).</span></p>", "ID": "1cc28287-a5c3-4a84-80cf-cc37e3bcfff8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Store and transport\nrefrigerated (2</span>", "ID": "84248134-3e71-4ffa-984e-3828997b25c9", "Styles": "color:black", "Classes": "None", "Text": "Store and transport refrigerated (2", "ParentId": "1cc28287-a5c3-4a84-80cf-cc37e3bcfff8"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b0</span>", "ID": "a69e10eb-7d6c-474b-82c7-882474956cb4", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b0", "ParentId": "1cc28287-a5c3-4a84-80cf-cc37e3bcfff8"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">C \u2013 8</span>", "ID": "85f174cf-3cfa-4c66-860f-702295d1478c", "Styles": "color:black", "Classes": "None", "Text": "C \u2013 8", "ParentId": "1cc28287-a5c3-4a84-80cf-cc37e3bcfff8"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:\nSymbol;color:black\">\u00b0</span>", "ID": "5da4fa6c-0f82-4e36-a37f-4206c18b47eb", "Styles": "font-family:\nSymbol;color:black", "Classes": "None", "Text": "\u00b0", "ParentId": "1cc28287-a5c3-4a84-80cf-cc37e3bcfff8"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">C).</span>", "ID": "9a7a40dc-beb2-460b-b394-7d0122dcd1ff", "Styles": "color:black", "Classes": "None", "Text": "C).", "ParentId": "1cc28287-a5c3-4a84-80cf-cc37e3bcfff8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not freeze.</span></p>", "ID": "ff3309a4-46fe-4872-a4a8-98eccd635e7c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Do not freeze.</span>", "ID": "1d9ee1c4-3195-4f56-95eb-8db307955204", "Styles": "None", "Classes": "None", "Text": "Do not freeze.", "ParentId": "ff3309a4-46fe-4872-a4a8-98eccd635e7c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Keep the vial in the\nouter carton in order to protect from light.</span></p>", "ID": "916a9a9a-2ef9-4b47-b6ab-4b205252e49d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Keep the vial in the\nouter carton in order to protect from light.</span>", "ID": "3748ed56-ef82-4dce-b489-57163476c34a", "Styles": "color:black", "Classes": "None", "Text": "Keep the vial in the outer carton in order to protect from light.", "ParentId": "916a9a9a-2ef9-4b47-b6ab-4b205252e49d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "33359805-545c-4f7d-a711-c755beef6472", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4c91fb0d-f80a-41e8-822b-69b4b97c2e3b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "33359805-545c-4f7d-a711-c755beef6472"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">For storage conditions after dilution of\nthe medicinal product, see section\u00a06.3.</span></p>", "ID": "13a1bac0-d0e6-4231-94a0-8f93dc9360fa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">For storage conditions after dilution of\nthe medicinal product, see section\u00a06.3.</span>", "ID": "a04d2baf-75eb-4305-a4c5-9337162793e0", "Styles": "None", "Classes": "None", "Text": "For storage conditions after dilution of the medicinal product, see section\u00a06.3.", "ParentId": "13a1bac0-d0e6-4231-94a0-8f93dc9360fa"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "17272215-7592-4652-a05c-5e938aa6e75d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6b992e17-a40d-44ee-921d-ba069e3cf31b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "17272215-7592-4652-a05c-5e938aa6e75d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.5\u00a0\u00a0\u00a0\u00a0 Nature and contents of container</span></b></p>", "ID": "648c3495-92fe-4ee7-b930-38af47362e6c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">6.5\u00a0\u00a0\u00a0\u00a0 Nature and contents of container</span></b>", "ID": "3d5a2275-5cd2-410b-9a8a-79c07d55bb1a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "648c3495-92fe-4ee7-b930-38af47362e6c"}, {"Element": "<span lang=\"EN-GB\">6.5\u00a0\u00a0\u00a0\u00a0 Nature and contents of container</span>", "ID": "3242cdaf-97f9-4232-839e-0975d7607858", "Styles": "None", "Classes": "None", "Text": "6.5\u00a0\u00a0\u00a0\u00a0 Nature and contents of container", "ParentId": "3d5a2275-5cd2-410b-9a8a-79c07d55bb1a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cabf601a-d4fa-4a65-9f35-2c1145b8e848", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d1eadd1d-d2b6-4a6c-b8ea-c54c8cb98d79", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cabf601a-d4fa-4a65-9f35-2c1145b8e848"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:black\">Arzerra 100\u00a0mg concentrate for solution for infusion</span></u></p>", "ID": "7f4e4af0-66a9-43a6-bad5-e2ffefcf9ad5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\" style=\"color:black\">Arzerra 100\u00a0mg concentrate for solution for infusion</span></u>", "ID": "ebb03f60-e7b4-4db3-ba28-965b8fc7dc0a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7f4e4af0-66a9-43a6-bad5-e2ffefcf9ad5"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Arzerra 100\u00a0mg concentrate for solution for infusion</span>", "ID": "21bb4a3d-28c4-44f4-ad9f-c885783c70c9", "Styles": "color:black", "Classes": "None", "Text": "Arzerra 100\u00a0mg concentrate for solution for infusion", "ParentId": "ebb03f60-e7b4-4db3-ba28-965b8fc7dc0a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "6ecbb1c7-cdbb-4039-84a9-94190f65a588", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "5852fc21-2a0a-4849-bba1-a9899903df7c", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "6ecbb1c7-cdbb-4039-84a9-94190f65a588"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Clear Type I glass vial\nwith a bromobutyl rubber stopper and aluminium over-seal, containing 5\u00a0ml\nof concentrate for solution for infusion.</span></p>", "ID": "46c3b0d8-d33b-4cc0-a990-22a7a963f6cf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Clear Type I glass vial\nwith a bromobutyl rubber stopper and aluminium over-seal, containing 5\u00a0ml\nof concentrate for solution for infusion.</span>", "ID": "5ff9f978-50b2-4579-81e2-e9c3fd7835a6", "Styles": "color:black", "Classes": "None", "Text": "Clear Type I glass vial with a bromobutyl rubber stopper and aluminium over-seal, containing 5\u00a0ml of concentrate for solution for infusion.", "ParentId": "46c3b0d8-d33b-4cc0-a990-22a7a963f6cf"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "471814c4-03c9-47ca-8875-a72c2d8df541", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "565ed4ec-8174-4979-bcb5-64c4af2b7ab9", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "471814c4-03c9-47ca-8875-a72c2d8df541"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Arzerra is available in\npacks of 3\u00a0vials.</span></p>", "ID": "069b01b2-eb09-48af-9cbf-5b8c07fd111c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Arzerra is available in\npacks of 3\u00a0vials.</span>", "ID": "28204b45-be1c-488f-bbf9-d1fd5ebe317a", "Styles": "color:black", "Classes": "None", "Text": "Arzerra is available in packs of 3\u00a0vials.", "ParentId": "069b01b2-eb09-48af-9cbf-5b8c07fd111c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "f08e701a-3964-43bf-919d-93440a64db96", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "493e26d2-8b37-47c2-8937-90b6a7ac787b", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "f08e701a-3964-43bf-919d-93440a64db96"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:black\">Arzerra 1000\u00a0mg concentrate for solution for infusion</span></u></p>", "ID": "add954c5-a9c8-45c5-8b9c-e06d75ff8a08", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\" style=\"color:black\">Arzerra 1000\u00a0mg concentrate for solution for infusion</span></u>", "ID": "3bd89924-b4c1-45b2-bd70-ed3586b88204", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "add954c5-a9c8-45c5-8b9c-e06d75ff8a08"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Arzerra 1000\u00a0mg concentrate for solution for infusion</span>", "ID": "db841251-b4fc-4f5f-bace-299121423fee", "Styles": "color:black", "Classes": "None", "Text": "Arzerra 1000\u00a0mg concentrate for solution for infusion", "ParentId": "3bd89924-b4c1-45b2-bd70-ed3586b88204"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "e80d239e-a5d6-4ae8-8650-8589982a6d57", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "b969b469-6e19-4f10-bd94-84972dc90561", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "e80d239e-a5d6-4ae8-8650-8589982a6d57"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Clear Type I glass vial\nwith a bromobutyl rubber stopper and aluminium over\u2011seal, containing\n50\u00a0ml of concentrate for solution for infusion.</span></p>", "ID": "6057a396-f494-49f6-b03c-9a196c41e04c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Clear Type I glass vial\nwith a bromobutyl rubber stopper and aluminium over\u2011seal, containing\n50\u00a0ml of concentrate for solution for infusion.</span>", "ID": "fe2f0032-837b-4cc2-ba2d-3041a337fec9", "Styles": "color:black", "Classes": "None", "Text": "Clear Type I glass vial with a bromobutyl rubber stopper and aluminium over\u2011seal, containing 50\u00a0ml of concentrate for solution for infusion.", "ParentId": "6057a396-f494-49f6-b03c-9a196c41e04c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "af61e289-c859-419d-8d20-d73c2bcd8608", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "b8032292-f5bd-48c7-95d9-58baa5f46160", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "af61e289-c859-419d-8d20-d73c2bcd8608"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Arzerra is available in\npacks of 1\u00a0vial.</span></p>", "ID": "30d3cf3e-e769-49d2-96d1-8f09d8882419", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Arzerra is available in\npacks of 1\u00a0vial.</span>", "ID": "b6e2c054-3702-4138-a6b1-f53e90092a9f", "Styles": "color:black", "Classes": "None", "Text": "Arzerra is available in packs of 1\u00a0vial.", "ParentId": "30d3cf3e-e769-49d2-96d1-8f09d8882419"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "99d1c559-44a3-478f-9b81-d3917c9805c2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "f6868c48-1a88-45e2-8c6e-b35fcd639bae", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "99d1c559-44a3-478f-9b81-d3917c9805c2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">6.6\u00a0\u00a0\u00a0\u00a0 </span></b><b><span lang=\"EN-GB\">Special\nprecautions for disposal and other handling</span></b></p>", "ID": "935abc25-a802-4fa7-ba4d-46588ab4f07b", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">6.6\u00a0\u00a0\u00a0\u00a0 </span></b>", "ID": "5ae2b638-ae10-4f31-ad2b-b3a453121cdb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "935abc25-a802-4fa7-ba4d-46588ab4f07b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">6.6\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "88b26d90-d3aa-4a45-b6d0-07b29509a91a", "Styles": "color:black", "Classes": "None", "Text": "6.6\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "5ae2b638-ae10-4f31-ad2b-b3a453121cdb"}, {"Element": "<b><span lang=\"EN-GB\">Special\nprecautions for disposal and other handling</span></b>", "ID": "7067ff84-10e7-4059-be67-16b5ab9882a9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "935abc25-a802-4fa7-ba4d-46588ab4f07b"}, {"Element": "<span lang=\"EN-GB\">Special\nprecautions for disposal and other handling</span>", "ID": "bb182177-7eb1-4e56-8202-738fc0d3a1a6", "Styles": "None", "Classes": "None", "Text": "Special precautions for disposal and other handling", "ParentId": "7067ff84-10e7-4059-be67-16b5ab9882a9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "89586752-2b96-49d2-bdba-c60cb3d23c06", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4469ea43-02c3-4a58-9ee7-00f329d5f653", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "89586752-2b96-49d2-bdba-c60cb3d23c06"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Dilution</span></u></p>", "ID": "b7515ef8-1a81-44e3-b1eb-75b470d0aee8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\">Dilution</span></u>", "ID": "dc2df9de-c7eb-4336-8403-3ef9d8c00d42", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b7515ef8-1a81-44e3-b1eb-75b470d0aee8"}, {"Element": "<span lang=\"EN-GB\">Dilution</span>", "ID": "6c0835ae-7525-4bbb-a34f-78e4dcf8df44", "Styles": "None", "Classes": "None", "Text": "Dilution", "ParentId": "dc2df9de-c7eb-4336-8403-3ef9d8c00d42"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "0b1be30d-bc8e-4c1d-801e-a96c22d0b435", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "07ba2cb6-4d4b-4474-9f8f-b3c0454648ab", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "0b1be30d-bc8e-4c1d-801e-a96c22d0b435"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Arzerra </span><span lang=\"EN-GB\">concentrate\nfor solution for infusion </span><span lang=\"EN-GB\">does not contain a\npreservative; therefore dilution should be carried out under aseptic\nconditions. The diluted solution for infusion must be used within 24\u00a0hours\nof preparation. Any unused solution remaining after this time should be\ndiscarded.</span></p>", "ID": "ba9f6389-1aec-40b3-bd71-31571ab4529a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Arzerra </span>", "ID": "f0631f3f-ecaa-4808-95d0-1167e741a466", "Styles": "None", "Classes": "None", "Text": "Arzerra ", "ParentId": "ba9f6389-1aec-40b3-bd71-31571ab4529a"}, {"Element": "<span lang=\"EN-GB\">concentrate\nfor solution for infusion </span>", "ID": "3db01eaa-a093-4fd0-adad-2e5c99282c4c", "Styles": "None", "Classes": "None", "Text": "concentrate for solution for infusion ", "ParentId": "ba9f6389-1aec-40b3-bd71-31571ab4529a"}, {"Element": "<span lang=\"EN-GB\">does not contain a\npreservative; therefore dilution should be carried out under aseptic\nconditions. The diluted solution for infusion must be used within 24\u00a0hours\nof preparation. Any unused solution remaining after this time should be\ndiscarded.</span>", "ID": "c6c8f505-a651-4fd5-9d18-9c6dac87018c", "Styles": "None", "Classes": "None", "Text": "does not contain a preservative; therefore dilution should be carried out under aseptic conditions. The diluted solution for infusion must be used within 24\u00a0hours of preparation. Any unused solution remaining after this time should be discarded.", "ParentId": "ba9f6389-1aec-40b3-bd71-31571ab4529a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "a7cc9367-3058-4474-9167-71bab301529d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "838d550b-7aad-4a1d-a69e-1bddb5c4fd29", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "a7cc9367-3058-4474-9167-71bab301529d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><u>Before\ndiluting Arzerra</u></i></p>", "ID": "35a55d0d-64c4-4464-84f8-547f2db5c473", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><u>Before\ndiluting Arzerra</u></i>", "ID": "eeb5f43a-15d9-4124-9d5b-8ff5fc9b374f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "35a55d0d-64c4-4464-84f8-547f2db5c473"}, {"Element": "<u>Before\ndiluting Arzerra</u>", "ID": "321e6fb2-366b-4897-8be9-4f29b41276c4", "Styles": "None", "Classes": "None", "Text": "Before diluting Arzerra", "ParentId": "eeb5f43a-15d9-4124-9d5b-8ff5fc9b374f"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\">Check the<i> </i><span lang=\"EN-GB\">Arzerra concentrate<i> </i>for particulate matter and discolouration\nprior to dilution. Ofatumumab should be a colourless to pale yellow solution.\nDo not use the Arzerra concentrate if there is discolouration.</span></p>", "ID": "7ca52807-69fe-444f-b9e3-e61265eacfd6", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "Check the", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i> </i>", "ID": "6ada06ab-3eb5-40c0-a0c5-99361dd63f81", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "7ca52807-69fe-444f-b9e3-e61265eacfd6"}, {"Element": "<span lang=\"EN-GB\">Arzerra concentrate<i> </i>for particulate matter and discolouration\nprior to dilution. Ofatumumab should be a colourless to pale yellow solution.\nDo not use the Arzerra concentrate if there is discolouration.</span>", "ID": "665defb1-201d-4954-a6b6-717360f6bcb7", "Styles": "None", "Classes": "None", "Text": "Arzerra concentratefor particulate matter and discolouration prior to dilution. Ofatumumab should be a colourless to pale yellow solution. Do not use the Arzerra concentrate if there is discolouration.", "ParentId": "7ca52807-69fe-444f-b9e3-e61265eacfd6"}, {"Element": "<i> </i>", "ID": "42af4198-eb0a-435a-8ab1-3b6d6fe27333", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "665defb1-201d-4954-a6b6-717360f6bcb7"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8d429643-1241-47cb-8b97-30504b9d3bf7", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "91015c59-db3f-4212-9972-c641130e18c9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8d429643-1241-47cb-8b97-30504b9d3bf7"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Do not shake\nthe ofatumumab vial for this inspection.</span></p>", "ID": "761de0a8-3aa4-4b36-876c-08e109c39a22", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Do not shake\nthe ofatumumab vial for this inspection.</span>", "ID": "46fa2113-3d22-4239-9f85-5730f9b7f267", "Styles": "None", "Classes": "None", "Text": "Do not shake the ofatumumab vial for this inspection.", "ParentId": "761de0a8-3aa4-4b36-876c-08e109c39a22"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "866b3214-d55e-4947-88b2-fc5ddd0b614d", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "074d5123-17cc-446f-9d31-7258b0982e76", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "866b3214-d55e-4947-88b2-fc5ddd0b614d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><u>How\nto dilute the solution for infusion</u></i></p>", "ID": "d858d5e2-0f93-4826-925f-852feb3a584d", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><u>How\nto dilute the solution for infusion</u></i>", "ID": "82f7d5b3-1453-4257-b825-bd3dd1d4cd23", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d858d5e2-0f93-4826-925f-852feb3a584d"}, {"Element": "<u>How\nto dilute the solution for infusion</u>", "ID": "2238ec65-7da1-4c8c-a8ba-56d5928ce914", "Styles": "None", "Classes": "None", "Text": "How to dilute the solution for infusion", "ParentId": "82f7d5b3-1453-4257-b825-bd3dd1d4cd23"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\">The <span lang=\"EN-GB\">Arzerra</span>\nconcentrate must be diluted in <span lang=\"EN-GB\">sodium chloride 9\u00a0mg/ml\n(0.9%) solution for injection</span> prior to administration, using aseptic\ntechnique.</p>", "ID": "96905d9b-96da-4dfd-8b24-03553993f866", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "The  concentrate must be diluted in  prior to administration, using aseptic technique.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Arzerra</span>", "ID": "5c5f8bd7-d186-4b42-a7be-5fedb2987356", "Styles": "None", "Classes": "None", "Text": "Arzerra", "ParentId": "96905d9b-96da-4dfd-8b24-03553993f866"}, {"Element": "<span lang=\"EN-GB\">sodium chloride 9\u00a0mg/ml\n(0.9%) solution for injection</span>", "ID": "c16de0c0-72f1-4ca9-a94e-bdc972a505fc", "Styles": "None", "Classes": "None", "Text": "sodium chloride 9\u00a0mg/ml (0.9%) solution for injection", "ParentId": "96905d9b-96da-4dfd-8b24-03553993f866"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "07f4b9c9-71cc-42c2-9d7e-d6e7c10247a7", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6b71269d-e6a9-451a-b09f-a91b8b969f97", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "07f4b9c9-71cc-42c2-9d7e-d6e7c10247a7"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Arzerra 100\u00a0mg concentrate for solution for infusion</span></i></p>", "ID": "50033739-864b-4cfb-b0b2-70380efb5baf", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><span lang=\"EN-GB\" style=\"color:black\">Arzerra 100\u00a0mg concentrate for solution for infusion</span></i>", "ID": "2362b67f-6ed2-496b-8618-8b432ae4a0a7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "50033739-864b-4cfb-b0b2-70380efb5baf"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Arzerra 100\u00a0mg concentrate for solution for infusion</span>", "ID": "b331d768-7a81-4e1b-98a0-50e572409c7d", "Styles": "color:black", "Classes": "None", "Text": "Arzerra 100\u00a0mg concentrate for solution for infusion", "ParentId": "2362b67f-6ed2-496b-8618-8b432ae4a0a7"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">300\u00a0mg dose: Use 3\u00a0vials (15\u00a0ml total, 5\u00a0ml per\nvial)</span></p>", "ID": "8c7f141d-2421-4b71-8596-fd6a8edb1fe8", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">300\u00a0mg dose: Use 3\u00a0vials (15\u00a0ml total, 5\u00a0ml per\nvial)</span>", "ID": "1cbaeb04-88b7-4f3e-add5-37da04f316a3", "Styles": "None", "Classes": "None", "Text": "300\u00a0mg dose: Use 3\u00a0vials (15\u00a0ml total, 5\u00a0ml per vial)", "ParentId": "8c7f141d-2421-4b71-8596-fd6a8edb1fe8"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif;color:black'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Withdraw and discard 15\u00a0ml from a\n1000\u00a0ml bag of sodium chloride 9\u00a0mg/ml (0.9%) solution for injection;</span></p>", "ID": "2118356d-ea45-415c-a214-5d2cd58c5d86", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif;color:black'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "2e3c8721-3059-4e78-8dc4-1ff301febd83", "Styles": "font-family:\"Tms Rmn\",serif;color:black", "Classes": "None", "Text": "-", "ParentId": "2118356d-ea45-415c-a214-5d2cd58c5d86"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "b1a93bef-83f1-45bb-8d50-6d76c8d3eb7e", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "2e3c8721-3059-4e78-8dc4-1ff301febd83"}, {"Element": "<span lang=\"EN-GB\">Withdraw and discard 15\u00a0ml from a\n1000\u00a0ml bag of sodium chloride 9\u00a0mg/ml (0.9%) solution for injection;</span>", "ID": "145e3735-4b51-42e9-a96f-04c8513c6421", "Styles": "None", "Classes": "None", "Text": "Withdraw and discard 15\u00a0ml from a 1000\u00a0ml bag of sodium chloride 9\u00a0mg/ml (0.9%) solution for injection;", "ParentId": "2118356d-ea45-415c-a214-5d2cd58c5d86"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif;color:black'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Withdraw 5\u00a0ml of ofatumumab from each of 3</span><span lang=\"EN-GB\">\u00a0</span><span lang=\"EN-GB\">vials and inject into the 1000\u00a0ml\nbag;</span></p>", "ID": "eedbc3fd-5e28-47f7-ad86-9be4e57dc2de", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif;color:black'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "cebfb23f-a8b0-4c92-917c-6da332f03654", "Styles": "font-family:\"Tms Rmn\",serif;color:black", "Classes": "None", "Text": "-", "ParentId": "eedbc3fd-5e28-47f7-ad86-9be4e57dc2de"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "d1605100-8ef1-435b-81cc-31c74282e50d", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "cebfb23f-a8b0-4c92-917c-6da332f03654"}, {"Element": "<span lang=\"EN-GB\">Withdraw 5\u00a0ml of ofatumumab from each of 3</span>", "ID": "40c88192-04ae-4192-84a5-dc96088413c8", "Styles": "None", "Classes": "None", "Text": "Withdraw 5\u00a0ml of ofatumumab from each of 3", "ParentId": "eedbc3fd-5e28-47f7-ad86-9be4e57dc2de"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c8fb9605-c74b-48d2-9591-845d4b607006", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "eedbc3fd-5e28-47f7-ad86-9be4e57dc2de"}, {"Element": "<span lang=\"EN-GB\">vials and inject into the 1000\u00a0ml\nbag;</span>", "ID": "214295fc-f0e7-433d-90f7-267181850df4", "Styles": "None", "Classes": "None", "Text": "vials and inject into the 1000\u00a0ml bag;", "ParentId": "eedbc3fd-5e28-47f7-ad86-9be4e57dc2de"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif;color:black'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Do not shake; mix diluted solution by gentle\ninversion.</span></p>", "ID": "b1cac929-51c7-4c20-bf7c-1b11f315eef2", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif;color:black'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "abbfe8e4-bc8e-45df-8279-95f30424fccd", "Styles": "font-family:\"Tms Rmn\",serif;color:black", "Classes": "None", "Text": "-", "ParentId": "b1cac929-51c7-4c20-bf7c-1b11f315eef2"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "0e4acc3f-dd27-4010-b22a-a1bff892362a", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "abbfe8e4-bc8e-45df-8279-95f30424fccd"}, {"Element": "<span lang=\"EN-GB\">Do not shake; mix diluted solution by gentle\ninversion.</span>", "ID": "4382b45e-f7c9-475a-a58a-63e43462b1b1", "Styles": "None", "Classes": "None", "Text": "Do not shake; mix diluted solution by gentle inversion.", "ParentId": "b1cac929-51c7-4c20-bf7c-1b11f315eef2"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4f6a9fc5-4eca-4b70-938d-e61ec5aaa8f7", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "34563e44-1908-44df-89f3-512f1fd0b333", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4f6a9fc5-4eca-4b70-938d-e61ec5aaa8f7"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Arzerra 1000\u00a0mg concentrate for solution for infusion</span></i></p>", "ID": "96638092-f493-4c08-88ce-4e52113a744b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><span lang=\"EN-GB\" style=\"color:black\">Arzerra 1000\u00a0mg concentrate for solution for infusion</span></i>", "ID": "ecfc51f4-ef50-446c-b6be-7ebf37dfbfea", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "96638092-f493-4c08-88ce-4e52113a744b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Arzerra 1000\u00a0mg concentrate for solution for infusion</span>", "ID": "3f99bacd-bb98-4269-9245-6f548c2d0038", "Styles": "color:black", "Classes": "None", "Text": "Arzerra 1000\u00a0mg concentrate for solution for infusion", "ParentId": "ecfc51f4-ef50-446c-b6be-7ebf37dfbfea"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">1000\u00a0mg dose: Use 1\u00a0vial (50\u00a0ml total, 50\u00a0ml per\nvial)</span></p>", "ID": "8748636b-828f-4943-b056-42b33bf3c8ec", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">1000\u00a0mg dose: Use 1\u00a0vial (50\u00a0ml total, 50\u00a0ml per\nvial)</span>", "ID": "3f54daa3-4a47-4472-b81b-9114f6b2322d", "Styles": "None", "Classes": "None", "Text": "1000\u00a0mg dose: Use 1\u00a0vial (50\u00a0ml total, 50\u00a0ml per vial)", "ParentId": "8748636b-828f-4943-b056-42b33bf3c8ec"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif;color:black'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Withdraw and discard 50\u00a0ml from a\n1000\u00a0ml bag of sodium chloride 9\u00a0mg/ml (0.9%) solution for injection;</span></p>", "ID": "b75fabca-3afd-45ea-8f14-9c5a66939e42", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif;color:black'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "80408e9e-34de-4e68-aba6-014ca28e1435", "Styles": "font-family:\"Tms Rmn\",serif;color:black", "Classes": "None", "Text": "-", "ParentId": "b75fabca-3afd-45ea-8f14-9c5a66939e42"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "20ed9d47-b30a-4675-8b16-0fbb1f9eab42", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "80408e9e-34de-4e68-aba6-014ca28e1435"}, {"Element": "<span lang=\"EN-GB\">Withdraw and discard 50\u00a0ml from a\n1000\u00a0ml bag of sodium chloride 9\u00a0mg/ml (0.9%) solution for injection;</span>", "ID": "3101b0b7-a7a4-4610-abb0-2ec86d23eed8", "Styles": "None", "Classes": "None", "Text": "Withdraw and discard 50\u00a0ml from a 1000\u00a0ml bag of sodium chloride 9\u00a0mg/ml (0.9%) solution for injection;", "ParentId": "b75fabca-3afd-45ea-8f14-9c5a66939e42"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif;color:black'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Withdraw 50\u00a0ml of ofatumumab from the vial\nand inject into the 1000\u00a0ml bag;</span></p>", "ID": "24b50770-5a6a-406c-b159-98d03d81e522", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif;color:black'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "9a6b5c6d-f66c-4ce0-99b4-aa26f3056655", "Styles": "font-family:\"Tms Rmn\",serif;color:black", "Classes": "None", "Text": "-", "ParentId": "24b50770-5a6a-406c-b159-98d03d81e522"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "1ff91e07-2e08-4ddf-9303-a62822d35004", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "9a6b5c6d-f66c-4ce0-99b4-aa26f3056655"}, {"Element": "<span lang=\"EN-GB\">Withdraw 50\u00a0ml of ofatumumab from the vial\nand inject into the 1000\u00a0ml bag;</span>", "ID": "789f4ab6-24ba-4128-91b5-150e643c88db", "Styles": "None", "Classes": "None", "Text": "Withdraw 50\u00a0ml of ofatumumab from the vial and inject into the 1000\u00a0ml bag;", "ParentId": "24b50770-5a6a-406c-b159-98d03d81e522"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif;color:black'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Do not shake; mix diluted solution by gentle\ninversion.</span></p>", "ID": "bb9c6243-9ec4-4262-aaa8-bafd2857dd36", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif;color:black'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "ffa968c1-94fa-48ce-89a9-d46a85a58329", "Styles": "font-family:\"Tms Rmn\",serif;color:black", "Classes": "None", "Text": "-", "ParentId": "bb9c6243-9ec4-4262-aaa8-bafd2857dd36"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "e0171de9-e55c-4850-997f-35dad862471e", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "ffa968c1-94fa-48ce-89a9-d46a85a58329"}, {"Element": "<span lang=\"EN-GB\">Do not shake; mix diluted solution by gentle\ninversion.</span>", "ID": "d9a78219-86f2-48c7-b023-ba3fbbe4350c", "Styles": "None", "Classes": "None", "Text": "Do not shake; mix diluted solution by gentle inversion.", "ParentId": "bb9c6243-9ec4-4262-aaa8-bafd2857dd36"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "19dcaa44-eb04-4703-9cae-a944a7b66fed", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "54723d86-257d-4fef-827b-68fc14a61707", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "19dcaa44-eb04-4703-9cae-a944a7b66fed"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">2000\u00a0mg dose: Use 2\u00a0vials (100\u00a0ml total, 50\u00a0ml\nper vial)</span></p>", "ID": "03ad1677-a1f2-4f5f-91ae-ae590bc45db7", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">2000\u00a0mg dose: Use 2\u00a0vials (100\u00a0ml total, 50\u00a0ml\nper vial)</span>", "ID": "cbc09b35-91e5-44ab-b6b7-fd382de5254e", "Styles": "None", "Classes": "None", "Text": "2000\u00a0mg dose: Use 2\u00a0vials (100\u00a0ml total, 50\u00a0ml per vial)", "ParentId": "03ad1677-a1f2-4f5f-91ae-ae590bc45db7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif;color:black'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Withdraw and discard 100\u00a0ml from a\n1000\u00a0ml bag of sodium chloride 9\u00a0mg/ml (0.9%) solution for injection;</span></p>", "ID": "4521e88a-f649-4385-a56b-55407f13d941", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif;color:black'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "25ac46d5-0ebf-4e37-aa01-4b7b735fd5c5", "Styles": "font-family:\"Tms Rmn\",serif;color:black", "Classes": "None", "Text": "-", "ParentId": "4521e88a-f649-4385-a56b-55407f13d941"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "7b842b03-d2db-4d3c-97bc-83c8b0eca624", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "25ac46d5-0ebf-4e37-aa01-4b7b735fd5c5"}, {"Element": "<span lang=\"EN-GB\">Withdraw and discard 100\u00a0ml from a\n1000\u00a0ml bag of sodium chloride 9\u00a0mg/ml (0.9%) solution for injection;</span>", "ID": "d1945a19-62a8-4559-8f87-6b39be45ada4", "Styles": "None", "Classes": "None", "Text": "Withdraw and discard 100\u00a0ml from a 1000\u00a0ml bag of sodium chloride 9\u00a0mg/ml (0.9%) solution for injection;", "ParentId": "4521e88a-f649-4385-a56b-55407f13d941"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif;color:black'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Withdraw 50\u00a0ml of ofatumumab from each of\n2\u00a0vials and inject into the 1000\u00a0ml bag;</span></p>", "ID": "86c4b0cb-549d-4fe5-ad4a-ac65919d3eb1", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif;color:black'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "24f07b5d-d337-4706-a8b4-363437ecde5b", "Styles": "font-family:\"Tms Rmn\",serif;color:black", "Classes": "None", "Text": "-", "ParentId": "86c4b0cb-549d-4fe5-ad4a-ac65919d3eb1"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "f41f7d51-639b-4dc4-8c51-73de8610d6fa", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "24f07b5d-d337-4706-a8b4-363437ecde5b"}, {"Element": "<span lang=\"EN-GB\">Withdraw 50\u00a0ml of ofatumumab from each of\n2\u00a0vials and inject into the 1000\u00a0ml bag;</span>", "ID": "890b1c12-1d90-4326-958f-008ebda645ca", "Styles": "None", "Classes": "None", "Text": "Withdraw 50\u00a0ml of ofatumumab from each of 2\u00a0vials and inject into the 1000\u00a0ml bag;", "ParentId": "86c4b0cb-549d-4fe5-ad4a-ac65919d3eb1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif;color:black'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Do not shake; mix diluted solution by gentle\ninversion.</span></p>", "ID": "b609e8eb-056a-40ea-9393-6363d5b71c34", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif;color:black'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "f4ece43e-006b-486c-8df1-accbdd061ed1", "Styles": "font-family:\"Tms Rmn\",serif;color:black", "Classes": "None", "Text": "-", "ParentId": "b609e8eb-056a-40ea-9393-6363d5b71c34"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "39ffc5f8-8509-4f30-a591-058bcbb837c0", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "f4ece43e-006b-486c-8df1-accbdd061ed1"}, {"Element": "<span lang=\"EN-GB\">Do not shake; mix diluted solution by gentle\ninversion.</span>", "ID": "a236ffbb-d5db-4903-88b1-19d573872931", "Styles": "None", "Classes": "None", "Text": "Do not shake; mix diluted solution by gentle inversion.", "ParentId": "b609e8eb-056a-40ea-9393-6363d5b71c34"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8a1e2985-719a-4dc4-b47f-9a5b54bfba12", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2c0e49ef-6d9e-4975-b9bc-23bf423f41b1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8a1e2985-719a-4dc4-b47f-9a5b54bfba12"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><u>How\nto administer the diluted solution</u></i></p>", "ID": "46f6dc1e-6f73-49f4-a754-5bef0b8fa7fb", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><u>How\nto administer the diluted solution</u></i>", "ID": "b944e4d4-00ab-4bfd-926a-f6b8e2b2fd3b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "46f6dc1e-6f73-49f4-a754-5bef0b8fa7fb"}, {"Element": "<u>How\nto administer the diluted solution</u>", "ID": "dd4c4b25-da3a-4005-88eb-8fc3d6567136", "Styles": "None", "Classes": "None", "Text": "How to administer the diluted solution", "ParentId": "b944e4d4-00ab-4bfd-926a-f6b8e2b2fd3b"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Arzerra must\nnot be administered as an intravenous push or bolus. Administer using an\nintravenous infusion pump</span><span lang=\"EN-GB\">.</span></p>", "ID": "ec0e3f61-5d61-427c-af64-1a2524cc2c52", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Arzerra must\nnot be administered as an intravenous push or bolus. Administer using an\nintravenous infusion pump</span>", "ID": "84a52275-2e68-4c81-9941-d5c3f8196b17", "Styles": "None", "Classes": "None", "Text": "Arzerra must not be administered as an intravenous push or bolus. Administer using an intravenous infusion pump", "ParentId": "ec0e3f61-5d61-427c-af64-1a2524cc2c52"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "945c4869-e205-404c-860e-6a2862beb215", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "ec0e3f61-5d61-427c-af64-1a2524cc2c52"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b11058b3-55f9-4c9f-a1fe-f49443b5c8d9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "41d3da97-984a-40b6-a664-f503dc8a5c1e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b11058b3-55f9-4c9f-a1fe-f49443b5c8d9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The infusion must be completed within\n24\u00a0hours after preparation. Discard any unused solution after this time.</span></p>", "ID": "36d6515c-69dc-4773-9167-1967805aca3f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">The infusion must be completed within\n24\u00a0hours after preparation. Discard any unused solution after this time.</span>", "ID": "0bc7a6ba-a087-41d1-a4ab-968cab7d4fb1", "Styles": "None", "Classes": "None", "Text": "The infusion must be completed within 24\u00a0hours after preparation. Discard any unused solution after this time.", "ParentId": "36d6515c-69dc-4773-9167-1967805aca3f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "78daeb90-306d-45f7-b24f-f801e50ee3ee", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d8205920-0ff0-447b-bc30-f9f46c491bea", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "78daeb90-306d-45f7-b24f-f801e50ee3ee"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Arzerra must not be mixed with, or\nadministered as an infusion with other medicinal products or intravenous\nsolutions. Flush line before and after ofatumumab administration with sodium\nchloride 9\u00a0mg/ml (0.9%) solution for injection to avoid this.</span></p>", "ID": "90e2da19-800f-4dc4-a35b-a1d5f3dbef63", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Arzerra must not be mixed with, or\nadministered as an infusion with other medicinal products or intravenous\nsolutions. Flush line before and after ofatumumab administration with sodium\nchloride 9\u00a0mg/ml (0.9%) solution for injection to avoid this.</span>", "ID": "7b244eba-3b78-4526-8772-c422db20e766", "Styles": "None", "Classes": "None", "Text": "Arzerra must not be mixed with, or administered as an infusion with other medicinal products or intravenous solutions. Flush line before and after ofatumumab administration with sodium chloride 9\u00a0mg/ml (0.9%) solution for injection to avoid this.", "ParentId": "90e2da19-800f-4dc4-a35b-a1d5f3dbef63"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e47d52a2-891b-4ce9-bfb7-ab5e0f15ab6f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4af3eaa6-21aa-4955-a8d9-8f9f28a44381", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e47d52a2-891b-4ce9-bfb7-ab5e0f15ab6f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Previously\nuntreated CLL and relapsed CLL</span></u></p>", "ID": "a234b8c7-490d-4ed7-a41d-fbe3727330ef", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\">Previously\nuntreated CLL and relapsed CLL</span></u>", "ID": "ee785d44-2fe7-47dd-8fd2-c545a4a3035d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a234b8c7-490d-4ed7-a41d-fbe3727330ef"}, {"Element": "<span lang=\"EN-GB\">Previously\nuntreated CLL and relapsed CLL</span>", "ID": "7355b142-c0cc-45e1-ac1e-bf86ec3b21fa", "Styles": "None", "Classes": "None", "Text": "Previously untreated CLL and relapsed CLL", "ParentId": "ee785d44-2fe7-47dd-8fd2-c545a4a3035d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "afa99c73-1ff1-4d05-8722-3d667662ce79", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6b82809b-a821-47a6-854f-6c4b4c0c9d2c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "afa99c73-1ff1-4d05-8722-3d667662ce79"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">For the first infusion, administer over\n4.5\u00a0hours </span><span lang=\"EN-GB\">(</span><span lang=\"EN-GB\">see\nsection\u00a04.2</span><i><span lang=\"EN-GB\">)</span></i><span lang=\"EN-GB\">, </span><span lang=\"EN-GB\">through a peripheral line or indwelling catheter, according to the\nschedule below:</span></p>", "ID": "393c7fc9-922e-49fe-a043-df6499e672c8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">For the first infusion, administer over\n4.5\u00a0hours </span>", "ID": "de295872-60e1-4011-a3f0-f0e66d7b948c", "Styles": "None", "Classes": "None", "Text": "For the first infusion, administer over 4.5\u00a0hours ", "ParentId": "393c7fc9-922e-49fe-a043-df6499e672c8"}, {"Element": "<span lang=\"EN-GB\">(</span>", "ID": "458b98f1-385b-41f9-b0f8-2af38b65d87a", "Styles": "None", "Classes": "None", "Text": "(", "ParentId": "393c7fc9-922e-49fe-a043-df6499e672c8"}, {"Element": "<span lang=\"EN-GB\">see\nsection\u00a04.2</span>", "ID": "1154b8a7-fa31-4b36-b684-a2454bf07f6a", "Styles": "None", "Classes": "None", "Text": "see section\u00a04.2", "ParentId": "393c7fc9-922e-49fe-a043-df6499e672c8"}, {"Element": "<i><span lang=\"EN-GB\">)</span></i>", "ID": "9c4e7cab-bbb3-4110-84f5-e7673bde2478", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "393c7fc9-922e-49fe-a043-df6499e672c8"}, {"Element": "<span lang=\"EN-GB\">)</span>", "ID": "067afc79-318c-416b-90a8-3ca729ff6b90", "Styles": "None", "Classes": "None", "Text": ")", "ParentId": "9c4e7cab-bbb3-4110-84f5-e7673bde2478"}, {"Element": "<span lang=\"EN-GB\">, </span>", "ID": "fa511cec-09d0-4f18-acf3-66c0cded3cf2", "Styles": "None", "Classes": "None", "Text": ", ", "ParentId": "393c7fc9-922e-49fe-a043-df6499e672c8"}, {"Element": "<span lang=\"EN-GB\">through a peripheral line or indwelling catheter, according to the\nschedule below:</span>", "ID": "d33007b5-110d-40ff-91f0-29b588409408", "Styles": "None", "Classes": "None", "Text": "through a peripheral line or indwelling catheter, according to the schedule below:", "ParentId": "393c7fc9-922e-49fe-a043-df6499e672c8"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ea5c6ca1-47b4-4dc6-ae02-604fdf862ad4", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4118ba71-3f95-4309-b090-44bd82252aef", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ea5c6ca1-47b4-4dc6-ae02-604fdf862ad4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">If the first infusion was completed without a severe adverse\nreaction, the remaining infusions of 1000\u00a0mg should be administered over\n4\u00a0hours (see section\u00a04.2</span><i><span lang=\"EN-GB\">)</span></i><span lang=\"EN-GB\">, through a peripheral line or indwelling catheter, </span><span lang=\"EN-GB\">according to the schedule below.</span><span lang=\"EN-GB\"> If any\ninfusion\u2011related adverse reactions are observed, infusion should be\ninterrupted and restarted when the patient\u2019s condition is stable (see </span><span lang=\"EN-GB\">section\u00a04.2 for further information).</span></p>", "ID": "c18a6409-c7fd-441f-9dc2-72f2bb4aff24", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">If the first infusion was completed without a severe adverse\nreaction, the remaining infusions of 1000\u00a0mg should be administered over\n4\u00a0hours (see section\u00a04.2</span>", "ID": "7c6b2034-f9c0-46f6-88d0-2b43a4d55ce2", "Styles": "None", "Classes": "None", "Text": "If the first infusion was completed without a severe adverse reaction, the remaining infusions of 1000\u00a0mg should be administered over 4\u00a0hours (see section\u00a04.2", "ParentId": "c18a6409-c7fd-441f-9dc2-72f2bb4aff24"}, {"Element": "<i><span lang=\"EN-GB\">)</span></i>", "ID": "0d25622f-ccf9-4b7b-b606-e9316b7dfce9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c18a6409-c7fd-441f-9dc2-72f2bb4aff24"}, {"Element": "<span lang=\"EN-GB\">)</span>", "ID": "d48a1d20-74ad-417e-9297-0fe423cd31e6", "Styles": "None", "Classes": "None", "Text": ")", "ParentId": "0d25622f-ccf9-4b7b-b606-e9316b7dfce9"}, {"Element": "<span lang=\"EN-GB\">, through a peripheral line or indwelling catheter, </span>", "ID": "6810d42d-33b6-45c7-a1bb-9dc64d820f6f", "Styles": "None", "Classes": "None", "Text": ", through a peripheral line or indwelling catheter, ", "ParentId": "c18a6409-c7fd-441f-9dc2-72f2bb4aff24"}, {"Element": "<span lang=\"EN-GB\">according to the schedule below.</span>", "ID": "a1503207-2cdf-4581-ac12-f28187407d81", "Styles": "None", "Classes": "None", "Text": "according to the schedule below.", "ParentId": "c18a6409-c7fd-441f-9dc2-72f2bb4aff24"}, {"Element": "<span lang=\"EN-GB\"> If any\ninfusion\u2011related adverse reactions are observed, infusion should be\ninterrupted and restarted when the patient\u2019s condition is stable (see </span>", "ID": "c8ce2438-81ca-499b-8eb9-9448b816ab90", "Styles": "None", "Classes": "None", "Text": " If any infusion\u2011related adverse reactions are observed, infusion should be interrupted and restarted when the patient\u2019s condition is stable (see ", "ParentId": "c18a6409-c7fd-441f-9dc2-72f2bb4aff24"}, {"Element": "<span lang=\"EN-GB\">section\u00a04.2 for further information).</span>", "ID": "dcb08188-aa37-45e0-83ac-1fa9d98213d5", "Styles": "None", "Classes": "None", "Text": "section\u00a04.2 for further information).", "ParentId": "c18a6409-c7fd-441f-9dc2-72f2bb4aff24"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "3feec0ff-dbcc-4db5-8009-3ca0901a030e", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "d902f816-1210-4eac-82ce-2ae927ca42e8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3feec0ff-dbcc-4db5-8009-3ca0901a030e"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "864c3a1f-3152-4b06-b3b4-7391f45aa791", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d902f816-1210-4eac-82ce-2ae927ca42e8"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><u><span lang=\"EN-GB\">Infusion schedule</span></u></i></p>", "ID": "1d59ee5a-4e06-4a78-8682-d0117be4f32e", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><u><span lang=\"EN-GB\">Infusion schedule</span></u></i>", "ID": "91d7529b-07b4-43e9-ab23-9b556f3662ae", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1d59ee5a-4e06-4a78-8682-d0117be4f32e"}, {"Element": "<u><span lang=\"EN-GB\">Infusion schedule</span></u>", "ID": "d476f06a-daba-423a-bb20-6d20a2782e7c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "91d7529b-07b4-43e9-ab23-9b556f3662ae"}, {"Element": "<span lang=\"EN-GB\">Infusion schedule</span>", "ID": "0432007d-bccb-4334-9f44-dea88d2159f5", "Styles": "None", "Classes": "None", "Text": "Infusion schedule", "ParentId": "d476f06a-daba-423a-bb20-6d20a2782e7c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "71c0393f-22c3-403b-aee5-49d538174cfe", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "aec7d6ee-3089-442f-a7f3-450b24982003", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "71c0393f-22c3-403b-aee5-49d538174cfe"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:100.0%;border-collapse:collapse;border:none\" width=\"100%\">\n<tr>\n<td rowspan=\"2\" style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Time after start of infusion (minutes)</span></p>\n</td>\n<td style=\"width:141.15pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion\u00a01</span></p>\n</td>\n<td style=\"width:146.55pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Subsequent infusions*</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:141.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0\u201130</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">12</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31\u201160</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">61\u201190</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">91\u2011120</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">121\u2011150</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">151\u2011180</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">300</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">180+</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\" style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">*If the\n  previous infusion was completed without severe infusion\u2011related ADRs.\n  If any infusion\u2011related ADRs are observed, infusion should be\n  interrupted and restarted when the patient\u2019s condition is stable (see </span><span lang=\"EN-GB\">section\u00a04.2 of the SmPC</span><span lang=\"EN-GB\">).</span></p>\n</td>\n</tr>\n</table>", "ID": "c6d703e2-36e6-406c-9e13-d77e5c8754a6", "Styles": "width:100.0%;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "           ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<tr>\n<td rowspan=\"2\" style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Time after start of infusion (minutes)</span></p>\n</td>\n<td style=\"width:141.15pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion\u00a01</span></p>\n</td>\n<td style=\"width:146.55pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Subsequent infusions*</span></p>\n</td>\n</tr>", "ID": "543a3833-c43a-485c-9f63-85ff28180ed2", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "c6d703e2-36e6-406c-9e13-d77e5c8754a6"}, {"Element": "<td rowspan=\"2\" style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Time after start of infusion (minutes)</span></p>\n</td>", "ID": "f60b982f-7a39-4087-8ce7-eb8ccfc98b7b", "Styles": "width:176.65pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "543a3833-c43a-485c-9f63-85ff28180ed2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Time after start of infusion (minutes)</span></p>", "ID": "89d5a18a-1c99-4869-92c6-9e697ea51a41", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f60b982f-7a39-4087-8ce7-eb8ccfc98b7b"}, {"Element": "<span lang=\"EN-GB\">Time after start of infusion (minutes)</span>", "ID": "47aed6d2-1729-4a9f-86e2-d4e0d9ed0a8d", "Styles": "None", "Classes": "None", "Text": "Time after start of infusion (minutes)", "ParentId": "89d5a18a-1c99-4869-92c6-9e697ea51a41"}, {"Element": "<td style=\"width:141.15pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion\u00a01</span></p>\n</td>", "ID": "2011a5d6-b8a0-4afd-986a-2f1f4e42269b", "Styles": "width:141.15pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "543a3833-c43a-485c-9f63-85ff28180ed2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion\u00a01</span></p>", "ID": "05a78250-2ecf-4548-857e-c8c54fd28159", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2011a5d6-b8a0-4afd-986a-2f1f4e42269b"}, {"Element": "<span lang=\"EN-GB\">Infusion\u00a01</span>", "ID": "d8c153f1-7442-47cd-a24a-78199430086a", "Styles": "None", "Classes": "None", "Text": "Infusion\u00a01", "ParentId": "05a78250-2ecf-4548-857e-c8c54fd28159"}, {"Element": "<td style=\"width:146.55pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Subsequent infusions*</span></p>\n</td>", "ID": "4d32ea09-a326-460d-a09f-ba3fea4f3eae", "Styles": "width:146.55pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "543a3833-c43a-485c-9f63-85ff28180ed2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Subsequent infusions*</span></p>", "ID": "a3dfd110-40d5-4fd5-b8f1-26c4b03c96e9", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4d32ea09-a326-460d-a09f-ba3fea4f3eae"}, {"Element": "<span lang=\"EN-GB\">Subsequent infusions*</span>", "ID": "51f5f6be-600f-4660-be0e-b06bd2c5ccdb", "Styles": "None", "Classes": "None", "Text": "Subsequent infusions*", "ParentId": "a3dfd110-40d5-4fd5-b8f1-26c4b03c96e9"}, {"Element": "<tr>\n<td style=\"width:141.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>\n</tr>", "ID": "33747ed7-8086-4c57-8d6f-c4c81636af5e", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "c6d703e2-36e6-406c-9e13-d77e5c8754a6"}, {"Element": "<td style=\"width:141.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>", "ID": "018db830-3ec5-4e69-bd83-6c803718d5f8", "Styles": "width:141.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "33747ed7-8086-4c57-8d6f-c4c81636af5e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>", "ID": "52793e15-5284-446a-9747-6de0cb74f748", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "018db830-3ec5-4e69-bd83-6c803718d5f8"}, {"Element": "<span lang=\"EN-GB\">Infusion rate (ml/hour)</span>", "ID": "3307b270-94b2-493c-b146-f9bac64e2a7f", "Styles": "None", "Classes": "None", "Text": "Infusion rate (ml/hour)", "ParentId": "52793e15-5284-446a-9747-6de0cb74f748"}, {"Element": "<td style=\"width:146.55pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>", "ID": "3b8e8f77-6b4d-471d-910d-d4b9a34ffc09", "Styles": "width:146.55pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "33747ed7-8086-4c57-8d6f-c4c81636af5e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>", "ID": "6d42d968-1793-4eb8-8beb-f4771993e80d", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3b8e8f77-6b4d-471d-910d-d4b9a34ffc09"}, {"Element": "<span lang=\"EN-GB\">Infusion rate (ml/hour)</span>", "ID": "96541750-5def-49f1-ac49-3b6a0fe3351d", "Styles": "None", "Classes": "None", "Text": "Infusion rate (ml/hour)", "ParentId": "6d42d968-1793-4eb8-8beb-f4771993e80d"}, {"Element": "<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0\u201130</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">12</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>\n</tr>", "ID": "4aa4fe41-c22d-403d-8aca-2c104b0b739b", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "c6d703e2-36e6-406c-9e13-d77e5c8754a6"}, {"Element": "<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0\u201130</span></p>\n</td>", "ID": "7252a0a0-8421-4c22-90f2-da99cfca6b1e", "Styles": "width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4aa4fe41-c22d-403d-8aca-2c104b0b739b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0\u201130</span></p>", "ID": "70f6aac7-5c90-4944-b878-0b5d577b07d9", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7252a0a0-8421-4c22-90f2-da99cfca6b1e"}, {"Element": "<span lang=\"EN-GB\">0\u201130</span>", "ID": "b452dcfd-0ce7-41b2-8075-7234984e5131", "Styles": "None", "Classes": "None", "Text": "0\u201130", "ParentId": "70f6aac7-5c90-4944-b878-0b5d577b07d9"}, {"Element": "<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">12</span></p>\n</td>", "ID": "69147ba8-5d0c-49e2-bfb4-e7d1a0b5aaf4", "Styles": "width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4aa4fe41-c22d-403d-8aca-2c104b0b739b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">12</span></p>", "ID": "a7558aa7-0d7b-43a9-b5f7-b5694b001d18", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "69147ba8-5d0c-49e2-bfb4-e7d1a0b5aaf4"}, {"Element": "<span lang=\"EN-GB\">12</span>", "ID": "1aa84890-8d3e-48cc-be1e-30d825bca891", "Styles": "None", "Classes": "None", "Text": "12", "ParentId": "a7558aa7-0d7b-43a9-b5f7-b5694b001d18"}, {"Element": "<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>", "ID": "2a5670e8-fe3f-4c47-9cb0-9c90b00d387d", "Styles": "width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4aa4fe41-c22d-403d-8aca-2c104b0b739b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>", "ID": "6c50c3d6-540f-4147-b399-3bd96c50f660", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2a5670e8-fe3f-4c47-9cb0-9c90b00d387d"}, {"Element": "<span lang=\"EN-GB\">25</span>", "ID": "f68dc30b-03bc-475b-926c-2098237fe9d8", "Styles": "None", "Classes": "None", "Text": "25", "ParentId": "6c50c3d6-540f-4147-b399-3bd96c50f660"}, {"Element": "<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31\u201160</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>\n</tr>", "ID": "ecd85e40-3ecb-412c-a8e8-94a3e0a37401", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "c6d703e2-36e6-406c-9e13-d77e5c8754a6"}, {"Element": "<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31\u201160</span></p>\n</td>", "ID": "806fc41d-64f5-4bf8-b4b2-c37a243b85a6", "Styles": "width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ecd85e40-3ecb-412c-a8e8-94a3e0a37401"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31\u201160</span></p>", "ID": "1c0be446-58ce-452a-81af-cc7abfd0824b", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "806fc41d-64f5-4bf8-b4b2-c37a243b85a6"}, {"Element": "<span lang=\"EN-GB\">31\u201160</span>", "ID": "41d94467-45d1-44c9-abb1-056cc24c7d2d", "Styles": "None", "Classes": "None", "Text": "31\u201160", "ParentId": "1c0be446-58ce-452a-81af-cc7abfd0824b"}, {"Element": "<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>", "ID": "30801693-909d-405d-a2e9-0348276079a3", "Styles": "width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ecd85e40-3ecb-412c-a8e8-94a3e0a37401"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>", "ID": "bb068cb6-b389-4717-9002-c5d0cb0b33d6", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "30801693-909d-405d-a2e9-0348276079a3"}, {"Element": "<span lang=\"EN-GB\">25</span>", "ID": "5c8ff87d-37f6-457f-afb8-bd0950e9288a", "Styles": "None", "Classes": "None", "Text": "25", "ParentId": "bb068cb6-b389-4717-9002-c5d0cb0b33d6"}, {"Element": "<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>", "ID": "c0fe7f35-bd9a-43a6-8950-a0a29f916685", "Styles": "width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ecd85e40-3ecb-412c-a8e8-94a3e0a37401"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>", "ID": "1ce4ae40-81b0-4b0e-9590-11cf3ae77ca5", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c0fe7f35-bd9a-43a6-8950-a0a29f916685"}, {"Element": "<span lang=\"EN-GB\">50</span>", "ID": "b5f6cc85-591c-4d6e-a250-91fe3d0fc1c0", "Styles": "None", "Classes": "None", "Text": "50", "ParentId": "1ce4ae40-81b0-4b0e-9590-11cf3ae77ca5"}, {"Element": "<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">61\u201190</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>\n</tr>", "ID": "1a245cc8-f6c3-4632-bafb-691036c50220", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "c6d703e2-36e6-406c-9e13-d77e5c8754a6"}, {"Element": "<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">61\u201190</span></p>\n</td>", "ID": "65ba6cb8-2477-400d-a7dd-e20193d439a8", "Styles": "width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1a245cc8-f6c3-4632-bafb-691036c50220"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">61\u201190</span></p>", "ID": "42bb37f9-b443-4f58-aae1-ccc30f6ee825", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "65ba6cb8-2477-400d-a7dd-e20193d439a8"}, {"Element": "<span lang=\"EN-GB\">61\u201190</span>", "ID": "c4de6e0a-a771-4699-b4d0-1cd60523e220", "Styles": "None", "Classes": "None", "Text": "61\u201190", "ParentId": "42bb37f9-b443-4f58-aae1-ccc30f6ee825"}, {"Element": "<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>", "ID": "02924346-2665-4ee9-8d4a-81d5617bf223", "Styles": "width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1a245cc8-f6c3-4632-bafb-691036c50220"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>", "ID": "54600635-a692-4014-93a0-01a0fb4be63e", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "02924346-2665-4ee9-8d4a-81d5617bf223"}, {"Element": "<span lang=\"EN-GB\">50</span>", "ID": "cdc6c169-c2ce-4abf-9b8f-19a7fdc79c1c", "Styles": "None", "Classes": "None", "Text": "50", "ParentId": "54600635-a692-4014-93a0-01a0fb4be63e"}, {"Element": "<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>", "ID": "0e710913-64ce-4ee4-adc2-cd49242c5807", "Styles": "width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1a245cc8-f6c3-4632-bafb-691036c50220"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>", "ID": "ed8a78f8-b6ab-4782-af6f-d3a7f31e6250", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0e710913-64ce-4ee4-adc2-cd49242c5807"}, {"Element": "<span lang=\"EN-GB\">100</span>", "ID": "df08283f-ea20-49fd-b380-00789fc01f69", "Styles": "None", "Classes": "None", "Text": "100", "ParentId": "ed8a78f8-b6ab-4782-af6f-d3a7f31e6250"}, {"Element": "<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">91\u2011120</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>\n</tr>", "ID": "a4f3eec8-806c-44b9-b103-c00164a73f5a", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "c6d703e2-36e6-406c-9e13-d77e5c8754a6"}, {"Element": "<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">91\u2011120</span></p>\n</td>", "ID": "ba3adc56-267a-4dcc-a5f9-437b08080e40", "Styles": "width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a4f3eec8-806c-44b9-b103-c00164a73f5a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">91\u2011120</span></p>", "ID": "6ed2106b-49a7-4927-a2cf-069b7b7dbba7", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ba3adc56-267a-4dcc-a5f9-437b08080e40"}, {"Element": "<span lang=\"EN-GB\">91\u2011120</span>", "ID": "c1dc34cd-9776-48be-a473-250a577987f3", "Styles": "None", "Classes": "None", "Text": "91\u2011120", "ParentId": "6ed2106b-49a7-4927-a2cf-069b7b7dbba7"}, {"Element": "<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>", "ID": "7c764638-59f4-4402-a677-534687163b7a", "Styles": "width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a4f3eec8-806c-44b9-b103-c00164a73f5a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>", "ID": "39335b37-92e9-4f98-9825-2bc2327bed71", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7c764638-59f4-4402-a677-534687163b7a"}, {"Element": "<span lang=\"EN-GB\">100</span>", "ID": "97f5fe8f-11ee-42b3-9cc0-99729987db31", "Styles": "None", "Classes": "None", "Text": "100", "ParentId": "39335b37-92e9-4f98-9825-2bc2327bed71"}, {"Element": "<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>", "ID": "21cab1c4-30cc-4d6d-b34e-90d4bc6043c2", "Styles": "width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a4f3eec8-806c-44b9-b103-c00164a73f5a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>", "ID": "77362e67-61fe-4fc2-a7ce-5e685d02aa60", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "21cab1c4-30cc-4d6d-b34e-90d4bc6043c2"}, {"Element": "<span lang=\"EN-GB\">200</span>", "ID": "e205e26d-cb37-40d8-b59a-36b9056366e1", "Styles": "None", "Classes": "None", "Text": "200", "ParentId": "77362e67-61fe-4fc2-a7ce-5e685d02aa60"}, {"Element": "<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">121\u2011150</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n</tr>", "ID": "04cf30c3-6022-45fe-9241-3b27fd7fdb15", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "c6d703e2-36e6-406c-9e13-d77e5c8754a6"}, {"Element": "<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">121\u2011150</span></p>\n</td>", "ID": "de0b2f36-a1b2-44d7-922d-3522884b9f93", "Styles": "width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "04cf30c3-6022-45fe-9241-3b27fd7fdb15"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">121\u2011150</span></p>", "ID": "1061525c-f231-4ad0-83dd-6de66317bff8", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "de0b2f36-a1b2-44d7-922d-3522884b9f93"}, {"Element": "<span lang=\"EN-GB\">121\u2011150</span>", "ID": "28366db2-2aee-4536-8692-7e7071f49108", "Styles": "None", "Classes": "None", "Text": "121\u2011150", "ParentId": "1061525c-f231-4ad0-83dd-6de66317bff8"}, {"Element": "<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>", "ID": "4001218d-d12f-4452-a24d-0e0fb810130e", "Styles": "width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "04cf30c3-6022-45fe-9241-3b27fd7fdb15"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>", "ID": "ab59b8f1-6860-4629-abd5-bb14169bd64a", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4001218d-d12f-4452-a24d-0e0fb810130e"}, {"Element": "<span lang=\"EN-GB\">200</span>", "ID": "fa305a81-1973-421a-8870-a4738b78ffe4", "Styles": "None", "Classes": "None", "Text": "200", "ParentId": "ab59b8f1-6860-4629-abd5-bb14169bd64a"}, {"Element": "<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>", "ID": "c7a399c6-5533-4689-ba2d-5bee66d5336c", "Styles": "width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "04cf30c3-6022-45fe-9241-3b27fd7fdb15"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>", "ID": "2f3206aa-9f42-4c03-83bd-a58db4b71473", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c7a399c6-5533-4689-ba2d-5bee66d5336c"}, {"Element": "<span lang=\"EN-GB\">400</span>", "ID": "5d9b1928-39a2-4722-8afe-7ff98c636114", "Styles": "None", "Classes": "None", "Text": "400", "ParentId": "2f3206aa-9f42-4c03-83bd-a58db4b71473"}, {"Element": "<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">151\u2011180</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">300</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n</tr>", "ID": "626986c3-939f-43e3-b7ef-04dce9925c35", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "c6d703e2-36e6-406c-9e13-d77e5c8754a6"}, {"Element": "<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">151\u2011180</span></p>\n</td>", "ID": "2a8a9e1e-aa66-4f0d-942b-19a9a9bdd32f", "Styles": "width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "626986c3-939f-43e3-b7ef-04dce9925c35"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">151\u2011180</span></p>", "ID": "d30c6bda-feab-4f72-835a-5215cac6c9ec", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2a8a9e1e-aa66-4f0d-942b-19a9a9bdd32f"}, {"Element": "<span lang=\"EN-GB\">151\u2011180</span>", "ID": "a20fe6cd-26ea-4506-93f6-b2a4345e17ba", "Styles": "None", "Classes": "None", "Text": "151\u2011180", "ParentId": "d30c6bda-feab-4f72-835a-5215cac6c9ec"}, {"Element": "<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">300</span></p>\n</td>", "ID": "fbf36376-a58d-404d-9369-85c19c82723e", "Styles": "width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "626986c3-939f-43e3-b7ef-04dce9925c35"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">300</span></p>", "ID": "0b29e6a5-4e2b-4bb7-8e57-0a6cfeac15be", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fbf36376-a58d-404d-9369-85c19c82723e"}, {"Element": "<span lang=\"EN-GB\">300</span>", "ID": "06f00a45-8d9f-46d5-8ead-f09a06c77f6b", "Styles": "None", "Classes": "None", "Text": "300", "ParentId": "0b29e6a5-4e2b-4bb7-8e57-0a6cfeac15be"}, {"Element": "<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>", "ID": "6ec89786-f772-4ff4-af51-08a2c320ef54", "Styles": "width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "626986c3-939f-43e3-b7ef-04dce9925c35"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>", "ID": "e2ad2c74-1895-41cb-9b95-ad75fccd6743", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6ec89786-f772-4ff4-af51-08a2c320ef54"}, {"Element": "<span lang=\"EN-GB\">400</span>", "ID": "35e8de69-f150-4c4e-94fb-ca1e2d6adc8e", "Styles": "None", "Classes": "None", "Text": "400", "ParentId": "e2ad2c74-1895-41cb-9b95-ad75fccd6743"}, {"Element": "<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">180+</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n</tr>", "ID": "c8f67905-d149-4a51-85be-b9e578abc8ad", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "c6d703e2-36e6-406c-9e13-d77e5c8754a6"}, {"Element": "<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">180+</span></p>\n</td>", "ID": "cd2c15bd-bdfa-4d5c-a3e7-7f5356e96ebc", "Styles": "width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c8f67905-d149-4a51-85be-b9e578abc8ad"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">180+</span></p>", "ID": "f38f1afd-bf97-49cd-9a8a-97e510c8647d", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cd2c15bd-bdfa-4d5c-a3e7-7f5356e96ebc"}, {"Element": "<span lang=\"EN-GB\">180+</span>", "ID": "3dbcbe5f-bc89-456b-8cf1-9b57d4ed10ca", "Styles": "None", "Classes": "None", "Text": "180+", "ParentId": "f38f1afd-bf97-49cd-9a8a-97e510c8647d"}, {"Element": "<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>", "ID": "45a9a2f8-20d6-4f24-8632-e98fef26bf2a", "Styles": "width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c8f67905-d149-4a51-85be-b9e578abc8ad"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>", "ID": "26fe1c92-32a3-47db-a103-b92c0d68b865", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "45a9a2f8-20d6-4f24-8632-e98fef26bf2a"}, {"Element": "<span lang=\"EN-GB\">400</span>", "ID": "162584cf-cfce-476f-9401-3d81e7b66b6a", "Styles": "None", "Classes": "None", "Text": "400", "ParentId": "26fe1c92-32a3-47db-a103-b92c0d68b865"}, {"Element": "<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>", "ID": "297b76cf-a52c-4e8c-8436-f0f1444f8c59", "Styles": "width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c8f67905-d149-4a51-85be-b9e578abc8ad"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>", "ID": "e588ff8a-e922-4c17-af7d-2d51965205be", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "297b76cf-a52c-4e8c-8436-f0f1444f8c59"}, {"Element": "<span lang=\"EN-GB\">400</span>", "ID": "8ab32f7c-a4c4-4f92-8a00-0a897d6cad1b", "Styles": "None", "Classes": "None", "Text": "400", "ParentId": "e588ff8a-e922-4c17-af7d-2d51965205be"}, {"Element": "<tr>\n<td colspan=\"3\" style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">*If the\n  previous infusion was completed without severe infusion\u2011related ADRs.\n  If any infusion\u2011related ADRs are observed, infusion should be\n  interrupted and restarted when the patient\u2019s condition is stable (see </span><span lang=\"EN-GB\">section\u00a04.2 of the SmPC</span><span lang=\"EN-GB\">).</span></p>\n</td>\n</tr>", "ID": "5dceb86e-7a9b-47ce-aa63-bd7acecb41e1", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "c6d703e2-36e6-406c-9e13-d77e5c8754a6"}, {"Element": "<td colspan=\"3\" style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">*If the\n  previous infusion was completed without severe infusion\u2011related ADRs.\n  If any infusion\u2011related ADRs are observed, infusion should be\n  interrupted and restarted when the patient\u2019s condition is stable (see </span><span lang=\"EN-GB\">section\u00a04.2 of the SmPC</span><span lang=\"EN-GB\">).</span></p>\n</td>", "ID": "ff24cd75-88a5-4742-8f38-f1d67b7f077a", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5dceb86e-7a9b-47ce-aa63-bd7acecb41e1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">*If the\n  previous infusion was completed without severe infusion\u2011related ADRs.\n  If any infusion\u2011related ADRs are observed, infusion should be\n  interrupted and restarted when the patient\u2019s condition is stable (see </span><span lang=\"EN-GB\">section\u00a04.2 of the SmPC</span><span lang=\"EN-GB\">).</span></p>", "ID": "56f9dd96-9e80-401c-8b5f-eabbd42ad449", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ff24cd75-88a5-4742-8f38-f1d67b7f077a"}, {"Element": "<span lang=\"EN-GB\">*If the\n  previous infusion was completed without severe infusion\u2011related ADRs.\n  If any infusion\u2011related ADRs are observed, infusion should be\n  interrupted and restarted when the patient\u2019s condition is stable (see </span>", "ID": "8ebd11df-d46f-4e9c-a9a2-975a9c69e9d3", "Styles": "None", "Classes": "None", "Text": "*If the   previous infusion was completed without severe infusion\u2011related ADRs.   If any infusion\u2011related ADRs are observed, infusion should be   interrupted and restarted when the patient\u2019s condition is stable (see ", "ParentId": "56f9dd96-9e80-401c-8b5f-eabbd42ad449"}, {"Element": "<span lang=\"EN-GB\">section\u00a04.2 of the SmPC</span>", "ID": "434fde45-274b-41aa-bd3f-33fc2892e9e4", "Styles": "None", "Classes": "None", "Text": "section\u00a04.2 of the SmPC", "ParentId": "56f9dd96-9e80-401c-8b5f-eabbd42ad449"}, {"Element": "<span lang=\"EN-GB\">).</span>", "ID": "95039259-5f96-47da-afe3-1a9b11abf8eb", "Styles": "None", "Classes": "None", "Text": ").", "ParentId": "56f9dd96-9e80-401c-8b5f-eabbd42ad449"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "45c3de8a-8521-4f56-877a-6629b6d15673", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e5736207-b32b-4303-8b50-8e8f3c83691e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "45c3de8a-8521-4f56-877a-6629b6d15673"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Refractory CLL</u></p>", "ID": "dfdabb57-eeaa-4fa7-a6bd-9bf2bcf0f555", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u>Refractory CLL</u>", "ID": "9881c152-6504-4e8c-b37c-08b360349508", "Styles": "None", "Classes": "None", "Text": "Refractory CLL", "ParentId": "dfdabb57-eeaa-4fa7-a6bd-9bf2bcf0f555"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a24e387c-d18f-48ec-94bb-eefd1cc8e33f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "92e5ff23-642c-4f14-a16c-9cb8676bfde3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a24e387c-d18f-48ec-94bb-eefd1cc8e33f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">For the first and second infusion,\nadminister over 6.5\u00a0hours (see section\u00a04.2), through a peripheral\nline or indwelling catheter, according to the schedule below:</span></p>", "ID": "119f9b7f-f705-4722-97fe-6d6117b3c457", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">For the first and second infusion,\nadminister over 6.5\u00a0hours (see section\u00a04.2), through a peripheral\nline or indwelling catheter, according to the schedule below:</span>", "ID": "13f1a378-633d-4d45-90f8-d22c34e9d593", "Styles": "None", "Classes": "None", "Text": "For the first and second infusion, administer over 6.5\u00a0hours (see section\u00a04.2), through a peripheral line or indwelling catheter, according to the schedule below:", "ParentId": "119f9b7f-f705-4722-97fe-6d6117b3c457"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "082bf6df-3a7e-433a-b8c5-1d06668c79e9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4bf9dd0d-e1d0-476a-9333-4a7555d19391", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "082bf6df-3a7e-433a-b8c5-1d06668c79e9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">If the second infusion was completed\nwithout a severe adverse reaction, the remaining infusions (3\u201112) should\nbe administered over 4\u00a0hours (see section\u00a04.2), through a peripheral\nline or indwelling catheter, according to the schedule below.</span><span lang=\"EN-GB\"> If any infusion\u2011related adverse reactions are observed,\ninfusion should be interrupted and restarted when the patient\u2019s condition is\nstable (see </span><span lang=\"EN-GB\">section\u00a04.2 for further information).</span></p>", "ID": "bcc50fb1-e74e-4c0a-afa0-f09fc88cece5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">If the second infusion was completed\nwithout a severe adverse reaction, the remaining infusions (3\u201112) should\nbe administered over 4\u00a0hours (see section\u00a04.2), through a peripheral\nline or indwelling catheter, according to the schedule below.</span>", "ID": "6c9bf6db-f7ca-41b4-afdc-72de2a53a693", "Styles": "None", "Classes": "None", "Text": "If the second infusion was completed without a severe adverse reaction, the remaining infusions (3\u201112) should be administered over 4\u00a0hours (see section\u00a04.2), through a peripheral line or indwelling catheter, according to the schedule below.", "ParentId": "bcc50fb1-e74e-4c0a-afa0-f09fc88cece5"}, {"Element": "<span lang=\"EN-GB\"> If any infusion\u2011related adverse reactions are observed,\ninfusion should be interrupted and restarted when the patient\u2019s condition is\nstable (see </span>", "ID": "e62beb52-0084-451d-9178-35c384f021c7", "Styles": "None", "Classes": "None", "Text": " If any infusion\u2011related adverse reactions are observed, infusion should be interrupted and restarted when the patient\u2019s condition is stable (see ", "ParentId": "bcc50fb1-e74e-4c0a-afa0-f09fc88cece5"}, {"Element": "<span lang=\"EN-GB\">section\u00a04.2 for further information).</span>", "ID": "dccb0116-7e20-42fb-8f5e-a07012dfef79", "Styles": "None", "Classes": "None", "Text": "section\u00a04.2 for further information).", "ParentId": "bcc50fb1-e74e-4c0a-afa0-f09fc88cece5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a6de0e7f-e47d-458d-ab3f-ff3ed04f5aab", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e5126532-f488-4eb9-8e35-04cb93fafed6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a6de0e7f-e47d-458d-ab3f-ff3ed04f5aab"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Infusion\nschedule</span></u></i></p>", "ID": "3a003312-b5e4-4472-b74f-c4eb769c482f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><u><span lang=\"EN-GB\">Infusion\nschedule</span></u></i>", "ID": "1f79abcd-1e55-42ea-85bf-093a833f8a34", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3a003312-b5e4-4472-b74f-c4eb769c482f"}, {"Element": "<u><span lang=\"EN-GB\">Infusion\nschedule</span></u>", "ID": "fca21151-61cc-4d7f-aa3f-dc95308bfed5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1f79abcd-1e55-42ea-85bf-093a833f8a34"}, {"Element": "<span lang=\"EN-GB\">Infusion\nschedule</span>", "ID": "515059d6-387d-445a-b181-311bebba2103", "Styles": "None", "Classes": "None", "Text": "Infusion schedule", "ParentId": "fca21151-61cc-4d7f-aa3f-dc95308bfed5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "4b8421da-b3b2-4b5d-89d6-b8a55bfec237", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "c61bbf13-902b-4170-977e-6c1e23257276", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4b8421da-b3b2-4b5d-89d6-b8a55bfec237"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "37d8af82-6e56-4471-aa66-2057b5a3fbac", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c61bbf13-902b-4170-977e-6c1e23257276"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "387f93a0-bd50-4f9d-97d9-ec16f8c47c0a", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "37d8af82-6e56-4471-aa66-2057b5a3fbac"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td rowspan=\"2\" style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Time after start of infusion (minutes)</span></p>\n</td>\n<td style=\"width:134.7pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusions\u00a01 and 2</span></p>\n</td>\n<td style=\"width:134.6pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusions\u00a03* to 12</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:134.7pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0\u201130</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">12</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31\u2011 60</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">61\u201190</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">91\u2011120</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">121+</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\" style=\"width:423.55pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"565\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">*If the\n  second infusion is completed without severe infusion\u2011related ADRs. If\n  any infusion\u2011related ADRs are observed, infusion should be interrupted\n  and restarted when the patient\u2019s condition is stable (see section\u00a04.2).</span></p>\n</td>\n</tr>\n</table>", "ID": "537119bf-8b51-4224-8e2c-02fb43ec665b", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "         ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<tr>\n<td rowspan=\"2\" style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Time after start of infusion (minutes)</span></p>\n</td>\n<td style=\"width:134.7pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusions\u00a01 and 2</span></p>\n</td>\n<td style=\"width:134.6pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusions\u00a03* to 12</span></p>\n</td>\n</tr>", "ID": "3fc02705-14e8-4c42-9aaa-8441312f8f47", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "537119bf-8b51-4224-8e2c-02fb43ec665b"}, {"Element": "<td rowspan=\"2\" style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Time after start of infusion (minutes)</span></p>\n</td>", "ID": "598d1fb2-4a59-408b-aed4-a2c5a3051110", "Styles": "width:154.25pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3fc02705-14e8-4c42-9aaa-8441312f8f47"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Time after start of infusion (minutes)</span></p>", "ID": "909cf2cd-0731-4d35-aeb1-014c8c1c7a97", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "598d1fb2-4a59-408b-aed4-a2c5a3051110"}, {"Element": "<span lang=\"EN-GB\">Time after start of infusion (minutes)</span>", "ID": "6c2c3dc1-ae9e-453c-b5cc-f79dbb33c320", "Styles": "None", "Classes": "None", "Text": "Time after start of infusion (minutes)", "ParentId": "909cf2cd-0731-4d35-aeb1-014c8c1c7a97"}, {"Element": "<td style=\"width:134.7pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusions\u00a01 and 2</span></p>\n</td>", "ID": "a2fbee24-f2ec-4f69-9931-8252a73d2f27", "Styles": "width:134.7pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3fc02705-14e8-4c42-9aaa-8441312f8f47"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusions\u00a01 and 2</span></p>", "ID": "65cfb299-e189-46b1-baf3-4b3e5cd358be", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a2fbee24-f2ec-4f69-9931-8252a73d2f27"}, {"Element": "<span lang=\"EN-GB\">Infusions\u00a01 and 2</span>", "ID": "60c573ec-e38e-4d58-86b4-3aa675541393", "Styles": "None", "Classes": "None", "Text": "Infusions\u00a01 and 2", "ParentId": "65cfb299-e189-46b1-baf3-4b3e5cd358be"}, {"Element": "<td style=\"width:134.6pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusions\u00a03* to 12</span></p>\n</td>", "ID": "1c2d84ec-8edf-4bf2-95ef-ca9bec3dc1ea", "Styles": "width:134.6pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3fc02705-14e8-4c42-9aaa-8441312f8f47"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusions\u00a03* to 12</span></p>", "ID": "ac5f4a91-c040-44fc-85f6-fa4ada21df6c", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1c2d84ec-8edf-4bf2-95ef-ca9bec3dc1ea"}, {"Element": "<span lang=\"EN-GB\">Infusions\u00a03* to 12</span>", "ID": "029e12bc-22d5-4237-b895-c774bf040280", "Styles": "None", "Classes": "None", "Text": "Infusions\u00a03* to 12", "ParentId": "ac5f4a91-c040-44fc-85f6-fa4ada21df6c"}, {"Element": "<tr>\n<td style=\"width:134.7pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>\n</tr>", "ID": "ecee151b-e214-4503-870e-6732d51d137e", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "537119bf-8b51-4224-8e2c-02fb43ec665b"}, {"Element": "<td style=\"width:134.7pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>", "ID": "964c19c0-e74d-448f-b222-d672fe470118", "Styles": "width:134.7pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ecee151b-e214-4503-870e-6732d51d137e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>", "ID": "17a669b5-d3a0-454f-a080-c74d55974a14", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "964c19c0-e74d-448f-b222-d672fe470118"}, {"Element": "<span lang=\"EN-GB\">Infusion rate (ml/hour)</span>", "ID": "f6e77ef4-e4ab-4103-8adf-8174b69af145", "Styles": "None", "Classes": "None", "Text": "Infusion rate (ml/hour)", "ParentId": "17a669b5-d3a0-454f-a080-c74d55974a14"}, {"Element": "<td style=\"width:134.6pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>", "ID": "1fe0bd4d-9b26-4c97-8312-84801612adcf", "Styles": "width:134.6pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ecee151b-e214-4503-870e-6732d51d137e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>", "ID": "1dfcd726-d72e-464d-8386-8a370eb0f0c2", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1fe0bd4d-9b26-4c97-8312-84801612adcf"}, {"Element": "<span lang=\"EN-GB\">Infusion rate (ml/hour)</span>", "ID": "91db9746-7407-465a-8fd9-dc3ca456ff2d", "Styles": "None", "Classes": "None", "Text": "Infusion rate (ml/hour)", "ParentId": "1dfcd726-d72e-464d-8386-8a370eb0f0c2"}, {"Element": "<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0\u201130</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">12</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>\n</tr>", "ID": "f0451486-c63d-4542-8d56-0df935e441d6", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "537119bf-8b51-4224-8e2c-02fb43ec665b"}, {"Element": "<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0\u201130</span></p>\n</td>", "ID": "3a8341a2-902d-4780-97eb-599c1086f934", "Styles": "width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f0451486-c63d-4542-8d56-0df935e441d6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0\u201130</span></p>", "ID": "af884540-a245-47cd-a3ef-54710a824e4b", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3a8341a2-902d-4780-97eb-599c1086f934"}, {"Element": "<span lang=\"EN-GB\">0\u201130</span>", "ID": "f0330063-e062-4751-8235-348bdb95d85e", "Styles": "None", "Classes": "None", "Text": "0\u201130", "ParentId": "af884540-a245-47cd-a3ef-54710a824e4b"}, {"Element": "<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">12</span></p>\n</td>", "ID": "26843f09-9e24-4ff1-aa41-add74854628c", "Styles": "width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f0451486-c63d-4542-8d56-0df935e441d6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">12</span></p>", "ID": "01b1408a-ce12-409e-b28a-ed39934c7240", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "26843f09-9e24-4ff1-aa41-add74854628c"}, {"Element": "<span lang=\"EN-GB\">12</span>", "ID": "fe8d47d9-fafa-4bba-a80d-05d582725d64", "Styles": "None", "Classes": "None", "Text": "12", "ParentId": "01b1408a-ce12-409e-b28a-ed39934c7240"}, {"Element": "<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>", "ID": "4038c52c-fbdc-48ca-86d0-e927291d57c9", "Styles": "width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f0451486-c63d-4542-8d56-0df935e441d6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>", "ID": "801b6a30-ad30-48dc-b030-0eec5c23a95a", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4038c52c-fbdc-48ca-86d0-e927291d57c9"}, {"Element": "<span lang=\"EN-GB\">25</span>", "ID": "f40fa713-9063-4d17-827f-4d82000dff22", "Styles": "None", "Classes": "None", "Text": "25", "ParentId": "801b6a30-ad30-48dc-b030-0eec5c23a95a"}, {"Element": "<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31\u2011 60</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>\n</tr>", "ID": "6a25e8ff-8bc0-4cb3-b18b-256fc45791d6", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "537119bf-8b51-4224-8e2c-02fb43ec665b"}, {"Element": "<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31\u2011 60</span></p>\n</td>", "ID": "a358d015-9a0c-45c5-96c8-808787a04d15", "Styles": "width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6a25e8ff-8bc0-4cb3-b18b-256fc45791d6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31\u2011 60</span></p>", "ID": "7a89d560-2ec3-4d2e-b9ba-2d67de430058", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a358d015-9a0c-45c5-96c8-808787a04d15"}, {"Element": "<span lang=\"EN-GB\">31\u2011 60</span>", "ID": "9d00c1ca-96c7-4ce5-8189-5eada7b18fb4", "Styles": "None", "Classes": "None", "Text": "31\u2011 60", "ParentId": "7a89d560-2ec3-4d2e-b9ba-2d67de430058"}, {"Element": "<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>", "ID": "b6856cb2-3d8f-4666-98c6-7393315298d0", "Styles": "width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6a25e8ff-8bc0-4cb3-b18b-256fc45791d6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>", "ID": "26b9f438-3afd-4458-bb25-01df1d896942", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b6856cb2-3d8f-4666-98c6-7393315298d0"}, {"Element": "<span lang=\"EN-GB\">25</span>", "ID": "b1295120-97b8-4226-a2e6-85804ddf7fde", "Styles": "None", "Classes": "None", "Text": "25", "ParentId": "26b9f438-3afd-4458-bb25-01df1d896942"}, {"Element": "<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>", "ID": "ca88b88f-fdba-47cd-86cc-38bf08374539", "Styles": "width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6a25e8ff-8bc0-4cb3-b18b-256fc45791d6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>", "ID": "870441e1-83df-4b3a-a798-1b9887212936", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ca88b88f-fdba-47cd-86cc-38bf08374539"}, {"Element": "<span lang=\"EN-GB\">50</span>", "ID": "9a7e49b5-ed21-4db0-9890-b025afab890b", "Styles": "None", "Classes": "None", "Text": "50", "ParentId": "870441e1-83df-4b3a-a798-1b9887212936"}, {"Element": "<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">61\u201190</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>\n</tr>", "ID": "6da9148c-d26d-4a9c-b6a0-7d48a448ede0", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "537119bf-8b51-4224-8e2c-02fb43ec665b"}, {"Element": "<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">61\u201190</span></p>\n</td>", "ID": "539c9ba7-13cb-48f2-8dc9-5c7ff2eb972a", "Styles": "width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6da9148c-d26d-4a9c-b6a0-7d48a448ede0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">61\u201190</span></p>", "ID": "6fd962ca-9355-447d-99fb-c62c24cda40e", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "539c9ba7-13cb-48f2-8dc9-5c7ff2eb972a"}, {"Element": "<span lang=\"EN-GB\">61\u201190</span>", "ID": "33d7f796-2dbd-4663-ac14-6cf360748e6e", "Styles": "None", "Classes": "None", "Text": "61\u201190", "ParentId": "6fd962ca-9355-447d-99fb-c62c24cda40e"}, {"Element": "<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>", "ID": "78dfcc80-f2e7-4568-a4ef-ee5ff2e541c5", "Styles": "width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6da9148c-d26d-4a9c-b6a0-7d48a448ede0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>", "ID": "7287cbd9-0e9f-4197-9518-464f98478e7e", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "78dfcc80-f2e7-4568-a4ef-ee5ff2e541c5"}, {"Element": "<span lang=\"EN-GB\">50</span>", "ID": "c3c090d3-6923-452d-b0f9-1e1a44e42daf", "Styles": "None", "Classes": "None", "Text": "50", "ParentId": "7287cbd9-0e9f-4197-9518-464f98478e7e"}, {"Element": "<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>", "ID": "b02bce15-d0a0-409d-b973-dd6f77f41139", "Styles": "width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6da9148c-d26d-4a9c-b6a0-7d48a448ede0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>", "ID": "c43a2c1e-66b6-4266-a4c1-b6cbdbc6fde4", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b02bce15-d0a0-409d-b973-dd6f77f41139"}, {"Element": "<span lang=\"EN-GB\">100</span>", "ID": "ade5f178-e50d-4c1b-ac0c-a5eff7e7315f", "Styles": "None", "Classes": "None", "Text": "100", "ParentId": "c43a2c1e-66b6-4266-a4c1-b6cbdbc6fde4"}, {"Element": "<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">91\u2011120</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>\n</tr>", "ID": "871bc98f-a01b-4ef9-ac59-82cc424caa4f", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "537119bf-8b51-4224-8e2c-02fb43ec665b"}, {"Element": "<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">91\u2011120</span></p>\n</td>", "ID": "f5da87b1-f732-498f-860c-b7fae8e5eac1", "Styles": "width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "871bc98f-a01b-4ef9-ac59-82cc424caa4f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">91\u2011120</span></p>", "ID": "bd8ac153-fefa-44b8-a324-db48e8ed2003", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f5da87b1-f732-498f-860c-b7fae8e5eac1"}, {"Element": "<span lang=\"EN-GB\">91\u2011120</span>", "ID": "70a3a051-db89-4b45-8354-22ff60b3ff54", "Styles": "None", "Classes": "None", "Text": "91\u2011120", "ParentId": "bd8ac153-fefa-44b8-a324-db48e8ed2003"}, {"Element": "<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>", "ID": "f0b7c19a-0b0e-4433-85b5-eb2c9e44a7a4", "Styles": "width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "871bc98f-a01b-4ef9-ac59-82cc424caa4f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>", "ID": "97d45aea-8267-49f1-bcc8-0d070449b4c0", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f0b7c19a-0b0e-4433-85b5-eb2c9e44a7a4"}, {"Element": "<span lang=\"EN-GB\">100</span>", "ID": "e655b541-02c0-4ad2-bd5e-a58616a33587", "Styles": "None", "Classes": "None", "Text": "100", "ParentId": "97d45aea-8267-49f1-bcc8-0d070449b4c0"}, {"Element": "<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>", "ID": "ca9237f7-1a3f-4539-9d6a-45abb965544b", "Styles": "width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "871bc98f-a01b-4ef9-ac59-82cc424caa4f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>", "ID": "c8caa452-e3fb-4848-a62f-21b2229111b9", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ca9237f7-1a3f-4539-9d6a-45abb965544b"}, {"Element": "<span lang=\"EN-GB\">200</span>", "ID": "64fccd88-ae03-4753-b769-033972b00e43", "Styles": "None", "Classes": "None", "Text": "200", "ParentId": "c8caa452-e3fb-4848-a62f-21b2229111b9"}, {"Element": "<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">121+</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n</tr>", "ID": "2b6d7b48-b101-4709-b757-40184ba803ee", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "537119bf-8b51-4224-8e2c-02fb43ec665b"}, {"Element": "<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">121+</span></p>\n</td>", "ID": "a2c9e8b0-af57-4d31-8987-7fb4c8a8fd38", "Styles": "width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2b6d7b48-b101-4709-b757-40184ba803ee"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">121+</span></p>", "ID": "aa84b18e-1557-4d2c-8db9-e89fcd18e8ed", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a2c9e8b0-af57-4d31-8987-7fb4c8a8fd38"}, {"Element": "<span lang=\"EN-GB\">121+</span>", "ID": "a2f3e741-3c8a-44fd-99b1-8bb1756b8bf3", "Styles": "None", "Classes": "None", "Text": "121+", "ParentId": "aa84b18e-1557-4d2c-8db9-e89fcd18e8ed"}, {"Element": "<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>", "ID": "9e61337d-c20e-4a78-98c9-641db6145a88", "Styles": "width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2b6d7b48-b101-4709-b757-40184ba803ee"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>", "ID": "d04f119c-061e-4dab-a2df-52d8e78ddda8", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9e61337d-c20e-4a78-98c9-641db6145a88"}, {"Element": "<span lang=\"EN-GB\">200</span>", "ID": "e1ce8a6f-1b70-4e95-bc07-412ceb69de04", "Styles": "None", "Classes": "None", "Text": "200", "ParentId": "d04f119c-061e-4dab-a2df-52d8e78ddda8"}, {"Element": "<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>", "ID": "cfaa1a73-7550-4b22-901e-880ec429c495", "Styles": "width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2b6d7b48-b101-4709-b757-40184ba803ee"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>", "ID": "9f4a88e4-7603-4d83-a29e-dc800174a503", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cfaa1a73-7550-4b22-901e-880ec429c495"}, {"Element": "<span lang=\"EN-GB\">400</span>", "ID": "5dae49da-10d2-449e-bea1-f611a27e1ef4", "Styles": "None", "Classes": "None", "Text": "400", "ParentId": "9f4a88e4-7603-4d83-a29e-dc800174a503"}, {"Element": "<tr>\n<td colspan=\"3\" style=\"width:423.55pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"565\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">*If the\n  second infusion is completed without severe infusion\u2011related ADRs. If\n  any infusion\u2011related ADRs are observed, infusion should be interrupted\n  and restarted when the patient\u2019s condition is stable (see section\u00a04.2).</span></p>\n</td>\n</tr>", "ID": "054336a6-997c-4603-8c85-735794fbcab4", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "537119bf-8b51-4224-8e2c-02fb43ec665b"}, {"Element": "<td colspan=\"3\" style=\"width:423.55pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"565\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">*If the\n  second infusion is completed without severe infusion\u2011related ADRs. If\n  any infusion\u2011related ADRs are observed, infusion should be interrupted\n  and restarted when the patient\u2019s condition is stable (see section\u00a04.2).</span></p>\n</td>", "ID": "1f52b9a9-7f79-4ec1-9f09-9eef599ab8ee", "Styles": "width:423.55pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "054336a6-997c-4603-8c85-735794fbcab4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">*If the\n  second infusion is completed without severe infusion\u2011related ADRs. If\n  any infusion\u2011related ADRs are observed, infusion should be interrupted\n  and restarted when the patient\u2019s condition is stable (see section\u00a04.2).</span></p>", "ID": "66d36de8-fa47-4e12-8c0c-7f538259efb6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1f52b9a9-7f79-4ec1-9f09-9eef599ab8ee"}, {"Element": "<span lang=\"EN-GB\">*If the\n  second infusion is completed without severe infusion\u2011related ADRs. If\n  any infusion\u2011related ADRs are observed, infusion should be interrupted\n  and restarted when the patient\u2019s condition is stable (see section\u00a04.2).</span>", "ID": "260e4771-e8db-43a9-9269-04696cb6c642", "Styles": "None", "Classes": "None", "Text": "*If the   second infusion is completed without severe infusion\u2011related ADRs. If   any infusion\u2011related ADRs are observed, infusion should be interrupted   and restarted when the patient\u2019s condition is stable (see section\u00a04.2).", "ParentId": "66d36de8-fa47-4e12-8c0c-7f538259efb6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4acfa52d-2ba6-498c-8f2c-dc062ebebb74", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a6fe548c-8eb7-4d0e-b5b8-c3fa0a9d603c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4acfa52d-2ba6-498c-8f2c-dc062ebebb74"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">If any adverse reactions are observed,\ninfusion rates should be reduced (see section\u00a04.2).</span></p>", "ID": "87bf7f7f-d93d-4fa0-ac30-29f6eba7f263", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">If any adverse reactions are observed,\ninfusion rates should be reduced (see section\u00a04.2).</span>", "ID": "daa8dc53-0c4c-46a3-9307-168d4593412e", "Styles": "None", "Classes": "None", "Text": "If any adverse reactions are observed, infusion rates should be reduced (see section\u00a04.2).", "ParentId": "87bf7f7f-d93d-4fa0-ac30-29f6eba7f263"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "09dd65ac-8a4d-45fc-8dc1-ecaea87807ba", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f0337ebc-c64c-4898-acaa-df5fa3c5fcf5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "09dd65ac-8a4d-45fc-8dc1-ecaea87807ba"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Disposal</span></u></p>", "ID": "4775fa97-722f-4e9b-929d-fc05e8f3d7c3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\">Disposal</span></u>", "ID": "67e21cd0-f785-4ccd-af34-20b7ba953459", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4775fa97-722f-4e9b-929d-fc05e8f3d7c3"}, {"Element": "<span lang=\"EN-GB\">Disposal</span>", "ID": "12248e0c-6aa6-4188-81be-14f14a072746", "Styles": "None", "Classes": "None", "Text": "Disposal", "ParentId": "67e21cd0-f785-4ccd-af34-20b7ba953459"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a04af51f-3509-443c-b539-d8770db32052", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5a352e7d-5794-4ff7-a525-3a80c5f00e4d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a04af51f-3509-443c-b539-d8770db32052"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Any unused medicinal product or waste\nmaterial should be disposed of in accordance with local requirements.</span></p>", "ID": "a19c3f84-c392-4281-88f6-4872bc914261", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Any unused medicinal product or waste\nmaterial should be disposed of in accordance with local requirements.</span>", "ID": "78fb3953-64ce-4c94-bec6-745198de8d17", "Styles": "None", "Classes": "None", "Text": "Any unused medicinal product or waste material should be disposed of in accordance with local requirements.", "ParentId": "a19c3f84-c392-4281-88f6-4872bc914261"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9b93b427-5620-4c39-8bf8-81bded4c9bd9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2adc3ef4-03f6-4f2e-948d-b137b41046f3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9b93b427-5620-4c39-8bf8-81bded4c9bd9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "57dce4cd-7536-49ce-9c3b-67947dfb3a54", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1492ed5c-d67e-45dc-ba79-100f51956794", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "57dce4cd-7536-49ce-9c3b-67947dfb3a54"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION HOLDER</span></b></p>", "ID": "517f74bc-4af2-4bd3-99de-15874f07970d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION HOLDER</span></b>", "ID": "8b741ef0-abbd-45ba-b997-91fb8b5f280e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "517f74bc-4af2-4bd3-99de-15874f07970d"}, {"Element": "<span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION HOLDER</span>", "ID": "c93f4827-1a15-4492-a940-d79ade58fb3a", "Styles": "None", "Classes": "None", "Text": "7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION HOLDER", "ParentId": "8b741ef0-abbd-45ba-b997-91fb8b5f280e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e4d9948b-096d-475d-968b-64047b2181c1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b7d4338b-9896-418b-b215-64de728ef687", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e4d9948b-096d-475d-968b-64047b2181c1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Novartis\nEuropharm Limited</span></p>", "ID": "fdce6ee9-6a4d-481e-9add-203252981c78", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Novartis\nEuropharm Limited</span>", "ID": "7366fbe7-fed8-4adc-a326-3612915383bf", "Styles": "None", "Classes": "None", "Text": "Novartis Europharm Limited", "ParentId": "fdce6ee9-6a4d-481e-9add-203252981c78"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Frimley\nBusiness Park</span></p>", "ID": "f7de7adf-abf8-4bba-ac65-af64c68c5031", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Frimley\nBusiness Park</span>", "ID": "6107ee20-fdd0-40a1-a195-bc741c86b4b9", "Styles": "None", "Classes": "None", "Text": "Frimley Business Park", "ParentId": "f7de7adf-abf8-4bba-ac65-af64c68c5031"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Camberley\nGU16 7SR</span></p>", "ID": "569196f3-d3be-4123-9bcc-c305f89d86fc", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Camberley\nGU16 7SR</span>", "ID": "78f291c9-a8b8-413c-bb0e-3bb99e539460", "Styles": "None", "Classes": "None", "Text": "Camberley GU16 7SR", "ParentId": "569196f3-d3be-4123-9bcc-c305f89d86fc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">United Kingdom</span></p>", "ID": "9de16a55-8d37-40a5-8884-f813cade4915", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">United Kingdom</span>", "ID": "afc898f1-c9df-47a4-bdf8-6a71639f2926", "Styles": "color:black", "Classes": "None", "Text": "United Kingdom", "ParentId": "9de16a55-8d37-40a5-8884-f813cade4915"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "49d1d960-331d-4c01-99f7-cfa1fa458d99", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c156b553-9728-4328-9418-e42f39204bd2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "49d1d960-331d-4c01-99f7-cfa1fa458d99"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2b60423e-6ecd-4a7c-ac2b-77a8bb135f20", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b173110a-1b49-4205-b8f6-71492f729408", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2b60423e-6ecd-4a7c-ac2b-77a8bb135f20"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION NUMBER(S)</span></b></p>", "ID": "50a90db1-c9fe-413a-ba66-aec605604cc9", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION NUMBER(S)</span></b>", "ID": "393fd426-4b40-4417-8dd6-4c2ef880012f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "50a90db1-c9fe-413a-ba66-aec605604cc9"}, {"Element": "<span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION NUMBER(S)</span>", "ID": "00afcfbd-1597-4a73-b6a7-911bf4f0274b", "Styles": "None", "Classes": "None", "Text": "8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION NUMBER(S)", "ParentId": "393fd426-4b40-4417-8dd6-4c2ef880012f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4b96e77f-37be-453d-89ca-965cf417ffde", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dba976c1-1023-4564-b466-407531b969b5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4b96e77f-37be-453d-89ca-965cf417ffde"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:black\">Arzerra 100\u00a0mg concentrate for solution for infusion</span></u></p>", "ID": "bf67240d-3a54-44f5-8d2e-7dca1ad8173b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\" style=\"color:black\">Arzerra 100\u00a0mg concentrate for solution for infusion</span></u>", "ID": "ee5ed9ee-7677-4156-968d-ac71efe44e11", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bf67240d-3a54-44f5-8d2e-7dca1ad8173b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Arzerra 100\u00a0mg concentrate for solution for infusion</span>", "ID": "977323ad-c7dd-4343-bbc5-c021e5ecd83a", "Styles": "color:black", "Classes": "None", "Text": "Arzerra 100\u00a0mg concentrate for solution for infusion", "ParentId": "ee5ed9ee-7677-4156-968d-ac71efe44e11"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "beb06193-0a90-4d61-af6a-d29ed29bb609", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "44d2dfa2-3277-40ab-9ad0-af0b68f9122d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "beb06193-0a90-4d61-af6a-d29ed29bb609"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU/1/10/625/001</span></p>", "ID": "8435b1ed-e436-43ed-8bfa-84b084ea47dc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">EU/1/10/625/001</span>", "ID": "cf99f65d-5b9a-488d-a2d3-6b9ebf4bd09e", "Styles": "None", "Classes": "None", "Text": "EU/1/10/625/001", "ParentId": "8435b1ed-e436-43ed-8bfa-84b084ea47dc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c74bb694-b4fb-414d-bb46-17e267e565d9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "65f4ab65-0767-4fb4-9c27-d29fa80b58a5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c74bb694-b4fb-414d-bb46-17e267e565d9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:black\">Arzerra 1000\u00a0mg concentrate for solution for infusion</span></u></p>", "ID": "d66ab7c1-dd75-4d7a-a1eb-b840f3a796fc", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\" style=\"color:black\">Arzerra 1000\u00a0mg concentrate for solution for infusion</span></u>", "ID": "79bd8afe-773b-4fa7-9731-1595ecac6d41", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d66ab7c1-dd75-4d7a-a1eb-b840f3a796fc"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Arzerra 1000\u00a0mg concentrate for solution for infusion</span>", "ID": "2da1b216-b938-412e-9487-598fda481b79", "Styles": "color:black", "Classes": "None", "Text": "Arzerra 1000\u00a0mg concentrate for solution for infusion", "ParentId": "79bd8afe-773b-4fa7-9731-1595ecac6d41"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "14c99bc1-d396-4daa-b32d-b311d7e19542", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5d974644-29ed-43c0-b0e6-68178589c2cc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "14c99bc1-d396-4daa-b32d-b311d7e19542"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">EU/1/10/625/003</span></p>", "ID": "4830c421-30ee-447b-8ba4-b7fd40fb5054", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"DE-CH\">EU/1/10/625/003</span>", "ID": "e1b6b6a9-c925-47b2-9bd8-a20b632c9df6", "Styles": "None", "Classes": "None", "Text": "EU/1/10/625/003", "ParentId": "4830c421-30ee-447b-8ba4-b7fd40fb5054"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e4a0427b-943b-482a-8ccb-adfe18cc5ae5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cd086edd-a506-46e3-af23-8bfbf6fb84d7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e4a0427b-943b-482a-8ccb-adfe18cc5ae5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c6f35824-7ebd-4ba4-8d0c-f3beb9bb16d4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5d60e2e5-4168-458b-bc53-7b8d2197f445", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c6f35824-7ebd-4ba4-8d0c-f3beb9bb16d4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF FIRST AUTHORISATION/RENEWAL\nOF THE AUTHORISATION</span></b></p>", "ID": "12a3cead-9ff1-4009-99c4-5705011786d9", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF FIRST AUTHORISATION/RENEWAL\nOF THE AUTHORISATION</span></b>", "ID": "7547f42f-1bd2-458f-a2fd-dcf141d79659", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "12a3cead-9ff1-4009-99c4-5705011786d9"}, {"Element": "<span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF FIRST AUTHORISATION/RENEWAL\nOF THE AUTHORISATION</span>", "ID": "23bcfdab-b9a6-4e1f-9f41-cdc791db1038", "Styles": "None", "Classes": "None", "Text": "9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION", "ParentId": "7547f42f-1bd2-458f-a2fd-dcf141d79659"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2a89c080-c3ee-4f44-846e-08993f8fadb8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6b75f78e-48e8-443c-86a6-2210d8b7f4f6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2a89c080-c3ee-4f44-846e-08993f8fadb8"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Date of\nfirst authorisation: </span><span lang=\"EN-GB\">19 April 2010</span></p>", "ID": "7f1945ea-389e-4dd5-a2ef-8ca212c0747e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Date of\nfirst authorisation: </span>", "ID": "e292be22-aa95-4f0c-9b47-4e42ab38a4ce", "Styles": "None", "Classes": "None", "Text": "Date of first authorisation: ", "ParentId": "7f1945ea-389e-4dd5-a2ef-8ca212c0747e"}, {"Element": "<span lang=\"EN-GB\">19 April 2010</span>", "ID": "42a7ffe0-e75c-4684-9fc1-68e332a8d38c", "Styles": "None", "Classes": "None", "Text": "19 April 2010", "ParentId": "7f1945ea-389e-4dd5-a2ef-8ca212c0747e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Date of latest renewal: 17 February 2015</span></p>", "ID": "f809197d-bb18-4edd-975c-8e65fb2cec31", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Date of latest renewal: 17 February 2015</span>", "ID": "66a6c2b7-9f89-48ae-8e8a-064595f50495", "Styles": "None", "Classes": "None", "Text": "Date of latest renewal: 17 February 2015", "ParentId": "f809197d-bb18-4edd-975c-8e65fb2cec31"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2ac6df38-9509-49d8-bb04-cff238f1f540", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4e5b5092-fb8d-409d-9182-ac155bb85149", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2ac6df38-9509-49d8-bb04-cff238f1f540"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "589cdab6-5e28-4653-be45-82833a22d7ea", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d511961d-99f2-4661-af8a-f508f9d76b9d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "589cdab6-5e28-4653-be45-82833a22d7ea"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 DATE OF REVISION OF THE TEXT</span></b></p>", "ID": "6924b562-bf50-4841-9e2f-01828bc94b46", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 DATE OF REVISION OF THE TEXT</span></b>", "ID": "c09b1d5e-d34e-477d-ae41-8cc3c3881c5b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6924b562-bf50-4841-9e2f-01828bc94b46"}, {"Element": "<span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 DATE OF REVISION OF THE TEXT</span>", "ID": "a818bcfa-2034-4c30-a45a-3356854a9ccb", "Styles": "None", "Classes": "None", "Text": "10.\u00a0\u00a0\u00a0\u00a0 DATE OF REVISION OF THE TEXT", "ParentId": "c09b1d5e-d34e-477d-ae41-8cc3c3881c5b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ae75eba8-0b3c-4d94-8798-b0290f536ee0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "aba28a59-41e2-4c79-93bf-d93fcffa863e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ae75eba8-0b3c-4d94-8798-b0290f536ee0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0cabc80e-572e-429d-b057-1a16a0d84ffb", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a7deff8c-52dc-481a-a44d-54ce056f3232", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0cabc80e-572e-429d-b057-1a16a0d84ffb"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Detailed\ninformation on this medicinal product </span><span lang=\"EN-GB\">is available on\nthe website of the European Medicines Agency (EMA) </span><span lang=\"EN-GB\"><a href=\"http://www.ema.europa.eu\"><span style=\"color:windowtext;text-decoration:\nnone\">http://www.ema.europa.eu</span></a></span><span lang=\"EN-GB\">/.</span></p>", "ID": "e117e1e4-c398-4392-89e6-ecf70bb4d122", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Detailed\ninformation on this medicinal product </span>", "ID": "533e8d5f-8456-4100-9afe-a266ea9d40c4", "Styles": "None", "Classes": "None", "Text": "Detailed information on this medicinal product ", "ParentId": "e117e1e4-c398-4392-89e6-ecf70bb4d122"}, {"Element": "<span lang=\"EN-GB\">is available on\nthe website of the European Medicines Agency (EMA) </span>", "ID": "9bffe48d-3f75-4213-9434-c3a15dd41951", "Styles": "None", "Classes": "None", "Text": "is available on the website of the European Medicines Agency (EMA) ", "ParentId": "e117e1e4-c398-4392-89e6-ecf70bb4d122"}, {"Element": "<span lang=\"EN-GB\"><a href=\"http://www.ema.europa.eu\"><span style=\"color:windowtext;text-decoration:\nnone\">http://www.ema.europa.eu</span></a></span>", "ID": "d2c0ff0a-f3c6-41fc-87f7-76f61847d756", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e117e1e4-c398-4392-89e6-ecf70bb4d122"}, {"Element": "<a href=\"http://www.ema.europa.eu\"><span style=\"color:windowtext;text-decoration:\nnone\">http://www.ema.europa.eu</span></a>", "ID": "28fd2d88-bd2b-491f-8b9f-fb3ca8d65386", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d2c0ff0a-f3c6-41fc-87f7-76f61847d756"}, {"Element": "<span style=\"color:windowtext;text-decoration:\nnone\">http://www.ema.europa.eu</span>", "ID": "68b27802-2c60-4bb9-996f-bbd503d552f0", "Styles": "color:windowtext;text-decoration:\nnone", "Classes": "None", "Text": "http://www.ema.europa.eu", "ParentId": "28fd2d88-bd2b-491f-8b9f-fb3ca8d65386"}, {"Element": "<span lang=\"EN-GB\">/.</span>", "ID": "51f01253-83c9-491c-a0e6-367c41602ca8", "Styles": "None", "Classes": "None", "Text": "/.", "ParentId": "e117e1e4-c398-4392-89e6-ecf70bb4d122"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "b519336f-845f-4fdf-983d-d92bffb0244d", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "eb10ad6d-f8d1-4b27-b7a8-43498516c133", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "b519336f-845f-4fdf-983d-d92bffb0244d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "1abb8c3c-adeb-43f2-97b1-ab5e72ef3d7f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "ef9f0f42-d0eb-4e4b-9cf9-204df7a3eb8e", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "1abb8c3c-adeb-43f2-97b1-ab5e72ef3d7f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "f8d5c755-ce20-4201-9864-743ba66469d3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "afd27faa-fe97-476b-b933-4edda14579be", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "f8d5c755-ce20-4201-9864-743ba66469d3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "866911cf-4f6a-4d94-89eb-829b9f725898", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "4c9fd304-8d62-4737-8fbb-556ce2cdbb81", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "866911cf-4f6a-4d94-89eb-829b9f725898"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "d878c89f-616e-400e-a8a0-53eee4703c84", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "e53e3960-5158-455a-8c8d-dfd2822d6336", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "d878c89f-616e-400e-a8a0-53eee4703c84"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "0f960256-56a7-49f3-beac-5967982c78a2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "efc050cd-8c6a-40e1-8e7b-044607609d82", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "0f960256-56a7-49f3-beac-5967982c78a2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "4f363110-13f2-4b2f-97de-d44ab403de08", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "56479c14-7678-442c-a668-c68a6a11968f", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "4f363110-13f2-4b2f-97de-d44ab403de08"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "01387734-d19d-452c-8ffc-77435bf9ca45", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "f5154813-9f16-4f81-9263-ded29e6ea6ce", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "01387734-d19d-452c-8ffc-77435bf9ca45"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9d2608de-2c59-4797-a954-c424673a9a14", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0476d237-f792-4c31-85cb-7c9e9dab4e7b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9d2608de-2c59-4797-a954-c424673a9a14"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f37b90ca-ba24-45bf-a51b-62374aec4e63", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "58ac0e27-e213-4421-b6c3-25e33b3582c9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f37b90ca-ba24-45bf-a51b-62374aec4e63"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5cd005c2-b172-4f92-9174-21adf276f9bb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a9c8f2f7-23d9-4fed-8e26-83e3fca8f4b7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5cd005c2-b172-4f92-9174-21adf276f9bb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c844328f-a4ac-455a-bf3a-96dad237ed1d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ec0ec3bf-891d-417f-bd5d-f27edb0f5b19", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c844328f-a4ac-455a-bf3a-96dad237ed1d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "541ec116-07eb-4097-8bfa-0fe07a68fcc9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "55dd4bc6-6357-4fcc-a28b-437b9c8bbce9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "541ec116-07eb-4097-8bfa-0fe07a68fcc9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cbc9927d-d1df-47fc-98bb-53f32c45b88e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ada0f4ee-46e3-4131-8e55-2ed844a53aa8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cbc9927d-d1df-47fc-98bb-53f32c45b88e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "49af2257-8dd6-469f-b066-8308d72ec526", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "69087654-2600-44d4-b385-75cb8f7e4971", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "49af2257-8dd6-469f-b066-8308d72ec526"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "35ad754c-6987-4dd3-925c-1a894932e000", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "41c49556-32d5-41e2-96f3-e35832d02cc0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "35ad754c-6987-4dd3-925c-1a894932e000"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9cd892bf-453b-4324-8f06-2da9bca95811", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "261f6f4c-3a5f-47c7-b8d2-c2ac9bcd6eb9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9cd892bf-453b-4324-8f06-2da9bca95811"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ab72dc91-1ec8-4f98-abbd-52d41d5bd62c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "da295d64-c666-401e-9f3a-974d2d32f00f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ab72dc91-1ec8-4f98-abbd-52d41d5bd62c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bef6c5e8-28f4-49f4-a8ff-11bfe9118293", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1b72f256-875a-44f2-8ed0-055646e4df9f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bef6c5e8-28f4-49f4-a8ff-11bfe9118293"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ae780dae-4528-47b4-99c2-794eb53025e3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ef0c218a-63bc-4e59-87e5-67f0d28afe2e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ae780dae-4528-47b4-99c2-794eb53025e3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "812f0921-4d72-4c22-bc23-c5269107ca5d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f4a6b8c3-c143-46ea-928a-d320bf04ca1d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "812f0921-4d72-4c22-bc23-c5269107ca5d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7f217057-f7fa-478c-8894-b116525d1d75", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b99b078e-00b8-4aff-9bd0-b39b1246f345", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7f217057-f7fa-478c-8894-b116525d1d75"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f515744d-f07f-4f87-b0e6-bf22c4af0729", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9ba179df-1492-41e0-805b-9ec42d400577", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f515744d-f07f-4f87-b0e6-bf22c4af0729"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "124a274a-7e19-44c1-a336-af86db14234c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d84bd559-ab1c-4f54-9cba-fdbb56f47e72", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "124a274a-7e19-44c1-a336-af86db14234c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "94596cf9-6232-4eaa-972a-42c61c599870", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "846a42c1-c77b-40d1-b0fd-ebc051d67a75", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "94596cf9-6232-4eaa-972a-42c61c599870"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">ANNEX\nII</span></b></p>", "ID": "3b823b10-8200-426f-8985-9c1ad4eb6bde", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">ANNEX\nII</span></b>", "ID": "771a39e6-1aee-4477-ba9d-5b3bae742ad1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3b823b10-8200-426f-8985-9c1ad4eb6bde"}, {"Element": "<span lang=\"EN-GB\">ANNEX\nII</span>", "ID": "21516330-c0d6-4a68-9eaa-77103fc6f08f", "Styles": "None", "Classes": "None", "Text": "ANNEX II", "ParentId": "771a39e6-1aee-4477-ba9d-5b3bae742ad1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ec0187ff-38c1-4a3a-9910-0c07e1b7a417", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "93246745-64c2-473f-9e25-2f4a352e3033", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ec0187ff-38c1-4a3a-9910-0c07e1b7a417"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt\"><b><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND\nMANUFACTURERS RESPONSIBLE FOR BATCH RELEASE</span></b></p>", "ID": "004d1917-209d-4ee6-a349-a3ab8aa0d094", "Styles": "margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND\nMANUFACTURERS RESPONSIBLE FOR BATCH RELEASE</span></b>", "ID": "3ae7905c-e0db-463f-b572-c23e9d0c647d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "004d1917-209d-4ee6-a349-a3ab8aa0d094"}, {"Element": "<span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND\nMANUFACTURERS RESPONSIBLE FOR BATCH RELEASE</span>", "ID": "d91aec43-094e-47d2-b6a1-cfac743efd17", "Styles": "None", "Classes": "None", "Text": "A.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE", "ParentId": "3ae7905c-e0db-463f-b572-c23e9d0c647d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "49bf68a4-ea7e-450e-a58b-98c3dc9881f8", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d53a1cb7-80a6-4400-89fe-9177886301d3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "49bf68a4-ea7e-450e-a58b-98c3dc9881f8"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt\"><b><span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>", "ID": "2e5214a0-5501-4a0c-b036-9ee0853abb2b", "Styles": "margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b>", "ID": "2f69862c-f297-4b41-be60-90224ac786e6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2e5214a0-5501-4a0c-b036-9ee0853abb2b"}, {"Element": "<span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</span>", "ID": "1d7012c5-51ce-48e2-9f05-fd4f932dd55d", "Styles": "None", "Classes": "None", "Text": "B.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE", "ParentId": "2f69862c-f297-4b41-be60-90224ac786e6"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ae733595-87f7-4901-891b-c8b42d799ccb", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cf40036a-d374-4f46-a61c-8a470178ec48", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ae733595-87f7-4901-891b-c8b42d799ccb"}, {"Element": "<p class=\"MsoBlockText\"><span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND\nREQUIREMENTS OF THE MARKETING AUTHORISATION</span></p>", "ID": "bdc1b5d7-f79d-4f84-8935-c4d493fef838", "Styles": "None", "Classes": "['MsoBlockText']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND\nREQUIREMENTS OF THE MARKETING AUTHORISATION</span>", "ID": "a0b0b417-8297-4109-aeb9-345eb2c8e588", "Styles": "None", "Classes": "None", "Text": "C.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION", "ParentId": "bdc1b5d7-f79d-4f84-8935-c4d493fef838"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d0db1b66-3eea-4251-ac2a-2c989e9b2038", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "268ccbfb-a42a-405c-b853-2e0e6aa01a40", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d0db1b66-3eea-4251-ac2a-2c989e9b2038"}, {"Element": "<p class=\"MsoBlockText\"><span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS\nWITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></p>", "ID": "7ec34a11-5a26-442b-9ddf-b131ed3d47c3", "Styles": "None", "Classes": "['MsoBlockText']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS\nWITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span>", "ID": "99167364-d6a3-426e-919e-327117356ff8", "Styles": "None", "Classes": "None", "Text": "D.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT", "ParentId": "7ec34a11-5a26-442b-9ddf-b131ed3d47c3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1d8b7905-a7e9-4135-848f-f7cbbf1d17bf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ad3b0a0d-360e-478d-a559-1cacc5990621", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1d8b7905-a7e9-4135-848f-f7cbbf1d17bf"}, {"Element": "<b><span lang=\"X-NONE\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>", "ID": "eac11bdb-d457-4365-a300-da236bd866b6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"X-NONE\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "9c7ec84b-f125-4d17-af3d-126c5734429c", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "eac11bdb-d457-4365-a300-da236bd866b6"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "a09db24a-874c-4acc-9e42-c41af7bea8ba", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "9c7ec84b-f125-4d17-af3d-126c5734429c"}, {"Element": "<p class=\"TitleB\"><span lang=\"X-NONE\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURERS OF THE BIOLOGICAL\nACTIVE SUBSTANCE AND MANUFACTURER</span>S<span lang=\"X-NONE\"> RESPONSIBLE FOR\nBATCH RELEASE</span></p>", "ID": "a9e34541-fa51-4bcb-8b6a-83f088feb18c", "Styles": "None", "Classes": "['TitleB']", "Text": "S", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"X-NONE\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURERS OF THE BIOLOGICAL\nACTIVE SUBSTANCE AND MANUFACTURER</span>", "ID": "b0ab95d6-c1a2-4405-a36e-7bf8e2596601", "Styles": "None", "Classes": "None", "Text": "A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER", "ParentId": "a9e34541-fa51-4bcb-8b6a-83f088feb18c"}, {"Element": "<span lang=\"X-NONE\"> RESPONSIBLE FOR\nBATCH RELEASE</span>", "ID": "c05a1ab3-b891-4f37-a7c4-e3d097cf94ce", "Styles": "None", "Classes": "None", "Text": " RESPONSIBLE FOR BATCH RELEASE", "ParentId": "a9e34541-fa51-4bcb-8b6a-83f088feb18c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:70.8pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "14d04e7c-154a-46fd-9fda-7caf2e1050af", "Styles": "margin-right:70.8pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "02c141ff-6d0b-450e-b1f6-8d0b5ef72ed1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "14d04e7c-154a-46fd-9fda-7caf2e1050af"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Name and address of the manufacturers of\nthe biological active substance</span></u></p>", "ID": "e61ca026-724c-47ad-b339-0c9f7b33f010", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\">Name and address of the manufacturers of\nthe biological active substance</span></u>", "ID": "f315a58d-a1df-49c6-8058-9aab64e1ad27", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e61ca026-724c-47ad-b339-0c9f7b33f010"}, {"Element": "<span lang=\"EN-GB\">Name and address of the manufacturers of\nthe biological active substance</span>", "ID": "868ca12e-fab0-44b8-9808-0804a65b4581", "Styles": "None", "Classes": "None", "Text": "Name and address of the manufacturers of the biological active substance", "ParentId": "f315a58d-a1df-49c6-8058-9aab64e1ad27"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:70.8pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0ffdf336-59ec-4ee3-b850-885506a189a2", "Styles": "margin-right:70.8pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a77b8010-32c7-4139-a66c-ddd57a693c4a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0ffdf336-59ec-4ee3-b850-885506a189a2"}, {"Element": "<p class=\"MsoNormal\">Lonza Biologics plc</p>", "ID": "7d6a4a70-90cf-441f-a790-65b4d60b3e25", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Lonza Biologics plc", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">228 Bath Road</p>", "ID": "a0a0052e-6ae0-401a-8205-556ea6d38b61", "Styles": "None", "Classes": "['MsoNormal']", "Text": "228 Bath Road", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">Slough, Berks SL1 4DX</p>", "ID": "bd8a8e1f-1e3f-445c-9b2a-58c7024a8ffe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Slough, Berks SL1 4DX", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">United Kingdom</p>", "ID": "06ccd827-273e-4eaa-8ff6-5a6d7bb65b55", "Styles": "None", "Classes": "['MsoNormal']", "Text": "United Kingdom", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "0e4f5d79-b6d7-408a-8448-95ea4623a49c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">Lonza Biologics, Inc.</p>", "ID": "db42b476-70b6-4fcd-9492-9302f7ad7565", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Lonza Biologics, Inc.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">101 International Drive</p>", "ID": "0d55ea59-782c-41a1-9031-645469b3927a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "101 International Drive", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">Portsmouth, NH 03801-2815</p>", "ID": "67b3f17d-f832-4d98-b33c-a2bc4511267f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Portsmouth, NH 03801-2815", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">United States</p>", "ID": "6dab135d-c1cf-42bc-8250-eacc66b8b7da", "Styles": "None", "Classes": "['MsoNormal']", "Text": "United States", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "019d01ca-3c8c-4399-acb0-184c886631a9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ae3a1cae-38ee-45fb-8906-50c84662e2dd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "019d01ca-3c8c-4399-acb0-184c886631a9"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Name and address of the manufacturers\nresponsible for batch release</span></u></p>", "ID": "dafabaeb-1a79-43a6-a2d0-3c01545d5a7a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\">Name and address of the manufacturers\nresponsible for batch release</span></u>", "ID": "67de77af-ab97-4394-8557-13e8b052bcb9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dafabaeb-1a79-43a6-a2d0-3c01545d5a7a"}, {"Element": "<span lang=\"EN-GB\">Name and address of the manufacturers\nresponsible for batch release</span>", "ID": "bfc80ca8-3307-4799-bd19-d4753d2a8a0f", "Styles": "None", "Classes": "None", "Text": "Name and address of the manufacturers responsible for batch release", "ParentId": "67de77af-ab97-4394-8557-13e8b052bcb9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "95d57b61-8edf-4f38-8149-5c6c95c6be2a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fd802c88-b24f-48cc-8df9-fba9cac653cc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "95d57b61-8edf-4f38-8149-5c6c95c6be2a"}, {"Element": "<p class=\"MsoNormal\">Glaxo Operations UK Ltd.</p>", "ID": "4f323064-63e6-4743-b7a6-6ea4c8a15db0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Glaxo Operations UK Ltd.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">Harmire Road</p>", "ID": "ea00c594-86ae-4a46-a624-43a2a3f7dc5f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Harmire Road", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">Barnard Castle</p>", "ID": "995e6b9a-f5e8-4e49-911c-9ba842828ba2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Barnard Castle", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">Durham, DL12 8DT</p>", "ID": "6372dab8-a0e6-40a7-8d38-902f96c9bfb0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Durham, DL12 8DT", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">United Kingdom</p>", "ID": "4c6a17f0-8466-4e18-96aa-dac19fbee9a6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "United Kingdom", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c2d2b3c9-7785-4800-943f-5bc777e082a3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "efdb5956-397f-441b-8d82-5cd2129e0281", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c2d2b3c9-7785-4800-943f-5bc777e082a3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Novartis Pharmaceuticals UK Limited</span></p>", "ID": "f5994939-091e-4030-b155-fedcbcd7b2ed", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Novartis Pharmaceuticals UK Limited</span>", "ID": "fac494ae-aefc-47c3-9d68-4b6592a42612", "Styles": "None", "Classes": "None", "Text": "Novartis Pharmaceuticals UK Limited", "ParentId": "f5994939-091e-4030-b155-fedcbcd7b2ed"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Frimley Business Park</span></p>", "ID": "09637104-7cde-4e44-a40f-c23c8a4d06ae", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Frimley Business Park</span>", "ID": "0c8cc843-32bd-4ad4-a19a-3373192c0bdb", "Styles": "None", "Classes": "None", "Text": "Frimley Business Park", "ParentId": "09637104-7cde-4e44-a40f-c23c8a4d06ae"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Frimley</span></p>", "ID": "386f31f3-219f-431f-977e-8ba2c90d6d69", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Frimley</span>", "ID": "4bea201e-e9b6-440a-b52e-90631a6cfee5", "Styles": "None", "Classes": "None", "Text": "Frimley", "ParentId": "386f31f3-219f-431f-977e-8ba2c90d6d69"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Camberley, Surrey GU16 7SR</span></p>", "ID": "3dffeb1d-1969-480b-81ea-2870f93c2836", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Camberley, Surrey GU16 7SR</span>", "ID": "db39faac-87c8-4828-8316-0dd187d2b818", "Styles": "None", "Classes": "None", "Text": "Camberley, Surrey GU16 7SR", "ParentId": "3dffeb1d-1969-480b-81ea-2870f93c2836"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">United Kingdom</span></p>", "ID": "45ed6a09-2332-4106-9dfa-f571ba1f28e2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">United Kingdom</span>", "ID": "616ae21f-b88b-4307-a88e-40bd8286f2bf", "Styles": "None", "Classes": "None", "Text": "United Kingdom", "ParentId": "45ed6a09-2332-4106-9dfa-f571ba1f28e2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "974a3517-8dcf-4060-800b-dccd4189f8bb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f88a7f99-6a4e-4e39-8e55-b24186505f5f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "974a3517-8dcf-4060-800b-dccd4189f8bb"}, {"Element": "<p class=\"Default\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Novartis Pharma GmbH</span></p>", "ID": "cde29f23-7661-4b5c-998c-f32f1352b6e2", "Styles": "None", "Classes": "['Default']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt\">Novartis Pharma GmbH</span>", "ID": "687beff9-be8a-477f-b3b1-4ff84d662495", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "Novartis Pharma GmbH", "ParentId": "cde29f23-7661-4b5c-998c-f32f1352b6e2"}, {"Element": "<p class=\"Default\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Roonstrasse 25</span></p>", "ID": "32a02258-3c06-4540-9068-58f13e4bfd3c", "Styles": "None", "Classes": "['Default']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt\">Roonstrasse 25</span>", "ID": "41431b05-cc2c-4a3f-86ab-340e981027da", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "Roonstrasse 25", "ParentId": "32a02258-3c06-4540-9068-58f13e4bfd3c"}, {"Element": "<p class=\"Default\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">90429 Nuremberg</span></p>", "ID": "41acfa6f-e770-4e24-98fa-f75dddb5edc1", "Styles": "None", "Classes": "['Default']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt\">90429 Nuremberg</span>", "ID": "78c01d01-978f-40db-bccb-ec521a988812", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "90429 Nuremberg", "ParentId": "41acfa6f-e770-4e24-98fa-f75dddb5edc1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Germany</span></p>", "ID": "816dd366-bb27-4881-96ec-298172174798", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Germany</span>", "ID": "a4b95944-f9c5-44f1-96a7-7629582fc072", "Styles": "None", "Classes": "None", "Text": "Germany", "ParentId": "816dd366-bb27-4881-96ec-298172174798"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "928aeb25-f808-457e-a11c-d39177e21d7d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "71f15c04-9a55-4f47-8fbd-1dcfb592d76a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "928aeb25-f808-457e-a11c-d39177e21d7d"}, {"Element": "<p class=\"MsoNormal\">The printed package leaflet of the medicinal product must\nstate the name and address of the manufacturer responsible for the release of\nthe concerned batch.</p>", "ID": "a63b5258-b0d5-49e0-8d5e-d195d434a94e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ea4df3ee-98b4-48c2-8ffb-c3efede25a58", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "761f8ae3-5e15-4970-8319-fcc917b331e6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ea4df3ee-98b4-48c2-8ffb-c3efede25a58"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dc249c2c-7920-434a-9001-ed48831aea86", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ed7c69da-a1c2-47ac-bc9f-b685896f40f1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dc249c2c-7920-434a-9001-ed48831aea86"}, {"Element": "<p class=\"TitleB\"><span lang=\"X-NONE\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING\nSUPPLY AND USE</span></p>", "ID": "7e2fa3f4-d0b7-4a40-a407-3482b988155c", "Styles": "None", "Classes": "['TitleB']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"X-NONE\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING\nSUPPLY AND USE</span>", "ID": "9431b0ad-cb2d-4fe1-8534-98d759e48618", "Styles": "None", "Classes": "None", "Text": "B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE", "ParentId": "7e2fa3f4-d0b7-4a40-a407-3482b988155c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e86d17d2-a4b3-48f6-9e10-961660fdf88a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "91afb259-101e-45a3-8a73-111345b80e8c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e86d17d2-a4b3-48f6-9e10-961660fdf88a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Medicinal product subject to restricted\nmedical prescription (see Annex I: Summary of Product Characteristics,\nsection\u00a04.2).</span></p>", "ID": "1316bf77-eb12-4553-a63f-353670af5b4f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Medicinal product subject to restricted\nmedical prescription (see Annex I: Summary of Product Characteristics,\nsection\u00a04.2).</span>", "ID": "9e00189a-567a-4aa5-9411-6e3c4c876665", "Styles": "None", "Classes": "None", "Text": "Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section\u00a04.2).", "ParentId": "1316bf77-eb12-4553-a63f-353670af5b4f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5870e40a-de65-4542-be86-489cf34d7188", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a35ebb96-f7ff-4012-be8f-b073c04f0bff", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5870e40a-de65-4542-be86-489cf34d7188"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bc6a13f3-68f3-4848-982f-f5a296518363", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c36840c6-4dac-4c0a-92e4-5b3ddab975df", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bc6a13f3-68f3-4848-982f-f5a296518363"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after:\navoid\"><span class=\"TitleBChar\"><span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND\nREQUIREMENTS OF THE MARKETING</span></span><b><span lang=\"EN-GB\"> AUTHORISATION</span></b></p>", "ID": "9f696f85-291c-4876-9821-04401c5091c0", "Styles": "margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span class=\"TitleBChar\"><span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND\nREQUIREMENTS OF THE MARKETING</span></span>", "ID": "faf942f6-d7ea-4208-8bc8-a6e36d3538bb", "Styles": "None", "Classes": "['TitleBChar']", "Text": "", "ParentId": "9f696f85-291c-4876-9821-04401c5091c0"}, {"Element": "<span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND\nREQUIREMENTS OF THE MARKETING</span>", "ID": "e849d95f-7350-49d8-af22-f28a8d867f01", "Styles": "None", "Classes": "None", "Text": "C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING", "ParentId": "faf942f6-d7ea-4208-8bc8-a6e36d3538bb"}, {"Element": "<b><span lang=\"EN-GB\"> AUTHORISATION</span></b>", "ID": "02adbf8d-846b-4268-be25-452461bba017", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9f696f85-291c-4876-9821-04401c5091c0"}, {"Element": "<span lang=\"EN-GB\"> AUTHORISATION</span>", "ID": "df815520-89f1-4823-bb4d-00376ef86efe", "Styles": "None", "Classes": "None", "Text": " AUTHORISATION", "ParentId": "02adbf8d-846b-4268-be25-452461bba017"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "30ee312e-bbfa-4a69-9f5e-c0193c097d13", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e8e527c0-45df-4e7e-b881-4f39e333a01b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "30ee312e-bbfa-4a69-9f5e-c0193c097d13"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Periodic Safety Update Reports</span></b></p>", "ID": "58120d51-0900-4311-9b3c-5bc935529a90", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "e78b493a-ad43-4233-bc68-86c4d6f3318c", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "58120d51-0900-4311-9b3c-5bc935529a90"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "f953ab00-1b3b-48c0-bf68-30a1c87df92b", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "e78b493a-ad43-4233-bc68-86c4d6f3318c"}, {"Element": "<b><span lang=\"EN-GB\">Periodic Safety Update Reports</span></b>", "ID": "2684da23-11e1-49a6-ba52-2386251d1569", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "58120d51-0900-4311-9b3c-5bc935529a90"}, {"Element": "<span lang=\"EN-GB\">Periodic Safety Update Reports</span>", "ID": "dfc5be8a-acf9-4fce-bc39-7ec96e1ab145", "Styles": "None", "Classes": "None", "Text": "Periodic Safety Update Reports", "ParentId": "2684da23-11e1-49a6-ba52-2386251d1569"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "56a5260c-6d49-4210-a21b-b2ae654ac54b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "11b420ae-9631-49f1-8384-67cbd0d65305", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "56a5260c-6d49-4210-a21b-b2ae654ac54b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The requirements for submission of periodic\nsafety update reports for this medicinal product are set out in the list of\nUnion reference dates (EURD list) provided for under Article 107c(7) of\nDirective 2001/83</span><span lang=\"EN-GB\">/EC</span><span lang=\"EN-GB\"> and any\nsubsequent updates published on the European medicines web-portal.</span></p>", "ID": "59aba072-9693-443b-a366-8d1c69688beb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">The requirements for submission of periodic\nsafety update reports for this medicinal product are set out in the list of\nUnion reference dates (EURD list) provided for under Article 107c(7) of\nDirective 2001/83</span>", "ID": "ce7d5c18-1210-44c7-a3ca-fb8f47dabc45", "Styles": "None", "Classes": "None", "Text": "The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83", "ParentId": "59aba072-9693-443b-a366-8d1c69688beb"}, {"Element": "<span lang=\"EN-GB\">/EC</span>", "ID": "5e9bbf0e-1f3c-4a46-a094-f1c91dd8fb3e", "Styles": "None", "Classes": "None", "Text": "/EC", "ParentId": "59aba072-9693-443b-a366-8d1c69688beb"}, {"Element": "<span lang=\"EN-GB\"> and any\nsubsequent updates published on the European medicines web-portal.</span>", "ID": "beaf1de1-aefd-40df-9556-d7a9b5745777", "Styles": "None", "Classes": "None", "Text": " and any subsequent updates published on the European medicines web-portal.", "ParentId": "59aba072-9693-443b-a366-8d1c69688beb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4155eb86-5ce4-4b8a-b511-1ea81b1ce3de", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "37310c9e-87c2-4819-9b09-37e289a761ae", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4155eb86-5ce4-4b8a-b511-1ea81b1ce3de"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4a8a2426-c438-4d2d-8d9d-5b77cb8d1308", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e9cafca4-2657-4d09-95b8-03636e3816db", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4a8a2426-c438-4d2d-8d9d-5b77cb8d1308"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after:\navoid\"><span class=\"TitleBChar\"><span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR\nRESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></span></p>", "ID": "e4cbce64-2722-4699-8c58-1d5a5192fd5b", "Styles": "margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span class=\"TitleBChar\"><span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR\nRESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></span>", "ID": "19575f92-9b55-4ec3-bcab-9140198cea4a", "Styles": "None", "Classes": "['TitleBChar']", "Text": "", "ParentId": "e4cbce64-2722-4699-8c58-1d5a5192fd5b"}, {"Element": "<span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR\nRESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span>", "ID": "1bf9238e-c025-4386-a150-f8d6d16730e5", "Styles": "None", "Classes": "None", "Text": "D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT", "ParentId": "19575f92-9b55-4ec3-bcab-9140198cea4a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.05pt;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "deae6902-2cda-44fc-afb3-ecae4a82bf03", "Styles": "margin-right:-.05pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d3bce2fb-3d4e-4501-a358-7d2c34f06af2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "deae6902-2cda-44fc-afb3-ecae4a82bf03"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Risk Management Plan (RMP)</span></b></p>", "ID": "c57a4e7f-834f-4066-a5fa-641b2c956802", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "cb456f11-4e6a-4bc0-8f8d-2ca8da1b38d3", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "c57a4e7f-834f-4066-a5fa-641b2c956802"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "3a6881bf-4837-4f90-a8b8-33fef03e3532", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "cb456f11-4e6a-4bc0-8f8d-2ca8da1b38d3"}, {"Element": "<b><span lang=\"EN-GB\">Risk Management Plan (RMP)</span></b>", "ID": "13aae12f-cb2e-403e-a8f3-b07b8e9ca5c3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c57a4e7f-834f-4066-a5fa-641b2c956802"}, {"Element": "<span lang=\"EN-GB\">Risk Management Plan (RMP)</span>", "ID": "af0fea7e-3c0e-4ac2-835f-caccd3fe0691", "Styles": "None", "Classes": "None", "Text": "Risk Management Plan (RMP)", "ParentId": "13aae12f-cb2e-403e-a8f3-b07b8e9ca5c3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.05pt;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8cd8d7d3-dc1e-4200-af53-b305d224d210", "Styles": "margin-right:-.05pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "45ea2afc-b9dc-4e95-b887-701eb76eaac1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8cd8d7d3-dc1e-4200-af53-b305d224d210"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The MAH shall perform the required\npharmacovigilance activities and interventions detailed in the agreed RMP\npresented in Module 1.8.2 of the Marketing Authorisation and any agreed\nsubsequent updates of the RMP.</span></p>", "ID": "b90d9b15-be4e-437f-8d37-7fb0babdcb6a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">The MAH shall perform the required\npharmacovigilance activities and interventions detailed in the agreed RMP\npresented in Module 1.8.2 of the Marketing Authorisation and any agreed\nsubsequent updates of the RMP.</span>", "ID": "46a69f8e-e50d-481a-9b1b-a7ee0ca2fc6b", "Styles": "None", "Classes": "None", "Text": "The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.", "ParentId": "b90d9b15-be4e-437f-8d37-7fb0babdcb6a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "14884148-26b1-438e-80ad-f0d6cba248d4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9c73f409-fd30-424a-af45-653f58e45806", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "14884148-26b1-438e-80ad-f0d6cba248d4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">An updated\nRMP should be submitted:</span></p>", "ID": "0d0e7745-875c-42f6-842c-c74cfaaa0db2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">An updated\nRMP should be submitted:</span>", "ID": "90f4c400-cb2b-4042-9721-e32d9c4c0f2e", "Styles": "None", "Classes": "None", "Text": "An updated RMP should be submitted:", "ParentId": "0d0e7745-875c-42f6-842c-c74cfaaa0db2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">At the request of the European Medicines Agency;</span></p>", "ID": "f2a6c981-bb00-4a72-9ac4-7c0abe2d63fa", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "a91681d6-922c-48e7-b342-138375617ed1", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "f2a6c981-bb00-4a72-9ac4-7c0abe2d63fa"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "5063d155-a304-4ef5-bba0-518da7225db2", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "a91681d6-922c-48e7-b342-138375617ed1"}, {"Element": "<span lang=\"EN-GB\">At the request of the European Medicines Agency;</span>", "ID": "24317c05-65ca-4f61-bfa4-e52e4d514c32", "Styles": "None", "Classes": "None", "Text": "At the request of the European Medicines Agency;", "ParentId": "f2a6c981-bb00-4a72-9ac4-7c0abe2d63fa"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Whenever the risk management system is modified,\nespecially as the result of new information being received that may lead to a\nsignificant change to the benefit/risk profile or as the result of an important\n(pharmacovigilance or risk minimisation) milestone being reached.</span></p>", "ID": "bf4739ad-cdbf-4628-a188-684e56ae8fc3", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "db97eb95-08a4-4bfb-ad65-cf10cb0e9071", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "bf4739ad-cdbf-4628-a188-684e56ae8fc3"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "571f0961-2303-4326-925d-002a548be5e9", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "db97eb95-08a4-4bfb-ad65-cf10cb0e9071"}, {"Element": "<span lang=\"EN-GB\">Whenever the risk management system is modified,\nespecially as the result of new information being received that may lead to a\nsignificant change to the benefit/risk profile or as the result of an important\n(pharmacovigilance or risk minimisation) milestone being reached.</span>", "ID": "447cd3e1-e9dc-4c6e-81fa-e66b23959518", "Styles": "None", "Classes": "None", "Text": "Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.", "ParentId": "bf4739ad-cdbf-4628-a188-684e56ae8fc3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.4pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bb7bc58b-dfec-4b59-8738-8da92f69f5e7", "Styles": "margin-right:-.4pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2fc04cfd-3741-40ad-9907-7ee074b0e9f4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bb7bc58b-dfec-4b59-8738-8da92f69f5e7"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "468d226e-33a4-45a2-bbcc-d454bebd7ab0", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "f4c2862a-4f44-4a31-8ec1-73e244c7076f", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "468d226e-33a4-45a2-bbcc-d454bebd7ab0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4b99bbfb-7dc1-49ff-ba6f-73242fb0fad3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b8b1ae1b-4e4b-40d1-b551-e09095266d15", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4b99bbfb-7dc1-49ff-ba6f-73242fb0fad3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "16ac763a-fea1-4c23-9954-4e6fe44b5d47", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c14bcad0-1f89-414e-bb37-28ce402c3c54", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "16ac763a-fea1-4c23-9954-4e6fe44b5d47"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ad762c2f-faa4-4b14-9e06-e4e58b2e33a1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "93524531-34c4-45d3-b281-2ca78d5ab5f8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ad762c2f-faa4-4b14-9e06-e4e58b2e33a1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "acd5b487-9a2c-46c4-982e-9df05dc4cc9f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e1b24203-8632-406a-a400-11b202fd482c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "acd5b487-9a2c-46c4-982e-9df05dc4cc9f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d60bad2c-3c83-4645-ab5f-f34a401b46d5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "870f6f2a-f61d-4e54-b617-8aa78c4bdf8d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d60bad2c-3c83-4645-ab5f-f34a401b46d5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7011ca46-fd3b-4fe8-bd98-9f4f63824e8e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1bbb4ec9-f8ee-4e7b-af41-2f1e0051c51b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7011ca46-fd3b-4fe8-bd98-9f4f63824e8e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4730b27f-e88e-457c-a649-5326928fa881", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b8727dbd-94d8-44a6-b6be-5340fe0a16ac", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4730b27f-e88e-457c-a649-5326928fa881"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c8cdeaad-2b24-40f0-ac70-97367ef6a2a8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "607d5e57-0010-4dd3-bcb9-c7fc8b6104d8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c8cdeaad-2b24-40f0-ac70-97367ef6a2a8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c43778cc-5b66-4993-aaa3-65b7c5cd6eee", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3aaf8c90-60cb-46cb-b568-a1a8920215f7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c43778cc-5b66-4993-aaa3-65b7c5cd6eee"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d9c1b61d-ec63-4e48-b822-63e10afb995a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c96a2570-7932-47e7-8e8e-6cd92e86ea01", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d9c1b61d-ec63-4e48-b822-63e10afb995a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c22257c0-3728-4496-9060-19f3f9d00afc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a710825b-fc5c-473e-b213-0640c2375896", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c22257c0-3728-4496-9060-19f3f9d00afc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "58ba81d2-5323-4df5-9bf0-e1c0c7a6b252", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0306a9e4-3fe3-4ad0-bcd5-afeedb380fe3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "58ba81d2-5323-4df5-9bf0-e1c0c7a6b252"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bc3c75a5-d206-468d-9b95-3d0e0b2ad4b2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5d5f047c-3c45-4bea-92bd-42abf150837c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bc3c75a5-d206-468d-9b95-3d0e0b2ad4b2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6050fca7-4691-4116-bccf-5c95613e2c31", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fa010079-c9d3-4051-bfb5-3d99d9feedc1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6050fca7-4691-4116-bccf-5c95613e2c31"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e449c435-8729-4144-947d-b1b3b338f05e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e9a96ad3-7c17-4853-8e3c-ce6ad0e6504b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e449c435-8729-4144-947d-b1b3b338f05e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "561d8761-3ae4-40a5-9a46-e48ced7e8824", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "188a41ea-8788-446e-858a-e112691c23bc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "561d8761-3ae4-40a5-9a46-e48ced7e8824"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "19d1bcba-f13d-4761-9649-41c73ee019f5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fb8b77fe-b43a-4678-9a29-fd0a80e9a72e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "19d1bcba-f13d-4761-9649-41c73ee019f5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3f9710ae-48f1-43ef-b34e-8c6b0691b28a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cf01e323-dc61-4a30-a448-0d92d95f89b8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3f9710ae-48f1-43ef-b34e-8c6b0691b28a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "53ede9d7-eff6-4e4e-ab3f-78dfa6121050", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b1cd5e0f-a676-470e-a9bf-d3afda69a547", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "53ede9d7-eff6-4e4e-ab3f-78dfa6121050"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1fef4971-d400-4dfe-b25a-d5b3892713a8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fbe88cc1-dc21-45cb-9406-97e3790f45f3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1fef4971-d400-4dfe-b25a-d5b3892713a8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fdd414b3-27e2-45dd-8576-740b673b5de9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0269a6fd-246b-4638-ab45-45dd745cdde1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fdd414b3-27e2-45dd-8576-740b673b5de9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2167346b-3c25-4a0e-bd92-31adb8c7f9ed", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dc3e8397-e990-4f3a-9e24-e955f4897464", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2167346b-3c25-4a0e-bd92-31adb8c7f9ed"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a5c3f997-cb4d-4360-aac4-0d7bb8731b4d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "49ebaef9-7d18-4c51-abee-561d4bd51539", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a5c3f997-cb4d-4360-aac4-0d7bb8731b4d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-right:28.3pt;text-align:center\"><b><span lang=\"EN-GB\">ANNEX III</span></b></p>", "ID": "da9ca9e0-266b-42d1-b142-08d73dc02748", "Styles": "margin-right:28.3pt;text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">ANNEX III</span></b>", "ID": "4bd54009-2fca-4a23-8a35-6141bbe15b62", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "da9ca9e0-266b-42d1-b142-08d73dc02748"}, {"Element": "<span lang=\"EN-GB\">ANNEX III</span>", "ID": "c35b5c38-e451-415a-be97-b227ed3770af", "Styles": "None", "Classes": "None", "Text": "ANNEX III", "ParentId": "4bd54009-2fca-4a23-8a35-6141bbe15b62"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "861e8981-6bc8-49da-be6d-02fb772bb1a6", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b8732409-4246-4c4c-a915-dddd27a60e27", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "861e8981-6bc8-49da-be6d-02fb772bb1a6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">LABELLING\n AND PACKAGE LEAFLET</span></b></p>", "ID": "8969fdfd-9129-4c42-8097-5250265090ce", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">LABELLING\n AND PACKAGE LEAFLET</span></b>", "ID": "62bf6da5-ff34-45a0-bbb5-c238f7fb1025", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8969fdfd-9129-4c42-8097-5250265090ce"}, {"Element": "<span lang=\"EN-GB\">LABELLING\n AND PACKAGE LEAFLET</span>", "ID": "7ad3fe3c-108d-4fae-94f6-7ae6e4c31c84", "Styles": "None", "Classes": "None", "Text": "LABELLING  AND PACKAGE LEAFLET", "ParentId": "62bf6da5-ff34-45a0-bbb5-c238f7fb1025"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "8146a636-6b24-4905-b75b-1ed9e25587d8", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "e4bcb24b-aafc-43fd-9ec4-327a903dbb13", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "8146a636-6b24-4905-b75b-1ed9e25587d8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0e534d58-5fcd-4689-9fe7-59ba5aa3062c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "73e75084-5a97-487a-8ce8-9239bf01a51e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0e534d58-5fcd-4689-9fe7-59ba5aa3062c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "800ad699-2f67-4075-b4ec-ec34f9e46681", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c2b321a4-9fba-44fd-9b61-fd1244df420f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "800ad699-2f67-4075-b4ec-ec34f9e46681"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "95b2a3be-b30f-432e-b054-fcb357066b18", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "62da63b9-8bb0-4b44-829f-69b58b83e826", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "95b2a3be-b30f-432e-b054-fcb357066b18"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a6183f22-969f-413c-bb57-eb9911ac0fc5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "67ab2fb5-6562-4b59-a07d-3c630bd00792", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a6183f22-969f-413c-bb57-eb9911ac0fc5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "835c51fc-e46c-43f7-a8f2-cef1e758be26", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "08d9287d-60df-4b85-8218-ba77ed681d62", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "835c51fc-e46c-43f7-a8f2-cef1e758be26"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0824e793-9a1b-4132-981d-299dc99b51f3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4ac92260-a1f1-495a-8ce8-b5ccff3ddf01", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0824e793-9a1b-4132-981d-299dc99b51f3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b83704e5-3fd4-4cd5-873a-651150f7a06d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ef17e544-3b72-4d18-ba5f-85116d7850e1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b83704e5-3fd4-4cd5-873a-651150f7a06d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "725e3a46-1b9e-40f4-99b2-630b38cef20e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3371674b-7e88-48cb-b28a-c650fce4e972", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "725e3a46-1b9e-40f4-99b2-630b38cef20e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "744b330f-3d58-46b7-b833-1c00ee9e73cd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8c35857c-97cb-4681-98e9-a150b9e6200b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "744b330f-3d58-46b7-b833-1c00ee9e73cd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "23fff58b-b004-44cf-aa5e-0bfdc0413b65", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dfd381d6-44e2-4d6a-8a72-0441ec482a55", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "23fff58b-b004-44cf-aa5e-0bfdc0413b65"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6fce68a1-bb91-4b57-9f7c-8cf81bd3ba2f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4216a62b-e6d6-4c3c-ab15-7b547aee999a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6fce68a1-bb91-4b57-9f7c-8cf81bd3ba2f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dd8cdb62-0161-4c6b-881f-e687055414c9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8a8bfa93-73b4-4174-83a5-116ed4362459", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dd8cdb62-0161-4c6b-881f-e687055414c9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e0741fdb-3590-455b-9b5b-28dee655032f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "13593c21-5bef-421e-9f1f-ac99a01a97a7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e0741fdb-3590-455b-9b5b-28dee655032f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c92bf55a-8cff-48fc-a66d-6e1d109d9634", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1e891734-15af-44ca-9213-2769589e3109", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c92bf55a-8cff-48fc-a66d-6e1d109d9634"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "66c32983-fd81-4aca-b3c0-ef984fb3c856", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e6f3af44-eba1-43aa-a44f-3dda6d8941bc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "66c32983-fd81-4aca-b3c0-ef984fb3c856"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "52b59a05-2d92-4ad2-af33-d32e56deb7b4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9bb1d25b-b0cf-4280-9b12-64014237dd7b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "52b59a05-2d92-4ad2-af33-d32e56deb7b4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "72ff19af-223c-4df0-a7ac-ebd8fa44816e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b14551fb-7e20-498f-a62f-d0809d180c16", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "72ff19af-223c-4df0-a7ac-ebd8fa44816e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "050012f7-9fa1-4856-9037-e94d549e4862", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cf09cb77-5aa1-4cba-9aea-e1409b7d0310", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "050012f7-9fa1-4856-9037-e94d549e4862"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f46b1fac-5556-4d58-8e95-1b17f1ac63b5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d3bc5132-2e83-4f11-95a8-4815fb0b08ee", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f46b1fac-5556-4d58-8e95-1b17f1ac63b5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "211485b9-ed0c-4dbd-9a87-e425cb03618b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ff820334-90f0-4fcc-be92-ed112491b6dc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "211485b9-ed0c-4dbd-9a87-e425cb03618b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e775f280-d2b6-4d33-8d97-e3eb7f7af1ca", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "08ae6a5f-f3e3-4dbc-a762-c0e468de50e4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e775f280-d2b6-4d33-8d97-e3eb7f7af1ca"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "311d5bdd-0685-45d8-99f2-60f6d22d21cb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "eafd7168-324e-43e0-8c18-d7e1ba9a5445", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "311d5bdd-0685-45d8-99f2-60f6d22d21cb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "66703a1f-0257-4cad-8bf6-5ecef95d0ccb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a988957d-7429-40db-bb69-409942e1bbe3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "66703a1f-0257-4cad-8bf6-5ecef95d0ccb"}, {"Element": "<p class=\"TitleA\"><span lang=\"X-NONE\">A. LABELLING</span></p>", "ID": "26767f40-32ae-4dfc-8f8c-7e56769e38f1", "Styles": "None", "Classes": "['TitleA']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"X-NONE\">A. LABELLING</span>", "ID": "09516ec4-4e68-44d5-a5c1-229f67bd6dca", "Styles": "None", "Classes": "None", "Text": "A. LABELLING", "ParentId": "26767f40-32ae-4dfc-8f8c-7e56769e38f1"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "ffadd4bf-4b55-43f6-bc7a-ec6fc033d89c", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black", "Classes": "None", "Text": " ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "5776bb6e-da20-473f-b03c-a8dc558cfa46", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "ffadd4bf-4b55-43f6-bc7a-ec6fc033d89c"}, {"Element": "<p class=\"MsoNormal\" style=\"background:white\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "be010060-011e-4b57-9c7e-2cea01d6aad4", "Styles": "background:white", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ddd1286c-30b6-4ff1-8997-92b4a94a50e3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "be010060-011e-4b57-9c7e-2cea01d6aad4"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">PARTICULARS\nTO APPEAR ON THE OUTER PACKAGING</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">CARTON</span></b></p>\n</div>", "ID": "b42c1454-07b9-402c-a18e-ad71e63413ac", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "    ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">PARTICULARS\nTO APPEAR ON THE OUTER PACKAGING</span></b></p>", "ID": "e8367f40-ef92-4908-9d3c-82592ea6b5dc", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b42c1454-07b9-402c-a18e-ad71e63413ac"}, {"Element": "<b><span lang=\"EN-GB\">PARTICULARS\nTO APPEAR ON THE OUTER PACKAGING</span></b>", "ID": "4f7654ab-a917-47c1-839e-3a8a30924223", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e8367f40-ef92-4908-9d3c-82592ea6b5dc"}, {"Element": "<span lang=\"EN-GB\">PARTICULARS\nTO APPEAR ON THE OUTER PACKAGING</span>", "ID": "23096d3a-baf2-4b54-86c9-a1fbc465f523", "Styles": "None", "Classes": "None", "Text": "PARTICULARS TO APPEAR ON THE OUTER PACKAGING", "ParentId": "4f7654ab-a917-47c1-839e-3a8a30924223"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "42c2e66c-8fb6-431f-9377-22b5f563f8e8", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b42c1454-07b9-402c-a18e-ad71e63413ac"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "094add3c-09d3-4000-bea0-14067d23860f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "42c2e66c-8fb6-431f-9377-22b5f563f8e8"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">CARTON</span></b></p>", "ID": "b6466d83-6f04-4370-97d7-35fd157f6ddb", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b42c1454-07b9-402c-a18e-ad71e63413ac"}, {"Element": "<b><span lang=\"EN-GB\">CARTON</span></b>", "ID": "5813636a-f68a-40ac-b27b-8cfc15b7da61", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b6466d83-6f04-4370-97d7-35fd157f6ddb"}, {"Element": "<span lang=\"EN-GB\">CARTON</span>", "ID": "39a8cf0d-a270-41b6-aac7-d42f939dcc2a", "Styles": "None", "Classes": "None", "Text": "CARTON", "ParentId": "5813636a-f68a-40ac-b27b-8cfc15b7da61"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dcca8bd5-c57e-41f8-a84b-e43b471096df", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "53c21ca4-6444-4852-bda0-a459e2fca452", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dcca8bd5-c57e-41f8-a84b-e43b471096df"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "249b83fc-b771-4115-ae4f-cc5459327ee2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1f8e35a0-931e-4a92-882e-5f6f7a71a73c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "249b83fc-b771-4115-ae4f-cc5459327ee2"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT</span></b></p>\n</div>", "ID": "95fb976c-77ec-4d26-a4b1-c11da0d11028", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT</span></b></p>", "ID": "5b3f600e-e3c2-4cc7-a92f-5466a285e0e3", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "95fb976c-77ec-4d26-a4b1-c11da0d11028"}, {"Element": "<b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT</span></b>", "ID": "6ba4305e-4e1d-4a92-bc2c-32fb3cf60a25", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5b3f600e-e3c2-4cc7-a92f-5466a285e0e3"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT</span>", "ID": "79672fb3-4dd8-4bfd-8470-38461546c408", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT", "ParentId": "6ba4305e-4e1d-4a92-bc2c-32fb3cf60a25"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "96f7bda4-c1a2-4111-924b-f4cac278444a", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b3da2daf-5b1f-41f5-9572-48512008a512", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "96f7bda4-c1a2-4111-924b-f4cac278444a"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Arzerra </span><span lang=\"EN-GB\" style=\"color:black\">100\u00a0mg concentrate for solution for\ninfusion</span></p>", "ID": "c79b835f-f902-4796-b9bb-dd5ba9f36265", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Arzerra </span>", "ID": "ccca5670-8261-4f90-a40e-496cebf566ac", "Styles": "None", "Classes": "None", "Text": "Arzerra ", "ParentId": "c79b835f-f902-4796-b9bb-dd5ba9f36265"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">100\u00a0mg concentrate for solution for\ninfusion</span>", "ID": "dc2e43f2-f317-4646-be89-d2bcd29582a8", "Styles": "color:black", "Classes": "None", "Text": "100\u00a0mg concentrate for solution for infusion", "ParentId": "c79b835f-f902-4796-b9bb-dd5ba9f36265"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">ofatumumab</span></p>", "ID": "acd220c1-94bd-4ddf-9344-3c8a58573e2c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">ofatumumab</span>", "ID": "aaed8967-6d9d-4304-be17-0d3d02af2422", "Styles": "None", "Classes": "None", "Text": "ofatumumab", "ParentId": "acd220c1-94bd-4ddf-9344-3c8a58573e2c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "86dc858d-a7e8-455f-8325-ec4d4dedb7a3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8f0eeacb-fae7-4a17-b36e-8643fa35fa10", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "86dc858d-a7e8-455f-8325-ec4d4dedb7a3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5af2a038-343d-4777-a053-502961cc220f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "75522bf4-b00c-4e25-b22a-d74f4fe957e4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5af2a038-343d-4777-a053-502961cc220f"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>\n</div>", "ID": "9a9f9ed2-d08d-4c49-bd3b-8388135561fd", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>", "ID": "0816ad1f-5efd-44d6-88cd-4f8ac73c944c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9a9f9ed2-d08d-4c49-bd3b-8388135561fd"}, {"Element": "<b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT OF ACTIVE SUBSTANCE(S)</span></b>", "ID": "b54df101-f1e2-45b1-a22a-159cf18223ce", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0816ad1f-5efd-44d6-88cd-4f8ac73c944c"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT OF ACTIVE SUBSTANCE(S)</span>", "ID": "8dc35bc3-2506-460f-a3c7-914c109386ce", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT OF ACTIVE SUBSTANCE(S)", "ParentId": "b54df101-f1e2-45b1-a22a-159cf18223ce"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "2813fed4-5359-4f71-aa06-c71d31c47a2f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "7da61faf-f9a1-4ed9-a0dc-dc6b15deadc1", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "2813fed4-5359-4f71-aa06-c71d31c47a2f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">One ml contains\n20\u00a0mg ofatumumab.</span></p>", "ID": "72a950d3-a2a9-4087-be04-347c97151272", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">One ml contains\n20\u00a0mg ofatumumab.</span>", "ID": "528f0e8f-87b3-4606-a249-85a560575315", "Styles": "color:black", "Classes": "None", "Text": "One ml contains 20\u00a0mg ofatumumab.", "ParentId": "72a950d3-a2a9-4087-be04-347c97151272"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each vial contains\n100\u00a0mg ofatumumab in 5\u00a0ml.</span></p>", "ID": "112ce68d-1e97-4621-b2ec-b4e5ec132441", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Each vial contains\n100\u00a0mg ofatumumab in 5\u00a0ml.</span>", "ID": "ec54ebad-fe12-426c-8c02-538f8b7cced8", "Styles": "color:black", "Classes": "None", "Text": "Each vial contains 100\u00a0mg ofatumumab in 5\u00a0ml.", "ParentId": "112ce68d-1e97-4621-b2ec-b4e5ec132441"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9eeea210-03bc-43ac-a8ed-43c9a611a59d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "38aba383-55d4-4383-b69d-420d5458c114", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9eeea210-03bc-43ac-a8ed-43c9a611a59d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "009f5c28-79bc-451c-acfe-b89f1063e63b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1e8bb71e-ff4e-4381-849e-b0fc6709d36f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "009f5c28-79bc-451c-acfe-b89f1063e63b"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST OF EXCIPIENTS</span></b></p>\n</div>", "ID": "c50af4ba-2d69-465b-bc51-4cbddb2d2552", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST OF EXCIPIENTS</span></b></p>", "ID": "1e1ba31b-af2a-4b33-a238-4a3b2ad2272b", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c50af4ba-2d69-465b-bc51-4cbddb2d2552"}, {"Element": "<b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST OF EXCIPIENTS</span></b>", "ID": "46517f33-91f0-40f8-ba9d-62127fa4fc01", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1e1ba31b-af2a-4b33-a238-4a3b2ad2272b"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST OF EXCIPIENTS</span>", "ID": "ed3cc37d-2819-402e-80b2-71620a9ecc10", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST OF EXCIPIENTS", "ParentId": "46517f33-91f0-40f8-ba9d-62127fa4fc01"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "8be098de-f237-46dd-867d-d8ad6fff7281", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "be27940a-d90c-488e-b694-13f8a6affab5", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "8be098de-f237-46dd-867d-d8ad6fff7281"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT\" style=\"color:black\">Also contains: arginine,\nsodium acetate (E262), </span><span lang=\"EN-GB\" style=\"color:black\">sodium\nchloride</span><span lang=\"PT\" style=\"color:black\">, polysorbate 80 (E433),\nedetate disodium (E386), hydrochloric acid (E507), </span><span lang=\"EN-GB\" style=\"color:black\">water for injections. See leaflet for further information.</span></p>", "ID": "c0513765-aca5-41fa-b65d-f92b1b87dea1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"PT\" style=\"color:black\">Also contains: arginine,\nsodium acetate (E262), </span>", "ID": "2a203660-ce6f-48ac-b691-8fa8ede3d957", "Styles": "color:black", "Classes": "None", "Text": "Also contains: arginine, sodium acetate (E262), ", "ParentId": "c0513765-aca5-41fa-b65d-f92b1b87dea1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">sodium\nchloride</span>", "ID": "3cf14bf9-ff81-48bc-84bc-bd025d34eadf", "Styles": "color:black", "Classes": "None", "Text": "sodium chloride", "ParentId": "c0513765-aca5-41fa-b65d-f92b1b87dea1"}, {"Element": "<span lang=\"PT\" style=\"color:black\">, polysorbate 80 (E433),\nedetate disodium (E386), hydrochloric acid (E507), </span>", "ID": "6f110c3f-8c51-451c-b8d3-6e58f9698ad0", "Styles": "color:black", "Classes": "None", "Text": ", polysorbate 80 (E433), edetate disodium (E386), hydrochloric acid (E507), ", "ParentId": "c0513765-aca5-41fa-b65d-f92b1b87dea1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">water for injections. See leaflet for further information.</span>", "ID": "deaca2d1-2172-4b53-9f1e-169afe2f3aeb", "Styles": "color:black", "Classes": "None", "Text": "water for injections. See leaflet for further information.", "ParentId": "c0513765-aca5-41fa-b65d-f92b1b87dea1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4a510a22-c6b3-4426-b536-f742587ebb14", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "285c31a2-c5d8-47e6-ad7c-4887ab10843d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4a510a22-c6b3-4426-b536-f742587ebb14"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "11a1e2b2-7ca4-48d9-9ae1-e434c9fa40c4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ed4e5132-8fa8-4e5c-b1c9-7c020be77bbf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "11a1e2b2-7ca4-48d9-9ae1-e434c9fa40c4"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM\n AND CONTENTS</span></b></p>\n</div>", "ID": "f49f3111-d90d-4b22-98a5-e21b20319db0", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM\n AND CONTENTS</span></b></p>", "ID": "b4cba743-81bc-4f45-8afe-b0b356ebde87", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f49f3111-d90d-4b22-98a5-e21b20319db0"}, {"Element": "<b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM\n AND CONTENTS</span></b>", "ID": "449df0d3-cb90-44cd-9dd3-36a65b7d5b19", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b4cba743-81bc-4f45-8afe-b0b356ebde87"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM\n AND CONTENTS</span>", "ID": "a64e1069-9438-4b0c-8a08-29645c7a33d6", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM  AND CONTENTS", "ParentId": "449df0d3-cb90-44cd-9dd3-36a65b7d5b19"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c1ea8947-cb17-4f59-82a7-5932d6416209", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4942714e-e7cd-41a1-8ae4-59d0d4f4fba2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c1ea8947-cb17-4f59-82a7-5932d6416209"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">Concentrate\nfor solution for infusion.</span></p>", "ID": "f876cfc6-76ac-46cb-9129-9fd5f9378853", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">Concentrate\nfor solution for infusion.</span>", "ID": "171ae09a-3be3-4379-ba3b-ac75a2041507", "Styles": "color:black;background:#D9D9D9", "Classes": "None", "Text": "Concentrate for solution for infusion.", "ParentId": "f876cfc6-76ac-46cb-9129-9fd5f9378853"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4650bb52-db50-4594-a87a-172ede8bf0a5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ba55f59e-71b4-4553-85f5-e45de4cc720e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4650bb52-db50-4594-a87a-172ede8bf0a5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"SV\">100\u00a0mg/5\u00a0ml</span></p>", "ID": "3e90b2b7-7229-48fa-89da-cf4987f06bb3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"SV\">100\u00a0mg/5\u00a0ml</span>", "ID": "c8acd925-799a-416c-a705-7d09bf36461c", "Styles": "None", "Classes": "None", "Text": "100\u00a0mg/5\u00a0ml", "ParentId": "3e90b2b7-7229-48fa-89da-cf4987f06bb3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"SV\">\u00a0</span></p>", "ID": "fa350288-0739-4a12-8e35-98a3a99d8502", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"SV\">\u00a0</span>", "ID": "1e73058a-28ac-463b-8441-9073e9624847", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fa350288-0739-4a12-8e35-98a3a99d8502"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"SV\">3\u00a0vials</span></p>", "ID": "fd1482b6-fdc0-4fbb-af9e-5b3afbbe13b8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"SV\">3\u00a0vials</span>", "ID": "3bd9cbd3-8ad4-457e-9ae6-99b755a0d1b5", "Styles": "None", "Classes": "None", "Text": "3\u00a0vials", "ParentId": "fd1482b6-fdc0-4fbb-af9e-5b3afbbe13b8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"SV\">\u00a0</span></p>", "ID": "bade93c1-ff46-4ae9-a991-ddd708f8cdf2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"SV\">\u00a0</span>", "ID": "f7ecfbb2-f83d-46d8-8f81-803b2ea7b26a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bade93c1-ff46-4ae9-a991-ddd708f8cdf2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"SV\">\u00a0</span></p>", "ID": "4c75b02e-e386-4908-aa9d-f70760d4208f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"SV\">\u00a0</span>", "ID": "459646fe-5b56-4c7e-968e-4a27d16859cd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4c75b02e-e386-4908-aa9d-f70760d4208f"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>\n</div>", "ID": "5076b447-740b-4408-9317-e1bb1c9acd82", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>", "ID": "3f29de23-d148-4c76-ad03-d0a6a42797a5", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5076b447-740b-4408-9317-e1bb1c9acd82"}, {"Element": "<b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD AND ROUTE(S) OF ADMINISTRATION</span></b>", "ID": "29b0e059-82bb-476d-a632-62d0ded34be7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3f29de23-d148-4c76-ad03-d0a6a42797a5"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD AND ROUTE(S) OF ADMINISTRATION</span>", "ID": "d8733cfe-4a92-41cf-b30a-0ff5c9bd0586", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD AND ROUTE(S) OF ADMINISTRATION", "ParentId": "29b0e059-82bb-476d-a632-62d0ded34be7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bdcda946-7cfd-4a5c-b9dd-3ea9ae08e17a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "240b5d6d-c8b3-45c8-be94-1551c1e72a02", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bdcda946-7cfd-4a5c-b9dd-3ea9ae08e17a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Read the package leaflet before use.</span></p>", "ID": "90f7700b-6983-48ff-8c8c-4e2b3b509d19", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Read the package leaflet before use.</span>", "ID": "18911c18-488c-46eb-ab22-48aef629c46f", "Styles": "None", "Classes": "None", "Text": "Read the package leaflet before use.", "ParentId": "90f7700b-6983-48ff-8c8c-4e2b3b509d19"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Intravenous use</span></p>", "ID": "976739d0-3c61-4393-bf2b-bbf322479fe3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Intravenous use</span>", "ID": "3ee63daa-84d4-4e2b-bca0-44c69ad8a978", "Styles": "None", "Classes": "None", "Text": "Intravenous use", "ParentId": "976739d0-3c61-4393-bf2b-bbf322479fe3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "91e2c153-c492-4b65-8051-e5130f8132de", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "99b7e120-7d31-43b9-b2e8-67ab9f47d9d0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "91e2c153-c492-4b65-8051-e5130f8132de"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fe68f6ac-5f5a-4b25-a82f-ae9e7b771f72", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1256f068-c965-4eab-9ff9-4b8a87370b52", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fe68f6ac-5f5a-4b25-a82f-ae9e7b771f72"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL WARNING THAT THE MEDICINAL\nPRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>\n</div>", "ID": "3c9d80e7-07a5-4f78-a290-a067ea31d779", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL WARNING THAT THE MEDICINAL\nPRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>", "ID": "ae89b3e5-11db-4398-8dfe-000caac6dad4", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3c9d80e7-07a5-4f78-a290-a067ea31d779"}, {"Element": "<b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL WARNING THAT THE MEDICINAL\nPRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b>", "ID": "7b1541ce-7cfe-4819-a242-8960257aeb25", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ae89b3e5-11db-4398-8dfe-000caac6dad4"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL WARNING THAT THE MEDICINAL\nPRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span>", "ID": "3fe4014a-8f63-4331-b6ef-80cc11e4b180", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN", "ParentId": "7b1541ce-7cfe-4819-a242-8960257aeb25"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "864ee855-822e-4464-b467-6dc6bc64bc66", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8a9356a1-53a3-4262-b9c1-967d94b1f058", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "864ee855-822e-4464-b467-6dc6bc64bc66"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep out of the sight and reach of\nchildren.</span></p>", "ID": "c9fbd9d5-61a9-4553-aa2f-96e8c187d911", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Keep out of the sight and reach of\nchildren.</span>", "ID": "c85096e9-0eea-4742-805c-b6f8fb3e8059", "Styles": "None", "Classes": "None", "Text": "Keep out of the sight and reach of children.", "ParentId": "c9fbd9d5-61a9-4553-aa2f-96e8c187d911"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e3d3bac2-201e-4732-9b0d-abd8e49d9d0c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "538f4bfd-774d-4a6e-a981-14a57d4227d0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e3d3bac2-201e-4732-9b0d-abd8e49d9d0c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ceb4e88c-ed08-4d83-a450-43c284faa5f9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "76aee748-db19-4707-bc6c-6bd9257f6b14", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ceb4e88c-ed08-4d83-a450-43c284faa5f9"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>\n</div>", "ID": "a8d5fb1f-5511-4b38-88a3-f157722c93f7", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>", "ID": "f89a6713-20ce-40a1-afe8-d8c7c327b8ea", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a8d5fb1f-5511-4b38-88a3-f157722c93f7"}, {"Element": "<b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER SPECIAL WARNING(S), IF NECESSARY</span></b>", "ID": "dc18db56-39c1-4ee7-a376-b2d73d7cd0f6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f89a6713-20ce-40a1-afe8-d8c7c327b8ea"}, {"Element": "<span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER SPECIAL WARNING(S), IF NECESSARY</span>", "ID": "c8ea58d6-58a1-41f9-ac53-ea865519e3a3", "Styles": "None", "Classes": "None", "Text": "7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER SPECIAL WARNING(S), IF NECESSARY", "ParentId": "dc18db56-39c1-4ee7-a376-b2d73d7cd0f6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5b4b5700-85c7-4b14-8b25-a8137d5ed42d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4f735f5d-c3b2-457f-862c-221b4db3f7e5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5b4b5700-85c7-4b14-8b25-a8137d5ed42d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3f3d82bc-75d4-4c8e-a4e5-56cadbb98455", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "de18984f-c1bd-484c-91aa-98366da09026", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3f3d82bc-75d4-4c8e-a4e5-56cadbb98455"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE</span></b></p>\n</div>", "ID": "df25075f-a32c-46e2-8649-6c9a70a170c9", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE</span></b></p>", "ID": "52e7fa68-98d2-4f4a-9d1f-21859be7c52f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "df25075f-a32c-46e2-8649-6c9a70a170c9"}, {"Element": "<b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE</span></b>", "ID": "f3f9af7d-ed78-48bb-a868-6b1cbe2723df", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "52e7fa68-98d2-4f4a-9d1f-21859be7c52f"}, {"Element": "<span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE</span>", "ID": "e048be5c-f5e8-42a6-9d73-14bc08f41559", "Styles": "None", "Classes": "None", "Text": "8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE", "ParentId": "f3f9af7d-ed78-48bb-a868-6b1cbe2723df"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7b399731-aa25-4311-bfa0-58d017e5054f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f834eb12-2501-48f8-ae50-ff5160c10326", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7b399731-aa25-4311-bfa0-58d017e5054f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP</span></p>", "ID": "49adabfd-c6df-41ce-a9e7-bcf22b4a542b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">EXP</span>", "ID": "560d49bc-9753-4d02-bd88-f4a57ccc3dc3", "Styles": "None", "Classes": "None", "Text": "EXP", "ParentId": "49adabfd-c6df-41ce-a9e7-bcf22b4a542b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "18f6ac0f-6746-4421-bd6f-93b520efd8b5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ab25f5c6-98e4-4898-8588-bfa6dea0d1ef", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "18f6ac0f-6746-4421-bd6f-93b520efd8b5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a91e1390-47e1-40ea-a705-8dc5eb3c5299", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "67606842-7b26-456d-b10d-65c4ea9865be", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a91e1390-47e1-40ea-a705-8dc5eb3c5299"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE\nCONDITIONS</span></b></p>\n</div>", "ID": "dea5885c-87fd-4be7-9fad-cc0f4781a843", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE\nCONDITIONS</span></b></p>", "ID": "3ec9c542-709f-4188-8f2f-07da4b60860d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dea5885c-87fd-4be7-9fad-cc0f4781a843"}, {"Element": "<b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE\nCONDITIONS</span></b>", "ID": "7e457579-f9b1-4e8b-816e-78f365f9fca4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3ec9c542-709f-4188-8f2f-07da4b60860d"}, {"Element": "<span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE\nCONDITIONS</span>", "ID": "2e6bdcb1-d3b9-4a39-890b-94297df1ca4f", "Styles": "None", "Classes": "None", "Text": "9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE CONDITIONS", "ParentId": "7e457579-f9b1-4e8b-816e-78f365f9fca4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1e50540f-1a88-41bf-a55e-d6a3b262771f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "163b01de-f75b-4552-8600-0c57fa1fe45c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1e50540f-1a88-41bf-a55e-d6a3b262771f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Store and\ntransport refrigerated.</span></p>", "ID": "20430ec9-41df-46c7-8478-2a1919b46a29", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Store and\ntransport refrigerated.</span>", "ID": "a1941817-f127-4ac2-a5a3-edf0acb7ccf9", "Styles": "None", "Classes": "None", "Text": "Store and transport refrigerated.", "ParentId": "20430ec9-41df-46c7-8478-2a1919b46a29"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Do not\nfreeze.</span></p>", "ID": "836ece06-3078-4d58-8a6b-1cbb2c9102a4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Do not\nfreeze.</span>", "ID": "0665c210-480f-4fa9-b3c3-48bcf138d7b4", "Styles": "None", "Classes": "None", "Text": "Do not freeze.", "ParentId": "836ece06-3078-4d58-8a6b-1cbb2c9102a4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep the vial in the outer carton in order\nto protect from light.</span></p>", "ID": "6dee1649-3a72-43c9-a7ad-ad22c34e61e6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Keep the vial in the outer carton in order\nto protect from light.</span>", "ID": "d5045aa0-2ab8-4b89-aab2-ade4eb2a3264", "Styles": "None", "Classes": "None", "Text": "Keep the vial in the outer carton in order to protect from light.", "ParentId": "6dee1649-3a72-43c9-a7ad-ad22c34e61e6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ddda36c3-359c-4e34-a4a2-7f7fe351ed10", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6b9a012b-b774-4a49-9804-cfb53afbb136", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ddda36c3-359c-4e34-a4a2-7f7fe351ed10"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "076b3e1d-6d84-4997-bd3d-b15f4716d61d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fa5feda1-f1fe-409e-ab40-eca30c66bd50", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "076b3e1d-6d84-4997-bd3d-b15f4716d61d"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS FOR DISPOSAL OF\nUNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL\nPRODUCTS, IF APPROPRIATE</span></b></p>\n</div>", "ID": "d9bca669-91bd-4cee-944b-dc40824ae6d8", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS FOR DISPOSAL OF\nUNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL\nPRODUCTS, IF APPROPRIATE</span></b></p>", "ID": "b8da0ed3-3121-4d20-aa1d-2c54a1f8dd27", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d9bca669-91bd-4cee-944b-dc40824ae6d8"}, {"Element": "<b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS FOR DISPOSAL OF\nUNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL\nPRODUCTS, IF APPROPRIATE</span></b>", "ID": "cc4342ea-184e-4146-bd0b-c06ff704641a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b8da0ed3-3121-4d20-aa1d-2c54a1f8dd27"}, {"Element": "<span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS FOR DISPOSAL OF\nUNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL\nPRODUCTS, IF APPROPRIATE</span>", "ID": "0ec1edfa-fddb-417a-be99-8e0c4c062ebd", "Styles": "None", "Classes": "None", "Text": "10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE", "ParentId": "cc4342ea-184e-4146-bd0b-c06ff704641a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c8c536e4-313a-47fd-8fbf-e09a1aa8c73a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f3e0d81e-3193-4214-a0ce-1cfb3efa21ff", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c8c536e4-313a-47fd-8fbf-e09a1aa8c73a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1bd0083d-6aef-4b2b-8657-493358c37178", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c3c21845-9e7f-451f-9758-b6d9c31a5c1e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1bd0083d-6aef-4b2b-8657-493358c37178"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0 NAME\n AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>\n</div>", "ID": "18daacca-3fde-4495-abbc-632bf53a7194", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0 NAME\n AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>", "ID": "2327eca4-a32b-4803-ac12-d27f157533f4", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18daacca-3fde-4495-abbc-632bf53a7194"}, {"Element": "<b><span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0 NAME\n AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b>", "ID": "9673f057-331c-4de8-b45d-fa0a66caf3d7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2327eca4-a32b-4803-ac12-d27f157533f4"}, {"Element": "<span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0 NAME\n AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span>", "ID": "b0d0298b-4c99-48b2-b6e2-ab0456cd398e", "Styles": "None", "Classes": "None", "Text": "11.\u00a0\u00a0\u00a0\u00a0 NAME  AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER", "ParentId": "9673f057-331c-4de8-b45d-fa0a66caf3d7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "0e99f9a3-0bf4-4aac-a8d7-ff0abfbd1a4f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "7773cb5f-1606-4ad1-a929-fce9c68a0155", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "0e99f9a3-0bf4-4aac-a8d7-ff0abfbd1a4f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Novartis Europharm Limited</span></p>", "ID": "ac75d129-e12a-4eb8-b26e-235339d59fdd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Novartis Europharm Limited</span>", "ID": "af02e529-ad64-49ca-8f16-e5bf7499b423", "Styles": "None", "Classes": "None", "Text": "Novartis Europharm Limited", "ParentId": "ac75d129-e12a-4eb8-b26e-235339d59fdd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Frimley Business Park</span></p>", "ID": "a0cfe4c1-420a-479c-9d3d-03175e1c73b6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Frimley Business Park</span>", "ID": "0175dc16-2f80-46f8-973f-90a5fbfceb32", "Styles": "None", "Classes": "None", "Text": "Frimley Business Park", "ParentId": "a0cfe4c1-420a-479c-9d3d-03175e1c73b6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Camberley GU16 7SR</span></p>", "ID": "9ef162ae-3656-4b65-9a20-5799ab96fa28", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Camberley GU16 7SR</span>", "ID": "6e641a66-8003-4594-9f1e-c080148ad5cc", "Styles": "None", "Classes": "None", "Text": "Camberley GU16 7SR", "ParentId": "9ef162ae-3656-4b65-9a20-5799ab96fa28"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">United Kingdom</span></p>", "ID": "6b40a1e5-822f-4831-a986-3cb153603dae", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">United Kingdom</span>", "ID": "9ba6dd77-92f8-4f39-9b5f-29ae98b023ee", "Styles": "color:black", "Classes": "None", "Text": "United Kingdom", "ParentId": "6b40a1e5-822f-4831-a986-3cb153603dae"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d5a2cd6a-9e8c-41db-8f99-5accbc49ca93", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "74148075-d489-4d65-aa9a-0ccec3d24de1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d5a2cd6a-9e8c-41db-8f99-5accbc49ca93"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "03b38483-315e-4fe9-bed8-1c7981893ff0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fcf440a9-5071-4da6-ac51-3a8474404e59", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "03b38483-315e-4fe9-bed8-1c7981893ff0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span></b></p>\n</div>", "ID": "3092612a-6935-404c-a97d-a817c6c42790", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span></b></p>", "ID": "f4bd176a-5628-4149-9039-e55ccbf9d7fe", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3092612a-6935-404c-a97d-a817c6c42790"}, {"Element": "<b><span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span></b>", "ID": "0c63478f-d1ae-4213-bfbc-2048c2eda66d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f4bd176a-5628-4149-9039-e55ccbf9d7fe"}, {"Element": "<span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span>", "ID": "517dafe4-f12b-4635-a1a9-7e0572e74ae0", "Styles": "None", "Classes": "None", "Text": "12.\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION NUMBER(S)", "ParentId": "0c63478f-d1ae-4213-bfbc-2048c2eda66d"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a827acae-4a10-4fa3-904b-35e8a17e9b22", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU/1/10/625/001</span></p>", "ID": "2c735fd0-4450-4fd1-8d93-a2dafbdb0114", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">EU/1/10/625/001</span>", "ID": "e26023ac-2027-43e8-9d87-a8ac964687dc", "Styles": "None", "Classes": "None", "Text": "EU/1/10/625/001", "ParentId": "2c735fd0-4450-4fd1-8d93-a2dafbdb0114"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "09b0f216-3290-4b65-9155-9ccd21ef6f95", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "4a47b8c6-ed84-4929-8a81-2ea8d7bb9d71", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b></p>\n</div>", "ID": "7f90b4d0-d138-4ed2-86b5-81eaa0540580", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b></p>", "ID": "a11bfd61-744a-43b9-a8fb-d45e9f7fbf9d", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7f90b4d0-d138-4ed2-86b5-81eaa0540580"}, {"Element": "<b><span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b>", "ID": "c481878a-67ec-478f-bca0-20d2dc95ce54", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a11bfd61-744a-43b9-a8fb-d45e9f7fbf9d"}, {"Element": "<span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span>", "ID": "d71cc328-9f8d-4414-95a3-c43c1297a55f", "Styles": "None", "Classes": "None", "Text": "13.\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER", "ParentId": "c481878a-67ec-478f-bca0-20d2dc95ce54"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "721b67db-aee2-4ca5-97dd-997395abfc1e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "80813c9a-a5c7-4b15-9a9c-4ff67b259b51", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "721b67db-aee2-4ca5-97dd-997395abfc1e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Lot</span></p>", "ID": "43de79a2-5a0a-4377-b77c-8859660066b6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Lot</span>", "ID": "0a4492d5-1a13-419a-8a90-c5da4df95253", "Styles": "None", "Classes": "None", "Text": "Lot", "ParentId": "43de79a2-5a0a-4377-b77c-8859660066b6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f0dd6a0e-5102-4e29-8646-2ccb20e46f70", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a292093d-7696-4cd6-8b7b-36119be3b956", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f0dd6a0e-5102-4e29-8646-2ccb20e46f70"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ddd205fe-7d13-4a3e-908d-0bf7752f1576", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7ad401ae-5992-4826-bb18-2edebba85972", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ddd205fe-7d13-4a3e-908d-0bf7752f1576"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>\n</div>", "ID": "189ed2e0-6871-4939-ab3d-d04db10d5894", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>", "ID": "b754bf6c-8cde-4256-ac90-898c588da6ef", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "189ed2e0-6871-4939-ab3d-d04db10d5894"}, {"Element": "<b><span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL CLASSIFICATION FOR SUPPLY</span></b>", "ID": "9d05477f-7493-4979-95ec-8311e101df76", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b754bf6c-8cde-4256-ac90-898c588da6ef"}, {"Element": "<span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL CLASSIFICATION FOR SUPPLY</span>", "ID": "365eaff5-f393-4049-bbae-a4ee888a91b9", "Styles": "None", "Classes": "None", "Text": "14.\u00a0\u00a0\u00a0\u00a0 GENERAL CLASSIFICATION FOR SUPPLY", "ParentId": "9d05477f-7493-4979-95ec-8311e101df76"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "432a37ce-cc74-4629-8ba1-04a2438d5e39", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "189d2344-c993-47d2-8531-d73df1568100", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "432a37ce-cc74-4629-8ba1-04a2438d5e39"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "eec135c6-984e-4569-8fa9-348696e7bb79", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "aa751cf1-5393-49fe-93a7-65cb25295362", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "eec135c6-984e-4569-8fa9-348696e7bb79"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span></b></p>\n</div>", "ID": "04baf0db-63be-466b-b336-7b669d9c1b4a", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span></b></p>", "ID": "5cee5472-6f81-42a9-9e72-ba6446613362", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "04baf0db-63be-466b-b336-7b669d9c1b4a"}, {"Element": "<b><span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span></b>", "ID": "18de39b6-d8ac-4f94-8717-73a8cef1eead", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5cee5472-6f81-42a9-9e72-ba6446613362"}, {"Element": "<span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span>", "ID": "074e0f28-f1a0-455a-9231-8d97252d0fa9", "Styles": "None", "Classes": "None", "Text": "15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS ON USE", "ParentId": "18de39b6-d8ac-4f94-8717-73a8cef1eead"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4241ad6b-fd47-4f5d-85a2-a6d2299e8eb9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "020311d5-ec93-4836-978e-cad3a8caf2f7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4241ad6b-fd47-4f5d-85a2-a6d2299e8eb9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e4412204-1b8e-4279-ada7-048409bd72f2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "46d4a6ac-0de8-4398-afa2-693f741fa392", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e4412204-1b8e-4279-ada7-048409bd72f2"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION\nIN BRAILLE</span></b></p>\n</div>", "ID": "bf1f1e8c-df3d-4ec8-b0c1-d8f314c496f6", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION\nIN BRAILLE</span></b></p>", "ID": "65349fbc-9dd3-4c95-a607-8c3f7ed960c6", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bf1f1e8c-df3d-4ec8-b0c1-d8f314c496f6"}, {"Element": "<b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION\nIN BRAILLE</span></b>", "ID": "2f2998ed-acef-4c8a-9565-052ca961a6c7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "65349fbc-9dd3-4c95-a607-8c3f7ed960c6"}, {"Element": "<span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION\nIN BRAILLE</span>", "ID": "5f062459-23eb-44cb-babd-371837c36c3a", "Styles": "None", "Classes": "None", "Text": "16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN BRAILLE", "ParentId": "2f2998ed-acef-4c8a-9565-052ca961a6c7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0799c66e-5f23-48a9-9f74-402947cd66ef", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "976855c2-e04f-4a61-b6f0-4b2ec06c6380", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0799c66e-5f23-48a9-9f74-402947cd66ef"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black;background:#CCCCCC\">Justification\nfor not including Braille accepted</span></p>", "ID": "ec656764-3212-4879-8dc1-a16ccbc41c8e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;background:#CCCCCC\">Justification\nfor not including Braille accepted</span>", "ID": "ebaf407a-7452-4ac6-96f8-418438bbc13b", "Styles": "color:black;background:#CCCCCC", "Classes": "None", "Text": "Justification for not including Braille accepted", "ParentId": "ec656764-3212-4879-8dc1-a16ccbc41c8e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "aaef8cff-f3e7-4feb-b21d-eb5d933a6d62", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0ae6d483-a627-4d60-9afd-09f98e6c1113", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "aaef8cff-f3e7-4feb-b21d-eb5d933a6d62"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "24dabca2-d8b8-491f-b749-fde71196bdc5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "117190c4-0bbd-4353-8a42-0be2329333e5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "24dabca2-d8b8-491f-b749-fde71196bdc5"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE</span></b></p>\n</div>", "ID": "f5488652-6934-47cb-8a90-1cb0572a6f7e", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE</span></b></p>", "ID": "3bebeae3-73e5-47b3-a29f-29c55fd5d45e", "Styles": "page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f5488652-6934-47cb-8a90-1cb0572a6f7e"}, {"Element": "<b><span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE</span></b>", "ID": "e57927e3-3da3-4bc6-9d0f-afdab83256a7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3bebeae3-73e5-47b3-a29f-29c55fd5d45e"}, {"Element": "<span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE</span>", "ID": "0afe55bb-626d-40ab-935a-17e1e2f2c26f", "Styles": "None", "Classes": "None", "Text": "17.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE", "ParentId": "e57927e3-3da3-4bc6-9d0f-afdab83256a7"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "29c3963f-6624-494b-ad29-cd5ff77996a9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "599c9627-82ac-41fd-82f5-503cf5030f39", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "29c3963f-6624-494b-ad29-cd5ff77996a9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">2D\nbarcode carrying the unique identifier included.</span></p>", "ID": "0c9a6c75-f529-4217-9fe0-c241921883a2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">2D\nbarcode carrying the unique identifier included.</span>", "ID": "484d9629-9aa8-4fb0-bd11-b914a0eb83de", "Styles": "color:black;background:#D9D9D9", "Classes": "None", "Text": "2D barcode carrying the unique identifier included.", "ParentId": "0c9a6c75-f529-4217-9fe0-c241921883a2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "32a33b16-4a92-475f-a5bb-57c4100cc3f4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8fb5f6f7-478f-4267-bc63-6b258f00212e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "32a33b16-4a92-475f-a5bb-57c4100cc3f4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ec2e7267-9582-453c-9cfb-da9f3e0d48d7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3b6563b6-47e5-43ee-9a80-0f7685428f59", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ec2e7267-9582-453c-9cfb-da9f3e0d48d7"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>\n</div>", "ID": "dc9659da-27e4-46ad-8f91-ffee4b3d054c", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>", "ID": "adeea7ef-0c36-4717-8e39-d1e4b0b886e3", "Styles": "page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dc9659da-27e4-46ad-8f91-ffee4b3d054c"}, {"Element": "<b><span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b>", "ID": "b7d93827-6298-41bf-b751-3d6258940843", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "adeea7ef-0c36-4717-8e39-d1e4b0b886e3"}, {"Element": "<span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER - HUMAN READABLE DATA</span>", "ID": "db79547d-cd3a-4e30-afb5-0b6b91d3e688", "Styles": "None", "Classes": "None", "Text": "18.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER - HUMAN READABLE DATA", "ParentId": "b7d93827-6298-41bf-b751-3d6258940843"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "57a548c5-7ec7-4e95-8a7e-adda3e61eafe", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "11d624a4-c555-4af2-a4ce-b3c00a285591", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "57a548c5-7ec7-4e95-8a7e-adda3e61eafe"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">PC:</span></p>", "ID": "9dbb887a-10a4-414e-ae18-9d7562cc2758", "Styles": "line-height:13.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">PC:</span>", "ID": "14fd5d07-ee1e-48f9-b5b4-864e24d268b8", "Styles": "None", "Classes": "None", "Text": "PC:", "ParentId": "9dbb887a-10a4-414e-ae18-9d7562cc2758"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">SN:</span></p>", "ID": "72424d09-faea-49ba-900f-60825dd23411", "Styles": "line-height:13.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">SN:</span>", "ID": "b3bcdb80-138c-4bb6-ad80-e227d4db2256", "Styles": "None", "Classes": "None", "Text": "SN:", "ParentId": "72424d09-faea-49ba-900f-60825dd23411"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><span lang=\"EN-GB\">NN:</span></p>", "ID": "80b2c255-b306-4e15-ba68-5524cc0c1ced", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">NN:</span>", "ID": "97d0a65f-e81e-4106-876f-249ede79ea02", "Styles": "None", "Classes": "None", "Text": "NN:", "ParentId": "80b2c255-b306-4e15-ba68-5524cc0c1ced"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "7e0ce7e3-f327-40f1-beac-cfb936200f71", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "593011a7-fae7-4608-af16-c15d9acd6fdf", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "7e0ce7e3-f327-40f1-beac-cfb936200f71"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><a name=\"_Hlk258415279\"><b><span lang=\"EN-GB\">MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE </span></b></a><b><span lang=\"EN-GB\">PAC</span></b><b><span lang=\"EN-GB\">KAGING UNITS</span></b></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">VIAL\nLABEL</span></b></p>\n</div>", "ID": "2afc2b8b-c0d8-471f-82fb-ab246ee3e875", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "    ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><a name=\"_Hlk258415279\"><b><span lang=\"EN-GB\">MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE </span></b></a><b><span lang=\"EN-GB\">PAC</span></b><b><span lang=\"EN-GB\">KAGING UNITS</span></b></p>", "ID": "b7067a06-e5fb-48fc-a7c9-317e3b2cccf4", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2afc2b8b-c0d8-471f-82fb-ab246ee3e875"}, {"Element": "<a name=\"_Hlk258415279\"><b><span lang=\"EN-GB\">MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE </span></b></a>", "ID": "8e897706-6892-4f65-89e8-e7aed37c93a0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b7067a06-e5fb-48fc-a7c9-317e3b2cccf4"}, {"Element": "<b><span lang=\"EN-GB\">MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE </span></b>", "ID": "5b00cfc1-764d-4dc1-a9d2-b7a380a16f21", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8e897706-6892-4f65-89e8-e7aed37c93a0"}, {"Element": "<span lang=\"EN-GB\">MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE </span>", "ID": "68a002a9-9275-459f-89ed-ec64344c1789", "Styles": "None", "Classes": "None", "Text": "MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE ", "ParentId": "5b00cfc1-764d-4dc1-a9d2-b7a380a16f21"}, {"Element": "<b><span lang=\"EN-GB\">PAC</span></b>", "ID": "1c6213c4-2fe7-473f-b732-f66e69b03015", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b7067a06-e5fb-48fc-a7c9-317e3b2cccf4"}, {"Element": "<span lang=\"EN-GB\">PAC</span>", "ID": "17e4d20f-1a1c-456e-a6ec-7c3f6e257aa6", "Styles": "None", "Classes": "None", "Text": "PAC", "ParentId": "1c6213c4-2fe7-473f-b732-f66e69b03015"}, {"Element": "<b><span lang=\"EN-GB\">KAGING UNITS</span></b>", "ID": "4daa958e-8b7a-42fc-a8ac-2741f56afd7f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b7067a06-e5fb-48fc-a7c9-317e3b2cccf4"}, {"Element": "<span lang=\"EN-GB\">KAGING UNITS</span>", "ID": "a179d280-88de-4163-b590-3df81977742d", "Styles": "None", "Classes": "None", "Text": "KAGING UNITS", "ParentId": "4daa958e-8b7a-42fc-a8ac-2741f56afd7f"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9b567fc8-dd47-4b6b-9228-a2b3495b8de6", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2afc2b8b-c0d8-471f-82fb-ab246ee3e875"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5155545f-cef8-4a71-bc1d-8bbc438402af", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9b567fc8-dd47-4b6b-9228-a2b3495b8de6"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">VIAL\nLABEL</span></b></p>", "ID": "1450922a-3131-41b6-a1e7-4e9832f27153", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2afc2b8b-c0d8-471f-82fb-ab246ee3e875"}, {"Element": "<b><span lang=\"EN-GB\">VIAL\nLABEL</span></b>", "ID": "49dbb97a-5757-4502-bac9-c9468e42954d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1450922a-3131-41b6-a1e7-4e9832f27153"}, {"Element": "<span lang=\"EN-GB\">VIAL\nLABEL</span>", "ID": "82fecb2e-1aaa-4c16-a138-848e0bcc09f5", "Styles": "None", "Classes": "None", "Text": "VIAL LABEL", "ParentId": "49dbb97a-5757-4502-bac9-c9468e42954d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "20805b29-4ac5-4552-9571-a930046187a1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "283937cc-9199-481e-ab85-b4a4489f624d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "20805b29-4ac5-4552-9571-a930046187a1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "40100bad-27d8-498b-b053-709437d42bc2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ba907b82-b095-4122-81a4-58bae567e2af", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "40100bad-27d8-498b-b053-709437d42bc2"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>\n</div>", "ID": "8e89b5c0-4a55-4667-a2c3-23c86cc79485", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>", "ID": "8b9a006b-52b5-4895-9749-8bc53d148e09", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8e89b5c0-4a55-4667-a2c3-23c86cc79485"}, {"Element": "<b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b>", "ID": "572ab623-87e8-433f-a45b-9686d49f9a9c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8b9a006b-52b5-4895-9749-8bc53d148e09"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span>", "ID": "23abd985-b80c-42c6-b54f-f6a5be1c55e0", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION", "ParentId": "572ab623-87e8-433f-a45b-9686d49f9a9c"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8097df6b-a255-4c30-b1be-c3b5ab39e61a", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1ebb90df-c637-463f-8464-ec93a9db6ee8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8097df6b-a255-4c30-b1be-c3b5ab39e61a"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"IT\">Arzerra<i> </i></span><span lang=\"IT\" style=\"color:black\">100\u00a0mg sterile concentrate</span></p>", "ID": "8f460d06-5207-4fd5-a9e2-49b7348223ee", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"IT\">Arzerra<i> </i></span>", "ID": "5fbea08c-c560-49e4-be3b-fbc22519d823", "Styles": "None", "Classes": "None", "Text": "Arzerra", "ParentId": "8f460d06-5207-4fd5-a9e2-49b7348223ee"}, {"Element": "<i> </i>", "ID": "201eeed6-11e4-4277-96fe-42c4a6984df5", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "5fbea08c-c560-49e4-be3b-fbc22519d823"}, {"Element": "<span lang=\"IT\" style=\"color:black\">100\u00a0mg sterile concentrate</span>", "ID": "39d76015-e06e-40cd-9b7e-e61d8838c3c4", "Styles": "color:black", "Classes": "None", "Text": "100\u00a0mg sterile concentrate", "ParentId": "8f460d06-5207-4fd5-a9e2-49b7348223ee"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">ofatumumab</span></p>", "ID": "80157b33-491e-4799-80db-fa8bd3844bd3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"IT\">ofatumumab</span>", "ID": "f3cde9e0-ae0d-4ed9-b0cb-9dfc892f0c39", "Styles": "None", "Classes": "None", "Text": "ofatumumab", "ParentId": "80157b33-491e-4799-80db-fa8bd3844bd3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">IV</span></p>", "ID": "3170a015-5ce7-4e4e-8cd7-cb4611e2d13a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"IT\">IV</span>", "ID": "7ad9d841-79f9-406c-b1af-110aed7755b2", "Styles": "None", "Classes": "None", "Text": "IV", "ParentId": "3170a015-5ce7-4e4e-8cd7-cb4611e2d13a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>", "ID": "3731def5-3192-4875-8fb7-589f6164111a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "e1b84e12-80c5-466c-a14f-929cfa970c8c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3731def5-3192-4875-8fb7-589f6164111a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>", "ID": "b11edf12-c422-4f01-9cca-7807fd547dc2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "842750c4-5c2f-464f-b973-3f10394a6d3f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b11edf12-c422-4f01-9cca-7807fd547dc2"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nOF ADMINISTRATION</span></b></p>\n</div>", "ID": "df7b3e9a-67aa-4ad6-8df0-2a6a1634f60d", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nOF ADMINISTRATION</span></b></p>", "ID": "cc341236-676e-4167-811b-da610d52572e", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "df7b3e9a-67aa-4ad6-8df0-2a6a1634f60d"}, {"Element": "<b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nOF ADMINISTRATION</span></b>", "ID": "8bdd0fae-4bd1-4d54-9dcc-e2d4d8c368f9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cc341236-676e-4167-811b-da610d52572e"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nOF ADMINISTRATION</span>", "ID": "b18784cd-357d-4ada-9365-81a85a89388f", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD OF ADMINISTRATION", "ParentId": "8bdd0fae-4bd1-4d54-9dcc-e2d4d8c368f9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "eb601297-6eca-4ddd-b0f9-b00d08fffcdc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cf3b54cc-35a2-4eee-9164-666ad2238f8e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "eb601297-6eca-4ddd-b0f9-b00d08fffcdc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c0fb7cc7-225b-485d-af1d-913b328d6f14", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "be3a9bbc-da9d-463a-898b-7a8164473348", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c0fb7cc7-225b-485d-af1d-913b328d6f14"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b></p>\n</div>", "ID": "d2c058de-37e8-4f35-8171-ffc922cdc9e7", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b></p>", "ID": "f0a26144-4d1a-45ae-84ea-6881a29f6b9c", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d2c058de-37e8-4f35-8171-ffc922cdc9e7"}, {"Element": "<b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b>", "ID": "aed554b8-cf5a-4749-a572-b0d01ef3fa6a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f0a26144-4d1a-45ae-84ea-6881a29f6b9c"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span>", "ID": "f42a59af-ca9d-47d7-be86-ccb052b163d0", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE", "ParentId": "aed554b8-cf5a-4749-a572-b0d01ef3fa6a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "865d997c-dcd5-4447-a1f3-a73c76112c56", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c9f30c26-3da9-4d8e-adf7-2d0a3e12c79c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "865d997c-dcd5-4447-a1f3-a73c76112c56"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP</span></p>", "ID": "20619756-4bed-43b5-9aed-512afcc46654", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">EXP</span>", "ID": "96e4786d-8e89-484d-8428-7afaa771d237", "Styles": "None", "Classes": "None", "Text": "EXP", "ParentId": "20619756-4bed-43b5-9aed-512afcc46654"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ee4884bc-191a-4261-8014-386aea457301", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7f97b109-2c01-4ae3-8e6b-3272fc9e08d4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ee4884bc-191a-4261-8014-386aea457301"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "555bf279-0dcc-42b2-9982-62a810d1cefb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "93d89f9b-bd31-4cdb-8af3-713998757c70", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "555bf279-0dcc-42b2-9982-62a810d1cefb"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b></p>\n</div>", "ID": "8b7f03c0-413d-427a-bd7e-89839b0c92ef", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b></p>", "ID": "19dba177-cfd5-430c-8d94-0640fe25f5b2", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8b7f03c0-413d-427a-bd7e-89839b0c92ef"}, {"Element": "<b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b>", "ID": "1be6063b-fc98-4b22-8958-68f91a2bbd15", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "19dba177-cfd5-430c-8d94-0640fe25f5b2"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span>", "ID": "c37ded38-4168-4d7c-ae94-5e5fce638163", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER", "ParentId": "1be6063b-fc98-4b22-8958-68f91a2bbd15"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "496a5033-33a5-4270-a748-cd1eae783fdb", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3203f7ea-d134-4e83-87b6-635190f296ad", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "496a5033-33a5-4270-a748-cd1eae783fdb"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">Lot</span></p>", "ID": "f1c7ae0d-a1a7-4617-85a6-1b977765f08f", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Lot</span>", "ID": "8970cbc8-e7ac-4aed-bc8d-0d59054cdcdb", "Styles": "None", "Classes": "None", "Text": "Lot", "ParentId": "f1c7ae0d-a1a7-4617-85a6-1b977765f08f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "64417d4c-59ab-4a8d-beb3-900e986b494a", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "06eb1cb3-4e50-4f59-be49-b206d944fd55", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "64417d4c-59ab-4a8d-beb3-900e986b494a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e3f48dcc-64a3-4732-839d-ada6722ab903", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cae12376-2b97-4a98-a56e-011d514fccf3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e3f48dcc-64a3-4732-839d-ada6722ab903"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS\nBY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>\n</div>", "ID": "88c76d6c-feb6-4176-a358-b26ecb55ba61", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS\nBY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>", "ID": "8c1c6682-3390-4bb8-a092-56d91359e00a", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "88c76d6c-feb6-4176-a358-b26ecb55ba61"}, {"Element": "<b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS\nBY WEIGHT, BY VOLUME OR BY UNIT</span></b>", "ID": "a2dcaae0-7f27-499a-a590-3c089f0e528b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8c1c6682-3390-4bb8-a092-56d91359e00a"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS\nBY WEIGHT, BY VOLUME OR BY UNIT</span>", "ID": "b2f9822e-eed3-4917-8732-9fe972938b9e", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT", "ParentId": "a2dcaae0-7f27-499a-a590-3c089f0e528b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6b3cf1b1-3f38-44de-a152-db34e8c507b3", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6fdd4159-3f18-4da1-bed0-02a396bbb4bb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6b3cf1b1-3f38-44de-a152-db34e8c507b3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">100\u00a0mg/5\u00a0ml</span></p>", "ID": "e6562e90-2f4d-499a-bfea-ee1115527bdb", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">100\u00a0mg/5\u00a0ml</span>", "ID": "b04a5ae7-77b7-4ace-a97c-36c99886ea10", "Styles": "None", "Classes": "None", "Text": "100\u00a0mg/5\u00a0ml", "ParentId": "e6562e90-2f4d-499a-bfea-ee1115527bdb"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "630979c7-279a-4f65-973b-a2f607eddc7c", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1b8febc6-17d1-48da-9a6f-580655d23a6a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "630979c7-279a-4f65-973b-a2f607eddc7c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2eeb6ccd-8310-4059-91c5-b8e9e8352c0d", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ade235b8-48b2-4db7-9d68-b28a55c05171", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2eeb6ccd-8310-4059-91c5-b8e9e8352c0d"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</span></b></p>\n</div>", "ID": "28416371-4a73-4ccb-9903-b3e68628f869", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</span></b></p>", "ID": "e0f50d62-8893-4dfd-b515-1df3cb72192f", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "28416371-4a73-4ccb-9903-b3e68628f869"}, {"Element": "<b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</span></b>", "ID": "6c56dd22-b2ec-48dc-89eb-92cc18b35b6f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e0f50d62-8893-4dfd-b515-1df3cb72192f"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</span>", "ID": "7e98ba69-7a21-446e-92ce-d6fab52abafa", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER", "ParentId": "6c56dd22-b2ec-48dc-89eb-92cc18b35b6f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f9629966-83e9-4eb2-bf11-f819910866b3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "334f081f-5800-4d8f-8446-61949777d6cc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f9629966-83e9-4eb2-bf11-f819910866b3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "99afb6bd-ead9-4973-a7e4-87aac78ba3f4", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "10666e90-e3df-41d0-bd8f-b54c2e29e9bf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "99afb6bd-ead9-4973-a7e4-87aac78ba3f4"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "d5624220-f129-4f23-b5d9-58955629aeeb", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black", "Classes": "None", "Text": " ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "286e9999-acbc-467a-b302-bfcbee4af8cf", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "d5624220-f129-4f23-b5d9-58955629aeeb"}, {"Element": "<p class=\"MsoNormal\" style=\"background:white\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f4a08993-35a0-4a65-aa1f-e37d824b8f8d", "Styles": "background:white", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a3f75c28-ddd6-43d2-814e-680d04d26566", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f4a08993-35a0-4a65-aa1f-e37d824b8f8d"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">PARTICULARS\nTO APPEAR ON THE OUTER PACKAGING</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">CARTON</span></b></p>\n</div>", "ID": "f0c8522f-971f-4f4d-b5b6-80f1d038e87f", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "    ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">PARTICULARS\nTO APPEAR ON THE OUTER PACKAGING</span></b></p>", "ID": "753b844b-7970-486d-9b7d-9e1fe9a6c3c7", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f0c8522f-971f-4f4d-b5b6-80f1d038e87f"}, {"Element": "<b><span lang=\"EN-GB\">PARTICULARS\nTO APPEAR ON THE OUTER PACKAGING</span></b>", "ID": "814f75d7-1656-429d-ae13-fc26a4ac2f47", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "753b844b-7970-486d-9b7d-9e1fe9a6c3c7"}, {"Element": "<span lang=\"EN-GB\">PARTICULARS\nTO APPEAR ON THE OUTER PACKAGING</span>", "ID": "6412f441-3605-440a-984f-cdef03cf7d56", "Styles": "None", "Classes": "None", "Text": "PARTICULARS TO APPEAR ON THE OUTER PACKAGING", "ParentId": "814f75d7-1656-429d-ae13-fc26a4ac2f47"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "160f8f3b-08de-4a04-a502-62f2182ea5cf", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f0c8522f-971f-4f4d-b5b6-80f1d038e87f"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b600cb05-cfdf-45fb-bb06-48d81a1ed118", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "160f8f3b-08de-4a04-a502-62f2182ea5cf"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">CARTON</span></b></p>", "ID": "4f3c1de9-528c-4b2f-a6bb-832df1184e09", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f0c8522f-971f-4f4d-b5b6-80f1d038e87f"}, {"Element": "<b><span lang=\"EN-GB\">CARTON</span></b>", "ID": "19472fd3-433b-49f8-82ac-79e0d0f20e76", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4f3c1de9-528c-4b2f-a6bb-832df1184e09"}, {"Element": "<span lang=\"EN-GB\">CARTON</span>", "ID": "0cfed1bc-8557-43aa-8462-6c15516c38db", "Styles": "None", "Classes": "None", "Text": "CARTON", "ParentId": "19472fd3-433b-49f8-82ac-79e0d0f20e76"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0e512193-0bba-4d5c-921c-26c14dc291ab", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9f59c911-9977-4a08-a93e-66cef7b196c1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0e512193-0bba-4d5c-921c-26c14dc291ab"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "30595873-f7eb-42ce-bc6b-04e93427fb7f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "64cd5a0f-b17a-42cc-ae8a-9e58821c3949", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "30595873-f7eb-42ce-bc6b-04e93427fb7f"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT</span></b></p>\n</div>", "ID": "033ce79d-401f-4e6e-b1d1-8c03ea8863bb", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT</span></b></p>", "ID": "c4c9eedd-3f29-4c66-9a78-543d807a5faa", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "033ce79d-401f-4e6e-b1d1-8c03ea8863bb"}, {"Element": "<b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT</span></b>", "ID": "e140044a-952c-45d9-beb4-f81852a798e4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c4c9eedd-3f29-4c66-9a78-543d807a5faa"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT</span>", "ID": "cb8ece4b-f17b-45ed-a19b-a89220c752c1", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT", "ParentId": "e140044a-952c-45d9-beb4-f81852a798e4"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "069fa397-84d9-469f-8c2b-0e6b3e9171cf", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0783af30-2e4c-4101-9ca9-2e1c99cf9ac0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "069fa397-84d9-469f-8c2b-0e6b3e9171cf"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Arzerra </span><span lang=\"EN-GB\" style=\"color:black\">1000\u00a0mg concentrate for solution for\ninfusion</span></p>", "ID": "4d67e1f6-7504-41f6-a650-c59f8e812733", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Arzerra </span>", "ID": "e280290b-5070-41f8-b568-2c1ad18c375f", "Styles": "None", "Classes": "None", "Text": "Arzerra ", "ParentId": "4d67e1f6-7504-41f6-a650-c59f8e812733"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">1000\u00a0mg concentrate for solution for\ninfusion</span>", "ID": "46a3a9af-f5d0-4452-9bb9-6e5c400ffde2", "Styles": "color:black", "Classes": "None", "Text": "1000\u00a0mg concentrate for solution for infusion", "ParentId": "4d67e1f6-7504-41f6-a650-c59f8e812733"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">ofatumumab</span></p>", "ID": "f069012f-2ce1-4435-ada3-7c9b7714d944", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">ofatumumab</span>", "ID": "a9c64dda-d16e-41d2-853e-28e34bcea736", "Styles": "None", "Classes": "None", "Text": "ofatumumab", "ParentId": "f069012f-2ce1-4435-ada3-7c9b7714d944"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c02a9641-342a-494d-9cb1-771905d5b233", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8636e150-f5e4-408e-b2c1-ab9f5b9e48c9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c02a9641-342a-494d-9cb1-771905d5b233"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7f96ccf7-97f0-45fd-ab0d-7da71f576bf9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "169b8fd3-b67f-45bc-ae2b-4a7c036b3e2d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7f96ccf7-97f0-45fd-ab0d-7da71f576bf9"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>\n</div>", "ID": "eb274c5d-8538-4a10-8ddc-d6e84715db13", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>", "ID": "01415dd3-0723-46f4-b231-6c66353632eb", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "eb274c5d-8538-4a10-8ddc-d6e84715db13"}, {"Element": "<b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT OF ACTIVE SUBSTANCE(S)</span></b>", "ID": "8cc80546-0f60-4460-b62f-88a09630c01c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "01415dd3-0723-46f4-b231-6c66353632eb"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT OF ACTIVE SUBSTANCE(S)</span>", "ID": "34588122-fc0a-45ff-bacd-6cac3c8479a2", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT OF ACTIVE SUBSTANCE(S)", "ParentId": "8cc80546-0f60-4460-b62f-88a09630c01c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "d302851e-738e-4380-be48-42bc65afd5d3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "7ea2160b-d8b3-43ed-8464-1205785c53e0", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "d302851e-738e-4380-be48-42bc65afd5d3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">One ml contains\n20\u00a0mg ofatumumab.</span></p>", "ID": "80c7767e-bba9-4412-8214-26a42c3248b9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">One ml contains\n20\u00a0mg ofatumumab.</span>", "ID": "f38e6d04-e8e7-4cd9-9390-dbc8e9fdc98a", "Styles": "color:black", "Classes": "None", "Text": "One ml contains 20\u00a0mg ofatumumab.", "ParentId": "80c7767e-bba9-4412-8214-26a42c3248b9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each vial contains\n1000\u00a0mg ofatumumab in 50\u00a0ml.</span></p>", "ID": "9c9f4f9e-007e-4f4e-b6c3-01111aba31e6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Each vial contains\n1000\u00a0mg ofatumumab in 50\u00a0ml.</span>", "ID": "ac0ece7c-4ba6-4216-83f8-33ccb66b7b3e", "Styles": "color:black", "Classes": "None", "Text": "Each vial contains 1000\u00a0mg ofatumumab in 50\u00a0ml.", "ParentId": "9c9f4f9e-007e-4f4e-b6c3-01111aba31e6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2da661dc-0c22-4615-8d1c-37c009e4269d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "184ab649-33d9-4470-bc4e-a7093239b17a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2da661dc-0c22-4615-8d1c-37c009e4269d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "28d21c22-b1ca-4365-842a-2d83bfcc37dd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7ffb3aa8-6a42-413c-a413-54c6be509463", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "28d21c22-b1ca-4365-842a-2d83bfcc37dd"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST OF EXCIPIENTS</span></b></p>\n</div>", "ID": "50a0f660-9565-4c89-87e4-3dbda8f63b3f", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST OF EXCIPIENTS</span></b></p>", "ID": "91025bbc-43ab-4499-9348-0c738315382d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "50a0f660-9565-4c89-87e4-3dbda8f63b3f"}, {"Element": "<b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST OF EXCIPIENTS</span></b>", "ID": "3b42e42a-b872-4b6e-986e-0c366d052166", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "91025bbc-43ab-4499-9348-0c738315382d"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST OF EXCIPIENTS</span>", "ID": "888cf058-c75f-4e5a-8168-f0ea3f6de8be", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST OF EXCIPIENTS", "ParentId": "3b42e42a-b872-4b6e-986e-0c366d052166"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "f6dfaced-feb9-4acc-97ab-49e3e077513b", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "3f2ccec5-ed8b-4b9a-961a-516cc138dc50", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "f6dfaced-feb9-4acc-97ab-49e3e077513b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT\" style=\"color:black\">Also contains: arginine,\nsodium acetate (E262), </span><span lang=\"EN-GB\" style=\"color:black\">sodium chloride</span><span lang=\"PT\" style=\"color:black\">, polysorbate 80 (E433), edetate disodium (E386),\nhydrochloric acid (E507), </span><span lang=\"EN-GB\" style=\"color:black\">water for\ninjections. See leaflet for further information.</span></p>", "ID": "2485a9c7-c3b1-4b37-8c49-00c602632ad6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"PT\" style=\"color:black\">Also contains: arginine,\nsodium acetate (E262), </span>", "ID": "25041e33-cb24-4bb9-9874-aa0d590489c3", "Styles": "color:black", "Classes": "None", "Text": "Also contains: arginine, sodium acetate (E262), ", "ParentId": "2485a9c7-c3b1-4b37-8c49-00c602632ad6"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">sodium chloride</span>", "ID": "70132d7c-7a48-4b18-9865-2315af4f7b10", "Styles": "color:black", "Classes": "None", "Text": "sodium chloride", "ParentId": "2485a9c7-c3b1-4b37-8c49-00c602632ad6"}, {"Element": "<span lang=\"PT\" style=\"color:black\">, polysorbate 80 (E433), edetate disodium (E386),\nhydrochloric acid (E507), </span>", "ID": "bfa77ede-0472-4000-92bd-b22537521a53", "Styles": "color:black", "Classes": "None", "Text": ", polysorbate 80 (E433), edetate disodium (E386), hydrochloric acid (E507), ", "ParentId": "2485a9c7-c3b1-4b37-8c49-00c602632ad6"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">water for\ninjections. See leaflet for further information.</span>", "ID": "31f185c9-ff4f-46a4-843e-250693f6aa6a", "Styles": "color:black", "Classes": "None", "Text": "water for injections. See leaflet for further information.", "ParentId": "2485a9c7-c3b1-4b37-8c49-00c602632ad6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1933458f-8281-48b8-9a96-a05b4a003a53", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "097d29ba-9264-4ffd-bedc-2be628dbe5ae", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1933458f-8281-48b8-9a96-a05b4a003a53"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b71bdb33-f03b-4030-b879-8c5d073487d7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "68c68958-20ad-4d38-bd77-bf12097596e2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b71bdb33-f03b-4030-b879-8c5d073487d7"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM\n AND CONTENTS</span></b></p>\n</div>", "ID": "0b2ca619-7763-4072-b934-8b977c2438be", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM\n AND CONTENTS</span></b></p>", "ID": "91408d80-7f15-444c-8f10-f6d3ce9ad840", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0b2ca619-7763-4072-b934-8b977c2438be"}, {"Element": "<b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM\n AND CONTENTS</span></b>", "ID": "f9af34dd-493c-4fa9-a0a6-afb6f82eeeaf", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "91408d80-7f15-444c-8f10-f6d3ce9ad840"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM\n AND CONTENTS</span>", "ID": "e6065f90-fc9a-4ed1-a42b-44c3b70f81c2", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM  AND CONTENTS", "ParentId": "f9af34dd-493c-4fa9-a0a6-afb6f82eeeaf"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cb32d242-7edf-4cb4-8014-6c1552c7596c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fcff57ee-b616-4bf4-a12e-355e0225ca6c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cb32d242-7edf-4cb4-8014-6c1552c7596c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">Concentrate\nfor solution for infusion.</span></p>", "ID": "980af772-43fb-44f1-ada6-79c9a5d4a8b0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">Concentrate\nfor solution for infusion.</span>", "ID": "f648e3ef-c020-4a0f-ad0d-9794d7692338", "Styles": "color:black;background:#D9D9D9", "Classes": "None", "Text": "Concentrate for solution for infusion.", "ParentId": "980af772-43fb-44f1-ada6-79c9a5d4a8b0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e649f35e-3cf2-44cd-b1f6-23c23ec3838d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8741bb53-7b06-49ff-b5a2-5e495fc2667b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e649f35e-3cf2-44cd-b1f6-23c23ec3838d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"SV\">1000\u00a0mg/50\u00a0ml</span></p>", "ID": "75385c44-b791-452c-820f-3cf8668b3779", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"SV\">1000\u00a0mg/50\u00a0ml</span>", "ID": "d75e6596-403f-4ed7-a8cd-a2f1807253db", "Styles": "None", "Classes": "None", "Text": "1000\u00a0mg/50\u00a0ml", "ParentId": "75385c44-b791-452c-820f-3cf8668b3779"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"SV\">\u00a0</span></p>", "ID": "daac2098-e2fc-472f-be53-7d59f95beb12", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"SV\">\u00a0</span>", "ID": "33362b26-93f2-484f-9109-95b7d5f4eba6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "daac2098-e2fc-472f-be53-7d59f95beb12"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"SV\">1\u00a0vial</span></p>", "ID": "8d4d0d70-f002-427c-a8c8-7ec97d976dbf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"SV\">1\u00a0vial</span>", "ID": "3cabec16-dc10-40b9-b269-d74822062101", "Styles": "None", "Classes": "None", "Text": "1\u00a0vial", "ParentId": "8d4d0d70-f002-427c-a8c8-7ec97d976dbf"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"SV\">\u00a0</span></p>", "ID": "0c3f6e89-56b5-48c4-9e93-df0e421b306e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"SV\">\u00a0</span>", "ID": "d84bd8db-0ddc-4440-a835-087abe03e00a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0c3f6e89-56b5-48c4-9e93-df0e421b306e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"SV\">\u00a0</span></p>", "ID": "e6bb9ac5-2c98-4d0f-9d42-461ac88eddee", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"SV\">\u00a0</span>", "ID": "97954ad7-7cd6-4def-a667-2bf816fc18f2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e6bb9ac5-2c98-4d0f-9d42-461ac88eddee"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>\n</div>", "ID": "444243ce-2688-49ec-9e79-3b65e7931356", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>", "ID": "53b2a996-3cbc-4f42-9f51-2c323b861506", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "444243ce-2688-49ec-9e79-3b65e7931356"}, {"Element": "<b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD AND ROUTE(S) OF ADMINISTRATION</span></b>", "ID": "9e615c36-1a8e-421f-b5d8-577c17289262", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "53b2a996-3cbc-4f42-9f51-2c323b861506"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD AND ROUTE(S) OF ADMINISTRATION</span>", "ID": "aab7f43b-9c0e-444c-a442-109eee96927b", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD AND ROUTE(S) OF ADMINISTRATION", "ParentId": "9e615c36-1a8e-421f-b5d8-577c17289262"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f5707cbb-5911-4d22-a7c8-ec5a55902244", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "46d43285-f36e-4499-b1ff-399a4a251222", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f5707cbb-5911-4d22-a7c8-ec5a55902244"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Read the package leaflet before use.</span></p>", "ID": "44088057-ff6e-4457-9c71-ebe87e740f80", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Read the package leaflet before use.</span>", "ID": "0ef77b97-4c73-4a51-ad24-2520830a639b", "Styles": "None", "Classes": "None", "Text": "Read the package leaflet before use.", "ParentId": "44088057-ff6e-4457-9c71-ebe87e740f80"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Intravenous use</span></p>", "ID": "b093fc4f-3946-401d-be3d-32227f8a2a40", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Intravenous use</span>", "ID": "1bd42d5d-c04a-4ca7-b3a3-6462165da3ab", "Styles": "None", "Classes": "None", "Text": "Intravenous use", "ParentId": "b093fc4f-3946-401d-be3d-32227f8a2a40"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f9d5d274-6b81-4688-a0eb-60448382bab8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1daed4cf-5b9a-4b87-9937-069abdeef0a9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f9d5d274-6b81-4688-a0eb-60448382bab8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "85a42f4f-db0e-4c1b-8deb-92f4ad00e0a1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fe8934e8-6163-4c9f-84f6-dd6bf7f717e2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "85a42f4f-db0e-4c1b-8deb-92f4ad00e0a1"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL WARNING THAT THE MEDICINAL\nPRODUCT MUST BE STORED OUT OF THE <span style=\"text-transform:uppercase\">sight\nand</span> REACH OF CHILDREN</span></b></p>\n</div>", "ID": "6e05f056-291b-4f9b-9629-73d5d12ef24e", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL WARNING THAT THE MEDICINAL\nPRODUCT MUST BE STORED OUT OF THE <span style=\"text-transform:uppercase\">sight\nand</span> REACH OF CHILDREN</span></b></p>", "ID": "61fff0aa-b9cc-4c7b-ba90-ab13039869cf", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6e05f056-291b-4f9b-9629-73d5d12ef24e"}, {"Element": "<b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL WARNING THAT THE MEDICINAL\nPRODUCT MUST BE STORED OUT OF THE <span style=\"text-transform:uppercase\">sight\nand</span> REACH OF CHILDREN</span></b>", "ID": "853b734d-aac9-427d-924d-74fe87e2219a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "61fff0aa-b9cc-4c7b-ba90-ab13039869cf"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL WARNING THAT THE MEDICINAL\nPRODUCT MUST BE STORED OUT OF THE <span style=\"text-transform:uppercase\">sight\nand</span> REACH OF CHILDREN</span>", "ID": "9eaf14f5-a5ac-4e85-89b2-14bf8c512eb8", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE  REACH OF CHILDREN", "ParentId": "853b734d-aac9-427d-924d-74fe87e2219a"}, {"Element": "<span style=\"text-transform:uppercase\">sight\nand</span>", "ID": "2e812148-465b-4aa4-8352-aca7c744daca", "Styles": "text-transform:uppercase", "Classes": "None", "Text": "sight and", "ParentId": "9eaf14f5-a5ac-4e85-89b2-14bf8c512eb8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d22282f7-46e3-4cdb-b102-1112bf2a2a7a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d568b9d6-9638-4cdd-8752-1961c4f985b8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d22282f7-46e3-4cdb-b102-1112bf2a2a7a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep out of the sight and reach of\nchildren.</span></p>", "ID": "bca6589b-88a4-4028-a17e-3870c8fa379f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Keep out of the sight and reach of\nchildren.</span>", "ID": "c27372a0-fbe1-42c3-aba1-898326f3a5ad", "Styles": "None", "Classes": "None", "Text": "Keep out of the sight and reach of children.", "ParentId": "bca6589b-88a4-4028-a17e-3870c8fa379f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "233c313e-2b70-4b45-a312-11917c606f94", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "536123e1-8f9b-4794-ba78-4b7e583eac2d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "233c313e-2b70-4b45-a312-11917c606f94"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bc28fb9c-03af-465f-9b64-360473d14b08", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a4b5a7f2-332f-4418-948c-abc95d88153f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bc28fb9c-03af-465f-9b64-360473d14b08"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER SPECIAL WARNING(S), IF\nNECESSARY</span></b></p>\n</div>", "ID": "6eaca898-9730-4d14-a794-29ad5c9b8e4f", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER SPECIAL WARNING(S), IF\nNECESSARY</span></b></p>", "ID": "416d6927-3fb3-47dc-91cf-5c1a34d35fc2", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6eaca898-9730-4d14-a794-29ad5c9b8e4f"}, {"Element": "<b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER SPECIAL WARNING(S), IF\nNECESSARY</span></b>", "ID": "57733d1b-71ba-4169-8196-eb4d11e538be", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "416d6927-3fb3-47dc-91cf-5c1a34d35fc2"}, {"Element": "<span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER SPECIAL WARNING(S), IF\nNECESSARY</span>", "ID": "92541861-3a24-4bf1-bb44-66208a4cf36e", "Styles": "None", "Classes": "None", "Text": "7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER SPECIAL WARNING(S), IF NECESSARY", "ParentId": "57733d1b-71ba-4169-8196-eb4d11e538be"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "af210536-16ac-4245-98a8-e3b9b7ddf036", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "72cc8068-3c54-424a-a555-0da2b096b394", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "af210536-16ac-4245-98a8-e3b9b7ddf036"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b4ed0fc7-ef6c-4c3d-9d57-a1f875da29ec", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5a0c98ae-5064-4d7e-9471-2c12019502c9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b4ed0fc7-ef6c-4c3d-9d57-a1f875da29ec"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE</span></b></p>\n</div>", "ID": "3c263bfb-85b5-4122-8696-918f3cbb5692", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE</span></b></p>", "ID": "7244e431-c37f-47fe-96e2-1636959c0d8d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3c263bfb-85b5-4122-8696-918f3cbb5692"}, {"Element": "<b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE</span></b>", "ID": "b99d8940-3dbc-491d-ac50-d81fa0d992b7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7244e431-c37f-47fe-96e2-1636959c0d8d"}, {"Element": "<span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE</span>", "ID": "98b6a43d-e95c-424e-a7a0-d85a8f2b1fb3", "Styles": "None", "Classes": "None", "Text": "8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE", "ParentId": "b99d8940-3dbc-491d-ac50-d81fa0d992b7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f3b52a21-6dd5-4a4f-8c64-b195181846e5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "033918eb-bf35-4031-ae72-fe4b2fb9c54d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f3b52a21-6dd5-4a4f-8c64-b195181846e5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP</span></p>", "ID": "0702615a-252b-4b2e-8f2d-9bfba0df6ab5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">EXP</span>", "ID": "07d0689c-91a0-4bd9-8120-a56e0cd5db9c", "Styles": "None", "Classes": "None", "Text": "EXP", "ParentId": "0702615a-252b-4b2e-8f2d-9bfba0df6ab5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6aa70a76-4678-4c6e-b86f-d2b93410e749", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f7b2d724-81f3-467d-9883-698aa05fd296", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6aa70a76-4678-4c6e-b86f-d2b93410e749"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "22a7cec7-c3f5-4623-8466-e3168f4014a3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0f950907-4630-498f-b747-c653810dfe27", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "22a7cec7-c3f5-4623-8466-e3168f4014a3"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE\nCONDITIONS</span></b></p>\n</div>", "ID": "0a90e4f8-01a1-4003-b0a0-3ca1e8dddaa2", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE\nCONDITIONS</span></b></p>", "ID": "5cd16a78-0548-4565-81e7-7d15ce0b3ed9", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0a90e4f8-01a1-4003-b0a0-3ca1e8dddaa2"}, {"Element": "<b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE\nCONDITIONS</span></b>", "ID": "19a274df-4e62-4ef6-8de3-987a12587cec", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5cd16a78-0548-4565-81e7-7d15ce0b3ed9"}, {"Element": "<span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE\nCONDITIONS</span>", "ID": "0e7cdb45-081f-4a7b-b91c-94dbb948d946", "Styles": "None", "Classes": "None", "Text": "9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE CONDITIONS", "ParentId": "19a274df-4e62-4ef6-8de3-987a12587cec"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "97a94a16-80fa-4a6d-b5f0-65dee5c4ae72", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "02b16185-c07a-48b7-868d-4a947b2306a4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "97a94a16-80fa-4a6d-b5f0-65dee5c4ae72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Store and\ntransport refrigerated.</span></p>", "ID": "e60014b5-43be-48fd-824e-136fc39cbe08", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Store and\ntransport refrigerated.</span>", "ID": "b4c17aa6-175a-4d19-8d69-a1ae72b1d2ec", "Styles": "None", "Classes": "None", "Text": "Store and transport refrigerated.", "ParentId": "e60014b5-43be-48fd-824e-136fc39cbe08"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Do not\nfreeze.</span></p>", "ID": "f0168200-64b0-477f-9459-3e4c30995d75", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Do not\nfreeze.</span>", "ID": "fe6ce234-a6d1-4dc6-a4cb-b8b9ea4ee1ea", "Styles": "None", "Classes": "None", "Text": "Do not freeze.", "ParentId": "f0168200-64b0-477f-9459-3e4c30995d75"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep the vial in the outer carton in order\nto protect from light.</span></p>", "ID": "cacd3104-61fb-496e-8c99-cc56d10ed369", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Keep the vial in the outer carton in order\nto protect from light.</span>", "ID": "61dcfb6a-4f68-4049-9f8e-207f28cff4e2", "Styles": "None", "Classes": "None", "Text": "Keep the vial in the outer carton in order to protect from light.", "ParentId": "cacd3104-61fb-496e-8c99-cc56d10ed369"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e8c6f92e-9add-4d41-99ec-964b4e0c5d55", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a485b237-c5b0-45eb-9277-a57d51c1f920", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e8c6f92e-9add-4d41-99ec-964b4e0c5d55"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a19ea902-6876-42ee-b833-9d034f686512", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "508b0e14-5bd9-4327-80f2-fcb91ec0c87a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a19ea902-6876-42ee-b833-9d034f686512"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS FOR DISPOSAL OF\nUNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL\nPRODUCTS, IF APPROPRIATE</span></b></p>\n</div>", "ID": "88cbe019-3903-4023-b9ce-5738d8fad42b", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS FOR DISPOSAL OF\nUNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL\nPRODUCTS, IF APPROPRIATE</span></b></p>", "ID": "d2bab4d1-4fa7-41f2-89a1-9b92aa7de20f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "88cbe019-3903-4023-b9ce-5738d8fad42b"}, {"Element": "<b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS FOR DISPOSAL OF\nUNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL\nPRODUCTS, IF APPROPRIATE</span></b>", "ID": "71d23aa8-5d89-4887-9f6c-a5c732d92dbd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d2bab4d1-4fa7-41f2-89a1-9b92aa7de20f"}, {"Element": "<span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS FOR DISPOSAL OF\nUNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL\nPRODUCTS, IF APPROPRIATE</span>", "ID": "f712cf69-44a4-4746-a641-99e1e62f860c", "Styles": "None", "Classes": "None", "Text": "10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE", "ParentId": "71d23aa8-5d89-4887-9f6c-a5c732d92dbd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2bf72210-5682-45a0-9636-f67f636b81f1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7db534d7-c28c-4d31-a49d-08723b64d458", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2bf72210-5682-45a0-9636-f67f636b81f1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a5c4a86f-8cb2-42da-9e38-0879e75aa62b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "780946e5-1304-451b-80c0-8d6c735ce679", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a5c4a86f-8cb2-42da-9e38-0879e75aa62b"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0 NAME\n AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>\n</div>", "ID": "eccea598-5eac-4e54-ae0e-bd5707a2594c", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0 NAME\n AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>", "ID": "20901580-7dfa-4403-8acb-428bc20d148c", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "eccea598-5eac-4e54-ae0e-bd5707a2594c"}, {"Element": "<b><span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0 NAME\n AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b>", "ID": "f4a3f926-25db-479a-b083-d82dd0880194", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "20901580-7dfa-4403-8acb-428bc20d148c"}, {"Element": "<span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0 NAME\n AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span>", "ID": "3de6bd7c-a43f-4d6d-889a-f28c0f007845", "Styles": "None", "Classes": "None", "Text": "11.\u00a0\u00a0\u00a0\u00a0 NAME  AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER", "ParentId": "f4a3f926-25db-479a-b083-d82dd0880194"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "3548c1f7-2b7f-4ad3-bfbc-afd83ab53e4b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "4f7a7156-d1ce-49e6-9692-5f77847f94b0", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "3548c1f7-2b7f-4ad3-bfbc-afd83ab53e4b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Novartis Europharm Limited</span></p>", "ID": "377da6b1-6680-47cf-bc52-ff36524ae563", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Novartis Europharm Limited</span>", "ID": "fc910e37-0b52-42b9-8401-ad7ff8901a04", "Styles": "None", "Classes": "None", "Text": "Novartis Europharm Limited", "ParentId": "377da6b1-6680-47cf-bc52-ff36524ae563"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Frimley Business Park</span></p>", "ID": "9913ac7a-d890-47e4-bfdb-5521e2b4d9a8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Frimley Business Park</span>", "ID": "a7a32c26-6b9c-4c1f-9cab-40de468ad538", "Styles": "None", "Classes": "None", "Text": "Frimley Business Park", "ParentId": "9913ac7a-d890-47e4-bfdb-5521e2b4d9a8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Camberley GU16 7SR</span></p>", "ID": "af91fc64-ac0b-43aa-8b22-e1a7a7ceecf8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Camberley GU16 7SR</span>", "ID": "01f7b0e7-cf81-4897-993c-fb28226f1134", "Styles": "None", "Classes": "None", "Text": "Camberley GU16 7SR", "ParentId": "af91fc64-ac0b-43aa-8b22-e1a7a7ceecf8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">United Kingdom</span></p>", "ID": "945298b3-5c1d-4cd1-9dad-9a06b4cc41e4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">United Kingdom</span>", "ID": "7e70e97c-bbd5-4547-a005-ce8f76336527", "Styles": "color:black", "Classes": "None", "Text": "United Kingdom", "ParentId": "945298b3-5c1d-4cd1-9dad-9a06b4cc41e4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "03962374-d843-4514-abb9-cd9ea23e0e06", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "87341686-baae-4c5b-90aa-12409bbc09cb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "03962374-d843-4514-abb9-cd9ea23e0e06"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "55bc09b0-5906-4b62-9b81-13eb359049ff", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9ea0cf96-56e9-44cd-b3e4-0fc862ccf300", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "55bc09b0-5906-4b62-9b81-13eb359049ff"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span></b></p>\n</div>", "ID": "a157e08f-7d46-4150-9f71-92c80159c98a", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span></b></p>", "ID": "3bcd000a-697f-443f-82a0-98eec394d71f", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a157e08f-7d46-4150-9f71-92c80159c98a"}, {"Element": "<b><span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span></b>", "ID": "5c2bddde-021a-40db-8690-76ba2817888d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3bcd000a-697f-443f-82a0-98eec394d71f"}, {"Element": "<span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span>", "ID": "e7915431-2e67-4ed7-ae6c-7c19c0835e6b", "Styles": "None", "Classes": "None", "Text": "12.\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION NUMBER(S)", "ParentId": "5c2bddde-021a-40db-8690-76ba2817888d"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "370d2067-0f29-48e8-8abc-1c108401eef8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">EU/<span lang=\"EN-GB\">1/10/625/003</span></p>", "ID": "d4ab08b2-a0f3-4038-a844-e7c04e8b0df3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "EU/", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">1/10/625/003</span>", "ID": "1ef2130d-6865-4314-8647-597ece54c0a6", "Styles": "None", "Classes": "None", "Text": "1/10/625/003", "ParentId": "d4ab08b2-a0f3-4038-a844-e7c04e8b0df3"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "d4fc7c24-c1c2-4dee-95cb-530aca45fcd1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "78688787-50a5-4b27-92c0-4d98dd6e2717", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b></p>\n</div>", "ID": "72c52a4c-bc1d-425f-9332-96704f2dcc6d", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b></p>", "ID": "e7fced40-a7bf-48e8-a35c-db3b2947d160", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "72c52a4c-bc1d-425f-9332-96704f2dcc6d"}, {"Element": "<b><span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b>", "ID": "1f4626ac-4981-4493-9345-b754d7156fa9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e7fced40-a7bf-48e8-a35c-db3b2947d160"}, {"Element": "<span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span>", "ID": "0da8248f-5cb8-4e62-9377-a2b20decaae4", "Styles": "None", "Classes": "None", "Text": "13.\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER", "ParentId": "1f4626ac-4981-4493-9345-b754d7156fa9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e3240ce1-8d8f-4191-bb9e-08be484b6c95", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "437dc595-a584-44c4-abb7-04db99d6ceb6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e3240ce1-8d8f-4191-bb9e-08be484b6c95"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Lot</span></p>", "ID": "9156951d-b7e4-4bd3-97f1-ea657f27d0c3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Lot</span>", "ID": "eeda4f10-4d69-49c9-bb0b-83c27d3a1c29", "Styles": "None", "Classes": "None", "Text": "Lot", "ParentId": "9156951d-b7e4-4bd3-97f1-ea657f27d0c3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "33064b16-bc3e-4432-a912-acd955ab1182", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d6d5e08a-6184-42fa-a445-d4c68e431759", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "33064b16-bc3e-4432-a912-acd955ab1182"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c795d7b0-ddef-4d35-a5d9-fbcccd6ad2cb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "85bdd195-61b4-4548-814f-acb4da020df1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c795d7b0-ddef-4d35-a5d9-fbcccd6ad2cb"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>\n</div>", "ID": "57a4dd9f-90d7-4042-a7d8-f4c021d94250", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>", "ID": "da595c9a-de33-404f-b749-a0ea9558bcf4", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "57a4dd9f-90d7-4042-a7d8-f4c021d94250"}, {"Element": "<b><span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL CLASSIFICATION FOR SUPPLY</span></b>", "ID": "89924e33-ba62-4346-8236-09fe84b8959b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "da595c9a-de33-404f-b749-a0ea9558bcf4"}, {"Element": "<span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL CLASSIFICATION FOR SUPPLY</span>", "ID": "6842b6a7-7bf8-474b-89d8-365aa4fff332", "Styles": "None", "Classes": "None", "Text": "14.\u00a0\u00a0\u00a0\u00a0 GENERAL CLASSIFICATION FOR SUPPLY", "ParentId": "89924e33-ba62-4346-8236-09fe84b8959b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a0ed32e4-d0b6-42b7-ae0a-c391ebc9dd1b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4ef03a93-3580-4e91-acb7-c0035db4f107", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a0ed32e4-d0b6-42b7-ae0a-c391ebc9dd1b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "93955700-59c5-4996-af3c-559d748b169a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "726fc123-5993-4bda-bb2e-7245b7a1b827", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "93955700-59c5-4996-af3c-559d748b169a"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span></b></p>\n</div>", "ID": "b7a86c64-9459-4192-aa31-eb35b10a875f", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span></b></p>", "ID": "f74fc8c3-63f7-4504-ac9f-aabec5f542aa", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b7a86c64-9459-4192-aa31-eb35b10a875f"}, {"Element": "<b><span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span></b>", "ID": "827ad2b2-363a-4742-8b32-2826e1012b2f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f74fc8c3-63f7-4504-ac9f-aabec5f542aa"}, {"Element": "<span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span>", "ID": "23f3f71a-9ce5-49a7-a0bd-fe295f5194ee", "Styles": "None", "Classes": "None", "Text": "15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS ON USE", "ParentId": "827ad2b2-363a-4742-8b32-2826e1012b2f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ba807137-ac1f-4f27-a062-27f24704ebb0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c72dbb6c-93ee-43d1-9b5a-12ee25bbf735", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ba807137-ac1f-4f27-a062-27f24704ebb0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "547ca2ef-1149-4aba-9ebc-afe31b282f92", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2e6f4fa9-30d5-40a6-9982-6c97929189b0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "547ca2ef-1149-4aba-9ebc-afe31b282f92"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION\nIN BRAILLE</span></b></p>\n</div>", "ID": "327f9ab2-ec8e-405e-b02d-4fbe9b8f319b", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION\nIN BRAILLE</span></b></p>", "ID": "e9e39680-cfd1-45b5-9e4a-372f3de9fd6f", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "327f9ab2-ec8e-405e-b02d-4fbe9b8f319b"}, {"Element": "<b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION\nIN BRAILLE</span></b>", "ID": "8341c899-1d71-47bc-afc4-0525ebd9371e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e9e39680-cfd1-45b5-9e4a-372f3de9fd6f"}, {"Element": "<span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION\nIN BRAILLE</span>", "ID": "4a83701d-176e-4573-a141-a0691811fccf", "Styles": "None", "Classes": "None", "Text": "16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN BRAILLE", "ParentId": "8341c899-1d71-47bc-afc4-0525ebd9371e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "27ad27b3-7d37-4634-ae02-920278a1195b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "35d829dd-627c-425b-addb-25a92ac34463", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "27ad27b3-7d37-4634-ae02-920278a1195b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black;background:#CCCCCC\">Justification\nfor not including Braille accepted</span></p>", "ID": "1c50b44b-a58c-4593-ae2b-87b91e4c94c4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;background:#CCCCCC\">Justification\nfor not including Braille accepted</span>", "ID": "5d5a768c-94d3-4bc2-9a18-649964980280", "Styles": "color:black;background:#CCCCCC", "Classes": "None", "Text": "Justification for not including Braille accepted", "ParentId": "1c50b44b-a58c-4593-ae2b-87b91e4c94c4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "85f36daa-ffd0-4720-8291-7e8f95db481b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "84ea44c2-8d31-4beb-99df-045237252f19", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "85f36daa-ffd0-4720-8291-7e8f95db481b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "20cad53a-f90a-49a4-b65f-d806498e5ced", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9460ed9c-27d7-459e-ba59-956e011137a6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "20cad53a-f90a-49a4-b65f-d806498e5ced"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE</span></b></p>\n</div>", "ID": "ffc48e1f-b268-4886-a1fb-a88a0635924d", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE</span></b></p>", "ID": "bf077812-8262-478c-a9ed-8b8a0d4555c4", "Styles": "page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ffc48e1f-b268-4886-a1fb-a88a0635924d"}, {"Element": "<b><span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE</span></b>", "ID": "ec57a887-f13e-427e-a8a0-fa0338893095", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bf077812-8262-478c-a9ed-8b8a0d4555c4"}, {"Element": "<span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE</span>", "ID": "bf3a1ff9-5a5c-4bba-a4f1-edc6ed4ee31a", "Styles": "None", "Classes": "None", "Text": "17.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE", "ParentId": "ec57a887-f13e-427e-a8a0-fa0338893095"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "caed1cf5-6836-443b-bb9d-ab8f6e24ab05", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5abbc74d-ae45-46fc-a84c-9cedfef9a6f1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "caed1cf5-6836-443b-bb9d-ab8f6e24ab05"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">2D\nbarcode carrying the unique identifier included.</span></p>", "ID": "4da03695-5660-4777-91e7-6fb604b58989", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">2D\nbarcode carrying the unique identifier included.</span>", "ID": "5db53ec3-e852-40b2-a215-25658c3dc4cf", "Styles": "color:black;background:#D9D9D9", "Classes": "None", "Text": "2D barcode carrying the unique identifier included.", "ParentId": "4da03695-5660-4777-91e7-6fb604b58989"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "32ebba1f-24ff-4ae1-80c1-97ef486f8691", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6bec85c2-4bc1-4565-a73c-525bf794cc7d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "32ebba1f-24ff-4ae1-80c1-97ef486f8691"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1e359d9f-ae85-4cac-bd6a-b141e268022d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "20808d07-fc26-4132-9cca-1c6872958979", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1e359d9f-ae85-4cac-bd6a-b141e268022d"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>\n</div>", "ID": "f566d1e8-8d86-4ee8-a592-d3e4c9193922", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>", "ID": "21a05676-cd62-4539-af36-e761a081eeaa", "Styles": "page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f566d1e8-8d86-4ee8-a592-d3e4c9193922"}, {"Element": "<b><span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b>", "ID": "97a135f0-d038-4a2e-9a04-07aa7f264278", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "21a05676-cd62-4539-af36-e761a081eeaa"}, {"Element": "<span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER - HUMAN READABLE DATA</span>", "ID": "0d8584d9-0570-4359-8b9f-10372bc81b01", "Styles": "None", "Classes": "None", "Text": "18.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER - HUMAN READABLE DATA", "ParentId": "97a135f0-d038-4a2e-9a04-07aa7f264278"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3bc47521-42b9-4ced-9e2f-1e563487cb61", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4b32cb26-ca74-4aac-964e-482767997318", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3bc47521-42b9-4ced-9e2f-1e563487cb61"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">PC:</span></p>", "ID": "12d0528d-ef19-4fef-bcb1-b380139ecdd3", "Styles": "line-height:13.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">PC:</span>", "ID": "4a054b8c-bfd9-490c-8764-58e9141188c1", "Styles": "None", "Classes": "None", "Text": "PC:", "ParentId": "12d0528d-ef19-4fef-bcb1-b380139ecdd3"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">SN:</span></p>", "ID": "a2e103d4-db64-4cb0-bb1d-7d627699cb4d", "Styles": "line-height:13.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">SN:</span>", "ID": "43674949-a280-4056-afad-34d8112eb236", "Styles": "None", "Classes": "None", "Text": "SN:", "ParentId": "a2e103d4-db64-4cb0-bb1d-7d627699cb4d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><span lang=\"EN-GB\">NN:</span></p>", "ID": "568821e2-a7d4-4933-b1b8-ffd340a3c1fc", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">NN:</span>", "ID": "043bf0c5-7339-49cc-80fb-207c7230936c", "Styles": "None", "Classes": "None", "Text": "NN:", "ParentId": "568821e2-a7d4-4933-b1b8-ffd340a3c1fc"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black;background:#CCCCCC'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "23dd86c9-1050-422e-81c5-0f805f0afa17", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black;background:#CCCCCC", "Classes": "None", "Text": " ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "9c8ab33a-55d2-49dd-8f2c-dd910cfd511d", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "23dd86c9-1050-422e-81c5-0f805f0afa17"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">MINIMUM\nPARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">VIAL\nLABEL</span></b></p>\n</div>", "ID": "d093d465-e8b8-4c3b-9e94-62f0247b23c4", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "    ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">MINIMUM\nPARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>", "ID": "3689cef8-5fcc-42b1-85d2-27d4a4402d78", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d093d465-e8b8-4c3b-9e94-62f0247b23c4"}, {"Element": "<b><span lang=\"EN-GB\">MINIMUM\nPARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b>", "ID": "c0a04f2d-a838-4205-8964-23175e3dc697", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3689cef8-5fcc-42b1-85d2-27d4a4402d78"}, {"Element": "<span lang=\"EN-GB\">MINIMUM\nPARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span>", "ID": "30c06804-558b-4a30-91d5-bd215dcb81ec", "Styles": "None", "Classes": "None", "Text": "MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS", "ParentId": "c0a04f2d-a838-4205-8964-23175e3dc697"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bf636e7c-24d0-456f-bf24-4c46b90fd641", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d093d465-e8b8-4c3b-9e94-62f0247b23c4"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "12570b04-dd09-42be-b092-8c8456f00042", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bf636e7c-24d0-456f-bf24-4c46b90fd641"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">VIAL\nLABEL</span></b></p>", "ID": "32cd4728-6016-40cb-9788-6f5bf65d9547", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d093d465-e8b8-4c3b-9e94-62f0247b23c4"}, {"Element": "<b><span lang=\"EN-GB\">VIAL\nLABEL</span></b>", "ID": "74a4b8d4-ba4a-4888-a02d-c6d54abb0bbb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "32cd4728-6016-40cb-9788-6f5bf65d9547"}, {"Element": "<span lang=\"EN-GB\">VIAL\nLABEL</span>", "ID": "3b6ebaea-6488-425b-b8b2-5e5d780198aa", "Styles": "None", "Classes": "None", "Text": "VIAL LABEL", "ParentId": "74a4b8d4-ba4a-4888-a02d-c6d54abb0bbb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4cbc368b-fefb-4046-831b-865af6f8532b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0cf78553-78b4-49ae-b219-3f11860cbfb5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4cbc368b-fefb-4046-831b-865af6f8532b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "51dc3a95-444d-4a10-acb7-2beca3b2cbd7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6104fe4e-a289-4345-9b24-7b0986963d6b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "51dc3a95-444d-4a10-acb7-2beca3b2cbd7"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>\n</div>", "ID": "29bbbc27-3e74-48a1-b7e3-78626998acd6", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>", "ID": "df61b873-44bd-4e47-8b99-43e3a2fdc4f4", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "29bbbc27-3e74-48a1-b7e3-78626998acd6"}, {"Element": "<b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b>", "ID": "b888f0f9-d727-4f6c-b995-763f310a7714", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "df61b873-44bd-4e47-8b99-43e3a2fdc4f4"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span>", "ID": "e7f5b19a-c722-438e-8bbd-192b8f5db70f", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION", "ParentId": "b888f0f9-d727-4f6c-b995-763f310a7714"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5b29ca4b-787d-4f2b-b6b9-8fe2043f8e85", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a423fad1-f4f0-43f7-a7d5-8291a3a9aaeb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5b29ca4b-787d-4f2b-b6b9-8fe2043f8e85"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"IT\">Arzerra<i> </i></span><span lang=\"IT\" style=\"color:black\">1000\u00a0mg sterile concentrate</span></p>", "ID": "b6781197-829a-44e7-8aa8-26bb2a82a6c4", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"IT\">Arzerra<i> </i></span>", "ID": "a628e82e-fabe-49de-ab27-0992d6791e48", "Styles": "None", "Classes": "None", "Text": "Arzerra", "ParentId": "b6781197-829a-44e7-8aa8-26bb2a82a6c4"}, {"Element": "<i> </i>", "ID": "1bf21659-fd6c-44cb-af6b-8b81be83d3e5", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "a628e82e-fabe-49de-ab27-0992d6791e48"}, {"Element": "<span lang=\"IT\" style=\"color:black\">1000\u00a0mg sterile concentrate</span>", "ID": "a9936add-dbd7-4866-acbd-6a85bc0c3250", "Styles": "color:black", "Classes": "None", "Text": "1000\u00a0mg sterile concentrate", "ParentId": "b6781197-829a-44e7-8aa8-26bb2a82a6c4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">ofatumumab</span></p>", "ID": "c820c4a1-e912-4dd5-a41f-95e16e27bc1e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"IT\">ofatumumab</span>", "ID": "42e169fb-9f3f-455d-b69a-c0c367f9092d", "Styles": "None", "Classes": "None", "Text": "ofatumumab", "ParentId": "c820c4a1-e912-4dd5-a41f-95e16e27bc1e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">IV</span></p>", "ID": "486a1808-f069-4b21-84e3-02d004027de2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"IT\">IV</span>", "ID": "34b548b1-c109-4410-bbae-4790cd8276a9", "Styles": "None", "Classes": "None", "Text": "IV", "ParentId": "486a1808-f069-4b21-84e3-02d004027de2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>", "ID": "40a831d8-26f1-448d-92b6-7127322cbc93", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "7b280e46-901f-4df5-9d14-4298d23147b1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "40a831d8-26f1-448d-92b6-7127322cbc93"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>", "ID": "ad72f724-737e-4922-bce2-086e0be28d89", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "dba81bc0-6367-4c0c-9aa2-fb7f7a627834", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ad72f724-737e-4922-bce2-086e0be28d89"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nOF ADMINISTRATION</span></b></p>\n</div>", "ID": "fa66e55f-d0ab-4405-ae70-5cced93a4b25", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nOF ADMINISTRATION</span></b></p>", "ID": "18cc3732-de89-4361-8e35-35a859db6234", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fa66e55f-d0ab-4405-ae70-5cced93a4b25"}, {"Element": "<b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nOF ADMINISTRATION</span></b>", "ID": "23f20c26-8dd4-46de-b4cb-2650e77e0da1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "18cc3732-de89-4361-8e35-35a859db6234"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nOF ADMINISTRATION</span>", "ID": "fe036d4c-a989-40f8-b49b-a067babf7d77", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD OF ADMINISTRATION", "ParentId": "23f20c26-8dd4-46de-b4cb-2650e77e0da1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a6aa8a6c-a227-4834-b1ef-4b0d49f34991", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "93867134-70c0-4c7b-b89a-fee402161402", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a6aa8a6c-a227-4834-b1ef-4b0d49f34991"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "49a490f4-c5da-4c2b-a21f-6829d636ff6d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1039d159-b65e-48be-9000-15304f0e6e94", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "49a490f4-c5da-4c2b-a21f-6829d636ff6d"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b></p>\n</div>", "ID": "aa07ae47-f829-4925-9ce1-140a8d6edc6e", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b></p>", "ID": "198d1e30-5dff-460a-b43e-309684bb0353", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "aa07ae47-f829-4925-9ce1-140a8d6edc6e"}, {"Element": "<b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b>", "ID": "6175ddd1-84a9-47f6-8ba9-25f807a1513e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "198d1e30-5dff-460a-b43e-309684bb0353"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span>", "ID": "67a02c43-046b-489c-a57d-89c664d61c18", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE", "ParentId": "6175ddd1-84a9-47f6-8ba9-25f807a1513e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "81dba5c9-9d86-4cdc-9b26-c58a1645f1ab", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "aaa2e573-ec16-4aa8-89be-65758332fd64", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "81dba5c9-9d86-4cdc-9b26-c58a1645f1ab"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP</span></p>", "ID": "04b7c9cd-772b-42e1-bf50-9cb1650dbb3d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">EXP</span>", "ID": "9409b78a-7480-4308-8108-aad3d878d41b", "Styles": "None", "Classes": "None", "Text": "EXP", "ParentId": "04b7c9cd-772b-42e1-bf50-9cb1650dbb3d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "96b40415-0c34-4cd3-8c2f-ae7ab29093e5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c1244577-df6a-4052-9795-48b443e2f87e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "96b40415-0c34-4cd3-8c2f-ae7ab29093e5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7f1439b6-91d7-476e-8593-67332654099c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e095dfaa-f9ec-4368-9a3e-34bb46725c7a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7f1439b6-91d7-476e-8593-67332654099c"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b></p>\n</div>", "ID": "a9350476-9745-4816-86ce-3baa893c74d7", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b></p>", "ID": "a6526be7-a27e-48c6-b6e3-63c75456fc3d", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a9350476-9745-4816-86ce-3baa893c74d7"}, {"Element": "<b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b>", "ID": "44cdffcb-bd58-4cb1-9889-6d763a79c16b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a6526be7-a27e-48c6-b6e3-63c75456fc3d"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span>", "ID": "d6e3b915-cde2-4235-ad98-4f3585e8f476", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER", "ParentId": "44cdffcb-bd58-4cb1-9889-6d763a79c16b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "082698f1-48a7-497c-8716-ddc624665931", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "55f82008-2e31-46d9-a10d-f944b822d8b4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "082698f1-48a7-497c-8716-ddc624665931"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">Lot</span></p>", "ID": "6ed78df6-c63c-4377-a5e1-4dc066a43ed1", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Lot</span>", "ID": "b3946172-4525-43be-824b-66c10424caf2", "Styles": "None", "Classes": "None", "Text": "Lot", "ParentId": "6ed78df6-c63c-4377-a5e1-4dc066a43ed1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "db263d2b-9fb3-4355-8648-a09296e506c6", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0c8ea9ef-0771-47b7-b71f-fe832120abc9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "db263d2b-9fb3-4355-8648-a09296e506c6"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bf725de9-2ffb-442a-8d48-d0eb88332cea", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "06d9b43d-b0be-4a16-893e-b175f5725e4b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bf725de9-2ffb-442a-8d48-d0eb88332cea"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS\nBY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>\n</div>", "ID": "fb72defa-395d-45bc-90fd-e758d7e4fc0e", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS\nBY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>", "ID": "b399100c-69bc-4934-9bdb-43f6e470822e", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fb72defa-395d-45bc-90fd-e758d7e4fc0e"}, {"Element": "<b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS\nBY WEIGHT, BY VOLUME OR BY UNIT</span></b>", "ID": "61cfa856-59fc-4f87-90a5-cfd6a7f6ac1e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b399100c-69bc-4934-9bdb-43f6e470822e"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS\nBY WEIGHT, BY VOLUME OR BY UNIT</span>", "ID": "0d10d51f-ca1b-4f24-9eba-5d8999e54633", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT", "ParentId": "61cfa856-59fc-4f87-90a5-cfd6a7f6ac1e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "96c67a63-ad2f-4596-9324-b29de48e42ae", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4cba1868-a53a-4ce1-b75d-6469c0d75d3e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "96c67a63-ad2f-4596-9324-b29de48e42ae"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">1000\u00a0mg/50\u00a0ml</span></p>", "ID": "7ae928c5-68cb-42fe-9959-cf351a3d48fb", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">1000\u00a0mg/50\u00a0ml</span>", "ID": "0ddd72b7-794b-4307-a5e1-9e9079bd3b08", "Styles": "None", "Classes": "None", "Text": "1000\u00a0mg/50\u00a0ml", "ParentId": "7ae928c5-68cb-42fe-9959-cf351a3d48fb"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "05c84817-fa31-4a06-8677-a0173d805510", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f605f17b-8f67-4f26-8632-577a1988a1de", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "05c84817-fa31-4a06-8677-a0173d805510"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "425e65bb-e67c-498e-a5f6-52d8b7df1a9b", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8238f865-4748-46d8-9f84-0db49dc4f1d4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "425e65bb-e67c-498e-a5f6-52d8b7df1a9b"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</span></b></p>\n</div>", "ID": "37af266f-11e6-4fc6-9703-987d41382ff1", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</span></b></p>", "ID": "a4806e18-7ad5-425d-925d-b55cb03bf615", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "37af266f-11e6-4fc6-9703-987d41382ff1"}, {"Element": "<b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</span></b>", "ID": "615305d0-3e25-44d5-835f-a56bc806f9cb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a4806e18-7ad5-425d-925d-b55cb03bf615"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</span>", "ID": "5672f50c-8aaa-459f-9a63-fbc57e4dee02", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER", "ParentId": "615305d0-3e25-44d5-835f-a56bc806f9cb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "59a5a3bc-b518-42a9-b857-f2f44f824660", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8c3c64f6-bd69-4212-bf39-9d8ca5f53bd7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "59a5a3bc-b518-42a9-b857-f2f44f824660"}, {"Element": "<b><u><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></u></b>", "ID": "ec9f8bf5-efea-431a-a08a-b6068f6c5ae9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></u>", "ID": "712e962e-48a7-400c-9cea-0bb1e7b72336", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ec9f8bf5-efea-431a-a08a-b6068f6c5ae9"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "eb145002-c749-402e-8ff1-e7dd470c65d3", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black", "Classes": "None", "Text": " ", "ParentId": "712e962e-48a7-400c-9cea-0bb1e7b72336"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "1916335d-8dbd-43ee-a5f6-408e0a8b2b25", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "eb145002-c749-402e-8ff1-e7dd470c65d3"}, {"Element": "<p class=\"MsoNormal\" style=\"background:white\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ba8e7c21-8230-4b83-90c7-236953c2c0e5", "Styles": "background:white", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ffb3aea2-999d-42e0-b4bc-e68a716bc8f4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ba8e7c21-8230-4b83-90c7-236953c2c0e5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b93bf04f-c5e9-4d90-8467-81a5ec594c68", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "381210d6-f80b-4177-9c29-76e16a5c2d95", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b93bf04f-c5e9-4d90-8467-81a5ec594c68"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4e96d715-44f6-4080-b204-21c33f35cd38", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "425e15b6-91a9-403c-9939-0550ae14f54f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4e96d715-44f6-4080-b204-21c33f35cd38"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fbafbb60-a943-436b-ada7-d0674c65518b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0ab2ea2f-c5d1-4981-9676-2ddcc70d132d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fbafbb60-a943-436b-ada7-d0674c65518b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "71198d25-8a0c-42f6-8c9a-40e5cf60142e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "69c7d08f-aec8-4dcd-bef3-74b7e96e1612", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "71198d25-8a0c-42f6-8c9a-40e5cf60142e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f6a87ed5-afef-487e-b3a9-9374449a4432", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6dbafdaa-085e-4a56-9153-9a628d41fccf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f6a87ed5-afef-487e-b3a9-9374449a4432"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8f53920e-ce76-41ee-88d0-95d4bbf2f53b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e74139f8-a815-4acf-942e-863a6d4fb3c8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8f53920e-ce76-41ee-88d0-95d4bbf2f53b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ed3ed32a-5d3b-41d0-91f5-a5eb8c3ed0ce", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "767c44d8-04fd-4aed-b112-e1d0934ad8d7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ed3ed32a-5d3b-41d0-91f5-a5eb8c3ed0ce"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "adf73828-2483-4544-a7d5-e692b8e04c7f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7e0ff35d-b4ad-4fb2-937f-2792cb2e0f46", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "adf73828-2483-4544-a7d5-e692b8e04c7f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fe1b8ac2-a465-4a01-adba-92ba3a694aaa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "07e8cb86-4bc9-4aa8-91ca-809107e2782f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fe1b8ac2-a465-4a01-adba-92ba3a694aaa"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "78fd8e49-fd1b-48af-a1b2-3d5e9130a265", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c70ec63c-3ca5-49a2-a249-c38152e319bd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "78fd8e49-fd1b-48af-a1b2-3d5e9130a265"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "346acbca-893d-462d-b031-10aee376b535", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8614af2c-7aac-484e-a1a1-f2a691317ab7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "346acbca-893d-462d-b031-10aee376b535"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "54fde46c-8743-4613-b847-85d3a620696e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ed775e0a-21c0-4673-bc8f-200e897afa2a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "54fde46c-8743-4613-b847-85d3a620696e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b91a67a8-155a-4045-87bd-d735d879f1ac", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e8ee3632-034e-448a-ae76-2b345505a712", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b91a67a8-155a-4045-87bd-d735d879f1ac"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2f879230-b1eb-42ea-8d10-857d1e8aa395", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b812beed-6b67-45cc-b454-dee87b05e64a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2f879230-b1eb-42ea-8d10-857d1e8aa395"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "124d46cb-f1d8-403f-bef8-8dea90a9e6e4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8b065c47-31a7-40f3-8306-eeb722fbd0e2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "124d46cb-f1d8-403f-bef8-8dea90a9e6e4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "de2d35d7-cf6f-4e62-b508-77a3e1231059", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a37d38bb-ee69-4440-9c3c-fcdf039adaae", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "de2d35d7-cf6f-4e62-b508-77a3e1231059"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "98c1e33f-1a06-4338-86bf-ebcd80c14d83", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bd2bc051-8bbd-4e68-ae85-6afe1a18e8b3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "98c1e33f-1a06-4338-86bf-ebcd80c14d83"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d9f1d661-cee8-47d6-90bb-637862c4ca0f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5f304c75-8226-47ca-97e5-2d17846d1544", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d9f1d661-cee8-47d6-90bb-637862c4ca0f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "09fbc957-b9f3-4b02-af64-dbfe5b9f2325", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f10d92e0-292f-494c-9c7b-377d8d86a726", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "09fbc957-b9f3-4b02-af64-dbfe5b9f2325"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d6a072ef-d956-4a09-a5b0-bcd90b80f19e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d6d95288-f943-48d7-a17f-d205e586c226", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d6a072ef-d956-4a09-a5b0-bcd90b80f19e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c20c6062-fe67-4841-83d9-cdd85d65f6a8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ecd28f19-68bf-4e0c-aca5-146afb0e2c74", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c20c6062-fe67-4841-83d9-cdd85d65f6a8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "75f410a1-53bc-418c-a87e-e776e9162a43", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f2ef6aec-c59b-4789-acb2-c5a8ccf59cb9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "75f410a1-53bc-418c-a87e-e776e9162a43"}, {"Element": "<p class=\"TitleA\"><span lang=\"X-NONE\">B. PACKAGE LEAFLET</span></p>", "ID": "81aaea1a-497d-4de8-9d33-2400daa8463b", "Styles": "None", "Classes": "['TitleA']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"X-NONE\">B. PACKAGE LEAFLET</span>", "ID": "3f7b3089-8708-49a1-bb74-21ddb4fdf31e", "Styles": "None", "Classes": "None", "Text": "B. PACKAGE LEAFLET", "ParentId": "81aaea1a-497d-4de8-9d33-2400daa8463b"}, {"Element": "<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>", "ID": "d21baa4d-2afe-4ba2-a95b-d0648e54594d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "2545da8b-dab6-4fca-bce8-6a626170f078", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "d21baa4d-2afe-4ba2-a95b-d0648e54594d"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "5f9d6c53-301f-4d14-9d6a-818a3c1c0e51", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "2545da8b-dab6-4fca-bce8-6a626170f078"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><a name=\"OLE_LINK1\"><b><span lang=\"EN-GB\">Package leaflet: Information for the user</span></b></a></p>", "ID": "d6861532-8737-4ebe-bc6d-4db751a09d70", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<a name=\"OLE_LINK1\"><b><span lang=\"EN-GB\">Package leaflet: Information for the user</span></b></a>", "ID": "c1dc8a76-c1c3-40b0-a1a9-87772cc75e47", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d6861532-8737-4ebe-bc6d-4db751a09d70"}, {"Element": "<b><span lang=\"EN-GB\">Package leaflet: Information for the user</span></b>", "ID": "5bc8b6de-0047-45d1-82d2-894e5bcb8852", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c1dc8a76-c1c3-40b0-a1a9-87772cc75e47"}, {"Element": "<span lang=\"EN-GB\">Package leaflet: Information for the user</span>", "ID": "4e50730a-71b9-43c3-b29a-64b9de6a7032", "Styles": "None", "Classes": "None", "Text": "Package leaflet: Information for the user", "ParentId": "5bc8b6de-0047-45d1-82d2-894e5bcb8852"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "07f866ed-fb9b-49c1-a5fb-07067ff5e39e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "29f5b4b6-ac47-46b5-b87c-a904824165e7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "07f866ed-fb9b-49c1-a5fb-07067ff5e39e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><b><span lang=\"EN-GB\">Arzerra </span></b><b><span lang=\"EN-GB\" style=\"color:black\">100\u00a0mg\nconcentrate for solution for infusion</span></b></p>", "ID": "59f6088c-36b9-4b94-b26b-ea6d99d42a73", "Styles": "text-align:center;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">Arzerra </span></b>", "ID": "392af52a-7e1d-4cea-9e8e-a88551fcf10e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "59f6088c-36b9-4b94-b26b-ea6d99d42a73"}, {"Element": "<span lang=\"EN-GB\">Arzerra </span>", "ID": "1f7efd6d-bac7-4443-a829-bf8319e12ea2", "Styles": "None", "Classes": "None", "Text": "Arzerra ", "ParentId": "392af52a-7e1d-4cea-9e8e-a88551fcf10e"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">100\u00a0mg\nconcentrate for solution for infusion</span></b>", "ID": "f4ec6349-c17f-44e1-ad0a-fb057d32ae64", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "59f6088c-36b9-4b94-b26b-ea6d99d42a73"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">100\u00a0mg\nconcentrate for solution for infusion</span>", "ID": "58589485-a52c-48d1-9705-04f1d0abaf29", "Styles": "color:black", "Classes": "None", "Text": "100\u00a0mg concentrate for solution for infusion", "ParentId": "f4ec6349-c17f-44e1-ad0a-fb057d32ae64"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><b><span lang=\"EN-GB\">Arzerra </span></b><b><span lang=\"EN-GB\" style=\"color:black\">1000\u00a0mg\nconcentrate for solution for infusion</span></b></p>", "ID": "7243752f-2891-477f-bb69-d0f7499edb0a", "Styles": "text-align:center;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">Arzerra </span></b>", "ID": "b70addd7-6d70-422b-a5a2-3f8aace661a3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7243752f-2891-477f-bb69-d0f7499edb0a"}, {"Element": "<span lang=\"EN-GB\">Arzerra </span>", "ID": "74810ff1-ea8c-4dc2-ba41-14b768ca060c", "Styles": "None", "Classes": "None", "Text": "Arzerra ", "ParentId": "b70addd7-6d70-422b-a5a2-3f8aace661a3"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">1000\u00a0mg\nconcentrate for solution for infusion</span></b>", "ID": "0bd2f4c0-b393-449f-82c1-8ee1dcb9a5bc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7243752f-2891-477f-bb69-d0f7499edb0a"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">1000\u00a0mg\nconcentrate for solution for infusion</span>", "ID": "41fe4cb4-0145-4bc0-a356-617115ca1e39", "Styles": "color:black", "Classes": "None", "Text": "1000\u00a0mg concentrate for solution for infusion", "ParentId": "0bd2f4c0-b393-449f-82c1-8ee1dcb9a5bc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">ofatumumab</span></p>", "ID": "8adc5d2c-e522-4b32-b2f3-0aa97b8a4a79", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">ofatumumab</span>", "ID": "4dca08a9-ead0-4f9c-8233-9833e9bc5f9c", "Styles": "None", "Classes": "None", "Text": "ofatumumab", "ParentId": "8adc5d2c-e522-4b32-b2f3-0aa97b8a4a79"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "eab7d26d-5c9a-44ea-a67a-4fceafedbe35", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f6c9bc7d-125d-4790-9031-434f25c00b8c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "eab7d26d-5c9a-44ea-a67a-4fceafedbe35"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Read all of this leaflet carefully\nbefore you are given this medicine because it contains important information\nfor you.</span></b></p>", "ID": "b5b95ee9-7643-4eae-a9cf-ad12bbf49fd5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">Read all of this leaflet carefully\nbefore you are given this medicine because it contains important information\nfor you.</span></b>", "ID": "fe275ea7-73d2-463a-827e-a330e90bbe2d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b5b95ee9-7643-4eae-a9cf-ad12bbf49fd5"}, {"Element": "<span lang=\"EN-GB\">Read all of this leaflet carefully\nbefore you are given this medicine because it contains important information\nfor you.</span>", "ID": "ebec8372-26d9-42ce-b0a8-cfe3f6a69ea0", "Styles": "None", "Classes": "None", "Text": "Read all of this leaflet carefully before you are given this medicine because it contains important information for you.", "ParentId": "fe275ea7-73d2-463a-827e-a330e90bbe2d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Keep this leaflet. You may need to read it\nagain.</span></p>", "ID": "7c309a80-98d2-4f47-84b3-4e94cef62e9b", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "8dc65d32-472a-4567-8668-4276fc160f5f", "Styles": "font-family:\"Tms Rmn\",serif", "Classes": "None", "Text": "-", "ParentId": "7c309a80-98d2-4f47-84b3-4e94cef62e9b"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "d7f76ce9-88d7-4dfd-963f-9e0861889d16", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "8dc65d32-472a-4567-8668-4276fc160f5f"}, {"Element": "<span lang=\"EN-GB\">Keep this leaflet. You may need to read it\nagain.</span>", "ID": "4b0d2e23-c59c-42a2-b99d-36a81921417c", "Styles": "None", "Classes": "None", "Text": "Keep this leaflet. You may need to read it again.", "ParentId": "7c309a80-98d2-4f47-84b3-4e94cef62e9b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">If you have any further questions, ask your\ndoctor or nurse.</span></p>", "ID": "d66ebb52-9b88-4d6c-baa7-b082b292e2db", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "6592e382-9042-430b-9dfb-f0a25c92637a", "Styles": "font-family:\"Tms Rmn\",serif", "Classes": "None", "Text": "-", "ParentId": "d66ebb52-9b88-4d6c-baa7-b082b292e2db"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "58dff02d-541a-4207-b7e0-888229e83192", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "6592e382-9042-430b-9dfb-f0a25c92637a"}, {"Element": "<span lang=\"EN-GB\">If you have any further questions, ask your\ndoctor or nurse.</span>", "ID": "2e8899c0-66de-4e6e-b19c-22a699901b55", "Styles": "None", "Classes": "None", "Text": "If you have any further questions, ask your doctor or nurse.", "ParentId": "d66ebb52-9b88-4d6c-baa7-b082b292e2db"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">If you get any side effects, talk to your doctor\nor nurse. This includes any possible side effects not listed in this leaflet.\nSee section\u00a04.</span></p>", "ID": "f9cdf378-317f-46f0-81df-bd3901de632e", "Styles": "margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Tms Rmn\",serif'>-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "a5a3822b-3a72-44ec-a4b2-dce7698a1117", "Styles": "font-family:\"Tms Rmn\",serif", "Classes": "None", "Text": "-", "ParentId": "f9cdf378-317f-46f0-81df-bd3901de632e"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "20a62d02-8d27-46fc-b379-cb977a6d6ffa", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "a5a3822b-3a72-44ec-a4b2-dce7698a1117"}, {"Element": "<span lang=\"EN-GB\">If you get any side effects, talk to your doctor\nor nurse. This includes any possible side effects not listed in this leaflet.\nSee section\u00a04.</span>", "ID": "4681136a-a0b1-4afc-9e06-34d067878937", "Styles": "None", "Classes": "None", "Text": "If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section\u00a04.", "ParentId": "f9cdf378-317f-46f0-81df-bd3901de632e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1dcf45fe-98a7-4110-b903-df6d34567fc0", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "96be17bc-04b7-4975-91a0-bafa9bcc6989", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1dcf45fe-98a7-4110-b903-df6d34567fc0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"EN-GB\">What is in\nthis leaflet</span></b></p>", "ID": "75435ab9-a4df-4d18-94ba-70a668dd66dd", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">What is in\nthis leaflet</span></b>", "ID": "8dc674c6-9787-4508-a666-91e2ccb6e245", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "75435ab9-a4df-4d18-94ba-70a668dd66dd"}, {"Element": "<span lang=\"EN-GB\">What is in\nthis leaflet</span>", "ID": "21edf96d-5962-4451-86e9-d12aa8ed92c2", "Styles": "None", "Classes": "None", "Text": "What is in this leaflet", "ParentId": "8dc674c6-9787-4508-a666-91e2ccb6e245"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-1.45pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6908d587-3bf9-4ae1-bc91-1eee18c438d0", "Styles": "margin-right:-1.45pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fdae9e40-81de-4afc-b7ab-8d88f4978b19", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6908d587-3bf9-4ae1-bc91-1eee18c438d0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-1.45pt\"><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Arzerra\nis and what it is used for</span></p>", "ID": "7f7df287-ec35-411f-a5a1-13655a3143f8", "Styles": "margin-right:-1.45pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Arzerra\nis and what it is used for</span>", "ID": "7381ea64-706a-4bfa-a135-7ed674ff060a", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Arzerra is and what it is used for", "ParentId": "7f7df287-ec35-411f-a5a1-13655a3143f8"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-1.45pt\"><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nyou need to know before you are given Arzerra</span></p>", "ID": "34132b1e-f1d9-4fe2-a705-e6fa9b6340cd", "Styles": "margin-right:-1.45pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nyou need to know before you are given Arzerra</span>", "ID": "009d3905-c1fc-42c2-8fbd-6b9675281fa6", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to know before you are given Arzerra", "ParentId": "34132b1e-f1d9-4fe2-a705-e6fa9b6340cd"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-1.45pt\"><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How Arzerra\nis given</span></p>", "ID": "43199a81-530b-4794-b36d-539ec5bbc82f", "Styles": "margin-right:-1.45pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How Arzerra\nis given</span>", "ID": "8465b3fc-7174-4994-beff-c2771108d0b1", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How Arzerra is given", "ParentId": "43199a81-530b-4794-b36d-539ec5bbc82f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-1.45pt\"><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible\nside effects</span></p>", "ID": "312c22f7-aaf6-4e1e-b935-c2d0e788ebd2", "Styles": "margin-right:-1.45pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible\nside effects</span>", "ID": "541355fc-d6ef-4396-8ff0-4c8e56c071c9", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side effects", "ParentId": "312c22f7-aaf6-4e1e-b935-c2d0e788ebd2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-1.45pt\"><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto store Arzerra</span></p>", "ID": "f6265677-19d2-484a-b7c0-137bd0a250c2", "Styles": "margin-right:-1.45pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto store Arzerra</span>", "ID": "57a6a8cc-e27c-40fa-8352-8cf2354083fd", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store Arzerra", "ParentId": "f6265677-19d2-484a-b7c0-137bd0a250c2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-1.45pt\"><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span><span lang=\"EN-GB\">Contents of the pack and other</span><span lang=\"EN-GB\"> information</span></p>", "ID": "6866fc24-cef2-4430-9051-463a6817e429", "Styles": "margin-right:-1.45pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "68f75f2f-e6ba-4bbb-bc20-52f03ad2b3bc", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "6866fc24-cef2-4430-9051-463a6817e429"}, {"Element": "<span lang=\"EN-GB\">Contents of the pack and other</span>", "ID": "4a39a90b-0105-4ee9-a125-259d94b1c290", "Styles": "None", "Classes": "None", "Text": "Contents of the pack and other", "ParentId": "6866fc24-cef2-4430-9051-463a6817e429"}, {"Element": "<span lang=\"EN-GB\"> information</span>", "ID": "b2e8c5d8-6a48-45c7-a3aa-e83cc3397d19", "Styles": "None", "Classes": "None", "Text": " information", "ParentId": "6866fc24-cef2-4430-9051-463a6817e429"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a2f40268-3f57-4894-ace8-be1f357c63e2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9775a45a-6b68-4b83-baa4-70c1a0e73013", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a2f40268-3f57-4894-ace8-be1f357c63e2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bb4fef43-8e52-42a7-8720-890fc325bc5c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9c19899d-0717-43cb-858a-cac546424908", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bb4fef43-8e52-42a7-8720-890fc325bc5c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Arzerra is and what it is used for</span></b></p>", "ID": "131589cb-6c5d-4baa-bbcc-f469aae56ff1", "Styles": "margin-right:-.1pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Arzerra is and what it is used for</span></b>", "ID": "2b3e07a4-1c18-4f9d-bc9d-1c32cd26e902", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "131589cb-6c5d-4baa-bbcc-f469aae56ff1"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Arzerra is and what it is used for</span>", "ID": "0198404f-4212-4213-b137-45826db38cbd", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Arzerra is and what it is used for", "ParentId": "2b3e07a4-1c18-4f9d-bc9d-1c32cd26e902"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3937eaa1-2f2d-4e24-87b1-79ba96e908a6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b2707ec0-615f-4ef9-90b2-71139879e170", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3937eaa1-2f2d-4e24-87b1-79ba96e908a6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Arzerra</span><span lang=\"EN-GB\"> contains ofatumumab</span><span lang=\"EN-GB\">, which belongs to a group of medicines called monoclonal antibodies.</span></p>", "ID": "41f0348a-45cb-43dd-9c6b-828837b1aa85", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Arzerra</span>", "ID": "ec2180a5-77d2-42d9-aae9-be4974b85bf3", "Styles": "None", "Classes": "None", "Text": "Arzerra", "ParentId": "41f0348a-45cb-43dd-9c6b-828837b1aa85"}, {"Element": "<span lang=\"EN-GB\"> contains ofatumumab</span>", "ID": "fcce4718-dea8-467e-9f4c-fe180f6234cb", "Styles": "None", "Classes": "None", "Text": " contains ofatumumab", "ParentId": "41f0348a-45cb-43dd-9c6b-828837b1aa85"}, {"Element": "<span lang=\"EN-GB\">, which belongs to a group of medicines called monoclonal antibodies.</span>", "ID": "06cce1dd-ec1d-42c9-af59-d592adc972cc", "Styles": "None", "Classes": "None", "Text": ", which belongs to a group of medicines called monoclonal antibodies.", "ParentId": "41f0348a-45cb-43dd-9c6b-828837b1aa85"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ddd612ec-2f20-4fea-aba2-c974b4478a21", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8652f5ea-4f7c-4ab3-a2b8-54256cea6671", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ddd612ec-2f20-4fea-aba2-c974b4478a21"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Arzerra</span></b><b><span lang=\"EN-GB\">\nis used to treat chronic lymphocytic leukaemia</span></b><span lang=\"EN-GB\"> (CLL).\n CLL is a cancer of the blood which affects </span><span lang=\"EN-GB\">a type of\nwhite blood cell called lymphocytes. The lymphocytes multiply too quickly and\nlive too long, so there are too many of them circulating in your blood. The\ndisease can also affect other organs in your body. </span><span lang=\"EN-GB\">The\nantibody in Arzerra recognises a substance on the surface of lymphocytes and\ncauses the lymphocyte to die.</span></p>", "ID": "8c1e606b-fdb3-4d56-9870-3bcd0e1cd8cd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">Arzerra</span></b>", "ID": "3a5f5b92-8daa-4ca8-ac3b-b4f425401970", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8c1e606b-fdb3-4d56-9870-3bcd0e1cd8cd"}, {"Element": "<span lang=\"EN-GB\">Arzerra</span>", "ID": "4371d22f-d1b3-45dd-bf3e-7a64f2b2f2d6", "Styles": "None", "Classes": "None", "Text": "Arzerra", "ParentId": "3a5f5b92-8daa-4ca8-ac3b-b4f425401970"}, {"Element": "<b><span lang=\"EN-GB\">\nis used to treat chronic lymphocytic leukaemia</span></b>", "ID": "68a0935f-7b7a-4415-95a6-0a7da9fa17f9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8c1e606b-fdb3-4d56-9870-3bcd0e1cd8cd"}, {"Element": "<span lang=\"EN-GB\">\nis used to treat chronic lymphocytic leukaemia</span>", "ID": "c1fb712f-1244-4e7c-a8aa-8660c71e4740", "Styles": "None", "Classes": "None", "Text": " is used to treat chronic lymphocytic leukaemia", "ParentId": "68a0935f-7b7a-4415-95a6-0a7da9fa17f9"}, {"Element": "<span lang=\"EN-GB\"> (CLL).\n CLL is a cancer of the blood which affects </span>", "ID": "809347ab-a12c-4b1c-84b0-0ddd6cdbfc95", "Styles": "None", "Classes": "None", "Text": " (CLL).  CLL is a cancer of the blood which affects ", "ParentId": "8c1e606b-fdb3-4d56-9870-3bcd0e1cd8cd"}, {"Element": "<span lang=\"EN-GB\">a type of\nwhite blood cell called lymphocytes. The lymphocytes multiply too quickly and\nlive too long, so there are too many of them circulating in your blood. The\ndisease can also affect other organs in your body. </span>", "ID": "31d234c0-1225-437a-bb92-a5dc1bae0116", "Styles": "None", "Classes": "None", "Text": "a type of white blood cell called lymphocytes. The lymphocytes multiply too quickly and live too long, so there are too many of them circulating in your blood. The disease can also affect other organs in your body. ", "ParentId": "8c1e606b-fdb3-4d56-9870-3bcd0e1cd8cd"}, {"Element": "<span lang=\"EN-GB\">The\nantibody in Arzerra recognises a substance on the surface of lymphocytes and\ncauses the lymphocyte to die.</span>", "ID": "ed30e215-0e7a-49ec-852e-37ff5e09dd73", "Styles": "None", "Classes": "None", "Text": "The antibody in Arzerra recognises a substance on the surface of lymphocytes and causes the lymphocyte to die.", "ParentId": "8c1e606b-fdb3-4d56-9870-3bcd0e1cd8cd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0d89eb6f-f63f-4250-8cbd-38e018017071", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e0a22f43-f827-4c08-b8ac-29e6ac602ff3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0d89eb6f-f63f-4250-8cbd-38e018017071"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "063ca22c-5529-4943-842c-b929e0de68d0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c337cfe3-5051-4236-a09f-fd517121d33c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "063ca22c-5529-4943-842c-b929e0de68d0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to know before you are given Arzerra</span></b></p>", "ID": "d7c04e88-d970-4d38-8fa9-15f64bacb319", "Styles": "margin-right:-.1pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to know before you are given Arzerra</span></b>", "ID": "abbffa34-4600-46c2-b42d-6520478a0115", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d7c04e88-d970-4d38-8fa9-15f64bacb319"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to know before you are given Arzerra</span>", "ID": "2584a105-8ce8-4bfb-b7c6-34583f8a69b6", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to know before you are given Arzerra", "ParentId": "abbffa34-4600-46c2-b42d-6520478a0115"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "be01af8e-b6be-4ae9-8e32-51407a8a0247", "Styles": "margin-right:-.1pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fec57569-c426-4167-8806-847cb5987dbb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "be01af8e-b6be-4ae9-8e32-51407a8a0247"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">You must\nnot be given Arzerra:</span></b></p>", "ID": "d9d6c0e0-726c-46b9-bb86-459d673cd24f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">You must\nnot be given Arzerra:</span></b>", "ID": "dbb85511-87bd-468b-9e42-ba07d04b02b3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d9d6c0e0-726c-46b9-bb86-459d673cd24f"}, {"Element": "<span lang=\"EN-GB\">You must\nnot be given Arzerra:</span>", "ID": "56d32efa-c36d-4bcd-88f2-2c2dfcf4fc3c", "Styles": "None", "Classes": "None", "Text": "You must not be given Arzerra:", "ParentId": "dbb85511-87bd-468b-9e42-ba07d04b02b3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">if you are allergic (hypersensitive) to\nofatumumab or any of the other ingredients of this medicine (listed in section\u00a06).</span></p>", "ID": "1509cda6-2246-454b-a063-9307ea966fe8", "Styles": "margin-left:28.35pt;text-indent:-27.8pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "84ed0a23-1384-43b3-8720-3b43c9b30f0f", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "1509cda6-2246-454b-a063-9307ea966fe8"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "7c429729-abfd-4d15-a001-c18af2b4701e", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "84ed0a23-1384-43b3-8720-3b43c9b30f0f"}, {"Element": "<span lang=\"EN-GB\">if you are allergic (hypersensitive) to\nofatumumab or any of the other ingredients of this medicine (listed in section\u00a06).</span>", "ID": "fbe1a77d-4504-4ea3-918b-c5651b7b9e2c", "Styles": "None", "Classes": "None", "Text": "if you are allergic (hypersensitive) to ofatumumab or any of the other ingredients of this medicine (listed in section\u00a06).", "ParentId": "1509cda6-2246-454b-a063-9307ea966fe8"}, {"Element": "<p class=\"MsoListParagraph\" style=\"margin-left:0in\"><span lang=\"EN-GB\" style=\"color:black\">Check with your doctor<b> </b></span><span lang=\"EN-GB\" style=\"color:black\">if you think this may apply to you.</span></p>", "ID": "065763b9-0a2f-43f9-baef-d32f901d0a39", "Styles": "margin-left:0in", "Classes": "['MsoListParagraph']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Check with your doctor<b> </b></span>", "ID": "e27b6206-a6e4-4ff6-ba0e-522e574c2ee3", "Styles": "color:black", "Classes": "None", "Text": "Check with your doctor", "ParentId": "065763b9-0a2f-43f9-baef-d32f901d0a39"}, {"Element": "<b> </b>", "ID": "80c71130-e926-448a-b936-7e4fbbc031f2", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "e27b6206-a6e4-4ff6-ba0e-522e574c2ee3"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">if you think this may apply to you.</span>", "ID": "673ceeae-7677-49b9-9c28-c0a972737eae", "Styles": "color:black", "Classes": "None", "Text": "if you think this may apply to you.", "ParentId": "065763b9-0a2f-43f9-baef-d32f901d0a39"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7d36ee83-dc51-4a4f-a185-b1cb58dcd709", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "76ee7476-2b6e-436e-ab28-b8b65579a853", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7d36ee83-dc51-4a4f-a185-b1cb58dcd709"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Warnings\nand precautions</span></b></p>", "ID": "4d932a5e-290d-4e46-8f0d-145c07146f21", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">Warnings\nand precautions</span></b>", "ID": "a0795f17-0d97-45e2-b2a2-c52c5cacc67a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4d932a5e-290d-4e46-8f0d-145c07146f21"}, {"Element": "<span lang=\"EN-GB\">Warnings\nand precautions</span>", "ID": "2e5e0a3a-5cd0-481f-ada4-39164e4b7297", "Styles": "None", "Classes": "None", "Text": "Warnings and precautions", "ParentId": "a0795f17-0d97-45e2-b2a2-c52c5cacc67a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Talk to your doctor or nurse before you are given Arzerra</span><span lang=\"EN-GB\" style=\"color:black\">:</span></p>", "ID": "513816e4-85e9-4213-9503-07cabe3d1fcc", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Talk to your doctor or nurse before you are given Arzerra</span>", "ID": "f0f349d1-5d1f-4c98-af05-5b799bc92939", "Styles": "None", "Classes": "None", "Text": "Talk to your doctor or nurse before you are given Arzerra", "ParentId": "513816e4-85e9-4213-9503-07cabe3d1fcc"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">:</span>", "ID": "cd4ab919-391c-4c25-a775-76ed5dec8598", "Styles": "color:black", "Classes": "None", "Text": ":", "ParentId": "513816e4-85e9-4213-9503-07cabe3d1fcc"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">if you have had <b>heart problems,</b></span></p>", "ID": "2989260f-1468-4b6e-82b6-58c9da26c06b", "Styles": "margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.8pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "58c1ef3c-7e29-44b1-b051-ce03560987f3", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "2989260f-1468-4b6e-82b6-58c9da26c06b"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "29175cc6-5c55-4793-94e6-98702f867e3e", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "58c1ef3c-7e29-44b1-b051-ce03560987f3"}, {"Element": "<span lang=\"EN-GB\">if you have had <b>heart problems,</b></span>", "ID": "141969cf-b80d-4efe-b642-2d5e8f680f67", "Styles": "None", "Classes": "None", "Text": "if you have had ", "ParentId": "2989260f-1468-4b6e-82b6-58c9da26c06b"}, {"Element": "<b>heart problems,</b>", "ID": "7d6cb098-c0ea-42fe-ae5d-248968e66d03", "Styles": "None", "Classes": "None", "Text": "heart problems,", "ParentId": "141969cf-b80d-4efe-b642-2d5e8f680f67"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">if you have <b>lung disease,</b></span></p>", "ID": "45b653f9-db23-4188-b452-cd6aa60e138b", "Styles": "margin-left:28.35pt;text-indent:-27.8pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "967cc8ea-3fb8-41cd-a453-5583c7535d0c", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "45b653f9-db23-4188-b452-cd6aa60e138b"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "2b280b20-8977-4c90-b2ce-2ed7b8cfb993", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "967cc8ea-3fb8-41cd-a453-5583c7535d0c"}, {"Element": "<span lang=\"EN-GB\">if you have <b>lung disease,</b></span>", "ID": "e57f6b97-fd24-481a-8095-91cba7b6f727", "Styles": "None", "Classes": "None", "Text": "if you have ", "ParentId": "45b653f9-db23-4188-b452-cd6aa60e138b"}, {"Element": "<b>lung disease,</b>", "ID": "a44bdfcd-d2ba-44d9-9b82-f68c09a7f335", "Styles": "None", "Classes": "None", "Text": "lung disease,", "ParentId": "e57f6b97-fd24-481a-8095-91cba7b6f727"}, {"Element": "<p class=\"MsoListParagraph\" style=\"margin-left:0in\"><span lang=\"EN-GB\" style=\"color:black\">Check with your doctor<b> </b>if you think any of these may\napply to you. You may need extra check-ups while you are being treated with\nArzerra.</span></p>", "ID": "a7adea96-f7f0-4de2-9785-3cc65d0130d5", "Styles": "margin-left:0in", "Classes": "['MsoListParagraph']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Check with your doctor<b> </b>if you think any of these may\napply to you. You may need extra check-ups while you are being treated with\nArzerra.</span>", "ID": "40d8e8f3-c3c1-477b-ae33-8715ade55094", "Styles": "color:black", "Classes": "None", "Text": "Check with your doctorif you think any of these may apply to you. You may need extra check-ups while you are being treated with Arzerra.", "ParentId": "a7adea96-f7f0-4de2-9785-3cc65d0130d5"}, {"Element": "<b> </b>", "ID": "4c49fd86-6db7-4989-927b-a6ce7faeae74", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "40d8e8f3-c3c1-477b-ae33-8715ade55094"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;vertical-align:baseline\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "40c03d0b-ac49-4712-a86d-435261c78de8", "Styles": "margin-right:-.1pt;vertical-align:baseline", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5989f31e-c1cd-4b87-88e5-b78cd94c964c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "40c03d0b-ac49-4712-a86d-435261c78de8"}, {"Element": "<p class=\"MsoListParagraph\" style=\"margin-left:0in\"><span lang=\"EN-GB\">Your doctor\nmay test the amount of electrolytes, such as magnesium and potassium, in your\nblood<b><span style=\"color:#1F497D\"> </span></b>before and during your\ntreatment with Arzerra.<b> </b>Your doctor may treat you if any electrolyte\nimbalance is detected.</span></p>", "ID": "950201a7-4d52-4496-b710-e1379d9483eb", "Styles": "margin-left:0in", "Classes": "['MsoListParagraph']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Your doctor\nmay test the amount of electrolytes, such as magnesium and potassium, in your\nblood<b><span style=\"color:#1F497D\"> </span></b>before and during your\ntreatment with Arzerra.<b> </b>Your doctor may treat you if any electrolyte\nimbalance is detected.</span>", "ID": "c99e6cd4-566c-4dfe-b5ae-6b42018da698", "Styles": "None", "Classes": "None", "Text": "Your doctor may test the amount of electrolytes, such as magnesium and potassium, in your bloodbefore and during your treatment with Arzerra.Your doctor may treat you if any electrolyte imbalance is detected.", "ParentId": "950201a7-4d52-4496-b710-e1379d9483eb"}, {"Element": "<b><span style=\"color:#1F497D\"> </span></b>", "ID": "5030eaaa-e11f-4234-ade3-28839972cd47", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c99e6cd4-566c-4dfe-b5ae-6b42018da698"}, {"Element": "<span style=\"color:#1F497D\"> </span>", "ID": "9bcf7fe2-7052-4f05-80ea-4b9fa62c34ad", "Styles": "color:#1F497D", "Classes": "None", "Text": " ", "ParentId": "5030eaaa-e11f-4234-ade3-28839972cd47"}, {"Element": "<b> </b>", "ID": "6aaa8a8d-37e5-4b8f-8139-bdab06e3dea9", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "c99e6cd4-566c-4dfe-b5ae-6b42018da698"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "a106bdd5-184f-4d48-a1cb-295ffed2bff0", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "c38d5863-9ccb-41c9-ad9e-70b785a7f023", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "a106bdd5-184f-4d48-a1cb-295ffed2bff0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Vaccination\nand Arzerra</span></b></p>", "ID": "635bf344-ecf9-429f-bf79-e72e800dee88", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">Vaccination\nand Arzerra</span></b>", "ID": "d695f813-8487-4c47-b815-695177037d55", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "635bf344-ecf9-429f-bf79-e72e800dee88"}, {"Element": "<span lang=\"EN-GB\">Vaccination\nand Arzerra</span>", "ID": "dc87ada7-6c69-408d-9d01-3513f28f00d8", "Styles": "None", "Classes": "None", "Text": "Vaccination and Arzerra", "ParentId": "d695f813-8487-4c47-b815-695177037d55"}, {"Element": "<p class=\"MsoNormal\">If you are having any vaccinations tell your doctor, or the\nperson giving you the vaccine, that you are being treated with Arzerra. <span lang=\"EN-GB\">Your response to the vaccine may be weakened</span> and you may not\nbe fully protected.</p>", "ID": "93760225-22e7-47fa-b7e0-3286c22bc0fd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "If you are having any vaccinations tell your doctor, or the person giving you the vaccine, that you are being treated with Arzerra.  and you may not be fully protected.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Your response to the vaccine may be weakened</span>", "ID": "f2ed90fe-d3a9-4de5-b4f7-53d992e30023", "Styles": "None", "Classes": "None", "Text": "Your response to the vaccine may be weakened", "ParentId": "93760225-22e7-47fa-b7e0-3286c22bc0fd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3738e861-729c-4fdf-a5f0-7242be1c4625", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "64151235-e55f-4ed4-9a09-07b6490dc892", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3738e861-729c-4fdf-a5f0-7242be1c4625"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Hepatitis\nB</span></b></p>", "ID": "851f9109-5d2c-4ae5-9c20-a659dac0a045", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">Hepatitis\nB</span></b>", "ID": "287d3686-6e49-46c5-8d6f-820452f5aedc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "851f9109-5d2c-4ae5-9c20-a659dac0a045"}, {"Element": "<span lang=\"EN-GB\">Hepatitis\nB</span>", "ID": "e1876d4e-b1fd-4fa9-9333-cd9286474fad", "Styles": "None", "Classes": "None", "Text": "Hepatitis B", "ParentId": "287d3686-6e49-46c5-8d6f-820452f5aedc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">You should be tested for hepatitis B (a\nliver disease) before starting Arzerra treatment. If you have had hepatitis B,\nArzerra could cause it to become active again. Your doctor may treat you with a\nsuitable anti-viral medicine to help prevent this.</span></p>", "ID": "70da1096-fdfc-4ee4-959e-73926be48d45", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">You should be tested for hepatitis B (a\nliver disease) before starting Arzerra treatment. If you have had hepatitis B,\nArzerra could cause it to become active again. Your doctor may treat you with a\nsuitable anti-viral medicine to help prevent this.</span>", "ID": "077d5f9b-60d0-4bfd-8425-71542a88b5b1", "Styles": "None", "Classes": "None", "Text": "You should be tested for hepatitis B (a liver disease) before starting Arzerra treatment. If you have had hepatitis B, Arzerra could cause it to become active again. Your doctor may treat you with a suitable anti-viral medicine to help prevent this.", "ParentId": "70da1096-fdfc-4ee4-959e-73926be48d45"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b35a4d1a-b41a-4acb-8177-2128378085ad", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cb7fb72e-6322-4643-ac4e-9cf231f4fb2b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b35a4d1a-b41a-4acb-8177-2128378085ad"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you have or have had hepatitis B, </span><span lang=\"EN-GB\">tell your doctor before you are given Arzerra</span><span lang=\"EN-GB\">.</span></p>", "ID": "5014e434-1d69-481f-bb21-d30028887ea1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">If you have or have had hepatitis B, </span>", "ID": "a06beabe-1128-42e9-aa97-2ae74e5d13cd", "Styles": "None", "Classes": "None", "Text": "If you have or have had hepatitis B, ", "ParentId": "5014e434-1d69-481f-bb21-d30028887ea1"}, {"Element": "<span lang=\"EN-GB\">tell your doctor before you are given Arzerra</span>", "ID": "ecf9d48b-ea85-47df-a6f9-8fe2966d9c18", "Styles": "None", "Classes": "None", "Text": "tell your doctor before you are given Arzerra", "ParentId": "5014e434-1d69-481f-bb21-d30028887ea1"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "f7e66c80-fb4e-4be6-9f72-25c7a31659a2", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "5014e434-1d69-481f-bb21-d30028887ea1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "417ad948-d538-4a65-96b2-8236055e6e9a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b1eff8f7-89fe-45f9-896e-847bba095dd1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "417ad948-d538-4a65-96b2-8236055e6e9a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Infusion\nreactions</span></b></p>", "ID": "fbb60a6f-b6c4-41bf-ba90-fbcb41dbb176", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">Infusion\nreactions</span></b>", "ID": "683d626c-5f77-4039-a5ee-6deb53af7e1e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fbb60a6f-b6c4-41bf-ba90-fbcb41dbb176"}, {"Element": "<span lang=\"EN-GB\">Infusion\nreactions</span>", "ID": "2f6d5d29-7269-46d6-b392-097b3bec28c0", "Styles": "None", "Classes": "None", "Text": "Infusion reactions", "ParentId": "683d626c-5f77-4039-a5ee-6deb53af7e1e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Medicines of this type (monoclonal\nantibodies) can cause infusion reactions when they are injected into the body.\nYou will be given medicines such as anti-histamines, steroids or pain relievers\nto help reduce any reaction. See also section\u00a04, \u2018Possible side effects\u2019.</span></p>", "ID": "6b16129a-f504-4a3f-81ce-de963edddec1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Medicines of this type (monoclonal\nantibodies) can cause infusion reactions when they are injected into the body.\nYou will be given medicines such as anti-histamines, steroids or pain relievers\nto help reduce any reaction. See also section\u00a04, \u2018Possible side effects\u2019.</span>", "ID": "4d89dab2-4bbe-4d81-9cd8-50ae2f9f69ee", "Styles": "None", "Classes": "None", "Text": "Medicines of this type (monoclonal antibodies) can cause infusion reactions when they are injected into the body. You will be given medicines such as anti-histamines, steroids or pain relievers to help reduce any reaction. See also section\u00a04, \u2018Possible side effects\u2019.", "ParentId": "6b16129a-f504-4a3f-81ce-de963edddec1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2617745d-982d-425e-beb8-1f6c4df7d721", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1621186e-9056-457e-850f-e425d30ef9e6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2617745d-982d-425e-beb8-1f6c4df7d721"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you think you have had such a reaction\nbefore, tell your doctor before you are given </span>Arzerra.</p>", "ID": "e7dc4267-1b37-49f7-ba65-8e8a55043cd7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Arzerra.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">If you think you have had such a reaction\nbefore, tell your doctor before you are given </span>", "ID": "ceafe8ef-f999-4c96-b6a7-09a061cd162f", "Styles": "None", "Classes": "None", "Text": "If you think you have had such a reaction before, tell your doctor before you are given ", "ParentId": "e7dc4267-1b37-49f7-ba65-8e8a55043cd7"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "552dae6b-8d73-4959-aaaa-16502e3ded54", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Progressive\nmultifocal leukoencephalopathy (PML)</span></b></p>", "ID": "bfb9096f-e4be-40a6-b9eb-070ed00a5ed2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">Progressive\nmultifocal leukoencephalopathy (PML)</span></b>", "ID": "3a0e78e7-bc19-4e12-8d5c-12646a04304b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bfb9096f-e4be-40a6-b9eb-070ed00a5ed2"}, {"Element": "<span lang=\"EN-GB\">Progressive\nmultifocal leukoencephalopathy (PML)</span>", "ID": "7b24c5d4-dce1-4387-83cc-aad4a4795cda", "Styles": "None", "Classes": "None", "Text": "Progressive multifocal leukoencephalopathy (PML)", "ParentId": "3a0e78e7-bc19-4e12-8d5c-12646a04304b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Progressive multifocal leukoencephalopathy\n(PML), a serious and life-threatening brain condition, has been reported with\nmedicines like Arzerra. </span><b><span lang=\"EN-GB\">Tell your doctor immediately</span></b><span lang=\"EN-GB\"> if you have memory loss, trouble thinking, difficulty with walking\nor loss of vision. If you had these symptoms prior to treatment with Arzerra, <b>tell\nyour doctor immediately</b> about any changes in these symptoms.</span></p>", "ID": "8e236d60-705a-481f-8ddc-3ae45f9bd8ee", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Progressive multifocal leukoencephalopathy\n(PML), a serious and life-threatening brain condition, has been reported with\nmedicines like Arzerra. </span>", "ID": "1e6f352a-9043-4d2d-a8c7-58407cc04a3d", "Styles": "None", "Classes": "None", "Text": "Progressive multifocal leukoencephalopathy (PML), a serious and life-threatening brain condition, has been reported with medicines like Arzerra. ", "ParentId": "8e236d60-705a-481f-8ddc-3ae45f9bd8ee"}, {"Element": "<b><span lang=\"EN-GB\">Tell your doctor immediately</span></b>", "ID": "d5d193c2-fe3e-4e92-986e-ae0bae89873f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8e236d60-705a-481f-8ddc-3ae45f9bd8ee"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor immediately</span>", "ID": "ab753e34-e533-4f4c-9b2e-42c73c5f6af6", "Styles": "None", "Classes": "None", "Text": "Tell your doctor immediately", "ParentId": "d5d193c2-fe3e-4e92-986e-ae0bae89873f"}, {"Element": "<span lang=\"EN-GB\"> if you have memory loss, trouble thinking, difficulty with walking\nor loss of vision. If you had these symptoms prior to treatment with Arzerra, <b>tell\nyour doctor immediately</b> about any changes in these symptoms.</span>", "ID": "b08014d9-6e0f-41ff-b379-9370d7b5d0b0", "Styles": "None", "Classes": "None", "Text": " if you have memory loss, trouble thinking, difficulty with walking or loss of vision. If you had these symptoms prior to treatment with Arzerra,  about any changes in these symptoms.", "ParentId": "8e236d60-705a-481f-8ddc-3ae45f9bd8ee"}, {"Element": "<b>tell\nyour doctor immediately</b>", "ID": "2659b646-5507-4c54-8f82-62211620e62b", "Styles": "None", "Classes": "None", "Text": "tell your doctor immediately", "ParentId": "b08014d9-6e0f-41ff-b379-9370d7b5d0b0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6376657a-0888-4191-b981-c3c79e9be1bb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b4abdcb4-c5e6-4931-afee-9e8695e0b976", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6376657a-0888-4191-b981-c3c79e9be1bb"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\navoid\"><b><span style=\"font-size:11.0pt\">Bowel obstruction</span></b></p>", "ID": "4df75201-35fc-4fa2-8d9e-fbc0b8bb5e5f", "Styles": "margin-top:0in;text-align:left;page-break-after:\navoid", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span style=\"font-size:11.0pt\">Bowel obstruction</span></b>", "ID": "e4583ffe-9b7f-40d2-872c-f191e3262a19", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4df75201-35fc-4fa2-8d9e-fbc0b8bb5e5f"}, {"Element": "<span style=\"font-size:11.0pt\">Bowel obstruction</span>", "ID": "8e23441a-10f2-4cf4-b4ad-3b1327dc518f", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "Bowel obstruction", "ParentId": "e4583ffe-9b7f-40d2-872c-f191e3262a19"}, {"Element": "<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><b><span style=\"font-size:11.0pt\">Contact your doctor immediately</span></b><span style=\"font-size:11.0pt\"> if you experience constipation, a swollen abdomen or\nabdominal pain. These could be symptoms of a blockage in the bowel, especially\nduring the early stages of your treatment.</span></p>", "ID": "c7ac6d8b-6a1a-4f9a-ac16-30505e61ec14", "Styles": "margin-top:0in;text-align:left", "Classes": "['Text']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span style=\"font-size:11.0pt\">Contact your doctor immediately</span></b>", "ID": "89c1af61-fae9-43f7-9001-76084bc98629", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c7ac6d8b-6a1a-4f9a-ac16-30505e61ec14"}, {"Element": "<span style=\"font-size:11.0pt\">Contact your doctor immediately</span>", "ID": "88289a9d-27db-4e74-9593-2976b06f36e5", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "Contact your doctor immediately", "ParentId": "89c1af61-fae9-43f7-9001-76084bc98629"}, {"Element": "<span style=\"font-size:11.0pt\"> if you experience constipation, a swollen abdomen or\nabdominal pain. These could be symptoms of a blockage in the bowel, especially\nduring the early stages of your treatment.</span>", "ID": "4ea9112c-8c02-420d-8b8d-4b6cd2b9fabf", "Styles": "font-size:11.0pt", "Classes": "None", "Text": " if you experience constipation, a swollen abdomen or abdominal pain. These could be symptoms of a blockage in the bowel, especially during the early stages of your treatment.", "ParentId": "c7ac6d8b-6a1a-4f9a-ac16-30505e61ec14"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "87dc1cd5-63b8-47d3-9d37-b61e5fd90c5f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a339bbec-a8cc-4ccb-9a7a-1da19c8ecc4d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "87dc1cd5-63b8-47d3-9d37-b61e5fd90c5f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Children\nand adolescents</span></b></p>", "ID": "c77592b5-0722-4f7c-9253-ec4f99358224", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">Children\nand adolescents</span></b>", "ID": "491dc6d7-df49-4f04-9807-25d4d1f4d7d7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c77592b5-0722-4f7c-9253-ec4f99358224"}, {"Element": "<span lang=\"EN-GB\">Children\nand adolescents</span>", "ID": "56e534ac-4e65-43f5-b145-ad91f4a58055", "Styles": "None", "Classes": "None", "Text": "Children and adolescents", "ParentId": "491dc6d7-df49-4f04-9807-25d4d1f4d7d7"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">It is not known\nwhether Arzerra works in children and adolescents. Therefore Arzerra is not\nrecommended for use in children and adolescents.</span></p>", "ID": "c5b5c672-9f46-44d6-9d90-87047c6fa853", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">It is not known\nwhether Arzerra works in children and adolescents. Therefore Arzerra is not\nrecommended for use in children and adolescents.</span>", "ID": "eb74b875-a554-4196-98fe-f7151df9c445", "Styles": "None", "Classes": "None", "Text": "It is not known whether Arzerra works in children and adolescents. Therefore Arzerra is not recommended for use in children and adolescents.", "ParentId": "c5b5c672-9f46-44d6-9d90-87047c6fa853"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f71cadbd-eaff-45f1-872f-d6ccec56c373", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fd22794f-cf0e-4cdf-b1ca-25244c60aa73", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f71cadbd-eaff-45f1-872f-d6ccec56c373"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Other\nmedicines and Arzerra</span></b></p>", "ID": "57140363-d5f4-4848-9ac2-9d1a3151af9a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">Other\nmedicines and Arzerra</span></b>", "ID": "445db7da-079e-4790-9870-3314d1ec90eb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "57140363-d5f4-4848-9ac2-9d1a3151af9a"}, {"Element": "<span lang=\"EN-GB\">Other\nmedicines and Arzerra</span>", "ID": "a0ec77f8-77b8-44d1-98cb-47e5bcb07cff", "Styles": "None", "Classes": "None", "Text": "Other medicines and Arzerra", "ParentId": "445db7da-079e-4790-9870-3314d1ec90eb"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Tell your doctor\nor pharmacist if you are using, have recently used or might use any other\nmedicines. This includes herbal medicines and other medicines you can obtain\nwithout a prescription.</span></p>", "ID": "06f07974-0c64-41c1-bb29-67003c504097", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor\nor pharmacist if you are using, have recently used or might use any other\nmedicines. This includes herbal medicines and other medicines you can obtain\nwithout a prescription.</span>", "ID": "840b5602-71eb-46c4-8bbd-58d75695913a", "Styles": "None", "Classes": "None", "Text": "Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. This includes herbal medicines and other medicines you can obtain without a prescription.", "ParentId": "06f07974-0c64-41c1-bb29-67003c504097"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c265e16f-b12a-4faf-85a4-c407212e22e6", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0749aba7-082a-4e4b-9521-2d54feecf866", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c265e16f-b12a-4faf-85a4-c407212e22e6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Pregnancy,\nbreast-feeding and fertility</span></b></p>", "ID": "40e7546b-5cab-4744-8f2a-a5267c729c7f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">Pregnancy,\nbreast-feeding and fertility</span></b>", "ID": "bcb7ef14-755d-4d54-99f8-d6bb689e9384", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "40e7546b-5cab-4744-8f2a-a5267c729c7f"}, {"Element": "<span lang=\"EN-GB\">Pregnancy,\nbreast-feeding and fertility</span>", "ID": "7ebf794d-3233-4b62-bc7d-acc122a91113", "Styles": "None", "Classes": "None", "Text": "Pregnancy, breast-feeding and fertility", "ParentId": "bcb7ef14-755d-4d54-99f8-d6bb689e9384"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Arzerra is not usually recommended for use during pregnancy.</span></p>", "ID": "897ab5f1-d9bb-47b6-80c9-1a307285bd04", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Arzerra is not usually recommended for use during pregnancy.</span>", "ID": "d0be1458-11f1-4580-b115-b35d90494f59", "Styles": "None", "Classes": "None", "Text": "Arzerra is not usually recommended for use during pregnancy.", "ParentId": "897ab5f1-d9bb-47b6-80c9-1a307285bd04"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\" style=\"color:black\">Tell your doctor if you are\npregnant or breast-feeding, think you may be pregnant, or are planning to have\na baby. </span><span lang=\"EN-GB\">Your doctor will weigh up the benefit to you\nagainst the risk to your baby of taking Arzerra while you're pregnant.</span></p>", "ID": "fdb57b0f-4041-4371-8846-6cf0dbd0f5c3", "Styles": "margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.8pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "339fe4d2-b46a-4328-bfaf-d9fa68eaa17f", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "fdb57b0f-4041-4371-8846-6cf0dbd0f5c3"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "ba0dde37-2a3d-4843-b3d0-ad3904024420", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "339fe4d2-b46a-4328-bfaf-d9fa68eaa17f"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Tell your doctor if you are\npregnant or breast-feeding, think you may be pregnant, or are planning to have\na baby. </span>", "ID": "50d87517-9c30-44e0-9114-71758a2d0979", "Styles": "color:black", "Classes": "None", "Text": "Tell your doctor if you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby. ", "ParentId": "fdb57b0f-4041-4371-8846-6cf0dbd0f5c3"}, {"Element": "<span lang=\"EN-GB\">Your doctor will weigh up the benefit to you\nagainst the risk to your baby of taking Arzerra while you're pregnant.</span>", "ID": "7940d67a-e3ad-4916-9ac6-670d1b921379", "Styles": "None", "Classes": "None", "Text": "Your doctor will weigh up the benefit to you against the risk to your baby of taking Arzerra while you're pregnant.", "ParentId": "fdb57b0f-4041-4371-8846-6cf0dbd0f5c3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\" style=\"color:black\">Use a reliable method of\ncontraception </span><span lang=\"EN-GB\" style=\"color:black\">to avoid becoming<b> </b>pregnant\nwhile you are being treated with Arzerra, </span>and for 12\u00a0months after\nyour last dose of Arzerra. Ask your doctor for advice if you are planning to\nbecome pregnant after this period.</p>", "ID": "2a7475f6-845f-4024-9b1b-f2cb16fc21cb", "Styles": "margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.8pt", "Classes": "['MsoNormal']", "Text": "and for 12\u00a0months after your last dose of Arzerra. Ask your doctor for advice if you are planning to become pregnant after this period.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "4412ba28-b6f0-4be1-acbc-258823748f4e", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "2a7475f6-845f-4024-9b1b-f2cb16fc21cb"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "ab08b4be-c154-45c8-b8e5-bca76fb285d8", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "4412ba28-b6f0-4be1-acbc-258823748f4e"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Use a reliable method of\ncontraception </span>", "ID": "a0c2a976-f7e8-40e2-80b4-70ed0bdeb543", "Styles": "color:black", "Classes": "None", "Text": "Use a reliable method of contraception ", "ParentId": "2a7475f6-845f-4024-9b1b-f2cb16fc21cb"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">to avoid becoming<b> </b>pregnant\nwhile you are being treated with Arzerra, </span>", "ID": "dd80046d-e5c7-4207-969a-06afd9be8fe1", "Styles": "color:black", "Classes": "None", "Text": "to avoid becomingpregnant while you are being treated with Arzerra, ", "ParentId": "2a7475f6-845f-4024-9b1b-f2cb16fc21cb"}, {"Element": "<b> </b>", "ID": "1ee49c02-435c-4014-985c-51584af3cb20", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "dd80046d-e5c7-4207-969a-06afd9be8fe1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">If you do become pregnant during treatment with\nArzerra, tell your doctor.</span></p>", "ID": "74f3e2b7-6a86-4c69-8b89-00c420d80c6c", "Styles": "margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.8pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "ba558429-588f-40a4-817e-71c0163f8b2b", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "74f3e2b7-6a86-4c69-8b89-00c420d80c6c"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "4855e4a8-bb4f-4f71-a03e-01b5c804076f", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "ba558429-588f-40a4-817e-71c0163f8b2b"}, {"Element": "<span lang=\"EN-GB\">If you do become pregnant during treatment with\nArzerra, tell your doctor.</span>", "ID": "a354082b-e1fd-4eb4-bc46-0a77e272a3f0", "Styles": "None", "Classes": "None", "Text": "If you do become pregnant during treatment with Arzerra, tell your doctor.", "ParentId": "74f3e2b7-6a86-4c69-8b89-00c420d80c6c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3dffeeeb-fee3-4456-8374-46a1e40e917a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ae238b7c-b541-4ea9-8512-a895f86ec49d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3dffeeeb-fee3-4456-8374-46a1e40e917a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">It is not known\nwhether the ingredients in Arzerra pass into human milk. Breast-feeding is not\nrecommended during treatment with Arzerra and for 12\u00a0months after the last\ndose.</span></p>", "ID": "11a6220a-c2c9-42b1-864e-fb19e8a218b1", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">It is not known\nwhether the ingredients in Arzerra pass into human milk. Breast-feeding is not\nrecommended during treatment with Arzerra and for 12\u00a0months after the last\ndose.</span>", "ID": "c4bc89cc-2648-47b5-a721-784cf75c4f7b", "Styles": "None", "Classes": "None", "Text": "It is not known whether the ingredients in Arzerra pass into human milk. Breast-feeding is not recommended during treatment with Arzerra and for 12\u00a0months after the last dose.", "ParentId": "11a6220a-c2c9-42b1-864e-fb19e8a218b1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "53c561c4-b942-43ed-b8bd-5f96032c4760", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f4f32908-b442-43ae-b906-a5dc36d7e53f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "53c561c4-b942-43ed-b8bd-5f96032c4760"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Driving\nand using machines</span></b></p>", "ID": "78fe2fe7-ee3a-4274-9272-6ddb77760e06", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">Driving\nand using machines</span></b>", "ID": "67af3dcd-5106-46d8-bded-7c27c1cfe8e3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "78fe2fe7-ee3a-4274-9272-6ddb77760e06"}, {"Element": "<span lang=\"EN-GB\">Driving\nand using machines</span>", "ID": "aaf158d5-6426-408d-8a62-747a9328b5e3", "Styles": "None", "Classes": "None", "Text": "Driving and using machines", "ParentId": "67af3dcd-5106-46d8-bded-7c27c1cfe8e3"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Arzerra is unlikely to affect your ability to drive or use\nmachines.</span></p>", "ID": "c6632f82-8004-4677-bcec-1f3749f01d16", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Arzerra is unlikely to affect your ability to drive or use\nmachines.</span>", "ID": "0224531e-31c9-4a7a-9730-cc358117dd09", "Styles": "color:black", "Classes": "None", "Text": "Arzerra is unlikely to affect your ability to drive or use machines.", "ParentId": "c6632f82-8004-4677-bcec-1f3749f01d16"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1d9a2e3c-4b27-4f15-af75-2eb444c4874e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1b5ccc0f-00fb-4fe6-9545-1424a384c555", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1d9a2e3c-4b27-4f15-af75-2eb444c4874e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Arzerra\ncontains sodium</span></b></p>", "ID": "07323fb7-5543-4a7e-b1c0-98b26c9380a3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">Arzerra\ncontains sodium</span></b>", "ID": "f27e8a1e-fc01-4c84-b2f4-251792c6e4b1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "07323fb7-5543-4a7e-b1c0-98b26c9380a3"}, {"Element": "<span lang=\"EN-GB\">Arzerra\ncontains sodium</span>", "ID": "4bb15955-23e6-4516-a490-25bcaf42421f", "Styles": "None", "Classes": "None", "Text": "Arzerra contains sodium", "ParentId": "f27e8a1e-fc01-4c84-b2f4-251792c6e4b1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Arzerra contains 34.8\u00a0mg sodium in\neach 300\u00a0mg dose, 116\u00a0mg sodium in each 1000\u00a0mg dose and\n232\u00a0mg sodium in each 2000\u00a0mg dose. You need to take this into\naccount if you are on a controlled sodium diet.</span></p>", "ID": "b9a4c578-9fb4-4e13-b7bf-f8a0b0946efe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Arzerra contains 34.8\u00a0mg sodium in\neach 300\u00a0mg dose, 116\u00a0mg sodium in each 1000\u00a0mg dose and\n232\u00a0mg sodium in each 2000\u00a0mg dose. You need to take this into\naccount if you are on a controlled sodium diet.</span>", "ID": "8104a869-54aa-479a-b609-e2672ed18ab3", "Styles": "None", "Classes": "None", "Text": "Arzerra contains 34.8\u00a0mg sodium in each 300\u00a0mg dose, 116\u00a0mg sodium in each 1000\u00a0mg dose and 232\u00a0mg sodium in each 2000\u00a0mg dose. You need to take this into account if you are on a controlled sodium diet.", "ParentId": "b9a4c578-9fb4-4e13-b7bf-f8a0b0946efe"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "03f83d36-5f8b-47cd-b8a0-3b3e6a4d4e89", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d103922a-dedc-4c26-9b59-c20897f05a7c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "03f83d36-5f8b-47cd-b8a0-3b3e6a4d4e89"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "12eb097f-98b2-45c8-ae0c-9d5b7878fa9b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5195101c-0a9c-4b6c-8683-326823aa6223", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "12eb097f-98b2-45c8-ae0c-9d5b7878fa9b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How Arzerra is given</span></b></p>", "ID": "73b1ff28-7b3a-42dc-888a-e1bc3b60f7b5", "Styles": "margin-right:-.1pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How Arzerra is given</span></b>", "ID": "7b594259-2000-4cad-8490-a34b28cfd476", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "73b1ff28-7b3a-42dc-888a-e1bc3b60f7b5"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How Arzerra is given</span>", "ID": "c8604383-4500-4be6-bc77-709f2b993961", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How Arzerra is given", "ParentId": "7b594259-2000-4cad-8490-a34b28cfd476"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f46d2ede-b8dd-4ad3-8cc1-5fbca9f8f044", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a197e380-435e-43a5-9035-9057955117cd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f46d2ede-b8dd-4ad3-8cc1-5fbca9f8f044"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">If you have any\nquestions on the use of Arzerra, ask the doctor or nurse who is giving you the\ninfusion.</span></p>", "ID": "8b78c51b-a591-4601-898b-6391306933dc", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">If you have any\nquestions on the use of Arzerra, ask the doctor or nurse who is giving you the\ninfusion.</span>", "ID": "fe54788a-d770-4994-885a-f69af35e7fa2", "Styles": "None", "Classes": "None", "Text": "If you have any questions on the use of Arzerra, ask the doctor or nurse who is giving you the infusion.", "ParentId": "8b78c51b-a591-4601-898b-6391306933dc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a151e864-d508-4316-9ebb-eb2f8a649531", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7aa3f42d-c72d-4b6a-a3ba-83797c9e8030", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a151e864-d508-4316-9ebb-eb2f8a649531"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">The usual dose</span></b></p>", "ID": "63bbf100-6756-44cc-97bb-590c3a3c2bda", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">The usual dose</span></b>", "ID": "a69a5388-61ee-4d02-acc6-5eecaf2b20c0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "63bbf100-6756-44cc-97bb-590c3a3c2bda"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">The usual dose</span>", "ID": "753a9103-e87f-4036-8a73-4f742a88be3c", "Styles": "color:black", "Classes": "None", "Text": "The usual dose", "ParentId": "a69a5388-61ee-4d02-acc6-5eecaf2b20c0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The usual dose of Arzerra for the first\ninfusion is 300\u00a0mg. This dose will be increased, usually to 1000\u00a0mg\nor 2000\u00a0mg, for the remaining infusions.</span></p>", "ID": "a03d7afc-5707-4788-8d9c-300e736d29a8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">The usual dose of Arzerra for the first\ninfusion is 300\u00a0mg. This dose will be increased, usually to 1000\u00a0mg\nor 2000\u00a0mg, for the remaining infusions.</span>", "ID": "aba4710d-d62d-4d4c-8ebe-fe36050f5ee3", "Styles": "None", "Classes": "None", "Text": "The usual dose of Arzerra for the first infusion is 300\u00a0mg. This dose will be increased, usually to 1000\u00a0mg or 2000\u00a0mg, for the remaining infusions.", "ParentId": "a03d7afc-5707-4788-8d9c-300e736d29a8"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "73f00273-6087-4093-9a31-14a29992ad23", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "a39f8e67-687e-458a-9895-01d3c13640b3", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "73f00273-6087-4093-9a31-14a29992ad23"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">How it is given</span></b></p>", "ID": "ecd9969e-bab6-4b03-953b-a05d0cbceb54", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">How it is given</span></b>", "ID": "db485882-cc0f-4241-96af-c1e3904e0727", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ecd9969e-bab6-4b03-953b-a05d0cbceb54"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">How it is given</span>", "ID": "3606632f-8d80-4120-9cc8-d96d9bb3cdbd", "Styles": "color:black", "Classes": "None", "Text": "How it is given", "ParentId": "db485882-cc0f-4241-96af-c1e3904e0727"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Arzerra is\ngiven into a vein (intravenously) as an infusion (a drip) over several hours.</span></p>", "ID": "b58b7eee-080b-4752-b106-9524a2810f9c", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Arzerra is\ngiven into a vein (intravenously) as an infusion (a drip) over several hours.</span>", "ID": "0605a842-8390-4f4e-9e07-82603f555322", "Styles": "None", "Classes": "None", "Text": "Arzerra is given into a vein (intravenously) as an infusion (a drip) over several hours.", "ParentId": "b58b7eee-080b-4752-b106-9524a2810f9c"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4d3f2f81-9e1b-4a5e-b067-053c992cba24", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8b6a7a91-0400-4084-8922-e01f19968c8d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4d3f2f81-9e1b-4a5e-b067-053c992cba24"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\">If you have\nnot been previously treated for CLL you will have a maximum of\n13\u00a0infusions.</span></b><span lang=\"EN-GB\"> You will be given an initial\ninfusion followed by a second infusion 7\u00a0days later. The remaining\ninfusions will then be given once a month for up to 11\u00a0months.</span></p>", "ID": "055f1b5c-0676-4763-bd6b-17bdade123b3", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">If you have\nnot been previously treated for CLL you will have a maximum of\n13\u00a0infusions.</span></b>", "ID": "9a57a82c-3804-4ff0-a930-985801666595", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "055f1b5c-0676-4763-bd6b-17bdade123b3"}, {"Element": "<span lang=\"EN-GB\">If you have\nnot been previously treated for CLL you will have a maximum of\n13\u00a0infusions.</span>", "ID": "b7aeaab3-4bac-48f8-8cb7-65f7620e1b19", "Styles": "None", "Classes": "None", "Text": "If you have not been previously treated for CLL you will have a maximum of 13\u00a0infusions.", "ParentId": "9a57a82c-3804-4ff0-a930-985801666595"}, {"Element": "<span lang=\"EN-GB\"> You will be given an initial\ninfusion followed by a second infusion 7\u00a0days later. The remaining\ninfusions will then be given once a month for up to 11\u00a0months.</span>", "ID": "3eaa5aa8-1caa-4f86-95e3-776cd7d53287", "Styles": "None", "Classes": "None", "Text": " You will be given an initial infusion followed by a second infusion 7\u00a0days later. The remaining infusions will then be given once a month for up to 11\u00a0months.", "ParentId": "055f1b5c-0676-4763-bd6b-17bdade123b3"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "e7af8609-7f6e-44b4-b7db-e369066e9648", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "ef01d76e-ce82-4372-911a-e7e9cff14301", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "e7af8609-7f6e-44b4-b7db-e369066e9648"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\">If you have\nbeen previously treated for CLL but the disease returns you will have a maximum\nof 7\u00a0infusions.</span></b><span lang=\"EN-GB\"> You will be given an initial\ninfusion followed by a second infusion 7\u00a0days later. The remaining\ninfusions will then be given once a month for up to 6\u00a0months.</span></p>", "ID": "d98ef57f-8c12-4fba-aa50-3f7b627065c1", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">If you have\nbeen previously treated for CLL but the disease returns you will have a maximum\nof 7\u00a0infusions.</span></b>", "ID": "02289477-6cdf-4ce1-8f42-ef62d33c471f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d98ef57f-8c12-4fba-aa50-3f7b627065c1"}, {"Element": "<span lang=\"EN-GB\">If you have\nbeen previously treated for CLL but the disease returns you will have a maximum\nof 7\u00a0infusions.</span>", "ID": "3d0a12a2-db94-4222-aa8b-748dd17e8314", "Styles": "None", "Classes": "None", "Text": "If you have been previously treated for CLL but the disease returns you will have a maximum of 7\u00a0infusions.", "ParentId": "02289477-6cdf-4ce1-8f42-ef62d33c471f"}, {"Element": "<span lang=\"EN-GB\"> You will be given an initial\ninfusion followed by a second infusion 7\u00a0days later. The remaining\ninfusions will then be given once a month for up to 6\u00a0months.</span>", "ID": "bc545e62-87a4-4e94-bf89-8fd4e62da67b", "Styles": "None", "Classes": "None", "Text": " You will be given an initial infusion followed by a second infusion 7\u00a0days later. The remaining infusions will then be given once a month for up to 6\u00a0months.", "ParentId": "d98ef57f-8c12-4fba-aa50-3f7b627065c1"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "d85e4367-a27f-49d0-82c5-7bc967f772f3", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "1f2f9e6a-dcdb-4b52-9607-8b006c13840a", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "d85e4367-a27f-49d0-82c5-7bc967f772f3"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\">If you have\nbeen previously treated for CLL </span></b><b><span lang=\"EN-GB\" style=\"color:black\">you will usually have a course of 12\u00a0infusions.</span></b><span lang=\"EN-GB\" style=\"color:black\"> You will be given an infusion once a week for\neight weeks. This is followed by a four- to five-week gap. The remaining\ninfusions will then be given once a month for four months.</span></p>", "ID": "9c56ed2c-57f1-495e-adde-42e065d68feb", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">If you have\nbeen previously treated for CLL </span></b>", "ID": "747326cb-0b80-4168-9c5e-6547eab1e464", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9c56ed2c-57f1-495e-adde-42e065d68feb"}, {"Element": "<span lang=\"EN-GB\">If you have\nbeen previously treated for CLL </span>", "ID": "8cb38794-72f9-40c7-a0c2-758b85d4702a", "Styles": "None", "Classes": "None", "Text": "If you have been previously treated for CLL ", "ParentId": "747326cb-0b80-4168-9c5e-6547eab1e464"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">you will usually have a course of 12\u00a0infusions.</span></b>", "ID": "a1541b60-b662-4be6-b8d4-190c990a2986", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9c56ed2c-57f1-495e-adde-42e065d68feb"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">you will usually have a course of 12\u00a0infusions.</span>", "ID": "21985948-e776-4f69-965f-abebe308b987", "Styles": "color:black", "Classes": "None", "Text": "you will usually have a course of 12\u00a0infusions.", "ParentId": "a1541b60-b662-4be6-b8d4-190c990a2986"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\"> You will be given an infusion once a week for\neight weeks. This is followed by a four- to five-week gap. The remaining\ninfusions will then be given once a month for four months.</span>", "ID": "8681cec6-a1b7-46bf-b3f4-2e38dabb7298", "Styles": "color:black", "Classes": "None", "Text": " You will be given an infusion once a week for eight weeks. This is followed by a four- to five-week gap. The remaining infusions will then be given once a month for four months.", "ParentId": "9c56ed2c-57f1-495e-adde-42e065d68feb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f77d2e20-e602-4b3f-b510-ccac969cce6f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "47a0f732-f86a-4b1b-9e5e-c24bd31563d2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f77d2e20-e602-4b3f-b510-ccac969cce6f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Medicines\ngiven before each infusion</span></b></p>", "ID": "738b26c9-e2d2-43aa-9fa7-211e2f022d52", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">Medicines\ngiven before each infusion</span></b>", "ID": "b2308533-7353-421d-8008-1d3a332268b4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "738b26c9-e2d2-43aa-9fa7-211e2f022d52"}, {"Element": "<span lang=\"EN-GB\">Medicines\ngiven before each infusion</span>", "ID": "89f2aea0-2bac-4754-886e-0c52ccc2377b", "Styles": "None", "Classes": "None", "Text": "Medicines given before each infusion", "ParentId": "b2308533-7353-421d-8008-1d3a332268b4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Before each infusion of Arzerra, you will\nbe given <b>pre-medication</b> \u2011 medicines which help to reduce any\ninfusion reactions. These may include anti-histamines, steroids and pain relievers.\nYou will be checked closely and if you do have any reactions these will be\ntreated.</span></p>", "ID": "6578dc52-bc28-4398-b869-b6166e9b0f1b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Before each infusion of Arzerra, you will\nbe given <b>pre-medication</b> \u2011 medicines which help to reduce any\ninfusion reactions. These may include anti-histamines, steroids and pain relievers.\nYou will be checked closely and if you do have any reactions these will be\ntreated.</span>", "ID": "94f4da36-cf7b-49ff-a0e9-f6c3f324fbc4", "Styles": "None", "Classes": "None", "Text": "Before each infusion of Arzerra, you will be given  \u2011 medicines which help to reduce any infusion reactions. These may include anti-histamines, steroids and pain relievers. You will be checked closely and if you do have any reactions these will be treated.", "ParentId": "6578dc52-bc28-4398-b869-b6166e9b0f1b"}, {"Element": "<b>pre-medication</b>", "ID": "75e3d40b-ac9d-4976-abdd-918b6f21d4af", "Styles": "None", "Classes": "None", "Text": "pre-medication", "ParentId": "94f4da36-cf7b-49ff-a0e9-f6c3f324fbc4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b1efd447-7ea1-437b-b119-a2b08f398dbe", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2546c755-9f22-4b0c-8a2b-6e0b0a08d684", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b1efd447-7ea1-437b-b119-a2b08f398dbe"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0a25c863-e8dc-45c7-abec-617898afea56", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "23dcd481-7a11-46d0-aa74-9fa5c145e961", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0a25c863-e8dc-45c7-abec-617898afea56"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side effects</span></b></p>", "ID": "26274c75-8eb2-4bdf-aba6-30c2bc0b5358", "Styles": "margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side effects</span></b>", "ID": "c985a6ed-3991-4183-8237-09d0ba97551a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "26274c75-8eb2-4bdf-aba6-30c2bc0b5358"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side effects</span>", "ID": "7e215fe1-3d30-4079-bd33-ad413eb303b8", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side effects", "ParentId": "c985a6ed-3991-4183-8237-09d0ba97551a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "43cc107d-6dd1-487c-8170-2ac57ada7a29", "Styles": "margin-right:-.1pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "77eb897b-8a23-42c5-b134-d905909fbe66", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "43cc107d-6dd1-487c-8170-2ac57ada7a29"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Like all\nmedicines, this medicine can cause side effects, although not everybody gets\nthem.</span></p>", "ID": "db58adee-97d9-43d9-aadd-5baa6e9725a7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Like all\nmedicines, this medicine can cause side effects, although not everybody gets\nthem.</span>", "ID": "fca25e85-315f-4529-a971-861de5927e05", "Styles": "None", "Classes": "None", "Text": "Like all medicines, this medicine can cause side effects, although not everybody gets them.", "ParentId": "db58adee-97d9-43d9-aadd-5baa6e9725a7"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "31c0acea-da5e-4641-a2d5-685df1be514a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0e7d3b9d-76f8-4589-9fec-71c94275ae5d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "31c0acea-da5e-4641-a2d5-685df1be514a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Infusion-related\nreactions</span></b></p>", "ID": "e97db5c5-a329-4768-834d-9e899801d4a1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">Infusion-related\nreactions</span></b>", "ID": "af30c6ec-ca16-4b74-bf54-af8ea429eed0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e97db5c5-a329-4768-834d-9e899801d4a1"}, {"Element": "<span lang=\"EN-GB\">Infusion-related\nreactions</span>", "ID": "755b49b2-9348-4325-b72d-c160549579f3", "Styles": "None", "Classes": "None", "Text": "Infusion-related reactions", "ParentId": "af30c6ec-ca16-4b74-bf54-af8ea429eed0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Medicines of this type (monoclonal\nantibodies) can cause infusion-related reactions, which are occasionally\nsevere, and can cause death. They are more likely during the first treatment.</span></p>", "ID": "4ab0e07f-ee51-43f2-b1dd-58ac08e223ec", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Medicines of this type (monoclonal\nantibodies) can cause infusion-related reactions, which are occasionally\nsevere, and can cause death. They are more likely during the first treatment.</span>", "ID": "71e02534-8fd0-4064-a2df-9dd0007e1528", "Styles": "None", "Classes": "None", "Text": "Medicines of this type (monoclonal antibodies) can cause infusion-related reactions, which are occasionally severe, and can cause death. They are more likely during the first treatment.", "ParentId": "4ab0e07f-ee51-43f2-b1dd-58ac08e223ec"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "266a8c2d-063f-47f3-901d-947f34aa324c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "701a9b33-86b0-4817-8b7d-b3c89c3319a1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "266a8c2d-063f-47f3-901d-947f34aa324c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Very\ncommon symptoms of an infusion-related reaction</span></b><span lang=\"EN-GB\">\n(may affect more than 1 in 10\u00a0people):</span></p>", "ID": "83a25b1e-4d67-414a-95a9-6534e3d2bb73", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">Very\ncommon symptoms of an infusion-related reaction</span></b>", "ID": "fd62cac5-f17e-4746-a70f-5aa9eb3a63d1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "83a25b1e-4d67-414a-95a9-6534e3d2bb73"}, {"Element": "<span lang=\"EN-GB\">Very\ncommon symptoms of an infusion-related reaction</span>", "ID": "f76f6da7-6957-4788-9167-74617d36149d", "Styles": "None", "Classes": "None", "Text": "Very common symptoms of an infusion-related reaction", "ParentId": "fd62cac5-f17e-4746-a70f-5aa9eb3a63d1"}, {"Element": "<span lang=\"EN-GB\">\n(may affect more than 1 in 10\u00a0people):</span>", "ID": "cad4657c-f062-41f9-8d4e-7ca91cecc5b4", "Styles": "None", "Classes": "None", "Text": " (may affect more than 1 in 10\u00a0people):", "ParentId": "83a25b1e-4d67-414a-95a9-6534e3d2bb73"}, {"Element": "<p class=\"Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">feeling sick (nausea)</span></p>", "ID": "a9b77170-c2e2-47d6-a684-ebc059246a1d", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['Bullet']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "4217ec82-eec0-4ceb-ab1c-8cb37ea887e0", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "a9b77170-c2e2-47d6-a684-ebc059246a1d"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "7a7bef1c-e2ae-4123-ac20-33cdd33c987f", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "4217ec82-eec0-4ceb-ab1c-8cb37ea887e0"}, {"Element": "<span lang=\"EN-GB\">feeling sick (nausea)</span>", "ID": "e0edd7d2-c929-4678-b115-57326b606aae", "Styles": "None", "Classes": "None", "Text": "feeling sick (nausea)", "ParentId": "a9b77170-c2e2-47d6-a684-ebc059246a1d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">high temperature</span></p>", "ID": "226686c9-1fb7-4ed0-b1dd-cbd117653fc7", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "c56a8db2-e65f-4787-8185-a5a080ca338a", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "226686c9-1fb7-4ed0-b1dd-cbd117653fc7"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "faafcccf-2291-414e-8580-22944963c2dd", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "c56a8db2-e65f-4787-8185-a5a080ca338a"}, {"Element": "<span lang=\"EN-GB\">high temperature</span>", "ID": "3eb741ed-8195-4403-97d9-48af920c6bb4", "Styles": "None", "Classes": "None", "Text": "high temperature", "ParentId": "226686c9-1fb7-4ed0-b1dd-cbd117653fc7"}, {"Element": "<p class=\"Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.8pt;line-height:normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">skin rash</span></p>", "ID": "48e7f465-b7cf-4c4e-b4e3-6ea795930991", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.8pt;line-height:normal", "Classes": "['Bullet']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "f5312828-d11b-438f-8db0-02944ef37e8d", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "48e7f465-b7cf-4c4e-b4e3-6ea795930991"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "57d4691e-464e-4057-8417-99c35a767248", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "f5312828-d11b-438f-8db0-02944ef37e8d"}, {"Element": "<span lang=\"EN-GB\">skin rash</span>", "ID": "f1cb25bf-9fdd-4366-8ecc-c82d4f16ef7d", "Styles": "None", "Classes": "None", "Text": "skin rash", "ParentId": "48e7f465-b7cf-4c4e-b4e3-6ea795930991"}, {"Element": "<p class=\"Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.8pt;line-height:normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">breathlessness, cough</span></p>", "ID": "0254f088-81be-4527-b84e-60b91141378f", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.8pt;line-height:normal", "Classes": "['Bullet']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "b260baec-5cac-4249-8d97-9d559db1b481", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "0254f088-81be-4527-b84e-60b91141378f"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "b888d631-6d87-4cf8-afa7-b21d7b7121f9", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "b260baec-5cac-4249-8d97-9d559db1b481"}, {"Element": "<span lang=\"EN-GB\">breathlessness, cough</span>", "ID": "826f723f-e585-43ad-86f3-c251ad21812e", "Styles": "None", "Classes": "None", "Text": "breathlessness, cough", "ParentId": "0254f088-81be-4527-b84e-60b91141378f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">diarrhoea</span></p>", "ID": "c443ef6f-b6e2-4442-908e-0064128fd151", "Styles": "margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "bb69b8ef-001c-48b0-9fe8-8a7fbd8b96d8", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "c443ef6f-b6e2-4442-908e-0064128fd151"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "666f49e1-00c1-4a10-bfdc-e24e13b4fadd", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "bb69b8ef-001c-48b0-9fe8-8a7fbd8b96d8"}, {"Element": "<span lang=\"EN-GB\">diarrhoea</span>", "ID": "442c056a-b7bb-41c7-be9e-ac047400e2c7", "Styles": "None", "Classes": "None", "Text": "diarrhoea", "ParentId": "c443ef6f-b6e2-4442-908e-0064128fd151"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">lack of energy</span></p>", "ID": "ee7d2314-35ee-4c9d-96d3-2b5ebc8ee96e", "Styles": "margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "9b703cbc-de93-4c20-b181-d2cc95ce9a6e", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "ee7d2314-35ee-4c9d-96d3-2b5ebc8ee96e"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "20a4d19f-0a1a-430a-b7f9-a437355843b8", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "9b703cbc-de93-4c20-b181-d2cc95ce9a6e"}, {"Element": "<span lang=\"EN-GB\">lack of energy</span>", "ID": "f1aa9bad-aa99-466e-af02-36ef544a8a5a", "Styles": "None", "Classes": "None", "Text": "lack of energy", "ParentId": "ee7d2314-35ee-4c9d-96d3-2b5ebc8ee96e"}, {"Element": "<p class=\"Bullet\" style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;\nline-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1156ede7-14ff-48e5-9dd2-becd31430e4f", "Styles": "margin:0in;margin-bottom:.0001pt;text-indent:0in;\nline-height:normal", "Classes": "['Bullet']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "36296e7b-3e1c-4d3f-9e65-6fcffcc0f119", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1156ede7-14ff-48e5-9dd2-becd31430e4f"}, {"Element": "<p class=\"Bullet\" style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;\nline-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Common symptoms\nof an infusion-related reaction</span></b><span lang=\"EN-GB\"> (may affect up to 1\nin 10\u00a0people):</span></p>", "ID": "1fe7734e-fd8c-4b4d-a93d-b7656a582312", "Styles": "margin:0in;margin-bottom:.0001pt;text-indent:0in;\nline-height:normal;page-break-after:avoid", "Classes": "['Bullet']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">Common symptoms\nof an infusion-related reaction</span></b>", "ID": "28d94bb2-5b73-472b-ba70-157cfb4e4d8f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1fe7734e-fd8c-4b4d-a93d-b7656a582312"}, {"Element": "<span lang=\"EN-GB\">Common symptoms\nof an infusion-related reaction</span>", "ID": "68e865d9-db32-4d90-adb4-d9bbdd0310eb", "Styles": "None", "Classes": "None", "Text": "Common symptoms of an infusion-related reaction", "ParentId": "28d94bb2-5b73-472b-ba70-157cfb4e4d8f"}, {"Element": "<span lang=\"EN-GB\"> (may affect up to 1\nin 10\u00a0people):</span>", "ID": "9ceb4f9e-3b91-4830-adc6-e25f0a896384", "Styles": "None", "Classes": "None", "Text": " (may affect up to 1 in 10\u00a0people):", "ParentId": "1fe7734e-fd8c-4b4d-a93d-b7656a582312"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">allergic reactions, sometimes severe where\nsymptoms include raised and itchy rash (hives), swelling of the face or the\nmouth (angioedema) causing difficulty breathing and collapse</span></p>", "ID": "e09cd09b-6682-4bce-81fa-a2a84194abd3", "Styles": "margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "807cc0c7-91ad-417f-aaee-9f89e4665b2b", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "e09cd09b-6682-4bce-81fa-a2a84194abd3"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "fd868787-5e6e-4a48-8136-d6d4b8c19f94", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "807cc0c7-91ad-417f-aaee-9f89e4665b2b"}, {"Element": "<span lang=\"EN-GB\">allergic reactions, sometimes severe where\nsymptoms include raised and itchy rash (hives), swelling of the face or the\nmouth (angioedema) causing difficulty breathing and collapse</span>", "ID": "3dd0b589-c682-42f4-8824-0ede983e1814", "Styles": "None", "Classes": "None", "Text": "allergic reactions, sometimes severe where symptoms include raised and itchy rash (hives), swelling of the face or the mouth (angioedema) causing difficulty breathing and collapse", "ParentId": "e09cd09b-6682-4bce-81fa-a2a84194abd3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">difficulty in breathing, shortness of breath,\nchest tightness, cough</span></p>", "ID": "d8172b10-a73a-4eb5-86ed-71db997d34bc", "Styles": "margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "56b37a99-77bb-4b02-abb9-d9a7838be490", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "d8172b10-a73a-4eb5-86ed-71db997d34bc"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "41f037da-1579-474c-8f30-a08a0d1a9c6d", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "56b37a99-77bb-4b02-abb9-d9a7838be490"}, {"Element": "<span lang=\"EN-GB\">difficulty in breathing, shortness of breath,\nchest tightness, cough</span>", "ID": "4a1f48f1-0dff-4cc6-afad-98076efd4687", "Styles": "None", "Classes": "None", "Text": "difficulty in breathing, shortness of breath, chest tightness, cough", "ParentId": "d8172b10-a73a-4eb5-86ed-71db997d34bc"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">low blood pressure (can cause light-headedness\nwhen you stand up)</span></p>", "ID": "15397a7d-e143-420a-9738-0206043f82a8", "Styles": "margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "402d3b47-1c55-4cdd-bf76-e17bcaf5611b", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "15397a7d-e143-420a-9738-0206043f82a8"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "8d2e9f25-c9b7-4ce5-ae5e-097eead194b1", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "402d3b47-1c55-4cdd-bf76-e17bcaf5611b"}, {"Element": "<span lang=\"EN-GB\">low blood pressure (can cause light-headedness\nwhen you stand up)</span>", "ID": "a2f8604e-814c-4e56-a2b5-a1d49770e0ec", "Styles": "None", "Classes": "None", "Text": "low blood pressure (can cause light-headedness when you stand up)", "ParentId": "15397a7d-e143-420a-9738-0206043f82a8"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">flushing</span></p>", "ID": "109b35c5-f78d-4081-94d3-5127cb8a63ad", "Styles": "margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "bde562e6-11fa-4bc2-bd0a-be7ff5e524d5", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "109b35c5-f78d-4081-94d3-5127cb8a63ad"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "fb2c4f17-6e08-48e8-a607-a62ec232200b", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "bde562e6-11fa-4bc2-bd0a-be7ff5e524d5"}, {"Element": "<span lang=\"EN-GB\">flushing</span>", "ID": "3179514d-bb26-468c-9a7d-52838ee33c95", "Styles": "None", "Classes": "None", "Text": "flushing", "ParentId": "109b35c5-f78d-4081-94d3-5127cb8a63ad"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">excessive sweating</span></p>", "ID": "0fa00dfe-428e-4b50-a3ba-8d0d24afa0b5", "Styles": "margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "25e3107f-9e2b-4eb4-8014-55a85e917cb7", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "0fa00dfe-428e-4b50-a3ba-8d0d24afa0b5"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "f9ad04d5-26f7-4b44-87de-867475378efd", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "25e3107f-9e2b-4eb4-8014-55a85e917cb7"}, {"Element": "<span lang=\"EN-GB\">excessive sweating</span>", "ID": "86d53a2a-1601-4cd3-a476-d27bb1fffe86", "Styles": "None", "Classes": "None", "Text": "excessive sweating", "ParentId": "0fa00dfe-428e-4b50-a3ba-8d0d24afa0b5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">shaking or shivering</span></p>", "ID": "51e99de7-d640-4e3e-b299-439ea76044f3", "Styles": "margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "d6753233-6736-4dd0-ada2-090495d0f628", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "51e99de7-d640-4e3e-b299-439ea76044f3"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "2384ed94-4fcb-4f0f-88ca-f98b7aefea94", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "d6753233-6736-4dd0-ada2-090495d0f628"}, {"Element": "<span lang=\"EN-GB\">shaking or shivering</span>", "ID": "3f1ff47c-34b7-48aa-a804-e4c10de45a2d", "Styles": "None", "Classes": "None", "Text": "shaking or shivering", "ParentId": "51e99de7-d640-4e3e-b299-439ea76044f3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">rapid heart beat</span></p>", "ID": "4cae507e-5a9d-4d03-a72c-3ac9a6dbf55e", "Styles": "margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "0a04fc07-399e-4cf5-8f3a-a52923302fc9", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "4cae507e-5a9d-4d03-a72c-3ac9a6dbf55e"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "3638f773-de98-4728-bdf8-9e2b1dd85300", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "0a04fc07-399e-4cf5-8f3a-a52923302fc9"}, {"Element": "<span lang=\"EN-GB\">rapid heart beat</span>", "ID": "763d590e-0661-4a13-950f-80c7e77d1981", "Styles": "None", "Classes": "None", "Text": "rapid heart beat", "ParentId": "4cae507e-5a9d-4d03-a72c-3ac9a6dbf55e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">headache</span></p>", "ID": "75683a69-88bf-4c80-b010-297f6f02e0e1", "Styles": "margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "020b2b1b-2b5c-4170-9722-bee234f4c0a5", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "75683a69-88bf-4c80-b010-297f6f02e0e1"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "a51bd933-8634-480c-91d3-9f7e1ca85a13", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "020b2b1b-2b5c-4170-9722-bee234f4c0a5"}, {"Element": "<span lang=\"EN-GB\">headache</span>", "ID": "720b6dbd-3c98-4adf-8f60-e97d32ef5016", "Styles": "None", "Classes": "None", "Text": "headache", "ParentId": "75683a69-88bf-4c80-b010-297f6f02e0e1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">back pain</span></p>", "ID": "27132095-91cd-45c5-8380-99456f1f22c9", "Styles": "margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "00b52f21-5a74-492b-9883-3ead7dc1462e", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "27132095-91cd-45c5-8380-99456f1f22c9"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "381168cb-0c43-4b2e-ba7b-bb19df55ae5a", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "00b52f21-5a74-492b-9883-3ead7dc1462e"}, {"Element": "<span lang=\"EN-GB\">back pain</span>", "ID": "cda4817d-1c7f-4452-9f68-06f264a1662c", "Styles": "None", "Classes": "None", "Text": "back pain", "ParentId": "27132095-91cd-45c5-8380-99456f1f22c9"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">high blood pressure</span></p>", "ID": "0806fb55-b15d-4f7c-b4b2-e77cde6fe9d6", "Styles": "margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "35c1ebbd-752b-4cf7-9052-afee9cc9ba3e", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "0806fb55-b15d-4f7c-b4b2-e77cde6fe9d6"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "2aed2c48-cfdd-4d2e-9435-0526b04c535a", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "35c1ebbd-752b-4cf7-9052-afee9cc9ba3e"}, {"Element": "<span lang=\"EN-GB\">high blood pressure</span>", "ID": "943a740c-bb08-4434-aa0b-e9516befbe0c", "Styles": "None", "Classes": "None", "Text": "high blood pressure", "ParentId": "0806fb55-b15d-4f7c-b4b2-e77cde6fe9d6"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">throat pain or irritation</span><a name=\"OLE_LINK2\"></a></p>", "ID": "41158201-e5d4-4365-bf4b-7d1f38fe9605", "Styles": "margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "33fbd6e5-0ebe-4ca2-85cf-e4a057f8df3b", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "41158201-e5d4-4365-bf4b-7d1f38fe9605"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "5bb8fae0-f92c-4a54-8a28-8a805ae6618b", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "33fbd6e5-0ebe-4ca2-85cf-e4a057f8df3b"}, {"Element": "<span lang=\"EN-GB\">throat pain or irritation</span>", "ID": "cf56b5b2-2549-46dd-931b-df8f33faa3b7", "Styles": "None", "Classes": "None", "Text": "throat pain or irritation", "ParentId": "41158201-e5d4-4365-bf4b-7d1f38fe9605"}, {"Element": "<a name=\"OLE_LINK2\"></a>", "ID": "1ac65c9b-42da-4e1f-8d24-b41f14373ada", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "41158201-e5d4-4365-bf4b-7d1f38fe9605"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">blocked nose.</span></p>", "ID": "7bc544d8-95a2-4e7e-b32e-4705aa179a3b", "Styles": "margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "fe8b9cbd-13ec-41b2-b05e-7e02b620f9f6", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "7bc544d8-95a2-4e7e-b32e-4705aa179a3b"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "2fbba0fa-ff95-4ce5-8100-ae9a0446716d", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "fe8b9cbd-13ec-41b2-b05e-7e02b620f9f6"}, {"Element": "<span lang=\"EN-GB\">blocked nose.</span>", "ID": "465a02ba-1b08-421f-a020-f7f0c7bb57d7", "Styles": "None", "Classes": "None", "Text": "blocked nose.", "ParentId": "7bc544d8-95a2-4e7e-b32e-4705aa179a3b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "20270e1a-94da-4335-8021-a3fcc36f34db", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dd3c0bcb-f1d4-4684-85db-9e556d7400f1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "20270e1a-94da-4335-8021-a3fcc36f34db"}, {"Element": "<p class=\"Bullet\" style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;\nline-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Uncommon\nsymptoms of an infusion-related reaction</span></b><span lang=\"EN-GB\"> (may\naffect up to 1 in 100\u00a0people):</span></p>", "ID": "4d4f7c97-ebee-495e-a984-791197f01502", "Styles": "margin:0in;margin-bottom:.0001pt;text-indent:0in;\nline-height:normal;page-break-after:avoid", "Classes": "['Bullet']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">Uncommon\nsymptoms of an infusion-related reaction</span></b>", "ID": "67c25c60-e4ce-4211-9a3a-4b5b572db7dc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4d4f7c97-ebee-495e-a984-791197f01502"}, {"Element": "<span lang=\"EN-GB\">Uncommon\nsymptoms of an infusion-related reaction</span>", "ID": "4ab2eaaf-f56a-4aea-b347-eabb43c26203", "Styles": "None", "Classes": "None", "Text": "Uncommon symptoms of an infusion-related reaction", "ParentId": "67c25c60-e4ce-4211-9a3a-4b5b572db7dc"}, {"Element": "<span lang=\"EN-GB\"> (may\naffect up to 1 in 100\u00a0people):</span>", "ID": "b9fc75b0-c67b-427f-aa34-777cf7c16962", "Styles": "None", "Classes": "None", "Text": " (may affect up to 1 in 100\u00a0people):", "ParentId": "4d4f7c97-ebee-495e-a984-791197f01502"}, {"Element": "<p class=\"MsoCommentText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span style=\"font-size:11.0pt;font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"X-NONE\" style=\"font-size:11.0pt\">anaphylactic reaction\nincluding anaphylactic shock, where symptoms include breathlessness or\ndifficult</span><span style=\"font-size:11.0pt\">y</span><span lang=\"X-NONE\" style=\"font-size:11.0pt\"> breathing, wheezing or coughing, light-headedness,\ndizziness, changes in levels of consciousness, hypotension, with or without\nmild generali</span><span style=\"font-size:11.0pt\">s</span><span lang=\"X-NONE\" style=\"font-size:11.0pt\">ed itching, skin reddening, swelling</span><span style=\"font-size:11.0pt\"> of the face and/or throat</span><span lang=\"X-NONE\" style=\"font-size:11.0pt\">, blue discolouration of the lips, tongue or skin</span></p>", "ID": "0ecb8428-564c-49fe-a586-2e28c1a19208", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoCommentText']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt;font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "dff8cd31-2b67-4be5-a4e9-eb17441e48ae", "Styles": "font-size:11.0pt;font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "0ecb8428-564c-49fe-a586-2e28c1a19208"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "4f443d48-2dd4-4c89-b3a1-a9d5b43946ec", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "dff8cd31-2b67-4be5-a4e9-eb17441e48ae"}, {"Element": "<span lang=\"X-NONE\" style=\"font-size:11.0pt\">anaphylactic reaction\nincluding anaphylactic shock, where symptoms include breathlessness or\ndifficult</span>", "ID": "4aa80ce5-7238-45ce-bdb7-67922895afca", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "anaphylactic reaction including anaphylactic shock, where symptoms include breathlessness or difficult", "ParentId": "0ecb8428-564c-49fe-a586-2e28c1a19208"}, {"Element": "<span style=\"font-size:11.0pt\">y</span>", "ID": "affa991b-8d35-4740-b487-0bc5ec4a864c", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "y", "ParentId": "0ecb8428-564c-49fe-a586-2e28c1a19208"}, {"Element": "<span lang=\"X-NONE\" style=\"font-size:11.0pt\"> breathing, wheezing or coughing, light-headedness,\ndizziness, changes in levels of consciousness, hypotension, with or without\nmild generali</span>", "ID": "658edf77-145c-4ca9-b126-dec168220f7c", "Styles": "font-size:11.0pt", "Classes": "None", "Text": " breathing, wheezing or coughing, light-headedness, dizziness, changes in levels of consciousness, hypotension, with or without mild generali", "ParentId": "0ecb8428-564c-49fe-a586-2e28c1a19208"}, {"Element": "<span style=\"font-size:11.0pt\">s</span>", "ID": "9f66da08-97e3-45ff-99a8-149c29954647", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "s", "ParentId": "0ecb8428-564c-49fe-a586-2e28c1a19208"}, {"Element": "<span lang=\"X-NONE\" style=\"font-size:11.0pt\">ed itching, skin reddening, swelling</span>", "ID": "04e5fe4d-7dde-4a9d-8373-65440d17aa4f", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "ed itching, skin reddening, swelling", "ParentId": "0ecb8428-564c-49fe-a586-2e28c1a19208"}, {"Element": "<span style=\"font-size:11.0pt\"> of the face and/or throat</span>", "ID": "e2b8e08e-a4aa-4b80-918a-cd833034aa20", "Styles": "font-size:11.0pt", "Classes": "None", "Text": " of the face and/or throat", "ParentId": "0ecb8428-564c-49fe-a586-2e28c1a19208"}, {"Element": "<span lang=\"X-NONE\" style=\"font-size:11.0pt\">, blue discolouration of the lips, tongue or skin</span>", "ID": "ae284b42-b6bb-407a-b98f-78e37c047fb4", "Styles": "font-size:11.0pt", "Classes": "None", "Text": ", blue discolouration of the lips, tongue or skin", "ParentId": "0ecb8428-564c-49fe-a586-2e28c1a19208"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">fluid in the lungs (pulmonary oedema) causing\nbreathlessness</span></p>", "ID": "f5e9116e-1418-41f4-916e-ca41084eb4ca", "Styles": "margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "f13da1d8-4f6b-48fe-a3e1-86f6ab4eee98", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "f5e9116e-1418-41f4-916e-ca41084eb4ca"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "5ab2e522-d1d1-47c5-bcbc-f37e96624a8e", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "f13da1d8-4f6b-48fe-a3e1-86f6ab4eee98"}, {"Element": "<span lang=\"EN-GB\">fluid in the lungs (pulmonary oedema) causing\nbreathlessness</span>", "ID": "e8ee1723-34c0-4a90-93d5-a290b863bb87", "Styles": "None", "Classes": "None", "Text": "fluid in the lungs (pulmonary oedema) causing breathlessness", "ParentId": "f5e9116e-1418-41f4-916e-ca41084eb4ca"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;page-break-after:\navoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Symbol;\ncolor:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">slow heart beat</span></p>", "ID": "e7955185-6a2a-4565-abe4-b4194bc69c53", "Styles": "margin-left:28.35pt;text-indent:-27.8pt;page-break-after:\navoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;\ncolor:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "f4114ca8-d6a7-453c-92b1-458f688826d3", "Styles": "font-family:Symbol;\ncolor:black", "Classes": "None", "Text": "\u00b7", "ParentId": "e7955185-6a2a-4565-abe4-b4194bc69c53"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "5aaefcd5-f5c7-4d00-99d6-5ff949310367", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "f4114ca8-d6a7-453c-92b1-458f688826d3"}, {"Element": "<span lang=\"EN-GB\">slow heart beat</span>", "ID": "6399ca27-bf00-43ab-a637-f80d765ad675", "Styles": "None", "Classes": "None", "Text": "slow heart beat", "ParentId": "e7955185-6a2a-4565-abe4-b4194bc69c53"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;page-break-after:\navoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Symbol;\ncolor:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">blue discolouration of the lips and extremities\n(possible symptoms of hypoxia)</span></p>", "ID": "cf9e7833-68a5-410e-a183-dfbf51b468b5", "Styles": "margin-left:28.35pt;text-indent:-27.8pt;page-break-after:\navoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;\ncolor:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "835c4f09-414e-458d-afb6-973f441fd628", "Styles": "font-family:Symbol;\ncolor:black", "Classes": "None", "Text": "\u00b7", "ParentId": "cf9e7833-68a5-410e-a183-dfbf51b468b5"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "d2162ea4-f58c-4ff5-96f3-25a681682b10", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "835c4f09-414e-458d-afb6-973f441fd628"}, {"Element": "<span lang=\"EN-GB\">blue discolouration of the lips and extremities\n(possible symptoms of hypoxia)</span>", "ID": "b5456ee9-76e6-42b2-a578-1d82ba59fc8c", "Styles": "None", "Classes": "None", "Text": "blue discolouration of the lips and extremities (possible symptoms of hypoxia)", "ParentId": "cf9e7833-68a5-410e-a183-dfbf51b468b5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "73efd72d-524e-4e2c-9e2b-bc080ed627d3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ae217526-9e7a-4d70-a5fa-8f71fa8c6883", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "73efd72d-524e-4e2c-9e2b-bc080ed627d3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><b><span lang=\"EN-GB\">Tell your doctor or a nurse immediately if you get\nany of these symptoms.</span></b></p>", "ID": "8dce1955-f2b2-4c84-86aa-52611a17f6d6", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">Tell your doctor or a nurse immediately if you get\nany of these symptoms.</span></b>", "ID": "2be0f59e-effc-465b-b087-f18a4b2372dc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8dce1955-f2b2-4c84-86aa-52611a17f6d6"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor or a nurse immediately if you get\nany of these symptoms.</span>", "ID": "a77c677a-6015-423b-bb89-06034d4a163d", "Styles": "None", "Classes": "None", "Text": "Tell your doctor or a nurse immediately if you get any of these symptoms.", "ParentId": "2be0f59e-effc-465b-b087-f18a4b2372dc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8cbf71de-a7a7-481c-9d2d-f1bdee06dd75", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0d6eca0a-81d1-44dd-97df-0624a2048033", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8cbf71de-a7a7-481c-9d2d-f1bdee06dd75"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Other\npossible side effects</span></b></p>", "ID": "13641fc4-deb9-48e1-9a50-35ee71534c91", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">Other\npossible side effects</span></b>", "ID": "45f56b0d-dad3-4709-8101-0f6ef79194c0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "13641fc4-deb9-48e1-9a50-35ee71534c91"}, {"Element": "<span lang=\"EN-GB\">Other\npossible side effects</span>", "ID": "bb69f30b-2aaf-4fc9-8865-ccf0f2a801b1", "Styles": "None", "Classes": "None", "Text": "Other possible side effects", "ParentId": "45f56b0d-dad3-4709-8101-0f6ef79194c0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3201eb5b-daeb-477b-bdf0-f8d943392b29", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1071c31f-7936-4ab9-9a9a-ec5e457adc8b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3201eb5b-daeb-477b-bdf0-f8d943392b29"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">Very common side effects</span></b></p>", "ID": "6bc0fef5-96b5-47ed-8b9c-229a8813cf2c", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">Very common side effects</span></b>", "ID": "3a21e75e-fad9-4947-a130-cb14d9db7931", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6bc0fef5-96b5-47ed-8b9c-229a8813cf2c"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Very common side effects</span>", "ID": "3c3892ba-e7df-44f3-bd24-e1a7df36a0cd", "Styles": "color:black", "Classes": "None", "Text": "Very common side effects", "ParentId": "3a21e75e-fad9-4947-a130-cb14d9db7931"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">These may affect more than 1 in 10\u00a0people:</span></p>", "ID": "3c4b9f42-c5a6-4990-acc9-e47ace69a987", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">These may affect more than 1 in 10\u00a0people:</span>", "ID": "55628241-2ff7-481e-9d9d-b3277709c91c", "Styles": "color:black", "Classes": "None", "Text": "These may affect more than 1 in 10\u00a0people:", "ParentId": "3c4b9f42-c5a6-4990-acc9-e47ace69a987"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">frequent infections, fever, chills, sore throat\nor mouth ulcers due to infections</span></p>", "ID": "d6f0f671-cbdd-410f-81af-28d20a367c54", "Styles": "margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "b5c64294-a735-4deb-8521-b9444c6fef4e", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "d6f0f671-cbdd-410f-81af-28d20a367c54"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "97dfaebc-f386-4f35-b6d3-e01d73c47af2", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "b5c64294-a735-4deb-8521-b9444c6fef4e"}, {"Element": "<span lang=\"EN-GB\">frequent infections, fever, chills, sore throat\nor mouth ulcers due to infections</span>", "ID": "db94d259-c7f7-46ac-b4d2-8295424a9c46", "Styles": "None", "Classes": "None", "Text": "frequent infections, fever, chills, sore throat or mouth ulcers due to infections", "ParentId": "d6f0f671-cbdd-410f-81af-28d20a367c54"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">fever, coughing, difficulty breathing, wheezing,\npossible symptoms of </span><span lang=\"EN-GB\">infections of the lungs or airways\n(respiratory tract) including pneumonia</span></p>", "ID": "16e28bdd-c1b4-4c95-bfc0-957a8c8a4aa1", "Styles": "margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "3a4814c6-1995-4878-9ed0-38a67fda404b", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "16e28bdd-c1b4-4c95-bfc0-957a8c8a4aa1"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "5dce2e29-79a1-4a5f-967b-31f54e11153a", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "3a4814c6-1995-4878-9ed0-38a67fda404b"}, {"Element": "<span lang=\"EN-GB\">fever, coughing, difficulty breathing, wheezing,\npossible symptoms of </span>", "ID": "ef8ea9f4-2df7-42fb-8092-a60633c0ad36", "Styles": "None", "Classes": "None", "Text": "fever, coughing, difficulty breathing, wheezing, possible symptoms of ", "ParentId": "16e28bdd-c1b4-4c95-bfc0-957a8c8a4aa1"}, {"Element": "<span lang=\"EN-GB\">infections of the lungs or airways\n(respiratory tract) including pneumonia</span>", "ID": "78fe6b1f-c637-4676-91ac-511e09a084ce", "Styles": "None", "Classes": "None", "Text": "infections of the lungs or airways (respiratory tract) including pneumonia", "ParentId": "16e28bdd-c1b4-4c95-bfc0-957a8c8a4aa1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">sore throat, feeling of pressure or pain in the\ncheeks and forehead</span><span lang=\"EN-GB\">, infections of the ear, nose or\nthroat.</span></p>", "ID": "5ef5bead-904e-4e60-91e8-a8c513a74725", "Styles": "margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "554cef56-476a-4f08-af05-a97f76f2c000", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "5ef5bead-904e-4e60-91e8-a8c513a74725"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "df27a480-2b5a-4b8a-bb8c-7c6baa0b379d", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "554cef56-476a-4f08-af05-a97f76f2c000"}, {"Element": "<span lang=\"EN-GB\">sore throat, feeling of pressure or pain in the\ncheeks and forehead</span>", "ID": "c69d36f1-5b2c-4f2f-8f4d-e3d4863dd13e", "Styles": "None", "Classes": "None", "Text": "sore throat, feeling of pressure or pain in the cheeks and forehead", "ParentId": "5ef5bead-904e-4e60-91e8-a8c513a74725"}, {"Element": "<span lang=\"EN-GB\">, infections of the ear, nose or\nthroat.</span>", "ID": "117f3fdc-b478-4419-abc8-975c12be9da6", "Styles": "None", "Classes": "None", "Text": ", infections of the ear, nose or throat.", "ParentId": "5ef5bead-904e-4e60-91e8-a8c513a74725"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "0c716537-4bba-4743-8066-172c8d0fa68b", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "5c2997af-450f-4f4f-aa66-0087e1c9bc6e", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "0c716537-4bba-4743-8066-172c8d0fa68b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Very common side effects that may show up in\nyour blood tests:</span></p>", "ID": "d04ac085-a16b-4954-83cc-b608492b671f", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Very common side effects that may show up in\nyour blood tests:</span>", "ID": "3c8e64a1-9880-4076-8e84-98b4bfbadfa0", "Styles": "color:black", "Classes": "None", "Text": "Very common side effects that may show up in your blood tests:", "ParentId": "d04ac085-a16b-4954-83cc-b608492b671f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">low levels of white blood cells (neutropenia)</span></p>", "ID": "90b167f0-df5d-492e-99ee-96db07ebfb84", "Styles": "margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "04225cb8-2685-4c60-ad08-f4612f5a6de5", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "90b167f0-df5d-492e-99ee-96db07ebfb84"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "4c0d69a4-834b-4eed-b9d9-67c415da61c8", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "04225cb8-2685-4c60-ad08-f4612f5a6de5"}, {"Element": "<span lang=\"EN-GB\">low levels of white blood cells (neutropenia)</span>", "ID": "2c3470fe-e251-4f5d-9bfc-1e231377ef35", "Styles": "None", "Classes": "None", "Text": "low levels of white blood cells (neutropenia)", "ParentId": "90b167f0-df5d-492e-99ee-96db07ebfb84"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\" style=\"color:black\">low levels of red blood\ncells (anaemia).</span></p>", "ID": "14a056bf-c1d1-4e6f-af16-3eb97c321689", "Styles": "margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "512903e0-39bf-4ac8-b2a5-14c179e6a123", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "14a056bf-c1d1-4e6f-af16-3eb97c321689"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "74206797-b3df-4ac0-b0d5-6617fae38cec", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "512903e0-39bf-4ac8-b2a5-14c179e6a123"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">low levels of red blood\ncells (anaemia).</span>", "ID": "1d18fe60-0d2f-412f-8893-a6f51e4a344b", "Styles": "color:black", "Classes": "None", "Text": "low levels of red blood cells (anaemia).", "ParentId": "14a056bf-c1d1-4e6f-af16-3eb97c321689"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "d3a154e2-5f6a-4527-9427-0f6ca8014ece", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "89931d65-bf82-43d3-b401-bbb2ecf8da6b", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "d3a154e2-5f6a-4527-9427-0f6ca8014ece"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">Common side effects</span></b></p>", "ID": "12939b68-ad84-4566-a238-c3ab3bfb7cf7", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">Common side effects</span></b>", "ID": "376f34aa-fe39-46ce-b18e-20401ba208fa", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "12939b68-ad84-4566-a238-c3ab3bfb7cf7"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Common side effects</span>", "ID": "d59a74a8-59f5-428a-ad17-75ec9bf9d483", "Styles": "color:black", "Classes": "None", "Text": "Common side effects", "ParentId": "376f34aa-fe39-46ce-b18e-20401ba208fa"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">These may affect up to 1 in 10\u00a0people:</span></p>", "ID": "36fa02be-f0a4-43f5-af1a-3dcf16fa69b1", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">These may affect up to 1 in 10\u00a0people:</span>", "ID": "439d15a0-6ee3-4e98-ad4c-71f0ba821f95", "Styles": "color:black", "Classes": "None", "Text": "These may affect up to 1 in 10\u00a0people:", "ParentId": "36fa02be-f0a4-43f5-af1a-3dcf16fa69b1"}, {"Element": "<p class=\"Listlevel1\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span style=\"font-size:11.0pt;font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span style=\"font-size:11.0pt\">fever or, alternatively, a very\nlow body temperature, chest pain, shortness of breath or rapid breathing,\nshaking, chills, confusion, dizziness, decreased urination and rapid pulse,\n(possible symptoms of blood infection)</span></p>", "ID": "f7dfadfb-16c4-43b3-a4cb-b10a8ed0c615", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt", "Classes": "['Listlevel1']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt;font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "1ffce266-48ad-4ad0-9a72-b3718d083460", "Styles": "font-size:11.0pt;font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "f7dfadfb-16c4-43b3-a4cb-b10a8ed0c615"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "6fd85e8f-b53b-4102-a184-336d26d2633b", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "1ffce266-48ad-4ad0-9a72-b3718d083460"}, {"Element": "<span style=\"font-size:11.0pt\">fever or, alternatively, a very\nlow body temperature, chest pain, shortness of breath or rapid breathing,\nshaking, chills, confusion, dizziness, decreased urination and rapid pulse,\n(possible symptoms of blood infection)</span>", "ID": "b261e74a-6068-4b80-bd2d-4a27a95cd8dd", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "fever or, alternatively, a very low body temperature, chest pain, shortness of breath or rapid breathing, shaking, chills, confusion, dizziness, decreased urination and rapid pulse, (possible symptoms of blood infection)", "ParentId": "f7dfadfb-16c4-43b3-a4cb-b10a8ed0c615"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">difficulty and pain when passing urine,\nexaggerated sense of needing to urinate,</span><span lang=\"EN-GB\"> urinary tract\ninfections</span></p>", "ID": "1305586f-5c8c-4d3f-807a-c7243175ba61", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "d2b3d04f-07dd-481f-ae12-3d22512891c9", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "1305586f-5c8c-4d3f-807a-c7243175ba61"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "70438473-599b-4cd3-a390-b9f6fb1a02b3", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "d2b3d04f-07dd-481f-ae12-3d22512891c9"}, {"Element": "<span lang=\"EN-GB\">difficulty and pain when passing urine,\nexaggerated sense of needing to urinate,</span>", "ID": "985996ea-24ec-4220-9408-800ad59d8a67", "Styles": "None", "Classes": "None", "Text": "difficulty and pain when passing urine, exaggerated sense of needing to urinate,", "ParentId": "1305586f-5c8c-4d3f-807a-c7243175ba61"}, {"Element": "<span lang=\"EN-GB\"> urinary tract\ninfections</span>", "ID": "324ed8e7-c2fc-4b19-b3be-150f3d1a8ef0", "Styles": "None", "Classes": "None", "Text": " urinary tract infections", "ParentId": "1305586f-5c8c-4d3f-807a-c7243175ba61"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">shingles, cold sores </span><span lang=\"EN-GB\">(possible\nsymptoms of herpes viral infection that can potentially be severe)</span><span lang=\"EN-GB\">.</span></p>", "ID": "6cc64e7d-5e52-4cff-bd81-bcc3a8489de1", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "fe438b13-83b7-463e-b5ea-626df8677d65", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "6cc64e7d-5e52-4cff-bd81-bcc3a8489de1"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "56625586-9ea5-4afd-bb5d-b098a2f14cb9", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "fe438b13-83b7-463e-b5ea-626df8677d65"}, {"Element": "<span lang=\"EN-GB\">shingles, cold sores </span>", "ID": "52fc6dbd-a6f1-4982-a8fd-15a18030736a", "Styles": "None", "Classes": "None", "Text": "shingles, cold sores ", "ParentId": "6cc64e7d-5e52-4cff-bd81-bcc3a8489de1"}, {"Element": "<span lang=\"EN-GB\">(possible\nsymptoms of herpes viral infection that can potentially be severe)</span>", "ID": "14bf90fe-f4a3-4400-aed1-2d0f5dae57f9", "Styles": "None", "Classes": "None", "Text": "(possible symptoms of herpes viral infection that can potentially be severe)", "ParentId": "6cc64e7d-5e52-4cff-bd81-bcc3a8489de1"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "5fe49273-ab54-4372-a443-8534eb6c1a06", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "6cc64e7d-5e52-4cff-bd81-bcc3a8489de1"}, {"Element": "<p class=\"Bullet\" style=\"margin:0in;margin-bottom:.0001pt;text-indent:0in;\nline-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ba49596a-e7a1-413f-aef4-2a0a766ad578", "Styles": "margin:0in;margin-bottom:.0001pt;text-indent:0in;\nline-height:normal", "Classes": "['Bullet']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cbecf28b-e8bf-4f12-b13b-956f55141508", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ba49596a-e7a1-413f-aef4-2a0a766ad578"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Common side effects that may show up in your\nblood tests:</span></p>", "ID": "421ed7e8-2890-4cc1-b0b3-799c151e8cd3", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Common side effects that may show up in your\nblood tests:</span>", "ID": "4814d7be-d703-4534-bc50-33359ad67c48", "Styles": "color:black", "Classes": "None", "Text": "Common side effects that may show up in your blood tests:", "ParentId": "421ed7e8-2890-4cc1-b0b3-799c151e8cd3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">low levels of platelets in the blood (cells that\nhelp blood to clot).</span></p>", "ID": "69502293-89a9-4103-a704-316b26d77b9d", "Styles": "margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "ee942484-4a64-4300-abc0-93d5bebf0850", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "69502293-89a9-4103-a704-316b26d77b9d"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "02e435b7-9874-474c-b06f-821e2bb0a605", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "ee942484-4a64-4300-abc0-93d5bebf0850"}, {"Element": "<span lang=\"EN-GB\">low levels of platelets in the blood (cells that\nhelp blood to clot).</span>", "ID": "6f4598a0-49d1-49ec-8e05-9f697f3d7cfb", "Styles": "None", "Classes": "None", "Text": "low levels of platelets in the blood (cells that help blood to clot).", "ParentId": "69502293-89a9-4103-a704-316b26d77b9d"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4ed32f58-d040-4350-af45-9d3f8df33964", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7af525a3-2764-4fa4-a200-e02fe94896af", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4ed32f58-d040-4350-af45-9d3f8df33964"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">Uncommon side effects</span></b></p>", "ID": "ad307c9b-e875-4ca8-808f-ff1cde38ca91", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">Uncommon side effects</span></b>", "ID": "d842be76-25c1-489b-aa7c-692fb14747aa", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ad307c9b-e875-4ca8-808f-ff1cde38ca91"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Uncommon side effects</span>", "ID": "baae44a5-8409-4540-b5ea-35d5008c024e", "Styles": "color:black", "Classes": "None", "Text": "Uncommon side effects", "ParentId": "d842be76-25c1-489b-aa7c-692fb14747aa"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">These may affect up to 1 in 100\u00a0people:</span></p>", "ID": "7dba80ea-ea39-4321-b1ae-f4a2896f0847", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">These may affect up to 1 in 100\u00a0people:</span>", "ID": "6e5237db-37da-4ea8-bb65-14f2316c4053", "Styles": "color:black", "Classes": "None", "Text": "These may affect up to 1 in 100\u00a0people:", "ParentId": "7dba80ea-ea39-4321-b1ae-f4a2896f0847"}, {"Element": "<p class=\"Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">blockage in the gut (intestine), which may feel\nlike stomach pain.</span></p>", "ID": "1980546f-b634-48e6-8f67-aae3a731b193", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['Bullet']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "f64abbab-ae2a-4f02-b81b-fa1ce8448df7", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "1980546f-b634-48e6-8f67-aae3a731b193"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "77e5761b-edb0-4f04-ad2b-9dd0f76bc412", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "f64abbab-ae2a-4f02-b81b-fa1ce8448df7"}, {"Element": "<span lang=\"EN-GB\">blockage in the gut (intestine), which may feel\nlike stomach pain.</span>", "ID": "c22f4efb-316a-415d-af0b-b9d2114d8c00", "Styles": "None", "Classes": "None", "Text": "blockage in the gut (intestine), which may feel like stomach pain.", "ParentId": "1980546f-b634-48e6-8f67-aae3a731b193"}, {"Element": "<p class=\"Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\nmargin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\" style=\"color:black\">If you have persistent\nstomach pain, <b>see your doctor as soon as possible.</b></span></p>", "ID": "02b52474-d4a7-461f-b490-7c6fddf0d635", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\nmargin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:normal", "Classes": "['Bullet']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "54bdc5c6-37b2-4527-91e1-0cde7eb2f694", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "02b52474-d4a7-461f-b490-7c6fddf0d635"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "c38c86ec-2b74-45c4-a7da-ed126c5c6a5b", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "54bdc5c6-37b2-4527-91e1-0cde7eb2f694"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">If you have persistent\nstomach pain, <b>see your doctor as soon as possible.</b></span>", "ID": "960764c7-67a3-4384-b769-eb05facea5b4", "Styles": "color:black", "Classes": "None", "Text": "If you have persistent stomach pain, ", "ParentId": "02b52474-d4a7-461f-b490-7c6fddf0d635"}, {"Element": "<b>see your doctor as soon as possible.</b>", "ID": "2582cad7-ad79-413c-a785-de42d64ca28d", "Styles": "None", "Classes": "None", "Text": "see your doctor as soon as possible.", "ParentId": "960764c7-67a3-4384-b769-eb05facea5b4"}, {"Element": "<p class=\"Listlevel1\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span style=\"font-size:11.0pt;font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span style=\"font-size:11.0pt\">yellow skin and eyes, nausea, loss\nof appetite, dark urine (possible symptoms of an infection or reactivation of\nhepatitis B virus)</span></p>", "ID": "497cc6d4-5650-44cf-a57e-b73444240861", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt", "Classes": "['Listlevel1']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt;font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "bbc9c9e1-5cc4-406d-9f9e-8f3bff65aff5", "Styles": "font-size:11.0pt;font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "497cc6d4-5650-44cf-a57e-b73444240861"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "4e325232-a182-4323-8fa0-15c8948dc858", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "bbc9c9e1-5cc4-406d-9f9e-8f3bff65aff5"}, {"Element": "<span style=\"font-size:11.0pt\">yellow skin and eyes, nausea, loss\nof appetite, dark urine (possible symptoms of an infection or reactivation of\nhepatitis B virus)</span>", "ID": "1dc0887e-bc76-4f3b-bbfe-db2c54d9e657", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "yellow skin and eyes, nausea, loss of appetite, dark urine (possible symptoms of an infection or reactivation of hepatitis B virus)", "ParentId": "497cc6d4-5650-44cf-a57e-b73444240861"}, {"Element": "<p class=\"Listlevel1\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span style=\"font-size:11.0pt;font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span style=\"font-size:11.0pt\">memory loss, trouble with\nthinking, and difficulty with walking or loss of vision (possible symptoms of\nprogressive multifocal leukoencephalopathy)</span></p>", "ID": "15943dab-7d36-4773-a163-66fc936d9a05", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt", "Classes": "['Listlevel1']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span style=\"font-size:11.0pt;font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "3eb95310-738e-4990-8254-5d3d6e445f5a", "Styles": "font-size:11.0pt;font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "15943dab-7d36-4773-a163-66fc936d9a05"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "a862388d-926f-4608-9a2b-adcae294aac7", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "3eb95310-738e-4990-8254-5d3d6e445f5a"}, {"Element": "<span style=\"font-size:11.0pt\">memory loss, trouble with\nthinking, and difficulty with walking or loss of vision (possible symptoms of\nprogressive multifocal leukoencephalopathy)</span>", "ID": "122d1ca6-8d84-40f0-b4a8-7eb0fecfa637", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "memory loss, trouble with thinking, and difficulty with walking or loss of vision (possible symptoms of progressive multifocal leukoencephalopathy)", "ParentId": "15943dab-7d36-4773-a163-66fc936d9a05"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Symbol;\ncolor:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\" style=\"color:black\">increase in potassium,\nphosphate and uric acid in the blood that can cause kidney problems (tumour\nlysis syndrome)</span></p>", "ID": "d25f7b68-f5a6-4992-aeb3-2831fd23f7ca", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;\ncolor:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "700e8f24-bc16-4b4a-9f88-33885a56aee3", "Styles": "font-family:Symbol;\ncolor:black", "Classes": "None", "Text": "\u00b7", "ParentId": "d25f7b68-f5a6-4992-aeb3-2831fd23f7ca"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "542d89e6-e163-4b15-97d5-3c1b6cdcb056", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "700e8f24-bc16-4b4a-9f88-33885a56aee3"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">increase in potassium,\nphosphate and uric acid in the blood that can cause kidney problems (tumour\nlysis syndrome)</span>", "ID": "3424119d-9fb1-4849-9ed2-9af703588b0e", "Styles": "color:black", "Classes": "None", "Text": "increase in potassium, phosphate and uric acid in the blood that can cause kidney problems (tumour lysis syndrome)", "ParentId": "d25f7b68-f5a6-4992-aeb3-2831fd23f7ca"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid;\ntext-autospace:none\"><span lang=\"EN-GB\">The symptoms of this condition include:</span></p>", "ID": "e3945762-9175-4d76-99f8-f32edef1d976", "Styles": "margin-left:28.35pt;page-break-after:avoid;\ntext-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">The symptoms of this condition include:</span>", "ID": "a1f98299-1b35-45ae-be80-96b7c0a5bc24", "Styles": "None", "Classes": "None", "Text": "The symptoms of this condition include:", "ParentId": "e3945762-9175-4d76-99f8-f32edef1d976"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">producing less urine than normal</span></p>", "ID": "27d705b7-b28a-4fa6-92a2-c9836fe9a7ac", "Styles": "margin-left:56.7pt;text-indent:-27.8pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "38bec0da-abb2-45d1-8003-1b5b9f1a8a11", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "27d705b7-b28a-4fa6-92a2-c9836fe9a7ac"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "df3415f7-be96-4586-9081-b98261fa8103", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "38bec0da-abb2-45d1-8003-1b5b9f1a8a11"}, {"Element": "<span lang=\"EN-GB\">producing less urine than normal</span>", "ID": "5461f7a7-80e1-42e9-87d5-3955805bc196", "Styles": "None", "Classes": "None", "Text": "producing less urine than normal", "ParentId": "27d705b7-b28a-4fa6-92a2-c9836fe9a7ac"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">muscle spasms.</span></p>", "ID": "4749d3dd-b1eb-4a88-93f6-c4de51afbf99", "Styles": "margin-left:56.7pt;text-indent:-27.8pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "50a2e921-619d-4498-a993-c309b223ecca", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "4749d3dd-b1eb-4a88-93f6-c4de51afbf99"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "69b6d4b1-71c6-4f6c-86f3-9f717cbf74b3", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "50a2e921-619d-4498-a993-c309b223ecca"}, {"Element": "<span lang=\"EN-GB\">muscle spasms.</span>", "ID": "cc52beb8-4785-47b8-9880-338949dc2f09", "Styles": "None", "Classes": "None", "Text": "muscle spasms.", "ParentId": "4749d3dd-b1eb-4a88-93f6-c4de51afbf99"}, {"Element": "<p class=\"MsoListParagraph\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">If you notice these symptoms, <b>contact your doctor as\nsoon as possible</b>.</span></p>", "ID": "6fd0d8f8-abea-4c91-9158-4189dc5b25e0", "Styles": "margin-left:28.35pt", "Classes": "['MsoListParagraph']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">If you notice these symptoms, <b>contact your doctor as\nsoon as possible</b>.</span>", "ID": "c80824e7-4da5-45ca-a28c-ffaea2cc09da", "Styles": "color:black", "Classes": "None", "Text": "If you notice these symptoms, .", "ParentId": "6fd0d8f8-abea-4c91-9158-4189dc5b25e0"}, {"Element": "<b>contact your doctor as\nsoon as possible</b>", "ID": "45e5ece6-d252-409a-859a-a88c99414c65", "Styles": "None", "Classes": "None", "Text": "contact your doctor as soon as possible", "ParentId": "c80824e7-4da5-45ca-a28c-ffaea2cc09da"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9517c77b-6d19-4bde-bb3d-333a52bd37cd", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f52e9b5c-fe1b-41b5-b687-e38b5d854e16", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9517c77b-6d19-4bde-bb3d-333a52bd37cd"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon side effects that may show up in your blood\ntests:</span></p>", "ID": "f6f0cb8a-84c9-46b1-99f7-6ee52d2a8223", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Uncommon side effects that may show up in your blood\ntests:</span>", "ID": "85230f47-9aba-4854-8ba3-8d26657e711b", "Styles": "color:black", "Classes": "None", "Text": "Uncommon side effects that may show up in your blood tests:", "ParentId": "f6f0cb8a-84c9-46b1-99f7-6ee52d2a8223"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">problems with blood clotting</span></p>", "ID": "cffe63eb-8cbd-4d35-8c22-efe7133885ac", "Styles": "margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "5d48f1f2-cf6d-453d-b830-a8b3b7cb7c29", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "cffe63eb-8cbd-4d35-8c22-efe7133885ac"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "8d57e17e-453a-4c8b-8ddb-aee4fde7264b", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "5d48f1f2-cf6d-453d-b830-a8b3b7cb7c29"}, {"Element": "<span lang=\"EN-GB\">problems with blood clotting</span>", "ID": "c95c7fce-d8d1-4a0a-b9d9-18c76a30c710", "Styles": "None", "Classes": "None", "Text": "problems with blood clotting", "ParentId": "cffe63eb-8cbd-4d35-8c22-efe7133885ac"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\" style=\"color:black\">the bone marrow failing to\nproduce enough red or white blood cells</span></p>", "ID": "cdabbea4-1ffe-48cb-bfe8-42d869900de0", "Styles": "margin-left:28.35pt;text-indent:-27.8pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "26942f92-1016-4372-8b6a-3e3f16afe2dc", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "cdabbea4-1ffe-48cb-bfe8-42d869900de0"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "d7e3e5c1-6363-40ec-add5-c89491ce90e0", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "26942f92-1016-4372-8b6a-3e3f16afe2dc"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">the bone marrow failing to\nproduce enough red or white blood cells</span>", "ID": "cd32299c-d340-4703-b4c4-de73dc40985f", "Styles": "color:black", "Classes": "None", "Text": "the bone marrow failing to produce enough red or white blood cells", "ParentId": "cdabbea4-1ffe-48cb-bfe8-42d869900de0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "366d604a-fd88-402a-9a17-11ace6de1ff1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "287ca3de-bde9-419d-b2ed-3feff3b8a76c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "366d604a-fd88-402a-9a17-11ace6de1ff1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Reporting\nof side effects</span></b></p>", "ID": "f79e87d7-542b-455b-acda-e8c015d70723", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">Reporting\nof side effects</span></b>", "ID": "54c6b922-aaca-4166-9c17-4d45ed751ac7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f79e87d7-542b-455b-acda-e8c015d70723"}, {"Element": "<span lang=\"EN-GB\">Reporting\nof side effects</span>", "ID": "04098620-ce61-4f0b-9362-cceda56df214", "Styles": "None", "Classes": "None", "Text": "Reporting of side effects", "ParentId": "54c6b922-aaca-4166-9c17-4d45ed751ac7"}, {"Element": "<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"X-NONE\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>If you\nget any side effects, talk to your doctor or nurse.<span style=\"color:red\"> </span>This\nincludes any possible side effects not listed in this leaflet. You can also\nreport side effects directly via <span style=\"color:black;background:#D9D9D9\">the\nnational reporting system listed in </span></span><a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span lang=\"X-NONE\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\nbackground:#D9D9D9'>Appendix V</span></a><span lang=\"X-NONE\" style='font-size:\n11.0pt;font-family:\"Times New Roman\",serif'>. By reporting side effects you can\nhelp provide more information on the safety of this medicine.</span></p>", "ID": "8c70e019-45ff-4ac5-baad-10d340b181e2", "Styles": "margin-bottom:0in;line-height:normal", "Classes": "['BodytextAgency']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"X-NONE\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>If you\nget any side effects, talk to your doctor or nurse.<span style=\"color:red\"> </span>This\nincludes any possible side effects not listed in this leaflet. You can also\nreport side effects directly via <span style=\"color:black;background:#D9D9D9\">the\nnational reporting system listed in </span></span>", "ID": "40a74f31-43e4-4bf5-a5bb-40ac0b7c7473", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "If you get any side effects, talk to your doctor or nurse.This includes any possible side effects not listed in this leaflet. You can also report side effects directly via ", "ParentId": "8c70e019-45ff-4ac5-baad-10d340b181e2"}, {"Element": "<span style=\"color:red\"> </span>", "ID": "7eceaa9d-ef49-4446-b580-56d598845440", "Styles": "color:red", "Classes": "None", "Text": " ", "ParentId": "40a74f31-43e4-4bf5-a5bb-40ac0b7c7473"}, {"Element": "<span style=\"color:black;background:#D9D9D9\">the\nnational reporting system listed in </span>", "ID": "f23bffe1-7fc1-4ede-9182-f9179da7ff10", "Styles": "color:black;background:#D9D9D9", "Classes": "None", "Text": "the national reporting system listed in ", "ParentId": "40a74f31-43e4-4bf5-a5bb-40ac0b7c7473"}, {"Element": "<a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span lang=\"X-NONE\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\nbackground:#D9D9D9'>Appendix V</span></a>", "ID": "972d2fb7-c479-4236-8fb7-2335c51b739c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8c70e019-45ff-4ac5-baad-10d340b181e2"}, {"Element": "<span lang=\"X-NONE\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\nbackground:#D9D9D9'>Appendix V</span>", "ID": "48e1fdc3-cb0a-4a8a-bb21-67c1ba343ec3", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif;\nbackground:#D9D9D9", "Classes": "None", "Text": "Appendix V", "ParentId": "972d2fb7-c479-4236-8fb7-2335c51b739c"}, {"Element": "<span lang=\"X-NONE\" style='font-size:\n11.0pt;font-family:\"Times New Roman\",serif'>. By reporting side effects you can\nhelp provide more information on the safety of this medicine.</span>", "ID": "823d8452-5b9a-4d59-a01b-8c7775793671", "Styles": "font-size:\n11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": ". By reporting side effects you can help provide more information on the safety of this medicine.", "ParentId": "8c70e019-45ff-4ac5-baad-10d340b181e2"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "4950c6d9-ae28-459d-b2e6-e2c81c6f39c0", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "04c5bc29-884b-4263-bce1-ce8b0b5523d9", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "4950c6d9-ae28-459d-b2e6-e2c81c6f39c0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7ffa171e-d1af-4dca-8403-0e1fcc29e85e", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "804b5ee6-cdb6-4bdb-9760-880dc1c42dbd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7ffa171e-d1af-4dca-8403-0e1fcc29e85e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store Arzerra</span></b></p>", "ID": "b5e41db5-e661-4ada-8ca9-12aee4a992bb", "Styles": "margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\nmargin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store Arzerra</span></b>", "ID": "94533b1b-953a-4824-b9b6-5a5812e2efe9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b5e41db5-e661-4ada-8ca9-12aee4a992bb"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store Arzerra</span>", "ID": "03feed98-22f3-4e84-9737-25d56b7ad420", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store Arzerra", "ParentId": "94533b1b-953a-4824-b9b6-5a5812e2efe9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2de6f6a5-75d0-431c-b351-674f981a3c3e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c75bb4d9-b4d8-454c-931f-c5ceb2cac4c7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2de6f6a5-75d0-431c-b351-674f981a3c3e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Keep this\nmedicine out of the sight and reach of children.</span></p>", "ID": "a6111b5f-4a55-42d7-9401-2565cd6b62f5", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Keep this\nmedicine out of the sight and reach of children.</span>", "ID": "e89491df-6153-4b32-aa18-ebcb954a3b05", "Styles": "None", "Classes": "None", "Text": "Keep this medicine out of the sight and reach of children.", "ParentId": "a6111b5f-4a55-42d7-9401-2565cd6b62f5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "76036c0c-4bbe-4ccf-80fd-ea69571cd01b", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b78767fa-22d4-404c-820c-85a3387e1c5b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "76036c0c-4bbe-4ccf-80fd-ea69571cd01b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Do not use this\nmedicine after the expiry date shown on the carton and vial label. The expiry\ndate refers to the last day of that month.</span></p>", "ID": "9eca528f-8285-4228-b4ac-5cbaa21e5cec", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Do not use this\nmedicine after the expiry date shown on the carton and vial label. The expiry\ndate refers to the last day of that month.</span>", "ID": "6045ecaa-1efd-48f3-84d2-313bff5db448", "Styles": "None", "Classes": "None", "Text": "Do not use this medicine after the expiry date shown on the carton and vial label. The expiry date refers to the last day of that month.", "ParentId": "9eca528f-8285-4228-b4ac-5cbaa21e5cec"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4672eb73-0223-4185-9814-bca8d41ea2a9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "645a8639-0e56-42aa-9913-503ff50e5816", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4672eb73-0223-4185-9814-bca8d41ea2a9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Store and transport refrigerated (2\u00a0C\n\u2013 8</span><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b0</span><span lang=\"EN-GB\">C).</span></p>", "ID": "5c8ddb4c-01ce-4cee-8b5f-918b5f5d2821", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Store and transport refrigerated (2\u00a0C\n\u2013 8</span>", "ID": "0776a71d-46b3-404f-bd72-75de4a53649c", "Styles": "None", "Classes": "None", "Text": "Store and transport refrigerated (2\u00a0C \u2013 8", "ParentId": "5c8ddb4c-01ce-4cee-8b5f-918b5f5d2821"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b0</span>", "ID": "1b48440b-855f-4f6d-a36b-4f1a4372d86c", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b0", "ParentId": "5c8ddb4c-01ce-4cee-8b5f-918b5f5d2821"}, {"Element": "<span lang=\"EN-GB\">C).</span>", "ID": "f44e2a53-a7ce-4bf3-9909-1e4f5b4dff8c", "Styles": "None", "Classes": "None", "Text": "C).", "ParentId": "5c8ddb4c-01ce-4cee-8b5f-918b5f5d2821"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not freeze.</span></p>", "ID": "009f2560-d0a0-4f84-94b6-6de47553657b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Do not freeze.</span>", "ID": "e341ac67-5e44-4243-924d-731eae027765", "Styles": "None", "Classes": "None", "Text": "Do not freeze.", "ParentId": "009f2560-d0a0-4f84-94b6-6de47553657b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep the vial in the outer carton in order\nto protect from light.</span></p>", "ID": "5b2419d1-d749-44d9-8e9a-97c1be317fbd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Keep the vial in the outer carton in order\nto protect from light.</span>", "ID": "7bc0fc63-c7da-41ac-ae78-7fe9ef27f479", "Styles": "None", "Classes": "None", "Text": "Keep the vial in the outer carton in order to protect from light.", "ParentId": "5b2419d1-d749-44d9-8e9a-97c1be317fbd"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "de559b58-487b-4a8a-9420-a80a2feb64c5", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c69fd06c-d318-4959-9897-35ca40941eb5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "de559b58-487b-4a8a-9420-a80a2feb64c5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Store the diluted infusion solution between\n2</span><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b0</span><span lang=\"EN-GB\">C\nand 8\u00a0C and use within 24\u00a0hours. Any unused infusion solution should\nbe discarded 24\u00a0hours after preparation.</span></p>", "ID": "335c4e76-d547-40c3-85d0-f4371b2626e0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Store the diluted infusion solution between\n2</span>", "ID": "a4b7fd62-2e6d-4e71-88a6-ba98182948e2", "Styles": "None", "Classes": "None", "Text": "Store the diluted infusion solution between 2", "ParentId": "335c4e76-d547-40c3-85d0-f4371b2626e0"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b0</span>", "ID": "352a41ee-bdd0-4923-a01e-0d039dce44dc", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b0", "ParentId": "335c4e76-d547-40c3-85d0-f4371b2626e0"}, {"Element": "<span lang=\"EN-GB\">C\nand 8\u00a0C and use within 24\u00a0hours. Any unused infusion solution should\nbe discarded 24\u00a0hours after preparation.</span>", "ID": "8c5d363c-9c0c-481d-9129-d1857589eb70", "Styles": "None", "Classes": "None", "Text": "C and 8\u00a0C and use within 24\u00a0hours. Any unused infusion solution should be discarded 24\u00a0hours after preparation.", "ParentId": "335c4e76-d547-40c3-85d0-f4371b2626e0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d88baf7d-bfd5-4836-9e9b-b684ddfa4eb8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b56574aa-3ebe-4254-bacd-165516b73660", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d88baf7d-bfd5-4836-9e9b-b684ddfa4eb8"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d5425303-de01-4a51-a297-e90d0d5c8019", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7bdc43d2-b712-45bf-85f7-bd9a2639b1a0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d5425303-de01-4a51-a297-e90d0d5c8019"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents\nof the pack and other information</span></b></p>", "ID": "91e76863-b75f-4c4d-a39d-55de34900307", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents\nof the pack and other information</span></b>", "ID": "2a593af5-4e02-4bd6-a454-756c8d4ab73d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "91e76863-b75f-4c4d-a39d-55de34900307"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents\nof the pack and other information</span>", "ID": "a8868aa4-18ac-4601-aed5-2f138b1b8433", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the pack and other information", "ParentId": "2a593af5-4e02-4bd6-a454-756c8d4ab73d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a1d8271b-e2c3-4609-bcfa-f536911c1076", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c3738624-af15-4ff8-a1da-2cbe77252c0b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a1d8271b-e2c3-4609-bcfa-f536911c1076"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">What\nArzerra contains</span></b></p>", "ID": "c3efbb9a-114e-46fa-a20d-320d27d5385b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">What\nArzerra contains</span></b>", "ID": "23d24fb3-b103-40e8-984d-2560c351b764", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c3efbb9a-114e-46fa-a20d-320d27d5385b"}, {"Element": "<span lang=\"EN-GB\">What\nArzerra contains</span>", "ID": "68d27795-0e75-41f2-a710-e722c6902e6e", "Styles": "None", "Classes": "None", "Text": "What Arzerra contains", "ParentId": "23d24fb3-b103-40e8-984d-2560c351b764"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">The active substance is ofatumumab. One ml of\nconcentrate contains 20\u00a0mg of ofatumumab.</span></p>", "ID": "01ced695-12c3-4847-b372-74417da982fb", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "1a711daa-834b-4f37-a476-17163776533b", "Styles": "None", "Classes": "None", "Text": "-", "ParentId": "01ced695-12c3-4847-b372-74417da982fb"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "663ddd93-65cc-4f0e-a4f3-108c295233ee", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "1a711daa-834b-4f37-a476-17163776533b"}, {"Element": "<span lang=\"EN-GB\">The active substance is ofatumumab. One ml of\nconcentrate contains 20\u00a0mg of ofatumumab.</span>", "ID": "946cbc75-35ce-4d63-836b-a9fd2af5664a", "Styles": "None", "Classes": "None", "Text": "The active substance is ofatumumab. One ml of concentrate contains 20\u00a0mg of ofatumumab.", "ParentId": "01ced695-12c3-4847-b372-74417da982fb"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"PT\" style=\"color:black\">-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">The other ingredients are </span><span lang=\"PT\" style=\"color:black\">arginine, sodium acetate (E262), </span><span lang=\"EN-GB\" style=\"color:black\">sodium chloride</span><span lang=\"PT\" style=\"color:black\">,\npolysorbate 80 (E433), edetate disodium (E386), hydrochloric acid (E507) (for\npH-adjustment), </span><span lang=\"EN-GB\" style=\"color:black\">water for\ninjections (see \u201cArzerra contains sodium\u201d under section\u00a02).</span></p>", "ID": "06516a9a-db0a-439c-8148-1bbde5a7e0cf", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"PT\" style=\"color:black\">-<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "41bc981b-470f-496d-bee9-b7f80fe9360d", "Styles": "color:black", "Classes": "None", "Text": "-", "ParentId": "06516a9a-db0a-439c-8148-1bbde5a7e0cf"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "3571eb9b-a292-4e9e-a83b-842f82fa9530", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "41bc981b-470f-496d-bee9-b7f80fe9360d"}, {"Element": "<span lang=\"EN-GB\">The other ingredients are </span>", "ID": "1deed984-ee26-4a82-878e-d7d8a3ca60b5", "Styles": "None", "Classes": "None", "Text": "The other ingredients are ", "ParentId": "06516a9a-db0a-439c-8148-1bbde5a7e0cf"}, {"Element": "<span lang=\"PT\" style=\"color:black\">arginine, sodium acetate (E262), </span>", "ID": "05cc7329-47a9-4f51-983c-4b888709674d", "Styles": "color:black", "Classes": "None", "Text": "arginine, sodium acetate (E262), ", "ParentId": "06516a9a-db0a-439c-8148-1bbde5a7e0cf"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">sodium chloride</span>", "ID": "6c35d565-d67a-48b3-bf81-eec495af45fc", "Styles": "color:black", "Classes": "None", "Text": "sodium chloride", "ParentId": "06516a9a-db0a-439c-8148-1bbde5a7e0cf"}, {"Element": "<span lang=\"PT\" style=\"color:black\">,\npolysorbate 80 (E433), edetate disodium (E386), hydrochloric acid (E507) (for\npH-adjustment), </span>", "ID": "83378529-8fea-4f1d-88dc-433746d4cfd6", "Styles": "color:black", "Classes": "None", "Text": ", polysorbate 80 (E433), edetate disodium (E386), hydrochloric acid (E507) (for pH-adjustment), ", "ParentId": "06516a9a-db0a-439c-8148-1bbde5a7e0cf"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">water for\ninjections (see \u201cArzerra contains sodium\u201d under section\u00a02).</span>", "ID": "0a97ebd0-6852-4243-9e53-0a65cef171ae", "Styles": "color:black", "Classes": "None", "Text": "water for injections (see \u201cArzerra contains sodium\u201d under section\u00a02).", "ParentId": "06516a9a-db0a-439c-8148-1bbde5a7e0cf"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "73820878-0347-4287-8384-b6c636d553a2", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cf2572a0-3854-4596-a858-9c0e1abe5943", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "73820878-0347-4287-8384-b6c636d553a2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">What\nArzerra looks like and contents of the pack</span></b></p>", "ID": "1a7ead95-a5b5-438c-9ae8-0799343fa4ca", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">What\nArzerra looks like and contents of the pack</span></b>", "ID": "511a0b2f-8e1b-4cb0-8b5c-4222979b9c42", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1a7ead95-a5b5-438c-9ae8-0799343fa4ca"}, {"Element": "<span lang=\"EN-GB\">What\nArzerra looks like and contents of the pack</span>", "ID": "6b1485eb-5304-4e97-b003-480cd9bd5c23", "Styles": "None", "Classes": "None", "Text": "What Arzerra looks like and contents of the pack", "ParentId": "511a0b2f-8e1b-4cb0-8b5c-4222979b9c42"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Arzerra is a </span><span lang=\"EN-GB\">colourless to pale yellow concentrate for solution</span><span lang=\"EN-GB\" style=\"color:black\"> for infusion.</span></p>", "ID": "fbcc47f4-8d1e-459c-80f5-980f7abda440", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Arzerra is a </span>", "ID": "87a6bf84-64de-4ed4-8e2d-9707726d3655", "Styles": "color:black", "Classes": "None", "Text": "Arzerra is a ", "ParentId": "fbcc47f4-8d1e-459c-80f5-980f7abda440"}, {"Element": "<span lang=\"EN-GB\">colourless to pale yellow concentrate for solution</span>", "ID": "e0b2ff46-e794-4094-993c-8fb93dee1bd1", "Styles": "None", "Classes": "None", "Text": "colourless to pale yellow concentrate for solution", "ParentId": "fbcc47f4-8d1e-459c-80f5-980f7abda440"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\"> for infusion.</span>", "ID": "7fa76240-eedb-4d08-a914-9048021592ac", "Styles": "color:black", "Classes": "None", "Text": " for infusion.", "ParentId": "fbcc47f4-8d1e-459c-80f5-980f7abda440"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "5f341a87-e9a1-4f20-a4fb-f8141d17cd7a", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "ddc32c84-0335-41e0-8c0a-a15177ffdb64", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "5f341a87-e9a1-4f20-a4fb-f8141d17cd7a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"EN-GB\" style=\"color:black\">Arzerra 100\u00a0mg</span></b><span lang=\"EN-GB\" style=\"color:black\"> is available in a pack containing 3\u00a0vials</span><span lang=\"EN-GB\">. Each glass vial is closed with a rubber stopper and aluminium\nover-seal</span><span lang=\"EN-GB\" style=\"color:black\">, and contains 5\u00a0ml\nof concentrate (100</span><span lang=\"EN-GB\">\u00a0</span><span lang=\"EN-GB\" style=\"color:black\">mg of ofatumumab).</span></p>", "ID": "b7fd7a16-bf12-47aa-83db-43cfe8da3460", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">Arzerra 100\u00a0mg</span></b>", "ID": "311bbec2-fb0b-4086-bb9a-9361525505be", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b7fd7a16-bf12-47aa-83db-43cfe8da3460"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Arzerra 100\u00a0mg</span>", "ID": "8315694c-caa9-4d28-960a-77771187fecf", "Styles": "color:black", "Classes": "None", "Text": "Arzerra 100\u00a0mg", "ParentId": "311bbec2-fb0b-4086-bb9a-9361525505be"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\"> is available in a pack containing 3\u00a0vials</span>", "ID": "185dd241-f76b-448b-880b-44397c99cf8c", "Styles": "color:black", "Classes": "None", "Text": " is available in a pack containing 3\u00a0vials", "ParentId": "b7fd7a16-bf12-47aa-83db-43cfe8da3460"}, {"Element": "<span lang=\"EN-GB\">. Each glass vial is closed with a rubber stopper and aluminium\nover-seal</span>", "ID": "7828f60d-3bee-4e95-b826-4a279ef8bfc4", "Styles": "None", "Classes": "None", "Text": ". Each glass vial is closed with a rubber stopper and aluminium over-seal", "ParentId": "b7fd7a16-bf12-47aa-83db-43cfe8da3460"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">, and contains 5\u00a0ml\nof concentrate (100</span>", "ID": "482fba40-db44-45ce-8f16-0a784464eed7", "Styles": "color:black", "Classes": "None", "Text": ", and contains 5\u00a0ml of concentrate (100", "ParentId": "b7fd7a16-bf12-47aa-83db-43cfe8da3460"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fcccffdb-79e0-4185-bcc7-7f01f88e3623", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b7fd7a16-bf12-47aa-83db-43cfe8da3460"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">mg of ofatumumab).</span>", "ID": "6227dd4e-2edc-4d84-b9cd-4e8dd0cc77cc", "Styles": "color:black", "Classes": "None", "Text": "mg of ofatumumab).", "ParentId": "b7fd7a16-bf12-47aa-83db-43cfe8da3460"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "2f804b72-4c76-46c4-8a9c-f6f4f805dbf3", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "0e964651-1f89-4457-99b2-80a9b61391e5", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "2f804b72-4c76-46c4-8a9c-f6f4f805dbf3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"EN-GB\" style=\"color:black\">Arzerra 1000\u00a0mg</span></b><span lang=\"EN-GB\" style=\"color:black\"> is available in a pack containing 1\u00a0vial</span><span lang=\"EN-GB\">. Each glass vial is closed with a rubber stopper and aluminium\nover-seal</span><span lang=\"EN-GB\" style=\"color:black\">, and contains 50\u00a0ml\nof concentrate (1000</span><span lang=\"EN-GB\">\u00a0</span><span lang=\"EN-GB\" style=\"color:black\">mg of ofatumumab).</span></p>", "ID": "ac02bbd3-81b6-44bb-be34-95f10d1fcd4b", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">Arzerra 1000\u00a0mg</span></b>", "ID": "4ccc452b-cbad-440b-a441-56cddf529925", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ac02bbd3-81b6-44bb-be34-95f10d1fcd4b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Arzerra 1000\u00a0mg</span>", "ID": "89e955a3-c046-4fab-89dc-13d58bdae3b6", "Styles": "color:black", "Classes": "None", "Text": "Arzerra 1000\u00a0mg", "ParentId": "4ccc452b-cbad-440b-a441-56cddf529925"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\"> is available in a pack containing 1\u00a0vial</span>", "ID": "86700b1b-f172-4aba-abbc-43aada631a81", "Styles": "color:black", "Classes": "None", "Text": " is available in a pack containing 1\u00a0vial", "ParentId": "ac02bbd3-81b6-44bb-be34-95f10d1fcd4b"}, {"Element": "<span lang=\"EN-GB\">. Each glass vial is closed with a rubber stopper and aluminium\nover-seal</span>", "ID": "e68d55a4-4f33-4367-bea6-c126c56a1be5", "Styles": "None", "Classes": "None", "Text": ". Each glass vial is closed with a rubber stopper and aluminium over-seal", "ParentId": "ac02bbd3-81b6-44bb-be34-95f10d1fcd4b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">, and contains 50\u00a0ml\nof concentrate (1000</span>", "ID": "6ae9ff04-5b60-475a-9a23-415b70aabf87", "Styles": "color:black", "Classes": "None", "Text": ", and contains 50\u00a0ml of concentrate (1000", "ParentId": "ac02bbd3-81b6-44bb-be34-95f10d1fcd4b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "96590429-8521-4b98-bd12-d15cc0ef3cce", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ac02bbd3-81b6-44bb-be34-95f10d1fcd4b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">mg of ofatumumab).</span>", "ID": "2ad72cea-8aa1-4ae5-a4b5-2e84bbdd9284", "Styles": "color:black", "Classes": "None", "Text": "mg of ofatumumab).", "ParentId": "ac02bbd3-81b6-44bb-be34-95f10d1fcd4b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "2056e31b-ba1c-4875-bc26-0827bf95ac99", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "65d407b9-6432-46fa-b926-57f7c42a27d7", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "2056e31b-ba1c-4875-bc26-0827bf95ac99"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Marketing Authorisation Holder</span></b></p>", "ID": "8401df4c-229a-4aef-862d-e645222a28b7", "Styles": "margin-right:-.1pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">Marketing Authorisation Holder</span></b>", "ID": "c827fff0-8c9b-4206-81cb-5a9101297c01", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8401df4c-229a-4aef-862d-e645222a28b7"}, {"Element": "<span lang=\"EN-GB\">Marketing Authorisation Holder</span>", "ID": "868e6aa1-f1b5-45f6-9be7-b4b4b0cbc0d5", "Styles": "None", "Classes": "None", "Text": "Marketing Authorisation Holder", "ParentId": "c827fff0-8c9b-4206-81cb-5a9101297c01"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Novartis\nEuropharm Limited</span></p>", "ID": "d8f78a82-e1f2-4dc8-b5b9-b67ac2f23fa5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Novartis\nEuropharm Limited</span>", "ID": "5930f80b-acb4-412c-894a-f17173a37f1d", "Styles": "None", "Classes": "None", "Text": "Novartis Europharm Limited", "ParentId": "d8f78a82-e1f2-4dc8-b5b9-b67ac2f23fa5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Frimley\nBusiness Park</span></p>", "ID": "04cea305-aa23-4aff-bfe8-f8136cdf5bf7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Frimley\nBusiness Park</span>", "ID": "a2969dff-418e-48f5-809b-abc09cf9b8ae", "Styles": "None", "Classes": "None", "Text": "Frimley Business Park", "ParentId": "04cea305-aa23-4aff-bfe8-f8136cdf5bf7"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Camberley\nGU16 7SR</span></p>", "ID": "f5203d2d-37f8-4904-b020-92bda759e868", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Camberley\nGU16 7SR</span>", "ID": "c6b21ea8-e8da-4cec-9273-45f1b9cd980e", "Styles": "None", "Classes": "None", "Text": "Camberley GU16 7SR", "ParentId": "f5203d2d-37f8-4904-b020-92bda759e868"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">United Kingdom</span></p>", "ID": "7a3a76ce-d431-4afa-93e4-e60dbcee9947", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">United Kingdom</span>", "ID": "b1fc8ce9-5b65-4bc6-834e-463c9c34a15e", "Styles": "color:black", "Classes": "None", "Text": "United Kingdom", "ParentId": "7a3a76ce-d431-4afa-93e4-e60dbcee9947"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3603d9cd-1056-4a22-8940-0ae1dc3fff23", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7079d373-fe12-4c6e-85af-b37c2af9cfaa", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3603d9cd-1056-4a22-8940-0ae1dc3fff23"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Manufacturer</span></b></p>", "ID": "02d2c0ca-9ad9-4870-9e92-2ee24e0a2921", "Styles": "margin-right:-.1pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">Manufacturer</span></b>", "ID": "fb7948dc-e62b-49d0-943d-2b74eda41430", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "02d2c0ca-9ad9-4870-9e92-2ee24e0a2921"}, {"Element": "<span lang=\"EN-GB\">Manufacturer</span>", "ID": "a3087d60-6668-4496-96d2-70c50f14f9c6", "Styles": "None", "Classes": "None", "Text": "Manufacturer", "ParentId": "fb7948dc-e62b-49d0-943d-2b74eda41430"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Glaxo Operations UK Limited (Trading as\nGlaxo Wellcome Operations), Harmire Road, Barnard Castle, County Durham, DL12\n8DT<span style=\"color:black\">,</span> United Kingdom</span></p>", "ID": "fa840cc7-e786-49b1-972d-910bbc461df8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Glaxo Operations UK Limited (Trading as\nGlaxo Wellcome Operations), Harmire Road, Barnard Castle, County Durham, DL12\n8DT<span style=\"color:black\">,</span> United Kingdom</span>", "ID": "2e1bf8ba-e443-49b0-8053-a2224419370b", "Styles": "None", "Classes": "None", "Text": "Glaxo Operations UK Limited (Trading as Glaxo Wellcome Operations), Harmire Road, Barnard Castle, County Durham, DL12 8DT United Kingdom", "ParentId": "fa840cc7-e786-49b1-972d-910bbc461df8"}, {"Element": "<span style=\"color:black\">,</span>", "ID": "c8775ebd-d28c-4e55-9393-fb0a12560276", "Styles": "color:black", "Classes": "None", "Text": ",", "ParentId": "2e1bf8ba-e443-49b0-8053-a2224419370b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">Novartis\nPharmaceuticals UK Limited, Frimley Business Park, Frimley, Camberley, Surrey\nGU16 7SR, United Kingdom</span></p>", "ID": "cee23c3a-36b1-4374-b51b-caafdc25ad70", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">Novartis\nPharmaceuticals UK Limited, Frimley Business Park, Frimley, Camberley, Surrey\nGU16 7SR, United Kingdom</span>", "ID": "3dd6b640-a823-4dbb-b0e9-af76b9c91b26", "Styles": "color:black;background:#D9D9D9", "Classes": "None", "Text": "Novartis Pharmaceuticals UK Limited, Frimley Business Park, Frimley, Camberley, Surrey GU16 7SR, United Kingdom", "ParentId": "cee23c3a-36b1-4374-b51b-caafdc25ad70"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">Novartis Pharma GmbH, Roonstrasse 25,\n90429 Nuremberg, Germany</span></p>", "ID": "9eb62ea9-b53d-4de7-8311-d581ec92598f", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">Novartis Pharma GmbH, Roonstrasse 25,\n90429 Nuremberg, Germany</span>", "ID": "fa7c2bd2-deb3-4750-a70d-9390d87b9b9e", "Styles": "color:black;background:#D9D9D9", "Classes": "None", "Text": "Novartis Pharma GmbH, Roonstrasse 25, 90429 Nuremberg, Germany", "ParentId": "9eb62ea9-b53d-4de7-8311-d581ec92598f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b2fc378e-ba8b-4504-a40f-a9b828526982", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5bf5f154-218b-4911-924e-7c5805dbb93a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b2fc378e-ba8b-4504-a40f-a9b828526982"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">For any\ninformation about this medicine, please contact the local representative of the\nMarketing Authorisation Holder:</span></p>", "ID": "e78e791b-59f1-4f95-9cb1-9fd8938c4739", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">For any\ninformation about this medicine, please contact the local representative of the\nMarketing Authorisation Holder:</span>", "ID": "2bca73c8-c846-4180-b0c5-aada966cd461", "Styles": "None", "Classes": "None", "Text": "For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:", "ParentId": "e78e791b-59f1-4f95-9cb1-9fd8938c4739"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "45a0c648-356e-4a46-a712-c5b59eda2087", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "94d8cc20-bed1-4320-a82d-45abceb66980", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "45a0c648-356e-4a46-a712-c5b59eda2087"}, {"Element": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:-1.7pt;border-collapse:collapse\" width=\"624\">\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"FR-BE\">Belgi\u00eb/Belgique/Belgien</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR-BE\">Novartis Pharma N.V.</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR-BE\">T\u00e9l/Tel: +32 2 246 16 11</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:1.7pt\"><span lang=\"FR\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"LT\">Lietuva</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-right:-22.45pt\"><span lang=\"LT\">Novartis\n  Pharma Services Inc.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-22.45pt\"><span lang=\"LT\">Tel: +370 5\n  269 16 50</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"BG\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Novartis Bulgaria EOOD</span></p>\n<p class=\"MsoNormal\"><span lang=\"BG\">\u0422\u0435\u043b:</span> +359 2 489 98\n  28</p>\n<p class=\"MsoNormal\"><b><span lang=\"NO-BOK\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Novartis Pharma N.V.</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR-BE\">T\u00e9l/Tel: +32 2 246 16 11</span></p>\n<p class=\"MsoNormal\"><span lang=\"NO-BOK\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"SV\">\u010cesk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"SV\">Novartis s.r.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +420 225 775 111</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"HU\">Magyarorsz\u00e1g</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"HU\">Novartis Hung\u00e1ria Kft.</span></p>\n<p class=\"MsoNormal\"><span lang=\"HU\">Tel.: +36 1 457 65 00</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b>Danmark</b></p>\n<p class=\"MsoNormal\">Novartis Healthcare A/S</p>\n<p class=\"MsoNormal\">Tlf: +45 39 16 84 00</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"MT\">Malta</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"MT\">Novartis Pharma Services Inc.</span></p>\n<p class=\"MsoNormal\"><span lang=\"MT\">Tel: +</span>356 <span lang=\"FR-CH\">2122 2872</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Deutschland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Novartis Pharma GmbH</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tel: +49 911 273 0</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"NL\">Nederland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"NL\">Novartis Pharma B.V.</span></p>\n<p class=\"MsoNormal\"><span lang=\"NL\">Tel: +31 26 37 82 555</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"ET\">Eesti</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ET\">Novartis Pharma Services Inc.</span></p>\n<p class=\"MsoNormal\"><span lang=\"ET\">Tel: +372 </span><span lang=\"EN-GB\">66 30 810</span></p>\n<p class=\"MsoNormal\"><span lang=\"ET\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"NO-BOK\">Norge</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"NO-BOK\">Novartis Norge AS</span></p>\n<p class=\"MsoNormal\"><span lang=\"NO-BOK\">Tlf: +47 23 05 20 00</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"EL\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ET\">Novartis (Hellas) A.E.B.E.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EL\">\u03a4\u03b7\u03bb</span><span lang=\"ET\">: +30\n  210 281 17 12</span></p>\n<p class=\"MsoNormal\"><span lang=\"ET\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-AT\">\u00d6sterreich</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-AT\">Novartis Pharma GmbH</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-AT\">Tel: +43 1 86 6570</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Novartis Farmac\u00e9utica, S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Tel: +34 93 306 42 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"PL\">Polska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PL\">Novartis Poland Sp. z o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"PL\">Tel.: +48 22 375 4888</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"FR\">France</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR\">Novartis Pharma S.A.S.</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR\">T\u00e9l: +33 1 55 47 66 00</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"PL\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"PT\">Portugal</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Novartis Farma - Produtos Farmac\u00eauticos,\n  S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT\">Tel: +351 21 000 8600</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Hrvatska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Novartis Hrvatska d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel. +385 1 6274 220</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"FR\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b>Rom\u00e2nia</b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">Novartis Pharma Services <span lang=\"EN-GB\">Romania SRL</span></p>\n<p class=\"MsoNormal\">Tel: +40 21 31299 01</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Ireland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Novartis Ireland Limited</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +353 1 260 12 55</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"SL\">Slovenija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"SL\">Novartis Pharma Services Inc.</span></p>\n<p class=\"MsoNormal\"><span lang=\"SL\">Tel: +386 1 300 75 50</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"IS\">\u00cdsland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IS\">Vistor hf.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">S\u00edmi</span><span lang=\"IS\">: +354 535 7000</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"SK\">Slovensk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"SK\">Novartis Slovakia s.r.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"SK\">Tel: +421 2 5542 5439</span></p>\n<p class=\"MsoNormal\"><span lang=\"SK\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Italia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Novartis Farma S.p.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: +39 02 96 54 1</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"FI\">Suomi/Finland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FI\">Novartis Finland Oy</span></p>\n<p class=\"MsoNormal\"><span lang=\"FI\">Puh/Tel: +358 </span><span lang=\"DE-CH\">(0)10\n  6133 200</span></p>\n<p class=\"MsoNormal\"><span lang=\"SV\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"EL\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">Novartis Pharma Services Inc.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EL\">\u03a4\u03b7\u03bb: +357 22 690 690</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EL\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"SV\">Sverige</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"SV\">Novartis Sverige AB</span></p>\n<p class=\"MsoNormal\"><span lang=\"SV\">Tel: +46 8 732 32 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"FI\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"LV\">Latvija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"LV\">SIA \u201cNovartis Baltics\u201d</span></p>\n<p class=\"MsoNormal\"><span lang=\"LV\">Tel: +371 67 887 070</span></p>\n<p class=\"MsoNormal\"><span lang=\"FI\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">United Kingdom</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Novartis Pharmaceuticals UK Ltd.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 1276 698370</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>\n</table>", "ID": "a89eb89f-b66c-4b37-8508-8e3beae85c66", "Styles": "margin-left:-1.7pt;border-collapse:collapse", "Classes": "['MsoNormalTable']", "Text": "                ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"FR-BE\">Belgi\u00eb/Belgique/Belgien</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR-BE\">Novartis Pharma N.V.</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR-BE\">T\u00e9l/Tel: +32 2 246 16 11</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:1.7pt\"><span lang=\"FR\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"LT\">Lietuva</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-right:-22.45pt\"><span lang=\"LT\">Novartis\n  Pharma Services Inc.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-22.45pt\"><span lang=\"LT\">Tel: +370 5\n  269 16 50</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">\u00a0</span></p>\n</td>\n</tr>", "ID": "c2039f08-6aca-4961-9666-4701ef3ceb92", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "a89eb89f-b66c-4b37-8508-8e3beae85c66"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"FR-BE\">Belgi\u00eb/Belgique/Belgien</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR-BE\">Novartis Pharma N.V.</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR-BE\">T\u00e9l/Tel: +32 2 246 16 11</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:1.7pt\"><span lang=\"FR\">\u00a0</span></p>\n</td>", "ID": "88732a45-4859-4f2f-a43d-ff7e01da1868", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "c2039f08-6aca-4961-9666-4701ef3ceb92"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"FR-BE\">Belgi\u00eb/Belgique/Belgien</span></b></p>", "ID": "f039f5bd-8243-46e1-b73c-57ad240c58e9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "88732a45-4859-4f2f-a43d-ff7e01da1868"}, {"Element": "<b><span lang=\"FR-BE\">Belgi\u00eb/Belgique/Belgien</span></b>", "ID": "281502f0-78af-45cd-8947-63e5491f2e45", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f039f5bd-8243-46e1-b73c-57ad240c58e9"}, {"Element": "<span lang=\"FR-BE\">Belgi\u00eb/Belgique/Belgien</span>", "ID": "23915b54-2660-4c58-b0c8-78c74ab6c172", "Styles": "None", "Classes": "None", "Text": "Belgi\u00eb/Belgique/Belgien", "ParentId": "281502f0-78af-45cd-8947-63e5491f2e45"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"FR-BE\">Novartis Pharma N.V.</span></p>", "ID": "0950dac2-8681-4577-a180-9170d9a4db9d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "88732a45-4859-4f2f-a43d-ff7e01da1868"}, {"Element": "<span lang=\"FR-BE\">Novartis Pharma N.V.</span>", "ID": "dbbf3584-ae3d-4cf3-9ead-a8295766e03c", "Styles": "None", "Classes": "None", "Text": "Novartis Pharma N.V.", "ParentId": "0950dac2-8681-4577-a180-9170d9a4db9d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"FR-BE\">T\u00e9l/Tel: +32 2 246 16 11</span></p>", "ID": "2ea23142-5b4e-4859-a4df-d634d85a76bd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "88732a45-4859-4f2f-a43d-ff7e01da1868"}, {"Element": "<span lang=\"FR-BE\">T\u00e9l/Tel: +32 2 246 16 11</span>", "ID": "3f1305e4-f48b-4794-8930-5e265b99ae9f", "Styles": "None", "Classes": "None", "Text": "T\u00e9l/Tel: +32 2 246 16 11", "ParentId": "2ea23142-5b4e-4859-a4df-d634d85a76bd"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:1.7pt\"><span lang=\"FR\">\u00a0</span></p>", "ID": "6d63fb6f-a51d-4e05-9718-0ccca7ec4239", "Styles": "margin-right:1.7pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "88732a45-4859-4f2f-a43d-ff7e01da1868"}, {"Element": "<span lang=\"FR\">\u00a0</span>", "ID": "ce10b128-a067-468f-a7f1-aadb83b3452e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6d63fb6f-a51d-4e05-9718-0ccca7ec4239"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"LT\">Lietuva</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-right:-22.45pt\"><span lang=\"LT\">Novartis\n  Pharma Services Inc.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-22.45pt\"><span lang=\"LT\">Tel: +370 5\n  269 16 50</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">\u00a0</span></p>\n</td>", "ID": "f0f6895b-dbce-499e-b54b-cd14ddf227d1", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "c2039f08-6aca-4961-9666-4701ef3ceb92"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"LT\">Lietuva</span></b></p>", "ID": "497f0333-d29a-440d-af5c-803a270ab9b7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f0f6895b-dbce-499e-b54b-cd14ddf227d1"}, {"Element": "<b><span lang=\"LT\">Lietuva</span></b>", "ID": "2350d546-752d-40a2-81d1-44d0dc9bd906", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "497f0333-d29a-440d-af5c-803a270ab9b7"}, {"Element": "<span lang=\"LT\">Lietuva</span>", "ID": "99cfdb28-f149-483e-b06c-e4b8caf634b5", "Styles": "None", "Classes": "None", "Text": "Lietuva", "ParentId": "2350d546-752d-40a2-81d1-44d0dc9bd906"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-22.45pt\"><span lang=\"LT\">Novartis\n  Pharma Services Inc.</span></p>", "ID": "b6bedc00-2c10-44a9-a15d-5209ede6d243", "Styles": "margin-right:-22.45pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f0f6895b-dbce-499e-b54b-cd14ddf227d1"}, {"Element": "<span lang=\"LT\">Novartis\n  Pharma Services Inc.</span>", "ID": "bc85d94f-5446-4c4b-acbc-dc604a4568fb", "Styles": "None", "Classes": "None", "Text": "Novartis   Pharma Services Inc.", "ParentId": "b6bedc00-2c10-44a9-a15d-5209ede6d243"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-22.45pt\"><span lang=\"LT\">Tel: +370 5\n  269 16 50</span></p>", "ID": "0fac049d-797e-47a8-ab60-8ca7178f00f9", "Styles": "margin-right:-22.45pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f0f6895b-dbce-499e-b54b-cd14ddf227d1"}, {"Element": "<span lang=\"LT\">Tel: +370 5\n  269 16 50</span>", "ID": "5ead0022-6f35-46f4-81c4-7fedcadeb057", "Styles": "None", "Classes": "None", "Text": "Tel: +370 5   269 16 50", "ParentId": "0fac049d-797e-47a8-ab60-8ca7178f00f9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"FR-CH\">\u00a0</span></p>", "ID": "3007cb05-7933-43a1-8000-79c04573f285", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f0f6895b-dbce-499e-b54b-cd14ddf227d1"}, {"Element": "<span lang=\"FR-CH\">\u00a0</span>", "ID": "c8b194c6-b8fc-4a10-9ecc-123cc63ece63", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3007cb05-7933-43a1-8000-79c04573f285"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"BG\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Novartis Bulgaria EOOD</span></p>\n<p class=\"MsoNormal\"><span lang=\"BG\">\u0422\u0435\u043b:</span> +359 2 489 98\n  28</p>\n<p class=\"MsoNormal\"><b><span lang=\"NO-BOK\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Novartis Pharma N.V.</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR-BE\">T\u00e9l/Tel: +32 2 246 16 11</span></p>\n<p class=\"MsoNormal\"><span lang=\"NO-BOK\">\u00a0</span></p>\n</td>\n</tr>", "ID": "e88a8c74-8e88-4113-8d42-b6c2af50ac23", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "a89eb89f-b66c-4b37-8508-8e3beae85c66"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"BG\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Novartis Bulgaria EOOD</span></p>\n<p class=\"MsoNormal\"><span lang=\"BG\">\u0422\u0435\u043b:</span> +359 2 489 98\n  28</p>\n<p class=\"MsoNormal\"><b><span lang=\"NO-BOK\">\u00a0</span></b></p>\n</td>", "ID": "1db4b7e8-7bd6-4231-80c4-ae7be3a461e3", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "e88a8c74-8e88-4113-8d42-b6c2af50ac23"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"BG\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>", "ID": "08fd9c8a-ae00-4c63-b6f8-e61ce14fa250", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1db4b7e8-7bd6-4231-80c4-ae7be3a461e3"}, {"Element": "<b><span lang=\"BG\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b>", "ID": "a0350468-4373-4781-ab3d-d47080f33d1f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "08fd9c8a-ae00-4c63-b6f8-e61ce14fa250"}, {"Element": "<span lang=\"BG\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span>", "ID": "5e70a9a0-6aaf-4c58-9887-485942cc91ec", "Styles": "None", "Classes": "None", "Text": "\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f", "ParentId": "a0350468-4373-4781-ab3d-d47080f33d1f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Novartis Bulgaria EOOD</span></p>", "ID": "47b81d22-cd88-4c55-8b76-de70a9ec8c31", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1db4b7e8-7bd6-4231-80c4-ae7be3a461e3"}, {"Element": "<span lang=\"EN-GB\">Novartis Bulgaria EOOD</span>", "ID": "670eeb0f-c1e3-40f9-ad5b-bee3e37ae188", "Styles": "None", "Classes": "None", "Text": "Novartis Bulgaria EOOD", "ParentId": "47b81d22-cd88-4c55-8b76-de70a9ec8c31"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"BG\">\u0422\u0435\u043b:</span> +359 2 489 98\n  28</p>", "ID": "9d50c31c-0f30-428d-bf28-50bd42ddeb17", "Styles": "None", "Classes": "['MsoNormal']", "Text": " +359 2 489 98   28", "ParentId": "1db4b7e8-7bd6-4231-80c4-ae7be3a461e3"}, {"Element": "<span lang=\"BG\">\u0422\u0435\u043b:</span>", "ID": "d05636ea-b138-4721-af9c-a99d2ada4a18", "Styles": "None", "Classes": "None", "Text": "\u0422\u0435\u043b:", "ParentId": "9d50c31c-0f30-428d-bf28-50bd42ddeb17"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"NO-BOK\">\u00a0</span></b></p>", "ID": "6cee235e-0803-495e-8bf9-d65e45f04d7a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1db4b7e8-7bd6-4231-80c4-ae7be3a461e3"}, {"Element": "<b><span lang=\"NO-BOK\">\u00a0</span></b>", "ID": "1a2612c4-bd2a-4fa9-b707-9b62de467e75", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6cee235e-0803-495e-8bf9-d65e45f04d7a"}, {"Element": "<span lang=\"NO-BOK\">\u00a0</span>", "ID": "ec9fceea-238c-4df9-9bcb-026dacb01905", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1a2612c4-bd2a-4fa9-b707-9b62de467e75"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Novartis Pharma N.V.</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR-BE\">T\u00e9l/Tel: +32 2 246 16 11</span></p>\n<p class=\"MsoNormal\"><span lang=\"NO-BOK\">\u00a0</span></p>\n</td>", "ID": "1271dc44-4e64-4b36-8b71-a5b9c65d0d89", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "e88a8c74-8e88-4113-8d42-b6c2af50ac23"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Luxembourg/Luxemburg</span></b></p>", "ID": "2801586c-ec60-4716-95c2-06c628e2a4d4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1271dc44-4e64-4b36-8b71-a5b9c65d0d89"}, {"Element": "<b><span lang=\"DE-CH\">Luxembourg/Luxemburg</span></b>", "ID": "46bec4b5-ca60-456b-a764-445ad93717e3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2801586c-ec60-4716-95c2-06c628e2a4d4"}, {"Element": "<span lang=\"DE-CH\">Luxembourg/Luxemburg</span>", "ID": "4a78bb05-f33e-4ae5-b61c-94d87de1f77a", "Styles": "None", "Classes": "None", "Text": "Luxembourg/Luxemburg", "ParentId": "46bec4b5-ca60-456b-a764-445ad93717e3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Novartis Pharma N.V.</span></p>", "ID": "d92c567b-9cac-4bf9-b2c8-fb6e42c1b33f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1271dc44-4e64-4b36-8b71-a5b9c65d0d89"}, {"Element": "<span lang=\"DE-CH\">Novartis Pharma N.V.</span>", "ID": "b7820b65-e558-491b-978b-0b3e0e1700b6", "Styles": "None", "Classes": "None", "Text": "Novartis Pharma N.V.", "ParentId": "d92c567b-9cac-4bf9-b2c8-fb6e42c1b33f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"FR-BE\">T\u00e9l/Tel: +32 2 246 16 11</span></p>", "ID": "8f8eba04-cf90-4d15-b9f2-68b2f8da7a94", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1271dc44-4e64-4b36-8b71-a5b9c65d0d89"}, {"Element": "<span lang=\"FR-BE\">T\u00e9l/Tel: +32 2 246 16 11</span>", "ID": "772e2150-1dea-4f0e-a285-2899d1d7477d", "Styles": "None", "Classes": "None", "Text": "T\u00e9l/Tel: +32 2 246 16 11", "ParentId": "8f8eba04-cf90-4d15-b9f2-68b2f8da7a94"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"NO-BOK\">\u00a0</span></p>", "ID": "ac3d079e-b6bc-494b-ae00-05081349c6fd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1271dc44-4e64-4b36-8b71-a5b9c65d0d89"}, {"Element": "<span lang=\"NO-BOK\">\u00a0</span>", "ID": "83c81a4b-dc4f-43df-97bc-eb0d808e453c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ac3d079e-b6bc-494b-ae00-05081349c6fd"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"SV\">\u010cesk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"SV\">Novartis s.r.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +420 225 775 111</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"HU\">Magyarorsz\u00e1g</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"HU\">Novartis Hung\u00e1ria Kft.</span></p>\n<p class=\"MsoNormal\"><span lang=\"HU\">Tel.: +36 1 457 65 00</span></p>\n</td>\n</tr>", "ID": "6dcf7d6f-8550-4757-9f43-1c10b66f51e4", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "a89eb89f-b66c-4b37-8508-8e3beae85c66"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"SV\">\u010cesk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"SV\">Novartis s.r.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +420 225 775 111</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>", "ID": "bbcb7fd4-993a-480b-bb1e-1b46f03e073c", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "6dcf7d6f-8550-4757-9f43-1c10b66f51e4"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"SV\">\u010cesk\u00e1 republika</span></b></p>", "ID": "d3142be9-d2d8-4ffb-b388-cda391e434e8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bbcb7fd4-993a-480b-bb1e-1b46f03e073c"}, {"Element": "<b><span lang=\"SV\">\u010cesk\u00e1 republika</span></b>", "ID": "bf349807-3909-42d2-a940-983814aa8533", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d3142be9-d2d8-4ffb-b388-cda391e434e8"}, {"Element": "<span lang=\"SV\">\u010cesk\u00e1 republika</span>", "ID": "d7ed4b4d-97bd-433f-9d6c-a2dd7b53e42b", "Styles": "None", "Classes": "None", "Text": "\u010cesk\u00e1 republika", "ParentId": "bf349807-3909-42d2-a940-983814aa8533"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"SV\">Novartis s.r.o.</span></p>", "ID": "0250b6bd-ef16-4823-bc3c-2a51cd2b9ff4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bbcb7fd4-993a-480b-bb1e-1b46f03e073c"}, {"Element": "<span lang=\"SV\">Novartis s.r.o.</span>", "ID": "f992aaf9-f532-4170-93ae-bc00d7b4c9ce", "Styles": "None", "Classes": "None", "Text": "Novartis s.r.o.", "ParentId": "0250b6bd-ef16-4823-bc3c-2a51cd2b9ff4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +420 225 775 111</span></p>", "ID": "c0849ae5-9fb3-4172-a600-6d047531ca29", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bbcb7fd4-993a-480b-bb1e-1b46f03e073c"}, {"Element": "<span lang=\"DE-CH\">Tel: +420 225 775 111</span>", "ID": "24e26687-2082-4cdd-8d02-ae9d6d72f407", "Styles": "None", "Classes": "None", "Text": "Tel: +420 225 775 111", "ParentId": "c0849ae5-9fb3-4172-a600-6d047531ca29"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>", "ID": "f282916b-f2a1-453a-b1bc-35ac4ea261a1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bbcb7fd4-993a-480b-bb1e-1b46f03e073c"}, {"Element": "<span lang=\"DE-CH\">\u00a0</span>", "ID": "af2014d5-56ff-469a-b38e-0446dd776cf5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f282916b-f2a1-453a-b1bc-35ac4ea261a1"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"HU\">Magyarorsz\u00e1g</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"HU\">Novartis Hung\u00e1ria Kft.</span></p>\n<p class=\"MsoNormal\"><span lang=\"HU\">Tel.: +36 1 457 65 00</span></p>\n</td>", "ID": "26211e9b-6709-4053-9f29-b93fcd17331e", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "6dcf7d6f-8550-4757-9f43-1c10b66f51e4"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"HU\">Magyarorsz\u00e1g</span></b></p>", "ID": "7a3bec03-ed65-4483-9996-b5725cd410a5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "26211e9b-6709-4053-9f29-b93fcd17331e"}, {"Element": "<b><span lang=\"HU\">Magyarorsz\u00e1g</span></b>", "ID": "be1fab92-be22-40d8-be09-267d7a61b53e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7a3bec03-ed65-4483-9996-b5725cd410a5"}, {"Element": "<span lang=\"HU\">Magyarorsz\u00e1g</span>", "ID": "8e90cde6-0199-4d77-973e-5e249e73e513", "Styles": "None", "Classes": "None", "Text": "Magyarorsz\u00e1g", "ParentId": "be1fab92-be22-40d8-be09-267d7a61b53e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"HU\">Novartis Hung\u00e1ria Kft.</span></p>", "ID": "763c8f42-e331-4e32-8ed0-42dddd762432", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "26211e9b-6709-4053-9f29-b93fcd17331e"}, {"Element": "<span lang=\"HU\">Novartis Hung\u00e1ria Kft.</span>", "ID": "27a1c35e-e3b2-4570-906a-ae074fb44528", "Styles": "None", "Classes": "None", "Text": "Novartis Hung\u00e1ria Kft.", "ParentId": "763c8f42-e331-4e32-8ed0-42dddd762432"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"HU\">Tel.: +36 1 457 65 00</span></p>", "ID": "9d39d40b-dfd7-43e0-a04f-059fb4aba187", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "26211e9b-6709-4053-9f29-b93fcd17331e"}, {"Element": "<span lang=\"HU\">Tel.: +36 1 457 65 00</span>", "ID": "06a18628-884c-4704-8405-62d51fc10b1c", "Styles": "None", "Classes": "None", "Text": "Tel.: +36 1 457 65 00", "ParentId": "9d39d40b-dfd7-43e0-a04f-059fb4aba187"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b>Danmark</b></p>\n<p class=\"MsoNormal\">Novartis Healthcare A/S</p>\n<p class=\"MsoNormal\">Tlf: +45 39 16 84 00</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"MT\">Malta</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"MT\">Novartis Pharma Services Inc.</span></p>\n<p class=\"MsoNormal\"><span lang=\"MT\">Tel: +</span>356 <span lang=\"FR-CH\">2122 2872</span></p>\n</td>\n</tr>", "ID": "b7f3be18-c58f-4553-be82-b9e09aee7b84", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "a89eb89f-b66c-4b37-8508-8e3beae85c66"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b>Danmark</b></p>\n<p class=\"MsoNormal\">Novartis Healthcare A/S</p>\n<p class=\"MsoNormal\">Tlf: +45 39 16 84 00</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>", "ID": "2577bf2a-7bce-4757-b8ed-015137f76504", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "b7f3be18-c58f-4553-be82-b9e09aee7b84"}, {"Element": "<p class=\"MsoNormal\"><b>Danmark</b></p>", "ID": "f5412a4a-49b3-4125-a31c-02274487351a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2577bf2a-7bce-4757-b8ed-015137f76504"}, {"Element": "<b>Danmark</b>", "ID": "f00967f3-a213-4e93-9c19-2956ae8130c5", "Styles": "None", "Classes": "None", "Text": "Danmark", "ParentId": "f5412a4a-49b3-4125-a31c-02274487351a"}, {"Element": "<p class=\"MsoNormal\">Novartis Healthcare A/S</p>", "ID": "d6c9fec7-71cb-4b07-b321-76e6d79d15b6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Novartis Healthcare A/S", "ParentId": "2577bf2a-7bce-4757-b8ed-015137f76504"}, {"Element": "<p class=\"MsoNormal\">Tlf: +45 39 16 84 00</p>", "ID": "f83079c6-579e-4318-9158-23874dd946a9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Tlf: +45 39 16 84 00", "ParentId": "2577bf2a-7bce-4757-b8ed-015137f76504"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "206e1b30-7a6f-4088-8864-0e383f8aade8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "2577bf2a-7bce-4757-b8ed-015137f76504"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"MT\">Malta</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"MT\">Novartis Pharma Services Inc.</span></p>\n<p class=\"MsoNormal\"><span lang=\"MT\">Tel: +</span>356 <span lang=\"FR-CH\">2122 2872</span></p>\n</td>", "ID": "9758ba2f-bde5-4760-b4b1-3fee0aefc293", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "b7f3be18-c58f-4553-be82-b9e09aee7b84"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"MT\">Malta</span></b></p>", "ID": "733a12f6-47d4-402c-bbf3-783b025731aa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9758ba2f-bde5-4760-b4b1-3fee0aefc293"}, {"Element": "<b><span lang=\"MT\">Malta</span></b>", "ID": "2b16c502-cdd0-442e-b9e6-e6653427379f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "733a12f6-47d4-402c-bbf3-783b025731aa"}, {"Element": "<span lang=\"MT\">Malta</span>", "ID": "aecc8299-1577-4564-ad55-e78721410499", "Styles": "None", "Classes": "None", "Text": "Malta", "ParentId": "2b16c502-cdd0-442e-b9e6-e6653427379f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"MT\">Novartis Pharma Services Inc.</span></p>", "ID": "3c9a00a7-dc0c-491f-a991-2968dc5809d6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9758ba2f-bde5-4760-b4b1-3fee0aefc293"}, {"Element": "<span lang=\"MT\">Novartis Pharma Services Inc.</span>", "ID": "f6e5133c-9492-4541-a73a-343aaec6ea22", "Styles": "None", "Classes": "None", "Text": "Novartis Pharma Services Inc.", "ParentId": "3c9a00a7-dc0c-491f-a991-2968dc5809d6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"MT\">Tel: +</span>356 <span lang=\"FR-CH\">2122 2872</span></p>", "ID": "b7765a51-b583-4693-96e6-db3254dad5bd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "356 ", "ParentId": "9758ba2f-bde5-4760-b4b1-3fee0aefc293"}, {"Element": "<span lang=\"MT\">Tel: +</span>", "ID": "df9e13fa-1fa7-4893-b21b-eb6e77fbd438", "Styles": "None", "Classes": "None", "Text": "Tel: +", "ParentId": "b7765a51-b583-4693-96e6-db3254dad5bd"}, {"Element": "<span lang=\"FR-CH\">2122 2872</span>", "ID": "734d93e1-e062-47a9-bb0b-f56b4c1648e2", "Styles": "None", "Classes": "None", "Text": "2122 2872", "ParentId": "b7765a51-b583-4693-96e6-db3254dad5bd"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Deutschland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Novartis Pharma GmbH</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tel: +49 911 273 0</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"NL\">Nederland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"NL\">Novartis Pharma B.V.</span></p>\n<p class=\"MsoNormal\"><span lang=\"NL\">Tel: +31 26 37 82 555</span></p>\n</td>\n</tr>", "ID": "564aa5a2-ee0b-45fa-a2a1-477e45ac8e0f", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "a89eb89f-b66c-4b37-8508-8e3beae85c66"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Deutschland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Novartis Pharma GmbH</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tel: +49 911 273 0</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">\u00a0</span></p>\n</td>", "ID": "5f1b1a87-08c8-4aaa-90a0-d9095c82bbed", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "564aa5a2-ee0b-45fa-a2a1-477e45ac8e0f"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE\">Deutschland</span></b></p>", "ID": "d367e51b-f6c6-44a2-8e38-9f375ab5893f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5f1b1a87-08c8-4aaa-90a0-d9095c82bbed"}, {"Element": "<b><span lang=\"DE\">Deutschland</span></b>", "ID": "36640640-e16a-465d-bd42-07df72cc55ee", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d367e51b-f6c6-44a2-8e38-9f375ab5893f"}, {"Element": "<span lang=\"DE\">Deutschland</span>", "ID": "f1c252db-1e1a-4a70-b6a1-9b04fb866e9d", "Styles": "None", "Classes": "None", "Text": "Deutschland", "ParentId": "36640640-e16a-465d-bd42-07df72cc55ee"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\">Novartis Pharma GmbH</span></p>", "ID": "603d69c5-cfe2-4f59-b951-20e8f1770bb6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5f1b1a87-08c8-4aaa-90a0-d9095c82bbed"}, {"Element": "<span lang=\"DE\">Novartis Pharma GmbH</span>", "ID": "abe4b21b-8f01-4e93-9b1f-7b4254666cce", "Styles": "None", "Classes": "None", "Text": "Novartis Pharma GmbH", "ParentId": "603d69c5-cfe2-4f59-b951-20e8f1770bb6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\">Tel: +49 911 273 0</span></p>", "ID": "0ee003fa-4fe0-4437-abc3-d260fdc961b2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5f1b1a87-08c8-4aaa-90a0-d9095c82bbed"}, {"Element": "<span lang=\"DE\">Tel: +49 911 273 0</span>", "ID": "6d69f545-2e18-424a-be46-c0e3cc508e30", "Styles": "None", "Classes": "None", "Text": "Tel: +49 911 273 0", "ParentId": "0ee003fa-4fe0-4437-abc3-d260fdc961b2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\">\u00a0</span></p>", "ID": "45f2339e-6334-42e5-b0bd-bd64c9c575a9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5f1b1a87-08c8-4aaa-90a0-d9095c82bbed"}, {"Element": "<span lang=\"DE\">\u00a0</span>", "ID": "f226829f-bb61-4ebd-8813-265ba53b0b4d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "45f2339e-6334-42e5-b0bd-bd64c9c575a9"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"NL\">Nederland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"NL\">Novartis Pharma B.V.</span></p>\n<p class=\"MsoNormal\"><span lang=\"NL\">Tel: +31 26 37 82 555</span></p>\n</td>", "ID": "47551d47-a46e-4bb6-bfa5-5373f4574e5e", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "564aa5a2-ee0b-45fa-a2a1-477e45ac8e0f"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"NL\">Nederland</span></b></p>", "ID": "a18de94b-e82d-4209-b647-0f35059793aa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "47551d47-a46e-4bb6-bfa5-5373f4574e5e"}, {"Element": "<b><span lang=\"NL\">Nederland</span></b>", "ID": "5b796a6f-4fd5-43a9-85a2-b1bfbf22c769", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a18de94b-e82d-4209-b647-0f35059793aa"}, {"Element": "<span lang=\"NL\">Nederland</span>", "ID": "342c8c78-ed95-43b2-b7c9-ae2bf7d5cd19", "Styles": "None", "Classes": "None", "Text": "Nederland", "ParentId": "5b796a6f-4fd5-43a9-85a2-b1bfbf22c769"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"NL\">Novartis Pharma B.V.</span></p>", "ID": "8cd9c8d4-33ba-4be9-bb26-1def2254f062", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "47551d47-a46e-4bb6-bfa5-5373f4574e5e"}, {"Element": "<span lang=\"NL\">Novartis Pharma B.V.</span>", "ID": "5031434d-a8b4-497f-87c5-f4a4f9587fda", "Styles": "None", "Classes": "None", "Text": "Novartis Pharma B.V.", "ParentId": "8cd9c8d4-33ba-4be9-bb26-1def2254f062"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"NL\">Tel: +31 26 37 82 555</span></p>", "ID": "3c84eb8e-f9f6-4c7f-9072-16f63fd97632", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "47551d47-a46e-4bb6-bfa5-5373f4574e5e"}, {"Element": "<span lang=\"NL\">Tel: +31 26 37 82 555</span>", "ID": "735bb230-991d-4392-8788-b973b7b7c4a6", "Styles": "None", "Classes": "None", "Text": "Tel: +31 26 37 82 555", "ParentId": "3c84eb8e-f9f6-4c7f-9072-16f63fd97632"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"ET\">Eesti</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ET\">Novartis Pharma Services Inc.</span></p>\n<p class=\"MsoNormal\"><span lang=\"ET\">Tel: +372 </span><span lang=\"EN-GB\">66 30 810</span></p>\n<p class=\"MsoNormal\"><span lang=\"ET\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"NO-BOK\">Norge</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"NO-BOK\">Novartis Norge AS</span></p>\n<p class=\"MsoNormal\"><span lang=\"NO-BOK\">Tlf: +47 23 05 20 00</span></p>\n</td>\n</tr>", "ID": "380bc587-ae9c-46ff-a161-4b741dcd6b15", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "a89eb89f-b66c-4b37-8508-8e3beae85c66"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"ET\">Eesti</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ET\">Novartis Pharma Services Inc.</span></p>\n<p class=\"MsoNormal\"><span lang=\"ET\">Tel: +372 </span><span lang=\"EN-GB\">66 30 810</span></p>\n<p class=\"MsoNormal\"><span lang=\"ET\">\u00a0</span></p>\n</td>", "ID": "8a920316-72e7-45de-8f4c-1df4fc851c5f", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "380bc587-ae9c-46ff-a161-4b741dcd6b15"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"ET\">Eesti</span></b></p>", "ID": "91f26f67-4eed-4b6b-8033-f5632c3d5aa5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8a920316-72e7-45de-8f4c-1df4fc851c5f"}, {"Element": "<b><span lang=\"ET\">Eesti</span></b>", "ID": "92cc57bc-7aee-4294-984b-189a08929de6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "91f26f67-4eed-4b6b-8033-f5632c3d5aa5"}, {"Element": "<span lang=\"ET\">Eesti</span>", "ID": "5a924ff0-a395-4156-bc58-2878166627fd", "Styles": "None", "Classes": "None", "Text": "Eesti", "ParentId": "92cc57bc-7aee-4294-984b-189a08929de6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"ET\">Novartis Pharma Services Inc.</span></p>", "ID": "89573146-ee84-4265-ae83-434fc397dc82", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8a920316-72e7-45de-8f4c-1df4fc851c5f"}, {"Element": "<span lang=\"ET\">Novartis Pharma Services Inc.</span>", "ID": "e5202525-700a-4e5d-9543-ff2f53fa0a5b", "Styles": "None", "Classes": "None", "Text": "Novartis Pharma Services Inc.", "ParentId": "89573146-ee84-4265-ae83-434fc397dc82"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"ET\">Tel: +372 </span><span lang=\"EN-GB\">66 30 810</span></p>", "ID": "2ab4950b-dd37-4697-b2ea-f3f245c1cd0d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8a920316-72e7-45de-8f4c-1df4fc851c5f"}, {"Element": "<span lang=\"ET\">Tel: +372 </span>", "ID": "9cf68af6-5379-430d-9e4c-e60846525452", "Styles": "None", "Classes": "None", "Text": "Tel: +372 ", "ParentId": "2ab4950b-dd37-4697-b2ea-f3f245c1cd0d"}, {"Element": "<span lang=\"EN-GB\">66 30 810</span>", "ID": "6b1a7950-ac6b-4b52-bc17-d6ebc5a39d9c", "Styles": "None", "Classes": "None", "Text": "66 30 810", "ParentId": "2ab4950b-dd37-4697-b2ea-f3f245c1cd0d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"ET\">\u00a0</span></p>", "ID": "75886383-6da0-4ff7-95c0-90ccfd9c812c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8a920316-72e7-45de-8f4c-1df4fc851c5f"}, {"Element": "<span lang=\"ET\">\u00a0</span>", "ID": "9e91427a-173f-4b0d-a36f-b1e759b2d311", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "75886383-6da0-4ff7-95c0-90ccfd9c812c"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"NO-BOK\">Norge</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"NO-BOK\">Novartis Norge AS</span></p>\n<p class=\"MsoNormal\"><span lang=\"NO-BOK\">Tlf: +47 23 05 20 00</span></p>\n</td>", "ID": "2880bdd1-7c8d-432d-ac67-e3a7a098a077", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "380bc587-ae9c-46ff-a161-4b741dcd6b15"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"NO-BOK\">Norge</span></b></p>", "ID": "38ac917e-a8ea-4056-999e-2dc38a2d1987", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2880bdd1-7c8d-432d-ac67-e3a7a098a077"}, {"Element": "<b><span lang=\"NO-BOK\">Norge</span></b>", "ID": "4a1baf09-b389-43eb-9155-5cc3cd7e4863", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "38ac917e-a8ea-4056-999e-2dc38a2d1987"}, {"Element": "<span lang=\"NO-BOK\">Norge</span>", "ID": "941bed69-6446-4acd-b39d-59e265e5d9ff", "Styles": "None", "Classes": "None", "Text": "Norge", "ParentId": "4a1baf09-b389-43eb-9155-5cc3cd7e4863"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"NO-BOK\">Novartis Norge AS</span></p>", "ID": "75174596-9f82-4f12-8636-58b8f834cc36", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2880bdd1-7c8d-432d-ac67-e3a7a098a077"}, {"Element": "<span lang=\"NO-BOK\">Novartis Norge AS</span>", "ID": "e1a716d5-ddad-40f4-b8da-5ce870f0b323", "Styles": "None", "Classes": "None", "Text": "Novartis Norge AS", "ParentId": "75174596-9f82-4f12-8636-58b8f834cc36"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"NO-BOK\">Tlf: +47 23 05 20 00</span></p>", "ID": "924fd31e-41ef-4d7f-b27e-cb86d5a18936", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2880bdd1-7c8d-432d-ac67-e3a7a098a077"}, {"Element": "<span lang=\"NO-BOK\">Tlf: +47 23 05 20 00</span>", "ID": "869b3be6-3de5-4218-93e7-917b8d5f16a2", "Styles": "None", "Classes": "None", "Text": "Tlf: +47 23 05 20 00", "ParentId": "924fd31e-41ef-4d7f-b27e-cb86d5a18936"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"EL\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ET\">Novartis (Hellas) A.E.B.E.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EL\">\u03a4\u03b7\u03bb</span><span lang=\"ET\">: +30\n  210 281 17 12</span></p>\n<p class=\"MsoNormal\"><span lang=\"ET\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-AT\">\u00d6sterreich</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-AT\">Novartis Pharma GmbH</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-AT\">Tel: +43 1 86 6570</span></p>\n</td>\n</tr>", "ID": "9d6067fc-92ef-4586-8b4e-73c554916c2b", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "a89eb89f-b66c-4b37-8508-8e3beae85c66"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"EL\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ET\">Novartis (Hellas) A.E.B.E.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EL\">\u03a4\u03b7\u03bb</span><span lang=\"ET\">: +30\n  210 281 17 12</span></p>\n<p class=\"MsoNormal\"><span lang=\"ET\">\u00a0</span></p>\n</td>", "ID": "7a29728a-5003-4765-9f76-df6d56ea4ce7", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "9d6067fc-92ef-4586-8b4e-73c554916c2b"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EL\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>", "ID": "1dad0503-848a-4d69-bc92-8e9362cf28dd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7a29728a-5003-4765-9f76-df6d56ea4ce7"}, {"Element": "<b><span lang=\"EL\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b>", "ID": "040df90b-dd60-4abf-b872-6aa2162b1e53", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1dad0503-848a-4d69-bc92-8e9362cf28dd"}, {"Element": "<span lang=\"EL\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span>", "ID": "f2105f22-12e0-4af3-aec5-ec15616c375a", "Styles": "None", "Classes": "None", "Text": "\u0395\u03bb\u03bb\u03ac\u03b4\u03b1", "ParentId": "040df90b-dd60-4abf-b872-6aa2162b1e53"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"ET\">Novartis (Hellas) A.E.B.E.</span></p>", "ID": "082e99a5-e656-4be8-85b5-c3a5c14649c8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7a29728a-5003-4765-9f76-df6d56ea4ce7"}, {"Element": "<span lang=\"ET\">Novartis (Hellas) A.E.B.E.</span>", "ID": "2d7bfc8c-b6a7-4beb-af0a-5698b1739b28", "Styles": "None", "Classes": "None", "Text": "Novartis (Hellas) A.E.B.E.", "ParentId": "082e99a5-e656-4be8-85b5-c3a5c14649c8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EL\">\u03a4\u03b7\u03bb</span><span lang=\"ET\">: +30\n  210 281 17 12</span></p>", "ID": "30c5690f-01f7-4a92-ad5c-151068cb7544", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7a29728a-5003-4765-9f76-df6d56ea4ce7"}, {"Element": "<span lang=\"EL\">\u03a4\u03b7\u03bb</span>", "ID": "33b48bb5-5512-4589-a315-0527ac20c945", "Styles": "None", "Classes": "None", "Text": "\u03a4\u03b7\u03bb", "ParentId": "30c5690f-01f7-4a92-ad5c-151068cb7544"}, {"Element": "<span lang=\"ET\">: +30\n  210 281 17 12</span>", "ID": "cde2bf7e-3b82-4fd4-87a1-272bc7340d0b", "Styles": "None", "Classes": "None", "Text": ": +30   210 281 17 12", "ParentId": "30c5690f-01f7-4a92-ad5c-151068cb7544"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"ET\">\u00a0</span></p>", "ID": "b22212cd-2af6-4c76-aedb-dade3444228a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7a29728a-5003-4765-9f76-df6d56ea4ce7"}, {"Element": "<span lang=\"ET\">\u00a0</span>", "ID": "f2b74371-01f5-408c-b822-f13eed941bf5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b22212cd-2af6-4c76-aedb-dade3444228a"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-AT\">\u00d6sterreich</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-AT\">Novartis Pharma GmbH</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-AT\">Tel: +43 1 86 6570</span></p>\n</td>", "ID": "36b1909b-e638-4cf8-913e-f6bd44279983", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "9d6067fc-92ef-4586-8b4e-73c554916c2b"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-AT\">\u00d6sterreich</span></b></p>", "ID": "5447f1e1-83fa-49fc-a30a-d1d4665951bb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "36b1909b-e638-4cf8-913e-f6bd44279983"}, {"Element": "<b><span lang=\"DE-AT\">\u00d6sterreich</span></b>", "ID": "e727d97a-23c9-41e8-a320-16cece23e2ae", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5447f1e1-83fa-49fc-a30a-d1d4665951bb"}, {"Element": "<span lang=\"DE-AT\">\u00d6sterreich</span>", "ID": "c3a0b0cc-396a-4ea3-a7bb-086a67a486db", "Styles": "None", "Classes": "None", "Text": "\u00d6sterreich", "ParentId": "e727d97a-23c9-41e8-a320-16cece23e2ae"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-AT\">Novartis Pharma GmbH</span></p>", "ID": "2b82fd5a-fcb0-4fc2-89a8-6097551e8328", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "36b1909b-e638-4cf8-913e-f6bd44279983"}, {"Element": "<span lang=\"DE-AT\">Novartis Pharma GmbH</span>", "ID": "7b8e1a3b-fab9-4faa-be12-c9f99868f3fe", "Styles": "None", "Classes": "None", "Text": "Novartis Pharma GmbH", "ParentId": "2b82fd5a-fcb0-4fc2-89a8-6097551e8328"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-AT\">Tel: +43 1 86 6570</span></p>", "ID": "1c1b4b90-0c30-4e0e-8156-2e174112cf4c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "36b1909b-e638-4cf8-913e-f6bd44279983"}, {"Element": "<span lang=\"DE-AT\">Tel: +43 1 86 6570</span>", "ID": "4ef5d182-2a04-4a3f-b607-971917479f6e", "Styles": "None", "Classes": "None", "Text": "Tel: +43 1 86 6570", "ParentId": "1c1b4b90-0c30-4e0e-8156-2e174112cf4c"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Novartis Farmac\u00e9utica, S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Tel: +34 93 306 42 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"PL\">Polska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PL\">Novartis Poland Sp. z o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"PL\">Tel.: +48 22 375 4888</span></p>\n</td>\n</tr>", "ID": "913e43a6-e7e2-441b-bfa6-1e811c4cd276", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "a89eb89f-b66c-4b37-8508-8e3beae85c66"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Novartis Farmac\u00e9utica, S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Tel: +34 93 306 42 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">\u00a0</span></p>\n</td>", "ID": "4d2185c3-74b5-415b-851d-9ab4469b5161", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "913e43a6-e7e2-441b-bfa6-1e811c4cd276"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a</span></b></p>", "ID": "b755a6cf-6f6c-4213-bf51-c54dfa95105a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4d2185c3-74b5-415b-851d-9ab4469b5161"}, {"Element": "<b><span lang=\"ES\">Espa\u00f1a</span></b>", "ID": "59b15bf6-20c3-448d-8be7-e9e074161efe", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b755a6cf-6f6c-4213-bf51-c54dfa95105a"}, {"Element": "<span lang=\"ES\">Espa\u00f1a</span>", "ID": "54c3e526-df1a-4c52-8c24-cb8d6ce54a8b", "Styles": "None", "Classes": "None", "Text": "Espa\u00f1a", "ParentId": "59b15bf6-20c3-448d-8be7-e9e074161efe"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"ES\">Novartis Farmac\u00e9utica, S.A.</span></p>", "ID": "5bef9925-a919-485e-99b0-d1fcd44f0a4c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4d2185c3-74b5-415b-851d-9ab4469b5161"}, {"Element": "<span lang=\"ES\">Novartis Farmac\u00e9utica, S.A.</span>", "ID": "bf4b17e2-f3c8-405d-bbe8-6976cc4a1d33", "Styles": "None", "Classes": "None", "Text": "Novartis Farmac\u00e9utica, S.A.", "ParentId": "5bef9925-a919-485e-99b0-d1fcd44f0a4c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"ES\">Tel: +34 93 306 42 00</span></p>", "ID": "58a04c30-60df-47d0-888e-434097b20e13", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4d2185c3-74b5-415b-851d-9ab4469b5161"}, {"Element": "<span lang=\"ES\">Tel: +34 93 306 42 00</span>", "ID": "341a765a-0745-4685-83d4-e9ccfcaf2036", "Styles": "None", "Classes": "None", "Text": "Tel: +34 93 306 42 00", "ParentId": "58a04c30-60df-47d0-888e-434097b20e13"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"ES\">\u00a0</span></p>", "ID": "7fa5668f-52e6-4f37-a27c-d5bc9c03e730", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4d2185c3-74b5-415b-851d-9ab4469b5161"}, {"Element": "<span lang=\"ES\">\u00a0</span>", "ID": "64e662ec-69fe-4304-9319-acf66abc47f0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7fa5668f-52e6-4f37-a27c-d5bc9c03e730"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"PL\">Polska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PL\">Novartis Poland Sp. z o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"PL\">Tel.: +48 22 375 4888</span></p>\n</td>", "ID": "a96cce9c-ceb5-4824-8c2e-0b94be1580b4", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "913e43a6-e7e2-441b-bfa6-1e811c4cd276"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"PL\">Polska</span></b></p>", "ID": "621c07ee-5371-4574-a113-b77da9a56d8c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a96cce9c-ceb5-4824-8c2e-0b94be1580b4"}, {"Element": "<b><span lang=\"PL\">Polska</span></b>", "ID": "9c38263c-3d2b-4332-84a3-3e69c4f3e25c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "621c07ee-5371-4574-a113-b77da9a56d8c"}, {"Element": "<span lang=\"PL\">Polska</span>", "ID": "d412df93-e9ad-442c-ba39-47da6a1300f0", "Styles": "None", "Classes": "None", "Text": "Polska", "ParentId": "9c38263c-3d2b-4332-84a3-3e69c4f3e25c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PL\">Novartis Poland Sp. z o.o.</span></p>", "ID": "fdda9fb9-50b0-4a55-8abd-9d8969b87194", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a96cce9c-ceb5-4824-8c2e-0b94be1580b4"}, {"Element": "<span lang=\"PL\">Novartis Poland Sp. z o.o.</span>", "ID": "d3d18f3f-2267-4907-824e-f97708642c21", "Styles": "None", "Classes": "None", "Text": "Novartis Poland Sp. z o.o.", "ParentId": "fdda9fb9-50b0-4a55-8abd-9d8969b87194"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PL\">Tel.: +48 22 375 4888</span></p>", "ID": "7cb7dff1-6177-42de-9318-06ccc22d9f1f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a96cce9c-ceb5-4824-8c2e-0b94be1580b4"}, {"Element": "<span lang=\"PL\">Tel.: +48 22 375 4888</span>", "ID": "8fa53619-2ae5-4a36-9b97-b8046edd17e8", "Styles": "None", "Classes": "None", "Text": "Tel.: +48 22 375 4888", "ParentId": "7cb7dff1-6177-42de-9318-06ccc22d9f1f"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"FR\">France</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR\">Novartis Pharma S.A.S.</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR\">T\u00e9l: +33 1 55 47 66 00</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"PL\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"PT\">Portugal</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Novartis Farma - Produtos Farmac\u00eauticos,\n  S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT\">Tel: +351 21 000 8600</span></p>\n</td>\n</tr>", "ID": "45ae6cd8-d143-4995-9038-b30018271f35", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "a89eb89f-b66c-4b37-8508-8e3beae85c66"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"FR\">France</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR\">Novartis Pharma S.A.S.</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR\">T\u00e9l: +33 1 55 47 66 00</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"PL\">\u00a0</span></b></p>\n</td>", "ID": "64554aec-36ec-4cbb-9e20-7690b33f0f74", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "45ae6cd8-d143-4995-9038-b30018271f35"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"FR\">France</span></b></p>", "ID": "229a4429-cebb-425e-bb15-b868fcf4d4a3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "64554aec-36ec-4cbb-9e20-7690b33f0f74"}, {"Element": "<b><span lang=\"FR\">France</span></b>", "ID": "74a94eeb-1cbd-4405-96bd-76ebde73d100", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "229a4429-cebb-425e-bb15-b868fcf4d4a3"}, {"Element": "<span lang=\"FR\">France</span>", "ID": "8381da87-12dd-48ab-9e49-59c3274b688f", "Styles": "None", "Classes": "None", "Text": "France", "ParentId": "74a94eeb-1cbd-4405-96bd-76ebde73d100"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"FR\">Novartis Pharma S.A.S.</span></p>", "ID": "08fa8df8-7829-4eb6-957c-f267cff1b083", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "64554aec-36ec-4cbb-9e20-7690b33f0f74"}, {"Element": "<span lang=\"FR\">Novartis Pharma S.A.S.</span>", "ID": "854f5e48-5b5a-416e-8b1c-cbb1badd9489", "Styles": "None", "Classes": "None", "Text": "Novartis Pharma S.A.S.", "ParentId": "08fa8df8-7829-4eb6-957c-f267cff1b083"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"FR\">T\u00e9l: +33 1 55 47 66 00</span></p>", "ID": "fb7f76c0-3db6-49c1-8b76-1facf1818096", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "64554aec-36ec-4cbb-9e20-7690b33f0f74"}, {"Element": "<span lang=\"FR\">T\u00e9l: +33 1 55 47 66 00</span>", "ID": "b7c396f0-73c5-4cea-a397-7ce6ec007d51", "Styles": "None", "Classes": "None", "Text": "T\u00e9l: +33 1 55 47 66 00", "ParentId": "fb7f76c0-3db6-49c1-8b76-1facf1818096"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"PL\">\u00a0</span></b></p>", "ID": "4bfe0cdd-cbb7-48c4-b3b7-6445ead675da", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "64554aec-36ec-4cbb-9e20-7690b33f0f74"}, {"Element": "<b><span lang=\"PL\">\u00a0</span></b>", "ID": "52894e68-0a79-44ed-8978-3fd5a2912127", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4bfe0cdd-cbb7-48c4-b3b7-6445ead675da"}, {"Element": "<span lang=\"PL\">\u00a0</span>", "ID": "4b671388-4638-48a5-aa03-82ad2eada493", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "52894e68-0a79-44ed-8978-3fd5a2912127"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"PT\">Portugal</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Novartis Farma - Produtos Farmac\u00eauticos,\n  S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT\">Tel: +351 21 000 8600</span></p>\n</td>", "ID": "696efd6b-42d3-4e57-a08b-9c3733fce01d", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "45ae6cd8-d143-4995-9038-b30018271f35"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"PT\">Portugal</span></b></p>", "ID": "0fb8d43e-6f45-45ef-82a6-2aa6f6859882", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "696efd6b-42d3-4e57-a08b-9c3733fce01d"}, {"Element": "<b><span lang=\"PT\">Portugal</span></b>", "ID": "c7e2b6db-d3c4-4e41-abbb-9df1be55d8c3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0fb8d43e-6f45-45ef-82a6-2aa6f6859882"}, {"Element": "<span lang=\"PT\">Portugal</span>", "ID": "36ac38f0-b07b-47f0-90ba-1046fd6e5e9c", "Styles": "None", "Classes": "None", "Text": "Portugal", "ParentId": "c7e2b6db-d3c4-4e41-abbb-9df1be55d8c3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"ES\">Novartis Farma - Produtos Farmac\u00eauticos,\n  S.A.</span></p>", "ID": "e2bdb318-e0ff-4d45-a8e6-39dd4f6a4b2f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "696efd6b-42d3-4e57-a08b-9c3733fce01d"}, {"Element": "<span lang=\"ES\">Novartis Farma - Produtos Farmac\u00eauticos,\n  S.A.</span>", "ID": "09bf9e69-6cd2-4af7-8b08-dd6b7ed70488", "Styles": "None", "Classes": "None", "Text": "Novartis Farma - Produtos Farmac\u00eauticos,   S.A.", "ParentId": "e2bdb318-e0ff-4d45-a8e6-39dd4f6a4b2f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT\">Tel: +351 21 000 8600</span></p>", "ID": "97571405-c514-485d-8e31-515985815549", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "696efd6b-42d3-4e57-a08b-9c3733fce01d"}, {"Element": "<span lang=\"PT\">Tel: +351 21 000 8600</span>", "ID": "9a0081a4-db2a-4a3c-8543-c465c1cff591", "Styles": "None", "Classes": "None", "Text": "Tel: +351 21 000 8600", "ParentId": "97571405-c514-485d-8e31-515985815549"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Hrvatska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Novartis Hrvatska d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel. +385 1 6274 220</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"FR\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b>Rom\u00e2nia</b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">Novartis Pharma Services <span lang=\"EN-GB\">Romania SRL</span></p>\n<p class=\"MsoNormal\">Tel: +40 21 31299 01</p>\n</td>\n</tr>", "ID": "1971549b-cfca-4bb4-acb4-6c81f9f4dcb5", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "a89eb89f-b66c-4b37-8508-8e3beae85c66"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Hrvatska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Novartis Hrvatska d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel. +385 1 6274 220</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"FR\">\u00a0</span></b></p>\n</td>", "ID": "cec6af5b-e3e7-4eb2-bcc3-e78150884913", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "1971549b-cfca-4bb4-acb4-6c81f9f4dcb5"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Hrvatska</span></b></p>", "ID": "db5ac6e2-93d1-43bd-8313-9e04dd3a4761", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cec6af5b-e3e7-4eb2-bcc3-e78150884913"}, {"Element": "<b><span lang=\"EN-GB\">Hrvatska</span></b>", "ID": "67491007-537a-4ff7-8ea1-cc59f3fd853c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "db5ac6e2-93d1-43bd-8313-9e04dd3a4761"}, {"Element": "<span lang=\"EN-GB\">Hrvatska</span>", "ID": "e096fda6-ceb8-4f4a-9c1e-acdcdbfff743", "Styles": "None", "Classes": "None", "Text": "Hrvatska", "ParentId": "67491007-537a-4ff7-8ea1-cc59f3fd853c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Novartis Hrvatska d.o.o.</span></p>", "ID": "5a5f0a4b-01a9-4eed-8f48-88f3580e27ca", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cec6af5b-e3e7-4eb2-bcc3-e78150884913"}, {"Element": "<span lang=\"EN-GB\">Novartis Hrvatska d.o.o.</span>", "ID": "46911f40-8b1b-4460-b917-58f805b08933", "Styles": "None", "Classes": "None", "Text": "Novartis Hrvatska d.o.o.", "ParentId": "5a5f0a4b-01a9-4eed-8f48-88f3580e27ca"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel. +385 1 6274 220</span></p>", "ID": "da1bf34b-0a4b-4331-87bd-19c0fd67a3b3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cec6af5b-e3e7-4eb2-bcc3-e78150884913"}, {"Element": "<span lang=\"EN-GB\">Tel. +385 1 6274 220</span>", "ID": "23213f48-c5e0-456c-b9ef-d439f8c74edd", "Styles": "None", "Classes": "None", "Text": "Tel. +385 1 6274 220", "ParentId": "da1bf34b-0a4b-4331-87bd-19c0fd67a3b3"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"FR\">\u00a0</span></b></p>", "ID": "a9df73ee-d868-42d6-89e4-83c807213ca1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cec6af5b-e3e7-4eb2-bcc3-e78150884913"}, {"Element": "<b><span lang=\"FR\">\u00a0</span></b>", "ID": "b5fa26ee-4ff3-40dd-9481-62d7bc2cc043", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a9df73ee-d868-42d6-89e4-83c807213ca1"}, {"Element": "<span lang=\"FR\">\u00a0</span>", "ID": "bf945b22-783d-49cb-9674-24aafde7a31d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b5fa26ee-4ff3-40dd-9481-62d7bc2cc043"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b>Rom\u00e2nia</b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">Novartis Pharma Services <span lang=\"EN-GB\">Romania SRL</span></p>\n<p class=\"MsoNormal\">Tel: +40 21 31299 01</p>\n</td>", "ID": "f1c84e99-3661-4e79-b191-2cf333fef871", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "1971549b-cfca-4bb4-acb4-6c81f9f4dcb5"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><b>Rom\u00e2nia</b></p>", "ID": "09809fa1-ed93-4207-870d-d9a3e98ef308", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f1c84e99-3661-4e79-b191-2cf333fef871"}, {"Element": "<b>Rom\u00e2nia</b>", "ID": "b227400f-1557-4e50-ac59-91c807b3f64a", "Styles": "None", "Classes": "None", "Text": "Rom\u00e2nia", "ParentId": "09809fa1-ed93-4207-870d-d9a3e98ef308"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\">Novartis Pharma Services <span lang=\"EN-GB\">Romania SRL</span></p>", "ID": "58575844-1429-4601-a0f6-db2d2f0a9005", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "Novartis Pharma Services ", "ParentId": "f1c84e99-3661-4e79-b191-2cf333fef871"}, {"Element": "<span lang=\"EN-GB\">Romania SRL</span>", "ID": "6b5d6f40-013b-4134-98b6-ff3767cbc048", "Styles": "None", "Classes": "None", "Text": "Romania SRL", "ParentId": "58575844-1429-4601-a0f6-db2d2f0a9005"}, {"Element": "<p class=\"MsoNormal\">Tel: +40 21 31299 01</p>", "ID": "6dd11376-14ec-4d34-9fc1-0d6f99229e0e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Tel: +40 21 31299 01", "ParentId": "f1c84e99-3661-4e79-b191-2cf333fef871"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Ireland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Novartis Ireland Limited</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +353 1 260 12 55</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"SL\">Slovenija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"SL\">Novartis Pharma Services Inc.</span></p>\n<p class=\"MsoNormal\"><span lang=\"SL\">Tel: +386 1 300 75 50</span></p>\n</td>\n</tr>", "ID": "20bff3ad-defc-493a-9252-94382a1bfa69", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "a89eb89f-b66c-4b37-8508-8e3beae85c66"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Ireland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Novartis Ireland Limited</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +353 1 260 12 55</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "bcf978e5-6a7e-4592-8ed1-45d8bd8fd4f3", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "20bff3ad-defc-493a-9252-94382a1bfa69"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Ireland</span></b></p>", "ID": "eda07fba-4b38-4863-8336-74a8e45a1ca3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bcf978e5-6a7e-4592-8ed1-45d8bd8fd4f3"}, {"Element": "<b><span lang=\"EN-GB\">Ireland</span></b>", "ID": "c624b63e-defc-4c42-a9fc-2c5f8c785bf2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "eda07fba-4b38-4863-8336-74a8e45a1ca3"}, {"Element": "<span lang=\"EN-GB\">Ireland</span>", "ID": "351b5005-c89c-4a6e-bc67-7f21391b3b4b", "Styles": "None", "Classes": "None", "Text": "Ireland", "ParentId": "c624b63e-defc-4c42-a9fc-2c5f8c785bf2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Novartis Ireland Limited</span></p>", "ID": "7b7f9782-56ce-445d-8ae0-7e60f47c5412", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bcf978e5-6a7e-4592-8ed1-45d8bd8fd4f3"}, {"Element": "<span lang=\"EN-GB\">Novartis Ireland Limited</span>", "ID": "0a854e69-9263-46ec-b00f-3880d9f6ac76", "Styles": "None", "Classes": "None", "Text": "Novartis Ireland Limited", "ParentId": "7b7f9782-56ce-445d-8ae0-7e60f47c5412"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +353 1 260 12 55</span></p>", "ID": "68dbb61a-9ef2-474f-8902-e02ec3db7e42", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bcf978e5-6a7e-4592-8ed1-45d8bd8fd4f3"}, {"Element": "<span lang=\"EN-GB\">Tel: +353 1 260 12 55</span>", "ID": "475e7b59-452e-49c7-973f-7d6af5cdc243", "Styles": "None", "Classes": "None", "Text": "Tel: +353 1 260 12 55", "ParentId": "68dbb61a-9ef2-474f-8902-e02ec3db7e42"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "bbd18660-888a-4d9a-b65d-4e31f1ddcc96", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bcf978e5-6a7e-4592-8ed1-45d8bd8fd4f3"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "aba165bb-14b3-4806-a21d-00c354e0a1c8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bbd18660-888a-4d9a-b65d-4e31f1ddcc96"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8c8c0d7d-7060-4856-9262-e1ef84a6f99d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "aba165bb-14b3-4806-a21d-00c354e0a1c8"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"SL\">Slovenija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"SL\">Novartis Pharma Services Inc.</span></p>\n<p class=\"MsoNormal\"><span lang=\"SL\">Tel: +386 1 300 75 50</span></p>\n</td>", "ID": "0009a55b-6ed7-4889-b6f1-4976e75bc263", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "20bff3ad-defc-493a-9252-94382a1bfa69"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"SL\">Slovenija</span></b></p>", "ID": "23132138-ad4d-4122-a6ea-d0b7738b39a3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0009a55b-6ed7-4889-b6f1-4976e75bc263"}, {"Element": "<b><span lang=\"SL\">Slovenija</span></b>", "ID": "a72351c2-af52-4a07-99af-a4b90b48cf04", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "23132138-ad4d-4122-a6ea-d0b7738b39a3"}, {"Element": "<span lang=\"SL\">Slovenija</span>", "ID": "377991d4-3168-4ec7-a780-f265c259be6a", "Styles": "None", "Classes": "None", "Text": "Slovenija", "ParentId": "a72351c2-af52-4a07-99af-a4b90b48cf04"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"SL\">Novartis Pharma Services Inc.</span></p>", "ID": "71579ee2-828e-4984-a654-faa9e03147e1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0009a55b-6ed7-4889-b6f1-4976e75bc263"}, {"Element": "<span lang=\"SL\">Novartis Pharma Services Inc.</span>", "ID": "41acc51a-b7c4-47c2-bc18-d3b05254feae", "Styles": "None", "Classes": "None", "Text": "Novartis Pharma Services Inc.", "ParentId": "71579ee2-828e-4984-a654-faa9e03147e1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"SL\">Tel: +386 1 300 75 50</span></p>", "ID": "e4c115d0-df61-4d36-917e-6d9da2cf0d1a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0009a55b-6ed7-4889-b6f1-4976e75bc263"}, {"Element": "<span lang=\"SL\">Tel: +386 1 300 75 50</span>", "ID": "562e6cfd-cc4b-44db-9bc4-3b00cfeddf1b", "Styles": "None", "Classes": "None", "Text": "Tel: +386 1 300 75 50", "ParentId": "e4c115d0-df61-4d36-917e-6d9da2cf0d1a"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"IS\">\u00cdsland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IS\">Vistor hf.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">S\u00edmi</span><span lang=\"IS\">: +354 535 7000</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"SK\">Slovensk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"SK\">Novartis Slovakia s.r.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"SK\">Tel: +421 2 5542 5439</span></p>\n<p class=\"MsoNormal\"><span lang=\"SK\">\u00a0</span></p>\n</td>\n</tr>", "ID": "e031ca3d-0588-4998-ac77-f78bd383e2d7", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "a89eb89f-b66c-4b37-8508-8e3beae85c66"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"IS\">\u00cdsland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IS\">Vistor hf.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">S\u00edmi</span><span lang=\"IS\">: +354 535 7000</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "43a3d4dd-6ded-43b3-91dd-64d6ae256f97", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "e031ca3d-0588-4998-ac77-f78bd383e2d7"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"IS\">\u00cdsland</span></b></p>", "ID": "937462db-47b4-4d4f-8104-c2b9d01e94e9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "43a3d4dd-6ded-43b3-91dd-64d6ae256f97"}, {"Element": "<b><span lang=\"IS\">\u00cdsland</span></b>", "ID": "753e241e-faea-4263-8478-bccd306c9864", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "937462db-47b4-4d4f-8104-c2b9d01e94e9"}, {"Element": "<span lang=\"IS\">\u00cdsland</span>", "ID": "1434323e-90b2-469a-b395-17be5d853c49", "Styles": "None", "Classes": "None", "Text": "\u00cdsland", "ParentId": "753e241e-faea-4263-8478-bccd306c9864"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IS\">Vistor hf.</span></p>", "ID": "8fb9b278-2274-4839-8921-a5148083014b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "43a3d4dd-6ded-43b3-91dd-64d6ae256f97"}, {"Element": "<span lang=\"IS\">Vistor hf.</span>", "ID": "5cd0d71b-bf23-48b6-a384-a7dc5cda59c2", "Styles": "None", "Classes": "None", "Text": "Vistor hf.", "ParentId": "8fb9b278-2274-4839-8921-a5148083014b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">S\u00edmi</span><span lang=\"IS\">: +354 535 7000</span></p>", "ID": "23cc9815-ace8-43e5-bc00-f81d8dd694d0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "43a3d4dd-6ded-43b3-91dd-64d6ae256f97"}, {"Element": "<span lang=\"EN-GB\">S\u00edmi</span>", "ID": "ca4b92fd-7ac0-45fb-a250-442978b5c344", "Styles": "None", "Classes": "None", "Text": "S\u00edmi", "ParentId": "23cc9815-ace8-43e5-bc00-f81d8dd694d0"}, {"Element": "<span lang=\"IS\">: +354 535 7000</span>", "ID": "7496ad66-000b-4cbb-8193-5f38376fee3f", "Styles": "None", "Classes": "None", "Text": ": +354 535 7000", "ParentId": "23cc9815-ace8-43e5-bc00-f81d8dd694d0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7a761e32-2329-4a3a-9505-d05bae84b4fd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "43a3d4dd-6ded-43b3-91dd-64d6ae256f97"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2c57f4ae-679d-489a-a51f-a8ab59123c23", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7a761e32-2329-4a3a-9505-d05bae84b4fd"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"SK\">Slovensk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"SK\">Novartis Slovakia s.r.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"SK\">Tel: +421 2 5542 5439</span></p>\n<p class=\"MsoNormal\"><span lang=\"SK\">\u00a0</span></p>\n</td>", "ID": "8d8194fc-ed7f-4787-95e5-b9da51672b68", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "e031ca3d-0588-4998-ac77-f78bd383e2d7"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"SK\">Slovensk\u00e1 republika</span></b></p>", "ID": "a6b7cf98-e924-4ff1-98ee-69fdd22ec09d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8d8194fc-ed7f-4787-95e5-b9da51672b68"}, {"Element": "<b><span lang=\"SK\">Slovensk\u00e1 republika</span></b>", "ID": "d9f12ea1-462c-4bbc-b594-88f11453ace3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a6b7cf98-e924-4ff1-98ee-69fdd22ec09d"}, {"Element": "<span lang=\"SK\">Slovensk\u00e1 republika</span>", "ID": "00beec7e-4d85-4374-8177-b8c391713180", "Styles": "None", "Classes": "None", "Text": "Slovensk\u00e1 republika", "ParentId": "d9f12ea1-462c-4bbc-b594-88f11453ace3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"SK\">Novartis Slovakia s.r.o.</span></p>", "ID": "046eeb29-72d2-4315-aea6-f158086bcc0b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8d8194fc-ed7f-4787-95e5-b9da51672b68"}, {"Element": "<span lang=\"SK\">Novartis Slovakia s.r.o.</span>", "ID": "8d42480e-b3ce-4848-a696-77950095d773", "Styles": "None", "Classes": "None", "Text": "Novartis Slovakia s.r.o.", "ParentId": "046eeb29-72d2-4315-aea6-f158086bcc0b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"SK\">Tel: +421 2 5542 5439</span></p>", "ID": "eceee020-03dc-43ef-b7c7-fb168df0a8aa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8d8194fc-ed7f-4787-95e5-b9da51672b68"}, {"Element": "<span lang=\"SK\">Tel: +421 2 5542 5439</span>", "ID": "d8c66280-a09b-4248-9f4e-0f0803caa8a5", "Styles": "None", "Classes": "None", "Text": "Tel: +421 2 5542 5439", "ParentId": "eceee020-03dc-43ef-b7c7-fb168df0a8aa"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"SK\">\u00a0</span></p>", "ID": "2842c1a1-a7c2-4b72-88af-a77b3e2200ff", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8d8194fc-ed7f-4787-95e5-b9da51672b68"}, {"Element": "<span lang=\"SK\">\u00a0</span>", "ID": "edee0baf-5daf-4af5-a805-2c651ef44651", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2842c1a1-a7c2-4b72-88af-a77b3e2200ff"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Italia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Novartis Farma S.p.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: +39 02 96 54 1</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"FI\">Suomi/Finland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FI\">Novartis Finland Oy</span></p>\n<p class=\"MsoNormal\"><span lang=\"FI\">Puh/Tel: +358 </span><span lang=\"DE-CH\">(0)10\n  6133 200</span></p>\n<p class=\"MsoNormal\"><span lang=\"SV\">\u00a0</span></p>\n</td>\n</tr>", "ID": "ac26772e-04b4-4f0c-9ab8-2673ac2c6c91", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "a89eb89f-b66c-4b37-8508-8e3beae85c66"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Italia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Novartis Farma S.p.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: +39 02 96 54 1</span></p>\n</td>", "ID": "c1502578-4ac1-456a-a348-f52f8dc26654", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "ac26772e-04b4-4f0c-9ab8-2673ac2c6c91"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"IT\">Italia</span></b></p>", "ID": "40a65e10-0ff7-41fb-bd8a-681aa011d750", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c1502578-4ac1-456a-a348-f52f8dc26654"}, {"Element": "<b><span lang=\"IT\">Italia</span></b>", "ID": "214cf5ad-f88b-492e-8381-0fda9e81580d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "40a65e10-0ff7-41fb-bd8a-681aa011d750"}, {"Element": "<span lang=\"IT\">Italia</span>", "ID": "aecca56e-2320-4565-9b5d-420db79b5d62", "Styles": "None", "Classes": "None", "Text": "Italia", "ParentId": "214cf5ad-f88b-492e-8381-0fda9e81580d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Novartis Farma S.p.A.</span></p>", "ID": "0c8b2556-03e9-431b-89b7-2da5b9d9d618", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c1502578-4ac1-456a-a348-f52f8dc26654"}, {"Element": "<span lang=\"IT\">Novartis Farma S.p.A.</span>", "ID": "7361b8a0-aa97-4666-b0df-d95ac6d2af01", "Styles": "None", "Classes": "None", "Text": "Novartis Farma S.p.A.", "ParentId": "0c8b2556-03e9-431b-89b7-2da5b9d9d618"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Tel: +39 02 96 54 1</span></p>", "ID": "822ff757-f083-4c52-9cda-83cfa65bedcd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c1502578-4ac1-456a-a348-f52f8dc26654"}, {"Element": "<span lang=\"IT\">Tel: +39 02 96 54 1</span>", "ID": "c3d33bc5-c12d-4e70-aefa-3786a343abdb", "Styles": "None", "Classes": "None", "Text": "Tel: +39 02 96 54 1", "ParentId": "822ff757-f083-4c52-9cda-83cfa65bedcd"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"FI\">Suomi/Finland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FI\">Novartis Finland Oy</span></p>\n<p class=\"MsoNormal\"><span lang=\"FI\">Puh/Tel: +358 </span><span lang=\"DE-CH\">(0)10\n  6133 200</span></p>\n<p class=\"MsoNormal\"><span lang=\"SV\">\u00a0</span></p>\n</td>", "ID": "65833cf0-9b29-4869-b20c-d1007d7e519a", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "ac26772e-04b4-4f0c-9ab8-2673ac2c6c91"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"FI\">Suomi/Finland</span></b></p>", "ID": "f17a4c0b-e4ec-4fb1-94b1-0848c25bc101", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "65833cf0-9b29-4869-b20c-d1007d7e519a"}, {"Element": "<b><span lang=\"FI\">Suomi/Finland</span></b>", "ID": "951d1777-8c07-4edf-ba42-fadf0f611ed0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f17a4c0b-e4ec-4fb1-94b1-0848c25bc101"}, {"Element": "<span lang=\"FI\">Suomi/Finland</span>", "ID": "00c78c39-2b78-4e46-848d-8c1c3a32ca04", "Styles": "None", "Classes": "None", "Text": "Suomi/Finland", "ParentId": "951d1777-8c07-4edf-ba42-fadf0f611ed0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"FI\">Novartis Finland Oy</span></p>", "ID": "0b991331-a86e-4d1e-9a64-5eaa41678428", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "65833cf0-9b29-4869-b20c-d1007d7e519a"}, {"Element": "<span lang=\"FI\">Novartis Finland Oy</span>", "ID": "fef3b760-2f25-4423-8b66-04b5c4f3b8d4", "Styles": "None", "Classes": "None", "Text": "Novartis Finland Oy", "ParentId": "0b991331-a86e-4d1e-9a64-5eaa41678428"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"FI\">Puh/Tel: +358 </span><span lang=\"DE-CH\">(0)10\n  6133 200</span></p>", "ID": "e6991e59-b48a-4bd8-bb42-010d37a6e97f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "65833cf0-9b29-4869-b20c-d1007d7e519a"}, {"Element": "<span lang=\"FI\">Puh/Tel: +358 </span>", "ID": "fe64b433-06ee-4573-bce4-854a5b63d8e2", "Styles": "None", "Classes": "None", "Text": "Puh/Tel: +358 ", "ParentId": "e6991e59-b48a-4bd8-bb42-010d37a6e97f"}, {"Element": "<span lang=\"DE-CH\">(0)10\n  6133 200</span>", "ID": "d291c362-89d7-448d-807e-2e75114ca7dd", "Styles": "None", "Classes": "None", "Text": "(0)10   6133 200", "ParentId": "e6991e59-b48a-4bd8-bb42-010d37a6e97f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"SV\">\u00a0</span></p>", "ID": "d94a5603-2aa8-48aa-8c2d-2d1c865d9886", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "65833cf0-9b29-4869-b20c-d1007d7e519a"}, {"Element": "<span lang=\"SV\">\u00a0</span>", "ID": "a4817465-3070-4eaa-ac36-feec6bcdc837", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d94a5603-2aa8-48aa-8c2d-2d1c865d9886"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"EL\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">Novartis Pharma Services Inc.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EL\">\u03a4\u03b7\u03bb: +357 22 690 690</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EL\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"SV\">Sverige</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"SV\">Novartis Sverige AB</span></p>\n<p class=\"MsoNormal\"><span lang=\"SV\">Tel: +46 8 732 32 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"FI\">\u00a0</span></p>\n</td>\n</tr>", "ID": "4e4d6c55-9425-40cc-a372-c5a07a256732", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "a89eb89f-b66c-4b37-8508-8e3beae85c66"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"EL\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">Novartis Pharma Services Inc.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EL\">\u03a4\u03b7\u03bb: +357 22 690 690</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EL\">\u00a0</span></b></p>\n</td>", "ID": "3d789bde-8d2d-40ca-adec-b01e861ab505", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "4e4d6c55-9425-40cc-a372-c5a07a256732"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EL\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span></b></p>", "ID": "08946cf9-7d83-4e93-b1ab-1071052fa6f7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3d789bde-8d2d-40ca-adec-b01e861ab505"}, {"Element": "<b><span lang=\"EL\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span></b>", "ID": "555ddc7e-076d-41fe-ab69-8456d2ca5df0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "08946cf9-7d83-4e93-b1ab-1071052fa6f7"}, {"Element": "<span lang=\"EL\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span>", "ID": "948673b5-6d92-461e-b067-7b873e0ef147", "Styles": "None", "Classes": "None", "Text": "\u039a\u03cd\u03c0\u03c1\u03bf\u03c2", "ParentId": "555ddc7e-076d-41fe-ab69-8456d2ca5df0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"FR-CH\">Novartis Pharma Services Inc.</span></p>", "ID": "f6e68754-3d28-4737-a19e-2d364fa01999", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3d789bde-8d2d-40ca-adec-b01e861ab505"}, {"Element": "<span lang=\"FR-CH\">Novartis Pharma Services Inc.</span>", "ID": "70704d02-502e-42f6-a611-d216ca27c9af", "Styles": "None", "Classes": "None", "Text": "Novartis Pharma Services Inc.", "ParentId": "f6e68754-3d28-4737-a19e-2d364fa01999"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EL\">\u03a4\u03b7\u03bb: +357 22 690 690</span></p>", "ID": "ba72836f-8777-44bc-b510-f21eb87eea6a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3d789bde-8d2d-40ca-adec-b01e861ab505"}, {"Element": "<span lang=\"EL\">\u03a4\u03b7\u03bb: +357 22 690 690</span>", "ID": "0c529c31-64db-42af-acc9-c4588bfd8751", "Styles": "None", "Classes": "None", "Text": "\u03a4\u03b7\u03bb: +357 22 690 690", "ParentId": "ba72836f-8777-44bc-b510-f21eb87eea6a"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EL\">\u00a0</span></b></p>", "ID": "a876714c-ea74-44a1-98c1-c2f890b5b5c8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3d789bde-8d2d-40ca-adec-b01e861ab505"}, {"Element": "<b><span lang=\"EL\">\u00a0</span></b>", "ID": "40745b7f-2d89-4e52-b51e-b222454a21a5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a876714c-ea74-44a1-98c1-c2f890b5b5c8"}, {"Element": "<span lang=\"EL\">\u00a0</span>", "ID": "1970b0dc-68c8-49d0-9665-1d6790a1a950", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "40745b7f-2d89-4e52-b51e-b222454a21a5"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"SV\">Sverige</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"SV\">Novartis Sverige AB</span></p>\n<p class=\"MsoNormal\"><span lang=\"SV\">Tel: +46 8 732 32 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"FI\">\u00a0</span></p>\n</td>", "ID": "52d599a7-d3e4-4ae7-8539-e41518b07168", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "4e4d6c55-9425-40cc-a372-c5a07a256732"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"SV\">Sverige</span></b></p>", "ID": "9ab7a0b5-efee-426f-b7bb-f7de218836ff", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "52d599a7-d3e4-4ae7-8539-e41518b07168"}, {"Element": "<b><span lang=\"SV\">Sverige</span></b>", "ID": "e3cf6cfe-0816-4ac5-9e5a-cf4fd276b3fb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9ab7a0b5-efee-426f-b7bb-f7de218836ff"}, {"Element": "<span lang=\"SV\">Sverige</span>", "ID": "cb750223-c1ef-4181-8b4f-ae7c6c909e7f", "Styles": "None", "Classes": "None", "Text": "Sverige", "ParentId": "e3cf6cfe-0816-4ac5-9e5a-cf4fd276b3fb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"SV\">Novartis Sverige AB</span></p>", "ID": "c7293588-b84d-4334-b28b-497e151adf2e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "52d599a7-d3e4-4ae7-8539-e41518b07168"}, {"Element": "<span lang=\"SV\">Novartis Sverige AB</span>", "ID": "bfd8ee9e-a476-4af9-a2c8-1e59dd2f446b", "Styles": "None", "Classes": "None", "Text": "Novartis Sverige AB", "ParentId": "c7293588-b84d-4334-b28b-497e151adf2e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"SV\">Tel: +46 8 732 32 00</span></p>", "ID": "8b059836-9f27-4d26-b816-49a85e97d200", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "52d599a7-d3e4-4ae7-8539-e41518b07168"}, {"Element": "<span lang=\"SV\">Tel: +46 8 732 32 00</span>", "ID": "f464b9d3-e575-4624-98f6-08ccbc9e1966", "Styles": "None", "Classes": "None", "Text": "Tel: +46 8 732 32 00", "ParentId": "8b059836-9f27-4d26-b816-49a85e97d200"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"FI\">\u00a0</span></p>", "ID": "1ba36813-61be-4be0-81bb-4ed5e36e0e6a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "52d599a7-d3e4-4ae7-8539-e41518b07168"}, {"Element": "<span lang=\"FI\">\u00a0</span>", "ID": "17c72207-6530-48f9-9c07-8a1f932125ac", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1ba36813-61be-4be0-81bb-4ed5e36e0e6a"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"LV\">Latvija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"LV\">SIA \u201cNovartis Baltics\u201d</span></p>\n<p class=\"MsoNormal\"><span lang=\"LV\">Tel: +371 67 887 070</span></p>\n<p class=\"MsoNormal\"><span lang=\"FI\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">United Kingdom</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Novartis Pharmaceuticals UK Ltd.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 1276 698370</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>", "ID": "f8577000-dece-4971-8415-92c133c95cf9", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "a89eb89f-b66c-4b37-8508-8e3beae85c66"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"LV\">Latvija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"LV\">SIA \u201cNovartis Baltics\u201d</span></p>\n<p class=\"MsoNormal\"><span lang=\"LV\">Tel: +371 67 887 070</span></p>\n<p class=\"MsoNormal\"><span lang=\"FI\">\u00a0</span></p>\n</td>", "ID": "4457d8f9-7c1d-4776-a590-ab4607f5dc9a", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "f8577000-dece-4971-8415-92c133c95cf9"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"LV\">Latvija</span></b></p>", "ID": "36a3769b-5fff-4d03-9657-c59edb92fcb3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4457d8f9-7c1d-4776-a590-ab4607f5dc9a"}, {"Element": "<b><span lang=\"LV\">Latvija</span></b>", "ID": "0aafa8cf-fe2f-438c-8d7a-7097332d7088", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "36a3769b-5fff-4d03-9657-c59edb92fcb3"}, {"Element": "<span lang=\"LV\">Latvija</span>", "ID": "7c7dc11b-68b0-41f9-9bdc-aac31dd722c8", "Styles": "None", "Classes": "None", "Text": "Latvija", "ParentId": "0aafa8cf-fe2f-438c-8d7a-7097332d7088"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"LV\">SIA \u201cNovartis Baltics\u201d</span></p>", "ID": "9b92a3b5-2ad2-4efe-8d04-97113fb60c3a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4457d8f9-7c1d-4776-a590-ab4607f5dc9a"}, {"Element": "<span lang=\"LV\">SIA \u201cNovartis Baltics\u201d</span>", "ID": "a27e7237-2b51-40a5-8c27-13ef422bbd22", "Styles": "None", "Classes": "None", "Text": "SIA \u201cNovartis Baltics\u201d", "ParentId": "9b92a3b5-2ad2-4efe-8d04-97113fb60c3a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"LV\">Tel: +371 67 887 070</span></p>", "ID": "8e38ae37-5c95-459a-97c2-55b7bf91faf6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4457d8f9-7c1d-4776-a590-ab4607f5dc9a"}, {"Element": "<span lang=\"LV\">Tel: +371 67 887 070</span>", "ID": "f29231df-6906-4de9-9122-1c22feb8895b", "Styles": "None", "Classes": "None", "Text": "Tel: +371 67 887 070", "ParentId": "8e38ae37-5c95-459a-97c2-55b7bf91faf6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"FI\">\u00a0</span></p>", "ID": "d0bbac34-f28a-42df-827d-5e225b3439b8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4457d8f9-7c1d-4776-a590-ab4607f5dc9a"}, {"Element": "<span lang=\"FI\">\u00a0</span>", "ID": "fc8ab859-7e3c-4112-a3b3-9a13af87b2e0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d0bbac34-f28a-42df-827d-5e225b3439b8"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">United Kingdom</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Novartis Pharmaceuticals UK Ltd.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 1276 698370</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>", "ID": "7fc9c12b-8c68-409b-9bc5-fc045cbbfc94", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "f8577000-dece-4971-8415-92c133c95cf9"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">United Kingdom</span></b></p>", "ID": "aeec956d-de06-4075-b5dc-a00660a59dcf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7fc9c12b-8c68-409b-9bc5-fc045cbbfc94"}, {"Element": "<b><span lang=\"EN-GB\">United Kingdom</span></b>", "ID": "9ba65366-f242-47d7-aabe-c93ece422766", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "aeec956d-de06-4075-b5dc-a00660a59dcf"}, {"Element": "<span lang=\"EN-GB\">United Kingdom</span>", "ID": "3e541b62-a5c1-49be-93a4-f7873a6edbd2", "Styles": "None", "Classes": "None", "Text": "United Kingdom", "ParentId": "9ba65366-f242-47d7-aabe-c93ece422766"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Novartis Pharmaceuticals UK Ltd.</span></p>", "ID": "bcce908a-7e12-4b37-916a-e62789ecfe77", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7fc9c12b-8c68-409b-9bc5-fc045cbbfc94"}, {"Element": "<span lang=\"EN-GB\">Novartis Pharmaceuticals UK Ltd.</span>", "ID": "c6188f4d-21e2-49a0-aceb-39341ef85a30", "Styles": "None", "Classes": "None", "Text": "Novartis Pharmaceuticals UK Ltd.", "ParentId": "bcce908a-7e12-4b37-916a-e62789ecfe77"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 1276 698370</span></p>", "ID": "1f4f75e5-b9c9-46aa-be99-fcb89a9b5584", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7fc9c12b-8c68-409b-9bc5-fc045cbbfc94"}, {"Element": "<span lang=\"EN-GB\">Tel: +44 1276 698370</span>", "ID": "a2a010e6-d29a-49e2-bb0f-c1b0455fdeab", "Styles": "None", "Classes": "None", "Text": "Tel: +44 1276 698370", "ParentId": "1f4f75e5-b9c9-46aa-be99-fcb89a9b5584"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "11ebf06d-b0a9-4ecd-b32d-cb07856f6553", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "7fc9c12b-8c68-409b-9bc5-fc045cbbfc94"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "50ca726f-77b5-4482-85cd-dafe2616238e", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5fcb42c6-356b-4156-975c-5dd74c8ffac8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "50ca726f-77b5-4482-85cd-dafe2616238e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">This\nleaflet was last revised in</span></b></p>", "ID": "bb2a4369-adb0-4324-9df2-4bc3e8d8df89", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">This\nleaflet was last revised in</span></b>", "ID": "cce94364-83d8-4d3a-846e-f36250fd8cfa", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bb2a4369-adb0-4324-9df2-4bc3e8d8df89"}, {"Element": "<span lang=\"EN-GB\">This\nleaflet was last revised in</span>", "ID": "40cdb39f-9f92-4550-9a4e-6fb8a8a62062", "Styles": "None", "Classes": "None", "Text": "This leaflet was last revised in", "ParentId": "cce94364-83d8-4d3a-846e-f36250fd8cfa"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7c431a67-d3a9-432b-af3e-483d5ca323c2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7f9f7afc-ccf0-4bdb-97f3-c8b05ac02233", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7c431a67-d3a9-432b-af3e-483d5ca323c2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "aea9a058-eb7c-456e-abe0-467cae545ba3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "87082524-349c-4e1f-af75-f7580fef36bb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "aea9a058-eb7c-456e-abe0-467cae545ba3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Detailed\ninformation on this medicine is available on the European Medicines Agency\n(EMA) web site: </span><span lang=\"EN-GB\">http://www.ema.europa.eu<span style=\"color:blue\">/.</span></span></p>", "ID": "276ec95f-7817-4448-ac54-9d16bfcac59f", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Detailed\ninformation on this medicine is available on the European Medicines Agency\n(EMA) web site: </span>", "ID": "edc47d91-909d-4ea2-9960-fe79526fee5d", "Styles": "None", "Classes": "None", "Text": "Detailed information on this medicine is available on the European Medicines Agency (EMA) web site: ", "ParentId": "276ec95f-7817-4448-ac54-9d16bfcac59f"}, {"Element": "<span lang=\"EN-GB\">http://www.ema.europa.eu<span style=\"color:blue\">/.</span></span>", "ID": "8a1e782f-110c-4343-bb8d-75e443d43a03", "Styles": "None", "Classes": "None", "Text": "http://www.ema.europa.eu", "ParentId": "276ec95f-7817-4448-ac54-9d16bfcac59f"}, {"Element": "<span style=\"color:blue\">/.</span>", "ID": "3a640ada-de3f-4258-8ff3-025af5a6333c", "Styles": "color:blue", "Classes": "None", "Text": "/.", "ParentId": "8a1e782f-110c-4343-bb8d-75e443d43a03"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "994d2332-b1cb-469f-9a2e-7f0046d7d8bd", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "ad0f3555-abb7-492b-8a39-83827d57b194", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "994d2332-b1cb-469f-9a2e-7f0046d7d8bd"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">The following\ninformation is intended for healthcare professionals only:</span></p>", "ID": "cbe0dd40-b922-42d0-a978-c525386c6c35", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">The following\ninformation is intended for healthcare professionals only:</span>", "ID": "15d34855-0f99-4bd9-88a3-27c147d7efea", "Styles": "None", "Classes": "None", "Text": "The following information is intended for healthcare professionals only:", "ParentId": "cbe0dd40-b922-42d0-a978-c525386c6c35"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5ca7ee84-5f36-4b85-9763-8d33b74a3e6e", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "db131fc7-e0db-4cb5-8d89-42c5f4609e0b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5ca7ee84-5f36-4b85-9763-8d33b74a3e6e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b>1)\u00a0\u00a0\u00a0\u00a0\u00a0 Before\ndiluting Arzerra</b></p>", "ID": "7eca932d-6605-4e46-bca3-96a36f6eb121", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b>1)\u00a0\u00a0\u00a0\u00a0\u00a0 Before\ndiluting Arzerra</b>", "ID": "41e05b9d-be33-43e5-92e0-3859207c3ccd", "Styles": "None", "Classes": "None", "Text": "1)\u00a0\u00a0\u00a0\u00a0\u00a0 Before diluting Arzerra", "ParentId": "7eca932d-6605-4e46-bca3-96a36f6eb121"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\">\u00a0</p>", "ID": "d4b47a83-59a3-4e7b-83cf-ed52686213f5", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\">Check the<i> </i><span lang=\"EN-GB\">Arzerra concentrate<i> </i>for particulate matter and discolouration\nprior to dilution. Ofatumumab should be a colourless to pale yellow solution.\nDo not use the Arzerra concentrate if there is discolouration.</span></p>", "ID": "4c57dc7b-eb9e-4e0e-b972-fc48bb4a5a7c", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "Check the", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i> </i>", "ID": "a9d8d3c0-54f0-4cfa-b0e5-8be888a82966", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "4c57dc7b-eb9e-4e0e-b972-fc48bb4a5a7c"}, {"Element": "<span lang=\"EN-GB\">Arzerra concentrate<i> </i>for particulate matter and discolouration\nprior to dilution. Ofatumumab should be a colourless to pale yellow solution.\nDo not use the Arzerra concentrate if there is discolouration.</span>", "ID": "152abc79-af04-4941-ba6d-237aa50b5e20", "Styles": "None", "Classes": "None", "Text": "Arzerra concentratefor particulate matter and discolouration prior to dilution. Ofatumumab should be a colourless to pale yellow solution. Do not use the Arzerra concentrate if there is discolouration.", "ParentId": "4c57dc7b-eb9e-4e0e-b972-fc48bb4a5a7c"}, {"Element": "<i> </i>", "ID": "e4725b35-b5d2-42d9-8387-ffc39e88f359", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "152abc79-af04-4941-ba6d-237aa50b5e20"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a89028b5-e1a6-44aa-b1e2-a19655d128b3", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fcd6589c-110f-402d-86f2-739294a8a528", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a89028b5-e1a6-44aa-b1e2-a19655d128b3"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Do not shake\nthe ofatumumab vial for this inspection.</span></p>", "ID": "78d448d1-9495-4ab0-b4ce-d9ab91a726af", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Do not shake\nthe ofatumumab vial for this inspection.</span>", "ID": "ae091a95-2d81-4c41-b006-57c199263a13", "Styles": "None", "Classes": "None", "Text": "Do not shake the ofatumumab vial for this inspection.", "ParentId": "78d448d1-9495-4ab0-b4ce-d9ab91a726af"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d6fa4e1b-7053-4bb8-b162-fa40a3d15c5b", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ca0e0b40-e00a-4714-9ded-b7a6d7b15774", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d6fa4e1b-7053-4bb8-b162-fa40a3d15c5b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">2)\u00a0\u00a0\u00a0\u00a0\u00a0 How to dilute the solution for infusion</span></b></p>", "ID": "b6b83c28-2648-4712-a822-845defa2df60", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">2)\u00a0\u00a0\u00a0\u00a0\u00a0 How to dilute the solution for infusion</span></b>", "ID": "995103ba-51d3-4f70-bacd-5e857d9cea3e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b6b83c28-2648-4712-a822-845defa2df60"}, {"Element": "<span lang=\"EN-GB\">2)\u00a0\u00a0\u00a0\u00a0\u00a0 How to dilute the solution for infusion</span>", "ID": "a9309c27-6df1-4c8c-9c3e-5a5d3940cb16", "Styles": "None", "Classes": "None", "Text": "2)\u00a0\u00a0\u00a0\u00a0\u00a0 How to dilute the solution for infusion", "ParentId": "995103ba-51d3-4f70-bacd-5e857d9cea3e"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\">\u00a0</p>", "ID": "d379c2b1-7f4d-4754-be12-6c52015222c4", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\">The <span lang=\"EN-GB\">Arzerra</span>\nconcentrate must be diluted in sodium chloride 9\u00a0mg/ml (0.9%) solution for\ninjection prior to administration, using aseptic technique.</p>", "ID": "4a298092-9476-4aa0-a151-4d663b7e0891", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "The  concentrate must be diluted in sodium chloride 9\u00a0mg/ml (0.9%) solution for injection prior to administration, using aseptic technique.", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Arzerra</span>", "ID": "0b90c16e-a4e8-451d-bfae-a0d710ee229d", "Styles": "None", "Classes": "None", "Text": "Arzerra", "ParentId": "4a298092-9476-4aa0-a151-4d663b7e0891"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "00c327a8-837f-4187-903d-fdabd0d0fa6b", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "20d2bd1f-8f72-4a41-bc7e-6cd2630df774", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "00c327a8-837f-4187-903d-fdabd0d0fa6b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">300\u00a0mg dose </span></b><span lang=\"EN-GB\">- Use three\n100\u00a0mg/5\u00a0ml vials (15\u00a0ml total, 5\u00a0ml per vial):</span></p>", "ID": "f84e9550-2304-454b-b34a-85bb139a0e52", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">300\u00a0mg dose </span></b>", "ID": "d5127da1-1885-42a4-9db0-f3ffc99c860a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f84e9550-2304-454b-b34a-85bb139a0e52"}, {"Element": "<span lang=\"EN-GB\">300\u00a0mg dose </span>", "ID": "a3f1a941-632b-4aee-bb6c-58b5e1d6018c", "Styles": "None", "Classes": "None", "Text": "300\u00a0mg dose ", "ParentId": "d5127da1-1885-42a4-9db0-f3ffc99c860a"}, {"Element": "<span lang=\"EN-GB\">- Use three\n100\u00a0mg/5\u00a0ml vials (15\u00a0ml total, 5\u00a0ml per vial):</span>", "ID": "53d7372f-d50d-4e8c-aef9-599a766b59b1", "Styles": "None", "Classes": "None", "Text": "- Use three 100\u00a0mg/5\u00a0ml vials (15\u00a0ml total, 5\u00a0ml per vial):", "ParentId": "f84e9550-2304-454b-b34a-85bb139a0e52"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Withdraw and discard 15\u00a0ml from a\n1000\u00a0ml bag of sodium chloride 9\u00a0mg/ml (0.9%) solution for injection;</span></p>", "ID": "d430d02c-1e3e-4183-90d8-e8616cdf13bf", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "85ad7dd3-3239-462f-b550-458074b73d48", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "d430d02c-1e3e-4183-90d8-e8616cdf13bf"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "ea31f5b9-7337-4890-81bf-1c3a2ee04177", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "85ad7dd3-3239-462f-b550-458074b73d48"}, {"Element": "<span lang=\"EN-GB\">Withdraw and discard 15\u00a0ml from a\n1000\u00a0ml bag of sodium chloride 9\u00a0mg/ml (0.9%) solution for injection;</span>", "ID": "13661e0e-fd50-475f-9e81-83b11e1ea88e", "Styles": "None", "Classes": "None", "Text": "Withdraw and discard 15\u00a0ml from a 1000\u00a0ml bag of sodium chloride 9\u00a0mg/ml (0.9%) solution for injection;", "ParentId": "d430d02c-1e3e-4183-90d8-e8616cdf13bf"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Withdraw 5\u00a0ml of ofatumumab from each of the\nthree 100\u00a0mg vials and inject into the 1000\u00a0ml bag;</span></p>", "ID": "0027d18e-dfc3-49b9-a139-6a78e5e544b4", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "aa4e0627-5ade-43ba-b012-8f60e0166f3b", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "0027d18e-dfc3-49b9-a139-6a78e5e544b4"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "3a32661d-2431-4ed5-9088-477e2bb7d92f", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "aa4e0627-5ade-43ba-b012-8f60e0166f3b"}, {"Element": "<span lang=\"EN-GB\">Withdraw 5\u00a0ml of ofatumumab from each of the\nthree 100\u00a0mg vials and inject into the 1000\u00a0ml bag;</span>", "ID": "682e7780-c2a4-4a07-8c99-09f7fcd56cbc", "Styles": "None", "Classes": "None", "Text": "Withdraw 5\u00a0ml of ofatumumab from each of the three 100\u00a0mg vials and inject into the 1000\u00a0ml bag;", "ParentId": "0027d18e-dfc3-49b9-a139-6a78e5e544b4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Do not shake; mix diluted solution by gentle\ninversion.</span></p>", "ID": "0d738605-7ef9-4126-b64c-5a000e5d98d4", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "7c3d4c0c-b722-45e2-a5b1-e56bc6c4ade6", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "0d738605-7ef9-4126-b64c-5a000e5d98d4"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "56b68a23-ff07-4030-af47-c7048f498fd2", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "7c3d4c0c-b722-45e2-a5b1-e56bc6c4ade6"}, {"Element": "<span lang=\"EN-GB\">Do not shake; mix diluted solution by gentle\ninversion.</span>", "ID": "7315ac66-4ef8-4bda-9148-e416275b54db", "Styles": "None", "Classes": "None", "Text": "Do not shake; mix diluted solution by gentle inversion.", "ParentId": "0d738605-7ef9-4126-b64c-5a000e5d98d4"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c1883fc2-913e-4dc4-aa96-4e5928f0d2aa", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "453b3a0d-8418-48cf-8d35-a1b54aa3b0b1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c1883fc2-913e-4dc4-aa96-4e5928f0d2aa"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">1000\u00a0mg dose </span></b><span lang=\"EN-GB\">\u2013 Use one\n1000\u00a0mg/50\u00a0ml vial (50\u00a0ml total, 50\u00a0ml per vial):</span></p>", "ID": "42291c27-adbf-43ec-a5b5-139b3ea08f08", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">1000\u00a0mg dose </span></b>", "ID": "098e56ab-09b3-4311-96da-38f4d65a6cd8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "42291c27-adbf-43ec-a5b5-139b3ea08f08"}, {"Element": "<span lang=\"EN-GB\">1000\u00a0mg dose </span>", "ID": "48c4a948-1fd2-44f8-9f8c-4cdb4dff7e3f", "Styles": "None", "Classes": "None", "Text": "1000\u00a0mg dose ", "ParentId": "098e56ab-09b3-4311-96da-38f4d65a6cd8"}, {"Element": "<span lang=\"EN-GB\">\u2013 Use one\n1000\u00a0mg/50\u00a0ml vial (50\u00a0ml total, 50\u00a0ml per vial):</span>", "ID": "ac4e5b8c-d135-41d0-9ee5-26ba91e9f25a", "Styles": "None", "Classes": "None", "Text": "\u2013 Use one 1000\u00a0mg/50\u00a0ml vial (50\u00a0ml total, 50\u00a0ml per vial):", "ParentId": "42291c27-adbf-43ec-a5b5-139b3ea08f08"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Withdraw and discard 50\u00a0ml from a 1000 ml\nbag of sodium chloride 9\u00a0mg/ml (0.9%) solution for injection;</span></p>", "ID": "1dbbf866-fda6-4e8f-a7f2-71fd90226dc1", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "dbe87524-65c2-4b20-9b10-110e46b8312a", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "1dbbf866-fda6-4e8f-a7f2-71fd90226dc1"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "6af9252e-e5f6-4866-8395-792f23c13584", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "dbe87524-65c2-4b20-9b10-110e46b8312a"}, {"Element": "<span lang=\"EN-GB\">Withdraw and discard 50\u00a0ml from a 1000 ml\nbag of sodium chloride 9\u00a0mg/ml (0.9%) solution for injection;</span>", "ID": "13f5b6f5-68b2-4951-b8d4-039ddd29b2f2", "Styles": "None", "Classes": "None", "Text": "Withdraw and discard 50\u00a0ml from a 1000 ml bag of sodium chloride 9\u00a0mg/ml (0.9%) solution for injection;", "ParentId": "1dbbf866-fda6-4e8f-a7f2-71fd90226dc1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Withdraw 50\u00a0ml of ofatumumab from the\n1000\u00a0mg vial and inject into the 1000\u00a0ml bag</span></p>", "ID": "ea2b2bba-8c72-4188-a591-63a5c42a6dea", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "009b84d2-189e-4ef9-8dcf-d8b0087b73bc", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "ea2b2bba-8c72-4188-a591-63a5c42a6dea"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "d82edf14-cfe4-489e-a44a-67007c95a902", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "009b84d2-189e-4ef9-8dcf-d8b0087b73bc"}, {"Element": "<span lang=\"EN-GB\">Withdraw 50\u00a0ml of ofatumumab from the\n1000\u00a0mg vial and inject into the 1000\u00a0ml bag</span>", "ID": "0a57231e-5a78-4aef-8e60-f16d699c5fa1", "Styles": "None", "Classes": "None", "Text": "Withdraw 50\u00a0ml of ofatumumab from the 1000\u00a0mg vial and inject into the 1000\u00a0ml bag", "ParentId": "ea2b2bba-8c72-4188-a591-63a5c42a6dea"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Do not shake; mix diluted solution by gentle\ninversion.</span></p>", "ID": "dca46cef-fcd6-4075-9fbd-fa1ee81658ee", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "d3782d71-d83c-4410-a0db-5689cbdb1fe3", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "dca46cef-fcd6-4075-9fbd-fa1ee81658ee"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "7e12611e-3ac3-4fa0-a087-5cd049205388", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "d3782d71-d83c-4410-a0db-5689cbdb1fe3"}, {"Element": "<span lang=\"EN-GB\">Do not shake; mix diluted solution by gentle\ninversion.</span>", "ID": "d7d68c14-316a-413f-8f73-2445ed2a29ac", "Styles": "None", "Classes": "None", "Text": "Do not shake; mix diluted solution by gentle inversion.", "ParentId": "dca46cef-fcd6-4075-9fbd-fa1ee81658ee"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b8d315a8-6d33-430d-8a11-c54123106a78", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "277e3fa2-4baa-4aee-9341-4de035af9c8c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b8d315a8-6d33-430d-8a11-c54123106a78"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">2000\u00a0mg dose </span></b><span lang=\"EN-GB\">\u2013 Use two\n1000\u00a0mg/50\u00a0ml vials (100\u00a0ml total, 50\u00a0ml per vial):</span></p>", "ID": "fb5fd634-175a-4166-a024-f971d0d4051b", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">2000\u00a0mg dose </span></b>", "ID": "c29c9d83-0fc6-49e9-afdb-29fa0bfc91de", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fb5fd634-175a-4166-a024-f971d0d4051b"}, {"Element": "<span lang=\"EN-GB\">2000\u00a0mg dose </span>", "ID": "932cbb93-1eb1-4fe9-97cd-3c1c1e335fb6", "Styles": "None", "Classes": "None", "Text": "2000\u00a0mg dose ", "ParentId": "c29c9d83-0fc6-49e9-afdb-29fa0bfc91de"}, {"Element": "<span lang=\"EN-GB\">\u2013 Use two\n1000\u00a0mg/50\u00a0ml vials (100\u00a0ml total, 50\u00a0ml per vial):</span>", "ID": "3b973ddd-d2f6-4cfd-b583-a3361df5afda", "Styles": "None", "Classes": "None", "Text": "\u2013 Use two 1000\u00a0mg/50\u00a0ml vials (100\u00a0ml total, 50\u00a0ml per vial):", "ParentId": "fb5fd634-175a-4166-a024-f971d0d4051b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Withdraw and discard 100\u00a0ml from a 1000 ml\nbag of sodium chloride 9\u00a0mg/ml (0.9%) solution for injection;</span></p>", "ID": "c3bbaf81-0d9c-492b-a252-0d0a470f5022", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "334745ff-4cfa-43d8-9547-a3708a0b6a18", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "c3bbaf81-0d9c-492b-a252-0d0a470f5022"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "77b2bd4f-41f1-4946-bf75-94311e0666b0", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "334745ff-4cfa-43d8-9547-a3708a0b6a18"}, {"Element": "<span lang=\"EN-GB\">Withdraw and discard 100\u00a0ml from a 1000 ml\nbag of sodium chloride 9\u00a0mg/ml (0.9%) solution for injection;</span>", "ID": "73d905f4-1a58-4f3a-a146-2bab9049db1d", "Styles": "None", "Classes": "None", "Text": "Withdraw and discard 100\u00a0ml from a 1000 ml bag of sodium chloride 9\u00a0mg/ml (0.9%) solution for injection;", "ParentId": "c3bbaf81-0d9c-492b-a252-0d0a470f5022"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Withdraw 50\u00a0ml of ofatumumab from each of the\ntwo 1000\u00a0mg vials and inject into the 1000\u00a0ml bag;</span></p>", "ID": "9bd5979e-915c-42fc-8541-f06a48027503", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "be846037-2a6a-49b1-9a1e-d006f45be13a", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "9bd5979e-915c-42fc-8541-f06a48027503"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "d586ef9a-d695-4794-ba4a-9b01769e60dc", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "be846037-2a6a-49b1-9a1e-d006f45be13a"}, {"Element": "<span lang=\"EN-GB\">Withdraw 50\u00a0ml of ofatumumab from each of the\ntwo 1000\u00a0mg vials and inject into the 1000\u00a0ml bag;</span>", "ID": "0ee0c443-c746-45f1-bde6-224c3e1aa6f1", "Styles": "None", "Classes": "None", "Text": "Withdraw 50\u00a0ml of ofatumumab from each of the two 1000\u00a0mg vials and inject into the 1000\u00a0ml bag;", "ParentId": "9bd5979e-915c-42fc-8541-f06a48027503"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Do not shake; mix diluted solution by gentle\ninversion.</span></p>", "ID": "9daa5d17-cab4-4308-9045-e10f3a6f4b99", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "70ad772b-bf44-4043-a9d3-3338cc2b406f", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "9daa5d17-cab4-4308-9045-e10f3a6f4b99"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "2d7713d9-d967-41f3-b666-46fcb3e9d3ef", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "70ad772b-bf44-4043-a9d3-3338cc2b406f"}, {"Element": "<span lang=\"EN-GB\">Do not shake; mix diluted solution by gentle\ninversion.</span>", "ID": "c1c65d25-0334-44b7-be64-aa95640a9922", "Styles": "None", "Classes": "None", "Text": "Do not shake; mix diluted solution by gentle inversion.", "ParentId": "9daa5d17-cab4-4308-9045-e10f3a6f4b99"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "499b1935-29c7-4366-a7fc-3d7483ff9278", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9caf10ee-18e5-4841-ada7-962ba96a84ff", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "499b1935-29c7-4366-a7fc-3d7483ff9278"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">3)\u00a0\u00a0\u00a0\u00a0\u00a0 How to administer the diluted solution</span></b></p>", "ID": "826483c5-5f20-48af-8009-80c3b84e30b5", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<b><span lang=\"EN-GB\">3)\u00a0\u00a0\u00a0\u00a0\u00a0 How to administer the diluted solution</span></b>", "ID": "5b3cfc7c-3dd8-4af0-b954-973c79f4b03e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "826483c5-5f20-48af-8009-80c3b84e30b5"}, {"Element": "<span lang=\"EN-GB\">3)\u00a0\u00a0\u00a0\u00a0\u00a0 How to administer the diluted solution</span>", "ID": "22384061-8a27-4fc7-8ea2-981c5b77dc4c", "Styles": "None", "Classes": "None", "Text": "3)\u00a0\u00a0\u00a0\u00a0\u00a0 How to administer the diluted solution", "ParentId": "5b3cfc7c-3dd8-4af0-b954-973c79f4b03e"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\">\u00a0</p>", "ID": "e88c7c73-8b89-453e-8d3e-0139a48467cf", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Arzerra must\nnot be administered as an intravenous push or bolus. Administer using an\nintravenous infusion pump</span><span lang=\"EN-GB\">.</span></p>", "ID": "863d0a4e-c966-4304-aa46-7f3d47c6a058", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Arzerra must\nnot be administered as an intravenous push or bolus. Administer using an\nintravenous infusion pump</span>", "ID": "f7d4c7ce-745d-4eef-8c0d-bf444348d4df", "Styles": "None", "Classes": "None", "Text": "Arzerra must not be administered as an intravenous push or bolus. Administer using an intravenous infusion pump", "ParentId": "863d0a4e-c966-4304-aa46-7f3d47c6a058"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "f8d722d4-a6ab-48ca-8789-e52f48a3ac1f", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "863d0a4e-c966-4304-aa46-7f3d47c6a058"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "efbb0d89-58fb-4f0a-bc33-d70854bf9cd2", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0436310f-cf49-4717-bb33-167b4fa79cce", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "efbb0d89-58fb-4f0a-bc33-d70854bf9cd2"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">The infusion\nmust be completed within 24\u00a0hours after preparation. Discard any unused\nsolution after this time.</span></p>", "ID": "75e1c0ef-8bce-414b-bd1f-59b877a2c97f", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">The infusion\nmust be completed within 24\u00a0hours after preparation. Discard any unused\nsolution after this time.</span>", "ID": "624ccd0f-7432-4814-aa83-5991296a77d9", "Styles": "None", "Classes": "None", "Text": "The infusion must be completed within 24\u00a0hours after preparation. Discard any unused solution after this time.", "ParentId": "75e1c0ef-8bce-414b-bd1f-59b877a2c97f"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "166544d4-1a7a-42fb-b70e-fdd94a25a97d", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ad401c6b-b578-4296-be85-3003bb20efd0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "166544d4-1a7a-42fb-b70e-fdd94a25a97d"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Arzerra must\nnot be mixed with, or administered as an infusion with other medicinal products\nor intravenous solutions. Flush line before and after ofatumumab administration\nwith sodium chloride 9\u00a0mg/ml (0.9%) solution for injection to avoid this.</span></p>", "ID": "53ee2d5d-c419-46fd-8fff-e23f0d5a8edf", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Arzerra must\nnot be mixed with, or administered as an infusion with other medicinal products\nor intravenous solutions. Flush line before and after ofatumumab administration\nwith sodium chloride 9\u00a0mg/ml (0.9%) solution for injection to avoid this.</span>", "ID": "acd2d951-141b-44fa-8f25-2dc7a36ca2f0", "Styles": "None", "Classes": "None", "Text": "Arzerra must not be mixed with, or administered as an infusion with other medicinal products or intravenous solutions. Flush line before and after ofatumumab administration with sodium chloride 9\u00a0mg/ml (0.9%) solution for injection to avoid this.", "ParentId": "53ee2d5d-c419-46fd-8fff-e23f0d5a8edf"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2746631d-a980-4606-8cec-37e93e9108cb", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8a57da46-2e5e-44ee-9777-ccab2a6be649", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2746631d-a980-4606-8cec-37e93e9108cb"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Previously\nuntreated CLL and relapsed CLL:</span></u></p>", "ID": "4b1c226b-141e-4945-83e8-fad67b49941a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\">Previously\nuntreated CLL and relapsed CLL:</span></u>", "ID": "82563e77-ee47-4d0e-924e-24c0bc14ee08", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4b1c226b-141e-4945-83e8-fad67b49941a"}, {"Element": "<span lang=\"EN-GB\">Previously\nuntreated CLL and relapsed CLL:</span>", "ID": "f56e544d-9a50-4dc6-be82-ebfe8ebc1941", "Styles": "None", "Classes": "None", "Text": "Previously untreated CLL and relapsed CLL:", "ParentId": "82563e77-ee47-4d0e-924e-24c0bc14ee08"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">For the\nfirst infusion, administer over 4.5 hours </span><span lang=\"EN-GB\">(</span><span lang=\"EN-GB\">see section\u00a04.2</span><span lang=\"EN-GB\"> of the SmPC), </span><span lang=\"EN-GB\">through a peripheral line or indwelling catheter, according to the\nschedule below:</span></p>", "ID": "1ee27937-f15a-490c-9926-920f5ef73058", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">For the\nfirst infusion, administer over 4.5 hours </span>", "ID": "098ff4c7-2898-402d-af9b-2f5164d4956a", "Styles": "None", "Classes": "None", "Text": "For the first infusion, administer over 4.5 hours ", "ParentId": "1ee27937-f15a-490c-9926-920f5ef73058"}, {"Element": "<span lang=\"EN-GB\">(</span>", "ID": "38182c2a-099c-4db1-b77c-67bea9b1b697", "Styles": "None", "Classes": "None", "Text": "(", "ParentId": "1ee27937-f15a-490c-9926-920f5ef73058"}, {"Element": "<span lang=\"EN-GB\">see section\u00a04.2</span>", "ID": "49007c9d-a0e2-4aa5-b973-d50d75f06fdc", "Styles": "None", "Classes": "None", "Text": "see section\u00a04.2", "ParentId": "1ee27937-f15a-490c-9926-920f5ef73058"}, {"Element": "<span lang=\"EN-GB\"> of the SmPC), </span>", "ID": "37116137-a042-4402-870e-0fd946303d5f", "Styles": "None", "Classes": "None", "Text": " of the SmPC), ", "ParentId": "1ee27937-f15a-490c-9926-920f5ef73058"}, {"Element": "<span lang=\"EN-GB\">through a peripheral line or indwelling catheter, according to the\nschedule below:</span>", "ID": "9f933566-498f-42e5-a9b7-ccd7e54d3f18", "Styles": "None", "Classes": "None", "Text": "through a peripheral line or indwelling catheter, according to the schedule below:", "ParentId": "1ee27937-f15a-490c-9926-920f5ef73058"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d50f6e18-4055-4379-b670-30db9ccd035c", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "77cefc18-54b0-400d-bdc2-ebf2c1235cd3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d50f6e18-4055-4379-b670-30db9ccd035c"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">If the first\ninfusion was completed without a severe adverse reaction, the remaining\ninfusions of 1000\u00a0mg should be administered over 4\u00a0hours (see\nsection\u00a04.2 of the SmPC), through a peripheral line or indwelling\ncatheter, according to the schedule below. If any infusion\u2011related\nadverse reactions are observed, infusion should be interrupted and restarted\nwhen the patient\u2019s condition is stable (see section\u00a04.2 of the SmPC).</span></p>", "ID": "d150de8f-9e6e-4dec-80a4-ec6be18b6d44", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">If the first\ninfusion was completed without a severe adverse reaction, the remaining\ninfusions of 1000\u00a0mg should be administered over 4\u00a0hours (see\nsection\u00a04.2 of the SmPC), through a peripheral line or indwelling\ncatheter, according to the schedule below. If any infusion\u2011related\nadverse reactions are observed, infusion should be interrupted and restarted\nwhen the patient\u2019s condition is stable (see section\u00a04.2 of the SmPC).</span>", "ID": "86998d26-87fc-44dd-9c34-c50838c097b2", "Styles": "None", "Classes": "None", "Text": "If the first infusion was completed without a severe adverse reaction, the remaining infusions of 1000\u00a0mg should be administered over 4\u00a0hours (see section\u00a04.2 of the SmPC), through a peripheral line or indwelling catheter, according to the schedule below. If any infusion\u2011related adverse reactions are observed, infusion should be interrupted and restarted when the patient\u2019s condition is stable (see section\u00a04.2 of the SmPC).", "ParentId": "d150de8f-9e6e-4dec-80a4-ec6be18b6d44"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "70c16ce4-f8c5-4f09-b0dc-210d9ce93656", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "b1b7ad47-ab7a-42d0-8933-7e2ce49a9f1f", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "70c16ce4-f8c5-4f09-b0dc-210d9ce93656"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><u><span lang=\"EN-GB\">Infusion schedule</span></u></i></p>", "ID": "1edb3317-5c2d-4438-a48f-01685bfd21de", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><u><span lang=\"EN-GB\">Infusion schedule</span></u></i>", "ID": "4cdfe4b1-c484-4439-b44f-aa024c2ef70a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1edb3317-5c2d-4438-a48f-01685bfd21de"}, {"Element": "<u><span lang=\"EN-GB\">Infusion schedule</span></u>", "ID": "c64439b6-6800-4cb2-82aa-7694e61d7333", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4cdfe4b1-c484-4439-b44f-aa024c2ef70a"}, {"Element": "<span lang=\"EN-GB\">Infusion schedule</span>", "ID": "939b46e7-9f76-407f-89d4-3ff879a05817", "Styles": "None", "Classes": "None", "Text": "Infusion schedule", "ParentId": "c64439b6-6800-4cb2-82aa-7694e61d7333"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "db96ad79-59cf-4611-8c2d-2f63b11d0b3d", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "13223551-7fbf-4fc5-b6be-07bb19ea0c29", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "db96ad79-59cf-4611-8c2d-2f63b11d0b3d"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:100.0%;border-collapse:collapse;border:none\" width=\"100%\">\n<tr>\n<td rowspan=\"2\" style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Time after start of infusion (minutes)</span></p>\n</td>\n<td style=\"width:141.15pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion\u00a01</span></p>\n</td>\n<td style=\"width:146.55pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Subsequent infusions*</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:141.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0\u201130</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">12</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31\u201160</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">61\u201190</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">91\u2011120</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">121\u2011150</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">151\u2011180</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">300</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">180+</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\" style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">*If the\n  previous infusion was completed without severe infusion\u2011related ADRs.\n  If any infusion\u2011related ADRs are observed, infusion should be\n  interrupted and restarted when the patient\u2019s condition is stable (see </span><span lang=\"EN-GB\">section\u00a04.2 of the SmPC</span><span lang=\"EN-GB\">).</span></p>\n</td>\n</tr>\n</table>", "ID": "2da54662-00b0-4b13-ad26-0c816d654077", "Styles": "width:100.0%;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "           ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<tr>\n<td rowspan=\"2\" style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Time after start of infusion (minutes)</span></p>\n</td>\n<td style=\"width:141.15pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion\u00a01</span></p>\n</td>\n<td style=\"width:146.55pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Subsequent infusions*</span></p>\n</td>\n</tr>", "ID": "1c4224e6-66d1-4276-afa4-6eb29409344f", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "2da54662-00b0-4b13-ad26-0c816d654077"}, {"Element": "<td rowspan=\"2\" style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Time after start of infusion (minutes)</span></p>\n</td>", "ID": "24dcd25c-88bd-4cdc-b68e-27c217e0f02a", "Styles": "width:176.65pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1c4224e6-66d1-4276-afa4-6eb29409344f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Time after start of infusion (minutes)</span></p>", "ID": "cb5ee934-2d5a-4d55-903b-d099b2d34a8e", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "24dcd25c-88bd-4cdc-b68e-27c217e0f02a"}, {"Element": "<span lang=\"EN-GB\">Time after start of infusion (minutes)</span>", "ID": "0b374d0f-cad8-4118-8266-b1a22a1bc423", "Styles": "None", "Classes": "None", "Text": "Time after start of infusion (minutes)", "ParentId": "cb5ee934-2d5a-4d55-903b-d099b2d34a8e"}, {"Element": "<td style=\"width:141.15pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion\u00a01</span></p>\n</td>", "ID": "1ae84e2e-206f-42da-b49d-c7556de4514c", "Styles": "width:141.15pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1c4224e6-66d1-4276-afa4-6eb29409344f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion\u00a01</span></p>", "ID": "644cc46d-59ba-4465-bb8b-c2ae26de6d0d", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1ae84e2e-206f-42da-b49d-c7556de4514c"}, {"Element": "<span lang=\"EN-GB\">Infusion\u00a01</span>", "ID": "db68bf8d-c9df-4b79-a513-0659da04c026", "Styles": "None", "Classes": "None", "Text": "Infusion\u00a01", "ParentId": "644cc46d-59ba-4465-bb8b-c2ae26de6d0d"}, {"Element": "<td style=\"width:146.55pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Subsequent infusions*</span></p>\n</td>", "ID": "36b66e3f-992a-4368-9c5b-1a1475ff2c2e", "Styles": "width:146.55pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1c4224e6-66d1-4276-afa4-6eb29409344f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Subsequent infusions*</span></p>", "ID": "fc526478-b374-4521-96ad-7befba3f7a8b", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "36b66e3f-992a-4368-9c5b-1a1475ff2c2e"}, {"Element": "<span lang=\"EN-GB\">Subsequent infusions*</span>", "ID": "ceb44bac-836a-4590-80ce-d3d8f42ebab9", "Styles": "None", "Classes": "None", "Text": "Subsequent infusions*", "ParentId": "fc526478-b374-4521-96ad-7befba3f7a8b"}, {"Element": "<tr>\n<td style=\"width:141.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>\n</tr>", "ID": "00a7496a-bfc0-4723-a79e-6896a76dc0f1", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "2da54662-00b0-4b13-ad26-0c816d654077"}, {"Element": "<td style=\"width:141.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>", "ID": "d4a4a113-566d-4752-9fc5-243e675d03e3", "Styles": "width:141.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "00a7496a-bfc0-4723-a79e-6896a76dc0f1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>", "ID": "3d32bcb6-f1b6-4e1a-b83f-8a1f561ede7f", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d4a4a113-566d-4752-9fc5-243e675d03e3"}, {"Element": "<span lang=\"EN-GB\">Infusion rate (ml/hour)</span>", "ID": "145960a2-b211-4b53-8dcc-fd91d539cafa", "Styles": "None", "Classes": "None", "Text": "Infusion rate (ml/hour)", "ParentId": "3d32bcb6-f1b6-4e1a-b83f-8a1f561ede7f"}, {"Element": "<td style=\"width:146.55pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>", "ID": "016e549d-4777-4be0-89e6-2c7ea8d7c7ae", "Styles": "width:146.55pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "00a7496a-bfc0-4723-a79e-6896a76dc0f1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>", "ID": "aae65db8-0a4e-4e10-bca0-9b6a77c8171a", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "016e549d-4777-4be0-89e6-2c7ea8d7c7ae"}, {"Element": "<span lang=\"EN-GB\">Infusion rate (ml/hour)</span>", "ID": "7c3ff028-dbb2-42d6-b236-e0a6906cafa9", "Styles": "None", "Classes": "None", "Text": "Infusion rate (ml/hour)", "ParentId": "aae65db8-0a4e-4e10-bca0-9b6a77c8171a"}, {"Element": "<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0\u201130</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">12</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>\n</tr>", "ID": "61355c21-8bea-44a4-a0bd-cd6fc6c23f2d", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "2da54662-00b0-4b13-ad26-0c816d654077"}, {"Element": "<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0\u201130</span></p>\n</td>", "ID": "655295f6-1190-41d8-bc5b-2e107c309bd0", "Styles": "width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "61355c21-8bea-44a4-a0bd-cd6fc6c23f2d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0\u201130</span></p>", "ID": "0419540f-5d1f-410c-956a-a0936cfc1ba9", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "655295f6-1190-41d8-bc5b-2e107c309bd0"}, {"Element": "<span lang=\"EN-GB\">0\u201130</span>", "ID": "b38724bc-dfac-4262-aebb-a4de277c89b4", "Styles": "None", "Classes": "None", "Text": "0\u201130", "ParentId": "0419540f-5d1f-410c-956a-a0936cfc1ba9"}, {"Element": "<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">12</span></p>\n</td>", "ID": "bdffe101-003a-4dab-bcec-e09e2ef5f686", "Styles": "width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "61355c21-8bea-44a4-a0bd-cd6fc6c23f2d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">12</span></p>", "ID": "df724333-d931-48ff-bf34-1573991196a0", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bdffe101-003a-4dab-bcec-e09e2ef5f686"}, {"Element": "<span lang=\"EN-GB\">12</span>", "ID": "44420f4b-88a7-41cb-8405-fd95318d2e03", "Styles": "None", "Classes": "None", "Text": "12", "ParentId": "df724333-d931-48ff-bf34-1573991196a0"}, {"Element": "<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>", "ID": "3d61040b-4a27-4d5e-b21c-2ec2d1ef7357", "Styles": "width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "61355c21-8bea-44a4-a0bd-cd6fc6c23f2d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>", "ID": "4dbf0405-4543-4a24-9657-4bd8c23587a7", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3d61040b-4a27-4d5e-b21c-2ec2d1ef7357"}, {"Element": "<span lang=\"EN-GB\">25</span>", "ID": "931a154e-b619-4010-bbf1-3528099a1ebd", "Styles": "None", "Classes": "None", "Text": "25", "ParentId": "4dbf0405-4543-4a24-9657-4bd8c23587a7"}, {"Element": "<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31\u201160</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>\n</tr>", "ID": "46b1ce5c-58b3-4167-9158-63b27833e2af", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "2da54662-00b0-4b13-ad26-0c816d654077"}, {"Element": "<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31\u201160</span></p>\n</td>", "ID": "2958b405-4c21-47d8-8ff4-8e140d0082dd", "Styles": "width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "46b1ce5c-58b3-4167-9158-63b27833e2af"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31\u201160</span></p>", "ID": "9f15b824-168a-4f8c-9b82-cab575cba9c8", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2958b405-4c21-47d8-8ff4-8e140d0082dd"}, {"Element": "<span lang=\"EN-GB\">31\u201160</span>", "ID": "f28de796-eee2-4f0b-9841-78169defeea5", "Styles": "None", "Classes": "None", "Text": "31\u201160", "ParentId": "9f15b824-168a-4f8c-9b82-cab575cba9c8"}, {"Element": "<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>", "ID": "8abeef23-77c9-4b33-ac4c-b6b79c96a692", "Styles": "width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "46b1ce5c-58b3-4167-9158-63b27833e2af"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>", "ID": "d88b41c0-4ee8-49da-a6fc-6fe160852754", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8abeef23-77c9-4b33-ac4c-b6b79c96a692"}, {"Element": "<span lang=\"EN-GB\">25</span>", "ID": "88691eeb-4a46-44e3-b203-e62d0e62bc37", "Styles": "None", "Classes": "None", "Text": "25", "ParentId": "d88b41c0-4ee8-49da-a6fc-6fe160852754"}, {"Element": "<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>", "ID": "076853f0-ddfd-40b1-9892-6146253dd8aa", "Styles": "width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "46b1ce5c-58b3-4167-9158-63b27833e2af"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>", "ID": "6df8ec94-da49-4915-b398-1a8f6fdba312", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "076853f0-ddfd-40b1-9892-6146253dd8aa"}, {"Element": "<span lang=\"EN-GB\">50</span>", "ID": "752cfcda-852b-425d-b49f-929df4d141a2", "Styles": "None", "Classes": "None", "Text": "50", "ParentId": "6df8ec94-da49-4915-b398-1a8f6fdba312"}, {"Element": "<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">61\u201190</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>\n</tr>", "ID": "5cab2025-1637-47be-8773-c81365ebb2be", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "2da54662-00b0-4b13-ad26-0c816d654077"}, {"Element": "<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">61\u201190</span></p>\n</td>", "ID": "be4f1e94-f159-4c2d-8361-86a1d204e738", "Styles": "width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5cab2025-1637-47be-8773-c81365ebb2be"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">61\u201190</span></p>", "ID": "e72bd01c-2308-4db2-9648-d27041a2784c", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "be4f1e94-f159-4c2d-8361-86a1d204e738"}, {"Element": "<span lang=\"EN-GB\">61\u201190</span>", "ID": "2b9f0610-bd30-44d0-ba0b-7fa62a76001e", "Styles": "None", "Classes": "None", "Text": "61\u201190", "ParentId": "e72bd01c-2308-4db2-9648-d27041a2784c"}, {"Element": "<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>", "ID": "7e449912-f825-4d24-99ae-34074b133c60", "Styles": "width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5cab2025-1637-47be-8773-c81365ebb2be"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>", "ID": "11abe796-8725-4ee3-9ae4-a61f7397fa1b", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7e449912-f825-4d24-99ae-34074b133c60"}, {"Element": "<span lang=\"EN-GB\">50</span>", "ID": "0272bf73-fefd-4d3c-a04f-34177db6638b", "Styles": "None", "Classes": "None", "Text": "50", "ParentId": "11abe796-8725-4ee3-9ae4-a61f7397fa1b"}, {"Element": "<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>", "ID": "ae2cc6b4-c8a4-4ca5-aa66-4e3232da96ed", "Styles": "width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5cab2025-1637-47be-8773-c81365ebb2be"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>", "ID": "81f77664-0189-44b6-9662-7433b76916dd", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ae2cc6b4-c8a4-4ca5-aa66-4e3232da96ed"}, {"Element": "<span lang=\"EN-GB\">100</span>", "ID": "7f078e03-f3be-477a-9374-54490bde28c1", "Styles": "None", "Classes": "None", "Text": "100", "ParentId": "81f77664-0189-44b6-9662-7433b76916dd"}, {"Element": "<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">91\u2011120</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>\n</tr>", "ID": "09538f5e-06db-4a2e-8027-09497035074d", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "2da54662-00b0-4b13-ad26-0c816d654077"}, {"Element": "<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">91\u2011120</span></p>\n</td>", "ID": "7aed6aa5-8c1f-46c3-971a-3739d9b95a93", "Styles": "width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "09538f5e-06db-4a2e-8027-09497035074d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">91\u2011120</span></p>", "ID": "287fcba4-dc27-4f68-b9ae-bfe3f0e32e7a", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7aed6aa5-8c1f-46c3-971a-3739d9b95a93"}, {"Element": "<span lang=\"EN-GB\">91\u2011120</span>", "ID": "88c610c1-2036-4f2a-ba72-842c9996599c", "Styles": "None", "Classes": "None", "Text": "91\u2011120", "ParentId": "287fcba4-dc27-4f68-b9ae-bfe3f0e32e7a"}, {"Element": "<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>", "ID": "dfd63715-b54e-4fa8-85d8-16f03a0636ce", "Styles": "width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "09538f5e-06db-4a2e-8027-09497035074d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>", "ID": "6665b5f2-0ede-4b94-b567-0777bfe1ddbf", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dfd63715-b54e-4fa8-85d8-16f03a0636ce"}, {"Element": "<span lang=\"EN-GB\">100</span>", "ID": "dc77d20b-c4a1-4653-848e-6d2c57785d24", "Styles": "None", "Classes": "None", "Text": "100", "ParentId": "6665b5f2-0ede-4b94-b567-0777bfe1ddbf"}, {"Element": "<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>", "ID": "0e8b0d75-75f7-44d9-86c4-2567516f2940", "Styles": "width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "09538f5e-06db-4a2e-8027-09497035074d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>", "ID": "9f2eac5d-eb8e-480e-9353-52d1cebd6296", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0e8b0d75-75f7-44d9-86c4-2567516f2940"}, {"Element": "<span lang=\"EN-GB\">200</span>", "ID": "3b3abbda-1f7c-436f-a7f9-6602394cb71d", "Styles": "None", "Classes": "None", "Text": "200", "ParentId": "9f2eac5d-eb8e-480e-9353-52d1cebd6296"}, {"Element": "<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">121\u2011150</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n</tr>", "ID": "a583a33d-7bf5-43c1-93ce-4384fd69f830", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "2da54662-00b0-4b13-ad26-0c816d654077"}, {"Element": "<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">121\u2011150</span></p>\n</td>", "ID": "75fed1e3-f2c9-4f50-b921-48e4519a7bbe", "Styles": "width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a583a33d-7bf5-43c1-93ce-4384fd69f830"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">121\u2011150</span></p>", "ID": "aa8b13ee-1e07-4738-a9c7-e0c5b9337327", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "75fed1e3-f2c9-4f50-b921-48e4519a7bbe"}, {"Element": "<span lang=\"EN-GB\">121\u2011150</span>", "ID": "30d9cd31-aa38-4580-bff3-325266f2a7ce", "Styles": "None", "Classes": "None", "Text": "121\u2011150", "ParentId": "aa8b13ee-1e07-4738-a9c7-e0c5b9337327"}, {"Element": "<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>", "ID": "55fdc228-40d0-4e95-9b2d-19a5993fee83", "Styles": "width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a583a33d-7bf5-43c1-93ce-4384fd69f830"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>", "ID": "1a91f13c-4d39-4be9-9300-e3e02719608c", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "55fdc228-40d0-4e95-9b2d-19a5993fee83"}, {"Element": "<span lang=\"EN-GB\">200</span>", "ID": "c06dc75f-20d4-4877-a333-515092153b79", "Styles": "None", "Classes": "None", "Text": "200", "ParentId": "1a91f13c-4d39-4be9-9300-e3e02719608c"}, {"Element": "<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>", "ID": "efb02fb9-a3a2-4bbd-bad8-b0fff7d996c3", "Styles": "width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a583a33d-7bf5-43c1-93ce-4384fd69f830"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>", "ID": "17aa9d44-de7f-4134-bcbc-0aad0e7d78fb", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "efb02fb9-a3a2-4bbd-bad8-b0fff7d996c3"}, {"Element": "<span lang=\"EN-GB\">400</span>", "ID": "df12e198-0fc7-4366-8dc0-7186333064e9", "Styles": "None", "Classes": "None", "Text": "400", "ParentId": "17aa9d44-de7f-4134-bcbc-0aad0e7d78fb"}, {"Element": "<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">151\u2011180</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">300</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n</tr>", "ID": "17b561af-35d3-46b1-ac04-00ab9b16d586", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "2da54662-00b0-4b13-ad26-0c816d654077"}, {"Element": "<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">151\u2011180</span></p>\n</td>", "ID": "b3c4674c-5965-4b01-92bb-4220188048c0", "Styles": "width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "17b561af-35d3-46b1-ac04-00ab9b16d586"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">151\u2011180</span></p>", "ID": "b14cbb62-43fc-40f9-8b78-09a20532589f", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b3c4674c-5965-4b01-92bb-4220188048c0"}, {"Element": "<span lang=\"EN-GB\">151\u2011180</span>", "ID": "8d0c0a9e-febc-4b84-a500-480d37c00a1c", "Styles": "None", "Classes": "None", "Text": "151\u2011180", "ParentId": "b14cbb62-43fc-40f9-8b78-09a20532589f"}, {"Element": "<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">300</span></p>\n</td>", "ID": "f6445059-3080-42ce-805e-ab0652d252c7", "Styles": "width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "17b561af-35d3-46b1-ac04-00ab9b16d586"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">300</span></p>", "ID": "ec406fa7-abaa-44c0-a9bf-375a15def9a3", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f6445059-3080-42ce-805e-ab0652d252c7"}, {"Element": "<span lang=\"EN-GB\">300</span>", "ID": "bd40ebd1-b5c9-499a-ae46-162542ca0332", "Styles": "None", "Classes": "None", "Text": "300", "ParentId": "ec406fa7-abaa-44c0-a9bf-375a15def9a3"}, {"Element": "<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>", "ID": "b7357615-4050-4fdd-a4f2-6395a4ae3b68", "Styles": "width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "17b561af-35d3-46b1-ac04-00ab9b16d586"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>", "ID": "763cb325-b4eb-4931-b7be-f0ea3d350e5c", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b7357615-4050-4fdd-a4f2-6395a4ae3b68"}, {"Element": "<span lang=\"EN-GB\">400</span>", "ID": "8c07e29d-8955-4b9e-a81d-9cc908a519de", "Styles": "None", "Classes": "None", "Text": "400", "ParentId": "763cb325-b4eb-4931-b7be-f0ea3d350e5c"}, {"Element": "<tr>\n<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">180+</span></p>\n</td>\n<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n</tr>", "ID": "f499d64f-cc8d-45dd-87cc-daad142614ec", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "2da54662-00b0-4b13-ad26-0c816d654077"}, {"Element": "<td style=\"width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">180+</span></p>\n</td>", "ID": "30d00c46-da18-4a2b-8b11-c87f65ec1607", "Styles": "width:176.65pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f499d64f-cc8d-45dd-87cc-daad142614ec"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">180+</span></p>", "ID": "5d5a5a6f-95b2-4dca-8454-2c6c2ef07221", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "30d00c46-da18-4a2b-8b11-c87f65ec1607"}, {"Element": "<span lang=\"EN-GB\">180+</span>", "ID": "2ac482a6-0f58-4821-9d21-101a04e67657", "Styles": "None", "Classes": "None", "Text": "180+", "ParentId": "5d5a5a6f-95b2-4dca-8454-2c6c2ef07221"}, {"Element": "<td style=\"width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"188\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>", "ID": "1d96ec55-fdf1-468d-9a78-462f5fa25054", "Styles": "width:141.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f499d64f-cc8d-45dd-87cc-daad142614ec"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>", "ID": "1252e8b2-ed17-4140-8cfa-133a94c3e571", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1d96ec55-fdf1-468d-9a78-462f5fa25054"}, {"Element": "<span lang=\"EN-GB\">400</span>", "ID": "526c63ea-869e-4889-a740-4a395b7f8914", "Styles": "None", "Classes": "None", "Text": "400", "ParentId": "1252e8b2-ed17-4140-8cfa-133a94c3e571"}, {"Element": "<td style=\"width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"195\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>", "ID": "4bbe7044-1196-4e2e-a876-74505c6a2e9a", "Styles": "width:146.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f499d64f-cc8d-45dd-87cc-daad142614ec"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>", "ID": "55792614-8265-4ed4-8f96-31964b720e36", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4bbe7044-1196-4e2e-a876-74505c6a2e9a"}, {"Element": "<span lang=\"EN-GB\">400</span>", "ID": "b2d50398-5c06-4905-b7e0-ffa0b252697e", "Styles": "None", "Classes": "None", "Text": "400", "ParentId": "55792614-8265-4ed4-8f96-31964b720e36"}, {"Element": "<tr>\n<td colspan=\"3\" style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">*If the\n  previous infusion was completed without severe infusion\u2011related ADRs.\n  If any infusion\u2011related ADRs are observed, infusion should be\n  interrupted and restarted when the patient\u2019s condition is stable (see </span><span lang=\"EN-GB\">section\u00a04.2 of the SmPC</span><span lang=\"EN-GB\">).</span></p>\n</td>\n</tr>", "ID": "272c2afe-dc13-45c8-8a3f-d78a6bd9e0f9", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "2da54662-00b0-4b13-ad26-0c816d654077"}, {"Element": "<td colspan=\"3\" style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">*If the\n  previous infusion was completed without severe infusion\u2011related ADRs.\n  If any infusion\u2011related ADRs are observed, infusion should be\n  interrupted and restarted when the patient\u2019s condition is stable (see </span><span lang=\"EN-GB\">section\u00a04.2 of the SmPC</span><span lang=\"EN-GB\">).</span></p>\n</td>", "ID": "5f11719f-ef89-477b-beb4-565594224858", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "272c2afe-dc13-45c8-8a3f-d78a6bd9e0f9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">*If the\n  previous infusion was completed without severe infusion\u2011related ADRs.\n  If any infusion\u2011related ADRs are observed, infusion should be\n  interrupted and restarted when the patient\u2019s condition is stable (see </span><span lang=\"EN-GB\">section\u00a04.2 of the SmPC</span><span lang=\"EN-GB\">).</span></p>", "ID": "737c1c54-a6e3-42cd-a44e-898914f13ab9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5f11719f-ef89-477b-beb4-565594224858"}, {"Element": "<span lang=\"EN-GB\">*If the\n  previous infusion was completed without severe infusion\u2011related ADRs.\n  If any infusion\u2011related ADRs are observed, infusion should be\n  interrupted and restarted when the patient\u2019s condition is stable (see </span>", "ID": "412ed153-3b00-4e3d-8da6-483ff7ade4f6", "Styles": "None", "Classes": "None", "Text": "*If the   previous infusion was completed without severe infusion\u2011related ADRs.   If any infusion\u2011related ADRs are observed, infusion should be   interrupted and restarted when the patient\u2019s condition is stable (see ", "ParentId": "737c1c54-a6e3-42cd-a44e-898914f13ab9"}, {"Element": "<span lang=\"EN-GB\">section\u00a04.2 of the SmPC</span>", "ID": "3f2f4856-7e5a-4850-ab1e-da98eec1ed27", "Styles": "None", "Classes": "None", "Text": "section\u00a04.2 of the SmPC", "ParentId": "737c1c54-a6e3-42cd-a44e-898914f13ab9"}, {"Element": "<span lang=\"EN-GB\">).</span>", "ID": "d3394978-1295-4611-b09e-3ebf4d9a0b92", "Styles": "None", "Classes": "None", "Text": ").", "ParentId": "737c1c54-a6e3-42cd-a44e-898914f13ab9"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "11074ea9-ef00-4015-961a-5030320aba79", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "04d5a300-dcad-4d1e-bed3-e37ce971e5a0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "11074ea9-ef00-4015-961a-5030320aba79"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Any unused medicinal product or waste\nmaterial should be disposed of in accordance with local requirements.</span></p>", "ID": "33d7cbdf-a9b7-4d2d-8e28-ad580f493c56", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Any unused medicinal product or waste\nmaterial should be disposed of in accordance with local requirements.</span>", "ID": "14ddc1f8-d693-42e5-920d-9be8e5ba3ce6", "Styles": "None", "Classes": "None", "Text": "Any unused medicinal product or waste material should be disposed of in accordance with local requirements.", "ParentId": "33d7cbdf-a9b7-4d2d-8e28-ad580f493c56"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4063af44-d945-42ba-8590-24e58f7a201f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fda0cf35-21ed-42e0-9c7e-fd2d83b6a65f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4063af44-d945-42ba-8590-24e58f7a201f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Refractory CLL:</u></p>", "ID": "13215ced-cc21-4c06-a15c-a433c7066fa2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u>Refractory CLL:</u>", "ID": "79c26174-1ace-47b8-a68b-5c342fba182a", "Styles": "None", "Classes": "None", "Text": "Refractory CLL:", "ParentId": "13215ced-cc21-4c06-a15c-a433c7066fa2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">For the first and second infusion, administer over 6.5\u00a0hours\n(see section\u00a04.2 of the SmPC), through a peripheral line or indwelling\ncatheter, according to the schedule below:</span></p>", "ID": "e867e0ec-66c2-4048-afeb-995a4c3305d5", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">For the first and second infusion, administer over 6.5\u00a0hours\n(see section\u00a04.2 of the SmPC), through a peripheral line or indwelling\ncatheter, according to the schedule below:</span>", "ID": "baffc48b-3578-4c24-b357-6683e53f4fe4", "Styles": "None", "Classes": "None", "Text": "For the first and second infusion, administer over 6.5\u00a0hours (see section\u00a04.2 of the SmPC), through a peripheral line or indwelling catheter, according to the schedule below:", "ParentId": "e867e0ec-66c2-4048-afeb-995a4c3305d5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b8473321-ed3b-4108-8b7b-6aa7d052cd28", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e9b151a2-9e6e-44da-821c-fcb36fe2786e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b8473321-ed3b-4108-8b7b-6aa7d052cd28"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">If the second infusion was completed without a severe adverse\nreaction, the remaining infusions (3\u201112) should be administered over\n4\u00a0hours (see section 4.2 of the SmPC), through a peripheral line or\nindwelling catheter, according to the schedule below. If any infusion\u2011related\nadverse reactions are observed, infusion should be interrupted and restarted\nwhen the patient\u2019s condition is stable (see section\u00a04.2 of the SmPC).</span></p>", "ID": "0b8ad82d-aaad-46aa-8312-129bc1077b29", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">If the second infusion was completed without a severe adverse\nreaction, the remaining infusions (3\u201112) should be administered over\n4\u00a0hours (see section 4.2 of the SmPC), through a peripheral line or\nindwelling catheter, according to the schedule below. If any infusion\u2011related\nadverse reactions are observed, infusion should be interrupted and restarted\nwhen the patient\u2019s condition is stable (see section\u00a04.2 of the SmPC).</span>", "ID": "6d85534a-c65d-4fae-a492-6d1819fe91ce", "Styles": "None", "Classes": "None", "Text": "If the second infusion was completed without a severe adverse reaction, the remaining infusions (3\u201112) should be administered over 4\u00a0hours (see section 4.2 of the SmPC), through a peripheral line or indwelling catheter, according to the schedule below. If any infusion\u2011related adverse reactions are observed, infusion should be interrupted and restarted when the patient\u2019s condition is stable (see section\u00a04.2 of the SmPC).", "ParentId": "0b8ad82d-aaad-46aa-8312-129bc1077b29"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "639dcd31-b9e7-4855-aa56-1ac8e8b19cfb", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "eb6c5e45-12ec-4c39-9d10-37e85e90801a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "639dcd31-b9e7-4855-aa56-1ac8e8b19cfb"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Infusion\nschedule</span></u></i></p>", "ID": "2963d0bd-d634-4af8-8312-05844afddd48", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<i><u><span lang=\"EN-GB\">Infusion\nschedule</span></u></i>", "ID": "309209b4-2391-494f-b899-438e45c18bb9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2963d0bd-d634-4af8-8312-05844afddd48"}, {"Element": "<u><span lang=\"EN-GB\">Infusion\nschedule</span></u>", "ID": "bf46c1b1-837f-4719-854e-efa8dae35d4e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "309209b4-2391-494f-b899-438e45c18bb9"}, {"Element": "<span lang=\"EN-GB\">Infusion\nschedule</span>", "ID": "3549dfbb-9b64-421d-84e6-c494831526f2", "Styles": "None", "Classes": "None", "Text": "Infusion schedule", "ParentId": "bf46c1b1-837f-4719-854e-efa8dae35d4e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "597daa34-2b66-4669-b2e7-ef308954b4a8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "4407a1c8-ad97-4a92-9806-2eb9c1609533", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "597daa34-2b66-4669-b2e7-ef308954b4a8"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "3d77ca41-1f0f-4936-9bd8-a88287be4ce3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4407a1c8-ad97-4a92-9806-2eb9c1609533"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "fe7d17a5-b550-4720-ac12-4fe8d7533cb6", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "3d77ca41-1f0f-4936-9bd8-a88287be4ce3"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td rowspan=\"2\" style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Time after start of infusion (minutes)</span></p>\n</td>\n<td style=\"width:134.7pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusions\u00a01 and 2</span></p>\n</td>\n<td style=\"width:134.6pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusions\u00a03* to 12</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:134.7pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0\u201130</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">12</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31\u2011 60</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">61\u201190</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">91\u2011120</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">121+</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\" style=\"width:423.55pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"565\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">*If the\n  second infusion was completed without severe infusion\u2011related ADRs. If\n  any infusion\u2011related ADRs are observed, infusion should be interrupted\n  and restarted when the patient\u2019s condition is stable (see section\u00a04.2).</span></p>\n</td>\n</tr>\n</table>", "ID": "11d9129e-0057-4373-bb2c-112a3530bde7", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "         ", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<tr>\n<td rowspan=\"2\" style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Time after start of infusion (minutes)</span></p>\n</td>\n<td style=\"width:134.7pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusions\u00a01 and 2</span></p>\n</td>\n<td style=\"width:134.6pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusions\u00a03* to 12</span></p>\n</td>\n</tr>", "ID": "7a2857d2-0bd4-4de4-85e4-042a6a44cfdd", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "11d9129e-0057-4373-bb2c-112a3530bde7"}, {"Element": "<td rowspan=\"2\" style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Time after start of infusion (minutes)</span></p>\n</td>", "ID": "f6446343-d92a-4b2a-9b99-b074d5883a46", "Styles": "width:154.25pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7a2857d2-0bd4-4de4-85e4-042a6a44cfdd"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Time after start of infusion (minutes)</span></p>", "ID": "d9098ed7-f8e1-44c3-82ae-089ae0cf7246", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f6446343-d92a-4b2a-9b99-b074d5883a46"}, {"Element": "<span lang=\"EN-GB\">Time after start of infusion (minutes)</span>", "ID": "fdbb045a-cb1d-4800-833e-72945dd5ff2a", "Styles": "None", "Classes": "None", "Text": "Time after start of infusion (minutes)", "ParentId": "d9098ed7-f8e1-44c3-82ae-089ae0cf7246"}, {"Element": "<td style=\"width:134.7pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusions\u00a01 and 2</span></p>\n</td>", "ID": "cc3eb719-2530-41cc-9cca-855d5a8d57f4", "Styles": "width:134.7pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7a2857d2-0bd4-4de4-85e4-042a6a44cfdd"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusions\u00a01 and 2</span></p>", "ID": "3c48df92-062b-4a23-8854-f3f038b5ebfb", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cc3eb719-2530-41cc-9cca-855d5a8d57f4"}, {"Element": "<span lang=\"EN-GB\">Infusions\u00a01 and 2</span>", "ID": "31d3ee7e-084d-42b6-92a1-8442c3a59cb8", "Styles": "None", "Classes": "None", "Text": "Infusions\u00a01 and 2", "ParentId": "3c48df92-062b-4a23-8854-f3f038b5ebfb"}, {"Element": "<td style=\"width:134.6pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusions\u00a03* to 12</span></p>\n</td>", "ID": "f7e1e2bd-c83d-48e7-9931-205c2976fdd7", "Styles": "width:134.6pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7a2857d2-0bd4-4de4-85e4-042a6a44cfdd"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusions\u00a03* to 12</span></p>", "ID": "6a8fd0af-d700-4b57-8d45-e377492d7081", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f7e1e2bd-c83d-48e7-9931-205c2976fdd7"}, {"Element": "<span lang=\"EN-GB\">Infusions\u00a03* to 12</span>", "ID": "6a29c98c-e643-439d-9915-b48545329b45", "Styles": "None", "Classes": "None", "Text": "Infusions\u00a03* to 12", "ParentId": "6a8fd0af-d700-4b57-8d45-e377492d7081"}, {"Element": "<tr>\n<td style=\"width:134.7pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>\n</tr>", "ID": "a3c29876-4aef-4425-9b10-c832272bf8b0", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "11d9129e-0057-4373-bb2c-112a3530bde7"}, {"Element": "<td style=\"width:134.7pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>", "ID": "83822e60-cee1-4320-b327-ff9704fc2ffe", "Styles": "width:134.7pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a3c29876-4aef-4425-9b10-c832272bf8b0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>", "ID": "cb640959-c322-4a3e-b19e-f77bc2667755", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "83822e60-cee1-4320-b327-ff9704fc2ffe"}, {"Element": "<span lang=\"EN-GB\">Infusion rate (ml/hour)</span>", "ID": "7b1e223e-fb60-4f43-8591-f74690e672c9", "Styles": "None", "Classes": "None", "Text": "Infusion rate (ml/hour)", "ParentId": "cb640959-c322-4a3e-b19e-f77bc2667755"}, {"Element": "<td style=\"width:134.6pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>\n</td>", "ID": "22ff32e9-e198-4fdf-9661-c0879e644e53", "Styles": "width:134.6pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a3c29876-4aef-4425-9b10-c832272bf8b0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infusion rate (ml/hour)</span></p>", "ID": "e739b7c6-bfdf-405b-9c2d-eea8eed68ca1", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "22ff32e9-e198-4fdf-9661-c0879e644e53"}, {"Element": "<span lang=\"EN-GB\">Infusion rate (ml/hour)</span>", "ID": "90225047-f547-4146-8fd4-45793e857b78", "Styles": "None", "Classes": "None", "Text": "Infusion rate (ml/hour)", "ParentId": "e739b7c6-bfdf-405b-9c2d-eea8eed68ca1"}, {"Element": "<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0\u201130</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">12</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>\n</tr>", "ID": "7141824d-8c7d-4d93-bfaa-def8e8c0fb03", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "11d9129e-0057-4373-bb2c-112a3530bde7"}, {"Element": "<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0\u201130</span></p>\n</td>", "ID": "f055934d-574f-48b0-99ce-9f2e41f0dedb", "Styles": "width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7141824d-8c7d-4d93-bfaa-def8e8c0fb03"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0\u201130</span></p>", "ID": "41114e2a-0667-4391-a81e-c3aec7ea5ee7", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f055934d-574f-48b0-99ce-9f2e41f0dedb"}, {"Element": "<span lang=\"EN-GB\">0\u201130</span>", "ID": "f1070962-a699-4aa9-962d-35017a5447b6", "Styles": "None", "Classes": "None", "Text": "0\u201130", "ParentId": "41114e2a-0667-4391-a81e-c3aec7ea5ee7"}, {"Element": "<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">12</span></p>\n</td>", "ID": "d4ad8b30-3a2e-41f9-a6e8-775cc5650dd8", "Styles": "width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7141824d-8c7d-4d93-bfaa-def8e8c0fb03"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">12</span></p>", "ID": "007d702f-a649-4b74-9cae-eb83f3d10d8b", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d4ad8b30-3a2e-41f9-a6e8-775cc5650dd8"}, {"Element": "<span lang=\"EN-GB\">12</span>", "ID": "bb4a2b25-a240-4d2b-b7bf-ccb87905eaa7", "Styles": "None", "Classes": "None", "Text": "12", "ParentId": "007d702f-a649-4b74-9cae-eb83f3d10d8b"}, {"Element": "<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>", "ID": "31219740-0530-4ddf-8da4-2157733b93b1", "Styles": "width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7141824d-8c7d-4d93-bfaa-def8e8c0fb03"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>", "ID": "e2697793-3d78-4041-af27-bdcd54155250", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "31219740-0530-4ddf-8da4-2157733b93b1"}, {"Element": "<span lang=\"EN-GB\">25</span>", "ID": "5143050a-e373-47de-9f61-52b3e7897ff3", "Styles": "None", "Classes": "None", "Text": "25", "ParentId": "e2697793-3d78-4041-af27-bdcd54155250"}, {"Element": "<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31\u2011 60</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>\n</tr>", "ID": "25d003d4-452a-4643-ac03-f3c5c166be10", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "11d9129e-0057-4373-bb2c-112a3530bde7"}, {"Element": "<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31\u2011 60</span></p>\n</td>", "ID": "f7c8a35b-2c83-4584-afc7-de41e9cd02ea", "Styles": "width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "25d003d4-452a-4643-ac03-f3c5c166be10"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31\u2011 60</span></p>", "ID": "ade76f27-148e-4e83-9748-802c14e7c80d", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f7c8a35b-2c83-4584-afc7-de41e9cd02ea"}, {"Element": "<span lang=\"EN-GB\">31\u2011 60</span>", "ID": "cdee7046-dddb-42c5-a057-ec1cb1d2ef67", "Styles": "None", "Classes": "None", "Text": "31\u2011 60", "ParentId": "ade76f27-148e-4e83-9748-802c14e7c80d"}, {"Element": "<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>\n</td>", "ID": "727c2fdb-5492-4f52-93b8-c48a38e5364b", "Styles": "width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "25d003d4-452a-4643-ac03-f3c5c166be10"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">25</span></p>", "ID": "64b95542-e987-4390-9c47-32e7d4283981", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "727c2fdb-5492-4f52-93b8-c48a38e5364b"}, {"Element": "<span lang=\"EN-GB\">25</span>", "ID": "1e9b5d1e-e9e5-49c2-8080-9acfd1a895bb", "Styles": "None", "Classes": "None", "Text": "25", "ParentId": "64b95542-e987-4390-9c47-32e7d4283981"}, {"Element": "<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>", "ID": "83e3d9a4-b747-4312-9c81-e89e56e81f4c", "Styles": "width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "25d003d4-452a-4643-ac03-f3c5c166be10"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>", "ID": "08ce1c66-d5be-48ba-ab0f-21390fe071bc", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "83e3d9a4-b747-4312-9c81-e89e56e81f4c"}, {"Element": "<span lang=\"EN-GB\">50</span>", "ID": "e01d3fb5-600e-4a4f-822d-9441c3e6dbfc", "Styles": "None", "Classes": "None", "Text": "50", "ParentId": "08ce1c66-d5be-48ba-ab0f-21390fe071bc"}, {"Element": "<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">61\u201190</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>\n</tr>", "ID": "24efa65d-0f1e-457b-9944-248f1b742549", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "11d9129e-0057-4373-bb2c-112a3530bde7"}, {"Element": "<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">61\u201190</span></p>\n</td>", "ID": "1dd58658-bd8a-446f-a441-b99e201f1c59", "Styles": "width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "24efa65d-0f1e-457b-9944-248f1b742549"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">61\u201190</span></p>", "ID": "23f24ad4-88d2-49f5-b706-b11182adbae6", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1dd58658-bd8a-446f-a441-b99e201f1c59"}, {"Element": "<span lang=\"EN-GB\">61\u201190</span>", "ID": "9ec436f8-5f2d-4662-b10f-d161e64a1efe", "Styles": "None", "Classes": "None", "Text": "61\u201190", "ParentId": "23f24ad4-88d2-49f5-b706-b11182adbae6"}, {"Element": "<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>\n</td>", "ID": "436e183e-200f-4971-aa0d-7106aa906079", "Styles": "width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "24efa65d-0f1e-457b-9944-248f1b742549"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">50</span></p>", "ID": "27e5c622-a3ab-47da-92ba-f22936fae899", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "436e183e-200f-4971-aa0d-7106aa906079"}, {"Element": "<span lang=\"EN-GB\">50</span>", "ID": "18a958c0-3e8d-4a58-b976-7223d738fab0", "Styles": "None", "Classes": "None", "Text": "50", "ParentId": "27e5c622-a3ab-47da-92ba-f22936fae899"}, {"Element": "<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>", "ID": "0eed5dd3-a46e-460e-98ce-a61fa7cc72be", "Styles": "width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "24efa65d-0f1e-457b-9944-248f1b742549"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>", "ID": "c6a00bdd-bd62-4d27-ad60-0b21693d8878", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0eed5dd3-a46e-460e-98ce-a61fa7cc72be"}, {"Element": "<span lang=\"EN-GB\">100</span>", "ID": "2ba69837-77bb-4c09-bc07-d2c2cba7fcd9", "Styles": "None", "Classes": "None", "Text": "100", "ParentId": "c6a00bdd-bd62-4d27-ad60-0b21693d8878"}, {"Element": "<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">91\u2011120</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>\n</tr>", "ID": "4afbf788-276b-40ab-962f-2f4b6cc8cec9", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "11d9129e-0057-4373-bb2c-112a3530bde7"}, {"Element": "<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">91\u2011120</span></p>\n</td>", "ID": "cca9813d-4ab8-4e08-bbfb-cc28e56a55ba", "Styles": "width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4afbf788-276b-40ab-962f-2f4b6cc8cec9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">91\u2011120</span></p>", "ID": "fb5ee401-a065-42e2-9ab2-927d9da5ee65", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cca9813d-4ab8-4e08-bbfb-cc28e56a55ba"}, {"Element": "<span lang=\"EN-GB\">91\u2011120</span>", "ID": "839c9402-5076-45a2-a96a-bf29237fc7a7", "Styles": "None", "Classes": "None", "Text": "91\u2011120", "ParentId": "fb5ee401-a065-42e2-9ab2-927d9da5ee65"}, {"Element": "<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>\n</td>", "ID": "91ad2285-6298-4b0e-add9-ca6a55c86b4d", "Styles": "width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4afbf788-276b-40ab-962f-2f4b6cc8cec9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">100</span></p>", "ID": "ae952984-7650-475a-be30-7009a7edecb1", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "91ad2285-6298-4b0e-add9-ca6a55c86b4d"}, {"Element": "<span lang=\"EN-GB\">100</span>", "ID": "95878512-1337-47eb-9e3d-8f690cf408c7", "Styles": "None", "Classes": "None", "Text": "100", "ParentId": "ae952984-7650-475a-be30-7009a7edecb1"}, {"Element": "<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>", "ID": "f17af1ab-4ff2-4ce6-b262-51a213f6bd5b", "Styles": "width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4afbf788-276b-40ab-962f-2f4b6cc8cec9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>", "ID": "79692c7e-f7c8-4830-977a-fa968b9ec9f1", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f17af1ab-4ff2-4ce6-b262-51a213f6bd5b"}, {"Element": "<span lang=\"EN-GB\">200</span>", "ID": "8c57f51a-e8e6-41b6-9364-a5c4483ec369", "Styles": "None", "Classes": "None", "Text": "200", "ParentId": "79692c7e-f7c8-4830-977a-fa968b9ec9f1"}, {"Element": "<tr>\n<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">121+</span></p>\n</td>\n<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>\n<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>\n</tr>", "ID": "91a89852-f34c-4000-8172-e156d6dbd00a", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "11d9129e-0057-4373-bb2c-112a3530bde7"}, {"Element": "<td style=\"width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"206\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">121+</span></p>\n</td>", "ID": "9726ab6b-ddf0-4bfa-8963-31de2278607a", "Styles": "width:154.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "91a89852-f34c-4000-8172-e156d6dbd00a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">121+</span></p>", "ID": "2e511baf-c908-433e-aab4-0aab1ce579e6", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9726ab6b-ddf0-4bfa-8963-31de2278607a"}, {"Element": "<span lang=\"EN-GB\">121+</span>", "ID": "848a12de-94dd-4e3a-9c39-5fa937ec9bf7", "Styles": "None", "Classes": "None", "Text": "121+", "ParentId": "2e511baf-c908-433e-aab4-0aab1ce579e6"}, {"Element": "<td style=\"width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>\n</td>", "ID": "edb34fe3-86d5-44aa-a36e-a100e16a42d9", "Styles": "width:134.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "91a89852-f34c-4000-8172-e156d6dbd00a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">200</span></p>", "ID": "57ad3b94-0198-4d4b-96c2-bf983b76f278", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "edb34fe3-86d5-44aa-a36e-a100e16a42d9"}, {"Element": "<span lang=\"EN-GB\">200</span>", "ID": "a39b3b52-09e6-46c6-85cd-91e649f49b57", "Styles": "None", "Classes": "None", "Text": "200", "ParentId": "57ad3b94-0198-4d4b-96c2-bf983b76f278"}, {"Element": "<td style=\"width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"179\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>\n</td>", "ID": "c40279d0-5ea3-4b72-92a1-379d9941cc4d", "Styles": "width:134.6pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "91a89852-f34c-4000-8172-e156d6dbd00a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">400</span></p>", "ID": "08204086-b76e-40c2-9c6b-f7cb7788e89f", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c40279d0-5ea3-4b72-92a1-379d9941cc4d"}, {"Element": "<span lang=\"EN-GB\">400</span>", "ID": "a86ab30f-9491-4e15-9da1-07e4d6695173", "Styles": "None", "Classes": "None", "Text": "400", "ParentId": "08204086-b76e-40c2-9c6b-f7cb7788e89f"}, {"Element": "<tr>\n<td colspan=\"3\" style=\"width:423.55pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"565\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">*If the\n  second infusion was completed without severe infusion\u2011related ADRs. If\n  any infusion\u2011related ADRs are observed, infusion should be interrupted\n  and restarted when the patient\u2019s condition is stable (see section\u00a04.2).</span></p>\n</td>\n</tr>", "ID": "5ea46d76-8049-4094-929c-139b13140575", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "11d9129e-0057-4373-bb2c-112a3530bde7"}, {"Element": "<td colspan=\"3\" style=\"width:423.55pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"565\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">*If the\n  second infusion was completed without severe infusion\u2011related ADRs. If\n  any infusion\u2011related ADRs are observed, infusion should be interrupted\n  and restarted when the patient\u2019s condition is stable (see section\u00a04.2).</span></p>\n</td>", "ID": "fe4ae036-23fa-40ab-8917-7423987161f5", "Styles": "width:423.55pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5ea46d76-8049-4094-929c-139b13140575"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">*If the\n  second infusion was completed without severe infusion\u2011related ADRs. If\n  any infusion\u2011related ADRs are observed, infusion should be interrupted\n  and restarted when the patient\u2019s condition is stable (see section\u00a04.2).</span></p>", "ID": "1e0dac63-b7d0-4420-bb00-9cba35be33d7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fe4ae036-23fa-40ab-8917-7423987161f5"}, {"Element": "<span lang=\"EN-GB\">*If the\n  second infusion was completed without severe infusion\u2011related ADRs. If\n  any infusion\u2011related ADRs are observed, infusion should be interrupted\n  and restarted when the patient\u2019s condition is stable (see section\u00a04.2).</span>", "ID": "13251436-81a0-47e8-9d8f-d068c33b4b1f", "Styles": "None", "Classes": "None", "Text": "*If the   second infusion was completed without severe infusion\u2011related ADRs. If   any infusion\u2011related ADRs are observed, infusion should be interrupted   and restarted when the patient\u2019s condition is stable (see section\u00a04.2).", "ParentId": "1e0dac63-b7d0-4420-bb00-9cba35be33d7"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "28d3228a-78db-44ca-abc7-83b84827aa75", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f1a727f6-2e37-4538-a4f4-3e8ee2dafa17", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "28d3228a-78db-44ca-abc7-83b84827aa75"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Any unused medicinal product or waste\nmaterial should be disposed of in accordance with local requirements.</span></p>", "ID": "89c72a1f-e692-44d3-aff4-1dbf97bb1de9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">Any unused medicinal product or waste\nmaterial should be disposed of in accordance with local requirements.</span>", "ID": "20228a8d-b341-4fb5-8988-ce5463c55792", "Styles": "None", "Classes": "None", "Text": "Any unused medicinal product or waste material should be disposed of in accordance with local requirements.", "ParentId": "89c72a1f-e692-44d3-aff4-1dbf97bb1de9"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0296ced0-8601-43eb-96a8-d848cab68b4f", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3202efd-8c36-4acf-bb65-5c60f6c0142b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bee0e1a2-4e19-4619-853d-8f2586051809", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0296ced0-8601-43eb-96a8-d848cab68b4f"}]}